<SEC-DOCUMENT>0001104659-21-043991.txt : 20210330
<SEC-HEADER>0001104659-21-043991.hdr.sgml : 20210330
<ACCEPTANCE-DATETIME>20210330170340
ACCESSION NUMBER:		0001104659-21-043991
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		91
CONFORMED PERIOD OF REPORT:	20201231
FILED AS OF DATE:		20210330
DATE AS OF CHANGE:		20210330

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			EYENOVIA, INC.
		CENTRAL INDEX KEY:			0001682639
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				471178401
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38365
		FILM NUMBER:		21787476

	BUSINESS ADDRESS:	
		STREET 1:		295 MADISON AVENUE,
		STREET 2:		SUITE 2400
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10017
		BUSINESS PHONE:		813-766-9539

	MAIL ADDRESS:	
		STREET 1:		295 MADISON AVENUE,
		STREET 2:		SUITE 2400
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10017
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>tm211152d1_10k.htm
<DESCRIPTION>FORM 10-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES<BR>
SECURITIES AND EXCHANGE COMMISSION<BR>
WASHINGTON, DC 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: black 1pt solid"><B>FORM&nbsp;10-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Wingdings"><FONT STYLE="font-family: Wingdings"><FONT STYLE="font-family: Wingdings">&#120;</FONT></FONT></FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><B>ANNUAL REPORT PURSUANT TO SECTION&nbsp;13 OR 15(d)&nbsp;OF THE SECURITIES EXCHANGE ACT OF 1934</B></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>For the fiscal
year ended: <U>December&nbsp;31, 2020</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>OR</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Wingdings"><B><FONT STYLE="font-family: Wingdings"><FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT></B></FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><B>TRANSITION REPORT PURSUANT TO SECTION&nbsp;13 OR 15(d)&nbsp;OF THE SECURITIES EXCHANGE ACT OF 1934</B></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>For the transition period from _________________
to ______________________</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>COMMISSION FILE NUMBER: <U>001-38365</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 14pt"><B>EYENOVIA,&nbsp;INC.<BR>
</B></FONT><B>(Exact name of Registrant as Specified in Its Charter)</B></P>

<P STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 43%; border-bottom: black 1pt solid; padding: 0.25pt 0.25pt 0.5pt; font-size: 10pt; text-align: center"><B>DELAWARE</B></TD>
    <TD STYLE="width: 14%; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="width: 43%; border-bottom: black 1pt solid; padding: 0.25pt 0.25pt 0.5pt; font-size: 10pt; text-align: center"><B>47-1178401</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: center">(State or Other Jurisdiction of<BR>
Incorporation or Organization)</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: center">(I.R.S. Employer<BR>
Identification No.)</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1pt solid; padding: 0.25pt 0.25pt 0.5pt; font-size: 10pt; text-align: center"><B>295 Madison Avenue, Suite&nbsp;2400<BR>
NEW YORK, NY</B></TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; padding: 0.25pt 0.25pt 0.5pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>10017</B></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: center">(Address of Principal Executive Offices)</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: center">(Zip Code)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Registrant&rsquo;s telephone number,
including area code: <U>(917) 289-1117</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Securities registered pursuant to Section&nbsp;12(b)&nbsp;of
the Act:</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 40%; border-bottom: black 1pt solid; padding: 0.25pt 0.25pt 0.5pt; font-size: 10pt; text-align: center">Title of each class</TD>
    <TD STYLE="width: 20%; border-bottom: black 1pt solid; padding: 0.25pt 0.25pt 0.5pt; font-size: 10pt; text-align: center">Trading Symbol(s)</TD>
    <TD STYLE="width: 40%; border-bottom: black 1pt solid; padding: 0.25pt 0.25pt 0.5pt; font-size: 10pt; text-align: center">Name of each exchange on which registered</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: center"><B>Common Stock, $0.0001 Par Value</B></TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: center"><B>EYEN</B></TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: center"><B>The Nasdaq Stock Market LLC</B></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Securities registered pursuant to Section&nbsp;12(g)&nbsp;of
the Act: none</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark if the registrant is a
well-known seasoned issuer, as defined in Rule&nbsp;405 of the Securities Act. Yes<FONT STYLE="font-family: Wingdings">&nbsp;&#168;</FONT>
No&nbsp; <FONT STYLE="font-family: Wingdings">&#120;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark if the registrant is not
required to file reports pursuant to Section&nbsp;13 or Section&nbsp;15(d)&nbsp;of the Act. Yes<FONT STYLE="font-family: Wingdings">&nbsp;<FONT STYLE="font-family: Wingdings">&#168;</FONT>
</FONT>No <FONT STYLE="font-family: Wingdings">&#120;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant:
(1)&nbsp;has filed all reports required to be filed by Section&nbsp;13 or 15(d)&nbsp;of the Securities Exchange Act of 1934 during the
preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&nbsp;has been subject
to such filing requirements for the past 90 days. Yes <FONT STYLE="font-family: Wingdings">&#120;</FONT>&nbsp; No <FONT STYLE="font-family: Wingdings">&#168;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&nbsp;405 of Regulation S-T during
the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes <FONT STYLE="font-family: Wingdings">&#120;
</FONT>No <FONT STYLE="font-family: Wingdings">&#168;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth
company. See the definitions of &ldquo;large accelerated filer,&rdquo; &ldquo;accelerated filer,&rdquo; &ldquo;smaller reporting
company,&rdquo; and &ldquo;emerging growth company&rdquo; in Rule&nbsp;12b-2 of the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 52%; padding: 0.25pt; font-size: 10pt; text-align: justify">Large accelerated filer <FONT STYLE="font-family: Wingdings">&#168;</FONT></TD>
    <TD STYLE="width: 48%; padding: 0.25pt; font-size: 10pt; text-align: justify">Accelerated filer <FONT STYLE="font-family: Wingdings">&#168;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt; font-size: 10pt">Non-accelerated filer <FONT STYLE="font-family: Wingdings"><FONT STYLE="font-family: Wingdings">&#120;</FONT></FONT></TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt">Smaller reporting company <FONT STYLE="font-family: Wingdings"><FONT STYLE="font-family: Wingdings">&#120;</FONT></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Emerging growth company <FONT STYLE="font-family: Wingdings"><FONT STYLE="font-family: Wingdings"><FONT STYLE="font-family: Wingdings">&#120;</FONT></FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any news or revised financial accounting
standards provided pursuant to Section&nbsp;13(a)&nbsp;of the Exchange Act. <FONT STYLE="font-family: Wingdings">&#168;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
has filed a report on and attestation to its management&rsquo;s assessment of the effectiveness of its internal control over financial
reporting under Section&nbsp;404(b)&nbsp;of the Sarbanes-Oxley Act (15 U.S.C 7262(b)) by the registered public accounting firm
that prepared or issued its audit report. <FONT STYLE="font-family: Wingdings"><FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
is a shell company (as defined in Rule&nbsp;12b-2 of the Act). Yes<FONT STYLE="font-family: Wingdings"><FONT STYLE="font-family: Wingdings">&nbsp;<FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT></FONT> No <FONT STYLE="font-family: Wingdings"><FONT STYLE="font-family: Wingdings"><FONT STYLE="font-family: Wingdings">&#120;</FONT></FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The aggregate market value of the voting
and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold
as of June&nbsp;30, 2020 (based on the closing price of $2.84 on June&nbsp;30, 2020, the last trading day of the registrant&rsquo;s
most recently completed second fiscal quarter), was approximately $32,427,910. Common stock held by each officer and director and
by each person known to the registrant who owned 10% or more of the outstanding common stock have been excluded in that such persons
may be deemed to be affiliates. This determination of affiliate status is not necessarily a conclusive determination for other
purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The number of outstanding shares of the registrant&rsquo;s
common stock was 25,623,577 as of March 29, 2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>DOCUMENTS INCORPORATED BY REFERENCE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Portions of the registrant&rsquo;s proxy
statement for its 2021 Annual Meeting of Stockholders currently scheduled to be held on June&nbsp;16, 2021 are incorporated by
reference into Part&nbsp;III hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Eyenovia,&nbsp;Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Form&nbsp;10-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>For Year Ended December&nbsp;31, 2020</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>TABLE OF CONTENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 91%; font-size: 10pt; text-align: left">PART&nbsp;I</TD>
    <TD STYLE="width: 9%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left"><A HREF="#s1_002">Item 1. Business</A></TD>
    <TD><A HREF="#s1_002">5</A></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left"><A HREF="#a1_001">Item 1A. Risk Factors</A></TD>
    <TD><A HREF="#a1_001">39</A></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left"><A HREF="#split005a_001">Item 1B. Unresolved Staff Comments</A></TD>
    <TD><A HREF="#split005a_001">67</A></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left"><A HREF="#split005a_002">Item 2. Properties</A></TD>
    <TD><A HREF="#split005a_002">67</A></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left"><A HREF="#split005a_003">Item 3. Legal Proceedings</A></TD>
    <TD><A HREF="#split005a_003">68</A></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left"><A HREF="#split005a_004">Item 4. Mine Safety Disclosures</A></TD>
    <TD><A HREF="#split005a_004">68</A></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">PART&nbsp;II</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left"><A HREF="#split005a_006">Item&nbsp;5. Market for Registrant&rsquo;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</A></TD>
    <TD><A HREF="#split005a_006">70</A></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left"><A HREF="#split005a_007">Item 6. Selected Financial Data</A></TD>
    <TD><A HREF="#split005a_007">70</A></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left"><A HREF="#split005a_008">Item&nbsp;7. Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operations</A></TD>
    <TD><A HREF="#split005a_008">70</A></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left"><A HREF="#a1_002">Item&nbsp;7A. Quantitative and Qualitative Disclosures About Risk</A></TD>
    <TD><A HREF="#a1_002">75</A></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left"><A HREF="#a1_003">Item&nbsp;8. Financial Statements and Supplementary Data</A></TD>
    <TD><A HREF="#a1_003">75</A></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left"><A HREF="#a1_004">Item&nbsp;9. Changes in and Disagreements With Accountants on Accounting and Financial Disclosures</A></TD>
    <TD><A HREF="#a1_004">75</A></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left"><A HREF="#a1_005">Item&nbsp;9A. Controls and Procedures</A></TD>
    <TD><A HREF="#a1_005">75</A></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left"><A HREF="#a1_006">Item&nbsp;9B. Other Information</A></TD>
    <TD><A HREF="#a1_006">76</A></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">PART&nbsp;III</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left"><A HREF="#a1_007">Item&nbsp;10. Directors, Executive Officers and Corporate Governance</A></TD>
    <TD><A HREF="#a1_007">77</A></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left"><A HREF="#a1_008">Item&nbsp;11. Executive Compensation</A></TD>
    <TD><A HREF="#a1_008">77</A></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left"><A HREF="#a1_009">Item&nbsp;12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</A></TD>
    <TD><A HREF="#a1_009">77</A></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left"><A HREF="#a1_010">Item&nbsp;13. Certain Relationships and Related Transactions, and Director Independence</A></TD>
    <TD><A HREF="#a1_010">77</A></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left"><A HREF="#a1_011">Item&nbsp;14. Principal Accounting Fees and Services</A></TD>
    <TD><A HREF="#a1_011">77</A></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">PART&nbsp;IV</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left"><A HREF="#a1_012">Item&nbsp;15. Exhibits, Financial Statement Schedules</A></TD>
    <TD><A HREF="#a1_012">78</A></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left"><A HREF="#a1_013">Item&nbsp;16. Form&nbsp;10-K Summary</A></TD>
    <TD><A HREF="#a1_013">80</A></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt"><A HREF="#a1_014">Signatures</A></TD>
    <TD><A HREF="#a1_014">81</A></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="s1_001"></A>PART&nbsp;I</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CAUTIONARY NOTE REGARDING FORWARD-LOOKING
STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Annual Report
on Form&nbsp;10-K contains &ldquo;forward-looking statements&rdquo; that involve risks and uncertainties, as well as assumptions
that, if they never materialize or prove incorrect, could cause our results to differ materially from those expressed or implied
by such forward-looking statements. The statements contained in this Annual Report on Form&nbsp;10-K that are not purely historical
are forward-looking statements within the meaning of Section&nbsp;27A of the Securities Act of 1933, as amended (&ldquo;Securities
Act&rdquo;), and Section&nbsp;21E of the Securities Exchange Act of 1934, as amended (&ldquo;Exchange Act&rdquo;). Such forward-looking
statements include our estimates regarding expenses, future revenue, capital requirements and our need for additional financing
and other financial items; any statements of the plans, strategies and objectives of management for future operations; any statements
about the advantages of our product candidates and platform technology; estimates regarding the potential market opportunity for
our product candidates and platform technology; statements regarding our clinical trials; factors that may affect our operating
results; statements about our ability to establish and maintain intellectual property rights; statements about our ability to retain
key personnel and hire necessary employees and appropriately staff our operations; statements related to future capital expenditures;
statements related to future economic conditions or performance; and other matters that do not relate strictly to historical facts
or statements of assumptions underlying any of the foregoing. Forward-looking statements are often identified by the use of words
such as, but not limited to, &ldquo;anticipate,&rdquo; &ldquo;believe,&rdquo; &ldquo;can,&rdquo; &ldquo;continue,&rdquo; &ldquo;could,&rdquo;
 &ldquo;estimate,&rdquo; &ldquo;expect,&rdquo; &ldquo;intend,&rdquo; &ldquo;may,&rdquo; &ldquo;might,&rdquo; &ldquo;will,&rdquo;
 &ldquo;plan,&rdquo; &ldquo;project,&rdquo; &ldquo;seek,&rdquo; &ldquo;should,&rdquo; &ldquo;target,&rdquo; &ldquo;would,&rdquo;
and similar expressions or variations intended to identify forward-looking statements. These statements are based on the beliefs
and assumptions of our management based on information currently available to management. Such forward-looking statements are subject
to risks, uncertainties and other important factors that could cause actual results and the timing of certain events to differ
materially from future results expressed or implied by such forward-looking statements. Factors that could cause or contribute
to such differences include, but are not limited to, those discussed in the section titled &ldquo;Summary Risk Factors&rdquo; described
below and &ldquo;Risk Factors&rdquo; included in Item 1A of Part&nbsp;I of this Annual Report on Form&nbsp;10-K, and the risks
discussed in our other SEC filings. Furthermore, such forward-looking statements speak only as of the date of this report. Except
as required by law, we undertake no obligation to update any forward-looking statements to reflect events or circumstances after
the date of such statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As used in this report,
the terms &ldquo;Eyenovia,&nbsp;Inc.,&rdquo; &ldquo;Eyenovia,&rdquo; &ldquo;Company,&rdquo; &ldquo;company,&rdquo; &ldquo;we,&rdquo;
 &ldquo;us,&rdquo; and &ldquo;our&rdquo; mean Eyenovia,&nbsp;Inc. and its subsidiaries unless the context indicates otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Summary Risk Factors</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Some of the factors that could materially
and adversely affect our financial condition, results of operations, cash flow, the market price of shares of our common stock
or our prospects include, but are not limited to, the following. You should read this summary together with the more detailed description
of each risk factor contained in Item 1A &ldquo;Risk Factors&rdquo; in this Annual Report on Form&nbsp;10-K.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">RISKS RELATED TO OUR FINANCIAL POSITION AND NEED FOR ADDITIONAL
CAPITAL</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="vertical-align: top">
  <TD STYLE="width: 0.25in">&nbsp;</TD>
  <TD STYLE="text-align: left; width: 0.25in; vertical-align: top"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
  <TD>We might not be able to continue as a going concern which would likely cause our stockholders to lose most or all of their investment.</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">We will need to raise additional capital in order to continue developing our product candidates
and to potentially manufacture and commercialize them.</TD></TR></TABLE>

<P STYLE="font: 5pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Raising additional capital may cause dilution to our existing stockholders, restrict our operations
or require us to relinquish rights to our technologies.</TD></TR></TABLE>

<P STYLE="font: 5pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">We have incurred operating losses since our inception. We expect to continue to incur losses for
the foreseeable future and might never achieve or maintain profitability.</TD></TR></TABLE>

<P STYLE="font: 5pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">We have a relatively short operating history.</TD></TR></TABLE>

<P STYLE="font: 5pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">We may be unable to use carryforward tax losses or benefit from favorable tax legislation to reduce
our taxes.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">RISKS RELATED TO DEVELOPMENT AND COMMERCIALIZATION OF OUR PRODUCT
CANDIDATES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">We or our licensees may encounter substantial delays in or failure of our clinical trials.</TD></TR></TABLE>

<P STYLE="font: 5pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">We or our licensees may find it difficult to enroll or maintain participation of an adequate number
of patients in our clinical trials.</TD></TR></TABLE>

<P STYLE="font: 5pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">We might not be able to develop marketable products utilizing our technology and we might not be
able to identify and successfully implement an alternative product development strategy.</TD></TR></TABLE>

<P STYLE="font: 5pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">The marketing approval process for our product candidates is expensive, time-consuming and uncertain
and may prevent us or our licensees from obtaining approvals for the commercialization.</TD></TR></TABLE>

<P STYLE="font: 5pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Our product candidates may cause undesirable side effects.</TD></TR></TABLE>

<P STYLE="font: 5pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">The market opportunities for our product candidates may be smaller than we believe they are.</TD></TR></TABLE>

<P STYLE="font: 5pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">The commercial success of our product candidates will depend in large part on the degree of market
acceptance.</TD></TR></TABLE>

<P STYLE="font: 5pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Our licensing partners may fail to use commercially reasonable efforts to commercialize our products.</TD></TR></TABLE>

<P STYLE="font: 5pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">We face competition in an environment of rapid technological change and our competitors may achieve
regulatory approval before us or develop therapies that are more effective than ours.</TD></TR></TABLE>

<P STYLE="font: 5pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">We might fail to establish and maintain effective manufacturing and
distribution processes.</P></TD></TR></TABLE>

<P STYLE="font: 5pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">We are exposed to the risk of claims seeking monetary damages by individuals and the risk of investigations
by regulatory authorities, which could cause us to incur substantial liabilities and limit commercialization.</TD></TR></TABLE>

<P STYLE="font: 5pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Product liability lawsuits against us could divert our resources and could cause us to incur substantial
liabilities and to limit commercialization of any products that we develop.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">RISKS RELATED TO REGULATORY APPROVAL AND LEGAL COMPLIANCE MATTERS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">We or our licensees might not be able to commercialize our product candidates.</TD></TR></TABLE>

<P STYLE="font: 5pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Failure to obtain marketing approval in foreign jurisdictions would prevent our product candidates
from being marketed in such jurisdictions.</TD></TR></TABLE>

<P STYLE="font: 5pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">The term restrictions for our products in the U.S. and other jurisdictions in which we have licensed
our products may limit how we manufacture and market our products.</TD></TR></TABLE>

<P STYLE="font: 5pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">We may be subject to substantial penalties if we fail to comply with regulatory requirements or
if we experience unanticipated problems with our products.</TD></TR></TABLE>

<P STYLE="font: 5pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Recently enacted and future legislation may affect our or our licensees&rsquo; ability to commercialize
our products and the prices we obtain for any products that are approved in the U.S. or foreign jurisdictions.</TD></TR></TABLE>

<P STYLE="font: 5pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">We are subject to certain laws governing our operations and if we fail to comply with these laws,
we could be subject to penalties, other remedial measures and legal expenses, be precluded from developing manufacturing and selling
products or be required to develop and implement costly compliance programs.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">RISKS RELATED TO OUR BUSINESS OPERATIONS AND MANAGING GROWTH</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">We are highly dependent on the services of our senior management team.</TD></TR></TABLE>

<P STYLE="font: 5pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">We have limited corporate infrastructure and may experience difficulties in managing growth.</TD></TR></TABLE>

<P STYLE="font: 5pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">We rely upon information technology and any failure, inadequacy, interruption or security lapse
of that technology, including any cyber security incidents, could harm our ability to operate our business effectively.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">RISKS RELATED TO OUR DEPENDENCE ON THIRD PARTIES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">We have limited clinical trial experience and we rely upon third parties in conducting and managing
our clinical trials.</TD></TR></TABLE>

<P STYLE="font: 5pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">We may need to contract with additional third parties for the manufacture of our product candidates,
particularly for commercialization.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">RISKS RELATED TO OUR INTELLECTUAL PROPERTY
AND POTENTIAL LITIGATION</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Our success depends on our ability to protect our intellectual property, proprietary technology
and trade secrets.</TD></TR></TABLE>

<P STYLE="font: 5pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Our patents covering our proprietary technology maybe subject to challenge, narrowing, circumvention
and invalidation by third parties.</TD></TR></TABLE>

<P STYLE="font: 5pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="font: 5pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">We cannot be sure that we were the first to make the technologies claimed in our patents or patent
applications or that we were the first to file for patent protection.</TD></TR></TABLE>

<P STYLE="font: 5pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">The patent application process is subject to numerous risks and there can be no assurance that
we will be successful in obtaining patents for which we have applied.</TD></TR></TABLE>

<P STYLE="font: 5pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Changes to the patent law in the U.S. or other jurisdictions could diminish the value of patents
in general, thereby impairing our ability to protect our products.</TD></TR></TABLE>

<P STYLE="font: 5pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">We may become involved in lawsuits to protect or enforce our patents or other intellectual property,
which could be expensive, time consuming and unsuccessful.</TD></TR></TABLE>

<P STYLE="font: 5pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">If we fail to comply with our obligations under our existing and any future intellectual property
licenses with third parties, we could lose license rights that are important to our business.</TD></TR></TABLE>

<P STYLE="font: 5pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">If our trademarks and trade names are not adequately protected, then we might not be able to build
name recognition in our marks of interest and our business may be adversely affected.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">RISKS RELATED TO OWNERSHIP OF OUR COMMON STOCK</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Our management and members of our Board of Directors have the ability to substantially influence
all matters submitted to stockholders for approval.</TD></TR></TABLE>

<P STYLE="font: 5pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">A significant portion of our total outstanding shares may be sold into the market in the near future,
which could cause the market price of our common stock to drop significantly.</TD></TR></TABLE>

<P STYLE="font: 5pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">The price of our common stock may be volatile and fluctuate substantially.</TD></TR></TABLE>

<P STYLE="font: 5pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">We have broad discretion in the use of our cash.</TD></TR></TABLE>

<P STYLE="font: 5pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Our business is subject to changing regulations regarding corporate governance, disclosure controls,
internal control over financial reporting, and other compliance areas that might increase both our costs and the risk of noncompliance.</TD></TR></TABLE>

<P STYLE="font: 5pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Failure to develop and maintain adequate financial controls could cause us to have material weaknesses.</TD></TR></TABLE>

<P STYLE="font: 5pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Provisions in our corporate charter documents and under Delaware law could make an acquisition
of us more difficult and may prevent attempts by our stockholders to replace or remove our current management.</TD></TR></TABLE>

<P STYLE="font: 5pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Our certificate of incorporation provides that the Court of Chancery of the State of Delaware is,
to the fullest extent permitted by law, the sole and exclusive forum for substantially all disputes between us and our stockholders.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 96px; text-align: justify"><A NAME="s1_002"></A><B>Item 1.</B></TD>
    <TD STYLE="text-align: justify"><B>Business. </B></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Corporate Information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We were organized as
a corporation under the laws of the State of Florida on March&nbsp;12, 2014 under the name &ldquo;PGP Holdings V,&nbsp;Inc.&rdquo;
On May&nbsp;5, 2014, we changed our name to Eyenovia,&nbsp;Inc. On October&nbsp;6, 2014, we reincorporated in the State of Delaware
by merging into Eyenovia,&nbsp;Inc., a Delaware corporation. Our principal executive office is located at 295 Madison Avenue, Suite&nbsp;2400,
New York, NY 10017, and our phone number is 917-289-1117. Our website is <I>www.eyenovia.com</I>. Information contained on, or
that can be accessed through, our website is not incorporated by reference into this report, and you should not consider information
on our website to be part of this report.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Overview</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are a clinical stage
ophthalmic company developing a pipeline of advanced therapeutics based on our proprietary microdose array print (MAP&trade;) platform
technology. We aim to achieve clinical microdosing of next-generation formulations of novel and existing ophthalmic pharmaceutical
agents using our high-precision targeted ocular delivery system, branded the Optejet&reg;. Optejet &micro;-therapeutics have the
potential to replace conventional eye dropper delivery and improve safety, tolerability, patient compliance and topical delivery
success for ophthalmic eye treatments. In the clinic, the Optejet has demonstrated that our targeted horizontal microdose delivery
can achieve a significantly higher rate of successful ocular topical delivery compared to the established rate reported with traditional
eye drops (~ 90% vs. ~ 50%). Our technology is designed to achieve single-digit &micro;l-volume physiologic drug delivery with
up to a 75% reduction in ocular drug and preservative topical dosing and has demonstrated significant improvement in the therapeutic
index in drugs used for mydriasis and IOP lowering through three Phase II and Phase III trials. Conventional eye formulations lack
high-precision micro-volume delivery and expose the ocular surface to approximately 300% more medication and preservatives than
are physiologically indicated leading to clinically recognized ocular and non-ocular side effects. Using the Optejet, we are developing
the next generation of smart ophthalmic therapeutics which target new indications or new combinations where there are currently
no comparable drug therapies approved by the U.S. Food and Drug Administration, or the FDA. Our microdose therapeutics follow the
FDA-designated pharmaceutical registration and regulatory process. Our products are classified by the FDA as drugs, and not medical
devices or drug-device combination products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our pipeline is currently
focused on the late-stage development of novel first-in-class therapeutic indications for an estimated over five million potential
patients with progressive myopia in the United States and estimated over one hundred million potential patients with age-related
near vision impairment, or presbyopia &ndash; indications where there is tremendous unmet need and no known existing FDA-approved
therapies. We are also developing the first microdose fixed combination ophthalmic pharmaceutical for mydriasis to address the
estimated over 100 million annual comprehensive eye exams with pupil dilation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">MicroPine is our first-in-class
topical therapy for the treatment of progressive myopia, a back-of-the-eye ocular disease associated with pathologic axial elongation
and sclero-retinal stretching. In the United States, myopia is estimated to affect approximately 25 million children, with up to
five million considered to be at risk for high myopia. In February&nbsp;2019, the FDA accepted our investigational new drug application,
or IND, to initiate a Phase III registration trial of MicroPine (the CHAPERONE study) to reduce the progression of myopia in children.
We enrolled the first patient in the CHAPERONE study in June&nbsp;2019. Due to the COVID-19 pandemic, we previously experienced
delays in trial enrollment and initiation as a result of reduced clinical trial activities and operations at investigator sites.
However, we have since been able to resume enrollment in the CHAPERONE study.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On October&nbsp;9,
2020, we entered into a License Agreement (the &ldquo;Bausch License Agreement&rdquo;) with a subsidiary of Bausch Health Companies
Inc. (&ldquo;Bausch Health&rdquo;) pursuant to which Bausch Health may develop and commercialize MicroPine in the United States
and Canada.&nbsp;Under the terms of the Bausch License Agreement, we received an upfront payment of $10.0 million and we may receive
up to a total of $35.0 million in additional payments, based on the achievement of certain regulatory and launch-based milestones.
Bausch Health also will pay us royalties on a tiered basis (ranging from mid-single digit to mid-teen percentages) on gross profits
from sales of MicroPine in the United States and Canada, subject to certain adjustments. Under the terms of the Bausch License
Agreement, Bausch Health is in the process of assuming oversight and has assumed the costs related to the ongoing CHAPERONE study.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">MicroLine is our pharmacologic
treatment for presbyopia. Presbyopia is a non-preventable, age-related hardening of the lens, which causes the gradual loss of
the eye&rsquo;s ability to focus at near and impairs near visual acuity. There currently are no known FDA-approved drugs for the
improvement of near vision in patients with presbyopia, although other companies have related therapies in their pipeline. We have
two planned Phase III VISION trials for MicroLine, and initiated the first of these trials in December&nbsp;2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On August&nbsp;10,
2020, we entered into a License Agreement (the &ldquo;Arctic Vision License Agreement&rdquo;) with Arctic Vision (Hong Kong) Limited
(&ldquo;Arctic Vision&rdquo;), pursuant to which Arctic Vision may develop and commercialize MicroPine and MicroLine in Greater
China (mainland China, Hong Kong, Macau and Taiwan) and South Korea. Under the terms of the Arctic Vision License Agreement, we
received an upfront payment of $4.0 million before any payments to Senju Pharmaceutical Co.,&nbsp;Ltd. (&ldquo;Senju&rdquo;). In
addition, we may receive up to a total of $41.75 million in additional payments, based on various development and regulatory milestones,
including the initiation of clinical research and approvals in Greater China and South Korea, and development costs. Arctic Vision
also will purchase its supply of MicroPine and MicroLine from us or, for such products not supplied by us, pay us a mid-single
digit percentage royalty on net sales of such products, subject to certain adjustments. We will pay a mid-double digit percentage
of such payments, royalties, or net proceeds of such supply to Senju pursuant to the Exclusive License Agreement with Senju dated
March&nbsp;8, 2015, as amended by the License Amendment dated April&nbsp;8, 2020, and a Letter Agreement dated August&nbsp;10,
2020 (the &ldquo;Senju License Agreement&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">MydCombi&trade; (or
MicroStat) is our fixed combination formulation of phenylephrine-tropicamide for mydriasis, designed to be a novel approach for
the estimated over one hundred million office-based comprehensive and diabetic eye exams performed every year in the United States.
We have completed two Phase III trials for MydCombi and announced positive results from these studies, known as MIST-1 and MIST-2.
In March&nbsp;2021, the FDA accepted our new drug application, or NDA, for MydCombi with an expected Prescription Drug User Fee
Act, or PDUFA, date of October&nbsp;28, 2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following summarizes
our product pipeline and anticipated milestones:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 23%; border-bottom: black 1pt solid; padding: 0.25pt 0.25pt 0.5pt; text-align: center"><B>Product <BR>
Candidate</B></TD>
    <TD STYLE="width: 2%; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="width: 39%; border-bottom: black 1pt solid; padding: 0.25pt 0.25pt 0.5pt; text-align: center"><B>Indication</B></TD>
    <TD STYLE="width: 2%; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="width: 34%; border-bottom: black 1pt solid; padding: 0.25pt 0.25pt 0.5pt; text-align: center"><B>Next Expected Milestones</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt; text-align: center">MicroLine </TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; text-align: center">Improvement in Near Vision in people with Presbyopia</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Phase 3 VISION-1 Topline Results expected
        2Q 2021</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt; text-align: center">MicroPine</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; text-align: center">Pediatric Myopia Progression (Near-Sightedness)</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; text-align: center">Phase 3 CHAPERONE Full Enrollment expected 4Q 2021</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt; text-align: center">MydCombi</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Pharmaceutical Mydriasis</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Pupil Dilation)</P></TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Expected PDUFA date October&nbsp;28, 2021</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Our Strategy</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our goal is to become
a leading developer and provider of advanced ophthalmic pharmaceuticals based upon our microdose array print platform technology
and digital health platform for interactive patient care. These unique therapeutics would be commercialized by us and/or our partners
globally. The key elements of our strategy to achieve this goal are:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>Establish a portfolio
of first-in-class piezo-print micro-therapeutic products for multiple eye treatments through the 505(b)(2)&nbsp;pathway with the
FDA.</I></B> We are focused on integrating our next-generation technology with therapeutic compounds already well established in
the topical treatment of ophthalmic indications. We believe that the 505(b)(2)&nbsp;registration pathway, which reduces development
risk compared to new molecular entity programs by working with known compounds with well-established safety and efficacy profiles,
will be available for our development pipeline. We believe our pipeline of patented micro-therapeutic product candidates is highly
differentiated by our improved tolerability and enhanced compliance profile and that our late-stage development programs could
lead to additional NDA submissions in novel indications where the products can have unique dosing and therapeutic profiles. We
believe that this could lead to favorable pricing and a reduced risk of generic substitution.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>Improve clinical
outcomes and patient experiences while providing an improved tolerability profile with our microdose therapeutics.</I></B> We believe
the Optejet will allow for high precision targeted microdosing for multiple eye treatments, while eliminating ophthalmic over-dosing
and reducing ocular exposure to toxic preservatives and pharmacologic ingredients compared to conventional eye drop delivery mechanisms.
Our clinical trials have demonstrated similar efficacy to eye drops, improved side effect profile and enhanced patient experience
with the Optejet as compared to conventional eye drops.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>Leverage our
electronic, smartphone-enabled &ldquo;e-health&rdquo; technology to introduce and develop patient-specific compliance monitoring
program.</I></B> The Optejet&rsquo;s mobile e-health technology is designed to track when a patient administers treatments, allowing
physicians to monitor patient compliance more accurately. We believe this could enhance patient compliance and improve compliance
monitoring by empowering patients and physicians with access to dynamic, real-time monitoring and compliance data for a more intelligent,
informed and personalized therapeutic paradigm.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>Develop next-generation
targeted microdose treatments for other ophthalmic diseases independently or in collaboration with third parties.</I></B> The Optejet
also may be suitable for new molecular entities and applications. Leveraging our existing platform technology, Eyenovia plans to
continue developing, either independently or through strategic relationships with third parties, other product candidates for various
eye diseases that can be administered using the Optejet and additional applications for the Optejet.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B><I>Develop
therapeutic solutions for ophthalmic conditions with high unmet needs and no approved therapy.</I></B> We plan to target chronic
ophthalmic conditions with a high unmet medical need. By leveraging our piezo-print microdosing technology, we aim to reach conditions
where there are no approved drug therapies. For example, our MicroPine program involves a proprietary formulation of low-dose atropine
intended to slow myopia progression in the pediatric population. There are currently no commercially-available therapies in the
United States to treat this indication.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>Limitations
of Conventional Eye Therapies</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our microdosing
platform technology aims to address the following issues associated with conventional eye drop-based therapies:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B><I>Dosing,
administration and waste of medication</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Multiple
third-party studies have confirmed challenges with administering conventional eye drops, which include overdosing, poor compliance,
imprecise dosing, variability in drop size, and difficulty with self-administration. One study in patients who were experienced
in using eye drops and undergoing treatment for glaucoma for at least six months documented that nine out of 10 patients were unable
to administer treatment correctly at the end of the six-month study. Patients on average administered almost twice the necessary
number of drops with a mean number of drops instilled at 1.8 (+/1 1.2) and one patient administered up to eight drops at one time.
In addition, approximately 75% of patients risked bottle contamination or potential ocular trauma by having the eye drop container
touch their eyes. Another larger study in 139 patients demonstrated that the proportion of patients who were able to correctly
administer their eye drops was only 22%&ndash;30%. Similarly, other studies have demonstrated that the vast majority of patients
either overdose or do not administer the required therapy to the eye correctly, which leads to unnecessary waste of medication.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B><I>Side
effects associated with conventional eye drop therapies</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Topical
eye therapies are administered using traditional eye drop pipette approaches. While average tear volume of the eye is 6&ndash;8
 &micro;L, current eyedrop therapies can involve administration of 30&ndash;50 &micro;L of liquid containing preservatives and pharmaceutical
ingredients. Thus, traditional drops can severely overdose the eye, which, depending on the ingredients, can be associated with
ocular side effects including hyperemia, or increased blood flow to the eye, redness, discomfort, stinging, blurred vision, burning,
itching, excessive tearing, eye pain, iris pigment changes, foreign body sensation, pigment discoloration, periorbital dermatitis
and sunken eye. For some topical medications, there also can be cardiovascular side effects such as changes in heart rate and arrhythmia
that are caused when medications are absorbed into the circulation system from overdosing both through conjunctiva absorption and
when drugs flow into the nose through the naso-lacrimal duct and are absorbed into the systemic circulation or swallowed. For example,
phenylephrine can cause cardiovascular adverse reactions including an increase in blood pressure, syncope, myocardial infarction,
tachycardia, arrhythmia and subarachnoid hemorrhage. Severe respiratory reactions and cardiac reactions, including death due to
bronchospasm in patients with asthma, and rarely death in association with cardiac failure, have been reported following systemic
or ophthalmic administration of timolol maleate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">MydCombi
contains phenylephrine and tropicamide. However, as demonstrated in our Phase III study for this product candidate, patients administering
MydCombi reported few ocular adverse events and no systemic adverse events when they administered our microdosed product candidate.
Compared with historical data for traditional eye drops, MydCombi appeared to be much better tolerated, with low systemic absorption
of phenylephrine alone.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">With the
Optejet platform technology, we believe that the known adverse event profile of pilocarpine, including headaches, also may be moderated
to make MicroLine the preferred choice for presbyopia over other potential pilocarpine drop options. The same is true with MicroPine,
where we believe that microdosing may result in a better tolerated product for children using topical ophthalmic atropine.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>Our Solution: The Optejet</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: -3.5in; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="tm211152d1_10ksp1img001.jpg" ALT=""><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: 0.5in"><B><IMG SRC="tm211152d1_10ksp1img002.jpg" ALT="">&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Optejet dispenser
delivers doses of 6&thinsp;&ndash;&thinsp;8 &micro;L, directly coating the corneal surface where 80% of intraocular drug penetration
occurs. We believe that microdosing may reduce drug and toxic preservative exposure by more than 75%, thus reducing ocular irritation,
and resulting in potentially gentler treatments without compromising the desired clinical effect. Our approach could also reduce
inadvertent waste associated with poor administration of conventional macrodose drops.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We believe that we
are one of the only companies with clinical stage technology for targeted microdosing of ophthalmic investigational therapies having
fully completed the Phase III clinical studies needed and made an NDA submission. The Optejet is based on MAP, which is also used
for pixel-sharp high-precision inkjet printing. The technology is optimized for and applied in ophthalmic delivery to achieve microdosing
that can be many times more precise than conventional eye droppers. In addition, our smart, electronic system provides the capability
to track when patients administer their medications and deliver this information to patients and physicians via Bluetooth connectivity.
Thus, physicians can make decisions regarding therapeutic regimens with knowledge of patient compliance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The FDA has provided
written feedback that our clinical development activities will be treated as drug development programs, because only the drug comes
into contact with the eye. Consequently, we do not anticipate needing separate FDA approval for the Optejet dispenser or being
required to comply with FDA medical device regulations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Microdose administration
of topical ophthalmic drugs with the Optejet has been tested in preclinical models and clinical trials and shown to provide many
advantages over administrations of eye drops. Key advantages of the Optejet include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>Dose reduction:</I></B>
Our microdose delivery technology is designed to achieve precise volumetric control at the microliter level to deliver 6&ndash;8
 &micro;L, which is the physiologic capacity of the tear film. This compares favorably to the volume of an eye drop (30&ndash;50
 &micro;L), which can result in overdosing, ocular toxicity and systemic leaching into the plasma.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="tm211152d1_10ksp1img003.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>Targeted dose
instillation:</I></B> The Optejet allows for targeted delivery to the ocular surface and cornea, avoiding the conjunctival cul-de-sac.
The micro-jet spray created by the piezo-electric vibrations is columnated and focused to provide accurate delivery to the corneal
surface where the majority of ocular penetration occurs. Additionally, the Optejet is designed with an LED targeting mechanism
to facilitate proper positioning and objective alignment, thus increasing the likelihood of successful dose delivery.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="tm211152d1_10ksp1img002.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>Speed of delivery:</I></B>
Our piezo-print technology is similar to high-precision ink-jet printing. Unlike a simple aerosolized mechanism, the Optejet is
designed with ejection control that creates a fast and targeted micro-jet delivery. Solution is dispensed to the ocular surface
in less than 100 milliseconds between the time the first droplet hits the corneal surface to the completion of dose delivery, which
is faster than the average involuntary blink response time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="tm211152d1_10ksp1img004.jpg" ALT="" STYLE="height: 183px; width: 500px">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>Smart electronics:</I></B>
A key feature of the Optejet is the embedded electronic, smartphone enabled &ldquo;e-health&rdquo; system, which we believe is
the first intelligent electronic delivery system for ophthalmic therapies. Our electronic functions are designed to enable patients
and physicians to track when doses are administered. We believe this technology will improve compliance and chronic disease management
by empowering patients and physicians with access to dynamic, real time monitoring and compliance data for a more intelligent and
personalized therapeutic paradigm.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Clinical Trial Results</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have an established
platform for microdose administration of ophthalmic solutions. Our preclinical and clinical studies suggest that a microdose of
approximately 8 &micro;L of medication results in clinical efficacy comparable to that of traditional eye drops, with the advantages
of fewer ocular side effects and less systemic exposure. We can use our platform technology with either new or existing molecular
entities. We have chosen the latter path for our initial pipeline product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Prior to initiation
of our Phase III clinical studies, we conducted multiple preclinical and early phase studies to validate our piezo-print microdose
delivery platform. Data from a canine model of glaucoma demonstrated more than 40% IOP lowering effect at microdose of 8&ndash;9
 &micro;L latanoprost. Another independent microdose study published in the Journal of Investigative Ophthalmology and Visual Science
in 2014 further demonstrated that 3 &micro;L microdose with timolol 0.5% can reduce systemic plasma levels of the drug by a factor
of 17.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Diurnal IOP Lowering Effect of a Microdose
of Latanoprost Delivered by Pipette vs. Piezo-Print Dispenser in a Canine Model</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="tm211152d1_10ksp1img005.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>IOP Lowering Effect of Micro-Therapeutic
Dose of Latanoprost in Canine Model</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><IMG SRC="tm211152d1_10ksp1img006.jpg" ALT="">&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Phase II EYN-1601
clinical trial compared the mydriatic effect of phenylephrine 10% microdosed (~7 &micro;L in volume) with the Optejet (EYN) to
phenylephrine 10% (PE 10%) and phenylephrine 2.5% (PE 2.5%) eye drops (each ~32 &micro;L in volume) in 24 eyes. At 75-minute peak
dilation, our microdose provided similar mydriatic results (at approximately 1/4 of the dose exposure) to the 10% phenylephrine
drops, and superior activity compared to 2.5% phenylephrine drops.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Shown below is mean
pupil diameter change from baseline for the 24 eyes studied. The asterisk at t=75 min indicates EYN is statistically better than
PE 2.5% (p=0.009).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>Pupil
Diameter,&nbsp;Increase from Baseline, MM</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="tm211152d1_10ksp1img007.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This study was also
informative with regard to systemic drug exposure of these topical treatments. As shown below, microdosed phenylephrine 10% (EYN1)
demonstrated 35&ndash;40% lower plasma levels as compared with phenylephrine 10% eye drops (PE 10%).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="tm211152d1_10ksp1img008.jpg" ALT="" STYLE="height: 344px; width: 650px">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As shown in the table
below, there were also fewer ocular adverse events in the microdosed group (EYN) suggesting an improvement in tolerability as compared
to 10% phenylephrine eye drops (PE 10%).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="font: 10pt Times New Roman, Times, Serif; width: 70%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="9" STYLE="border-bottom: black 1pt solid; padding: 0.25pt 0.25pt 0.5pt; text-align: center"><B>OCULAR ADVERSE EVENTS BY TREATMENT</B></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: black 1pt solid; padding: 0.25pt 0.25pt 0.5pt"><B>Adverse Event Description</B></TD>
    <TD STYLE="padding: 0.25pt 0.25pt 1.25pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; padding: 0.25pt 0.25pt 0.5pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PE 10%</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Eyedrops)</B></P></TD>
    <TD STYLE="padding: 0.25pt 0.25pt 1.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt 0.25pt 1.25pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; border-bottom: black 1pt solid; padding: 0.25pt 0.25pt 0.5pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EYN</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(PE 10% microdose)</B></P></TD>
    <TD STYLE="padding: 0.25pt 0.25pt 1.25pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="width: 64%; padding: 0.25pt">Ocular blurriness</TD>
    <TD STYLE="width: 1%; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="width: 1%; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="width: 15%; padding: 0.25pt; text-align: right">1</TD>
    <TD STYLE="width: 1%; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="width: 1%; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="width: 1%; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="width: 15%; padding: 0.25pt; text-align: right">0</TD>
    <TD STYLE="width: 1%; padding: 0.25pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding: 0.25pt">Ocular burning/stinging/irritation</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; text-align: right">4</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; text-align: right">1</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding: 0.25pt">Ocular dryness</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; text-align: right">2</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; text-align: right">0</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding: 0.25pt"><I>Subtotal by Treatment Group</I></TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; text-align: right">7</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; text-align: right">1</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The EYE-103 study investigated
a combination of phenylephrine and tropicamide microdose treatment administered using the Optejet compared to conventional eye
drops in 102 subjects (204 eyes). In this study, microdosing produced equivalent pupil dilation to eye drops and 91% of participants
preferred medication administration with the Optejet versus eye drops (6% preferred eye drops, while 3% expressed no preference
[p &lt; 0.0001]). On a scale of 1 to 10, with 10 being most favorable, general satisfaction scores were higher with Optejet administration
versus eye drops (9.8 &plusmn; 0.6 for Optejet vs 5.8 &plusmn; 3.0 for eye drops). Ocular comfort scores were nearly two times
better with the Optejet than with eye drops.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="tm211152d1_10ksp1img009.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In 2018, Eyenovia completed
a third early phase trial (EYN-POC-PG-21) to extend the findings of the two previous trials evaluating Optejet administration of
mydriatic agents. This study was a single-center, open-label, prospective, crossover design evaluating the usability, patient tolerability,
and proof-of-concept of microdose administration of commercial latanoprost 0.005% using the Optejet. Thirty healthy volunteer subjects
(60 eyes) were evaluated for eligibility and consented to study participation. Subsequently, at each of three treatment visits,&nbsp;IOP
was measured in the morning. Afterwards, on Treatment Days 1 and 2, a single 8-&micro;L microdose of latanoprost 0.005% ophthalmic
solution was administered to each eye using the Optejet. On the morning of Treatment Day 3, each subject received 2 &times; 8-&micro;L
Optejet microdoses (administered approximately 5 minutes apart) in one eye and the other eye received a single eye drop of latanoprost
0.005% ophthalmic solution. For each treatment day,&nbsp;IOP was measured 1, 7, 12, and 24 hours after receiving medication and
a mean diurnal IOP (DIOP) was calculated from the four readings. As shown below, mean DIOP after medication administration on Days
1 and 2 was lowered by 25.0% and 28.7%, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="tm211152d1_10ksp1img010.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>Mean bilateral DIOP and percent change
in DIOP in eyes dosed using the Optejet through</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>Treatment Day 2 (N = 29 pairs of eyes
from 29 evaluable subjects)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As shown below, on
Day 3, mean DIOP was 35.5% lower than baseline for eyes receiving microdose latanoprost 0.005% using the Optejet, and 35.0% lower
than baseline for eyes receiving a single drop of latanoprost 0.005%.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="tm211152d1_10ksp1img011.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps"><B>DIOP
at Day 3 (N=29 Eyes of 29 Subjects per Treatment)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">No clinically significant
changes were noted in slit lamp observations (including hyperemia) for any subjects who received study treatment and no adverse
events were reported. Subjects reported no-to-negligible ocular discomfort after medication administration using the Optejet.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Investigator-administered
medication using the Optejet was evaluated in 60 eyes (1 spray/eye) on Days 1 and 2, and in 30 eyes (2 sprays/eye) on Day 3. Optejet
administration was successful on the first attempt in 172 of the 180 cases (96%). Subject head movement and/or blinking and investigator
proficiency with Optejet use resulted in the need for additional administration in the remaining 4% of cases, the majority of
which (6/8) occurred on Day 1. Administration success was achieved on the first attempt on all Day 3 cases. There were no reports
of unintentional overdosing, tear fluid overflow, or the dispenser nozzle touching the eye.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Split-Segment; Name: 2 -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In a separate evaluation,
subjects were trained on Optejet self-administration with sterile water and then asked to demonstrate Optejet use in each eye during
the afternoon of each treatment day. By the afternoon of Day 3, qualified Eyenovia representatives judged that almost 90% of subjects
were able to demonstrate accurate self-administration using the Optejet.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This study demonstrated
Optejet medication administration to be easy to perform, safe, and comfortable to study subjects. Additionally, Optejet microdose
administration of 0.005% latanoprost resulted in mean DIOP reduction similar to reported literature for use of latanoprost 0.005%
ophthalmic solution administered as traditional eye drops.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Based on the results
of these studies further validating microdose delivery of ophthalmic medication, we initiated Phase III programs in mydriasis in
late 2018 and progressive myopia in 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Our Product Candidates</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Eyenovia is currently
focused on three programs: MicroLine (for presbyopia), MicroPine (for progressive myopia) and MydCombi (for mydriasis).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>MicroLine</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">MicroLine is our proprietary
microdosed version of pilocarpine, a well understood ophthalmic medication that can dose-dependently induce miosis, or a contraction
of the pupil. It is a direct acting cholinergic parasympathomimetic agent that stimulates muscarinic acetylcholine receptors present
on smooth muscles, including those in the iris and ciliary body. As a result, pilocarpine causes contraction of the iris sphincter
muscle, which causes miosis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Reducing pupil size
with pilocarpine has been shown to improve near visual acuity in individuals who have presbyopia. In Benozzi et al, 2012, subjects
aged 45&#8210;50 years who bilaterally self-administered both pilocarpine 1% and diclofenac 0.1% eyedrops every 6 hours during
the day for up to 5 years reported good improvement in near vision without compromising distance vision. Thus, pilocarpine&rsquo;s
miotic effect may be useful in treating the increasingly compromised near vision that parallels the development of presbyopia.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>Background of
Presbyopia and Market Opportunity</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Presbyopia is the gradual
decrease in the ability of the eye&rsquo;s natural lens to accommodate in near vision, resulting in a loss of focus on near objects.
In general, onset is around age 40 and is almost universal in adults over the age of 60. In the United States, there are approximately
113 million people with presbyopia; 53 million of them are between the ages of 40 and 55.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For many people, presbyopia
is among the first overt signs of aging. There are psychological factors accompanying the use of spectacles and bifocals for the
first time, as well as situational inconvenience for either not being able to see well or having to use a vision aiding device.
With MicroLine, we plan to introduce a pharmaceutical option for improving near vision that can work as a companion to spectacles,
for when patients wish not to use their reading glasses. Our market research indicates the highest interest in the product concept
among people aged 40 to 55 years who otherwise have normal vision, representing a potential market of approximately 18 million
people.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>Phase III Clinical
Development Programs</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are evaluating whether
topical ocular microdosing of pilocarpine using the Optejet dispenser in presbyopic individuals can effectively improve near vision
without compromising distance vision and without causing the undesirable side effects of traditionally administered pilocarpine.
We have two Phase III studies, VISION-1 and VISION-2. VISION-1 began enrolling in 2020. The VISION studies will evaluate the safety,
tolerability, and efficacy of an Optejet-administered microdosing of pilocarpine as an ophthalmic spray versus placebo.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 15; Options: NewSection; Value: 14 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>MicroPine</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A key therapeutic program
for Eyenovia is our first-in-class topical treatment for progressive myopia, a back-of-the-eye disease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>Background of
Progressive Myopia and Market Opportunity</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Myopia is an ocular
disorder that results in blurry vision when looking at distant objects. This happens when the eyeball is too long or corneal curvature
is too steep causing light entering the eye to be incorrectly focused. Myopia is one of the most common refractive errors seen
in children. Myopia that is present in young children tends to increase through the school years. As myopia progresses, so does
the risk of retinal detachment, cataracts, myopia maculopathy and even blindness. It is estimated that over 25 million children
in the United States suffer from progressive myopia, with approximately 5 million children being at high risk.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Examples of Retinal Changes Due to Myopia</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="tm211152d1_10ksp2img001.jpg" ALT="" STYLE="height: 108pt; width: 106.5pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Progressive Myopia with Retinal Atrophy
Changes</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="tm211152d1_10ksp2img002.jpg" ALT="" STYLE="height: 132pt; width: 330.75pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">While currently there
are no FDA-approved therapies for myopia progression, there is growing evidence of the therapeutic benefit of topical atropine
ophthalmic solution, an anticholinergic agent used for pupil dilation and treatment of lazy eye, as a treatment to slow progression.
Academic groups have demonstrated that low dose atropine solution reduces myopia progression 60-70%, with sustained effect through
three years. A recent therapeutic evidence assessment and review by the American Academy of Ophthalmology, indicates Level 1 (highest)
evidence of efficacy for low dose atropine for reduction of progressive myopia (Ophthalmology 2017;124:1857-1866; Ophthalmology
2016; 123(2)&nbsp;391:399)). While atropine 1% ophthalmic solution is FDA-approved and commercially available in the United States
for pupil dilation and treatment of lazy eye, commonly reported side effects such as burning and stinging during drop administration,
and blurred vision and light sensitivity associated with its use make it undesirable for the treatment of progressive myopia in
the pediatric population, thus impeding the drug&rsquo;s clinical utility and adoption for myopia progression.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 16; Value: 14 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="tm211152d1_10ksp2img003.jpg" ALT="" STYLE="height: 246pt; width: 355.5pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our MicroPine program involves the development
of a micro-formulation (dilute and low volume) of atropine ophthalmic solution for reduction of myopia progression in children.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>Phase III Clinical
Development Program</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The FDA accepted Eyenovia&rsquo;s
IND to initiate our single Phase III registration trial of MicroPine (the CHAPERONE study) to reduce the progression of myopia in children.
Eyenovia enrolled its first patient in the CHAPERONE study in June&nbsp;2019 and expects enrollment to be completed in late 2021. The
trial is a U.S.-based, multi-center, randomized, double-masked study enrolling more than 400 children and adolescents. Participants will
be equally randomized to receive nightly treatment with either of two MicroPine treatment concentrations or a placebo control arm. The
primary assessment of efficacy is based on reduction in myopia progression after 3 years of medication use. If the primary objectives
of our Phase III study are met, we plan to submit an NDA based on this study as well as existing literature demonstrating the efficacy
of low-dose atropine to reduce the progression of myopia in children to the FDA for marketing approval of MicroPine to slow the progression
of myopia under the 505(b)(2)&nbsp;pathway.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>MydCombi</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">MydCombi is a unique
fixed combination micro-formulation product candidate for mydriasis (eye dilation) intended to facilitate the over one hundred
million estimated office-based comprehensive and diabetic eye exams and four million ophthalmic surgical dilations performed every
year in the United States. Our fixed combination product candidate has been developed to facilitate efficient pupil dilation with
the potential to reduce unintended effects of conventionally administered mydriatic agents. We believe the market for MydCombi
exceeds $250 million in the United States alone.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B><I>Background of Mydriasis and Market
Opportunity</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There are over an estimated
one hundred million topical mydriatic applications performed every year as a required part of the comprehensive dilated eye exam
and standard retina fundoscopy for diabetic retinopathy screening, macular degeneration evaluation, glaucoma optic disc evaluation
and many other back-of-the-eye conditions. There are an additional estimated four million applications for ocular surgery. Most
optometrist and ophthalmologist offices maintain bottles of both phenylephrine and tropicamide eyedrops and use the drops in combination.
Each bottle is used on multiple patients, which carries a risk of contamination and ocular infection. The bottles are purchased
directly from suppliers and are not subject to insurance reimbursement. Our combination therapy, if approved, will allow the purchase
of one product for eye dilation. Additionally, the Optejet does not come in direct contact with the eye, thus minimizing the risk
of infection.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 17; Value: 14 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Most dilated eye exams
require two separate topical pharmacologic agents/drops be administered sequentially (tropicamide, followed by phenylephrine).
All current mydriatic formulations use conventional macrodose drop delivery (30&ndash;50 &micro;L), which can significantly overdose
the ocular surface whose physiologic capacity is only 6&ndash;8 &micro;L. Studies demonstrate that standard macrodosed pharmacologic
dilation is associated with significant ocular discomfort and mild-moderate eye pain. On the standard visual analogue scale for
pain, such discomfort can exceed the levels of pain associated with a flu vaccine subcutaneous injection. Additionally, there are
systemic safety concerns with mydriatic macrodosing for retinopathy of prematurity retinal screening and pediatric dilated eye
exams. Studies comparing microdosed phenylephrine and cyclopentolate to traditional eye drops (30&ndash;50 &micro;L drop size)
in premature babies and in full-term infants have shown equivalent pupil dilation with drop sizes ranging from 5&ndash;8 &micro;L
while reducing systemic levels by more than 50%.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">With millions of patients
exposed to mydriatic pharmacologic agents every year, we are developing a microdose alternative whereby the Optejet can be deployed
to reduce ocular and systemic exposure by more than 75%. This potential improvement stems from lowering the dose from the 30&ndash;50
 &micro;L in standard drops to just 8 &micro;L with MicroStat combined with targeted delivery to the ocular surface. We expect to
achieve similar mydriatic activity as drops without the high incidence of unwanted side effects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Pharmacologic mydriasis: dilated pupil
after application</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="tm211152d1_10ksp2img004.jpg" ALT="" STYLE="height: 103.5pt; width: 214.5pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Phase III Clinical Development Program</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We completed the Phase
III clinical trials of fixed-combination tropicamide 1% and phenylephrine 2.5% administered using the Optejet for mydriasis in
November&nbsp;2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The MicroStat program
consisted of two Phase III randomized, controlled, cross-over clinical studies evaluating pupil dilation with our fixed combination
product (MicroStat) in comparison with the individual drug components (phenylephrine 2.5% and tropicamide 1%, respectively) (the
MIST-1 study), and with a placebo (the MIST-2 study). The primary endpoint for each study was the mean change in pupil diameter
at 35 minutes post-drug administration.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The MIST-1 study was
a double-masked, active-controlled, three-period cross-over superiority study evaluating MicroStat ophthalmic solution versus the
two individual drug components contained in MicroStat (phenylephrine 2.5% and tropicamide 1% ophthalmic solutions). All study drugs
were administered using the Optejet.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Volunteer participants
were evaluated for study eligibility during a screening visit and enrolled after providing study consent. Subjects meeting all
inclusion/exclusion criteria were scheduled for three treatment visits, which occurred at least two days, but no more than seven
days apart. At each treatment visit, baseline measurements were taken, then one of the three study drugs was administered to both
eyes in two separate instances, approximately five minutes apart. Afterwards, efficacy and safety assessments were performed at
specific time intervals, including pupil diameter measured by digital pupillometry in highly photopic conditions established by
using a fully-charged transilluminator at the brightest setting. Subjects were equally randomized to receive all three treatments
according to one of the six possible sequences of study drug administration.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 18; Value: 14 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The MIST-1 study was
double-masked so that there were no differences in drug presentation. Study drug administration was performed by seven different
trained personnel during the trial. To maintain masking, personnel who administered study drug were not allowed to perform post-drug
administration ophthalmic assessments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A total of 64 subjects
were randomized to receive the study drug. Two subjects withdrew after the first treatment visit; therefore, the resulting per-protocol
analysis population consisted of 62 subjects (124 eyes). Mean pupil diameter for each eye at baseline and at 35 minutes post-drug
administration is shown graphically below. At 35 minutes, the treatment group difference between MicroStat and tropicamide 1% was
0.440 mm (SE 0.1839), which was statistically significant (p = 0.0183). The treatment group difference between MicroStat and phenylephrine
2.5% at the same timepoint was 3.638 mm (SE 0.1817), which was also statistically significant (p &lt;0.0001). Since the null hypothesis
was rejected for both sets of comparisons, the primary endpoint was met.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Pupil Diameter by Treatment at Baseline
and 35 Minutes<BR>
(PP Population)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="tm211152d1_10ksp2img005.jpg" ALT="" STYLE="height: 189pt; width: 278.25pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Mean &plusmn; Standard Deviation</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Tx A = phenylephrine 2.5%-tropicamide 1%;
Tx B = tropicamide 1%; Tx C = phenylephrine 2.5%.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As shown below, at
35 minutes post-drug administration, MicroStat achieved a clinically meaningful pupil diameter &ge; 6.0 mm in 95.2% of right eyes
and 93.5% of left eyes compared to a lower proportion for tropicamide 1% (79.0% and 77.4% of right and left eyes, respectively)
and for phenylephrine 2.5% (1.6% for both right and left eyes). MicroStat also achieved a pupil diameter &ge; 7.0 mm in 67.7% of
right and left eyes compared to a lower proportion for tropicamide 1% (43.5% and 41.9% or right and left eyes, respectively) and
for phenylephrine 2.5% (0% for right and left eyes).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Proportion of Eyes Achieving Pupil Diameter
 &ge; 6.0 mm and &ge; 7.0 mm at 35 Minutes<BR>
(PP Population)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="margin-left: 0.5in; font: 10pt Times New Roman, Times, Serif; width: 90%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; border-bottom: black 1pt solid; padding: 0.25pt 0.25pt 0.5pt; font-size: 10pt"><B>35 Min Post Dose</B></TD>
    <TD STYLE="white-space: nowrap; padding: 0.25pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="white-space: nowrap; border-bottom: black 1pt solid; padding: 0.25pt 0.25pt 0.5pt; font-size: 10pt; text-align: center"><B>MicroStat</B></TD>
    <TD STYLE="white-space: nowrap; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding: 0.25pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="white-space: nowrap; border-bottom: black 1pt solid; padding: 0.25pt 0.25pt 0.5pt; font-size: 10pt; text-align: center"><B>Tropicamide 1%</B></TD>
    <TD STYLE="white-space: nowrap; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding: 0.25pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="white-space: nowrap; border-bottom: black 1pt solid; padding: 0.25pt 0.25pt 0.5pt; font-size: 10pt; text-align: center"><B>Phenylephrine 2.5%</B></TD>
    <TD STYLE="white-space: nowrap; padding: 0.25pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; border-bottom: black 1pt solid; padding: 0.25pt 0.25pt 0.5pt; font-size: 10pt"><B>Combined Visits<BR>
(1, 2, 3)</B></TD>
    <TD STYLE="white-space: nowrap; padding: 0.25pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; border-bottom: black 1pt solid; padding: 0.25pt 0.25pt 0.5pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>OD</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(N=62)</B></P></TD>
    <TD STYLE="white-space: nowrap; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding: 0.25pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; border-bottom: black 1pt solid; padding: 0.25pt 0.25pt 0.5pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>OS</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(N=62)</B></P></TD>
    <TD STYLE="white-space: nowrap; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding: 0.25pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; border-bottom: black 1pt solid; padding: 0.25pt 0.25pt 0.5pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>OD</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(N=62)</B></P></TD>
    <TD STYLE="white-space: nowrap; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding: 0.25pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; border-bottom: black 1pt solid; padding: 0.25pt 0.25pt 0.5pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>OS</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(N=62)</B></P></TD>
    <TD STYLE="white-space: nowrap; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding: 0.25pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; border-bottom: black 1pt solid; padding: 0.25pt 0.25pt 0.5pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>OD</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(N=62)</B></P></TD>
    <TD STYLE="white-space: nowrap; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding: 0.25pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; border-bottom: black 1pt solid; padding: 0.25pt 0.25pt 0.5pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>OS</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(N=62)</B></P></TD>
    <TD STYLE="white-space: nowrap; padding: 0.25pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="white-space: nowrap; padding: 0.25pt; font-size: 10pt">Pupil diameter &ge; 6.0 mm</TD>
    <TD STYLE="white-space: nowrap; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding: 0.25pt; font-size: 10pt; text-align: right">59 (95.2</TD>
    <TD STYLE="white-space: nowrap; padding: 0.25pt; font-size: 10pt">)%</TD>
    <TD STYLE="white-space: nowrap; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding: 0.25pt; font-size: 10pt; text-align: right">58 (93.5</TD>
    <TD STYLE="white-space: nowrap; padding: 0.25pt; font-size: 10pt">)%</TD>
    <TD STYLE="white-space: nowrap; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding: 0.25pt; font-size: 10pt; text-align: right">49 (79.0</TD>
    <TD STYLE="white-space: nowrap; padding: 0.25pt; font-size: 10pt">)%</TD>
    <TD STYLE="white-space: nowrap; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding: 0.25pt; font-size: 10pt; text-align: right">48 (77.4</TD>
    <TD STYLE="white-space: nowrap; padding: 0.25pt; font-size: 10pt">)%</TD>
    <TD STYLE="white-space: nowrap; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding: 0.25pt; font-size: 10pt; text-align: right">1 (1.6</TD>
    <TD STYLE="white-space: nowrap; padding: 0.25pt; font-size: 10pt">)%</TD>
    <TD STYLE="white-space: nowrap; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding: 0.25pt; font-size: 10pt; text-align: right">1 (1.6</TD>
    <TD STYLE="white-space: nowrap; padding: 0.25pt; font-size: 10pt">)%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="white-space: nowrap; padding: 0.25pt; font-size: 10pt">Pupil diameter &lt; 6.0 mm</TD>
    <TD STYLE="white-space: nowrap; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding: 0.25pt; font-size: 10pt; text-align: right">3 (4.8</TD>
    <TD STYLE="white-space: nowrap; padding: 0.25pt; font-size: 10pt">)%</TD>
    <TD STYLE="white-space: nowrap; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding: 0.25pt; font-size: 10pt; text-align: right">4 (6.5</TD>
    <TD STYLE="white-space: nowrap; padding: 0.25pt; font-size: 10pt">)%</TD>
    <TD STYLE="white-space: nowrap; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding: 0.25pt; font-size: 10pt; text-align: right">13 (21.0</TD>
    <TD STYLE="white-space: nowrap; padding: 0.25pt; font-size: 10pt">)%</TD>
    <TD STYLE="white-space: nowrap; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding: 0.25pt; font-size: 10pt; text-align: right">14 (22.6</TD>
    <TD STYLE="white-space: nowrap; padding: 0.25pt; font-size: 10pt">)%</TD>
    <TD STYLE="white-space: nowrap; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding: 0.25pt; font-size: 10pt; text-align: right">61 (98.4</TD>
    <TD STYLE="white-space: nowrap; padding: 0.25pt; font-size: 10pt">)%</TD>
    <TD STYLE="white-space: nowrap; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding: 0.25pt; font-size: 10pt; text-align: right">61 ( 98.4</TD>
    <TD STYLE="white-space: nowrap; padding: 0.25pt; font-size: 10pt">)%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="white-space: nowrap; width: 34%; padding: 0.25pt; font-size: 10pt">Pupil diameter &ge; 7.0 mm</TD>
    <TD STYLE="white-space: nowrap; width: 1%; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; width: 1%; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; width: 8%; padding: 0.25pt; font-size: 10pt; text-align: right">42 (67.7</TD>
    <TD STYLE="white-space: nowrap; width: 1%; padding: 0.25pt; font-size: 10pt">)%</TD>
    <TD STYLE="white-space: nowrap; width: 1%; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; width: 1%; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; width: 8%; padding: 0.25pt; font-size: 10pt; text-align: right">42 (67.7</TD>
    <TD STYLE="white-space: nowrap; width: 1%; padding: 0.25pt; font-size: 10pt">)%</TD>
    <TD STYLE="white-space: nowrap; width: 1%; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; width: 1%; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; width: 8%; padding: 0.25pt; font-size: 10pt; text-align: right">27 (43.5</TD>
    <TD STYLE="white-space: nowrap; width: 1%; padding: 0.25pt; font-size: 10pt">)%</TD>
    <TD STYLE="white-space: nowrap; width: 1%; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; width: 1%; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; width: 8%; padding: 0.25pt; font-size: 10pt; text-align: right">26 (41.9</TD>
    <TD STYLE="white-space: nowrap; width: 1%; padding: 0.25pt; font-size: 10pt">)%</TD>
    <TD STYLE="white-space: nowrap; width: 1%; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; width: 1%; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; width: 8%; padding: 0.25pt; font-size: 10pt; text-align: right">0</TD>
    <TD STYLE="white-space: nowrap; width: 1%; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; width: 1%; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; width: 1%; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; width: 8%; padding: 0.25pt; font-size: 10pt; text-align: right">0</TD>
    <TD STYLE="white-space: nowrap; width: 1%; padding: 0.25pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="white-space: nowrap; padding: 0.25pt; font-size: 10pt">Pupil diameter &lt; 7.0 mm</TD>
    <TD STYLE="white-space: nowrap; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding: 0.25pt; font-size: 10pt; text-align: right">20 (32.3</TD>
    <TD STYLE="white-space: nowrap; padding: 0.25pt; font-size: 10pt">)%</TD>
    <TD STYLE="white-space: nowrap; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding: 0.25pt; font-size: 10pt; text-align: right">20 (32.3</TD>
    <TD STYLE="white-space: nowrap; padding: 0.25pt; font-size: 10pt">)%</TD>
    <TD STYLE="white-space: nowrap; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding: 0.25pt; font-size: 10pt; text-align: right">35 (56.5</TD>
    <TD STYLE="white-space: nowrap; padding: 0.25pt; font-size: 10pt">)%</TD>
    <TD STYLE="white-space: nowrap; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding: 0.25pt; font-size: 10pt; text-align: right">36 (58.1</TD>
    <TD STYLE="white-space: nowrap; padding: 0.25pt; font-size: 10pt">)%</TD>
    <TD STYLE="white-space: nowrap; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding: 0.25pt; font-size: 10pt; text-align: right">62 (100.0</TD>
    <TD STYLE="white-space: nowrap; padding: 0.25pt; font-size: 10pt">)%</TD>
    <TD STYLE="white-space: nowrap; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding: 0.25pt; font-size: 10pt; text-align: right">62 (100.0</TD>
    <TD STYLE="white-space: nowrap; padding: 0.25pt; font-size: 10pt">)%</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The rate of treatment
emergent adverse events, or TEAEs, was low, and consistent with those observed with commercially available dilating eye drops (e.g.
blurry vision and stinging). Two TEAEs were reported in the MicroStat eyes, while four TEAEs were reported in each of the other
two treatment groups. All events were mild in nature. No non-ocular adverse events were reported.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 19; Value: 14 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The MIST-2 Study was
a multi-center, double-masked, placebo-controlled, three-period crossover superiority study evaluating MicroStat ophthalmic solution
versus placebo. Both study drugs were administered using the Optejet.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Volunteer participants
were evaluated for study eligibility during a screening visit and enrolled after providing study consent. Subjects meeting all
inclusion/exclusion criteria were scheduled for three treatment visits, which occurred at least two days, but no more than seven
days apart. A two-sequence, three-period crossover design was used. At each treatment visit, baseline measurements were taken,
then either the investigational drug or the placebo was administered to both eyes in two separate instances, approximately five
minutes apart. Only one study drug was administered per treatment visit, and subjects were equally randomized to one of two sequences,
ABB and BAA, where A was the Eyenovia fixed combination and B was placebo. Afterwards, efficacy and safety assessments were performed
at specific time intervals, including pupil diameter measured by digital pupillometry in highly photopic conditions established
by using a fully-charged transilluminator at the brightest setting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Like MIST-1, this study
was double-masked so that there were no differences in drug presentation. Study drug administration was performed by five different
trained personnel and, to maintain masking, personnel who administered study drug were not allowed to perform post-drug administration
ophthalmic assessments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A total of 70 subjects
at two investigational sites were randomized to receive study drug. One subject withdrew after the first treatment visit; therefore,
the resulting per-protocol analysis population consisted of 69 subjects (138 eyes). Mean pupil diameter for each eye at baseline
and at 35 minutes post-drug administration is shown graphically below. At 35 minutes, the treatment group difference between MydCombi
and placebo was 4.63 mm (SE 0.0544), which was highly statistically significant (p &lt; 0.0001); consequently, the null hypothesis
was rejected and the primary endpoint was met.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Pupil Diameter by Eye and Treatment at
Baseline and 35 Minutes<BR>
(PP Population)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="tm211152d1_10ksp2img006.jpg" ALT="" STYLE="height: 185.25pt; width: 327.75pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0.5in">Mean &plusmn; Standard Deviation</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">As shown in the table below, at 35 minutes
post-drug administration, MydCombi achieved a clinically meaningful pupil diameter &ge; 6.0 mm in 92.8%% of right eyes and 94.2%
of left eyes and pupil diameter &ge; 7.0 mm in 69.6% of right and 68.1% of left eyes. None of the eyes in the placebo group achieved
similar dilation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 20; Value: 14 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Proportion of Eyes Achieving Pupil Diameter
 &ge; 6.0 mm and &ge; 7.0 mm at 35 Minutes<BR>
(PP Population)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="font: 10pt Times New Roman, Times, Serif; width: 85%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; border-bottom: black 1pt solid; padding: 0.25pt 0.25pt 0.5pt; font-size: 10pt"><B>35 Min Post Dose</B></TD>
    <TD STYLE="white-space: nowrap; padding: 0.25pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="white-space: nowrap; border-bottom: black 1pt solid; padding: 0.25pt 0.25pt 0.5pt; font-size: 10pt; text-align: center"><B>MydCombi</B></TD>
    <TD STYLE="white-space: nowrap; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding: 0.25pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="white-space: nowrap; border-bottom: black 1pt solid; padding: 0.25pt 0.25pt 0.5pt; font-size: 10pt; text-align: center"><B>Placebo</B></TD>
    <TD STYLE="white-space: nowrap; padding: 0.25pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; border-bottom: black 1pt solid; padding: 0.25pt 0.25pt 0.5pt; font-size: 10pt"><B>Combined Visits (1, 2, 3)</B></TD>
    <TD STYLE="white-space: nowrap; padding: 0.25pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; border-bottom: black 1pt solid; padding: 0.25pt 0.25pt 0.5pt; font-size: 10pt; text-align: center"><B>OD (N=69)</B></TD>
    <TD STYLE="white-space: nowrap; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding: 0.25pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; border-bottom: black 1pt solid; padding: 0.25pt 0.25pt 0.5pt; font-size: 10pt; text-align: center"><B>OS (N=69)</B></TD>
    <TD STYLE="white-space: nowrap; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding: 0.25pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; border-bottom: black 1pt solid; padding: 0.25pt 0.25pt 0.5pt; font-size: 10pt; text-align: center"><B>OD (N=69)</B></TD>
    <TD STYLE="white-space: nowrap; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding: 0.25pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; border-bottom: black 1pt solid; padding: 0.25pt 0.25pt 0.5pt; font-size: 10pt; text-align: center"><B>OS (N=69)</B></TD>
    <TD STYLE="white-space: nowrap; padding: 0.25pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="white-space: nowrap; width: 48%; padding: 0.25pt; font-size: 10pt; text-align: justify">Pupil diameter &ge; 6.0 mm</TD>
    <TD STYLE="white-space: nowrap; width: 1%; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; width: 1%; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; width: 10%; padding: 0.25pt; font-size: 10pt; text-align: right">64 (92.8</TD>
    <TD STYLE="white-space: nowrap; width: 1%; padding: 0.25pt; font-size: 10pt">)%</TD>
    <TD STYLE="white-space: nowrap; width: 1%; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; width: 1%; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; width: 10%; padding: 0.25pt; font-size: 10pt; text-align: right">65 (94.2</TD>
    <TD STYLE="white-space: nowrap; width: 1%; padding: 0.25pt; font-size: 10pt">)%</TD>
    <TD STYLE="white-space: nowrap; width: 1%; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; width: 1%; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; width: 10%; padding: 0.25pt; font-size: 10pt; text-align: right">0</TD>
    <TD STYLE="white-space: nowrap; width: 1%; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; width: 1%; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; width: 1%; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; width: 10%; padding: 0.25pt; font-size: 10pt; text-align: right">0</TD>
    <TD STYLE="white-space: nowrap; width: 1%; padding: 0.25pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="white-space: nowrap; padding: 0.25pt; font-size: 10pt; text-align: justify">Pupil diameter &lt; 6.0 mm</TD>
    <TD STYLE="white-space: nowrap; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding: 0.25pt; font-size: 10pt; text-align: right">5 (7.2</TD>
    <TD STYLE="white-space: nowrap; padding: 0.25pt; font-size: 10pt">)%</TD>
    <TD STYLE="white-space: nowrap; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding: 0.25pt; font-size: 10pt; text-align: right">4 (5.8</TD>
    <TD STYLE="white-space: nowrap; padding: 0.25pt; font-size: 10pt">)%</TD>
    <TD STYLE="white-space: nowrap; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding: 0.25pt; font-size: 10pt; text-align: right">69 (100.0</TD>
    <TD STYLE="white-space: nowrap; padding: 0.25pt; font-size: 10pt">)%</TD>
    <TD STYLE="white-space: nowrap; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding: 0.25pt; font-size: 10pt; text-align: right">69 (100.0</TD>
    <TD STYLE="white-space: nowrap; padding: 0.25pt; font-size: 10pt">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="white-space: nowrap; padding: 0.25pt; font-size: 10pt; text-align: justify">Pupil diameter &ge; 7.0 mm</TD>
    <TD STYLE="white-space: nowrap; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding: 0.25pt; font-size: 10pt; text-align: right">48 (69.6</TD>
    <TD STYLE="white-space: nowrap; padding: 0.25pt; font-size: 10pt">)%</TD>
    <TD STYLE="white-space: nowrap; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding: 0.25pt; font-size: 10pt; text-align: right">47 (68.1</TD>
    <TD STYLE="white-space: nowrap; padding: 0.25pt; font-size: 10pt">)%</TD>
    <TD STYLE="white-space: nowrap; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding: 0.25pt; font-size: 10pt; text-align: right">0</TD>
    <TD STYLE="white-space: nowrap; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding: 0.25pt; font-size: 10pt; text-align: right">0</TD>
    <TD STYLE="white-space: nowrap; padding: 0.25pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="white-space: nowrap; padding: 0.25pt; font-size: 10pt; text-align: justify">Pupil diameter &lt; 7.0 mm</TD>
    <TD STYLE="white-space: nowrap; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding: 0.25pt; font-size: 10pt; text-align: right">21 (30.4</TD>
    <TD STYLE="white-space: nowrap; padding: 0.25pt; font-size: 10pt">)%</TD>
    <TD STYLE="white-space: nowrap; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding: 0.25pt; font-size: 10pt; text-align: right">22 (31.9</TD>
    <TD STYLE="white-space: nowrap; padding: 0.25pt; font-size: 10pt">)%</TD>
    <TD STYLE="white-space: nowrap; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding: 0.25pt; font-size: 10pt; text-align: right">69 (100.0</TD>
    <TD STYLE="white-space: nowrap; padding: 0.25pt; font-size: 10pt">)%</TD>
    <TD STYLE="white-space: nowrap; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding: 0.25pt; font-size: 10pt; text-align: right">69 (100.0</TD>
    <TD STYLE="white-space: nowrap; padding: 0.25pt; font-size: 10pt">)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Two TEAEs (one event
of mild instillation site pain and one event of moderate photophobia) were reported in the MydCombi group, while none were reported
with the use of placebo. No non-ocular adverse events were reported. Essentially pain-free mydriasis was achieved without the use
of a topical anesthetic, which is often the practice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The outcomes of MIST-1
and MIST-2 are consistent. As shown below, in both studies, MydCombi achieved a mean change in pupil size between 4.6 mm and 4.8
mm at 35 minutes post-dose. In both studies, between 93% and 95% of eyes treated with the fixed combination mydriatic drug achieved
a pupil diameter &ge; 6.0 mm at this same timepoint. Additionally, in MIST-1, the median time to maximum post-baseline pupil diameter
with &ge; 1.0 mm increase from baseline for fixed combination solution was 73.0 minutes, while in MIST-2, it was 71.0 minutes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Efficacy of MydCombi in MIST-1 and MIST-2
Studies (PP Populations)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 85%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; padding-bottom: 1pt; padding-left: 0.25pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center; padding-left: 0.25pt">MIST-1</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center; padding-left: 0.25pt">MIST-2</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 68%; font-size: 10pt; text-align: left; padding-left: 0.25pt">Mean change in pupil diameter from baseline at 35 minutes</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 15%; font-size: 10pt; text-align: left; padding-left: 0.25pt">4.6 mm right eyes<BR> 4.7 mm left eyes</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 15%; font-size: 10pt; text-align: left; padding-left: 0.25pt">4.7 mm right eyes<BR> 4.8 mm left eyes</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.25pt">Proportion of eyes with pupil diameter &ge; 6.0 mm at 35 minutes</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.25pt">95.2% of right eyes <BR> 93.5% of left eyes</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.25pt">92.8% of right eyes <BR> 94.2% of left eyes</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.25pt">Median time to maximum post-baseline pupil diameter with &ge; 1.0 mm increase from baseline</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; padding-left: 0.25pt">73.0 minutes</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; padding-left: 0.25pt">71.0 minutes</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The consistency of
these results validates the robustness of the study designs and demonstrates the impressive treatment effect of MydCombi. More
generally, these outcomes serve to further validate the bioavailability and efficacy of Optejet drug administration to the ocular
surface.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">With the primary objectives
of our Phase III program met, in December&nbsp;2020, we submitted an NDA to the FDA for marketing approval in the United States.
In March&nbsp;2021, the FDA accepted our NDA with an expected PDUFA date of October&nbsp;28, 2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Our Technology</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Optejet comes in
two parts:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify">the base contains the electronic components which enable generation of control signals designed to ensure consistent, accurate columnated arrays of micro-droplets, as well as dose tracking via Bluetooth connectivity; and</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify">the disposable cartridge which contains the drug formulation in a primary drug container, targeted dosing system and piezo-driven ejector nozzle, and comes in one-month doses. </TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For administration
of our product candidates, the patient receives both the base and the disposable cartridge. For refills, the patient receives only
the disposable cartridge. Patients deliver their dose by attaching the cartridge to the base, pressing an activation button which
loads a single drug dose, then, holding it between one and two inches from the eye while looking directly into an illuminated circle,
pressing a second button to emit the micro-droplet delivered medication. The micro-droplets are emitted in a quickly repeating
array, that in aggregate form a micro-jet. Solution is dispensed to the ocular surface in less than 100 milliseconds between the
time the first droplet hits the corneal surface to the completion of dose delivery, which is faster than the average involuntary
blink response time. The patient feels a wet sensation on the eye, but does not experience any pain, as demonstrated in studies
to date. Several acute clinical trials have been performed to date that demonstrate the Optejet&rsquo;s usability. As a precise
and quick-delivered microdose, it does not drip down the face or drain down the naso-lacrimal duct thereby minimizing delivery
of extra product or preservatives to the eye. The rechargeable base has intelligent power management and precision designed circuitry
that maximizes battery life allowing for infrequent recharging, while providing consistent dose delivery over the life of each
cartridge.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 21; Value: 14 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our system is based
on piezo-driven printer technology, which is also used for high-precision ink jet printing. In ink jet printing, piezo technology
enables ink to be sprayed with precision to form letters and numbers on paper. Our patented system takes aspects of piezo driven
printer technology, and applies it to the delivery of therapeutics to the eye.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Sales and Marketing</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are taking a staged
approach to the commercialization of our products, retaining rights for MydCombi to potentially optimize the introduction of the
technology to the market, and establishing partnerships with licensees for products that require a larger investment in terms of
sales force and distribution. Our management team and directors, which are leading the commercialization planning of our lead product
candidates in the United States, have substantial experience in the commercialization of ophthalmic therapeutics.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">MydCombi is our first
expected commercial product. MydCombi is a cash-pay pharmaceutical supply, administered and purchased by clinics and doctors for
in-office use. The cost of the product is folded into the established reimbursement for the comprehensive eye exam and thus lends
itself to a single specialty-pharmacy distribution model without the need for formulary negotiations and contracting at the managed
care level. As such, we estimate MydCombi sales and marketing costs will be significantly below that of a conventional prescription-based
pharmaceutical product. As a highly differentiated product with meaningful benefits for both providers and patients, we anticipate
fast adoption, especially because part of our strategy is to maintain good economics for the practice. Lastly, we believe that
we can be successful with a limited in-person sales force as there is no active competition in this space.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">MicroLine is our second
expected product for commercialization. Like MydCombi, MicroLine would also be &ldquo;cash-pay,&rdquo; negating the need for infrastructure
focused on managed care reimbursement. We currently have licensed MicroLine to Arctic Vision for development and commercialization
in Greater China and South Korea. Unless we establish additional partnerships for MicroLine, we plan to expand our sales force
from approximately ten to fifty people in the United States and focus on promotion in the optometrist office. We also plan to leverage
the experience that these offices have had with MydCombi to speed acceptance and prescribing of MicroLine to appropriate patients.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">MicroPine is our third
expected product for commercialization. MicroPine is a more standard therapeutic, likely reimbursed by payers after negotiating
for formulary position. We have licensed MicroPine to Arctic Vision in Greater China and Korea, and to Bausch Health in the United
States and Canada. In both cases, our licensee will be responsible for commercialization within their own sales and marketing structures.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Manufacturing</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For clinical supply,
we currently rely on a combination of limited internal manufacturing capacity and third-party manufacturers located in the United
States and abroad. We manage such production with all our vendors on a purchase order basis. Relationships with vendors of critical
components are governed by applicable service and supply agreements or purchase order terms. We do not currently have long-term
agreements with these manufacturers or any other third-party suppliers. We intend to procure quantities on a purchase order basis
for our clinical production. If any of our existing third-party suppliers should become unavailable to us for any reason, we believe
that there are a number of potential replacements, although we might experience a delay in our ability to obtain alternately sourced
quantities of materials or services due to their unique and specialized nature.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 22; Value: 14 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We plan to use multiple
contract manufacturing organizations, or CMOs, for the potential commercialization of some of our product candidates, as we have
limited internal capacity to produce commercial supplies and might not be able to implement further manufacturing processes internally.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Competition</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The biotechnology and
pharmaceutical industries are characterized by rapidly advancing technologies, intense competition and a strong emphasis on proprietary
products. While we believe that our technologies, knowledge, experience and scientific resources provide us with competitive advantages,
we face potential competition from many different sources. Any product candidates that we successfully develop and commercialize
may also compete with existing therapies and new therapies that may become available in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our potential competitors
include large pharmaceutical and biotechnology companies, and specialty pharmaceutical and generic or biosimilar drug companies.
Many of our competitors have significantly greater financial and human resources and expertise in research and development, manufacturing,
preclinical testing, conducting clinical trials, obtaining regulatory approvals and marketing approved products than we do. Smaller
and other early stage companies may also prove to be significant competitors, particularly through collaborative arrangements with
large and established companies. These third parties compete with us in recruiting and retaining qualified scientific and management
personnel, establishing clinical trial sites and patient enrollment for clinical trials, as well as in acquiring products, product
candidates or other technologies that we may target to in-license or acquire in pursuit of our updated business plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For MydCombi, we are
not aware of any micro-therapeutics nor of any existing FDA-approved phenylephrine-tropicamide topical fixed combination even in
standard macrodose. There are competitive macrodose drop formulations of individual therapeutics such as phenylephrine and tropicamide
for mydriasis by companies such as Akorn, Alcon and others, as well as pharmacies that compound the combination on an individual
basis for physicians.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For MicroLine, we are
not aware of FDA-approved drugs for the improvement of near vision in patients with presbyopia. There are other pharmaceutical
companies developing therapies for presbyopia, none of which makes use of microdosing technology or deliver medication as a spray.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We expect that both
MydCombi and MicroLine would be &ldquo;cash pay&rdquo; products, as MydCombi is purchased directly by offices and used routinely
in eye exams, and MicroLine would be considered an &ldquo;aesthetic&rdquo; prescription product not generally covered by third
party insurance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For MicroPine, we are
not aware of any FDA-approved drugs to slow the progression of myopia. There are other versions of traditional eye drop atropine
under development by other pharmaceutical companies for this indication. There also are versions of compounded topical atropine
that have not been tested for their safety or efficacy that are dispensed on an individual basis to patients.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Intellectual Property</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our success may depend
on our ability to obtain, maintain and enforce our proprietary rights related to our products and other technologies. We must also
operate without infringing the valid, proprietary rights of others while preventing others from infringing our proprietary rights.
We will seek to protect our proprietary position by, among other methods, filing U.S. and foreign patent applications. We may also
rely on trade secrets and know-how for some proprietary methods, methods of manufacture, and systems and devices. We continue innovating
our technologies, and will file appropriate U.S. and foreign patent applications for our future innovations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>Patents</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of December&nbsp;31,
2020, we owned nine U.S. issued and allowed utility patents, one issued design patent, and nine pending U.S. patent applications,
as well as 53 issued foreign patents, 35 pending foreign patent applications, and one pending international PCT application.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 23; Value: 14 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Patent coverage within
the portfolio includes issued and pending patent applications related to the following devices and methods:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify">A piezoelectric device configured to generate an ejected stream of droplets is the subject of one patent family. The device ejects droplets having an average ejected droplet diameter greater than 20 microns and an average initial droplet ejecting velocity between 0.5 m/s and 10 m/s. Furthermore, the stream of droplets is generated with low entrained airflow so that at least 75% of the mass is deposited on the eye. U.S. patents for these devices are expected to expire in 2031.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify">A method of delivering a medicament or solution to an eye with a piezo-ejector device is the subject of another patent family. The method involves delivering an average droplet size of 20 microns to 100 microns in diameter with an average initial droplet ejecting velocity between 1 m/s and 10 m/s to the eye. About 85% to 100% of the ejected mass of droplets is deposited on the eye. U.S. patents for these methods are expected to expire in 2031.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify">A device having a piezo-ejector that generates a directed stream of droplets through specially shaped openings in the piezo-ejector is the subject of still another patent family. The openings provide laminar flow through the openings. Laminar flow is provided by shaping the openings with a gradual slope change so that an external entry radius has a circular shape which reduces airflow while providing laminar flow through the openings. U.S. patents related to these devices are expected to expire in 2033.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify">A piezo-electric ejector device having a microcontroller which auto-tunes the ejector mechanism is the subject of another patent family. The device generates at least one cycle in a range of drive signal frequencies and obtains time-energy product feedback from a decay signal emitted by the actuator. U.S. patents related to these devices are expected to expire in 2033.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify">A method of monitoring the treatment of ophthalmic subjects by capturing images of the eye is the subject of another patent family. Images of the eye are taken which are sufficient to obtain information about the diagnosis or health of the eye. The data is stored and analyzed to monitor treatment. U.S. patents related to this method are expected to expire in 2031.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify">A fluid ejector having a fluid loading plate in parallel arrangement with an ejector mechanism is the subject of patent family patented in Europe. The fluid loading plate forms a capillary separation with the ejector mechanism to generate capillary fluid flow. The fluid loading plate is also attached to the reservoir (at a fluid reservoir interface) and to the ejector mechanism (at an ejector mechanism interface) and may have one or more fluid channels from the fluid reservoir interface to the ejector mechanism interface. The ejector produces a stream of droplets having a droplet diameter greater than 15 microns with the stream having low entrained airflow so that the pressure of the stream will be substantially imperceptible.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The expiry of any patent
depends upon the legal term for patents in that particular country. In the United States, the patent term is generally 20 years
from the earliest claimed filing date of a non-provisional patent application. In the United States, a patent&rsquo;s term may
be lengthened by patent term adjustment which compensates a patentee for administrative delays by the United States Patent and
Trademark Office, or the USPTO, in examining and granting a patent. A patent term may also be shortened if a patent is terminally
disclaimed over another patent or application.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Drug Price Competition
and Patent Term Restoration Act of 1984, or the Hatch-Waxman Act, permits a patent term extension of up to five years beyond the
expiration date of a U.S. patent as partial compensation for the length of time the drug is under regulatory review while the patent
is in force.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A patent term extension
cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval, only one patent applicable
to each regulatory review period may be extended and only those claims covering the approved drug, a method for using it or a method
for manufacturing it may be extended. We cannot provide any assurance that any patent term extension with respect to any U.S. patent
will be obtained and, if obtained, the duration of such extension. Similar patent term extension/reduction provisions are available
in the European Union and other jurisdictions. In the future, if and when our product candidates receive approval by the FDA or
foreign regulatory authorities, we will apply for patent term extensions on issued patents covering our products to the extent
available under the applicable law, depending upon the length of any such clinical trials for any product and other factors. The
expiration dates referred to above are without regard to potential patent term extension or other market exclusivity that may be
available to us. However, we cannot provide any assurances that any such patent term extension of a foreign patent will be obtained
and, if obtained, the duration of such extension.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 24; Value: 14 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In Asia, we have been
granted a patent in each of China and South Korea and two patents in Japan that describe a piezoelectric device configured to generate
an ejected stream of droplets with a particular droplet diameter and ejection velocity. We also have seven additional patents granted
in China, five additional patents granted in Japan, and four patents granted in Singapore, all related to aspects of the piezoelectric
device and methods of using the device.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>Trademarks</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our products are marketed
under trademarks and service marks that are owned by us. The following words are trademarks in our Company&rsquo;s trademark portfolio
and are the subject of either registration, or application for registration, in the United States: EYENOVIA&reg;, OPTEJET&trade;,
EYELATOVA&trade;, EYETANO&trade;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition to the
trademarks noted above, we will file trademark applications for new trademarks registrations to protect our market positions in
the United States and other jurisdictions on an ongoing basis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>Proprietary Technology</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition to patents,
we may rely on trade secrets and proprietary know-how to protect our technology. We endeavor to protect our proprietary technology
and processes in the appropriate manner to maintain their secrecy including confidentiality agreements when dealing with third
parties. We also seek to preserve the integrity and confidentiality of our data and trade secrets by maintaining physical security
of our premises and physical and electronic security of our information technology systems. We also require invention assignment
agreements with our employees, consultants, and contractors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Government Regulation and Product Approvals</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Government authorities
in the United States, at federal, state and local levels, and in other countries and jurisdictions, including the European Union,
extensively regulate, among other things, the research, development, testing, manufacture, quality control, approval, packaging,
storage, recordkeeping, labeling, advertising, promotion, distribution, marketing, post-approval monitoring and reporting, and
import and export of pharmaceutical products. The processes for obtaining regulatory approvals in the United States and in foreign
countries and jurisdictions, along with subsequent compliance with applicable statutes and regulations and other regulatory authorities,
require the expenditure of substantial time and financial resources.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Review and Approval of Drugs in the
United States</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the United States,
the FDA regulates drug products under the Food, Drug, and Cosmetic Act, or FDCA, and implementing regulations. The process of obtaining
regulatory approvals and the subsequent compliance with appropriate federal, state, local and foreign statutes and regulations
requires the expenditure of substantial time and financial resources. The failure to comply with applicable requirements under
the FDCA and other applicable laws at any time during the product development process, approval process or after approval may subject
an applicant and/or sponsor to a variety of administrative or judicial sanctions, including refusal by the FDA to approve pending
applications, withdrawal of an approval, imposition of a clinical hold, issuance of warning letters and other types of letters,
voluntary product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals
of government contracts, restitution, disgorgement of profits, or civil or criminal investigations and penalties brought by the
FDA and the Department of Justice or other governmental entities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">An applicant seeking
approval to market and distribute a new drug product in the United States must typically undertake the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify">completion of preclinical laboratory tests, animal studies and formulation studies in compliance with the FDA&rsquo;s good laboratory practice, or GLP, regulations;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify">submission to the FDA of an IND which must take effect before human clinical trials may begin;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 25; Value: 14 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify">approval by an institutional review board, or IRB, an independent committee charged with protecting the rights and welfare of human research subjects participating in clinical trials, before each clinical trial site may initiate clinical trial enrollment;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify">performance of adequate and well-controlled human clinical trial(s)&nbsp;in accordance with good clinical practices, or GCP, to establish the safety and efficacy of the proposed drug product for each indication;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify">preparation and submission to the FDA of an NDA;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify">review of the product by an FDA advisory committee, where appropriate or if applicable;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify">satisfactory completion of one or more FDA inspections of the manufacturing facility or facilities at which the product, or components thereof, are produced to assess compliance with current Good Manufacturing Practices, or cGMP, requirements and to assure that the facilities, methods and controls are adequate to preserve the product&rsquo;s identity, strength, quality and purity;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify">satisfactory completion of FDA audits of selected clinical trial sites to assure compliance with GCPs and the integrity of the clinical data;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify">payment of user fees, with few exceptions, and securing FDA approval of the NDA; and</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify">compliance with any post-approval requirements, including Risk Evaluation and Mitigation Strategies, or REMS, and post-approval studies required by the FDA.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>Preclinical Studies</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Preclinical studies
include laboratory evaluation of the purity and stability of the manufactured drug substance or active pharmaceutical ingredient
and the formulated drug or drug product, as well as <I>in vitro</I> and animal studies to assess the safety and activity of the
drug for initial testing in humans and to establish a rationale for therapeutic use. The conduct of preclinical studies is subject
to federal regulations and requirements, including GLP regulations. The results of the preclinical tests, together with manufacturing
information, analytical data, any available clinical data or literature and plans for clinical trials, among other things, are
submitted to the FDA as part of an IND. Some long-term preclinical testing, such as animal tests of reproductive adverse events
and carcinogenicity, may continue after the IND is submitted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>The IND and IRB
Processes</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">An IND is an exemption
from the FDCA that allows an unapproved drug to be shipped in interstate commerce for use in an investigational clinical trial
and a request for FDA authorization to administer an investigational drug to humans. Such authorization must be secured prior to
interstate shipment and administration of any new drug that is not the subject of an approved NDA. In support of a request for
an IND, applicants must submit a protocol for each clinical trial and any subsequent protocol amendments must be submitted to the
FDA as part of the IND. In addition, the results of the preclinical tests, together with manufacturing information, analytical
data, any available clinical data or literature and plans for clinical trials, among other things, are submitted to the FDA as
part of an IND. The FDA requires a 30-day waiting period after the acceptance of each IND before clinical trials may begin. This
waiting period is designed to allow the FDA to review the IND to determine whether human research subjects will be exposed to unreasonable
health risks. At any time during this 30-day period, the FDA may raise concerns or questions about the conduct of the clinical
trials as outlined in the IND and impose a clinical hold. In this case, the IND sponsor and the FDA must resolve any outstanding
concerns before clinical trials can begin.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Following commencement
of a clinical trial under an IND, the FDA may also place a clinical hold or partial clinical hold on that clinical trial. A clinical
hold is an order issued by the FDA to the sponsor to delay a proposed clinical investigation or to suspend an ongoing investigation.
A partial clinical hold is a delay or suspension of only part of the clinical work requested under the IND. For example, a specific
protocol or part of a protocol is not allowed to proceed, while other protocols may do so. No more than 30 days after imposition
of a clinical hold or partial clinical hold, the FDA will provide the sponsor a written explanation of the basis for the hold.
Following issuance of a clinical hold or partial clinical hold, an investigation may only resume after the FDA has notified the
sponsor that the investigation may proceed. The FDA will base that determination on information provided by the sponsor correcting
the deficiencies previously cited or otherwise satisfying the FDA that the investigation can proceed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 26; Value: 14 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A sponsor may choose,
but is not required, to conduct a foreign clinical study under an IND. When a foreign clinical study is conducted under an IND,
all FDA IND requirements must be met unless waived. When the foreign clinical study is not conducted under an IND, the sponsor
must ensure that the study complies with FDA certain regulatory requirements in order to use the study as support for an IND or
application for marketing approval. Specifically, such studies must be conducted in accordance with good clinical practice, or
GCP, including review and approval by an independent ethics committee, or IEC, and informed consent from subjects. The FDA&rsquo;s
regulations are intended to help ensure the protection of human subjects enrolled in non-IND foreign clinical studies, as well
as the quality and integrity of the resulting data. They further help ensure that non-IND foreign studies are conducted in a manner
comparable to that required for IND studies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition to the
foregoing IND requirements, an IRB representing each institution participating in the clinical trial must review and approve the
plan for any clinical trial before it commences at that institution, and the IRB must conduct continuing review and reapprove the
study at least annually. The IRB must review and approve, among other things, the study protocol and informed consent information
to be provided to study subjects. An IRB must operate in compliance with FDA regulations. An IRB can suspend or terminate approval
of a clinical trial at its institution, or an institution it represents, if the clinical trial is not being conducted in accordance
with the IRB&rsquo;s requirements or if the product candidate has been associated with unexpected serious harm to patients.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Additionally, some
clinical trials are overseen by an independent group of qualified experts organized by the trial sponsor, known as a data safety
monitoring board or committee. This group provides authorization for whether or not a clinical trial may move forward at designated
check points based on access that only the group maintains to available data from the study. Suspension or termination of development
during any phase of clinical trials can occur if it is determined that the participants or patients are being exposed to an unacceptable
health risk. Other reasons for suspension or termination may be made by us based on evolving business objectives and/or competitive
climate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Information about certain
clinical trials must be submitted within specific timeframes to the National Institutes of Health, or NIH, for public dissemination
on its ClinicalTrials.gov website.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>Human Clinical
Trials in Support of an NDA</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Clinical trials involve
the administration of the investigational product to human subjects under the supervision of qualified investigators in accordance
with GCP requirements, which include, among other things, the requirement that all research subjects provide their informed consent
in writing before their participation in any clinical trial. Clinical trials are conducted in accordance with written study protocols
detailing, among other things, study objectives, participant inclusion and exclusion criteria, the parameters to be used in monitoring
safety and the effectiveness criteria to be evaluated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Human clinical trials
are typically conducted in three sequential phases, which may overlap or be combined:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify">Phase I. The drug is initially introduced into healthy human subjects or, in certain indications such as cancer, patients with the target disease or condition and tested for safety, dosage tolerance, absorption, metabolism, distribution, excretion and, if possible, to gain an early indication of its effectiveness and to determine optimal dosage.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify">Phase II. The drug is administered to a limited patient population to identify possible adverse effects and safety risks, to preliminarily evaluate the efficacy of the product for specific targeted diseases and to determine dosage tolerance and optimal dosage.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify">Phase III. The drug is administered to an expanded patient population, generally at geographically dispersed clinical trial sites, in well-controlled clinical trials to generate enough data to statistically evaluate the efficacy and safety of the product for approval, to establish the overall risk-benefit profile of the product and to provide adequate information for the labeling of the product.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Progress reports detailing
the results of the clinical trials must be submitted at least annually to the FDA and more frequently if serious adverse events
occur. In addition,&nbsp;IND safety reports must be submitted to the FDA for any of the following: serious and unexpected suspected
adverse reactions; findings from other studies or animal or <I>in vitro</I> testing that suggest a significant risk in humans exposed
to the drug; and any clinically important increase in the case of a serious suspected adverse reaction over that listed in the
protocol or investigator brochure. Phase I, Phase II and Phase III clinical trials might not be completed successfully within any
specified period, or at all. Furthermore, the FDA or the sponsor may suspend or terminate a clinical trial at any time on various
grounds, including a finding that the research subjects are being exposed to an unacceptable health risk. Similarly, an IRB can
suspend or terminate approval of a clinical trial at its institution, or an institution it represents, if the clinical trial is
not being conducted in accordance with the IRB&rsquo;s requirements or if the drug has been associated with unexpected serious
harm to patients. The FDA will typically inspect one or more clinical sites to assure compliance with GCP and the integrity of
the clinical data submitted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 27; Value: 14 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Concurrent with clinical
trials, companies often complete additional animal studies and must also develop additional information about the chemistry and
physical characteristics of the drug as well as finalize a process for manufacturing the product in commercial quantities in accordance
with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the drug candidate
and, among other things, must develop methods for testing the identity, strength, quality, purity, and potency of the final drug.
Additionally, appropriate packaging must be selected and tested and stability studies must be conducted to demonstrate that the
drug candidate does not undergo unacceptable deterioration over its shelf life.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>Submission of
an NDA to the FDA</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Assuming successful
completion of required clinical testing and other requirements, the results of the preclinical studies and clinical trials, together
with detailed information relating to the product&rsquo;s chemistry, manufacture, controls and proposed labeling, among other things,
are submitted to the FDA as part of an NDA requesting approval to market the drug product for one or more indications. Under federal
law, the submission of most NDAs is subject to an application user fee, which for federal fiscal year 2021 is $2.9 million for
an application requiring clinical data. The sponsor of an approved NDA is also subject to an annual prescription drug program fee,
which for fiscal year 2021 is $0.3 million. Certain exceptions and waivers are available for some of these fees, such as an exception
from the application fee for drugs with orphan designation and a waiver for certain small businesses. Eyenovia is currently eligible
for a waiver of the application fees under the small business provisions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The FDA conducts a
preliminary review of an NDA within 60 days of its receipt and informs the sponsor by the 74th day after the FDA&rsquo;s receipt
of the submission to determine whether the application is sufficiently complete to permit substantive review. The FDA may request
additional information rather than accept an NDA for filing. In this event, the application must be resubmitted with the additional
information. The resubmitted application is also subject to review before the FDA accepts it for filing. Once the submission is
accepted for filing, the FDA begins an in-depth substantive review. The FDA has agreed to certain performance goals in the review
process of NDAs. Most such applications are meant to be reviewed within 10 months from the date of filing, and most applications
for &ldquo;priority review&rdquo; products are meant to be reviewed within six months of filing. For applications of drug products
that are not new molecular entities, FDA aims to conduct standard reviews within 10 months of receipt of the NDA and priority reviews
within six months of receipt of the NDA. The review process may be extended by the FDA for three additional months to consider
new information or clarification provided by the applicant to address an outstanding deficiency identified by the FDA following
the original submission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Before approving an
NDA, the FDA typically will inspect the facility or facilities where the product is or will be manufactured. These pre-approval
inspections may cover all facilities associated with an NDA submission, including drug component manufacturing (such as active
pharmaceutical ingredients), finished drug product manufacturing, and control testing laboratories. The FDA will not approve an
application unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate
to assure consistent production of the product within required specifications. Additionally, before approving an NDA, the FDA will
typically inspect one or more clinical sites to assure compliance with GCP.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, as a condition
of approval, the FDA may require an applicant to develop a REMS. REMS use risk minimization strategies beyond the professional
labeling to ensure that the benefits of the product outweigh the potential risks. To determine whether a REMS is needed, the FDA
will consider the size of the population likely to use the product, seriousness of the disease, expected benefit of the product,
expected duration of treatment, seriousness of known or potential adverse events, and whether the product is a new molecular entity.
REMS can include medication guides, physician communication plans for healthcare professionals, and elements to assure safe use,
or ETASU. ETASU may include, but are not limited to, special training or certification for prescribing or dispensing, dispensing
only under certain circumstances, special monitoring, and the use of patient registries. The FDA may require a REMS before approval
or post-approval if it becomes aware of a serious risk associated with use of the product. The requirement for a REMS can materially
affect the potential market and profitability of a product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 28; Value: 14 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The FDA may refer an
application for a novel drug to an advisory committee or explain why such referral was not made. Typically, an advisory committee
is a panel of independent experts, including clinicians and other scientific experts, that reviews, evaluates and provides a recommendation
as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendations of an advisory
committee, but it considers such recommendations carefully when making decisions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>The FDA&rsquo;s
Decision on an NDA</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On the basis of the
FDA&rsquo;s evaluation of the NDA and accompanying information, including the results of the inspection of the manufacturing facilities,
the FDA may issue an approval letter or a complete response letter. An approval letter authorizes commercial marketing of the product
with specific prescribing information for specific indications. A complete response letter generally outlines the deficiencies
in the submission and may require substantial additional testing or information in order for the FDA to reconsider the application.
If and when those deficiencies have been addressed to the FDA&rsquo;s satisfaction in a resubmission of the NDA, the FDA will issue
an approval letter. The FDA has committed to reviewing such resubmissions in two or six months depending on the type of information
included. Even with submission of this additional information, the FDA ultimately may decide that the application does not satisfy
the regulatory criteria for approval.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If the FDA approves
a product, it may limit the approved indications for use for the product, require that contraindications, warnings or precautions
be included in the product labeling, require that post-approval studies, including Phase IV clinical trials, be conducted to further
assess the drug&rsquo;s safety after approval, require testing and surveillance programs to monitor the product after commercialization,
or impose other conditions, including distribution restrictions or other risk management mechanisms, including REMS, which can
materially affect the potential market and profitability of the product. The FDA may prevent or limit further marketing of a product
based on the results of post-market studies or surveillance programs. After approval, many types of changes to the approved product,
such as adding new indications, manufacturing changes and additional labeling claims, are subject to further testing requirements
and FDA review and approval.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>Post-Approval
Requirements</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Drugs manufactured
or distributed pursuant to FDA approvals are subject to pervasive and continuing regulation by the FDA, including, among other
things, requirements relating to recordkeeping, periodic reporting, product sampling and distribution, advertising and promotion
and reporting of adverse experiences with the product. After approval, most changes to the approved product, such as adding new
indications or other labeling claims, are subject to prior FDA review and approval.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, drug manufacturers
and other entities involved in the manufacture and distribution of approved drugs are required to register their establishments
with the FDA and state agencies, and are subject to periodic unannounced inspections by the FDA and these state agencies for compliance
with cGMP requirements. Changes to the manufacturing process are strictly regulated and often require prior FDA approval before
being implemented. FDA regulations also require investigation and correction of any deviations from cGMP and impose reporting and
documentation requirements upon the sponsor and any third-party manufacturers that the sponsor may decide to use. Accordingly,
manufacturers must continue to expend time, money, and effort in the area of production and quality control to maintain cGMP compliance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Once an approval is
granted, the FDA may withdraw the approval if compliance with regulatory requirements and standards is not maintained or if problems
occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events
of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may
result in revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical trials
to assess new safety risks; or imposition of distribution or other restrictions under a REMS program. Other potential consequences
include, among other things:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 29; Value: 14 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify">restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market or product recalls;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify">fines, warning letters or holds on post-approval clinical trials;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify">refusal of the FDA to approve pending NDAs or supplements to approved NDAs, or suspension or revocation of product approvals;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify">product seizure or detention, or refusal to permit the import or export of products; or</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify">injunctions or the imposition of civil or criminal penalties.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The FDA strictly regulates
marketing, labeling, advertising and promotion of products that are placed on the market. Drugs may be promoted only for the approved
indications and in accordance with the provisions of the approved label. The FDA and other agencies actively enforce the laws and
regulations prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted off-label uses
may be subject to significant liability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, the distribution
of prescription pharmaceutical products is subject to the Prescription Drug Marketing Act, or PDMA, which regulates the distribution
of drugs and drug samples at the federal level, and sets minimum standards for the registration and regulation of drug distributors
by the states. Both the PDMA and state laws limit the distribution of prescription pharmaceutical product samples and impose requirements
to ensure accountability in distribution.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>Section&nbsp;505(b)(2)&nbsp;NDAs</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NDAs for most new drug
products are based on two full clinical trials which must contain substantial evidence of the safety and efficacy of the proposed
new product. These applications are submitted under Section&nbsp;505(b)(1)&nbsp;of the FDCA. The FDA is, however, authorized to
approve an alternative type of NDA under Section&nbsp;505(b)(2)&nbsp;of the FDCA. This type of application allows the applicant
to rely, in part, on the FDA&rsquo;s previous findings of safety and efficacy for a similar product, or published literature. Specifically,
Section&nbsp;505(b)(2)&nbsp;applies to NDAs for a drug for which the investigations made to show whether or not the drug is safe
for use and effective in use and relied upon by the applicant for approval of the application &ldquo;were not conducted by or for
the applicant and for which the applicant has not obtained a right of reference or use from the person by or for whom the investigations
were conducted.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Thus, Section&nbsp;505(b)(2)&nbsp;authorizes
the FDA to approve an NDA based on safety and effectiveness data that were not developed by the applicant. NDAs filed under Section&nbsp;505(b)(2)&nbsp;may
provide an alternate and potentially more expeditious pathway to FDA approval for new or improved formulations or new uses of previously
approved products. If the Section&nbsp;505(b)(2)&nbsp;applicant can establish that reliance on the FDA&rsquo;s previous approval
is scientifically appropriate, the applicant may eliminate the need to conduct certain preclinical studies or clinical trials of
the new product. The FDA may also require companies to perform additional studies or measurements to support the change from the
approved product. The FDA may then approve the new drug candidate for all or some of the label indications for which the referenced
product has been approved, as well as for any new indication sought by the Section&nbsp;505(b)(2)&nbsp;applicant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>Abbreviated New
Drug Applications for Generic Drugs</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In 1984, with passage
of the Hatch-Waxman Amendments to the FDCA, Congress authorized the FDA to approve generic drugs that are the same as drugs previously
approved by the FDA under the NDA provisions of the statute. To obtain approval of a generic drug, an applicant must submit an
abbreviated new drug application, or ANDA, to the agency. In support of such applications, a generic manufacturer may rely on the
preclinical and clinical testing previously conducted for a drug product previously approved under an NDA, known as the reference-listed
drug, or RLD.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Specifically, in order
for an ANDA to be approved, the FDA must find that the generic version is identical to the RLD with respect to the active ingredients,
the route of administration, the dosage form, and the strength of the drug. At the same time, the FDA must also determine that
the generic drug is &ldquo;bioequivalent&rdquo; to the innovator drug. Under the statute, a generic drug is bioequivalent to an
RLD if&thinsp; &ldquo;the rate and extent of absorption of the drug do not show a significant difference from the rate and extent
of absorption of the listed drug.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 30; Value: 14 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Upon approval of an
ANDA, the FDA indicates whether the generic product is &ldquo;therapeutically equivalent&rdquo; to the RLD in its publication Approved
Drug Products with Therapeutic Equivalence Evaluations, also referred to as the Orange Book. Clinicians and pharmacists consider
a therapeutic equivalent generic drug to be fully substitutable for the RLD. In addition, by operation of certain state laws and
numerous health insurance programs, the FDA&rsquo;s designation of therapeutic equivalence often results in substitution of the
generic drug without the knowledge or consent of either the prescribing clinicians or patient.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Hatch-Waxman
Amendments, the FDA might not approve an ANDA until any applicable period of non-patent exclusivity for the RLD has expired. The
FDCA provides a period of five years of non-patent data exclusivity for a new drug containing a new chemical entity. For the purposes
of this provision, a new chemical entity, or NCE, is a drug that contains no active moiety that has previously been approved by
the FDA in any other NDA. An active moiety is the molecule or ion responsible for the physiological or pharmacological action of
the drug substance. In cases where such NCE exclusivity has been granted, an ANDA may not be filed with the FDA until the expiration
of five years unless the submission is accompanied by a Paragraph IV certification, in which case the applicant may submit its
application four years following the original product approval.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The FDCA also provides
for a period of three years of exclusivity if the NDA includes reports of one or more new clinical investigations, other than bioavailability
or bioequivalence studies, that were conducted by or for the applicant and are essential to the approval of the application. This
three-year exclusivity period often protects changes to a previously approved drug product, such as a new dosage form, route of
administration, combination or indication. Three-year exclusivity would be available for a drug product that contains a previously
approved active moiety, provided the statutory requirement for a new clinical investigation is satisfied. Unlike five-year NCE
exclusivity, an award of three-year exclusivity does not block the FDA from accepting ANDAs seeking approval for generic versions
of the drug as of the date of approval of the original drug product. The FDA typically makes decisions about awards of data exclusivity
shortly before a product is approved.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B><I>Hatch-Waxman Patent Certification
and the 30-Month Stay</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Upon approval of an
NDA or a supplement thereto, NDA sponsors are required to list with the FDA each patent with claims that cover the applicant&rsquo;s
product or an approved method of using the product. Each of the patents listed by the NDA sponsor is published in the Orange Book.
When an ANDA applicant files its application with the FDA, the applicant is required to certify to the FDA concerning any patents
listed for the reference product in the Orange Book, except for patents covering methods of use for which the ANDA applicant is
not seeking approval. To the extent that the Section&nbsp;505(b)(2)&nbsp;applicant is relying on studies conducted for an already
approved product, the applicant is required to certify to the FDA concerning any patents listed for the approved product in the
Orange Book to the same extent that an ANDA applicant would.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Specifically, the applicant
must certify with respect to each patent that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify">the required patent information has not been filed;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify">the listed patent has expired;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify">the listed patent has not expired, but will expire on a particular date and approval is sought after patent expiration; or</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify">the listed patent is invalid, unenforceable or will not be infringed by the new product. </TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A certification that
the new product will not infringe the already approved product&rsquo;s listed patents or that such patents are invalid or unenforceable
is called a Paragraph IV certification. If the applicant does not challenge the listed patents or indicates that it is not seeking
approval of a patented method of use, the ANDA application will not be approved until all the listed patents claiming the referenced
product have expired (other than method of use patents involving indications for which the ANDA applicant is not seeking approval).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If the ANDA applicant
has provided a Paragraph IV certification to the FDA, the applicant must also send notice of the Paragraph IV certification to
the NDA and patent holders once the ANDA has been accepted for filing by the FDA. The NDA and patent holders may then initiate
a patent infringement lawsuit in response to the notice of the Paragraph IV certification. The filing of a patent infringement
lawsuit within 45 days after the receipt of a Paragraph IV certification automatically prevents the FDA from approving the ANDA
until the earlier of 30 months after the receipt of the Paragraph IV notice, expiration of the patent, or a decision in the infringement
case that is favorable to the ANDA applicant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 31; Options: NewSection; Value: 30 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> <!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To the extent that
the Section&nbsp;505(b)(2)&nbsp;applicant is relying on studies conducted for an already approved product, the applicant is required
to certify to the FDA concerning any patents listed for the approved product in the Orange Book to the same extent that an ANDA
applicant would. As a result, approval of a Section&nbsp;505(b)(2)&nbsp;NDA can be stalled until all the listed patents claiming
the referenced product have expired, until any non-patent exclusivity, such as exclusivity for obtaining approval of a new chemical
entity, listed in the Orange Book for the referenced product has expired, and, in the case of a Paragraph IV certification and
subsequent patent infringement suit, until the earlier of 30 months, settlement of the lawsuit or a decision in the infringement
case that is favorable to the Section&nbsp;505(b)(2)&nbsp;applicant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>Pediatric Studies
and Exclusivity</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Pediatric
Research Equity Act of 2003, an NDA or supplement thereto must contain data that are adequate to assess the safety and effectiveness
of the drug product for the claimed indications in all relevant pediatric subpopulations, and to support dosing and administration
for each pediatric subpopulation for which the product is safe and effective. With enactment of the Food and Drug Administration
Safety and Innovation Act, or FDASIA, in 2012, sponsors must also submit pediatric study plans prior to the assessment data. Those
plans must contain an outline of the proposed pediatric study or studies the applicant plans to conduct, including study objectives
and design, any deferral or waiver requests, and other information required by regulation. The applicant, the FDA, and the FDA&rsquo;s
internal review committee must then review the information submitted, consult with each other, and agree upon a final plan. The
FDA or the applicant may request an amendment to the plan at any time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The FDA may, on its
own initiative or at the request of the applicant, grant deferrals for submission of some or all pediatric data until after approval
of the product for use in adults, or full or partial waivers from the pediatric data requirements. Additional requirements and
procedures relating to deferral requests and requests for extension of deferrals are contained in FDASIA. Unless otherwise required
by regulation, the pediatric data requirements do not apply to products with orphan designation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pediatric exclusivity
is another type of non-patent marketing exclusivity in the United States and, if granted, provides for the attachment of an additional
six months of marketing protection to the term of any existing regulatory exclusivity, including the non-patent and orphan exclusivity.
This six-month exclusivity may be granted if an NDA sponsor submits pediatric data that fairly respond to a written request from
the FDA for such data. The data do not need to show the product to be effective in the pediatric population studied; rather, if
the clinical trial is deemed to fairly respond to the FDA&rsquo;s request, the additional protection is granted. If reports of
requested pediatric studies are submitted to and accepted by the FDA within the statutory time limits, whatever statutory or regulatory
periods of exclusivity or patent protection cover the product are extended by six months. This is not a patent term extension,
but it effectively extends the regulatory period during which the FDA cannot approve another application.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>Patent Term Restoration
and Extension</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A patent claiming a
new drug product may be eligible for a limited patent term extension under the Hatch-Waxman Amendments, which permits a patent
restoration of up to five years for patent term lost during product development and the FDA regulatory review. The restoration
period granted is typically one-half the time between the effective date of an IND and the submission date of an NDA, plus the
time between the submission date of an NDA and the ultimate approval date. Patent term restoration cannot be used to extend the
remaining term of a patent past a total of 14 years from the product&rsquo;s approval date. Only one patent applicable to an approved
drug product is eligible for the extension, and the application for the extension must be submitted prior to the expiration of
the patent in question. A patent that covers multiple drugs for which approval is sought can only be extended in connection with
one of the approvals. The USPTO reviews and approves the application for any patent term extension or restoration in consultation
with the FDA. We cannot provide any assurance that any patent term extension with respect to any U.S. patent will be obtained and,
if obtained, the duration of such extension, in connection with any of our product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 32; Value: 30 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> <!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>The 21st Century
Cures Act</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On December&nbsp;13,
2016, President Obama signed the 21st Century Cures Act, or the Cures Act, into law. The Cures Act is designed to modernize and
personalize healthcare, spur innovation and research, and streamline the discovery and development of new therapies through increased
federal funding of particular programs. It authorizes increased funding for the FDA to spend on innovation projects. The new law
also amends the Public Health Service Act, or the PHSA, to reauthorize and expand funding for the NIH. The Act establishes the
NIH Innovation Fund to pay for the cost of development and implementation of a strategic plan, early stage investigators and research.
It also charges NIH with leading and coordinating expanded pediatric research. Further, the Cures Act directs the Centers for Disease
Control and Prevention to expand surveillance of neurological diseases.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">With amendments to
the FDCA and the PHSA, Title III of the Cures Act seeks to accelerate the discovery, development, and delivery of new medicines
and medical technologies. To that end, and among other provisions, the Cures Act reauthorizes the existing priority review voucher
program for certain drugs intended to treat rare pediatric diseases until 2020; creates a new priority review voucher program for
drug applications determined to be material national security threat medical countermeasure applications; revises the FDCA to streamline
review of combination product applications; requires FDA to evaluate the potential use of&thinsp; &ldquo;real world evidence&rdquo;
to help support approval of new indications for approved drugs; provides a new &ldquo;limited population&rdquo; approval pathway
for antibiotic and antifungal drugs intended to treat serious or life-threatening infections; and authorizes FDA to designate a
drug as a &ldquo;regenerative advanced therapy,&rdquo; thereby making it eligible for certain expedited review and approval designations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Review and Approval of Drug Products
in the European Union</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In order to market
any product outside of the United States, a company must also comply with numerous and varying regulatory requirements of other
countries and jurisdictions regarding quality, safety and efficacy and governing, among other things, clinical trials, marketing
authorization, commercial sales and distribution of products. Whether or not it obtains FDA approval for a product, the company
would need to obtain the necessary approvals by the comparable foreign regulatory authorities before it can commence clinical trials
or marketing of the product in those countries or jurisdictions. The approval process ultimately varies between countries and jurisdictions
and can involve additional product testing and additional administrative review periods. The time required to obtain approval in
other countries and jurisdictions might differ from and be longer than that required to obtain FDA approval. Regulatory approval
in one country or jurisdiction does not ensure regulatory approval in another, but a failure or delay in obtaining regulatory approval
in one country or jurisdiction may negatively impact the regulatory process in others.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>Procedures Governing
Approval of Drug Products in the European Union</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the European
Clinical Trials Directive, a system for the approval of clinical trials in the European Union has been implemented through national
legislation of the member states. Under this system, an applicant must obtain approval from the competent national authority of
a European Union member state in which the clinical trial is to be conducted. Furthermore, the applicant may only start a clinical
trial after a competent ethics committee has issued a favorable opinion. Clinical trial application must be accompanied by an investigational
medicinal product dossier with supporting information prescribed by the European Clinical Trials Directive and corresponding national
laws of the member states and further detailed in applicable guidance documents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To obtain marketing
approval of a product under European Union regulatory systems, an applicant must submit a marketing authorization application,
or MAA, either under a centralized or decentralized procedure. The centralized procedure provides for the grant of a single marketing
authorization by the European Commission that is valid for all European Union member states. The centralized procedure is compulsory
for specific products, including for medicines produced by certain biotechnological processes, products designated as orphan medicinal
products, advanced therapy products and products with a new active substance indicated for the treatment of certain diseases. For
products with a new active substance indicated for the treatment of other diseases and products that are highly innovative or for
which a centralized process is in the interest of patients, the centralized procedure may be optional.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the centralized
procedure, the Committee for Medicinal Products for Human Use, or the CHMP, established at the European Medicines Agency, or EMA,
is responsible for conducting the initial assessment of a product. The CHMP is also responsible for several post-authorization
and maintenance activities, such as the assessment of modifications or extensions to an existing marketing authorization. Under
the centralized procedure in the European Union, the maximum timeframe for the evaluation of an MAA is 210 days, excluding clock
stops, when additional information or written or oral explanation is to be provided by the applicant in response to questions of
the CHMP. Accelerated evaluation might be granted by the CHMP in exceptional cases, when a medicinal product is of major interest
from the point of view of public health and in particular from the viewpoint of therapeutic innovation. In this circumstance, the
EMA ensures that the opinion of the CHMP is given within 150 days.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 33; Value: 30 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> <!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The decentralized procedure
is available to applicants who wish to market a product in various European Union member states where such product has not received
marketing approval in any European Union member states before. The decentralized procedure provides for approval by one or more
other, or concerned, member states of an assessment of an application performed by one member state designated by the applicant,
known as the reference member state. Under this procedure, an applicant submits an application based on identical dossiers and
related materials, including a draft summary of product characteristics, and draft labeling and package leaflet, to the reference
member state and concerned member states. The reference member state prepares a draft assessment report and drafts of the related
materials within 210 days after receipt of a valid application. Within 90 days of receiving the reference member state&rsquo;s
assessment report and related materials, each concerned member state must decide whether to approve the assessment report and related
materials.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If a member state cannot
approve the assessment report and related materials on the grounds of potential serious risk to public health, the disputed points
are subject to a dispute resolution mechanism and may eventually be referred to the European Commission, whose decision is binding
on all member states.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Within this framework,
manufacturers may seek approval of hybrid medicinal products under Article&nbsp;10(3)&nbsp;of Directive 2001/83/EC. Hybrid applications
rely, in part, on information and data from a reference product and new data from appropriate preclinical tests and clinical trials.
Such applications are necessary when the proposed product does not meet the strict definition of a generic medicinal product, or
bioavailability studies cannot be used to demonstrate bioequivalence, or there are changes in the active substance(s), therapeutic
indications, strength, pharmaceutical form or route of administration of the generic product compared to the reference medicinal
product. In such cases the results of tests and clinical trials must be consistent with the data content standards required in
the Annex to the Directive 2001/83/EC, as amended by Directive 2003/63/EC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Hybrid medicinal product
applications have automatic access to the centralized procedure when the reference product was authorized for marketing via that
procedure. Where the reference product was authorized via the decentralized procedure, a hybrid application may be accepted for
consideration under the centralized procedure if the applicant shows that the medicinal product constitutes a significant therapeutic,
scientific or technical innovation, or the granting of a community authorization for the medicinal product is in the interest of
patients at the community level.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>Clinical Trial
Approval in the European Union</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Requirements for the
conduct of clinical trials in the European Union including Good Clinical Practice, or GCP, are set forth in the Clinical Trials
Directive 2001/20/EC and the GCP Directive 2005/28/EC. Pursuant to Directive 2001/20/EC and Directive 2005/28/EC, as amended, a
system for the approval of clinical trials in the European Union has been implemented through national legislation of the E.U.
member states. Under this system, approval must be obtained from the competent national authority of each E.U. member state in
which a study is planned to be conducted. To this end, a clinical trial application is submitted, which must be supported by an
investigational medicinal product dossier, or IMPD, and further supporting information prescribed by Directive 2001/20/EC and Directive
2005/28/EC and other applicable guidance documents. Furthermore, a clinical trial may only be started after a competent ethics
committee has issued a favorable opinion on the clinical trial application in that country.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In April&nbsp;2014,
the E.U. passed the new Clinical Trials Regulation, (EU) No 536/2014, which will replace the current Clinical Trials Directive
2001/20/EC. To ensure that the rules&nbsp;for clinical trials are identical throughout the European Union, the new E.U. clinical
trials legislation was passed as a regulation that is directly applicable in all E.U. member states. All clinical trials performed
in the European Union are required to be conducted in accordance with the Clinical Trials Directive 2001/20/EC until the new Clinical
Trials Regulation (EU) No 536/2014 becomes applicable. According to the current plans of EMA, the new Clinical Trials Regulation
will become applicable in 2019. The Clinical Trials Directive 2001/20/EC will, however, still apply three years from the date of
entry into application of the Clinical Trials Regulation to (i)&nbsp;clinical trials applications submitted before the entry into
application and (ii)&nbsp;clinical trials applications submitted within one year after the entry into application if the sponsor
opts for old system.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 34; Value: 30 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> <!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The new Clinical Trials
Regulation aims to simplify and streamline the approval of clinical trial in the European Union. The main characteristics of the
regulation include: a streamlined application procedure via a single entry point, the E.U. portal; a single set of documents to
be prepared and submitted for the application as well as simplified reporting procedures that will spare sponsors from submitting
broadly identical information separately to various bodies and different member states; a harmonized procedure for the assessment
of applications for clinical trials, which is divided in two parts (Part&nbsp;I is assessed jointly by all member states concerned,
and Part&nbsp;II is assessed separately by each member state concerned); strictly defined deadlines for the assessment of clinical
trial applications; and the involvement of the ethics committees in the assessment procedure in accordance with the national law
of the member state concerned but within the overall timelines defined by the Clinical Trials Regulation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>Periods of Authorization
and Renewals</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Marketing authorization
is valid for five years in principle and the marketing authorization may be renewed after five years on the basis of a re-evaluation
of the risk-benefit balance by the EMA or by the competent authority of the authorizing member state. To this end, the marketing
authorization holder must provide the EMA or the competent authority with a consolidated version of the file in respect of quality,
safety and efficacy, including all variations introduced since the marketing authorization was granted, at least six months before
the marketing authorization ceases to be valid. Once renewed, the marketing authorization is valid for an unlimited period, unless
the European Commission or the competent authority decides, on justified grounds relating to pharmacovigilance, to proceed with
one additional five-year renewal. Any authorization which is not followed by the actual placing of the drug on the European Union
market (in case of centralized procedure) or on the market of the authorizing member state within three years after authorization
ceases to be valid (the so-called sunset clause).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>Data and Market
Exclusivity in the European Union</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the European Union,
new chemical entities qualify for eight years of data exclusivity upon marketing authorization and an additional two years of market
exclusivity. This data exclusivity, if granted, prevents regulatory authorities in the European Union from referencing the innovator&rsquo;s
data to assess a generic (abbreviated) application for eight years, after which generic marketing authorization can be submitted,
and the innovator&rsquo;s data may be referenced, but not approved for two years. The overall 10-year period will be extended to
a maximum of 11 years if, during the first eight years of those 10 years, the marketing authorization holder obtains an authorization
for one or more new therapeutic indications which, during the scientific evaluation prior to their authorization, are held to bring
a significant clinical benefit in comparison with existing therapies. Even if a compound is considered to be a new chemical entity
and the sponsor is able to gain the prescribed period of data exclusivity, another company nevertheless could also market another
version of the product if such company can complete a full MAA with a complete database of pharmaceutical test, preclinical tests
and clinical trials and obtain marketing approval of its product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>Regulatory Requirements
after Marketing Authorization</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As in the United States,
both marketing authorization holders and manufacturers of medicinal products are subject to comprehensive regulatory oversight
by the EMA and the competent authorities of the individual E.U. Member States both before and after grant of the manufacturing
and marketing authorizations. The holder of an E.U. marketing authorization for a medicinal product must, for example, comply with
E.U. pharmacovigilance legislation and its related regulations and guidelines which entail many requirements for conducting pharmacovigilance,
or the assessment and monitoring of the safety of medicinal products. The manufacturing process for medicinal products in the European
Union is also highly regulated and regulators may shut down manufacturing facilities that they believe do not comply with regulations.
Manufacturing requires a manufacturing authorization, and the manufacturing authorization holder must comply with various requirements
set out in the applicable E.U. laws, including compliance with E.U. cGMP standards when manufacturing medicinal products and active
pharmaceutical ingredients.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the European Union,
the advertising and promotion of approved products are subject to E.U. Member States&rsquo; laws governing promotion of medicinal
products, interactions with clinicians, misleading and comparative advertising and unfair commercial practices. In addition, other
legislation adopted by individual E.U. Member States may apply to the advertising and promotion of medicinal products. These laws
require that promotional materials and advertising in relation to medicinal products comply with the product&rsquo;s Summary of
Product Characteristics, or SmPC, as approved by the competent authorities. Promotion of a medicinal product that does not comply
with the SmPC is considered to constitute off-label promotion, which is prohibited in the European Union.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 35; Value: 30 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> <!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Pharmaceutical Coverage, Pricing and
Reimbursement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our MydCombi and MicroLine
product candidates are intended as &ldquo;cash pay&rdquo; and therefore are not likely subject to the significant uncertainty that
exists as to the coverage and reimbursement status of products approved by the FDA and other government authorities. The sales
of MicroPine, however, would likely depend in part on the extent to which third-party payors, including government health programs
in the United States such as Medicare and Medicaid, commercial health insurers and managed care organizations, provide coverage,
and establish adequate reimbursement levels for, such products. The process for determining whether a payor will provide coverage
for a product may be separate from the process for setting the price or reimbursement rate that the payor will pay for the product
once coverage is approved. Third-party payors are increasingly challenging the prices charged, examining the medical necessity,
and reviewing the cost-effectiveness of medical products and services and imposing controls to manage costs. Third-party payors
may limit coverage to specific products on an approved list, or formulary, which might not include all of the approved products
for a particular indication.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In order to secure
coverage and reimbursement for any product that might be approved for sale, a company may need to conduct expensive pharmacoeconomic
studies in order to demonstrate the medical necessity and cost-effectiveness of the product, in addition to the costs required
to obtain FDA or other comparable regulatory approvals. Nonetheless, product candidates might not be considered medically necessary
or cost effective. Additionally, a payor&rsquo;s decision to provide coverage for a drug product does not imply that an adequate
reimbursement rate will be approved. Further, one payor&rsquo;s determination to provide coverage for a drug product does not assure
that other payors will also provide coverage for the drug product. Third-party reimbursement might not be sufficient to maintain
price levels high enough to realize an appropriate return on investment in product development.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The containment of
healthcare costs also has become a priority of federal, state and foreign governments and the prices of drugs have been a focus
in this effort. Governments have shown significant interest in implementing cost-containment programs, including price controls,
restrictions on reimbursement and requirements for substitution of generic products. Adoption of price controls and cost-containment
measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures, could further limit a
company&rsquo;s revenue generated from the sale of any approved products. Coverage policies and third-party reimbursement rates
may change at any time. Even if favorable coverage and reimbursement status is attained for one or more products for which a company
or its collaborators receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in
the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Outside the United
States, ensuring adequate coverage and payment for our product candidates will face challenges. Pricing of prescription pharmaceuticals
is subject to governmental control in many countries. Pricing negotiations with governmental authorities can extend well beyond
the receipt of regulatory marketing approval for a product and may require us to conduct a clinical trial that compares the cost
effectiveness of our product candidates or products to other available therapies. The conduct of such a clinical trial could be
expensive and result in delays in our commercialization efforts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the European Union,
pricing and reimbursement schemes vary widely from country to country. Some countries provide that drug products may be marketed
only after a reimbursement price has been agreed. Some countries may require the completion of additional studies that compare
the cost-effectiveness of a particular drug candidate to currently available therapies. For example, the European Union provides
options for its member states to restrict the range of drug products for which their national health insurance systems provide
reimbursement and to control the prices of medicinal products for human use. European Union member states may approve a specific
price for a drug product or it may instead adopt a system of direct or indirect controls on the profitability of the company placing
the drug product on the market. Other member states allow companies to fix their own prices for drug products, but monitor and
control company profits. The downward pressure on healthcare costs in general, particularly prescription drugs, has become intense.
As a result, increasingly high barriers are being erected to the entry of new products. In addition, in some countries, cross-border
imports from low-priced markets exert competitive pressure that may reduce pricing within a country. Any country that has price
controls or reimbursement limitations for drug products might not allow favorable reimbursement and pricing arrangements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 36; Value: 30 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> <!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Healthcare Law and Regulation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Arrangements with healthcare
providers, pharmacists, consultants, third-party payors and customers are subject to broadly applicable healthcare laws and regulations
that may constrain our business and/or financial arrangements. Applicable federal and state healthcare laws and regulations include
without limitation the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the federal Anti-Kickback Statute, which prohibits persons and entities from knowingly and willfully
soliciting, offering, receiving or providing remuneration, directly or indirectly, in cash or in kind, if one purpose of the remuneration
is to induce or reward either the referral of an individual for, or the purchase, order or recommendation of, any good or service,
for which payment may be made, in whole or in part, under a federal healthcare program such as Medicare and Medicaid;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the federal civil and criminal false claims laws, including the civil False Claims Act, and civil
monetary penalties laws, which prohibit individuals or entities from, among other things, knowingly presenting, or causing to be
presented, to the federal government, claims for payment that are false or fraudulent or making a false statement to avoid, decrease
or conceal an obligation to pay money to the federal government;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which created
additional federal criminal laws that prohibit, among other things, knowingly and willingly executing, or attempting to execute,
a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the Health Information Technology for Economic and Clinical Health Act and its implementing regulations,
which amended HIPAA to impose additional obligations, including mandatory contractual terms regarding the privacy, security and
transmission of individually identifiable health information;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the federal transparency requirements known as the federal Physician Payments Sunshine Act, under
the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010, or the
Affordable Care Act, which requires certain manufacturers of drugs, devices, biologics and medical supplies to report annually
to the Centers for Medicare&nbsp;&amp; Medicaid Services, or CMS, within the United States Department of Health and Human Services,
information related to payments and other transfers of value to clinicians and teaching hospitals and clinician ownership and investment
interests; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">analogous state and foreign laws and regulations, such as state anti-kickback and false claims
laws, which may apply to healthcare items or services that are reimbursed by non-governmental third-party payors, including private
insurers.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Some state laws require pharmaceutical
companies to comply with the pharmaceutical industry&rsquo;s voluntary compliance guidelines and the relevant compliance guidance
promulgated by the federal government in addition to requiring drug manufacturers to report information related to payments to
clinicians and other healthcare providers or marketing expenditures. State and foreign laws also govern the privacy and security
of health information in some circumstances, many of which differ from each other in significant ways and often are not preempted
by HIPAA, thus complicating compliance efforts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Changes in the Healthcare Marketplace</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A primary trend in
the U.S. healthcare industry and elsewhere is cost containment. There have been several federal and state proposals during the
last few years regarding the pricing of pharmaceutical and biopharmaceutical products, limiting coverage and reimbursement for
drugs and other medical products, government control, and other changes to the healthcare system in the United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 37; Value: 30 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> <!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Patient Protection
and Affordable Care Act of 2010, or ACA, included provisions related to the coverage of and payment for prescription drugs under
government healthcare programs. With regard to pharmaceutical products, among other things, the ACA was designed to expand and
increase industry rebates for drugs covered under Medicaid programs, impose an annual fee on branded pharmaceutical manufacturers
and make changes to the coverage requirements under the Medicare Part&nbsp;D program. Although the ACA continues to be the subject
of various and ongoing repeal efforts, cost containment for prescription drugs will likely remain a priority under the incoming
administration as efforts to curb drug prices enjoy relatively high levels of political support. Among the provisions of the ACA
of importance to our potential drug candidates are:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">an annual, nondeductible fee on any entity that manufactures or imports specified branded prescription
drugs and biologic products, apportioned among these entities according to their market share in certain government healthcare
programs, although this fee would not apply to sales of certain products approved exclusively for orphan indications;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">expansion of eligibility criteria for Medicaid programs by, among other things, allowing states
to offer Medicaid coverage to certain individuals with income at or below 133% of the federal poverty level, thereby potentially
increasing a manufacturer&rsquo;s Medicaid rebate liability;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">expanded manufacturers&rsquo; rebate liability under the Medicaid Drug Rebate Program by increasing
the minimum rebate for both branded and generic drugs and revising the definition of &ldquo;average manufacturer price,&rdquo;
or AMP, for calculating and reporting Medicaid drug rebates on outpatient prescription drug prices and extending rebate liability
to prescriptions for individuals enrolled in Medicare Advantage plans;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">addressed a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate
Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">expanded the types of entities eligible for the 340B drug discount program;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">established the Medicare Part&nbsp;D coverage gap discount program by requiring manufacturers to
provide a 50% point-of-sale-discount off the negotiated price of applicable brand drugs to eligible beneficiaries during their
coverage gap period as a condition for the manufacturers&rsquo; outpatient drugs to be covered under Medicare Part&nbsp;D;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct
comparative clinical effectiveness research, along with funding for such research;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">the Independent Payment Advisory Board, or IPAB, which has authority to recommend certain changes
to the Medicare program to reduce expenditures by the program that could result in reduced payments for prescription drugs. However,
the IPAB implementation has been not been clearly defined. The ACA provided that under certain circumstances,&nbsp;IPAB recommendations
will become law unless Congress enacts legislation that will achieve the same or greater Medicare cost savings; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">established the Center for Medicare and Medicaid Innovation within CMS to test innovative payment
and service delivery models to lower Medicare and Medicaid spending, potentially including prescription drug spending.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pharmaceutical pricing
was a focus of the Trump administration, which also continued efforts to repeal the ACA. It remains to be seen, however, what direction
the new Biden administration will take, and what impact it will have on the availability and cost of healthcare goods and services.
The elimination of the ACA&rsquo;s individual mandate, which imposed penalties to individuals who failed to obtain insurance coverage,
could ultimately result in fewer individuals having health insurance coverage, which changes to the ACA&rsquo;s minimum coverage
requirements may lead to policies with less generous benefits. While the timing and scope of any potential future legislation to
repeal and replace ACA provisions is highly uncertain in many respects, it is also possible that some of the ACA provisions that
generally are not favorable for the research-based pharmaceutical industry could also be repealed along with ACA coverage expansion
provisions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 38; Value: 30 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> <!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Employees</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of March 29, 2021, we
had 31 full-time and 3 part-time employees. We also engage various consultants and contractors.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Available Information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Annual Reports
on Form&nbsp;10-K, Quarterly Reports on Form&nbsp;10-Q, Current Reports on Form&nbsp;8-K, and amendments to those reports filed
or furnished pursuant to Section&nbsp;13(a)&nbsp;or 15(d)&nbsp;of the Exchange Act, are available free of charge on our website
at www.eyenovia.com as soon as reasonably practicable after electronically filing or furnishing such material to the SEC. The SEC
maintains a website (www.sec.gov) that includes our reports, proxy statements and other information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 39; Value: 30 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> <!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 11%; font-size: 10pt"><B><A NAME="a1_001"></A>Item 1A.</B></TD>
    <TD STYLE="width: 89%; font-size: 10pt"><B>Risk Factors.</B></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>Investing in our common stock involves
a high degree of risk. You should carefully consider the risks described below, as well as the other information in this report,
including our financial statements and the related notes and &ldquo;Management&rsquo;s Discussion and Analysis of Financial Condition
and Results of Operations,&rdquo; before deciding whether to invest in our common stock. The occurrence of any of the events or
developments described below could harm our business, financial condition, results of operations and growth prospects. In such
an event, the market price of our common stock could decline and you might lose all or part of your investment.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>RISKS RELATED TO OUR FINANCIAL POSITION
AND NEED FOR ADDITIONAL CAPITAL</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>We might not be able to continue as a going concern which would
likely cause our stockholders to lose most or all of their investment.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; text-align: justify; margin: 0pt 0">Our audited financial statements for the year ended December 31, 2020 were prepared under the assumption that we would continue as a going
concern. However, our independent registered public accounting firm included a &ldquo;going concern&rdquo; explanatory paragraph in its
report on our financial statements for the year ended December 31, 2020, indicating that, without additional sources of funding, our cash
at December 31, 2020 is not sufficient for us to operate as a going concern for a period of at least one year from the date that the financial
statements included in this Annual Report on Form 10-K are issued. Management&rsquo;s plans concerning these matters, including our need
to raise additional capital, are described in Note 2 &ndash; Summary of Significant Accounting Policies &ndash; Liquidity and Going Concern
of our financial statements included within this Annual Report on Form 10-K, however, management cannot assure you that its plans will
be successful. In light of the foregoing, there is substantial doubt about our ability to continue as a going concern. If we cannot continue
as a viable entity, our stockholders would likely lose most or all of their investment in us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We will need to raise additional
capital in order to continue developing our product candidates and to potentially manufacture and commercialize them. Such funding
might not be available on acceptable terms, or at all. Failure to obtain this necessary capital may force us to delay, limit or
terminate certain of our product development and commercialization efforts or to continue operations.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We require substantial
additional funding to continue our research and development activities. We also need substantial funding to advance potential
manufacturing and commercialization, and fund our operating expenses and other activities into next year. If additional capital is not
available when needed, including because of general market conditions, we may need to significantly scale back or reprioritize our
research and development activities, manufacturing and commercialization plans, and potentially even cease our operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We will require substantial
funds to discover, develop, protect and conduct research and development for our product candidates, including preclinical testing
for future product candidates and clinical trials of any of our product candidates, and to potentially manufacture and market any
such product that may be approved for commercial sale. Even if we are successful in raising additional capital, such funds may
prove to be insufficient for these activities. Our financing needs may change substantially because of research and development,
manufacturing and commercialization-related costs, competition, clinical trials and costs arising from additional regulatory approvals.
We might not succeed in raising needed additional funds. The timing of our need for additional funds will depend on a number of
factors, which factors are difficult to predict or may be outside of our control, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify">the resources, time and costs required to initiate and complete research and development, to initiate and complete preclinical studies and clinical trials and to obtain regulatory approvals for our product candidates;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify">progress in our research and development programs;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify">the timing, receipt and amount of milestone, royalty and other payments from any current or future collaborators, if any; and</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify">costs necessary to protect our intellectual property. </TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If our estimates and
predictions relating to any of these factors are incorrect, we may need to modify our operating plan. Additional funds might not
be available to us on acceptable terms, or at all, when needed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Raising additional capital may cause
dilution to our existing stockholders, restrict our operations or require us to relinquish rights to our technologies.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Until such time as
we can generate substantial product revenues, we may attempt to finance our cash needs through equity offerings, debt financings,
government and/or other third-party grants or other third-party funding, marketing and distribution arrangements and other collaborations,
strategic alliances and licensing arrangements. To the extent that we raise additional capital through the sale of equity or convertible
debt securities, our investors&rsquo; ownership interest will be diluted. Debt financing, if available, may involve agreements
that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making
capital expenditures or declaring dividends. If we are unable to obtain funding on a timely basis, we may be required to significantly
curtail one or more clinical research or development programs or delay manufacturing and commercialization plans, which would adversely
impact potential revenues, results of operations and our financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 40; Value: 30 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> <!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we raise additional
capital through future collaborations, strategic alliances or third-party licensing arrangements, we may have to relinquish valuable
rights to our intellectual property, future revenue streams, research programs or product candidates, or grant licenses on terms
that might not be favorable to us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We have incurred operating losses
since our inception. We expect to continue to incur losses for the foreseeable future and might never achieve or maintain profitability.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have incurred net
losses of&thinsp;approximately $77.4 million since inception, have not generated any product sales revenue and have not achieved
profitable operations. Our net losses were approximately $19.8 million and $21.2 million for the years ended December&nbsp;31,
2020 and 2019, respectively. We expect to continue to incur substantial losses in future periods while we continue to test and
prepare our product candidates for the market. It could be a year or more, if ever, before we have a commercialized drug. The net
losses we incur may fluctuate significantly from quarter to quarter and year to year. We anticipate that our expenses will increase
substantially if, and as, we:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify">continue the ongoing development of our product candidates;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify">seek marketing approvals for our current and future product candidates that successfully complete clinical trials;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify">continue to develop a sales, marketing and distribution infrastructure to commercialize any product candidate for which we may obtain marketing approval;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify">develop, maintain, expand and protect our intellectual property portfolio;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify">implement additional operational, financial and management systems; and</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify">attract, hire and retain additional administrative, clinical, regulatory and scientific personnel; and </TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">initiate preclinical studies and clinical trials for any additional product candidates that we
may pursue in the future;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Even if we are able
to generate revenues from the sale of our potential products, we might not become profitable and may need to obtain additional
funding to continue operations. If we fail to become profitable or are unable to sustain profitability on a continuing basis, then
we may be unable to continue our operations at planned levels and be forced to reduce our operations. Even if we do achieve profitability,
we might not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to become and remain profitable
would decrease the value of our company and could impair our ability to raise capital, expand our business or continue our operations.
In addition, because of the numerous risks and uncertainties associated with product development, we are unable to predict the
timing or amount of increased expenses, or when, or if, we will be able to achieve or maintain profitability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Our relatively short operating history
may make it difficult for investors to evaluate the success of our business to date and to assess our future viability.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are a clinical stage
company which commenced active operations in 2014. Our operations to date have been primarily limited to organizing and staffing
our company, business planning, raising capital and developing our product candidates. Additionally, during the year ended December&nbsp;31,
2020, we entered into licensing agreements with Bausch Health, for the development and commercialization of MicroPine in the United
States and Canada, and Arctic Vision, for the development and commercialization of MicroPine and MicroLine in Greater China and
South Korea. We also submitted an NDA for Mydcombi for pharmacologic mydriasis and initiated our Phase  III Chaperone studies for
presbyopia. However, we have not yet demonstrated our ability to obtain marketing approval, manufacture a commercial scale product
or arrange for a third party to do so on our behalf, or conduct sales and marketing activities necessary for successful product
commercialization. We will need to transition from a company with a product development focus to a company capable of supporting
commercial and manufacturing activities in the near future. We might not be successful in such a transition. In addition, we may
encounter unforeseen expenses, difficulties, complications, delays and other known and unknown factors during such transition.
Consequently, any predictions about our future success or viability might not be as accurate as they could be if we had a longer
operating history.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 41; Value: 30 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> <!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>If we are unable to use carryforward
tax losses or benefit from favorable tax legislation to reduce our taxes, our business, results of operations and financial condition
may be adversely affected.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have incurred significant
net operating losses since our inception in July&nbsp;2014. As of December&nbsp;31, 2020, we had federal net operating loss carry-forwards
of approximately $60.0 million, of which, approximately $10.8 million will expire at various dates from 2034 to 2037 for
federal purposes. If we are unable to use carryforward tax losses to reduce our future taxable basis for corporate tax purposes,
our business, results of operations and financial condition may be adversely affected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Net operating loss
and tax credit carry-forwards are subject to review and possible adjustment by the Internal Revenue Service and state tax authorities
and may become subject to an annual limitation in the event of certain cumulative changes in the ownership interest of significant
stockholders over a three-year period in excess of 50%, as defined under Sections 382 and 383 of the Internal Revenue Code of 1986,
as amended, as well as similar state provisions. This could limit the amount of tax attributes that can be utilized annually to
offset future taxable income or tax liabilities. Pre-July&nbsp;15, 2019, net operating loss carryforwards of approximately $35,000,000
are subject to an annual limitation of approximately $918,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The federal and state
income tax returns are generally subject to tax examinations. To the extent we have tax attribute carryforwards, the tax years
in which the attribute was generated may still be adjusted upon examination by the Internal Revenue Service or state tax authorities
to the extent utilized in a future period. Any unfavorable tax adjustment could have a significant impact on our results of operations
and future cash flows. Furthermore, if the United States government decides to eliminate, or reduce the scope or the rate of any
tax benefit, either of which it could decide to do at any time, our results of operations could be adversely affected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>RISKS RELATED TO DEVELOPMENT AND COMMERCIALIZATION
OF OUR PRODUCT CANDIDATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We or our licensees may encounter
substantial delays in or failure of our clinical trials.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If the clinical trials
that we or our licensees are required to conduct to gain regulatory approval are delayed or unsuccessful, we might not be able
to market our product candidates. Additionally, because our product candidates are based on new technologies, we expect that our
human clinical trials will require extensive research and development and have substantial manufacturing and processing costs.
Accordingly, our clinical trial costs could be significantly higher than other conventional therapeutic technologies or drug products
and could be delayed if we do not have adequate means to fund them.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may experience delays
in any phase of the development and commercial launch of our product candidates, including during research and development and
clinical trials. Conducting a clinical trial is time-consuming and expensive, particularly human clinical trials, and the outcome
of any clinical trial is uncertain. The completion of any of these clinical trials may be delayed or halted for numerous reasons,
including, but not limited to, the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify">patients do not enroll in our clinical trials (including due to any adverse impacts of the coronavirus pandemic and resulting social distancing and shelter in place orders) or results from patients are not received at the expected rate;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify">patients discontinue participation in a clinical trial prior to the scheduled endpoint set forth in the clinical protocol at a higher than expected rate, especially if such discontinuations interfere with our ability to assess the efficacy of our drug candidate;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify">patients experience adverse events from our treatment;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify">patients get hurt during a clinical trial for a variety of reasons that might not be related to our product candidates, including the advanced stage of their disease and other medical problems;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify">third-party clinical investigators do not perform the clinical trials in accordance with the anticipated schedule or consistent with the clinical trial protocol and good clinical practices or other third-party organizations do not perform data collection and analysis in a timely or accurate manner;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify">the FDA,&nbsp;IRBs, European Union regulatory authorities, or the European Medicines Agency, and national authorities, or other regulatory authorities do not approve a clinical trial protocol or place a clinical trial on hold;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify">enrollment and sample size of our clinical trials may be substantially different than estimated which may lead to longer timelines and larger expenses;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 42; Value: 30 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> <!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify">third-party clinical investigators engage in activities that, even if not directly associated with our clinical trials, result in their debarment, loss of licensure, or other legal or regulatory sanction;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify">regulatory inspections of manufacturing facilities, which may, among other things, require us to undertake corrective action or suspend the clinical trials;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify">changes in governmental regulations or administrative actions;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify">the interim results of the clinical trial, if any, are inconclusive or negative; and</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify">the study design, although approved and completed, is inadequate to demonstrate effectiveness and safety.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our dependence upon
clinical trials in developing product candidates may impede them from reaching advanced stages of development and might prevent
all or part of our commercial operations. To date, the situations regarding potential delays in research and development activities
and clinical trials have yet to occur in a manner which adversely affects our research and development activities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We or our licensees may find it difficult
to enroll or maintain participation of an adequate number of patients in our clinical trials, which could delay or prevent us or
our licensees from proceeding with clinical trials of our product candidates.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Identifying and qualifying
patients to participate in our clinical trials is critical to our success. Patient enrollment depends on many factors, including
the size and nature of the patient population, eligibility criteria for the clinical trial, the proximity of patients to clinical
sites and their ability and willingness to participate in our trials (which may be adversely affected due to personal or environmental
factors, including pandemics like COVID-19 and the resulting social distancing and shelter in place orders), the design of the
clinical protocol, the availability of competing clinical trials, the availability of new drugs approved for the indication the
clinical trial is investigating, and clinicians&rsquo; and patients&rsquo; perceptions as to the potential advantages of the drug
being studied in relation to other available therapies. Any inability to locate, enroll and maintain participation of a sufficient
number of patients in our clinical trials would result in significant delays, could require us to abandon one or more clinical
trials altogether and could delay or prevent our receipt of necessary regulatory approvals. Delays in our clinical trials may also
result in increased development costs for our product candidates, which would cause the value of our company to decline and limit
our ability to obtain additional financing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, any negative
results we may report in clinical trials of our product candidates may make it difficult or impossible to recruit and retain patients
in other clinical trials of that same product candidate. Delays in the enrollment for any clinical trial of our product candidates
will increase our costs, slow down our product development and approval process and delay or potentially jeopardize our ability
to commence product sales and generate revenue. In addition, some of the factors that cause, or lead to, a delay in the commencement
or completion of clinical trials may also ultimately lead to the denial of regulatory approval of our product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We might not be able to develop marketable
products utilizing our technology and we might not be able to identify and successfully implement an alternative product development
strategy.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The approach we have
adopted to discover and develop product candidates is new and may never lead to marketable products. We have concentrated our efforts
on developing therapeutic product candidates utilizing new advanced technology for drug delivery. To our knowledge, no person or
company has developed any therapeutic product utilizing the same technology and no such ophthalmic micro-therapeutic product has
been approved for marketing to date. We are leading a new field of ophthalmic micro-therapeutic research and development and the
scientific discoveries that form the basis for our efforts to develop products are relatively new. The scientific evidence to support
the feasibility of developing such products and treatments based on these discoveries is limited. Our focus solely on developing
products utilizing our proprietary technology, as opposed to more traditional technology, increases the risks associated with investing
in our stock. If we are unsuccessful in developing product candidates utilizing our technology or finding additional applications
for our technology, we may be required to change the scope and direction of our product development activities. If we are not able
to identify and successfully implement an alternative product development strategy, our business may fail.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 43; Value: 30 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> <!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Even if we or our licensees complete
the necessary preclinical studies for any new product candidates and clinical trials for certain of our existing product candidates,
the marketing approval process is expensive, time-consuming and uncertain and may prevent us or our licensees from obtaining approvals
for the commercialization of some of our product candidates. If we or our licensees are not able to obtain, or if there are delays
in obtaining, required regulatory approvals, we or our licensees would not be able to commercialize our product candidates, and
our ability to generate revenue or receive licensing payments would be materially impaired.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our business depends
on the success of our lead research and development programs, some of which will require additional clinical testing before we
can seek regulatory approval and potentially launch commercial sales. In addition, we do not have any products that have gained
regulatory approval. Our business and future success depends on our ability to obtain regulatory approval of and then successfully
manufacture and commercialize our lead product candidates either alone or with our licensees. We are currently in Phase III clinical
trials for MicroLine and MicroPine and our and our licensees ability to develop, obtain regulatory approval for, and successfully
commercialize, these and any future product candidates will depend on several factors, including the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify">further ascertaining the FDA&rsquo;s expectations with respect to the nonclinical and clinical testing requirements across our development programs;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify">successful completion of our current clinical trials or any future clinical trials, which will depend substantially upon the satisfactory performance of third-party contractors;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify">successful achievement of the objectives of planned clinical trials, including manufacturability qualification of devices;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify">receipt of marketing approvals from the FDA, and similar regulatory authorities outside the United States;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify">establishing commercial manufacturing and supply arrangements;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify">establishing a manufacturing and commercial infrastructure;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify">acceptance of the products by patients, the medical community and third-party payors;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify">establishing market share while competing with other therapies;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify">successfully executing any pricing and/or reimbursement strategy;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify">a continued acceptable safety and adverse event profile of the products following regulatory approval; and</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify">qualifying for, identifying, registering, maintaining, enforcing and defending intellectual property rights and claims covering the products.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our business strategy includes
developing several pipeline product candidates over the next approximately 3-4 years which will require additional clinical development,
regulatory review and approval in multiple jurisdictions, substantial investment, access to sufficient commercial manufacturing capacity
and significant marketing efforts before we can generate any revenue from product sales. We are not permitted to market or promote any
of our product candidates before we receive regulatory approval from the FDA or comparable foreign regulatory authorities, and we may
never receive such regulatory approval for any of our product candidates. If we are unable to develop or receive marketing approval in
a timely manner or at all, we could experience significant delays or an inability to commercialize the product, which would materially
and adversely affect our business, financial condition and results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Our product candidates may cause
undesirable side effects or have other properties that could delay or prevent their regulatory approval, limit the commercial potential
or result in significant negative consequences following any potential marketing approval.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If our product candidates
are associated with undesirable side effects or have characteristics that are unexpected, we may need to abandon our development
or limit development to certain uses or subpopulations in which the undesirable side effects or other characteristics are less
prevalent, less severe or more acceptable from a risk-benefit perspective. Any serious adverse or undesirable side effects identified
during the development of our product candidates could interrupt, delay or halt clinical trials and could result in the denial
of regulatory approval by the FDA or other regulatory authorities for any or all targeted indications, and in turn prevent us from
commercializing our product candidates and generating revenues from their sale. In addition, if any of our product candidates receive
regulatory approval and we or others later identify undesirable adverse effects caused by the product, we could face one or more
of the following consequences:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 44; Value: 30 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> <!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify">regulatory authorities may require the addition of labeling statements, such as a boxed warning or a contraindication, or other safety labeling changes;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify">regulatory authorities may require a Risk Evaluation and Mitigation Strategy;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify">regulatory authorities may withdraw their approval of the product;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify">regulatory authorities may seize the product;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify">we may be required to change the way that the product is administered, or conduct additional clinical trials or we may need to recall the product;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px"></TD>
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify">we may be subject to litigation or product liability claims fines, injunctions or criminal penalties; and</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify">our reputation may suffer.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>If the market opportunities for our
product candidates are smaller than we believe they are, our product revenues may be adversely affected and our business may suffer.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are currently focusing
efforts on our Mydcombi product, and we have licensed commercialization rights to MicroPine and MicroLine in Greater China (mainland
China, Hong Kong, Macau and Taiwan) and South Korea to Arctic Vision (with Senju retaining such licensed rights in the rest of
Asia) and to MicroPine in the United States and Canada to Bausch Health. Our understanding of both the number of people who have
needs for our products, as well as the subset of people who have the potential to benefit from our product candidates in varying
countries, are based on estimates in published literature. While we believe these estimates are reasonable, they may prove to be
incorrect and new studies may reduce the estimated incidence or prevalence of mydriasis, progressive myopia and presbyopia. The
number of patients in the United States and elsewhere may turn out to be lower than expected or these patients might not be otherwise
amenable to our product candidates or may become increasingly difficult to identify and access, all of which would adversely affect
our business, financial condition, results of operations and prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>The commercial success of our product
candidates will depend in large part on the degree of market acceptance among ophthalmologists and optometrists, patients, patient
advocacy groups, third-party payors and the medical community.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Even if we receive
regulatory approval to market our product candidates, our product candidates might not gain market acceptance upon their commercial
introduction, which could prevent us from becoming profitable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may have difficulties
convincing the medical community, third-party payors and consumers to accept and use any of our product candidates that may be
approved for commercialization in the future. Other factors that we believe will affect market acceptance of our product candidates
include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify">the timing of our receipt of any marketing approvals, the terms of any approvals and the countries in which approvals are obtained;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify">safety, efficacy and ease of administration of our product candidates;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify">the success of physician education programs;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify">the availability of any government and third-party payor reimbursement;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify">the pricing of our product candidates, particularly as compared to alternative treatment methods and medications;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify">the extent to which alternative treatment methods and medications are more readily available as compared to the availability of any product candidates that we may develop in the future; and</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify">the prevalence and severity of any adverse effects.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Our licensing partners may fail to use commercially reasonable
efforts to commercialize certain of our products.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our licensing partners
are contractually obligated to use commercially reasonable efforts in the commercialization of the products for which they have
negotiated a license. Uncovering that one or more of our partners is not using commercially reasonable efforts could take time
to discover and time to remedy, during which the sales of our products candidates could be lower than we expect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 45; Value: 30 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> <!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Split-Segment; Name: 4 -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We face competition in an environment
of rapid technological change and the possibility that our competitors may achieve regulatory approval before us or develop therapies
that are more advanced or effective than ours, may adversely affect our financial condition and our or our licensees ability to
successfully market or commercialize our product candidates.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The specialty pharma
market is highly competitive. If we or our licensees are unable to compete effectively with any existing products, new treatment
methods and new technologies, we may be unable to commercialize our current or any future therapeutic products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The specialty pharma
market is subject to rapid technological change and is significantly affected by existing rival products and medical procedures,
new product introductions and the market activities of other participants. Pharmaceutical and biotechnology companies, academic
institutions, governmental agencies and other public and private research organizations may pursue the research and development
of technologies, drugs or other therapeutic products for the treatment of some or all of the diseases we are targeting. We may
also face competition from products which have already been approved and accepted by the medical community for the treatment of
these same indications.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As a result of any
of the foregoing factors, our competitors may develop or commercialize products with significant advantages over any therapeutic
products that we may develop. If our competitors are more successful in commercializing their products than we are, their success
could adversely affect our competitive position and harm our business prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>If we fail to establish and maintain effective
manufacturing and distribution processes our business may be adversely affected.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have limited resources
for the manufacturing, sales, marketing and distribution of drug products. To achieve commercial success for the product candidates for
which we obtain marketing approval, we will need to establish and maintain an adequate sales force, and additional manufacturing, marketing
and distribution capabilities, either ourselves or through collaborations or other arrangements with third parties. In addition, failure
to secure contracts with manufacturers, wholesalers, retailers, or specialty pharmacies could negatively impact the production and distribution
of our potential products, and failure to coordinate financial systems could negatively impact our ability to accurately report product
revenue. If we are unable to effectively establish and manage the manufacturing and distribution process, the commercial launch and sales
of our potential products may be delayed or severely compromised and our results of operations may be harmed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We are exposed to the risk of claims
seeking monetary damages by individuals and the risk of investigations by regulatory authorities, which could cause us to incur
substantial liabilities and to limit commercialization of any products that we develop.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are exposed to the
risk of claims seeking monetary damages being filed against us for loss or harm suffered by participants of our clinical trials
or for loss or harm suffered by users of any drug that may receive approval for commercialization in the future. In either event,
the FDA or the regulatory authorities of other countries or regions may commence investigations of the safety and effectiveness
of any such clinical trial or commercialized drug, the manufacturing processes and facilities or marketing programs utilized in
respect of any such clinical trial or drug. Such investigations may result in mandatory or voluntary recalls of any commercialized
drug or other significant enforcement action such as limiting the indications for which any such drug may be used, or suspension
or withdrawal of approval for any such drug. Investigations by the FDA or any other regulatory authority in other countries or
regions also could delay or prevent the completion of any of our other clinical development programs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Product liability lawsuits against
us could divert our resources and could cause us to incur substantial liabilities and to limit commercialization of any products
that we develop.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We face an inherent
risk of product liability exposure related to the use of our product candidates that we develop in human clinical trials. We face
an even greater risk if we commercially sell any products that we develop. If we cannot successfully defend ourselves against claims
that our product candidates or products caused injuries, we will incur substantial liabilities. Regardless of merit or eventual
outcome, liability claims may result in:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify">decreased demand for any product candidates or products that we develop;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 46; Options: NewSection; Value: 45 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify">injury to our reputation and significant negative media attention;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify">withdrawal of clinical trial participants;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify">significant costs to defend the related litigation;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify">substantial monetary awards to clinical trial participants or patients;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify">loss of revenue;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify">reduced time and attention of our management to pursue our business strategy; and</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify">the inability to commercialize any products that we develop.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our insurance policies
might not fully cover the risk of loss associated with our operations. We may need to increase our insurance coverage as we expand
or undertake new our clinical trials for existing and future product candidates. We will need to further increase our insurance
coverage if we commence commercialization of any of the product candidates for which we obtain marketing approval. Insurance coverage
is increasingly expensive. We might not be able to maintain insurance coverage at a reasonable cost or in an amount adequate to
satisfy any liability that may arise. In the event that we are required to pay damages for any such claim, we may be forced to
seek bankruptcy or to liquidate because our asset and revenue base may be insufficient to satisfy the payment of damages and any
insurance that we have obtained or may obtain for product or clinical trial liability might not provide sufficient coverage against
potential liabilities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>RISKS RELATED TO REGULATORY APPROVAL
OF OUR PRODUCT CANDIDATES AND </B><B>OTHER LEGAL COMPLIANCE MATTERS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>If we or our licensees are not able
to obtain, or if there are delays in obtaining, required regulatory approvals, we might not be able to commercialize our product
candidates, and our ability to generate revenue would be materially impaired.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our product candidates
are subject to extensive and burdensome governmental regulations relating to product development, manufacturing, marketing and
commercialization, and sale, in addition to the laws and regulations applicable to clinical trials. Rigorous preclinical testing
and clinical trials and related regulatory approval processes are required in the United States and in many foreign jurisdictions
before a new product may be offered or sold. Satisfaction of these and other regulatory requirements is costly, time-consuming,
uncertain and subject to unanticipated delays.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the United States,
the product candidates we intend to develop and market are regulated by the FDA under its drug development and review process.
The time required to obtain FDA and other approvals for our product candidates is unpredictable. Before such product candidates
can be marketed, we must obtain FDA approval of an IND permitting the conduct of clinical trials, then we must successfully complete
human testing, and the FDA must approve our NDA. Even after successful completion of clinical testing, there is a risk that the
FDA may request further information from us, disagree with our findings or otherwise undertake a lengthy review of our submission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">It is possible that
FDA will not approve any application we submit. It is possible that none of the product candidates that we may develop will obtain
the appropriate regulatory approvals necessary for us to commence the offer and sale of such products. Any delay or failure in
obtaining required approvals could have a material adverse effect on our ability to generate revenues from a particular prospective
product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Failure to obtain marketing approval
in foreign jurisdictions would prevent our product candidates from being marketed in such jurisdictions.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Because we intend to
market any therapy that we may develop in jurisdictions in addition to the United States, such as Canada, Asia, and possibly the
European Union, we will likely incur the same costs or more in satisfying foreign regulatory requirements governing the conduct
of clinical trials, manufacturing and marketing and commercialization of our product candidates. Approval by the FDA by itself
does not assure approval by regulatory authorities outside the United States and approval by one regulatory authority outside the
United States does not ensure approval by regulatory authorities in other countries or jurisdictions or by the FDA. Each of these
foreign regulatory approval processes includes all of the risks associated with the FDA approval process, as well as risks attributable
to having to satisfy local regulations within each of these foreign jurisdictions. In addition, any failure or delay in obtaining
regulatory approval in one country may negatively affect the regulatory process in other countries. Our inability to obtain regulatory
approval outside the United States may adversely compromise our business prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 47; Value: 45 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>The terms of approvals, ongoing regulations
and post-marketing restrictions for our products in the United States and other jurisdictions in which we have licensed our products
may limit how we manufacture and market our products, which could materially impair our ability to generate revenue.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Once marketing approval
has been granted, an approved product and its manufacturer and marketer are subject to ongoing review and extensive regulation.
Regulatory authorities, including the FDA in the United States and similar regulatory bodies in other jurisdictions in which we
have licensed our products, closely regulate the post-approval marketing and promotion of drugs to ensure drugs are marketed only
for the approved indications and in accordance with the provisions of the approved labeling and regulatory requirements. The FDA,
and similar regulatory bodies in other jurisdictions in which we have licensed our products, impose stringent restrictions on manufacturers&rsquo;
communications regarding off-label use and if we do not restrict the marketing of our products only to their approved indications,
we may be subject to enforcement action for off-label marketing. We, and any potential collaborators we may have in the future,
must therefore comply with requirements concerning advertising and promotion for any of our products for which we or our collaborators
obtain marketing approval. Thus, if any of our product candidates receive marketing approval, the accompanying label may limit
the approved use of our product, which could limit sales of the product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, manufacturers
of approved products and those manufacturers&rsquo; facilities are required to comply with extensive requirements of the FDA and
similar regulatory bodies in other jurisdictions in which we have licensed our products, including, for example, ensuring that
quality control and manufacturing procedures conform to cGMP or similar requirements applicable to drug manufacturers, which include
requirements relating to quality control and quality assurance as well as the corresponding maintenance of records and documentation
and reporting requirements. We, any contract manufacturers we may engage in the future, our future collaborators and their contract
manufacturers will also be subject to other regulatory requirements, including submissions of safety and other post-marketing information
and reports, registration and listing requirements, requirements regarding the distribution of samples to clinicians, recordkeeping,
and costly post-marketing studies or clinical trials and surveillance to monitor the safety or efficacy of the product such as
the requirement to implement a risk evaluation and mitigation strategy. Our third party manufacturers&rsquo; inability to satisfy
the chemistry, manufacturing and control concerns of regulatory bodies such as the FDA would either prevent us from completing
clinical trials or prevent us from obtaining regulatory approval for marketing, either of which would significantly compromise
our business prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We may be subject to substantial
penalties if we fail to comply with regulatory requirements or if we experience unanticipated problems with our products.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Violations of the Food
Drug and Cosmetics Act (&ldquo;FDCA&rdquo;) relating to the promotion or manufacturing of drug products may lead to investigations
by the FDA, Department of Justice, and/or state Attorneys General alleging violations of federal and state healthcare fraud and
abuse laws, as well as state consumer protection laws in the United States and we face similar regulatory requirements in other
jurisdictions in which we have licensed our products. In addition, later discovery of previously unknown adverse events or other
problems with our products, manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may yield
various results, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify">restrictions on such products, manufacturers or manufacturing processes;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify">restrictions on the labeling or marketing of a product;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify">restrictions on product distribution or use;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify">requirements to conduct post-marketing studies or clinical trials;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify">warning letters;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify">withdrawal of the products from the market;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify">refusal to approve pending applications or supplements to approved applications that we submit;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify">recall of products;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify">fines, restitution or disgorgement of profits or revenues;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify">suspension or withdrawal of marketing approvals;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 48; Value: 45 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify">refusal to permit the import or export of our products;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify">product seizure or detention; or</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify">injunctions or the imposition of civil or criminal penalties.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We are subject to federal and state
healthcare fraud and abuse laws, false claims laws and health information privacy and security laws. If we are unable to comply,
or have not fully complied, with such laws, we could face substantial penalties.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are subject to various
U.S. state and federal laws and regulations as well as those of certain foreign jurisdictions. Among the laws applicable to us
are those related to fraud and abuse related to healthcare programs and services, including without limitation the federal anti-kickback
statute, the federal False Claims Act, the federal physician self-referral law, and the prohibition against beneficiary inducements,
among others. Changes in these and other laws may require changes in our business to maintain compliance with legal requirements.
Any finding of our failure to comply with such laws and regulations could have a material adverse effect on our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our operations may
be directly or indirectly affected by various U.S. federal and state healthcare fraud and abuse laws, including the federal anti-kickback
statute, which prohibits any person from knowingly and willfully offering, paying, soliciting or receiving remuneration, directly
or indirectly, in return for or to induce the referring, ordering, leasing, purchasing or arranging for or recommending the ordering,
purchasing or leasing of an item or service for which payment may be made under U.S. federal healthcare programs, such as the Medicare
and Medicaid programs. The U.S. federal anti-kickback statute is very broad in scope. In addition, violations of the federal anti-kickback
statute can lead to prosecution under the federal False Claims Act, which imposes per-claim penalties up to nearly $24,000 in addition
to treble damages. Because of the potential for such substantial monetary penalties, those under investigation for potential or
actual violations of the anti-kickback statute and the False Claims Act have a strong incentive to settle their cases with the
government rather than risk litigation. For that reason, some provisions of these laws have not been uniformly or definitively
interpreted by existing case law or regulations. In addition, many states have adopted laws similar to the U.S. federal anti-kickback
statute, and some of these laws are broader than that statute in that their prohibitions are not limited to items or services paid
for by a U.S. federal healthcare program but, instead, apply regardless of the source of payment. Violations of these laws could
result in fines, imprisonment or exclusion from government-sponsored programs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Additionally, our relationships
with customers and third-party payors will be subject to applicable anti-kickback, fraud and abuse and other healthcare laws and
regulations, which may expose us to criminal sanctions, civil penalties, program exclusion, contractual damages, reputational harm
and diminished profits and future earnings.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Healthcare providers,
physicians and third-party payors play a primary role in the recommendation of any product candidates for which we obtain marketing
approval. Our future arrangements with third-party payors and customers may expose us to broadly applicable fraud and abuse and
other healthcare laws and regulations that may constrain the business or financial arrangements and relationships through which
we plan to market, sell and distribute products for which we obtain marketing approval.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Some state laws require
pharmaceutical companies to comply with the pharmaceutical industry&rsquo;s voluntary compliance guidelines and the relevant compliance
guidance promulgated by the federal government and federal and state laws may require drug manufacturers to report information
related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures. State
and foreign laws also govern the privacy and security of health information in some circumstances, many of which differ from each
other in significant ways and often are not preempted by the Health Insurance Portability and Accountability Act, thus complicating
compliance efforts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Efforts to ensure that
our business arrangements with third parties comply with applicable healthcare laws and regulations will involve substantial costs.
It is possible that governmental authorities will conclude that our business practices might not comply with current or future
statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations
are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject
to significant civil, criminal and administrative penalties, damages, fines, exclusion from government funded healthcare programs,
such as Medicare and Medicaid, and the curtailment or restructuring of our operations. If any of the physicians or other providers
or entities with whom we expect to do business are found to be out of compliance with applicable laws, they may be subject to criminal,
civil or administrative sanctions, including exclusions from government funded healthcare programs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 49; Value: 45 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Recently enacted and future legislation
may affect our or our licensees&rsquo; ability to commercialize our products and the prices we obtain for any products that are approved
in the United States or foreign jurisdictions, which would harm our business.</I></B></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the United States
and some foreign jurisdictions, there have been a number of legislative and regulatory changes and proposed changes regarding the
healthcare system that could affect our ability to profitably sell or commercialize our product candidates for which we obtain
marketing approval. The pharmaceutical industry has been a particular focus of these efforts and have been significantly affected
by legislative initiatives regarding pricing stability and transparency and other topics of reform. Current laws, as well as other
healthcare reform measures that may be adopted in the future, may result in more rigorous coverage criteria and in additional downward
pressure on the price that we receive for any FDA approved product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The United States Medicare
Prescription Drug,&nbsp;Improvement, and Modernization Act of 2003, or the Medicare Modernization Act, changed the way Medicare
covers and pays for pharmaceutical products. The legislation expanded Medicare coverage for drug purchases by the elderly and introduced
a new reimbursement methodology based on average sales prices for clinician administered drugs. In addition, this legislation provided
authority for limiting the number of drugs that will be covered in any therapeutic class. Cost reduction initiatives in this and
similar legislation could decrease the coverage and price that we receive for any approved products. While the Medicare Modernization
Act applies only to drug benefits for Medicare beneficiaries, private payors often follow Medicare coverage policy and payment
limitations in setting their own reimbursement rates. Therefore, any reduction in reimbursement that results from changes in laws
applicable to federal and state healthcare programs may result in similar reduction in payment from private payors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As is discussed above,
several provisions of the ACA are important to our business, including, without limitation, our ability to commercialize our product
candidates and the prices we may obtain for any of our product candidates that are approved for sale. Provisions of the ACA that
are potentially important to our business include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify">an annual, nondeductible fee on any entity that manufactures or imports specified branded prescription drugs and biologic products;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify">an increase in the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify">a new Medicare Part&nbsp;D coverage gap discount program, in which participating manufacturers must agree to offer 50% point-of-sale discounts off negotiated drug prices during the coverage gap period as a condition for the manufacturer&rsquo;s outpatient drugs to be covered under Medicare Part&nbsp;D;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify">expansion of healthcare fraud and abuse laws, including the federal False Claims Act and the federal Anti-Kickback Statute, and the addition of new government investigative powers, and enhanced penalties for noncompliance;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify">extension of manufacturers&rsquo; Medicaid rebate liability</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify">expansion of eligibility criteria for Medicaid programs; and</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify">expansion of the entities eligible for discounts under the Public Health Service pharmaceutical pricing program.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, other
legislative changes have been proposed and adopted since the ACA was enacted. The Budget Control Act of 2011, for instance, included
measures for spending reductions by Congress. A Joint Select Committee on Deficit Reduction, tasked with recommending a targeted
deficit reduction of at least $1.2 trillion for the years 2013 through 2021, was unable to reach required goals, thereby triggering
the legislation&rsquo;s automatic reduction to several government programs (&ldquo;Sequestration&rdquo;). These changes included
aggregate reductions to Medicare payments to providers of up to 2% per fiscal year, which went into effect in April&nbsp;2013 and
will remain in effect through 2027 unless additional Congressional action is taken. The American Taxpayer Relief Act of 2012, among
other things, reduced Medicare payments to several providers and increased the statute of limitations period for the government
to recover overpayments to providers from three to five years. These and similar laws, including ongoing legislative efforts to
promote transparency and contain costs related to pharmaceutical prices, may result in additional reductions in Medicare and other
third-party rates and otherwise affect the prices we may obtain for any of our product candidates for which we may obtain regulatory
approval or the frequency with which any such product candidate is prescribed or used.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 50; Value: 45 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Continued efforts to
reform the healthcare marketplace and delivery system could have an adverse effect on anticipated revenue from product candidates
that we may successfully develop and for which we may obtain marketing approval and may affect our overall financial condition
and ability to develop or commercialize product candidates. We expect that future reform efforts will continue to prioritize reductions
in Medicare and other healthcare spending, more rigorous reimbursement criteria, new payment methodologies and additional downward
pressure on the price that we receive for any approved product and/or the level of reimbursement physicians receive for administering
any approved product we might bring to market. Reductions in reimbursement levels may negatively impact the prices we receive or
the frequency with which any products we may develop are prescribed or administered. Any reduction in reimbursement from Medicare
or other government programs may result in a similar reduction in payments from private payors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The cost of prescription
pharmaceuticals has also been the subject of considerable discussion in the United States, members of both political parties continue
to seek ways to address rising costs through new legislative and administrative measures. To date, there have been several laws
passed in recent years aimed at curbing the cost of drugs, and additional legislation has been proposed on this subject. It is
unclear how the incoming administration will seek to implement these and other measures.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The pricing of prescription
pharmaceuticals is also subject to governmental controls outside the United States, which vary widely from country to country.
As a result, we might obtain regulatory approval for a product in a particular country, but then be subjected to pricing regulations
in that country that delay the commercial launch of the product and negatively impact the revenues able to be generated from the
sale of the product in that country. In these countries, pricing negotiations with governmental authorities can take considerable
time after the receipt of marketing approval for a product. To obtain reimbursement or pricing approval in some countries, we may
be required to conduct a clinical trial that compares the cost-effectiveness of our product candidates to other available therapies.
If reimbursement of our products is unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels, our
ability to generate revenues and become profitable could be impaired.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We are subject to anti-corruption
laws, as well as export control laws, customs laws, sanctions laws and other laws governing our operations. If we fail to comply
with these laws, we could be subject to civil or criminal penalties, other remedial measures and legal expenses, be precluded from
developing manufacturing and selling products outside the United States or be required to develop and implement costly compliance
programs, which could adversely affect our business, results of operations and financial condition.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are subject to anti-corruption
laws, as well as export control laws, customs laws, sanctions laws and other laws governing our operations. If we fail to comply
with these laws, we could be subject to civil or criminal penalties, other remedial measures and legal expenses, be precluded from
developing manufacturing and selling products outside the United States or be required to develop and implement costly compliance
programs, which could adversely affect our business, results of operations and financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our operations are
subject to anti-corruption laws, including the United States Foreign Corrupt Practices Act, or FCPA, and the United Kingdom Bribery
Act 2010, or Bribery Act, which apply wherever we do business around the world. We may also become subject to local anti-corruption
laws in countries where we may do business in the future, such as Canada&rsquo;s Corruption of Foreign Public Officials Act, the
Criminal Law and Anti-unfair Competition Law of the People&rsquo;s Republic of China, the Hong Kong Prevention of Bribery Ordinance,
and the Act on Preventing Bribery of Foreign Public Officials in International Business Transactions, or OECD Anti-Bribery Convention,
enacted by the Organisation for Economic Co-operation and Development, and adopted by South Korea along with more than 40 other
countries, and which is designed to criminalize bribery of public officials in connection with international business transactions.
The Bribery Act, FCPA, the OECD Anti-Bribery Convention, and similar international treaties and various countries&rsquo; local
anti-corruption laws, referred to as Anti-Corruption Laws, generally prohibit us, our officers, and our employees and intermediaries
from bribing, being bribed or making other prohibited payments to government officials or other persons to obtain or retain business
or gain some other business advantage. Compliance with the FCPA, for example, is expensive and difficult, particularly in countries
in which corruption is a recognized problem. In addition, the FCPA presents particular challenges in the pharmaceutical industry,
because, in many countries, hospitals are operated by the government, and doctors and other hospital employees are considered foreign
officials. Certain payments to hospitals in connection with clinical trials and other work have been deemed to be improper payments
to government officials and have led to FCPA enforcement actions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 51; Value: 45 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may in the future
operate in jurisdictions that pose a high risk of potential violations of Anti-Corruption Laws, and we may participate in collaborations
and relationships with third parties whose actions could potentially subject us to liability under Anti-Corruption Laws. In addition,
we cannot predict the nature, scope or effect of future regulatory requirements to which our international operations might be
subject or the manner in which existing laws might be administered or interpreted. As we expand our operations outside of the United
States, we will need to dedicate additional resources to comply with numerous laws and regulations in each jurisdiction in which
we plan to operate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are also subject
to other laws and regulations governing our potential international operations, including regulations administered by the governments
of the United Kingdom and the United States, and authorities in the European Union, including applicable export control regulations,
economic sanctions on countries and persons, customs requirements and currency exchange regulations, collectively referred to as
the Trade Control laws. In addition, various laws, regulations and executive orders also restrict the use and dissemination outside
of the United States, or the sharing with certain non-United States nationals, of information classified for national security
purposes, as well as certain products and technical data relating to those products. If we expand our presence outside of the United
States, it will require us to dedicate additional resources to comply with these laws, and these laws may preclude us from developing,
manufacturing, or selling certain products and product candidates outside of the United States, which could limit our growth potential
and increase our development costs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We might not be completely
effective in ensuring our compliance with all applicable Anti-Corruption Laws or other legal requirements, including Trade Control
laws. If we are not in compliance with Anti-Corruption Laws or Trade Control laws, we may be subject to criminal and civil penalties,
disgorgement and other sanctions and remedial measures, and legal expenses, which could have an adverse impact on our business,
financial condition, results of operations and liquidity. The SEC also may suspend or bar issuers from trading securities on United
States exchanges for violations of the FCPA&rsquo;s accounting provisions. Any investigation of any potential violations of Anti-Corruption
Laws or Trade Control laws by U.K., U.S. or other authorities could also have an adverse impact on our reputation, our business,
results of operations and financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>RISKS RELATED TO OUR BUSINESS OPERATIONS
AND MANAGING GROWTH</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We are highly dependent on the services
of our senior management team, including our Chief Executive Officer and Chief Medical Officer, Dr.&nbsp;Ianchulev, and if we are
not able to retain these members of our management team or recruit and retain additional management, clinical, scientific and sales
personnel, our business will be harmed.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are highly dependent
on our senior management team, including our Chief Executive Officer and Chief Medical Officer, Dr.&nbsp;Ianchulev. The employment
agreements we have with our executive officers do not prevent such persons from terminating their employment with us at any time.
The loss of the services of any of these persons could impede the achievement of our research, development and commercialization
objectives.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, we are
dependent on our continued ability to attract, retain and motivate highly qualified additional management, clinical, scientific,
and sales personnel. If we are not able to retain our management and to attract, on acceptable terms, additional qualified personnel
necessary for the continued development of our business and commercialization of our product candidates, we might not be able to
sustain our operations or grow.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We might not be able
to attract or retain qualified personnel in the future due to the intense competition for qualified personnel among biotechnology,
pharmaceutical and other businesses. Many of the other pharmaceutical companies that we compete against for qualified personnel
and consultants have greater financial and other resources, different risk profiles and a longer history in the industry than we
do. They also may provide more diverse opportunities and better chances for career advancement. Some of these characteristics may
be more appealing to high-quality candidates and consultants than what we have to offer. If we are unable to continue to attract,
retain and motivate high-quality personnel and consultants to accomplish our business objectives, the rate and success at which
we can discover and develop drug candidates and our business will be limited and we may experience constraints on our development
objectives.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 52; Value: 45 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our future performance
will also depend, in part, on our ability to successfully integrate newly hired executive officers into our management team and
our ability to develop an effective working relationship among senior management. Our failure to integrate these individuals and
create effective working relationships among.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We have limited corporate infrastructure
and may experience difficulties in managing growth.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of March&nbsp;29, 2021,
we had only 31 full time employees and we rely on third-party contractors for the provision of professional and other services. As our
development and commercialization plans and strategies develop, we expect to need additional managerial, operational, sales, marketing,
financial, legal and other resources. Our management may need to divert a disproportionate amount of its attention away from our day-to-day
operations and devote a substantial amount of time to managing these growth activities. We might not be able to effectively manage the
expansion of our operations, which may result in weaknesses in our infrastructure, operational inefficiencies, loss of business opportunities,
loss of employees and reduced productivity among remaining employees. Our expected growth could require significant capital expenditures
and may divert financial resources from other projects, such as the development of our current and potential future drug candidates. If
our management is unable to effectively manage our growth, our expenses may increase more than expected, our ability to generate and grow
revenue could be reduced and we might not be able to implement our business strategy. Our future financial performance, our ability to
commercialize drug candidates, develop a scalable infrastructure and compete effectively will depend, in part, on our ability to effectively
manage any future growth.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We rely upon information technology
and any failure, inadequacy, interruption or security lapse of that technology, including any cyber security incidents, could harm
our ability to operate our business effectively.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our business operations
could suffer in the event of system failure. Despite the implementation of security measures, our internal computer systems and
those of our contract research organizations, and other contractors and consultants are vulnerable to damage from computer viruses,
unauthorized access, natural disasters, terrorism, war and telecommunication and electrical failures. If such an event were to
occur and cause interruptions in our operations, it could result in a material disruption of our drug development programs. For
example, the loss of clinical trial data from completed or ongoing or planned clinical trials could result in delays in our regulatory
approval efforts and significantly increase our costs to recover or reproduce the data. To the extent that any disruption or security
breach were to result in a loss of or damage to our data or applications, or inappropriate disclosure of confidential or proprietary
information, we could incur liability and further development of our product candidates could be delayed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>RISKS RELATED TO OUR DEPENDENCE ON THIRD
PARTIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We have limited clinical trial experience.
We rely upon third parties in conducting and managing our clinical trials, and those third parties might not perform satisfactorily,
including failing to meet deadlines for the completion of such clinical trials.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have limited experience
in conducting and managing the clinical trials necessary to obtain regulatory approvals for our product candidates and, as part
of our various licensing agreements, we rely on our licensees and certain other third parties for some of our clinical development
activities. Reliance on third parties reduces our control over these activities and does not relieve us of our responsibilities.
For example, we remain responsible for ensuring that each of our clinical trials is conducted in accordance with the general investigational
plan and protocols for the clinical trial. Moreover, the FDA requires us to comply with standards, commonly referred to as good
clinical practices for conducting, recording and reporting the results of clinical trials to assure that data and reported results
are credible and accurate and that the rights, integrity and confidentiality of clinical trial participants are protected. We are
also required to register ongoing clinical trials and post the results of completed clinical trials on a government-sponsored database,
ClinicalTrials.gov, within specified timeframes. Failure to do so can result in fines, adverse publicity and civil and criminal
sanctions. If any third parties we engage do not successfully carry out their contractual duties, meet expected deadlines or conduct
our clinical trials in accordance with regulatory requirements or our stated protocols, we might not be able to obtain, or may
be delayed in obtaining, marketing approvals for our product candidates and will not be able to, or may be delayed in our efforts
to, successfully commercialize our product candidates. If these third parties do not successfully carry out their contractual duties
or meet expected deadlines, we may be required to replace them, which may delay the affected clinical trial.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 53; Value: 45 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We may need to contract with additional
third parties for the manufacture of our product candidates, particularly for commercialization, just as we do to provide materials
required for the production of the Optejet and for some of our current research and development activities. This reliance on third
parties increases the risk that we will not have sufficient quantities of our product candidates or such quantities at an acceptable
cost, which could delay, prevent or impair our development and commercialization efforts.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We do not currently
operate and might not be able to timely implement adequate internal manufacturing facilities for additional clinical or commercial
production of our product candidates. In addition, we rely on a number of third parties for the supply of parts, formulations,
active pharmaceutical ingredients, and other materials required for our research and development activities. If are unable to establish
adequate manufacturing processes internally or we are unable to reach and maintain agreements with third parties to help us, our
research and development, manufacturing, and commercialization activities would be delayed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We rely on third parties
to provide the materials required for our research and development activities. Obtaining these materials can require various approvals
as well as reaching a purchase or commercial agreement on acceptable terms with the provider of the materials. We might not be
able to reach agreements with a sufficient number of suppliers or do so on acceptable terms. If we are unable to reach acceptable
agreements with a sufficient number of suppliers of materials, our research and development activities will be delayed and our
ability to implement our business plan will be compromised.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our manufacturing process
is complicated and expensive and it requires months of advance planning. We rely on a limited number of manufacturers for our current
supply of product candidates and may need to rely on them extensively for adequate supply of our products during commercialization.
If we were unable to acquire the necessary amount of deliverables to complete our clinical trials and ultimately commercialize
our products, our progress could be delayed substantially.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Additional potential
risks related to reliance on third-party manufacturers include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify">manufacturing delays if our third-party manufacturers are compromised due to environmental or political factors or health epidemics and pandemics such as the coronavirus, they do not satisfactorily perform according to the terms of their agreements with us, or they give greater priority to the supply of other products over our product candidates or otherwise; </TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify">delays in obtaining regulatory approval for our product candidates, if our third-party manufacturers fail to satisfy or comply with regulatory requirements;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify">the possible termination or nonrenewal of the agreement by the third party at a time that is costly or inconvenient for us;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify">the possible breach of the manufacturing agreement by the third party;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify">product loss due to contamination, equipment failure or improper installation or operation of equipment or operator error;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify">the failure of the third-party manufacturer to comply with applicable regulatory requirements; and</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify">the possible misappropriation of our proprietary information, including our trade secrets and know-how. </TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>If we, our service providers or our
third-party manufacturers fail to comply with environmental, health and safety laws and regulations, we could become subject to
fines or penalties or incur costs that could harm our business.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we, our service
providers, or any third-party manufacturers fail to comply with laws regulating the protection of the environment and health and
human safety, we could be subject to enforcement actions and our business prospects could be adversely affected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 54; Value: 45 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our research and development
activities, and the research and development activities of our service providers and third-party manufacturers, may involve the
use of hazardous materials and chemicals or the maintenance of various flammable and toxic chemicals. Failure to adequately handle
and dispose of these materials could lead to liabilities for resulting damages, which could be substantial. We also may be subject
to numerous environmental, health and workplace safety laws and regulations, including those governing laboratory procedures, exposure
to blood-home pathogens and the handling of bio-hazardous materials.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we, our service
providers, or any third-party manufacturers fail to comply with applicable federal, state or foreign laws or regulations, we could
be subject to enforcement actions, which could adversely affect our ability to develop, market and sell our product candidates
successfully and could harm our reputation and lead to reduced acceptance of our product candidates. These enforcement actions
may include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify">restrictions on, or prohibitions against, marketing our product candidates;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify">restrictions on importation of our product candidates;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify">suspension of review or refusal to approve new or pending applications;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify">suspension or withdrawal of product approvals;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify">product seizures;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify">injunctions; and</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify">civil and criminal penalties and fines.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>RISKS RELATED TO OUR INTELLECTUAL PROPERTY
AND POTENTIAL LITIGATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Our success depends on our ability
to protect our intellectual property and proprietary technology.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our success depends
in large part on our ability to obtain and maintain patent, trade secret and other intellectual property protection in the United
States and other countries with respect to our proprietary product candidates. If we do not adequately protect our intellectual
property rights, competitors may be able to erode, negate or preempt any competitive advantage we may have, which could harm our
business and ability to achieve profitability. To protect our proprietary position, we file patent applications in the United States
and abroad related to our novel product candidates that are important to our business. The patent application and approval process
is expensive and time-consuming and we might not be able to file and prosecute all necessary or desirable patent applications at
a reasonable cost or in a timely manner.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If the scope of the
patent protection we obtain is not sufficiently broad, we might not be able to prevent others from developing and commercializing
technology and products similar or identical to ours. The degree of patent protection we require to successfully compete in the
marketplace may be unavailable or severely limited in some cases and might not adequately protect our rights or permit us to gain
or keep any competitive advantage. Although we enter into non-disclosure and confidentiality agreements with parties who have access
to confidential or patentable aspects of our research and development output, such as our employees, contractors and other third
parties, any of these parties may breach the agreements and disclose such output before a patent application is filed, thereby
jeopardizing our ability to seek patent protection. In addition, publications of discoveries in the scientific literature often
lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published
until 18 months after filing, or in some cases not at all. Therefore, we cannot be certain that we were the first to make the inventions
claimed in our patents or pending patent applications, or that we were the first to file for patent protection of such inventions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The patent position
of biotechnology and pharmaceutical companies generally is highly uncertain, involves complex legal and factual questions, and
has been the subject of much litigation in recent years. As a result, the issuance, scope, validity, enforceability, and commercial
value of our patent rights may be uncertain. Our pending and future patent applications might not result in patents being issued
which protect our technology or product candidates or which effectively prevent others from commercializing competitive technologies
and product candidates. In addition, the coverage claimed in a patent application can be significantly reduced before the patent
is issued, and its scope can be reinterpreted after issuance. Even if our patent applications issue as patents, they might not
issue in a form that will provide us with any meaningful protection, prevent competitors or other third parties from competing
with us, or otherwise provide us with any competitive advantage. In addition, changes in either the patent laws or interpretation
of the patent laws in the United States and other countries may diminish the value of our patents or narrow the scope of our patent
protection. In addition, the laws of foreign countries might not protect our rights to the same extent or in the same manner as
the laws of the United States. For example, patent laws in various jurisdictions, including significant commercial markets such
as Europe, restrict the patentability of methods of treatment of the human body more than United States law does.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 55; Value: 45 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Some of our future
patents and patent applications may be co-owned with third parties. If we are unable to obtain an exclusive license to any such
third-party co-owners&rsquo; interest in such patents or patent applications, such co-owners may be able to license their rights
to other third parties, including our competitors, and our competitors could market competing products and technology. In addition,
we would need the cooperation of any such co-owners of our patents in order to enforce such patents against third parties, and
such cooperation might not be provided to us. Furthermore, we, or any future partners, collaborators, or licensees, may fail to
identify patentable aspects of inventions made in the course of development and commercialization activities before it is too late
to obtain patent protection on them. Therefore, we may miss potential opportunities to strengthen our patent position. Any of the
foregoing could have a material adverse effect on our business, financial condition, results of operations, and prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Our patents covering our proprietary
technology maybe subject to challenge, narrowing, circumvention and invalidation by third parties.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any of our patents
may be challenged, narrowed, circumvented, or invalidated by third parties. The issuance of a patent is not conclusive as to its
inventorship, scope, validity, or enforceability, and our patents may be challenged in the courts or patent offices in the United
States and abroad. We may be subject to a third party preissuance submission of prior art to the USPTO or become involved in opposition,
derivation, revocation, reexamination, post-grant and <I>inter partes</I> review, or interference proceedings challenging our patent
rights or the patent rights of others. An adverse determination in any such submission, proceeding or litigation could reduce the
scope of, or invalidate, our patent rights, allow third parties to commercialize our technology or products and compete directly
with us, without payment to us, or result in our inability to manufacture or commercialize products without infringing third-party
patent rights. Moreover, we may have to participate in interference proceedings declared by the USPTO to determine priority of
invention or in post-grant challenge proceedings, such as oppositions in a foreign patent office, that challenge priority of invention
or other features of patentability. Such challenges may result in loss of patent rights, loss of exclusivity, or in patent claims
being narrowed, invalidated, or held unenforceable, which could limit our ability to stop others from using or commercializing
similar or identical technology and products, or limit the duration of the patent protection of our technology and product candidates.
Such proceedings also may result in substantial cost and require significant time from our scientists and management, even if the
eventual outcome is favorable to us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, our competitors
and other third parties may be able to circumvent our patents by developing similar or alternative technologies or products in
a non-infringing manner. For example, a third party may develop a competitive therapy that provides benefits similar to our product
candidates but that uses a technology that falls outside the scope of our patent protection. Our competitors may also seek approval
to market generic versions of any approved products and in connection with seeking such approval may claim that our patents are
invalid, unenforceable or not infringed. In these circumstances, we may need to defend or assert our patents, or both, including
by filing lawsuits alleging patent infringement. In any of these types of proceedings, a court or other agency with jurisdiction
may find our patents invalid or unenforceable, or that our competitors are competing in a non-infringing manner. Thus, even if
we have valid and enforceable patents, these patents still might not provide protection against competing products or processes
sufficient to achieve our business objectives. If the patent protection provided by the patents and patent applications we hold
or pursue with respect to our product candidates is not sufficiently broad to impede such competition, our ability to successfully
commercialize our product candidates could be negatively affected, which could have a material adverse effect on our business,
financial condition, results of operations, and prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We cannot be sure that we were the
first to make the technologies claimed in our patents or patent applications or that we were the first to file for patent protection.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Assuming the other
requirements for patentability are met, currently, the first to file a patent application is generally entitled to the patent.
However, prior to March&nbsp;16, 2013, in the United States, the first to invent was entitled to the patent. Publications of discoveries
in the scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions
are not published until 18 months after filing, or in some cases not at all. Therefore, we cannot be certain that we were the first
to make the inventions claimed in our patents or pending patent applications, or that we were the first to file for patent protection
of such inventions. Similarly, we cannot be certain that parties from whom we may license or purchase patent rights were the first
to make relevant claimed inventions or were the first to file for patent protection for them. If third parties have filed patent
applications on inventions claimed in our patents or applications on or before March&nbsp;15, 2013, an interference proceeding
in the United States can be initiated by such third parties to determine the first to invent any of the subject matter covered
by the patent claims of our applications. If third parties have filed such applications after March&nbsp;15, 2013, a derivation
proceeding in the United States can be initiated by such third parties to determine whether our invention was derived from theirs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 56; Value: 45 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>The patent application process is
subject to numerous risks and there can be no assurance that we will be successful in obtaining patents for which we have applied.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pending patent applications
cannot be enforced against third parties practicing the technology claimed in such applications unless and until a patent issues
from such applications. The patent application process is subject to numerous risks and uncertainties, and there can be no assurance
that we or any of our future development partners will be successful in protecting our product candidates by obtaining and defending
patents. These risks and uncertainties include the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify">the USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other provisions during the patent process. There are situations in which noncompliance can result in abandonment or lapse of a patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. In such an event, competitors might be able to enter the market earlier than would otherwise have been the case;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify">the coverage claimed in a patent application can be significantly reduced before the patent is issued, and its scope can be reinterpreted after issuance;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify">patent applications might not result in any patents being issued;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify">patents that may be issued or in-licensed may be challenged, invalidated, modified, revoked, circumvented, narrowed, found to be unenforceable or otherwise might not provide any competitive advantage;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify">our competitors, many of whom have substantially greater resources and many of whom have made significant investments in competing technologies, may seek or may have already obtained patents that will limit, interfere with or eliminate our ability to make, use, and sell our potential product candidates;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify">there may be significant pressure on the U.S. government and international governmental bodies to limit the scope of patent protection both inside and outside the United States for disease treatments that prove successful, as a matter of public policy regarding worldwide health concerns; and</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify">countries other than the United States may have patent laws less favorable to patentees than those upheld by United States courts, allowing foreign competitors a better opportunity to create, develop and market competing product candidates. </TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any of the foregoing
events could have a material adverse effect on our business, financial condition, results of operations, and prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>It is difficult and costly to protect
our intellectual property and our proprietary technologies, and we might not be able to ensure their protection.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our commercial success
will depend in part on obtaining and maintaining patent protection and trade secret protection for the composition, use and structure
of our products and product candidates, the methods used to manufacture them, the related therapeutic targets and associated methods
of treatment as well as on successfully defending these patents against potential third-party challenges. Our ability to protect
our products and product candidates from unauthorized making, using, selling, offering to sell or importing by third parties is
dependent on the extent to which we have rights under valid and enforceable patents that cover these activities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 57; Value: 45 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The ultimate determination
by the USPTO or by a court or other trier of fact in the United States, or corresponding foreign national patent offices or courts,
on whether a claim meets all requirements of patentability cannot be assured. Although we have conducted searches for third-party
publications, patents and other information that may affect the patentability of claims in our various patent applications and
patents, we cannot be certain that all relevant information has been identified. Accordingly, we cannot predict the breadth of
claims that may be allowed or enforced in our patents or patent applications, in our licensed patents or patent applications or
in third-party patents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We cannot provide assurances
that any of our patent applications will be found to be patentable, including over our own prior art patents, or will issue as
patents. Neither can we make assurances as to the scope of any claims that may issue from our pending and future patent applications
nor to the outcome of any proceedings by any potential third parties that could challenge the patentability, validity or enforceability
of our patents and patent applications in the United States or foreign jurisdictions. Any such challenge, if successful, could
limit patent protection for our products and product candidates and/or materially harm our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The degree of future
protection for our proprietary rights is uncertain because legal means afford only limited protection and might not adequately
protect our rights or permit us to gain or keep our competitive advantage. For example:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify">we might not be able to generate sufficient data to support full patent applications that protect the entire breadth of developments in one or more of our programs;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify">it is possible that one or more of our pending patent applications will not become an issued patent or, if issued, that the patent(s)&nbsp;will be insufficient to protect our technology, provide us with a basis for commercially viable products or provide us with any competitive advantages;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify">if our pending applications issue as patents, they may be challenged by third parties as not infringed, invalid or unenforceable under United States or foreign laws; or</TD></TR>
<TR STYLE="vertical-align: top">
    <TD></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify">if issued, the patents under which we hold rights might not be valid or enforceable.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, to the
extent that we are unable to obtain and maintain patent protection for one of our products or product candidates or in the event
that such patent protection expires, it may no longer be cost-effective to extend our portfolio by pursuing additional development
of a product or product candidate for follow-on indications. Any of the foregoing could have a material adverse effect on our business,
financial condition, results of operations, and prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Obtaining and maintaining patent
protection of our technologies depends on compliance with various procedural, document submission, fee payment and other requirements
imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these
requirements.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Periodic maintenance
fees, renewal fees, annuity fees and various other governmental fees on patents and applications are required to be paid to the
USPTO and various governmental patent agencies outside of the United States in several stages over the lifetime of the patents
and applications. The USPTO and various non- U.S. governmental patent agencies require compliance with a number of procedural,
documentary, fee payment and other similar provisions during the patent application process and after a patent has issued. There
are situations in which non-compliance can result in abandonment or lapse of the patent or patent application, resulting in partial
or complete loss of patent rights in the relevant jurisdiction. Under the terms of some of our licenses or future licenses, we
may not have the ability to maintain or prosecute patents in the portfolio, and must therefore rely on third parties to comply
with these requirements. Failure by us or our licensors to maintain protection of our patent portfolio could have a material adverse
effect on our business, financial condition, results of operations, and prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, it is
possible that defects of form in the preparation or filing of our patents or patent applications may exist, or may arise in the
future, for example with respect to proper priority claims, inventorship, claim scope, or requests for patent term adjustments.
If we fail to establish, maintain or protect such patents and other intellectual property rights, such rights may be reduced or
eliminated. If any of our present or future partners, collaborators, licensees, or licensors, are not fully cooperative or disagree
with us as to the prosecution, maintenance or enforcement of any patent rights, such patent rights could be compromised. If there
are material defects in the form, preparation, prosecution, or enforcement of our patents or patent applications, such patents
may be invalid and/or unenforceable, and such applications may never result in valid, enforceable patents. Any of these outcomes
could impair our ability to prevent competition from third parties, which may have a material adverse effect on our business, financial
condition, results of operations, and prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 58; Value: 45 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Patent terms may be inadequate to
protect our competitive position on our products for an adequate amount of time and if we do not obtain protection under the Hatch-Waxman
Amendments and similar non- U.S. legislation for extending the term of patents covering each of our product candidates, our business
may be materially harmed.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Patents have a limited
lifespan. In the United States, the natural expiration of a patent is generally 20 years after it is filed. Various extensions
may be available, however, the life of a patent, and the protection it affords, is limited. Given the amount of time required for
the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before
or shortly after such candidates are commercialized. As a result, our patent portfolio might not provide us with adequate and continuing
patent protection sufficient to exclude others from commercializing products similar to our product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Depending upon the
timing, duration and conditions of FDA marketing approval of our product candidates, one or more of our U.S. patents may be eligible
for limited patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984, referred to as the
Hatch-Waxman Amendments and similar legislation in the European Union. The Hatch-Waxman Amendments permit a patent term extension
of up to five years for a patent covering an approved product as compensation for effective patent term lost during product development
and the FDA regulatory review process. A patent term extension cannot extend the remaining term of a patent beyond a total of 14
years from the date of product approval, only one patent may be extended and only those claims covering the approved drug, a method
for using it, or a method for manufacturing it may be extended. However, we might not receive an extension if we fail to apply
within applicable deadlines, fail to apply prior to expiration of relevant patents or otherwise fail to satisfy applicable requirements.
Moreover, the length of the extension could be less than we request. If we are unable to obtain patent term extension or the term
of any such extension is less than we request, the period during which we can enforce our patent rights for that product will be
shortened and our competitors may obtain approval to market competing products sooner. As a result, our revenue from applicable
products could be reduced and could have a material adverse effect on our business, financial condition, results of operations,
and prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Changes to the patent law in the
United States or other jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our
products.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our success is heavily
dependent on intellectual property, particularly patents. Obtaining and enforcing patents in the biopharmaceutical industry involves
both technological and legal complexity and is therefore costly, time consuming and inherently uncertain. The Leahy-Smith America
Invents Act, or the America Invents Act, reformed U.S. patent law in part by changing the U.S. patent system from a &ldquo;first
to invent&rdquo; system to a &ldquo;first inventor to file&rdquo; system, expanding the definition of prior art, and developing
a post-grant review system. This legislation changed U.S. patent law in a way that may weaken our ability to obtain patent protection
in the United States for those applications filed after March&nbsp;16, 2013.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Further, the America
Invents Act created new procedures to challenge the validity of issued patents in the United States, including post-grant review
and <I>inter partes</I> review proceedings, which some third parties have been using to cause the cancellation of selected or all
claims of issued patents of competitors. For a patent with an effective filing date of March&nbsp;16, 2013 or later, a petition
for post-grant review can be filed by a third party in a nine-month window from issuance of the patent. A petition for <I>inter
partes</I> review can be filed immediately following the issuance of a patent if the patent has an effective filing date prior
to March&nbsp;16, 2013. A petition for <I>inter partes</I> review can be filed after the nine-month period for filing a post-grant
review petition has expired for a patent with an effective filing date of March&nbsp;16, 2013 or later. Post-grant review proceedings
can be brought on any ground of invalidity, whereas <I>inter partes</I> review proceedings can only raise an invalidity challenge
based on published prior art and patents. These adversarial actions at the USPTO review patent claims without the presumption of
validity afforded to U.S. patents in lawsuits in U.S. federal courts, and use a lower burden of proof than used in litigation in
U.S. federal courts. Therefore, it is generally considered easier for a competitor or third party to have a U.S. patent invalidated
in a USPTO post-grant review or <I>inter partes</I> review proceeding than invalidated in a litigation in a U.S. federal court.
If any of our patents are challenged by a third party in such a USPTO proceeding, there is no guarantee that we, our licensors
or collaborators will be successful in defending the patent, which would result in a loss of the challenged patent right to us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 59; Value: 45 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, recent
court rulings in cases such as <I>Association for Molecular Pathology v. Myriad Genetics,&nbsp;Inc., BRCA1-&nbsp;&amp; BRCA2-Based
Hereditary Cancer Test Patent Litigation, Promega Corp. v. Life Technologies Corp. and Abbvie Deutschland GmbH v. Janssen Biotech,&nbsp;Inc.</I>
have narrowed the scope of patent protection available in certain circumstances and weakened the rights of patent owners in certain
situations. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination
of events has created uncertainty with respect to the value of patents once obtained. Depending on future actions by the U.S. Congress,
the U.S. courts, the USPTO and the relevant law-making bodies in other countries, the laws and regulations governing patents could
change in unpredictable ways that would weaken our ability to obtain new patents or to enforce our existing patents and patents
that we might obtain in the future. Any changes to patent law in the United States or other jurisdictions that impairs our ability
to protect our product candidates could have a material adverse effect on our business, financial condition, results of operations,
and prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We might not be able to enforce our
intellectual property rights throughout the world.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Filing, prosecuting,
enforcing and defending patents on our product candidates in all countries throughout the world would be prohibitively expensive,
and our intellectual property rights in some foreign countries can be less extensive than those in the United States. The requirements
for patentability may differ in certain countries, particularly in developing countries; thus, even in countries where we do pursue
patent protection, there can be no assurance that any patents will issue with claims that cover our products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Moreover, our ability
to protect and enforce our intellectual property rights may be adversely affected by unforeseen changes in foreign intellectual
property laws. Many companies have encountered significant problems in protecting and defending intellectual property rights in
certain foreign jurisdictions. The legal systems of some countries, including India, China and other developing countries, do not
favor the enforcement of patents and other intellectual property rights. This could make it difficult for us to stop the infringement
of our patents or the misappropriation of our other intellectual property rights. For example, many foreign countries have compulsory
licensing laws under which a patent owner must grant licenses to third parties. Consequently, we might not be able to prevent third
parties from practicing our inventions in certain foreign countries. Competitors may use our technologies in jurisdictions where
we have not obtained patent protection to develop and market their own products and, further, may export otherwise infringing products
to territories where we have patent protection, if our ability to enforce our patents to stop infringing activities is inadequate.
These products may compete with our products, and our patents or other intellectual property rights might not be effective or sufficient
to prevent them from competing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Agreements through
which we license patent rights might not give us sufficient rights to permit us to pursue enforcement of our licensed patents or
defense of any claims asserting the invalidity of these patents (or control of enforcement or defense) of such patent rights in
all relevant jurisdictions as requirements may vary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Proceedings to enforce
our patent rights in foreign jurisdictions, whether or not successful, could result in substantial costs and divert our efforts
and resources from other aspects of our business. Moreover, such proceedings could put our patents at risk of being invalidated
or interpreted narrowly and our patent applications at risk of not issuing and could provoke third parties to assert claims against
us. We might not prevail in any lawsuits that we initiate and the damages or other remedies awarded, if any, might not be commercially
meaningful. Furthermore, while we intend to protect our intellectual property rights in major markets for our products, we cannot
ensure that we will be able to initiate or maintain similar efforts in all jurisdictions in which we may wish to market our products.
Accordingly, our efforts to protect our intellectual property rights in such countries may be inadequate. Any of the foregoing
could have a material adverse effect on our business, financial condition, results of operations, and prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 60; Value: 45 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Split-Segment; Name: 5 -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>If we are sued for infringing, misappropriating,
or otherwise violating intellectual property rights of third parties, such litigation could be costly and time consuming and could
prevent or delay us from developing or commercializing our product candidates.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our commercial success
depends, in part, on our ability to develop, manufacture, market and sell our product candidates without infringing, misappropriating,
or otherwise violating the intellectual property and other proprietary rights of third parties. Third parties may have U.S. and
non-U.S. issued patents and pending patent applications relating to compounds, methods of manufacturing compounds and/or methods
of use for the treatment of the disease indications for which we are developing our product candidates that may cover our product
candidates or approach to complement inhibition. If any third-party patents or patent applications are found to cover our product
candidates or their methods of use or manufacture, or our approach to complement inhibition, we might not be free to manufacture
or market our product candidates as planned without obtaining a license, which might not be available on commercially reasonable
terms, or at all.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There is a substantial
amount of intellectual property litigation in the biotechnology and pharmaceutical industries, and we may become party to, or threatened
with, litigation or other adversarial proceedings regarding intellectual property rights with respect to our product candidates,
including interference and post-grant proceedings before the USPTO. There may be third-party patents or patent applications with
claims to materials, formulations, methods of manufacture or methods for treatment related to the composition, use or manufacture
of our product candidates. We cannot guarantee that any of our patent searches or analyses including, but not limited to, the identification
of relevant patents, the scope of patent claims or the expiration of relevant patents are complete or thorough, nor can we be certain
that we have identified each and every patent and pending application in the United States and abroad that is relevant to or necessary
for the commercialization of our product candidates in any jurisdiction. Because patent applications can take many years to issue,
there may be currently pending patent applications which may later result in issued patents that our product candidates may be
accused of infringing. In addition, third parties may obtain patents in the future and claim that use of our technologies infringes
upon these patents. Accordingly, third parties may assert infringement claims against us based on intellectual property rights
that exist now or arise in the future. The outcome of intellectual property litigation is subject to uncertainties that cannot
be adequately quantified in advance. The pharmaceutical and biotechnology industries have produced a significant number of patents,
and it might not always be clear to industry participants, including us, which patents cover various types of products or methods
of use or manufacture. The scope of protection afforded by a patent is subject to interpretation by the courts, and the interpretation
is not always uniform. If we are sued for patent infringement, we would need to demonstrate that our product candidates, products
or methods either do not infringe the patent claims of the relevant patent or that the patent claims are invalid or unenforceable,
and we might not be able to do this. Proving invalidity is difficult. For example, in the United States, proving invalidity requires
a showing of clear and convincing evidence to overcome the presumption of validity enjoyed by issued patents. Even if we are successful
in these proceedings, we may incur substantial costs and the time and attention of our management and scientific personnel could
be diverted in pursuing these proceedings, which could significantly harm our business and operating results. In addition, we might
not have sufficient resources to bring these actions to a successful conclusion. Further, the outcome of intellectual property
litigation is subject to uncertainties that cannot be adequately quantified in advance, including the demeanor and credibility
of witnesses and the identity of any adverse party. This is especially true in intellectual property cases that may turn on the
testimony of experts as to technical facts upon which experts may reasonably disagree.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we are found to
infringe, misappropriate, or otherwise violate a third party&rsquo;s intellectual property rights, we could be forced, including
by court order, to cease developing, manufacturing or commercializing the infringing product candidate or product. Alternatively,
we may be required to obtain a license from such third party in order to use the infringing technology and continue developing,
manufacturing or marketing the infringing product candidate or product. However, we might not be able to obtain any required license
on commercially reasonable terms or at all. Even if we were able to obtain a license, it could be non-exclusive, thereby giving
our competitors access to the same technologies licensed to us; alternatively or additionally it could include terms that impede
or destroy our ability to compete successfully in the commercial marketplace. In addition, we could be found liable for monetary
damages, including treble damages and attorneys&rsquo; fees if we are found to have willfully infringed a patent. A finding of
infringement could prevent us from commercializing our product candidates or force us to cease some of our business operations,
which could harm our business. Claims that we have misappropriated the confidential information or trade secrets of third parties
could have a similar negative impact on our business. Any of the foregoing could have a material adverse effect on our business,
financial condition, results of operations, and prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 61; Options: NewSection; Value: 60 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> <!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We may be subject to claims by third
parties asserting that our employees or we have misappropriated their intellectual property, or claiming ownership of what we regard
as our own intellectual property and proprietary technology.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Many of our current
and former employees and our licensors&rsquo; current and former employees, including our senior management, were previously employed
at universities or at other biotechnology or pharmaceutical companies, including some which may be competitors or potential competitors.
Although we try to ensure that our employees do not use the proprietary information or know-how of others in their work for us,
we may be subject to claims that we or these employees have used or disclosed intellectual property, including trade secrets or
other proprietary information, of any such third party. Litigation may be necessary to defend against such claims. If we fail in
defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel
or sustain damages. Such intellectual property rights could be awarded to a third party, and we could be required to obtain a license
from such third party to commercialize our technology or products. Such a license might not be available on commercially reasonable
terms or at all. Even if we are successful in defending against such claims, litigation could result in substantial costs and be
a distraction to management.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, while
we typically require our employees, consultants and contractors who may be involved in the development of intellectual property
to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each
party who in fact develops intellectual property that we regard as our own, which may result in claims by or against us related
to the ownership of such intellectual property. If we fail in prosecuting or defending any such claims, in addition to paying monetary
damages, we may lose valuable intellectual property rights. Even if we are successful in prosecuting or defending against such
claims, litigation could result in substantial costs and be a distraction to our senior management and scientific personnel. Any
of the foregoing could have a material adverse effect on our business, financial condition, results of operations, and prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We may become involved in lawsuits
to protect or enforce our patents or other intellectual property, which could be expensive, time consuming and unsuccessful.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Competitors may infringe,
misappropriate, or otherwise violate our patents, trademarks, copyrights or other intellectual property. To counter infringement
or unauthorized use, we may be required to file infringement claims, which can be expensive and time consuming and divert the time
and attention of our management and scientific personnel. Any claims we assert against perceived infringers could provoke these
parties to assert counterclaims against us alleging that we infringe their patents, in addition to counterclaims asserting that
our patents are invalid or unenforceable, or both. In any patent infringement proceeding, there is a risk that a court will decide
that a patent of ours is invalid or unenforceable, in whole or in part, and that we do not have the right to stop the other party
from using the invention at issue. There is also a risk that, even if the validity of such patents is upheld, the court will construe
the patent&rsquo;s claims narrowly or decide that we do not have the right to stop the other party from using the invention at
issue on the grounds that our patent claims do not cover the invention. An adverse outcome in a litigation or proceeding involving
one or more of our patents could limit our ability to assert those patents against those parties or other competitors, and may
curtail or preclude our ability to exclude third parties from making and selling similar or competitive products. Similarly, if
we assert trademark infringement claims, a court may determine that the marks we have asserted are invalid or unenforceable, or
that the party against whom we have asserted trademark infringement has superior rights to the marks in question. In this case,
we could ultimately be forced to cease use of such trademarks.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Further, the outcome
of intellectual property litigation is subject to uncertainties that cannot be adequately quantified in advance, including the
demeanor and credibility of witnesses and the identity of any adverse party. This is especially true in intellectual property cases
that may turn on the testimony of experts as to technical facts upon which experts may reasonably disagree.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Even if we establish
infringement, the court may decide not to grant an injunction against further infringing activity and instead award only monetary
damages, which might not be an adequate remedy. Furthermore, because of the substantial amount of discovery required in connection
with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure
during litigation. There could also be public announcements of the results of hearings, motions or other interim proceedings or
developments. If securities analysts or investors perceive these results to be negative, it could adversely affect the price of
our common shares. Moreover, there can be no assurance that we will have sufficient financial or other resources to file and pursue
such infringement claims, which typically last for years before they are concluded. Even if we ultimately prevail in such claims,
the monetary cost of such litigation and the diversion of the attention of our management and scientific personnel could outweigh
any benefit we receive as a result of the proceedings. Any such litigation could have a material adverse effect on our business,
financial condition, results of operations, and prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 62; Value: 60 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> <!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>If we fail to comply with our obligations
under our existing and any future intellectual property licenses with third parties, we could lose license rights that are important
to our business.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may be reliant upon
licenses to certain patent rights and proprietary technology form third parties that are important or necessary to the development
of our product candidates. These and other licenses might not provide exclusive rights to use such intellectual property and technology
in all relevant fields of use and in all territories in which we may wish to develop or commercialize our technology and products
in the future. As a result, we might not be able to prevent competitors from developing and commercializing competitive products
in territories included in all of our licenses. Our licensors may have relied on third party consultants or collaborators or funds
from third parties such that our licensors are not the sole and exclusive owners of the patents we in-license. This could have
a material adverse effect on our competitive position, business, financial conditions, results of operations and prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, the agreements
under which we license patent rights might not give us control over patent prosecution or maintenance, so that we might not be
able to control which claims or arguments are presented and might not be able to secure, maintain, or successfully enforce necessary
or desirable patent protection from those patent rights. We cannot be certain that patent prosecution and maintenance activities
by our licensors will be conducted in compliance with applicable laws and regulations or will result in valid and enforceable patents.
Even if we are permitted to pursue such enforcement or defense, we will require the cooperation of our licensors, and cannot guarantee
that we would receive it and on what terms. We cannot be certain that our licensors will allocate sufficient resources or prioritize
their or our enforcement of such patents or defense of such claims to protect our interests in any licensed patents. If we cannot
obtain patent protection, or enforce existing or future patents against third parties, it could have a material adverse effect
on our business, financial condition, results of operations, and prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Further, the agreements
under which we currently license intellectual property or technology to or from third parties are complex, and certain provisions
in such agreements may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that
may arise could narrow what we believe to be the scope of our rights to the relevant intellectual property or technology, or increase
what we believe to be our financial or other obligations under the relevant agreement, either of which could have a material adverse
effect on our business, financial conditions, results of operations, and prospects. Moreover, if disputes over intellectual property
that we license prevent or impair our ability to maintain our licensing arrangements on commercially acceptable terms, we may be
unable to successfully develop and commercialize the affected product candidates, which could have a material adverse effect on
our business, financial conditions, results of operations, and prospects. Disputes may arise regarding intellectual property subject
to a licensing agreement, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify">the scope of rights granted under the license agreement and other interpretation-related issues;</TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify">the extent to which our technology and processes infringe on intellectual property of the licensor that is not subject to the licensing agreement;</TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify">the sublicensing of patent and other rights under current and any future collaborative development relationships;</TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify">our diligence obligations under any license agreement and what activities satisfy such obligations;</TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify">the inventorship and ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our license counterparties and us and our partners; and</TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify">the priority of invention of patented technology.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In spite of our efforts,
our license counterparties might conclude that we have materially breached our license agreements and might therefore terminate
the license agreements, which may remove our ability to develop and commercialize the product candidates and technology covered
by these license agreements. If any in-licenses are terminated, competitors would have the freedom to seek regulatory approval
of, and to market, products identical to ours. It is possible that we may be unable to obtain any additional licenses that we require
at a reasonable cost or on reasonable terms, if at all. In that event, we may be required to expend significant time and resources
to redesign our product candidates, technology, or the methods for manufacturing them or to develop or license replacement technology,
all of which might not be feasible on a technical or commercial basis. If we are unable to do so, we may be unable to develop or
commercialize the affected product candidates, which could harm our business, financial condition, results of operations, and prospects
significantly. Any of these events could have a material adverse effect on our competitive position, business, financial conditions,
results of operations, and prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 63; Value: 60 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> <!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>If we are unable to protect the confidentiality
of our trade secrets, the value of our technology could be negatively impacted and our business would be harmed.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition to the
protection afforded by patents, we also rely on trade secret protection for certain aspects of our intellectual property. However,
trade secrets are difficult to protect. We seek to protect these trade secrets, in part, by entering into non-disclosure and confidentiality
agreements with parties who have access to them, such as our employees, consultants, independent contractors, advisors, contract
manufacturers, suppliers and other third parties. We also enter into confidentiality and invention or patent assignment agreements
with employees and certain consultants. Any party with whom we have executed such an agreement may breach that agreement and disclose
our proprietary information, including our trade secrets, and we might not be able to obtain adequate remedies for such breaches.
Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming,
and the outcome is unpredictable. Additionally, if the steps taken to maintain our trade secrets are deemed inadequate, we may
have insufficient recourse against third parties for misappropriating the trade secret. Further, if any of our trade secrets were
to be lawfully obtained or independently developed by a competitor, we would have no right to prevent such third party, or those
to whom they communicate such technology or information, from using that technology or information to compete with us. If any of
our trade secrets were to be disclosed to or independently developed by a competitor, it could have a material adverse effect on
our business, financial condition, results of operations, and prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>If our trademarks and trade names
are not adequately protected, then we might not be able to build name recognition in our marks of interest and our business may
be adversely affected.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our trademarks or trade
names, including Optejet, may be challenged, infringed, circumvented or declared generic or determined to be infringing on other
marks. We rely on both registration and common law protection for our trademarks. We might not be able to protect our rights to
these trademarks and trade names or may be forced to stop using these names, which we need for name recognition by potential partners
or customers in our markets of interest. During trademark registration proceedings, we may receive rejections. Although we would
be given an opportunity to respond to those rejections, we may be unable to overcome such rejections. In addition, in the USPTO
and in comparable agencies in many foreign jurisdictions, third parties are given an opportunity to oppose pending trademark applications
and to seek to cancel registered trademarks. Opposition or cancellation proceedings may be filed against our trademarks, and our
trademarks might not survive such proceedings. If we are unable to establish name recognition based on our trademarks and trade
names, we might not be able to compete effectively and our business may be adversely affected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>RISKS RELATED TO OWNERSHIP OF OUR COMMON
STOCK</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Our management and members of our
Board of Directors have the ability to substantially influence all matters submitted to stockholders for approval.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of March&nbsp;29, 2021,
our management and members of our Board of Directors, in the aggregate, beneficially owned shares representing approximately 18.0% of
our capital stock. As a result, they can substantially influence all matters submitted to our stockholders for approval, as well as our
management and affairs. For example, these persons would substantially influence the election of directors and approval of any merger,
consolidation or sale of all or substantially all of our assets. This concentration of voting power could delay or prevent an acquisition
of our company on terms that other stockholders desire or result in management of our company that our public stockholders disagree with.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 64; Value: 60 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> <!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>A significant portion of our total
outstanding shares may be sold into the market in the near future, which could cause the market price of our common stock to drop
significantly, even if our business is performing well.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Sales of a substantial number
of shares of our common stock in the public market could occur at any time, subject to certain restrictions. These sales, or the perception
in the market that holders of a large number of shares intend to sell shares, could reduce the market price of our common stock. As of
March&nbsp;29,2021, we had 25,623,577 shares of common stock outstanding, and 1,357,853 shares of common stock issuable upon exercise
of warrants also issued in the March&nbsp;2020 private placement, which may be resold without restriction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>The price of our common stock may
be volatile and fluctuate substantially, which could result in substantial losses for purchasers of our common stock.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The stock market historically
has experienced extreme price and volume fluctuations, such as those seen in February&nbsp;2020 as a result of concerns the coronavirus
will impact the economy worldwide. As a result of this volatility and because the public market for our stock is new, you might not be
able to sell your common stock at or above the price at which you purchase it. From our IPO in January&nbsp;2018 through March&nbsp;29,
2021, the per share trading price of our common stock has been as high as $10.74 and as low as $1.77. It might continue to fluctuate significantly
in response to various factors, some of which are beyond our control. These factors include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify">general economic, industry and market conditions, including as a result of the coronavirus pandemic;</TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify">our ability to successfully conduct clinical trials, submit NDAs and gain marketing approval for our product candidates;</TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify">results of clinical trials of our product candidates or those of our competitors;</TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify">the success of competitive products or technologies;</TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify">commencing, maintaining, or terminating of licensing agreements and other collaborations;</TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify">regulatory or legal developments in the United States and other countries;</TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify">developments or disputes concerning patent applications, issued patents or other proprietary rights;</TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify">the recruitment or departure of key personnel;</TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify">the level of expenses related to any of our product candidates or clinical development programs;</TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify">the results of our efforts to discover, develop, acquire or in-license additional product candidates;</TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify">actual or anticipated changes in estimates as to financial results, development timelines or recommendations by securities analysts;</TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify">our inability to obtain or delays in obtaining adequate product supply for any approved product or inability to do so at acceptable prices;</TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify">disputes or other developments relating to proprietary rights, including patents, litigation matters and our ability to obtain patent protection for our technologies;</TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify">significant lawsuits, including patent or stockholder litigation;</TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify">variations in our financial results or those of companies that are perceived to be similar to us;</TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify">changes in the structure of healthcare payment systems;</TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify">market conditions in the pharmaceutical and biotechnology sectors;</TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify">the other factors described in this &ldquo;Risk Factors&rdquo; section.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We have broad discretion in the use
of our cash, including the net proceeds from our financings, and might not use them effectively.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our management will
have broad discretion in the application of our cash, including the net proceeds from our December&nbsp;2018, July&nbsp;2019 and
August&nbsp;2020 public offerings of common stock, and March&nbsp;2020 private placement, and could spend our cash in ways that
do not improve our results of operations or enhance the value of our common stock. The failure by our management to apply these
funds effectively could result in financial losses that could have a material adverse effect on our business, cause the price of
our common stock to decline and delay the development of our product candidates. Pending their use, we may invest our cash, including
the net proceeds from our financings, in a manner that does not produce income or that loses value.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 65; Value: 60 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> <!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Our business is subject to changing
regulations regarding corporate governance, disclosure controls, internal control over financial reporting, and other compliance
areas that will increase both our costs and the risk of noncompliance.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As a public company,
we are subject to the reporting requirements of the Exchange Act, the Sarbanes-Oxley Act of 2002, or the Sarbanes-Oxley Act, the
Dodd-Frank Act, and the rules&nbsp;and regulations of our stock exchange. The requirements of these rules&nbsp;and regulations
will increase our legal, accounting, and financial compliance costs, will make some activities more difficult, time-consuming,
and costly, and may also place undue strain on our personnel, systems, and resources.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Sarbanes-Oxley
Act requires, among other things, that we maintain effective disclosure controls and procedures and internal control over financial
reporting. Commencing with our fiscal year ending December&nbsp;31, 2018, we performed system and process evaluation and testing
of our internal control over financial reporting so that management could report on the effectiveness of our internal control over
financial reporting, as required by Section&nbsp;404 of the Sarbanes-Oxley Act. Our compliance with Section&nbsp;404 of the Sarbanes-Oxley
Act requires that we incur substantial accounting expense and expend significant management efforts. Prior to our IPO, we had never
been required to test our internal controls within a specified period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are required to
disclose changes made to our internal control and procedures on a quarterly basis. However, our independent registered public accounting
firm will not be required to formally attest to the effectiveness of our internal control over financial reporting pursuant to
Section&nbsp;404 of the Sarbanes-Oxley Act until we are no longer an &ldquo;emerging growth company&rdquo; as defined in the Jumpstart
Our Business Startups Act of 2012 (JOBS Act), if we take advantage of the exemption available under the JOBS Act to the auditor
attestation requirement in Section&nbsp;404(b)&nbsp;of the Sarbanes-Oxley Act. If we are not able to comply with the requirements
of Section&nbsp;404 of the Sarbanes-Oxley Act in a timely manner, the market price of our stock could decline and we could be subject
to sanctions or investigations by the stock exchange on which our common stock is listed, the SEC, or other regulatory authorities,
which would require additional financial and management resources.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Failure to develop and maintain adequate
financial controls could cause us to have material weaknesses, which could adversely affect our operations and financial position.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">An internal control
system, no matter how well-designed, cannot provide absolute assurance that misstatements due to error or fraud will not occur
or that all control issues and instances of fraud will be detected. If we are not able to comply with the requirements of Section&nbsp;404
of the Sarbanes-Oxley Act in a timely manner, or if we are unable to maintain proper and effective internal controls, we might
not be able to produce timely and accurate financial statements. If that were to happen, the market price of our stock could decline
and we could be subject to sanctions or investigations by the stock exchange on which our common stock is listed, the SEC, or other
regulatory authorities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any failure to develop
or maintain effective controls, or any difficulties encountered in their implementation or improvement, could harm our operating
results or cause us to fail to meet our reporting obligations. Any failure to implement and maintain effective internal controls
also could adversely affect the results of periodic management evaluations regarding the effectiveness of our internal control
over financial reporting that we are required to include in our periodic reports filed with the SEC under Section&nbsp;404 of the
Sarbanes-Oxley Act. Ineffective disclosure controls and procedures or internal control over financial reporting could also cause
investors to lose confidence in our reported financial and other information, which would likely have a negative effect on the
trading price of our common stock. Implementing any appropriate changes to our internal controls may require specific compliance
training of our directors, officers, and employees, entail substantial costs in order to modify our existing accounting systems,
and take a significant period of time to complete. Such changes may not be effective, however, in maintaining the adequacy of our
internal controls, and any failure to maintain that adequacy, or consequent inability to produce accurate financial statements
on a timely basis, could increase our operating costs and could materially impair our ability to operate our business. In the event
that we are not able to demonstrate compliance with Section&nbsp;404 of the Sarbanes-Oxley Act in a timely manner, that our internal
controls are perceived as inadequate, or that we are unable to produce timely or accurate financial statements, investors may lose
confidence in our operating results and our stock price could decline.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 66; Value: 60 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> <!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We are an &ldquo;emerging growth
company&rdquo; and the reduced disclosure requirements applicable to emerging growth companies may make our common stock less attractive
to investors.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are an emerging
growth company. Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards until such
time as those standards apply to private companies. We have elected to avail ourselves of this exemption from new or revised accounting
standards.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For as long as we continue
to be an emerging growth company, we intend to take advantage of certain other exemptions from various reporting requirements that
are applicable to other public companies including, but not limited to, reduced disclosure obligations regarding executive compensation
in our periodic reports and proxy statements, exemptions from the requirements of holding a nonbinding advisory vote on executive
compensation and stockholder approval of any golden parachute payments not previously approved, and exemptions from the requirements
of auditor attestation reports on the effectiveness of our internal control over financial reporting. We cannot predict if investors
will find our common stock less attractive because we will rely on these exemptions. If some investors find our common stock less
attractive as a result, there may be a less active trading market for our common stock and our stock price may be more volatile.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We will remain an emerging
growth company until the earliest of (i)&nbsp;the end of the fiscal year in which the market value of our common stock that is
held by non-affiliates exceeds $700 million as of June&nbsp;30 of that fiscal year, (ii)&nbsp;the end of the fiscal year in which
we have total annual gross revenue of $1.07 billion or more during such fiscal year, (iii)&nbsp;the date on which we issue more
than $1 billion in non-convertible debt in a three-year period, or (iv)&nbsp;December&nbsp;31, 2023.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Provisions in our corporate charter
documents and under Delaware law could make an acquisition of us, which may be beneficial to our stockholders, more difficult and
may prevent attempts by our stockholders to replace or remove our current management.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Provisions in our certificate
of incorporation, and our bylaws may discourage, delay or prevent a merger, acquisition or other change in control of us that stockholders
may consider favorable, including transactions in which you might otherwise receive a premium for your shares. These provisions
also could limit the price that investors might be willing to pay in the future for shares of our common stock, thereby depressing
the market price of our common stock. In addition, because our Board of Directors is responsible for appointing the members of
our management team, these provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current
management by making it more difficult for stockholders to replace members of our Board. Among other things, these provisions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify">allow the authorized number of our directors to be changed only by resolution adopted by a majority of our Board;</TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify">limit the manner in which stockholders can remove directors from the Board, as may be permitted by law;</TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify">establish advance notice requirements for stockholder proposals that can be acted on at stockholder meetings and nominations to our Board;</TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify">limit who may call stockholder meetings;</TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify">authorize our Board to issue preferred stock without stockholder approval, which could be used to institute a stockholder rights plan, or so-called &ldquo;poison pill,&rdquo; that would work to dilute the stock ownership of a potential hostile acquirer, effectively preventing acquisitions that have not been approved by our Board; and</TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify">require all stockholder action to take place at duly called stockholder meetings and disallow the ability of our stockholders to act by majority written consent.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Moreover, because we
are incorporated in Delaware, we are governed by the provisions of Section&nbsp;203 of the Delaware General Corporation Law, which
prohibits a person who owns in excess of 15% of our outstanding voting stock from merging or combining with us for a period of
three years after the date of the transaction in which the person acquired in excess of 15% of our outstanding voting stock, unless
the merger or combination is approved in a prescribed manner.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 67; Value: 60 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> <!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B><I>Our certificate
of incorporation provides that the Court of Chancery of the State of Delaware is, to the fullest extent permitted by law, the sole
and exclusive forum for substantially all disputes between us and our stockholders. These choice of forum provisions could limit
the ability of stockholders to obtain a favorable judicial forum for disputes with us or our directors, officers or employees.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Unless we consent to
the selection of an alternative forum, our certificate of incorporation provides that the Court of Chancery of the State of Delaware,
or the Court of Chancery, will be, to the fullest extent permitted by law, the sole and exclusive forum for any derivative action
or proceeding brought on our behalf; any action asserting a claim of breach of fiduciary duty owed by any of our directors, officers
or other employees or agent to the Company or our stockholders; any action asserting a claim against us arising pursuant to the
Delaware General Corporation Law, or DGCL, or our certificate of incorporation or bylaws; any action to enforce or determine the
validity of our certificate of incorporation or bylaws; or any action asserting a claim against us that is governed by the internal
affairs doctrine. Since the choice of forum provisions are only applicable to &ldquo;the fullest extent permitted by law,&rdquo;
as provided in our certificate of incorporation, the provisions do not designate the Court of Chancery as the exclusive forum for
any derivative action or other claim for which the applicable statute creates exclusive jurisdiction in another forum. As such,
the choice of forum provisions do not apply to any actions arising under the Securities Act of 1933, as amended or the Exchange
Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">These
choice of forum provisions may limit a stockholder&rsquo;s ability to bring a claim in a judicial forum that it finds favorable
for disputes with us or our directors, officers or other employees, which may discourage such lawsuits against us and our directors,
officers and other employees. Alternatively, if a court were to find the choice of forum provisions contained in our certificate
of incorporation to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such
action in other jurisdictions, which could materially adversely affect our business, financial condition and operating results.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Because we do not anticipate paying
any cash dividends on our common stock in the foreseeable future, capital appreciation, if any, will be your sole source of gain.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have never declared
or paid cash dividends on our common stock. We currently intend to retain all of our future earnings, if any, to finance the growth
and development of our business. In addition, the terms of any future debt agreements may preclude us from paying dividends. As
a result, capital appreciation, if any, of our common stock will be your sole source of gain for the foreseeable future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>If securities analysts do not continue
to publish research or reports about our business or if they publish negative evaluations of our stock, the price of our stock
could decline.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The trading market
for our common stock will rely, in part, on the research and reports that industry or financial analysts publish about us or our
business. If securities analysts do not continue coverage of us, the trading price of our stock could decrease. Additionally, if
one or more of the analysts covering our business downgrade their evaluations of our stock, the price of our stock could decline.
If one or more of these analysts cease to cover our stock, we could lose visibility in the market for our stock, which in turn
could cause our stock price to decline.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px; font-size: 10pt"><A NAME="split005a_001"></A><B>Item 1B.</B></TD>
    <TD STYLE="font-size: 10pt"><B>Unresolved Staff Comments.</B></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Smaller reporting companies
such as us are not required to provide the information required by this Item.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px; font-size: 10pt"><A NAME="split005a_002"></A><B>Item 2.</B></TD>
    <TD STYLE="font-size: 10pt"><B>Properties.</B></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our principal executive
offices are located in approximately 3,800 square feet of office space in New York City, NY. In addition, we lease approximately
1,000 square feet of office space in Reno, Nevada where we perform certain of our research and development activities. We also
lease approximately 4,500 square feet for a planned commercial manufacturing facility in Redwood City, California and 120 square
feet of office space in Newport Beach, California for clinical and marketing team offices.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We believe that our
existing facilities are adequate to meet our current needs, and that suitable additional alternative spaces will be available in
the future on commercially reasonable terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 68; Value: 60 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> <!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.75in"><A NAME="split005a_003"></A><B>Item 3.</B></TD><TD><B>Legal Proceedings.</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">None.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px; font-size: 10pt"><A NAME="split005a_004"></A><B>Item 4.</B></TD>
    <TD STYLE="font-size: 10pt"><B>Mine Safety Disclosures.</B></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Executive Officers </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table sets forth
information concerning our executive officers as of March&nbsp;29, 2021:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1pt solid; width: 36%; font-size: 10pt; text-align: left"><B>Name</B></TD>
    <TD STYLE="text-align: center; width: 1%">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; width: 5%; font-size: 10pt; text-align: center"><B>Age</B></TD>
    <TD STYLE="text-align: center; width: 1%">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; width: 57%; font-size: 10pt; text-align: center"><B>Position</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: justify">Tsontcho Ianchulev, M.D., M.P.H.</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">47</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">Chief Executive Officer, Chief Medical Officer and Director</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: justify">John Gandolfo</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">60</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">Chief Financial Officer and Secretary</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: justify">Michael Rowe</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">59</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">Chief Operating Officer </TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: justify">Jennifer &ldquo;Ginger&rdquo; Clasby</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">67</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">Vice President of Regulatory and Clinical</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: justify">Luke Clauson</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">43</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt">Vice President, Research&nbsp;&amp; Development, Manufacturing</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Dr.&nbsp;Ianchulev</B>
has been serving as our Chief Executive Officer, Chief Medical Officer and a member of our Board of Directors since March&nbsp;2014.
From 2009 to 2016, he was the chief medical officer and the head of technology and business development for Transcend Medical,&nbsp;Inc.
(acquired by Novartis AG (NYSE: NVS)/Alcon Inc. (NYSE: ALC)). Prior to that, while at Genentech,&nbsp;Inc. (previously NYSE: DNA, before
going private in 2009), Dr.&nbsp;Ianchulev headed the ophthalmology research group and directed the development and the FDA approval
of Lucentis. Dr.&nbsp;Ianchulev currently serves as a director of the ASCRS Foundation, and is a member of the board of directors of
Iantrek,&nbsp;Inc. and AEye,&nbsp;Inc. He was formerly chairman of the board of directors of ianTECH,&nbsp;Inc. from 2014 until its acquisition
by Carl Zeiss Meditec AG (ETR: AFX) in December&nbsp;2018. Dr.&nbsp;Ianchulev received his B.S. from the University of Rochester. He
received both his M.D. and an M.P.H. from Harvard University and completed his specialty training at the Doheny Eye Institute. Currently,
Dr.&nbsp;Ianchulev serves as a professor in the New York Eye and Ear Infirmary of Mount Sinai.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>John Gandolfo</B>
has been serving as our Chief Financial Officer and Secretary since December&nbsp;2017. Mr.&nbsp;Gandolfo has approximately 30
years of experience as a chief financial officer of multiple rapidly growing private and publicly held companies with a primary
focus in the life sciences, healthcare and medical device areas. Mr.&nbsp;Gandolfo has had direct responsibility over capital raising,
including five public offerings, financial management, mergers and acquisition transactions and SEC reporting throughout his professional
career. Prior to joining Eyenovia, Mr.&nbsp;Gandolfo was Chief Financial Officer of Xtant Medical Holdings,&nbsp;Inc. (NYSE: XTNT)
from July&nbsp;2010 through August&nbsp;2017. Prior to joining Xtant, he served as the Chief Financial Officer for Progenitor Cell
Therapy, L.L.C., the global contract development and manufacturing services platform of the Hitachi Chemical Co.,&nbsp;Ltd. (now
known as Showa Denko Materials,&nbsp;Co.,&nbsp;Ltd.) Regenerative Medicine Business Sector, represented in the United States by
Hitachi Chemical Advanced Therapeutics Solutions, LLC (now known as Minaris Regenerative Medicine, LLC), a manufacturer of stem
cell therapies, from January&nbsp;2009 to June&nbsp;2010. Prior to joining Progenitor, Mr.&nbsp;Gandolfo served as the Chief Financial
Officer of Power Medical Interventions,&nbsp;Inc. (acquired by Covidien Public Limited Company, which was in turn acquired by Medtronic
Public Limited Company (NYSE: MDT)), a publicly held developer and manufacturer of computerized surgical stapling and cutter systems,
from January&nbsp;2007 to January&nbsp;2009. Prior to joining Power Medical Interventions, Mr.&nbsp;Gandolfo was the Chief Financial
Officer of Bioject Medical Technologies Inc., a then publicly held supplier of needle-free drug delivery systems to the pharmaceutical
and biotechnology industries, from September&nbsp;2001 to May&nbsp;2006, and he served on the Bioject&rsquo;s board of directors
from September&nbsp;2006 through May&nbsp;2007. Prior to joining Bioject, Mr.&nbsp;Gandolfo was the Chief Financial Officer of
Capital Access Network,&nbsp;Inc. (now known as CAN Capital,&nbsp;Inc.), a privately held specialty finance company, from 2000
through September&nbsp;2001, and Xceed Software,&nbsp;Inc. (OTC: EXDW), an Internet consulting firm, from 1999 to 2000. From 1994
to 1999, Mr.&nbsp;Gandolfo was Chief Financial Officer and Chief Operating Officer of Impath,&nbsp;Inc., a then publicly held,
cancer-focused healthcare information company. From 1987 through 1994, he was Chief Financial Officer of Medical Resources,&nbsp;Inc.,
a then publicly held manager of diagnostic imaging centers throughout the United States. Mr.&nbsp;Gandolfo currently serves on
the board of directors and audit and compensation committees of Odyssey Group International,&nbsp;Inc. (OTC: ODYY) and on the board
and audit committee of electroCore,&nbsp;Inc. (NASDAQ:ECOR). Mr.&nbsp;Gandolfo received his B.A. in business administration from
Rutgers University. He is a certified public accountant (inactive status) who began his professional career at Price Waterhouse.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 69; Value: 60 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> <!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Michael Rowe </B>has
served as the Company&rsquo;s Chief Operating Officer since January&nbsp;2021. Prior to that, he served as the Company&rsquo;s
Vice President, Commercial since October&nbsp;2019, having first joined the Company in July&nbsp;2018 as Vice President, Marketing.
From February&nbsp;2016 to June&nbsp;2018, Mr.&nbsp;Rowe was Senior Director of U.S. and Global Marketing, Ophthalmology at Aerie
Pharmaceuticals,&nbsp;Inc. (NASDAQ: AERI), where he was responsible for the United States and international commercialization of
glaucoma and ocular hypertension products. From July&nbsp;2010 until February&nbsp;2016, Mr.&nbsp;Rowe served in various strategic
management roles at Allergan plc (since acquired by AbbVie Inc. (NYSE: ABBV)), most recently as the Head of Corporate Competitive
Intelligence, where he supported multiple corporate strategic initiatives as well as strategic planning for the company&rsquo;s
worldwide glaucoma franchise. Mr.&nbsp;Rowe also has held senior marketing roles at Bayer Healthcare Pharmaceuticals Inc., Women
First HealthCare,&nbsp;Inc. (a former public company) and senior marketing and health economics roles at Pfizer Inc. (NYSE: PFE).
Mr.&nbsp;Rowe received an M.S. from <FONT STYLE="background-color: white">Rensselaer Polytechnic Institute </FONT>and received
a B.A. from <FONT STYLE="background-color: white">The State University of New York at Stony Brook</FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Jennifer &ldquo;Ginger&rdquo;
Clasby</B> has served as the Company&rsquo;s Vice President of Regulatory and Clinical since January&nbsp;2021. Prior to that,
she served as the Company&rsquo;s Vice President, Clinical Operations since September&nbsp;2017. From July&nbsp;2009 to May&nbsp;2017,
she served as Vice President, Clinical&nbsp;&amp; Regulatory Affairs/Quality Assurance at Transcend Medical,&nbsp;Inc. In that
position, she was responsible for overseeing clinical operations and regulatory processes for the company&rsquo;s clinical trials
in the United States, Europe and Latin America, as well as worldwide regulatory affairs, quality assurance and compliance activities.
She was also a pivotal executive with Promedica International, a contract research organization, from 1994 to 2009. Prior to that,
Ms.&nbsp;Clasby worked with ophthalmic device companies American Medical Optics, a division of America Hospital Supply Corporation
(currently known as Johnson&nbsp;&amp; Johnson Vision Care,&nbsp;Inc.) and Optical Radiation Corporation (now part of EssilorLuxottica
SA (Euronext Paris: EL)) in various roles for approximately 14 years in the areas of clinical affairs, manufacturing operations,
marketing and sales. She has served on the University of California-Irvine Extension Life Science Advisory Committee and the Orange
County Regulatory Affairs Discussion Group. She holds an M.S. degree in Industrial Engineering from Arizona State University and
B.S. degrees in mathematics and physics from Guilford College.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Luke Clauson</B>
has been serving as our Vice President, Research&nbsp;&amp; Development and Manufacturing since August&nbsp;2017, as our Vice President,
Research&nbsp;&amp; Development. He founded a medical device-focused engineering development company,&nbsp;Innovative Drive Corporation,
that has helped businesses of all sizes conceptualize and bring dozens of products to market, including several in ophthalmology,
in 2004 and has been serving as its President since then. Mr.&nbsp;Clauson has been the President and a director of Inspire Products,&nbsp;Inc.
since 2012 and also serves on the board of directors of Mimicmotion,&nbsp;Inc. From 2016 until 2018, he was Chief Operating Officer
of ianTECH,&nbsp;Inc. From 2009 to 2016, Mr.&nbsp;Clauson was Vice President, Research&nbsp;&amp; Development and Operations at
Transcend Medical. He started his engineering career at Cardica,&nbsp;Inc. (now Dex Liquidating Co.), where he ultimately directed
product development for the core anastomotic business. Mr.&nbsp;Clauson has extensive experience in designing, validating, achieving
regulatory approval and scaling for commercialization with multiple products. He holds a B.Sc. in mechanical engineering from the
University of California, Davis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 70; Value: 60 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> <!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="split005a_005"></A>PART&nbsp;II</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px; font-size: 10pt"><A NAME="split005a_006"></A><B>Item 5.</B></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><B>Market for Registrant&rsquo;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.</B></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Market for Common Equity</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our common stock trades
on the Nasdaq Capital Market under the symbol &ldquo;EYEN.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Based upon information furnished
by our transfer agent, at March&nbsp;29, 2021, we had approximately 130 holders of record of our common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Dividend Policy</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have never declared
dividends on our equity securities, and currently do not plan to declare dividends on shares of our common stock in the foreseeable
future. We expect to retain our future earnings, if any, for use in the operation and expansion of our business. Subject to the
foregoing, the payment of cash dividends in the future, if any, will be at the discretion of our Board of Directors and will depend
upon such factors as earnings levels, capital requirements, our overall financial condition and any other factors deemed relevant
by our Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Securities Authorized for Issuance under
Equity Compensation Plans</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">See Item 12 of this
report for disclosure regarding securities authorized for issuance under equity compensation plans required by Item 201(d)&nbsp;of
Regulation S-K.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Recent Sales of Unregistered Securities</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">None.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Purchases of Equity Securities by the
Issuer and Affiliated Purchasers</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.25in">None.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px; font-size: 10pt"><A NAME="split005a_007"></A><B>Item 6.</B></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><B>Selected Financial Data.</B></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Smaller reporting companies
such as us are not required to provide the information required by this Item.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px; font-size: 10pt"><A NAME="split005a_008"></A><B>Item 7.</B></TD>
    <TD STYLE="font-size: 10pt"><B>Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operation </B></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>The following discussion
and analysis is based on, and should be read in conjunction with our financial statements for the years ended December&nbsp;31,
2020 and 2019, which are included elsewhere in this Annual Report on Form&nbsp;10-K. This Management&rsquo;s Discussion and Analysis
of Financial Condition and Results of Operations contains statements that are forward-looking. These statements are based on current
expectations and assumptions that are subject to risk, uncertainties and other factors. These statements are often identified by
the use of words such as &ldquo;may,&rdquo; &ldquo;will,&rdquo; &ldquo;expect,&rdquo; &ldquo;believe,&rdquo; &ldquo;anticipate,&rdquo;
 &ldquo;intend,&rdquo; &ldquo;could,&rdquo; &ldquo;estimate,&rdquo; or &ldquo;continue,&rdquo; and similar expressions or variations.
Actual results could differ materially because of the factors discussed in &ldquo;Risk Factors&rdquo; elsewhere in this Annual
Report on Form&nbsp;10-K, and other factors that we have not identified.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 71; Value: 60 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> <!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Overview</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We are a clinical stage ophthalmic company
developing a pipeline of advanced therapeutics based on our proprietary microdose array print (MAP&trade;) platform technology.
We aim to achieve clinical microdosing of next-generation formulations of well-established ophthalmic pharmaceutical agents using
our high-precision targeted ocular delivery system, branded the Optejet&reg;, which has the potential to replace conventional eye
dropper delivery and improve safety, tolerability, patient compliance and topical delivery success for ophthalmic eye treatments.
In the clinic, the Optejet has demonstrated the ability to horizontally deliver ophthalmic medication with a success rate significantly
higher than traditional eye drops (~ 90% vs. ~ 50%). Our technology also can deliver up to a 75% reduction in ocular drug and preservative
exposure and has demonstrated significant improvement in the therapeutic index in drugs used for mydriasis and IOP lowering through
three Phase II and Phase III trials. Using the Optejet, we are developing the next generation of smart ophthalmic therapeutics
which target new indications or new combinations where there are currently no comparable drug therapies approved by the U.S. Food
and Drug Administration, or the FDA. Our microdose therapeutics follow the FDA-designated pharmaceutical registration and regulatory
process. Our products are classified by the FDA as drugs, and not medical devices or drug-device combination products. Our pipeline
is currently focused on the late-stage development of microdosed medications for progressive myopia, presbyopia, and mydriasis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">MicroPine is our first-in-class topical
therapy for the treatment of progressive myopia, a back-of-the-eye ocular disease associated with pathologic axial elongation and
sclero-retinal stretching. In the United States, myopia is estimated to affect approximately 25 million children, with up to 5
million considered to be at risk for high myopia. In February&nbsp;2019, the FDA accepted our investigational new drug application,
or IND, to initiate a Phase III registration trial of MicroPine (the CHAPERONE study) to reduce the progression of myopia in children.
We enrolled the first patient in the CHAPERONE study in June&nbsp;2019. Due to the COVID-19 pandemic, we previously experienced
delays in trial enrollment and initiation as a result of reduced clinical trial activities and operations at investigator sites.
However, we have since been able to resume enrollment in the CHAPERONE study.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On October&nbsp;9, 2020, we
entered into the Bausch License Agreement, pursuant to which Bausch Health may develop and commercialize MicroPine in the United States
and Canada. Under the terms of the Bausch License Agreement, we received an upfront payment of $10.0 million and we may receive up to
a total of $35.0 million in additional payments, based on the achievement of certain regulatory and launch-based milestones. Bausch Health
also will pay us royalties on a tiered basis (ranging from mid-single digit to mid-teen percentages) on gross profits from sales of MicroPine
in the United States and Canada, subject to certain adjustments. Under the terms of the Bausch License Agreement, Bausch Health has assumed
oversight and costs related to the ongoing CHAPERONE study.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">MicroLine is our pharmacologic treatment
for presbyopia. Presbyopia is a non-preventable, age-related hardening of the lens, which causes the gradual loss of the eye&rsquo;s
ability to focus on nearby objects. There currently are no known FDA-approved drugs for the improvement of near vision in patients
with presbyopia, although other companies have related therapies in their pipeline. We have two planned Phase III VISION trials
for MicroLine, and initiated the first of these trials in December&nbsp;2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On August&nbsp;10, 2020, we entered into
the Arctic Vision License Agreement, pursuant to which Arctic Vision may develop and commercialize MicroPine and MicroLine in Greater
China (mainland China, Hong Kong, Macau and Taiwan) and South Korea. Under the terms of the Arctic Vision License Agreement, we
received an upfront payment of $4.0 million before any payments to Senju. In addition, we may receive up to a total of $41.75 million
in additional payments, based on various development and regulatory milestones, including the initiation of clinical research and
approvals in Greater China and South Korea, and development costs. Arctic Vision also will purchase its supply of MicroPine and
MicroLine from us or, for such products not supplied by us, pay us a mid-single digit percentage royalty on net sales of such products,
subject to certain adjustments. We will pay a mid-double digit percentage of such payments, royalties, or net proceeds of such
supply to Senju pursuant to the Senju License Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">MicroStat (or Mydcombi&trade;)
is our fixed combination formulation of phenylephrine-tropicamide for mydriasis, designed to be a novel approach for the estimated 80
million office-based comprehensive eye exams performed every year in the United States. We have completed two Phase III trials for MicroStat
and announced positive results from these studies, known as MIST-1 and MIST-2. In March&nbsp;2021, the FDA accepted our NDA for MydCombi
with an expected PDUFA date of October&nbsp;28, 2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 72; Value: 60 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> <!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Historically, we have financed
our operations principally through equity offerings, including our initial public offering, numerous public offerings in 2018, 2019 and
August&nbsp;2020, and our private placement that closed in March&nbsp;2020. Recently we also have generated cash through licensing arrangements.
<FONT STYLE="color: #212529">Based upon our current operating plan, there is substantial doubt about our ability to continue as a going
concern for a period of at least the next twelve months. Our ability to continue as a going concern depends on our ability to raise additional
capital, through the sale of equity or debt securities to support our future operations. If we are unable to secure additional capital,
we may be required to curtail our research and development initiatives and take additional measures&nbsp;to reduce costs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our net losses were $19.8 million and $21.2
million for the years ended December&nbsp;31, 2020 and 2019. As of December&nbsp;31, 2020, we had working capital and an accumulated
deficit of $15.2 million and $77.4 million, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Financial Overview</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Revenue and Cost of Revenue</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In August&nbsp;and
October&nbsp;2020, we entered into the Arctic Vision License Agreement and Bausch License Agreement, respectively. Both of these
agreements provide for the Company to earn revenue from an upfront licensing fee, the achievement of various development and regulatory
milestones, and royalty income on sales of licensed products. Pursuant to the Senju License agreement, we will pay a mid-double
digit percentage of such payments from the Arctic Vision License Agreement to Senju. See Note 9 &ndash; Commitments and Contingencies
and Note 10 &ndash; Related Party Transactions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Research and Development Expenses</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Research and development
expenses are incurred in connection with the research and development of our microdose therapeutics and consist primarily of contract
service expenses. Given where we are in our life cycle, we do not separately track research and development expenses by project.
Our research and development expenses consist of:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify">direct clinical and non-clinical expenses, which include expenses incurred under agreements with contract research organizations, contract manufacturing organizations, and costs associated with preclinical activities, development activities and regulatory activities;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify">personnel-related expenses, which include expenses related to consulting agreements with individuals that have since entered into employment agreements with us as well as salaries and other compensation of employees that is attributable to research and development activities; and</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify">facilities and other expenses, which include direct and allocated expenses for rent and maintenance of facilities, marketing, insurance and other supplies used in research and development activities.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We expense research
and development costs as incurred. We record costs for some development activities, such as clinical trials, based on an evaluation
of the progress to completion of specific tasks using data such as subject enrollment, clinical site activations or other information
our vendors provide to us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We expect that our
research and development expenses will increase with the continuation of the aforementioned initiatives.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>General and Administrative Expenses</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">General and administrative
expenses consist primarily of payroll and related expenses, legal and other professional services, and non-cash stock-based compensation
expense. We anticipate that our general and administrative expenses will increase in the future as we increase our headcount to
support our continued research and development and the potential commercialization of our product candidates. We also anticipate
increased expenses related to audit, legal, regulatory, and tax-related services associated with maintaining compliance with our
exchange listing and SEC requirements. In addition, director and officer insurance premiums and investor relations costs associated
with being a public company are expected to increase in future periods.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 73; Value: 60 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> <!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Results of Operations</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Year Ended December&nbsp;31, 2020
Compared with Year Ended December&nbsp;31, 2019</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Revenue and Cost of Revenue</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In August&nbsp;2020, we
received a $4.0 million upfront payment under the Arctic Vision License Agreement, and made a related payment of $1.6 million to
Senju. This upfront payment has not yet met the revenue recognition criteria under U.S. GAAP, and has been recorded as $4.0 million
of deferred license fee and $1.6 million of deferred cost of revenue. In October&nbsp;2020, we received a $10.0 million upfront
payment under the Bausch Health License Agreement. This upfront payment has also not yet met the revenue recognition criteria under
U.S. GAAP and has been recorded as $10.0 million of deferred license fee. In December&nbsp;2020, in connection with the achievement of
a milestone under the Arctic Vision License Agreement, we recognized $2.0 million of revenue, and accrued $0.8 million of cost of
revenue (due to Senju).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Research and Development Expenses</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Research and development
expenses for the year ended December&nbsp;31, 2020 totaled $13.3&nbsp;million, a decrease of $0.8&nbsp;million, or 6%, as compared
to $14.1&nbsp;million recorded for the year ended December&nbsp;31, 2019. Research and development expenses consisted of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 88%; font: 10pt Times New Roman, Times, Serif; margin-right: 0.5in; margin-left: 0.5in">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-size: 10pt; font-weight: bold; text-align: center">For the Year Ended</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December&nbsp;31,</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2020</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2019</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 74%; font-size: 10pt; text-align: left">Direct clinical and non-clinical expenses</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">6,717,452</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">7,830,488</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Personnel-related expenses</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">3,688,948</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">3,136,860</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Supplies and materials</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">1,438,928</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">1,666,284</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Non-cash stock-based compensation expenses</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">1,350,894</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">1,459,055</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; padding-bottom: 1pt">Other</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">67,595</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">9,762</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Total research and development expenses</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">13,263,817</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">14,102,449</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The decrease in direct
clinical and non-clinical expenses is primarily due to cost reimbursements from Arctic Vision and Bausch Health (contra expense)
and reduced activity due to COVID-19 austerity measures. The increase in personnel-related expenses is primarily due to new hires
in the R&amp;D group. The decrease in supplies and materials is primarily due to COVID-19 austerity measures. The decrease in stock-based
compensation expense is primarily due to the timing of vesting of certain equity awards. The increase in other expense reflects
the depreciation of additional equipment purchased for clinical trials.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>General and Administrative Expenses</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">General and administrative
expenses for the year ended December&nbsp;31, 2020 totaled $7.7&nbsp;million, an increase of $0.5&nbsp;million, or 7%, as compared to
$7.2&nbsp;million recorded for the year ended December&nbsp;31, 2019. The increase was primarily attributable to increases of $0.2 million
in payroll related expenses due to new hires, $0.4 million in patent expense, and $0.8 million in legal costs related to business development
activities. This was offset by decreases of $0.4 million in travel expense and $0.2 million in meetings primarily due to COVID-19 austerity
measures, as well as decreases of $0.1 million in filing fees and $0.1 million in consulting fees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Liquidity and Going Concern</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Since inception, we
have experienced negative cash flows from operations. At December&nbsp;31, 2020, our accumulated deficit since inception was $77.4&nbsp;million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">At December 31, 2020, we had a cash and cash equivalents balance of $28.4 million, working capital of $15.2 million and stockholders&rsquo;
equity of $15.3 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 74; Value: 60 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> <!-- Field: Sequence; Type: Arabic; Name: PageNo -->73<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Split-Segment; Name: 6 -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">At December&nbsp;31,
2020, we had $0.5 million of debt outstanding. On May&nbsp;8, 2020, we received cash proceeds of <FONT STYLE="color: #212529">$463,353
pursuant to a loan provided in connection with the Paycheck Protection Program under the CARES Act </FONT>(the &ldquo;PPP Loan&rdquo;).
The PPP Loan provides for monthly installment payments of $19,508 beginning in August&nbsp;2021 with the remaining balance due
on May&nbsp;3, 2022, the maturity date. The PPP Loan bears interest at a fixed rate of 1.00% per annum.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">These conditions raise substantial doubt about our ability to continue as a going concern for at least one year from the date that the
financial statements included elsewhere in this Annual Report on Form 10-K are issued. Our financial statements do not include adjustments
to the amounts and classification of assets and liabilities that may be necessary should we be unable to continue as a going concern.
Our ability to continue as a going concern depends on our ability to raise additional capital through the sale of equity or debt securities
to support our future operations. Our operating needs include the planned costs to operate our business, including amounts required to
fund research and development activities including clinical studies, working capital and capital expenditures. Our future capital requirements
and the adequacy of our available funds will depend on many factors, including our ability to successfully commercialize our products
and services, competing technological and market developments, and the need to enter into collaborations with other companies or acquire
other companies or technologies to enhance or complement our product and service offerings. If we are unable to secure additional capital,
we may be required to curtail our research and development initiatives and take additional measures to reduce costs in order to conserve
our cash.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the year ended
December&nbsp;31, 2020 and 2019, our sources and uses of cash were as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Net cash used in operating
activities for the year ended December&nbsp;31, 2020 was $6.4&nbsp;million, which includes cash used to fund a net loss of $19.8&nbsp;million,
reduced by $2.6 million of non-cash expenses, offset by $10.8 million of net cash provided by changes in the levels of operating
assets and liabilities. Net cash used in operating activities for the year ended December&nbsp;31, 2019 was $18.9&nbsp;million,
which includes cash used to fund a net loss of $21.2&nbsp;million, reduced by $2.5 million of non-cash expenses and $0.3 million
of net cash used in changes in the levels of operating assets and liabilities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Net cash used in investing
activities was $0.3 million and $0.2&nbsp;million for the years ended December&nbsp;31, 2020 and 2019, respectively, which was
attributable to purchases of property and equipment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Net cash provided by
financing activities for the year ended December&nbsp;31, 2020 totaled $20.9&nbsp;million, which was primarily attributable to
$12.4 million of net proceeds from the sale of common stock in our August&nbsp;2020 public offering, $5.6 million of net proceeds
from the sale of common stock and warrants in our March&nbsp;2020 private placement, $2.9 million of proceeds from the exercise
of warrants issued in our March&nbsp;2020 private placement and options and $0.5 million from the proceeds of the PPP Loan, offset
by $0.5 million from the repayment of notes payable. Net cash provided by financing activities for the year ended December&nbsp;31,
2019 totaled $13.5&nbsp;million, which was primarily attributable to $13.0 million of net proceeds from the sale of common stock
in our July&nbsp;2019 public offering and $0.6 million of proceeds from the exercise of stock options.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Risks and Uncertainties</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Due to the COVID-19 pandemic,
we previously experienced delays in trial enrollment and initiation of our Phase III registration trial of our MicroPine drug candidate
(the CHAPERONE study) as a result of reduced clinical trial activities and operations at investigator sites. However, we have since been
able to resume enrollment in that study.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Off-Balance Sheet Arrangements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There are no off-balance
sheet arrangements between us and any other entity that have, or are reasonably likely to have, a current or future effect on financial
conditions, changes in financial conditions, revenues or expenses, results of operations, liquidity, capital expenditures or capital
resources that is material to stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Critical Accounting Policies</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our critical accounting
policies are included in Note 2 &ndash; Summary of Significant Accounting Policies of our financial statements included within
this Annual Report on Form&nbsp;10-K.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 75; Options: NewSection; Value: 74 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->74<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Recently Issued Accounting Standards</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our recently issued
accounting standards are included in Note 2 &ndash; Summary of Significant Accounting Policies of our financial statements included
within this Annual Report on Form&nbsp;10-K.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px; font-size: 10pt"><B><A NAME="a1_002"></A>Item 7A.</B></TD>
    <TD STYLE="font-size: 10pt"><B>Quantitative and Qualitative Disclosures About Market Risk.</B></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Smaller reporting companies
such as us are not required to provide the information required by this Item.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px; font-size: 10pt"><B><A NAME="a1_003"></A>Item 8.</B></TD>
    <TD STYLE="font-size: 10pt"><B>Financial Statements and Supplementary Data.</B></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">See the financial statements
included at the end of this report beginning on page&nbsp;F-1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px; font-size: 10pt"><B><A NAME="a1_004"></A>Item 9.</B></TD>
    <TD STYLE="font-size: 10pt"><B>Changes in and Disagreements With Accountants on Accounting and Financial Disclosure.</B></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px; font-size: 10pt"><B><A NAME="a1_005"></A>Item 9A.</B></TD>
    <TD STYLE="font-size: 10pt"><B>Controls and Procedures.</B></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Evaluation of Disclosure Controls and
Procedures</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of the end of the
period covered by this Annual Report on Form&nbsp;10-K, we carried out an evaluation, under the supervision and with the participation
of our management, including our principal executive officer and principal financial and accounting officer, of the effectiveness
of the design and operation of our disclosure controls and procedures as defined in Rules&nbsp;13a-15(e)&nbsp;and 15d-15(e)&nbsp;of
the Securities Exchange Act of 1934, as amended (the &ldquo;Exchange Act&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In designing and evaluating
our disclosure controls and procedures, management recognizes that any disclosure controls and procedures, no matter how well designed
and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design of disclosure
controls and procedures must reflect the fact that there are resource constraints and that management is required to apply its
judgment in evaluating the benefits of possible controls and procedures relative to their costs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Based on their evaluation,
our principal executive officer and principal financial and accounting officer concluded that as of December&nbsp;31, 2020 our
disclosure controls and procedures were designed to, and were effective to, provide assurance at a reasonable level that the information
we are required to disclose in reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported
within the time periods specified in SEC rules&nbsp;and forms, and that such information is accumulated and communicated to our
management, including our principal executive officer and principal financial and accounting officer, as appropriate, to allow
timely decisions regarding required disclosures as of December&nbsp;31, 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Management's Report on Internal Control
over Financial Reporting</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our management, including
our principal executive officer and principal financial officer, is responsible for establishing and maintaining adequate internal
control over financial reporting (as defined in Rules&nbsp;13a-15(f)&nbsp;and 15d-15(f)&nbsp;under the Exchange Act). Internal
control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting
and the preparation of financial statements for external purposes in accordance with U.S. GAAP. Our internal control over financial
reporting includes those policies and procedures that: (i)&nbsp;pertain to the maintenance of records that, in reasonable detail,
accurately and fairly reflect the transactions and dispositions of our assets; (ii)&nbsp;provide reasonable assurance that transactions
are recorded as necessary to permit preparation of financial statements in accordance with U.S. GAAP, and that our receipts and
expenditures are being made only in accordance with authorizations of our management and directors; and (iii)&nbsp;provide reasonable
assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of our assets that could have
a material effect on the financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 76; Value: 74 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->75<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the supervision
and with the participation of our management, including our principal executive officer and principal financial officer, we conducted
an evaluation of the effectiveness of our internal control over financial reporting as of December&nbsp;31, 2020, based on the
Internal Control-Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO)
(2013 Framework). Based on this evaluation under the 2013 Framework, our principal executive officer and principal financial officer
have concluded that our internal control over financial reporting was effective as of December&nbsp;31, 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Changes in Internal Control over Financial
Reporting</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There has been no change
in our internal control over financial reporting that occurred during the fourth quarter of 2020 that has materially affected,
or is reasonably likely to materially affect, our internal control over financial reporting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Attestation Report of Registered Public
Accounting Firm</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Annual Report
on Form&nbsp;10-K does not include an attestation report of our independent registered public accounting firm due to an exemption
established by the JOBS Act for emerging growth companies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px; font-size: 10pt"><B><A NAME="a1_006"></A>Item 9B.</B></TD>
    <TD STYLE="font-size: 10pt"><B>Other Information.</B></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">None.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 77; Value: 74 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->76<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PART&nbsp;III</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0px">&nbsp;</TD>
    <TD STYLE="width: 72px; font-size: 10pt"><B><A NAME="a1_007"></A>Item 10.</B></TD>
    <TD STYLE="font-size: 10pt"><B>Directors, Executive Officers, and Corporate Governance.</B></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Information required
by this Item concerning our directors is incorporated by reference from the sections captioned &ldquo;Election of Directors&rdquo;
and &ldquo;Corporate Governance Matters&rdquo; contained in our proxy statement related to the 2021 Annual Meeting of Stockholders
currently scheduled to be held on June&nbsp;16, 2021, which we intend to file with the SEC within 120 days of the end of our fiscal
year pursuant to General Instruction G(3)&nbsp;of Form&nbsp;10-K.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The information required
by this Item concerning our Audit Committee is incorporated by reference from the section captioned &ldquo;Corporate Governance
Matters&mdash;Board Committees&mdash;Audit Committee&rdquo; contained in our proxy statement related to the 2021 Annual Meeting
of Stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have adopted a code
of business conduct and ethics relating to the conduct of our business by all of our employees, executive officers, and directors.
The policy is posted on our website, <U>www.eyenoviabio.com</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The information required
by this Item concerning our executive officers is set forth at the end of Part&nbsp;I of this Annual Report on Form&nbsp;10-K.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The information required
by this Item concerning compliance with Section&nbsp;16(a)&nbsp;of the Exchange Act is incorporated by reference from the section
of the proxy statement captioned &ldquo;Delinquent Section&nbsp;16(a)&nbsp;Reports.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0px">&nbsp;</TD>
    <TD STYLE="width: 72px; font-size: 10pt"><B><A NAME="a1_008"></A>Item 11.</B></TD>
    <TD STYLE="font-size: 10pt"><B>Executive Compensation.</B></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The information required
by this Item is incorporated by reference to the information under the sections captioned &ldquo;Executive Compensation,&rdquo;
and &ldquo;Director Compensation&rdquo; in the proxy statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0px"></TD><TD STYLE="width: 72px; text-align: left"><B><A NAME="a1_009"></A>Item 12.</B></TD><TD STYLE="text-align: justify"><B>Security Ownership of Certain Beneficial Owners and
Management and Related Stockholder Matters.</B></TD>
</TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table
provides information as of December&nbsp;31, 2020 about our common stock that may be issued upon the exercise of options, warrants
and rights under all of our existing equity compensation plans (including individual arrangements):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Equity Compensation Plan Information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Plan Category</TD><TD STYLE="text-align: center; font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; font-size: 10pt; font-weight: bold; border-bottom: Black 1pt solid">Number of securities<BR> to be issued upon<BR> exercise of <BR>
outstanding<BR> options, warrants <BR>
and<BR> rights</TD><TD STYLE="text-align: center; padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="text-align: center; font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Weighted-average<BR> exercise price of<BR> outstanding options,<BR> warrants and rights</TD><TD STYLE="text-align: center; padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="text-align: center; font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; font-size: 10pt; font-weight: bold; border-bottom: Black 1pt solid">Number of<BR> securities remaining<BR> available for future issuance<BR> under equity compensation<BR> plans (excluding securities<BR> reflected in column (a))</TD><TD STYLE="text-align: center; padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Equity compensation plans approved by security holders:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.25in; width: 48%; font-size: 10pt; text-align: left">2014 Equity Incentive Plan, as amended</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 14%; font-size: 10pt; text-align: right">1,140,630</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 14%; font-size: 10pt; text-align: right">2.88</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 14%; font-size: 10pt; text-align: right">15,333</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in; font-size: 10pt; text-align: left">Amended and Restated 2018 Omnibus Stock Incentive Plan</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">2,423,993</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">3.57</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">502,853</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Equity compensation plans not approved by security holders</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">Total</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">3,564,623</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">3.34</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">518,186</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The other information
required by this Item is incorporated by reference to the information under the section captioned &ldquo;Security Ownership of
Certain Beneficial Owners and Management&rdquo; contained in the proxy statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0px">&nbsp;</TD>
    <TD STYLE="width: 72px; font-size: 10pt"><B><A NAME="a1_010"></A>Item 13.</B></TD>
    <TD STYLE="font-size: 10pt"><B>Certain Relationships and Related Transactions, and Director Independence. </B></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The information required
by this Item is incorporated by reference to the information under the section captioned &ldquo;Certain Relationships and Related-Party
Transactions&rdquo; and &ldquo;Corporate Governance Matters&rdquo; in the proxy statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0px">&nbsp;</TD>
    <TD STYLE="width: 72px; font-size: 10pt"><B><A NAME="a1_011"></A>Item 14.</B></TD>
    <TD STYLE="font-size: 10pt"><B>Principal Accounting Fees and Services.</B></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The information required
by this Item is incorporated by reference to the information under the section captioned &ldquo;Audit Committee Report&rdquo; in
the proxy statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 78; Value: 74 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->77<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PART&nbsp;IV</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0px">&nbsp;</TD>
    <TD STYLE="width: 72px; font-size: 10pt"><B><A NAME="a1_012"></A>Item 15.</B></TD>
    <TD STYLE="font-size: 10pt"><B>Exhibits, Financial Statement Schedules.</B></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt">(a)</TD>
    <TD STYLE="font-size: 10pt">List of documents filed as part of this report:</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt">1.</TD>
    <TD STYLE="font-size: 10pt">Financial Statements:</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The financial statements of
the Company and the related reports of the Company&rsquo;s independent registered public accounting firm thereon have been filed
under Item 8 hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt">2.</TD>
    <TD STYLE="font-size: 10pt">Financial Statement Schedules:</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">None.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt">3.</TD>
    <TD STYLE="font-size: 10pt">Exhibit&nbsp;Index</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in">The following is a list of
exhibits filed as part of this Annual Report on Form&nbsp;10-K:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center; font-size: 10pt; vertical-align: top">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="7" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Incorporated by Reference (Unless Otherwise Indicated)</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center; font-size: 10pt; font-weight: bold; vertical-align: bottom">Exhibit<BR> Number</TD><TD STYLE="vertical-align: bottom; text-align: center; font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center; font-size: 10pt; font-weight: bold; border-bottom: Black 1pt solid">Exhibit&nbsp;Description</TD><TD STYLE="vertical-align: bottom; text-align: center; font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; vertical-align: bottom; font-size: 10pt; font-weight: bold; text-align: center">Form</TD><TD STYLE="vertical-align: bottom; text-align: center; font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; vertical-align: bottom; font-size: 10pt; font-weight: bold; text-align: center">File No.</TD><TD STYLE="vertical-align: bottom; text-align: center; font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; vertical-align: bottom; font-size: 10pt; font-weight: bold; text-align: center">Exhibit</TD><TD STYLE="vertical-align: bottom; text-align: center; font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; vertical-align: bottom; font-size: 10pt; font-weight: bold; text-align: center">Filing Date</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: top; width: 8%; font-size: 10pt; text-align: center"><A HREF="https://www.sec.gov/Archives/edgar/data/1682639/000114420418004366/tv484256_ex3-1.htm" STYLE="-sec-extract: exhibit">3.1</A></TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 34%; font-size: 10pt; text-align: left"><A HREF="https://www.sec.gov/Archives/edgar/data/1682639/000114420418004366/tv484256_ex3-1.htm" STYLE="-sec-extract: exhibit">Third Amended and Restated Certificate of Incorporation</A></TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 12%; font-size: 10pt; text-align: center"><A HREF="https://www.sec.gov/Archives/edgar/data/1682639/000114420418004366/tv484256_ex3-1.htm" STYLE="-sec-extract: exhibit">8-K</A></TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 14%; font-size: 10pt; text-align: center"><A HREF="https://www.sec.gov/Archives/edgar/data/1682639/000114420418004366/tv484256_ex3-1.htm" STYLE="-sec-extract: exhibit">001-38365</A></TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 12%; font-size: 10pt; text-align: center"><A HREF="https://www.sec.gov/Archives/edgar/data/1682639/000114420418004366/tv484256_ex3-1.htm" STYLE="-sec-extract: exhibit">3.1</A></TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 14%; font-size: 10pt; text-align: center"><A HREF="https://www.sec.gov/Archives/edgar/data/1682639/000114420418004366/tv484256_ex3-1.htm" STYLE="-sec-extract: exhibit">January&nbsp;29, 2018</A></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center; font-size: 10pt; vertical-align: top">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: center; font-size: 10pt; vertical-align: top">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: center; font-size: 10pt; vertical-align: top">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: center; font-size: 10pt; vertical-align: top">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: center; font-size: 10pt; vertical-align: top">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center"><A HREF="https://www.sec.gov/Archives/edgar/data/1682639/000114420418034222/tv495935_ex3-1x1.htm" STYLE="-sec-extract: exhibit">3.1.1</A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left"><A HREF="https://www.sec.gov/Archives/edgar/data/1682639/000114420418034222/tv495935_ex3-1x1.htm" STYLE="-sec-extract: exhibit">Certificate of Amendment to the Third Amended and Restated Certificate of Incorporation</A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center"><A HREF="https://www.sec.gov/Archives/edgar/data/1682639/000114420418034222/tv495935_ex3-1x1.htm" STYLE="-sec-extract: exhibit">8-K</A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center"><A HREF="https://www.sec.gov/Archives/edgar/data/1682639/000114420418034222/tv495935_ex3-1x1.htm" STYLE="-sec-extract: exhibit">001-38365</A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center"><A HREF="https://www.sec.gov/Archives/edgar/data/1682639/000114420418034222/tv495935_ex3-1x1.htm" STYLE="-sec-extract: exhibit">3.1.1</A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center"><A HREF="https://www.sec.gov/Archives/edgar/data/1682639/000114420418034222/tv495935_ex3-1x1.htm" STYLE="-sec-extract: exhibit">June&nbsp;14, 2018</A></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center; font-size: 10pt; vertical-align: top">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: center; font-size: 10pt; vertical-align: top">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: center; font-size: 10pt; vertical-align: top">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: center; font-size: 10pt; vertical-align: top">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: center; font-size: 10pt; vertical-align: top">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center"><A HREF="https://www.sec.gov/Archives/edgar/data/1682639/000114420418014097/tv488018_ex3-1.htm" STYLE="-sec-extract: exhibit">3.2</A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left"><A HREF="https://www.sec.gov/Archives/edgar/data/1682639/000114420418014097/tv488018_ex3-1.htm" STYLE="-sec-extract: exhibit">Amended and Restated Bylaws</A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center"><A HREF="https://www.sec.gov/Archives/edgar/data/1682639/000114420418014097/tv488018_ex3-1.htm" STYLE="-sec-extract: exhibit">8-K</A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center"><A HREF="https://www.sec.gov/Archives/edgar/data/1682639/000114420418014097/tv488018_ex3-1.htm" STYLE="-sec-extract: exhibit">001-38365</A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center"><A HREF="https://www.sec.gov/Archives/edgar/data/1682639/000114420418014097/tv488018_ex3-1.htm" STYLE="-sec-extract: exhibit">3.1</A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center"><A HREF="https://www.sec.gov/Archives/edgar/data/1682639/000114420418014097/tv488018_ex3-1.htm" STYLE="-sec-extract: exhibit">March&nbsp;12, 2018</A></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center; font-size: 10pt; vertical-align: top">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: center; font-size: 10pt; vertical-align: top">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: center; font-size: 10pt; vertical-align: top">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: center; font-size: 10pt; vertical-align: top">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: center; font-size: 10pt; vertical-align: top">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center"><A HREF="tm211152d1_ex4-1.htm">4.1</A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><A HREF="tm211152d1_ex4-1.htm">Description of Securities</A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center"><A HREF="tm211152d1_ex4-1.htm">--</A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center"><A HREF="tm211152d1_ex4-1.htm">--</A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center"><A HREF="tm211152d1_ex4-1.htm">--</A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center"><A HREF="tm211152d1_ex4-1.htm">Filed herewith</A></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center"><A HREF="https://www.sec.gov/Archives/edgar/data/1682639/000110465920037871/tm2011864d2_ex4-1.htm" STYLE="-sec-extract: exhibit">4.2</A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left"><A HREF="https://www.sec.gov/Archives/edgar/data/1682639/000110465920037871/tm2011864d2_ex4-1.htm" STYLE="-sec-extract: exhibit">Form&nbsp;of Class&nbsp;A Warrant issued on March&nbsp;24, 2020</A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center"><A HREF="https://www.sec.gov/Archives/edgar/data/1682639/000110465920037871/tm2011864d2_ex4-1.htm" STYLE="-sec-extract: exhibit">8-K</A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center"><A HREF="https://www.sec.gov/Archives/edgar/data/1682639/000110465920037871/tm2011864d2_ex4-1.htm" STYLE="-sec-extract: exhibit">001-38365</A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center"><A HREF="https://www.sec.gov/Archives/edgar/data/1682639/000110465920037871/tm2011864d2_ex4-1.htm" STYLE="-sec-extract: exhibit">4.1</A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center"><A HREF="https://www.sec.gov/Archives/edgar/data/1682639/000110465920037871/tm2011864d2_ex4-1.htm" STYLE="-sec-extract: exhibit">March&nbsp;25, 2020</A></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center"><A HREF="https://www.sec.gov/Archives/edgar/data/1682639/000110465920037871/tm2011864d2_ex4-2.htm" STYLE="-sec-extract: exhibit">4.3</A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left"><A HREF="https://www.sec.gov/Archives/edgar/data/1682639/000110465920037871/tm2011864d2_ex4-2.htm" STYLE="-sec-extract: exhibit">Form&nbsp;of Class&nbsp;B Warrant issued on March&nbsp;24, 2020</A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center"><A HREF="https://www.sec.gov/Archives/edgar/data/1682639/000110465920037871/tm2011864d2_ex4-2.htm" STYLE="-sec-extract: exhibit">8-K</A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center"><A HREF="https://www.sec.gov/Archives/edgar/data/1682639/000110465920037871/tm2011864d2_ex4-2.htm" STYLE="-sec-extract: exhibit">001-38365</A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center"><A HREF="https://www.sec.gov/Archives/edgar/data/1682639/000110465920037871/tm2011864d2_ex4-2.htm" STYLE="-sec-extract: exhibit">4.2</A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center"><A HREF="https://www.sec.gov/Archives/edgar/data/1682639/000110465920037871/tm2011864d2_ex4-2.htm" STYLE="-sec-extract: exhibit">March&nbsp;25, 2020</A></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center"><A HREF="https://www.sec.gov/Archives/edgar/data/1682639/000157104917008733/t1703004_ex10-1.htm" STYLE="-sec-extract: exhibit">10.1</A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left"><A HREF="https://www.sec.gov/Archives/edgar/data/1682639/000157104917008733/t1703004_ex10-1.htm" STYLE="-sec-extract: exhibit">Exclusive License Agreement, dated March&nbsp;18, 2015, between Eyenovia,&nbsp;Inc. and Senju Pharmaceutical Co.,&nbsp;Ltd.</A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center"><A HREF="https://www.sec.gov/Archives/edgar/data/1682639/000157104917008733/t1703004_ex10-1.htm" STYLE="-sec-extract: exhibit">S-1</A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center"><A HREF="https://www.sec.gov/Archives/edgar/data/1682639/000157104917008733/t1703004_ex10-1.htm" STYLE="-sec-extract: exhibit">333-222162</A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center"><A HREF="https://www.sec.gov/Archives/edgar/data/1682639/000157104917008733/t1703004_ex10-1.htm" STYLE="-sec-extract: exhibit">10.1</A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center"><A HREF="https://www.sec.gov/Archives/edgar/data/1682639/000157104917008733/t1703004_ex10-1.htm" STYLE="-sec-extract: exhibit">December&nbsp;19, 2017</A></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center"><A HREF="https://www.sec.gov/Archives/edgar/data/1682639/000110465920095393/tm2020508d1_ex10-24.htm" STYLE="-sec-extract: exhibit">10.1.1#</A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left"><A HREF="https://www.sec.gov/Archives/edgar/data/1682639/000110465920095393/tm2020508d1_ex10-24.htm" STYLE="-sec-extract: exhibit">Amendment to the Exclusive License Agreement by and between Eyenovia,&nbsp;Inc. and Senju Pharmaceutical Co.,&nbsp;Ltd., dated April&nbsp;8, 2020</A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center"><A HREF="https://www.sec.gov/Archives/edgar/data/1682639/000110465920095393/tm2020508d1_ex10-24.htm" STYLE="-sec-extract: exhibit">10-Q</A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center"><A HREF="https://www.sec.gov/Archives/edgar/data/1682639/000110465920095393/tm2020508d1_ex10-24.htm" STYLE="-sec-extract: exhibit">001-38365</A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center"><A HREF="https://www.sec.gov/Archives/edgar/data/1682639/000110465920095393/tm2020508d1_ex10-24.htm" STYLE="-sec-extract: exhibit">10.24</A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center"><A HREF="https://www.sec.gov/Archives/edgar/data/1682639/000110465920095393/tm2020508d1_ex10-24.htm" STYLE="-sec-extract: exhibit">August&nbsp;14, 2020</A></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center"><A HREF="https://www.sec.gov/Archives/edgar/data/1682639/000110465920095393/tm2020508d1_ex10-27.htm" STYLE="-sec-extract: exhibit">10.1.2#</A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left"><A HREF="https://www.sec.gov/Archives/edgar/data/1682639/000110465920095393/tm2020508d1_ex10-27.htm" STYLE="-sec-extract: exhibit">Letter Agreement by and between Eyenovia,&nbsp;Inc. and Senju Pharmaceutical Co.,&nbsp;Ltd., dated August&nbsp;10, 2020</A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center"><A HREF="https://www.sec.gov/Archives/edgar/data/1682639/000110465920095393/tm2020508d1_ex10-27.htm" STYLE="-sec-extract: exhibit">10-Q</A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center"><A HREF="https://www.sec.gov/Archives/edgar/data/1682639/000110465920095393/tm2020508d1_ex10-27.htm" STYLE="-sec-extract: exhibit">001-38365</A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center"><A HREF="https://www.sec.gov/Archives/edgar/data/1682639/000110465920095393/tm2020508d1_ex10-27.htm" STYLE="-sec-extract: exhibit">10.27</A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center"><A HREF="https://www.sec.gov/Archives/edgar/data/1682639/000110465920095393/tm2020508d1_ex10-27.htm" STYLE="-sec-extract: exhibit">August&nbsp;14, 2020</A></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 79; Value: 74 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->78<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center; width: 8%"><A HREF="https://www.sec.gov/Archives/edgar/data/1682639/000157104917008733/t1703004_ex10-10.htm" STYLE="-sec-extract: exhibit">10.2*</A></TD><TD STYLE="font-size: 10pt; width: 2%">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; width: 34%"><A HREF="https://www.sec.gov/Archives/edgar/data/1682639/000157104917008733/t1703004_ex10-10.htm" STYLE="-sec-extract: exhibit">Master Consulting Services Agreement, dated November&nbsp;4, 2014, between Eyenovia,&nbsp;Inc. and Private Medical Equity,&nbsp;Inc.</A></TD><TD STYLE="font-size: 10pt; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center; width: 12%"><A HREF="https://www.sec.gov/Archives/edgar/data/1682639/000157104917008733/t1703004_ex10-10.htm" STYLE="-sec-extract: exhibit">S-1</A></TD><TD STYLE="font-size: 10pt; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center; width: 14%"><A HREF="https://www.sec.gov/Archives/edgar/data/1682639/000157104917008733/t1703004_ex10-10.htm" STYLE="-sec-extract: exhibit">333-222162</A></TD><TD STYLE="font-size: 10pt; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center; width: 12%"><A HREF="https://www.sec.gov/Archives/edgar/data/1682639/000157104917008733/t1703004_ex10-10.htm" STYLE="-sec-extract: exhibit">10.10</A></TD><TD STYLE="font-size: 10pt; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center; width: 14%"><A HREF="https://www.sec.gov/Archives/edgar/data/1682639/000157104917008733/t1703004_ex10-10.htm" STYLE="-sec-extract: exhibit">December&nbsp;19, 2017</A></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center"><A HREF="https://www.sec.gov/Archives/edgar/data/1682639/000114420419008865/tv512687_ex10-16.htm" STYLE="-sec-extract: exhibit">10.3*</A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left"><A HREF="https://www.sec.gov/Archives/edgar/data/1682639/000114420419008865/tv512687_ex10-16.htm" STYLE="-sec-extract: exhibit">Executive Employment Agreement, dated February&nbsp;15, 2019, by and between the Company and Tsontcho Ianchulev.</A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center"><A HREF="https://www.sec.gov/Archives/edgar/data/1682639/000114420419008865/tv512687_ex10-16.htm" STYLE="-sec-extract: exhibit">8-K</A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center"><A HREF="https://www.sec.gov/Archives/edgar/data/1682639/000114420419008865/tv512687_ex10-16.htm" STYLE="-sec-extract: exhibit">001-38365</A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center"><A HREF="https://www.sec.gov/Archives/edgar/data/1682639/000114420419008865/tv512687_ex10-16.htm" STYLE="-sec-extract: exhibit">10.16</A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center"><A HREF="https://www.sec.gov/Archives/edgar/data/1682639/000114420419008865/tv512687_ex10-16.htm" STYLE="-sec-extract: exhibit">February&nbsp;19, 2019</A></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center"><A HREF="https://www.sec.gov/Archives/edgar/data/1682639/000114420419008865/tv512687_ex10-17.htm" STYLE="-sec-extract: exhibit">10.4*</A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left"><A HREF="https://www.sec.gov/Archives/edgar/data/1682639/000114420419008865/tv512687_ex10-17.htm" STYLE="-sec-extract: exhibit">Executive Employment Agreement, dated February&nbsp;15, 2019, by and between the Company and John Gandolfo.</A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center"><A HREF="https://www.sec.gov/Archives/edgar/data/1682639/000114420419008865/tv512687_ex10-17.htm" STYLE="-sec-extract: exhibit">8-K</A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center"><A HREF="https://www.sec.gov/Archives/edgar/data/1682639/000114420419008865/tv512687_ex10-17.htm" STYLE="-sec-extract: exhibit">001-38365</A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center"><A HREF="https://www.sec.gov/Archives/edgar/data/1682639/000114420419008865/tv512687_ex10-17.htm" STYLE="-sec-extract: exhibit">10.17</A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center"><A HREF="https://www.sec.gov/Archives/edgar/data/1682639/000114420419008865/tv512687_ex10-17.htm" STYLE="-sec-extract: exhibit">February&nbsp;19, 2019</A></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center"><A HREF="https://www.sec.gov/Archives/edgar/data/1682639/000114420419008865/tv512687_ex10-18.htm" STYLE="-sec-extract: exhibit">10.5*</A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left"><A HREF="https://www.sec.gov/Archives/edgar/data/1682639/000114420419008865/tv512687_ex10-18.htm" STYLE="-sec-extract: exhibit">Executive Employment Agreement, dated February&nbsp;15, 2019, by and between the Company and Luke Clauson.</A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center"><A HREF="https://www.sec.gov/Archives/edgar/data/1682639/000114420419008865/tv512687_ex10-18.htm" STYLE="-sec-extract: exhibit">8-K</A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center"><A HREF="https://www.sec.gov/Archives/edgar/data/1682639/000114420419008865/tv512687_ex10-18.htm" STYLE="-sec-extract: exhibit">001-38365</A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center"><A HREF="https://www.sec.gov/Archives/edgar/data/1682639/000114420419008865/tv512687_ex10-18.htm" STYLE="-sec-extract: exhibit">10.18</A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center"><A HREF="https://www.sec.gov/Archives/edgar/data/1682639/000114420419008865/tv512687_ex10-18.htm" STYLE="-sec-extract: exhibit">February&nbsp;19, 2019</A></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center"><A HREF="https://www.sec.gov/Archives/edgar/data/1682639/000114420419008865/tv512687_ex10-19.htm" STYLE="-sec-extract: exhibit">10.6*</A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left"><A HREF="https://www.sec.gov/Archives/edgar/data/1682639/000114420419008865/tv512687_ex10-19.htm" STYLE="-sec-extract: exhibit">Executive Employment Agreement, dated February&nbsp;15, 2019, by and between the Company and Michael Rowe.</A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center"><A HREF="https://www.sec.gov/Archives/edgar/data/1682639/000114420419008865/tv512687_ex10-19.htm" STYLE="-sec-extract: exhibit">8-K</A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center"><A HREF="https://www.sec.gov/Archives/edgar/data/1682639/000114420419008865/tv512687_ex10-19.htm" STYLE="-sec-extract: exhibit">001-38365</A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center"><A HREF="https://www.sec.gov/Archives/edgar/data/1682639/000114420419008865/tv512687_ex10-19.htm" STYLE="-sec-extract: exhibit">10.19</A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center"><A HREF="https://www.sec.gov/Archives/edgar/data/1682639/000114420419008865/tv512687_ex10-19.htm" STYLE="-sec-extract: exhibit">February&nbsp;19, 2019</A></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center"><A HREF="https://www.sec.gov/Archives/edgar/data/1682639/000114420419008865/tv512687_ex10-20.htm" STYLE="-sec-extract: exhibit">10.7*</A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left"><A HREF="https://www.sec.gov/Archives/edgar/data/1682639/000114420419008865/tv512687_ex10-20.htm" STYLE="-sec-extract: exhibit">Executive Employment Agreement, dated February&nbsp;15, 2019, by and between the Company and Jennifer Clasby.</A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center"><A HREF="https://www.sec.gov/Archives/edgar/data/1682639/000114420419008865/tv512687_ex10-20.htm" STYLE="-sec-extract: exhibit">8-K</A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center"><A HREF="https://www.sec.gov/Archives/edgar/data/1682639/000114420419008865/tv512687_ex10-20.htm" STYLE="-sec-extract: exhibit">001-38365</A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center"><A HREF="https://www.sec.gov/Archives/edgar/data/1682639/000114420419008865/tv512687_ex10-20.htm" STYLE="-sec-extract: exhibit">10.20</A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center"><A HREF="https://www.sec.gov/Archives/edgar/data/1682639/000114420419008865/tv512687_ex10-20.htm" STYLE="-sec-extract: exhibit">February&nbsp;19, 2019</A></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center"><A HREF="https://www.sec.gov/Archives/edgar/data/1682639/000114420419008865/tv512687_ex10-21.htm" STYLE="-sec-extract: exhibit">10.8</A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left"><A HREF="https://www.sec.gov/Archives/edgar/data/1682639/000114420419008865/tv512687_ex10-21.htm" STYLE="-sec-extract: exhibit">Form&nbsp;of Nondisclosure, Assignment of Inventions and Noncompetition Agreement.</A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center"><A HREF="https://www.sec.gov/Archives/edgar/data/1682639/000114420419008865/tv512687_ex10-21.htm" STYLE="-sec-extract: exhibit">8-K</A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center"><A HREF="https://www.sec.gov/Archives/edgar/data/1682639/000114420419008865/tv512687_ex10-21.htm" STYLE="-sec-extract: exhibit">001-38365</A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center"><A HREF="https://www.sec.gov/Archives/edgar/data/1682639/000114420419008865/tv512687_ex10-21.htm" STYLE="-sec-extract: exhibit">10.21</A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center"><A HREF="https://www.sec.gov/Archives/edgar/data/1682639/000114420419008865/tv512687_ex10-21.htm" STYLE="-sec-extract: exhibit">February&nbsp;19, 2019</A></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center"><A HREF="https://www.sec.gov/Archives/edgar/data/1682639/000114420419040097/tv527418_ex10-14.htm" STYLE="-sec-extract: exhibit">10.9*</A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left"><A HREF="https://www.sec.gov/Archives/edgar/data/1682639/000114420419040097/tv527418_ex10-14.htm" STYLE="-sec-extract: exhibit">Eyenovia,&nbsp;Inc. 2014 Equity Incentive Plan, as amended.</A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center"><A HREF="https://www.sec.gov/Archives/edgar/data/1682639/000114420419040097/tv527418_ex10-14.htm" STYLE="-sec-extract: exhibit">S-8</A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center"><A HREF="https://www.sec.gov/Archives/edgar/data/1682639/000114420419040097/tv527418_ex10-14.htm" STYLE="-sec-extract: exhibit">333-233278</A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center"><A HREF="https://www.sec.gov/Archives/edgar/data/1682639/000114420419040097/tv527418_ex10-14.htm" STYLE="-sec-extract: exhibit">10.14</A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center"><A HREF="https://www.sec.gov/Archives/edgar/data/1682639/000114420419040097/tv527418_ex10-14.htm" STYLE="-sec-extract: exhibit">August&nbsp;14, 2019</A></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center"><A HREF="https://www.sec.gov/Archives/edgar/data/1682639/000114420419040097/tv527418_ex10-15.htm" STYLE="-sec-extract: exhibit">10.10*</A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left"><A HREF="https://www.sec.gov/Archives/edgar/data/1682639/000114420419040097/tv527418_ex10-15.htm" STYLE="-sec-extract: exhibit">Form&nbsp;of Nonqualified Stock Option Agreement.</A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center"><A HREF="https://www.sec.gov/Archives/edgar/data/1682639/000114420419040097/tv527418_ex10-15.htm" STYLE="-sec-extract: exhibit">S-8</A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center"><A HREF="https://www.sec.gov/Archives/edgar/data/1682639/000114420419040097/tv527418_ex10-15.htm" STYLE="-sec-extract: exhibit">333-23378</A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center"><A HREF="https://www.sec.gov/Archives/edgar/data/1682639/000114420419040097/tv527418_ex10-15.htm" STYLE="-sec-extract: exhibit">10.15</A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center"><A HREF="https://www.sec.gov/Archives/edgar/data/1682639/000114420419040097/tv527418_ex10-15.htm" STYLE="-sec-extract: exhibit">August&nbsp;14, 2019</A></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center"><A HREF="https://www.sec.gov/Archives/edgar/data/1682639/000110465920037871/tm2011864d2_ex10-23.htm" STYLE="-sec-extract: exhibit">10.11</A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left"><A HREF="https://www.sec.gov/Archives/edgar/data/1682639/000110465920037871/tm2011864d2_ex10-23.htm" STYLE="-sec-extract: exhibit">Registration Rights Agreement, dated March&nbsp;23, 2020, between Eyenovia,&nbsp;Inc. and the investors named therein</A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center"><A HREF="https://www.sec.gov/Archives/edgar/data/1682639/000110465920037871/tm2011864d2_ex10-23.htm" STYLE="-sec-extract: exhibit">8-K</A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center"><A HREF="https://www.sec.gov/Archives/edgar/data/1682639/000110465920037871/tm2011864d2_ex10-23.htm" STYLE="-sec-extract: exhibit">001-38365</A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center"><A HREF="https://www.sec.gov/Archives/edgar/data/1682639/000110465920037871/tm2011864d2_ex10-23.htm" STYLE="-sec-extract: exhibit">10.23</A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center"><A HREF="https://www.sec.gov/Archives/edgar/data/1682639/000110465920037871/tm2011864d2_ex10-23.htm" STYLE="-sec-extract: exhibit">March&nbsp;25, 2020</A></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center"><A HREF="https://www.sec.gov/Archives/edgar/data/1682639/000110465920058791/tm2018919d1_ex10-24.htm" STYLE="-sec-extract: exhibit">10.12</A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left"><A HREF="https://www.sec.gov/Archives/edgar/data/1682639/000110465920058791/tm2018919d1_ex10-24.htm" STYLE="-sec-extract: exhibit">Promissory Note and Agreement dated May&nbsp;3, 2020</A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center"><A HREF="https://www.sec.gov/Archives/edgar/data/1682639/000110465920058791/tm2018919d1_ex10-24.htm" STYLE="-sec-extract: exhibit">8-K</A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center"><A HREF="https://www.sec.gov/Archives/edgar/data/1682639/000110465920058791/tm2018919d1_ex10-24.htm" STYLE="-sec-extract: exhibit">001-38365</A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center"><A HREF="https://www.sec.gov/Archives/edgar/data/1682639/000110465920058791/tm2018919d1_ex10-24.htm" STYLE="-sec-extract: exhibit">10.24</A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center"><A HREF="https://www.sec.gov/Archives/edgar/data/1682639/000110465920058791/tm2018919d1_ex10-24.htm" STYLE="-sec-extract: exhibit">May&nbsp;8, 2020</A></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center"><A HREF="https://www.sec.gov/Archives/edgar/data/1682639/000110465920080545/tm2023724d2_ex10-25.htm" STYLE="-sec-extract: exhibit">10.13*</A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left"><A HREF="https://www.sec.gov/Archives/edgar/data/1682639/000110465920080545/tm2023724d2_ex10-25.htm" STYLE="-sec-extract: exhibit">Eyenovia,&nbsp;Inc. Amended and Restated 2018 Omnibus Stock Incentive Plan</A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center"><A HREF="https://www.sec.gov/Archives/edgar/data/1682639/000110465920080545/tm2023724d2_ex10-25.htm" STYLE="-sec-extract: exhibit">8-K</A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center"><A HREF="https://www.sec.gov/Archives/edgar/data/1682639/000110465920080545/tm2023724d2_ex10-25.htm" STYLE="-sec-extract: exhibit">001-38365</A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center"><A HREF="https://www.sec.gov/Archives/edgar/data/1682639/000110465920080545/tm2023724d2_ex10-25.htm" STYLE="-sec-extract: exhibit">10.25</A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center"><A HREF="https://www.sec.gov/Archives/edgar/data/1682639/000110465920080545/tm2023724d2_ex10-25.htm" STYLE="-sec-extract: exhibit">July&nbsp;2, 2020</A></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center"><A HREF="https://www.sec.gov/Archives/edgar/data/1682639/000114420418034222/tv495935_ex10-14.htm" STYLE="-sec-extract: exhibit">10.14*</A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left"><A HREF="https://www.sec.gov/Archives/edgar/data/1682639/000114420418034222/tv495935_ex10-14.htm" STYLE="-sec-extract: exhibit">Form&nbsp;of Notice of Stock Option Grant and Award Agreement</A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center"><A HREF="https://www.sec.gov/Archives/edgar/data/1682639/000114420418034222/tv495935_ex10-14.htm" STYLE="-sec-extract: exhibit">8-K</A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center"><A HREF="https://www.sec.gov/Archives/edgar/data/1682639/000114420418034222/tv495935_ex10-14.htm" STYLE="-sec-extract: exhibit">001-38365</A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center"><A HREF="https://www.sec.gov/Archives/edgar/data/1682639/000114420418034222/tv495935_ex10-14.htm" STYLE="-sec-extract: exhibit">10.14</A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center"><A HREF="https://www.sec.gov/Archives/edgar/data/1682639/000114420418034222/tv495935_ex10-14.htm" STYLE="-sec-extract: exhibit">June&nbsp;14, 2018</A></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 80; Value: 74 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->79<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center; width: 8%"><A HREF="https://www.sec.gov/Archives/edgar/data/1682639/000114420418034222/tv495935_ex10-15.htm" STYLE="-sec-extract: exhibit">10.15*</A></TD><TD STYLE="font-size: 10pt; width: 2%">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; width: 34%"><A HREF="https://www.sec.gov/Archives/edgar/data/1682639/000114420418034222/tv495935_ex10-15.htm" STYLE="-sec-extract: exhibit">Form&nbsp;of Restricted Stock Award Agreement</A></TD><TD STYLE="font-size: 10pt; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center; width: 12%"><A HREF="https://www.sec.gov/Archives/edgar/data/1682639/000114420418034222/tv495935_ex10-15.htm" STYLE="-sec-extract: exhibit">8-K</A></TD><TD STYLE="font-size: 10pt; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center; width: 14%"><A HREF="https://www.sec.gov/Archives/edgar/data/1682639/000114420418034222/tv495935_ex10-15.htm" STYLE="-sec-extract: exhibit">001-38365</A></TD><TD STYLE="font-size: 10pt; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center; width: 12%"><A HREF="https://www.sec.gov/Archives/edgar/data/1682639/000114420418034222/tv495935_ex10-15.htm" STYLE="-sec-extract: exhibit">10.15</A></TD><TD STYLE="font-size: 10pt; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center; width: 14%"><A HREF="https://www.sec.gov/Archives/edgar/data/1682639/000114420418034222/tv495935_ex10-15.htm" STYLE="-sec-extract: exhibit">June&nbsp;14, 2018</A></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center"><A HREF="https://www.sec.gov/Archives/edgar/data/1682639/000110465920095393/tm2020508d1_ex10-28.htm" STYLE="-sec-extract: exhibit">10.16#</A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left"><A HREF="https://www.sec.gov/Archives/edgar/data/1682639/000110465920095393/tm2020508d1_ex10-28.htm" STYLE="-sec-extract: exhibit">License Agreement by and between Eyenovia,&nbsp;Inc. and Artic Vision (Hong Kong) Limited, dated August&nbsp;10, 2020</A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center"><A HREF="https://www.sec.gov/Archives/edgar/data/1682639/000110465920095393/tm2020508d1_ex10-28.htm" STYLE="-sec-extract: exhibit">10-Q</A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center"><A HREF="https://www.sec.gov/Archives/edgar/data/1682639/000110465920095393/tm2020508d1_ex10-28.htm" STYLE="-sec-extract: exhibit">001-38365</A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center"><A HREF="https://www.sec.gov/Archives/edgar/data/1682639/000110465920095393/tm2020508d1_ex10-28.htm" STYLE="-sec-extract: exhibit">10.28</A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center"><A HREF="https://www.sec.gov/Archives/edgar/data/1682639/000110465920095393/tm2020508d1_ex10-28.htm" STYLE="-sec-extract: exhibit">August&nbsp;14, 2020</A></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center"><A HREF="https://www.sec.gov/Archives/edgar/data/1682639/000110465920114142/tm2032947d1_ex10-1.htm" STYLE="-sec-extract: exhibit">10.17#</A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left"><A HREF="https://www.sec.gov/Archives/edgar/data/1682639/000110465920114142/tm2032947d1_ex10-1.htm" STYLE="-sec-extract: exhibit">License Agreement by and between Eyenovia,&nbsp;Inc. and Bausch Health Ireland Limited, dated October&nbsp;9, 2020.</A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center"><A HREF="https://www.sec.gov/Archives/edgar/data/1682639/000110465920114142/tm2032947d1_ex10-1.htm" STYLE="-sec-extract: exhibit">8-K</A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center"><A HREF="https://www.sec.gov/Archives/edgar/data/1682639/000110465920114142/tm2032947d1_ex10-1.htm" STYLE="-sec-extract: exhibit">001-38365</A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center"><A HREF="https://www.sec.gov/Archives/edgar/data/1682639/000110465920114142/tm2032947d1_ex10-1.htm" STYLE="-sec-extract: exhibit">10.1</A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center"><A HREF="https://www.sec.gov/Archives/edgar/data/1682639/000110465920114142/tm2032947d1_ex10-1.htm" STYLE="-sec-extract: exhibit">October&nbsp;13, 2020</A></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center"><A HREF="tm211152d1_ex23-1.htm">23.1</A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left"><A HREF="tm211152d1_ex23-1.htm">Consent of Marcum LLP</A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center"><A HREF="tm211152d1_ex23-1.htm">--</A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center"><A HREF="tm211152d1_ex23-1.htm">--</A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center"><A HREF="tm211152d1_ex23-1.htm">--</A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center"><A HREF="tm211152d1_ex23-1.htm">Filed herewith</A></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center"><A HREF="tm211152d1_ex31-1.htm">31.1</A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left"><A HREF="tm211152d1_ex31-1.htm">Certification of the Principal Executive Officer pursuant to Section&nbsp;302 of the Sarbanes-Oxley Act of 2002</A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center"><A HREF="tm211152d1_ex31-1.htm">--</A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center"><A HREF="tm211152d1_ex31-1.htm">--</A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center"><A HREF="tm211152d1_ex31-1.htm">--</A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center"><A HREF="tm211152d1_ex31-1.htm">Filed herewith</A></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center"><A HREF="tm211152d1_ex31-2.htm">31.2</A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left"><A HREF="tm211152d1_ex31-2.htm">Certification of the Principal Financial Officer pursuant to Section&nbsp;302 of the Sarbanes-Oxley Act of 2002</A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center"><A HREF="tm211152d1_ex31-2.htm">--</A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center"><A HREF="tm211152d1_ex31-2.htm">--</A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center"><A HREF="tm211152d1_ex31-2.htm">--</A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center"><A HREF="tm211152d1_ex31-2.htm">Filed herewith</A></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center"><A HREF="tm211152d1_ex32-1.htm">32.1</A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left"><A HREF="tm211152d1_ex32-1.htm">Certification of the Principal Executive Officer pursuant to Section&nbsp;906 of the Sarbanes-Oxley Act of 2002</A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center"><A HREF="tm211152d1_ex32-1.htm">--</A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center"><A HREF="tm211152d1_ex32-1.htm">--</A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center"><A HREF="tm211152d1_ex32-1.htm">--</A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center"><A HREF="tm211152d1_ex32-1.htm">Filed herewith</A></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center"><A HREF="tm211152d1_ex32-2.htm">32.2</A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left"><A HREF="tm211152d1_ex32-2.htm">Certification of the Principal Financial Officer pursuant to Section&nbsp;906 of the Sarbanes-Oxley Act of 2002</A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center"><A HREF="tm211152d1_ex32-2.htm">--</A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center"><A HREF="tm211152d1_ex32-2.htm">--</A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center"><A HREF="tm211152d1_ex32-2.htm">--</A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center"><A HREF="tm211152d1_ex32-2.htm">Filed herewith</A></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center">101</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">Interactive data files pursuant to Rule&nbsp;405&nbsp;of&nbsp;Regulation S-T: (i)&nbsp;Balance Sheets as of December&nbsp;31, 2020 and 2019; (ii)&nbsp;Statements of Operations for the Years Ended December&nbsp;31, 2020 and 2019; (iii)&nbsp;Statements of Changes in Stockholders&rsquo; Equity for the Years Ended December&nbsp;31, 2020 and 2019; (iv)&nbsp;Statements of Cash Flows for the Years Ended December&nbsp;31, 2020 and 2019; and (v)&nbsp;Notes to Financial Statements</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center">--</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center">--</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center">--</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center">Filed herewith</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">* Management contract or other compensatory plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"># Portions of this exhibit have been redacted
in compliance with&nbsp;Regulation S-K&nbsp;Item&nbsp;601(b)(10).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0px">&nbsp;</TD>
    <TD STYLE="width: 62px"><B><A NAME="a1_013"></A>Item 16.</B></TD>
    <TD><B>Form&nbsp;10-K Summary.</B></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">None.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 81; Value: 74 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->80<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a1_014"></A>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
of Sections 13 or 15(d)&nbsp;of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned, thereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><B>EYENOVIA,&nbsp;INC.</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 57%">&nbsp;</TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 38%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Date: March 30, 2021</TD>
    <TD>By:</TD>
    <TD STYLE="border-bottom: black 1pt solid">/s/ Tsontcho Ianchulev</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Tsontcho Ianchulev</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Chief Executive Officer </TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>(Principal Executive Officer)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
of the Securities Exchange Act of 1934, this report has been signed by the following persons on behalf of the registrant and in
the capacities and on the dates indicated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 34%; border-bottom: black 1pt solid; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Signature</B></FONT></TD>
    <TD STYLE="width: 1%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 44%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Title</B></FONT></TD>
    <TD STYLE="width: 1%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 20%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Date</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">/s/ Tsontcho Ianchulev</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Chief Executive Officer</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">March&nbsp;30, 2021</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Tsontcho Ianchulev</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">(Principal Executive Officer) and Director</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">/s/ John Gandolfo</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Chief Financial Officer</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">March&nbsp;30, 2021</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">John Gandolfo</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">(Principal Financial and Accounting Officer)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">/s/ Fredric N. Eshelman</FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">Chairman of the Board and Director</FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">March&nbsp;30, 2021</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Fredric N. Eshelman</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">/s/ Curt H. LaBelle</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Director</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">March&nbsp;30, 2021</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Curt H. LaBelle</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">/s/ Kenneth B. Lee,&nbsp;Jr.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Director</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">March&nbsp;30, 2021</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Kenneth B. Lee,&nbsp;Jr.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">/s/ Ernest Mario</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Director</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">March&nbsp;30, 2021</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Ernest Mario</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">/s/ Charles E. Mather IV</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Director</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">March&nbsp;30, 2021</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Charles E. Mather IV</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">/s/ Anthony Y. Sun</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Director</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">March&nbsp;30, 2021</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Anthony Y. Sun</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 82; Value: 74 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->81<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EYENOVIA,&nbsp;INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>INDEX TO FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 93%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 7%; text-align: center"><B>Page&nbsp;Number</B></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD><B><U>Years Ended December&nbsp;31, 2020 and 2019</U></B></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in"><A HREF="#s6_001">Report of Independent Registered Public Accounting Firm</A></TD>
    <TD STYLE="text-align: center"><A HREF="#s6_001">F-2</A></TD></TR>
<TR STYLE="background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in"><A HREF="#s6_002">Balance Sheets as of December&nbsp;31, 2020 and 2019</A></TD>
    <TD STYLE="text-align: center"><A HREF="#s6_002">F-3</A></TD></TR>
<TR STYLE="background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in"><A HREF="#s6_003">Statements of Operations for the Years Ended December&nbsp;31, 2020 and 2019</A></TD>
    <TD STYLE="text-align: center"><A HREF="#s6_003">F-4</A></TD></TR>
<TR STYLE="background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in"><A HREF="#s6_004">Statements of Changes in Stockholders&rsquo; Equity for the Years Ended December&nbsp;31, 2020 and 2019</A></TD>
    <TD STYLE="text-align: center"><A HREF="#s6_004">F-5</A></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="padding-left: 0.25in">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in"><A HREF="#s6_005">Statements of Cash Flows for the Years Ended December&nbsp;31, 2020 and 2019</A></TD>
    <TD STYLE="text-align: center"><A HREF="#s6_005">F-6</A></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="padding-left: 0.25in">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in"><A HREF="#s7_001">Notes to Financial Statements</A></TD>
    <TD STYLE="text-align: center"><A HREF="#s7_001">F-7</A></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 83; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U><A NAME="s6_001"></A>REPORT OF INDEPENDENT REGISTERED PUBLIC
ACCOUNTING FIRM</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; color: #201F1E">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; color: #201F1E">To the
Shareholders and Board of Directors of</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; color: #201F1E">Eyenovia,
Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; color: #201F1E">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>Opinion on the Financial
Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">We have audited the accompanying
balance sheets of Eyenovia, Inc. (the &ldquo;Company&rdquo;) as of December 31, 2020 and 2019, the related statements of operations, changes
in stockholders&rsquo; equity and cash flows for each of the two years in the period ended December 31, 2020, and the related notes (collectively
referred to as the &ldquo;financial statements&rdquo;).&nbsp; In our opinion, the financial statements present fairly, in all material
respects, the financial position of the Company as of December 31, 2020 and 2019, and the results of its operations and its cash flows
for each of the two years in the period ended December 31, 2020, in conformity with accounting principles generally accepted in the United
States of America .</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; color: #201F1E"><B>Explanatory Paragraph &ndash;
Going Concern</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; color: #201F1E"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; color: #201F1E">The accompanying
financial statements have been prepared assuming that the Company will continue as a going concern. As more fully described in Note<B>&nbsp;</B>2,
the Company has incurred significant losses and needs to raise additional funds to meet its obligations and sustain its operations for
a reasonable period of time, which is considered to be one year from the issuance of the financial statements. These conditions raise
substantial doubt about the Company's ability to continue as a going concern. Management's plans in regard to these matters are also described
in Note 2. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; color: #201F1E">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; color: #201F1E"><B>Basis for Opinion</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; color: #201F1E">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; color: #201F1E">These
financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company's
financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board
(United States) (&quot;PCAOB&quot;) and are required to be independent with respect to the Company in accordance with the U.S. federal
securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; color: #201F1E">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; color: #201F1E">We conducted
our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable
assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not
required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we
are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion
on the effectiveness of the Company's internal control over financial reporting. Accordingly, we express no such opinion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; color: #201F1E">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; color: #201F1E">Our audits
included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud,
and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts
and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates
made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable
basis for our opinion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; color: #201F1E">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; color: #201F1E">/s/ Marcum&nbsp;<FONT STYLE="font-variant: small-caps">llp</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; color: #201F1E"><FONT STYLE="font-variant: small-caps">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; color: #201F1E">Marcum&nbsp;<FONT STYLE="font-variant: small-caps">llp</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; color: #201F1E"><FONT STYLE="font-variant: small-caps">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; color: #201F1E">We have served as the Company&rsquo;s
auditor since 2017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; color: #201F1E">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; color: #201F1E">New York, NY</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; color: #201F1E">March 30, 2021</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 84; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>EYENOVIA,&nbsp;INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B><A NAME="s6_002"></A>Balance Sheets</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">December 31,</TD><TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2020</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2019</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif">Assets</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Current Assets:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.375in; text-align: left">Cash and cash equivalents</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">28,371,828</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">14,152,601</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.375in; text-align: left">Deferred license costs</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,600,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.375in; text-align: left">License receivable</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">2,966,039</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.375in; text-align: left">Prepaid expenses and other current assets</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">453,478</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">196,680</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.75in; text-align: left">Total Current Assets</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">33,391,345</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">14,349,281</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Property and equipment, net</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">396,380</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">230,538</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Security deposit</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">119,035</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">117,800</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.75in; text-align: left">Total Assets</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">33,906,760</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">14,697,619</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Liabilities and Stockholders' Equity</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Current Liabilities:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.375in; text-align: left">Accounts payable</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,461,665</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,541,358</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.375in; text-align: left">Accrued compensation</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,150,672</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">916,873</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.375in; text-align: left">Accrued expenses and other current liabilities</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,480,692</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">453,430</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.375in; text-align: left">Deferred rent - current portion</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">7,809</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.375in; text-align: left">Deferred license fee</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">14,000,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.375in; text-align: left">Notes payable - current portion</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">97,539</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD COLSPAN="2" STYLE="padding-left: 0.375in; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.75in; text-align: left">Total Current Liabilities</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">18,198,377</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">2,911,661</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Deferred rent - non-current portion</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 37%">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 1%">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; width: 10%">38,684</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 1%">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 1%">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; width: 10%">45,351</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 1%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Notes payable - non-current portion</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">365,814</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.75in; text-align: left">Total Liabilities</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">18,602,875</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">2,957,012</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Commitments and contingencies (Note 9)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Stockholders' Equity:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.375in">Preferred stock, $0.0001 par value, 6,000,000 shares authorized;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.625in">0 shares issued and outstanding as of December 31, 2020 and</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.625in; text-align: left">2019, respectively</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.375in">Common stock, $0.0001 par value, 90,000,000 shares authorized;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.625in; text-align: left">24,978,585 and 17,100,726 shares issued and outstanding</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.625in">as of December 31, 2020 and 2019, respectively</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">2,498</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,710</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.375in; text-align: left">Additional paid-in capital</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">92,742,306</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">69,409,949</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.375in; text-align: left">Accumulated deficit</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(77,440,919</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(57,671,052</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.75in; text-align: left">Total Stockholders' Equity</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">15,303,885</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">11,740,607</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.75in; text-align: left">Total Liabilities and Stockholders' Equity</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">33,906,760</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">14,697,619</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">The accompanying notes are an integral part of these financial statements.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 85; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>EYENOVIA,&nbsp;INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B><A NAME="s6_003"></A>Statements of Operations</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">For the Years Ended</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">December 31,</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2020</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2019</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Operating Income</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.375in; width: 74%">Revenue</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">2,000,000</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; font: bold 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="width: 1%; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.375in; padding-bottom: 1pt">Cost of revenue</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(800,000</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.75in; text-align: left">Gross Profit</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,200,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Operating Expenses:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.375in; text-align: left">Research and development</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">13,263,817</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">14,102,449</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.375in; text-align: left; padding-bottom: 1pt">General and administrative</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">7,725,408</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">7,206,095</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.75in; text-align: left; padding-bottom: 1pt">Total Operating Expenses</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">20,989,225</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">21,308,544</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.75in; text-align: left">Loss From Operations</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(19,789,225</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(21,308,544</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Other Income (Expense):</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.375in; text-align: left">Small Business Administration Economic</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.5in; text-align: left">Injury Disaster Grant</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">10,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.375in; text-align: left">Interest expense</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(17,042</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.375in; text-align: left; padding-bottom: 1pt">Interest income</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">26,400</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">151,786</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-left: 0.75in; text-align: left; padding-bottom: 2.5pt">Net Loss</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(19,769,867</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(21,156,758</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.75in">Net Loss Per Share</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.875in; text-align: left; padding-bottom: 2.5pt">- Basic and Diluted</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(0.94</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(1.47</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.75in">Weighted Average Number of</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.875in">Common Shares Outstanding</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.875in; text-align: left; padding-bottom: 2.5pt">- Basic and Diluted</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">21,054,706</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">14,349,738</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The accompanying notes are an integral part of these financial statements.</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 86; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><B>EYENOVIA,&nbsp;INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><B><A NAME="s6_004"></A>Statements
of Changes in Stockholders' Equity</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="18" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">For the Years Ended December 31, 2020 and 2019</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Additional</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Total</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Common Stock</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Paid-In</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Accumulated</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Stockholders'</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Shares</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Amount</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Capital</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Deficit</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Equity</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 35%">Balance - January 1, 2019</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right">11,468,996</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right">1,147</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right">53,388,216</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right">(36,514,294</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right">16,875,069</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Issuance of common stock in public offering [1]</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">5,046,763</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">505</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">12,958,070</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">12,958,575</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Exercise of stock options on cashless basis</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">236,466</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">24</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(24</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Exercise of stock options</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">348,501</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">34</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">551,743</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">551,777</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Stock-based compensation</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">2,511,944</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">2,511,944</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Net loss</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(21,156,758</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(21,156,758</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif">Balance - December 31, 2019</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">17,100,726</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,710</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">69,409,949</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(57,671,052</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">11,740,607</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Issuance of common stock and warrants</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.125in; text-align: left">in private placement [2]</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">2,675,293</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">267</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">5,451,475</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">5,451,742</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Issuance of common stock in public offering [3]</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">3,833,334</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">383</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">12,495,325</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">12,495,708</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Exercise of stock warrants</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,332,841</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">134</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">2,820,228</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">2,820,362</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Exercise of stock options</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">36,391</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">4</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">82,157</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">82,161</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Stock-based compensation</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">2,483,172</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">2,483,172</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Net loss</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(19,769,867</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(19,769,867</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif">Balance - December 31, 2020</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">24,978,585</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">2,498</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">92,742,306</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(77,440,919</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">15,303,885</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">[1] Includes
gross proceeds of $14,030,001, less total issuance costs of $1,071,426.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">[2] Includes
gross proceeds of $5,984,931, less total issuance costs of $533,189.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">[3] Includes
gross proceeds of $13,800,002, less total issuance costs of $1,304,294.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">The
accompanying notes are an integral part of these financial statements. </FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 87; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>EYENOVIA,&nbsp;INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B><A NAME="s6_005"></A>Statements of Cash Flows</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-size: 10pt; font-weight: bold; text-align: center">For the Years Ended</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">December 31,</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2020</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2019</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">Cash Flows From Operating Activities</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 74%; font-size: 10pt; text-align: left; padding-left: 10pt">Net loss</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">(19,769,867</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">)</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">(21,156,758</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 10pt">Adjustments to reconcile net loss to net cash</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 10pt">used in operating activities:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 20pt">Depreciation of property and equipment</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">95,415</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">15,343</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 20pt">Stock-based compensation</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">2,483,172</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">2,511,944</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 10pt">Changes in operating assets and liabilities:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 20pt">Prepaid expenses and other current assets</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">218,418</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(63,924</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 20pt">License receivable</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(2,966,039</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 20pt">Deferred license costs</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(1,600,000</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 20pt">Accounts payable</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(79,693</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">31,834</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 20pt">Accrued compensation</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">233,799</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">4,769</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 20pt">Accrued expenses and other current liabilities</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">1,000,612</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(266,283</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 20pt">Deferred license fee</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">14,000,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 20pt">Security deposit</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(1,235</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 20pt">Deferred rent</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">1,142</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">3,767</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt; padding-left: 20pt">Net Cash Used In Operating Activities</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(6,384,276</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(18,919,308</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">Cash Flows From Investing Activities</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 10pt">Purchases of property and equipment</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(261,257</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(166,643</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt; padding-left: 20pt">Net Cash Used In Investing Activities</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(261,257</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(166,643</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">Cash Flows From Financing Activities</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 10pt">Proceeds from sale of common stock in public offering [1]</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">13,214,949</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 10pt">Proceeds from sale of common stock and warrants in private placement [2]</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">5,569,136</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 10pt">Proceeds from sale of common stock in public offering [3]</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">12,734,002</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 10pt">Proceeds from exercise of stock warrants</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">2,820,362</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 10pt">Proceeds from PPP 7(a) Loan</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">463,353</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 10pt">Repayments of notes payable</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(475,216</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 10pt">Payment of offering issuance costs</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(329,038</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(256,374</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 10pt">Proceeds from exercise of stock options</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">82,161</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">551,777</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt; padding-left: 20pt">Net Cash Provided By Financing Activities</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">20,864,760</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">13,510,352</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; padding-left: 20pt">Net Increase (Decrease) in Cash and Cash Equivalents</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">14,219,227</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(5,575,599</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Cash and cash equivalents - Beginning of Year</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">14,152,601</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">19,728,200</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Cash and cash equivalents - End of Year</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">28,371,828</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">14,152,601</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">[1] Includes gross proceeds of $14,030,001, less issuance costs of $815,052 deducted directly from the offering proceeds.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">[2] Includes gross proceeds of $5,984,931, less issuance costs of $415,795 deducted directly from the private placement proceeds.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">[3] Includes gross proceeds of $13,800,002, less issuance costs of $1,066,000 deducted directly from the offering proceeds.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">Supplemental Disclosure of Cash Flow Information:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 10pt">Cash paid during the periods for:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 74%; font-size: 10pt; padding-bottom: 2.5pt; padding-left: 0.375in">Interest</TD><TD STYLE="width: 1%; font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">13,974</TD><TD STYLE="width: 1%; padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">-</TD><TD STYLE="width: 1%; padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">Supplemental Disclosure of Non-Cash Investing and Financing Activities</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 2.5pt; padding-left: 10pt">Exercise of stock options on a cashless basis</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">24</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 2.5pt; padding-left: 10pt">Accrued purchases of leasehold improvements</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">42,500</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">The accompanying notes are an integral part of these financial statements.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 88; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Split-Segment; Name: 7 -->
<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>EYENOVIA,&nbsp;INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><A NAME="s7_001"></A>NOTES TO THE FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>FOR THE YEARS ENDED DECEMBER 31, 2020
AND 2019</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Note 1 &ndash; Business Organization and Nature of Operations</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Eyenovia,&nbsp;Inc. (&ldquo;Eyenovia&rdquo;
or the &ldquo;Company&rdquo;) was organized as a corporation under the laws of the State of Florida on March&nbsp;12, 2014 under
the name, PGP Holdings V,&nbsp;Inc. On May&nbsp;5, 2014, PGP Holdings V,&nbsp;Inc. changed its name to Eyenovia,&nbsp;Inc. On October&nbsp;6,
2014, Eyenovia,&nbsp;Inc. reincorporated in the State of Delaware by merging into Eyenovia,&nbsp;Inc., a Delaware corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Eyenovia. Inc. (&ldquo;Eyenovia&rdquo; or the
 &ldquo;Company&rdquo;) is a clinical stage ophthalmic company developing a pipeline of advanced therapeutics based on its propriety array
print (MAP<SUP>TM</SUP>) platform technology.&nbsp;Eyenovia aims to achieve clinical microdosing of next-generation formulations of novel
and existing ophthalmic pharmaceutical agents using its high-precision targeted ocular delivery system, branded the Opejet<SUP>&reg;</SUP>,
which has the potential to replace conventional eye dropper delivery and improve safety, tolerability, patient compliance and topical
delivery success for ophthalmic eye treatments. In the clinic, the Optejet has demonstrated the ability to horizontally deliver ophthalmic
medication with a success rate significantly higher than that of traditional eye drops (~ 90% vs. ~ 50%). Using its proprietary delivery
technology, Eyenovia is developing the next generation of smart ophthalmic therapies which target new indications or new combinations
where there are currently no comparable drug therapies approved by the U.S. Food and Drug Administration (the &ldquo;FDA&rdquo;). Eyenovia&rsquo;s
microdose therapeutics follow the FDA-designated pharmaceutical registration and regulatory process. Its products are classified by the
FDA as drugs, and not medical devices or drug-device combination products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Risks and Uncertainties</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Due to the COVID-19 pandemic, the Company initially
experienced delays in trial enrollment and initiation of its Phase III registration trial of its MicroPine drug candidate (the CHAPERONE
study) as a result of reduced clinical trial activities and operations at trial sites. However, the Company has since been able to resume
enrollment in that study.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.75in"><B>Note
2 &ndash; Summary of Significant Accounting Policies</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Liquidity and Going Concern</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of December 31, 2020, the Company had cash and cash equivalents of approximately $28.4 million and an accumulated deficit of approximately
$77.4 million. For the year ended December 31, 2020, the Company incurred net losses of approximately $19.8 million and used cash in operations
of approximately $6.4 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company does not have recurring revenue and has not yet achieved profitability. The Company expects to continue to incur cash outflows
from operations. The Company expects that its research and development and general and administrative expenses will continue to increase
and, as a result, it will eventually need to generate significant product revenues to achieve profitability. These circumstances raise
substantial doubt about the Company&rsquo;s ability to continue as a going concern for at least one year from the date that these financial
statements are issued. Implementation of the Company&rsquo;s plans and its ability to continue as a going concern will depend upon the
Company&rsquo;s ability to raise further capital, through the sale of additional equity or debt securities or otherwise, to support its
future operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&rsquo;s operating needs include the planned costs to operate its business, including amounts required to fund working capital
and capital expenditures. The Company&rsquo;s future capital requirements and the adequacy of its available funds will depend on many
factors, including the Company&rsquo;s ability to successfully commercialize its products and services, competing technological and market
developments, and the need to enter into collaborations with other companies or acquire other companies or technologies to enhance or
complement its product and service offerings. If the Company is unable to secure additional capital, it may be required to curtail its
research and development initiatives and take additional measures to reduce costs in order to conserve its cash.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 89; Options: NewSection; Value: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EYENOVIA,&nbsp;INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NOTES TO THE FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FOR THE YEARS ENDED DECEMBER 31, 2020
AND 2019</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Note 2 &ndash; Summary of Significant
Accounting Policies &ndash; Continued</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Use of Estimates</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Preparation of financial statements in
conformity with accounting principles generally accepted in the United States of America (&ldquo;U.S. GAAP&rdquo;) requires management
to make estimates, judgments and assumptions that affect the amounts reported in the financial statements and the amounts disclosed
in the related notes to the financial statements. The Company bases its estimates and judgments on historical experience and on
various other assumptions that it believes are reasonable under the circumstances. The amounts of assets and liabilities reported
in the Company&rsquo;s balance sheets and the amounts of expenses reported for each of the periods presented are affected by estimates
and assumptions, which are used for, but not limited to, fair value calculations for equity securities, establishment of valuation
allowances for deferred tax assets, stock-based compensation, the recoverability and useful lives of long-lived assets, the recovery
of deferred costs and the deferral of revenues. Certain of the Company&rsquo;s estimates could be affected by external conditions,
including those unique to the Company and general economic conditions. It is reasonably possible that actual results could differ
from those estimates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">See Note 2 - Summary of Significant Accounting
Policies&thinsp;&mdash;&thinsp;Stock-Based Compensation for additional discussion of the use of estimates in estimating the fair
value of the Company&rsquo;s common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Cash and Cash Equivalents</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company considers all highly liquid
investments with an original maturity of three months or less to be cash equivalents in the financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has cash deposits and U.S. treasury
bills in financial institutions which, at times, may be in excess of Federal Deposit Insurance Corporation (&ldquo;FDIC&rdquo;) insurance
limits. The Company has not experienced losses in such accounts and periodically evaluates the creditworthiness of its financial institutions.
As of December&nbsp;31, 2020 and 2019, the Company had cash and cash equivalent balances in excess of FDIC insurance limits of $28,121,828
and $13,902,601, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Property and Equipment, Net</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Property and equipment are stated at cost,
net of accumulated depreciation, which is recorded commencing at the in-service date using the straight-line method at rates sufficient
to charge the cost of depreciable assets to operations over their estimated useful lives, which range from 1 to 10 years. Leasehold
improvements are amortized over the lesser of (a)&nbsp;the useful life of the asset; or (b)&nbsp;the remaining lease term. Maintenance
and repairs are charged to operations as incurred. The Company capitalizes costs attributable to the betterment of property and
equipment when such betterment extends the useful life of the assets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Impairment of Long-lived Assets</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company reviews for the impairment
of long-lived assets whenever events or changes in circumstances indicate that the carrying amount of an asset might not be recoverable.
An impairment would be recognized when estimated future cash flows expected to result from the use of the asset and its eventual
disposition are less than its carrying amount. The Company did not record any impairment losses during the years ended December&nbsp;31,
2020 and 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 90; Options: NewSection; Value: 8 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EYENOVIA,&nbsp;INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NOTES TO THE FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FOR THE YEARS ENDED DECEMBER 31, 2020
AND 2019</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Note 2 &ndash; Summary of Significant
Accounting Policies &ndash; Continued</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Preferred Stock</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company applies the accounting standards
for distinguishing liabilities from equity when determining the classification and measurement of its preferred stock. Preferred
shares subject to mandatory redemption are classified as liability instruments and are measured at fair value. Conditionally redeemable
preferred shares (including preferred shares that feature redemption rights that are either within the control of the holder or
subject to redemption upon the occurrence of uncertain events not solely within the Company&rsquo;s control) are classified as
temporary equity. At all other times, preferred shares are classified as stockholders&rsquo; equity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Fair Value of Financial Instruments</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company measures the fair value of
financial assets and liabilities based on Accounting Standards Codification (&ldquo;ASC&rdquo;) Topic 820 &ldquo;Fair Value Measurements
and Disclosures&rdquo; (&ldquo;ASC 820&rdquo;), which defines fair value, establishes a framework for measuring fair value, and
expands disclosures about fair value measurements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ASC 820 defines fair value as the exchange
price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous
market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes
a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable
inputs when measuring fair value. ASC 820 describes three levels of inputs that may be used to measure fair value:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Level 1 &mdash; quoted prices in active
markets for identical assets or liabilities;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Level 2 &mdash; quoted prices for similar
assets and liabilities in active markets or inputs that are observable; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Level 3 &mdash; inputs that are unobservable
(for example, cash flow modeling inputs based on assumptions).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The carrying amounts of the Company&rsquo;s
financial instruments, such as cash and cash equivalents, accounts payable, accrued expenses and other current liabilities approximate
fair values due to the short-term nature of these instruments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Income Taxes</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company is subject to Federal, New
York State and City, and State of California income taxes and files tax returns in those jurisdictions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company recognizes deferred tax
assets and liabilities for the expected future tax consequences of items that have been included or excluded in the
consolidated financial statements or tax returns. Deferred tax assets and liabilities are determined on the basis of the
difference between the tax basis of assets and liabilities and their respective financial reporting amounts (&ldquo;temporary
differences&rdquo;) at enacted tax rates in effect for the years in which such temporary differences are expected to
reverse.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company utilizes a recognition threshold
and measurement process for financial statement recognition and measurement of a tax position taken or expected to be taken in
a tax return.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&rsquo;s policy is to classify
assessments, if any, for tax-related interest as interest expense and penalties as general and administrative expenses in the consolidated
statements of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 91; Value: 8 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EYENOVIA,&nbsp;INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NOTES TO THE FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FOR THE YEARS ENDED DECEMBER 31, 2020
AND 2019</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Note 2 &ndash; Summary of Significant
Accounting Policies &ndash; Continued</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Revenue Recognition</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our revenues are generated primarily through
research, development and commercialization agreements. The terms of such agreements may contain multiple promised goods and services, which may include (i) licenses to our intellectual property,
and (ii) in certain cases, payment in connection with the manufacturing and delivery of clinical supply materials. Payments to us under these arrangements typically include one or more of
the following: non-refundable, upfront license fees; milestone payments; payments for clinical product supply, and royalties on future
product sales.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We analyze our arrangements to assess whether
such arrangements involve joint operating activities. For collaboration arrangements that are deemed to be within the scope of ASC Topic
808, &ldquo;Collaborative Arrangements&rdquo; (&ldquo;ASC 808&rdquo;), we allocate the contract consideration between such joint operating
activities and elements that are reflective of a vendor-customer relationship and, therefore, within the scope of ASC Topic 606, &ldquo;Revenue
from Contracts with Customers&rdquo; (&ldquo;ASC 606&rdquo;). Our policy is to recognize amounts allocated to joint operating activities
as a reduction in research and development expense.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> Under ASC 606, we recognize revenue when
our customers obtain control of promised goods or services, in an amount that reflects the consideration which we expect to receive
in exchange for those goods or services. To determine revenue recognition for arrangements that we determine are within the scope of
ASC 606, we perform the following five steps:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><U>Step 1:</U> Identify the contract with the customer;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><U>Step 2:</U> Identify the performance obligations in the contract;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><U>Step 3:</U> Determine the transaction price;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><U>Step 4:</U> Allocate the transaction price to the performance obligations in the contract; and</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><U>Step 5:</U> Recognize revenue when the company satisfies a performance obligation.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We must make significant judgments in our revenue recognition process, including identifying performance obligations in the contract,
estimating the amount of variable consideration to include in the transaction price and allocating the transaction price to each performance
obligation. In addition, arrangements that include rights to additional goods or services that are exercisable at a customer&rsquo;s discretion
are generally considered discretionary purchase options. We assess if these options provide a material right to the customer and if so,
they are considered performance obligations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">For upfront license fees, we must consider how many performance obligations are in the contract and, if more than one, how to allocate
the fee to those performance obligations upon satisfaction of the performance obligation(s). Milestone payments represent variable consideration
that will be recognized when the performance obligation is achieved. Sales-based royalty payments derived from usage of intellectual property
are recognized when those sales occur.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During 2020, the Company entered into a license
agreement (the &ldquo;Arctic Vision License Agreement&rdquo;) with Arctic Vision (Hong Kong) Limited (&ldquo;Arctic Vision&rdquo;) and
a license agreement (the &ldquo;Bausch License Agreement&rdquo;) with Bausch Health Companies, Inc. (&ldquo;Bausch Health&rdquo;). Each
license has three revenue components: 1) an upfront license fee; 2) milestone payments and 3) royalty payments. See Note 9 &ndash; Commitments
and Contingencies for additional details.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 92; Value: 8 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EYENOVIA,&nbsp;INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NOTES TO THE FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FOR THE YEARS ENDED DECEMBER 31, 2020
AND 2019</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Note 2 &ndash; Summary of Significant
Accounting Policies &ndash; Continued</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Deferred License Fee</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company enters into license agreements which provides for the receipt
of non-refundable, upfront licensing payments. These payments are recorded as deferred license fees and will be earned and recognized
as revenue upon the satisfaction of performance obligations. See Note 9 &ndash; Commitments and Contingencies for additional details.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Deferred License Costs</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company enters into license agreements which
provides for payment of license costs in connection with the Company&rsquo;s receipt of license fees. These payments are recorded as
deferred license costs and will be recorded as an expense when the related license fee revenue is recognized. See Note 10 &ndash; Related
Party Transactions for additional details.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Research and Development</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Research and development expenses are charged
to operations as incurred. The Company records prepaid expenses on its balance sheet for the payment of research and development
expenses in advance of services being provided.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Stock-Based Compensation</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company measures the cost of services
received in exchange for an award of equity instruments based on the fair value of the award. The fair value of the award is measured
on the grant date and the fair value amount is then recognized over the period during which services are required to be provided
in exchange for the award, usually the vesting period. Upon the exercise of an option, the Company issues new shares of common
stock out of the shares reserved for issuance under its equity plans.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Net Loss Per Common Share</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Basic net loss per common share is computed
by dividing net loss by the weighted average number of common shares outstanding during the period. Diluted loss per share reflects
the potential dilution that could occur if securities or other instruments to issue common stock were exercised or converted into
common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following securities are excluded from
the calculation of weighted average dilutive common shares because their inclusion would have been anti-dilutive:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 64%; font: 10pt Times New Roman, Times, Serif; margin-right: 3in">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December&nbsp;31,</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2020</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2019</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 68%; font-size: 10pt">Warrants</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; font-size: 10pt; text-align: right">2,011,313</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; font-size: 10pt; text-align: right">-</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">Options</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">3,427,705</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">2,237,438</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">Restricted stock units</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">104,083</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">60,355</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Total potentially dilutive shares</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">5,543,101</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">2,297,793</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Subsequent Events</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has evaluated subsequent events
through the date which the financial statements were issued. Based upon the evaluation, the Company did not identify any recognized
or non-recognized subsequent events that would have required adjustment or disclosure in the financial statements, except as disclosed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 93; Value: 8 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EYENOVIA,&nbsp;INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NOTES TO THE FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FOR THE YEARS ENDED DECEMBER 31, 2020
AND 2019</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Note 2 &ndash; Summary of Significant Accounting Policies
 &ndash; Continued</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Recently Adopted Accounting Pronouncements</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In July&nbsp;2017, the FASB issued Accounting
Standards Update (&ldquo;ASU&rdquo;) 2017-11 &ldquo;Earnings Per Share (Topic 260) and Derivatives and Hedging (Topic 815) - Accounting
for Certain Financial Instruments with Down Round Features&rdquo; (&ldquo;ASU 2017-11&rdquo;). Equity-linked instruments, such
as warrants and convertible instruments may contain down round features that result in the strike price being reduced on the basis
of the pricing of future equity offerings. Under ASU 2017-11, a down round feature will no longer require a freestanding equity-linked
instrument (or embedded conversion option) to be classified as a liability that is remeasured at fair value through the income
statement (i.e. marked-to-market). However, other features of the equity-linked instrument (or embedded conversion option) must
still be evaluated to determine whether liability or equity classification is appropriate. Equity classified instruments are not
marked-to-market. For earnings per share (&quot;EPS&quot;) reporting, the ASU requires companies to recognize the effect of the
down round feature only when it is triggered by treating it as a dividend and as a reduction of income available to common shareholders
in basic EPS. The amendments in this ASU are effective for all entities for fiscal years, and interim periods within those fiscal
years, beginning after December&nbsp;15, 2019. This standard, which the Company adopted on January&nbsp;1, 2020, did not have a
material impact on the Company&rsquo;s financial position, results of operations, or cash flows.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In March&nbsp;2020, the FASB issued ASU
2020-03 &ldquo;Codification Improvements to Financial Instruments&rdquo; (&ldquo;ASU 2020-03&rdquo;). ASU 2020-03 improves and
clarifies various financial instruments topics. ASU 2020-03 includes seven different issues that describe the areas of improvement
and the related amendments to GAAP, intended to make the standards easier to understand and apply by eliminating inconsistencies
and providing clarifications. The Company adopted ASU 2020-03 upon issuance, which did not have a material impact on the Company&rsquo;s
financial position, results of operations or cash flow.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Recently Issued Accounting Pronouncements</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In February&nbsp;2016, the FASB issued ASU 2016-02
 &ldquo;Leases (Topic 842)&rdquo; (&ldquo;ASU 2016-02&rdquo;). ASU 2016-02 requires that a lessee recognize the assets and liabilities
that arise from operating leases. A lessee should recognize in the statement of financial position a liability to make lease payments
(the lease liability) and a right-of-use asset representing its right to use the underlying asset for the lease term. For leases with
a term of 12 months or less, a lessee is permitted to make an accounting policy election by class of underlying asset not to recognize
lease assets and lease liabilities. In transition, lessees and lessors are required to recognize and measure leases at the beginning of
the earliest period presented using a modified retrospective approach. ASU 2016-02, as amended, is now effective for fiscal years beginning
after December&nbsp;15, 2021, and interim periods within fiscal years beginning after December&nbsp;15, 2022. The FASB issued ASU 2019-01
 &ldquo;Leases (Topic 842) Codification Improvements&rdquo; in March&nbsp;2019 and ASU 2018-10 &ldquo;Codification Improvements to Topic
842, Leases&rdquo; and ASU 2018-11 &ldquo;Leases (Topic 842) Targeted Improvements&rdquo; in July&nbsp;2018, and ASU 2018-20 &ldquo;Leases
(Topic 842) - Narrow Scope Improvements for Lessors&rdquo; in December&nbsp;2018. ASU 2019-01, ASU 2018-10 and ASU 2018-20 provide certain
amendments that affect narrow aspects of the guidance issued in ASU 2016-02. ASU 2018-11 allows all entities adopting ASU 2016-02 to choose
an additional (and optional) transition method of adoption, under which an entity initially applies the new leases standard at the adoption
date and recognizes a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption. The Company
is currently evaluating ASU 2016-02 and its impact on its financial position, results of operations, and cash flows. The Company intends
to adopt the ASU effective January 1, 2021 with no material impact.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 94; Value: 8 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EYENOVIA,&nbsp;INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NOTES TO THE FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FOR THE YEARS ENDED DECEMBER 31, 2020
AND 2019</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Note 2 &ndash; Summary of Significant Accounting Policies
 &ndash; Continued</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Recently Issued Accounting Pronouncements
- Continued</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In August&nbsp;2018, the FASB issued ASU
No.&nbsp;2018-13 &ldquo;Fair Value Measurement (Topic 820): Disclosure Framework&mdash;Changes to the Disclosure Requirements for
Fair Value Measurement&rdquo; (&ldquo;ASU 2018-13&rdquo;). The amendments in ASU 2018-13 modify the disclosure requirements on
fair value measurements based on the concepts in the FASB Concepts Statement, including the consideration of costs and benefits.
The amendments on changes in unrealized gains and losses, the range and weighted average of significant unobservable inputs used
to develop Level 3 fair value measurements, and the narrative description of measurement uncertainty should be applied prospectively
for only the most recent interim or annual period presented in the initial fiscal year of adoption. All other amendments should
be applied retrospectively to all periods presented upon their effective date. The amendments are effective for fiscal years beginning
after December&nbsp;15, 2020. Early adoption is permitted, including adoption in an interim period. The Company is currently evaluating
ASU 2018-13 and its impact on its financial position, results of operations and cash flows.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #1D1C1D"><FONT STYLE="background-color: white">In
December&nbsp;2019, the FASB issued ASU 2019-12, &ldquo;Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes,&rdquo;
which is intended to simplify various aspects related to accounting for income taxes. ASU 2019-12 removes certain exceptions to
the general principles in Topic 740 and also clarifies and amends existing guidance to improve consistent application. ASU 2019-12
is effective for fiscal years beginning after December&nbsp;15, 2021. The Company is currently evaluating ASU 2019-12 and its impact
financial position, results of operations, and cash flows.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Note 3 &ndash; Prepaid Expenses and
Other Current Assets</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of December&nbsp;31, 2020 and 2019,
prepaid expenses and other current assets consisted of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 88%; font: 10pt Times New Roman, Times, Serif; margin-right: 1in">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December&nbsp;31,</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2020</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2019</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 68%; font-size: 10pt; text-align: left">Payroll tax receivable</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 12%; font-size: 10pt; text-align: right">151,942</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 12%; font-size: 10pt; text-align: right">95,233</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Prepaid insurance expenses</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">110,094</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">33,923</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Prepaid research and development expenses</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">17,978</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Prepaid licenses and subscriptions</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">57,051</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Prepaid patent expenses</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">12,404</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Prepaid conference expenses</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">29,403</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">10,600</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Prepaid board of directors expenses</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">68,250</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Prepaid rent and security deposit</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">25,004</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">2,463</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; padding-bottom: 1pt">Other</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">11,734</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">24,079</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Total prepaid expenses and other current assets</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">453,478</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">196,680</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 95; Value: 8 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EYENOVIA,&nbsp;INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NOTES TO THE FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FOR THE YEARS ENDED DECEMBER 31, 2020
AND 2019</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Note 4 &ndash; Property and Equipment,
Net</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of December&nbsp;31, 2020 and 2019,
property and equipment consisted of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 88%; font: 10pt Times New Roman, Times, Serif; margin-right: 1in">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December&nbsp;31,</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2020</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2019</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 68%; font-size: 10pt">Equipment</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 12%; font-size: 10pt; text-align: right">435,521</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 12%; font-size: 10pt; text-align: right">229,529</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Leasehold improvements</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">137,765</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">82,500</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">573,286</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">312,029</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Less: accumulated depreciation and amortization</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(176,906</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(81,491</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Property and equipment, net</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">396,380</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">230,538</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Depreciation and amortization expense was
$95,415 and $15,343 for the years ended December&nbsp;31, 2020 and 2019, respectively, of which $67,595 and $9,762 was included
within research and development expenses and $27,820 and $5,581 was included in general and administrative expenses in the statements
of operations for the years ended December&nbsp;31, 2020 and 2019, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Note 5 &ndash; Accrued Expenses and
Other Current Liabilities</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of December&nbsp;31, 2020 and 2019,
accrued expenses and other current liabilities consisted of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 88%; font: 10pt Times New Roman, Times, Serif; margin-right: 1in">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December 31,</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; font-size: 10pt">&nbsp;</TD><TD STYLE="white-space: nowrap; font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2020</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="white-space: nowrap; font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2019</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 68%; font-size: 10pt; text-align: left">Accrued research and development expenses</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 12%; font-size: 10pt; text-align: right">348,254</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 12%; font-size: 10pt; text-align: right">208,175</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Accrued consulting and professional services</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">235,355</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">97,396</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Credit card payable</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">50,002</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">56,979</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Leasehold improvements</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">42,500</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Accrued franchise tax</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">32,480</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">40,995</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Accrued travel and entertainment expenses</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">7,385</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Accrued licensing fees</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">804,447</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Accrued interest</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">3,068</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Accrued expense reimbursements</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">5,459</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; padding-bottom: 1pt">Other</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">1,627</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Total accrued expenses and other current liabilities</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">1,480,692</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">453,430</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Note 6 &ndash; Accrued Compensation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As of December&nbsp;31, 2020 and 2019, accrued compensation
consisted of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 91%; font: 10pt Times New Roman, Times, Serif; margin-right: 1.75in">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December&nbsp;31,</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2020</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2019</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 68%; font-size: 10pt; text-align: left">Accrued bonus expenses</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 12%; font-size: 10pt; text-align: right">938,873</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 12%; font-size: 10pt; text-align: right">897,839</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Accrued payroll expenses</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">211,799</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">19,034</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Total accrued compensation</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">1,150,672</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">916,873</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 96; Value: 8 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EYENOVIA,&nbsp;INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NOTES TO THE FINANCIAL STATEMENTS</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FOR THE YEARS ENDED DECEMBER 31, 2020
AND 2019</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Note 7 &ndash; Notes Payable</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of December&nbsp;31, 2020 and 2019,
notes payable consisted of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="10" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December&nbsp;31, 2020</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="10" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December&nbsp;31, 2019</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center">Current</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center">Non-Current</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center">Current</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center">Non-Current</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Portion</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Portion</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Total</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Portion</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Portion</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Total</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 34%; font-size: 10pt; text-align: left">Paycheck Protection Program loan</TD><TD STYLE="width: 2%; font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 7%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">97,539</TD><TD STYLE="width: 1%; padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 7%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">365,814</TD><TD STYLE="width: 1%; padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 7%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">463,353</TD><TD STYLE="width: 1%; padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 7%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">-</TD><TD STYLE="width: 1%; padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 7%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">-</TD><TD STYLE="width: 1%; padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 7%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">-</TD><TD STYLE="width: 1%; padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">Total</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">97,539</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">365,814</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">463,353</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February&nbsp;24, 2020, the Company
issued a note payable (the &ldquo;Note&rdquo;) for the purchase of a directors&rsquo; and officers&rsquo; liability insurance policy.
The Note was payable in nine monthly payments of $53,750 for an aggregate principal amount of $475,216. The Note accrues interest
at a rate of 4.29% per year and matured on November&nbsp;24, 2020. During the year ended December&nbsp;31, 2020, the Company repaid
the principal amount of the Note.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May&nbsp;8, 2020, the Company received
cash proceeds of $463,353 pursuant to a loan provided in connection with the Paycheck Protection Program under the CARES Act (the
 &ldquo;PPP Loan&rdquo;). The PPP Loan provides for monthly installment payments of $19,508 beginning in August&nbsp;2021 with the
remaining balance due on May&nbsp;3, 2022, the maturity date. The PPP Loan bears interest at a fixed rate of 1.00% per annum. The
Company will be applying for loan forgiveness on the PPP Loan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under the terms of the CARES Act, as amended
by the Paycheck Protection Program Flexibility Act of 2020, the Company is eligible to apply for and receive forgiveness for all
or a portion of its PPP Loan. Such forgiveness will be determined, subject to limitations, based on the use of the loan proceeds
for certain permissible purposes as set forth in the PPP Loan, including, but not limited to, payroll costs and mortgage interest,
rent or utility costs (collectively, &ldquo;Qualifying Expenses&rdquo;) incurred during the 24 weeks subsequent to funding, and
on the maintenance of employee and compensation levels following the funding of the PPP Loan. The Company intends to use the proceeds
of its PPP Loan for Qualifying Expenses. However, no assurance is provided that the Company will be able to obtain forgiveness
of its PPP Loan in whole or in part. Any amounts that are not forgiven incur interest at 1.0% per annum and monthly repayments
of principal and interest are deferred until six months after the Small Business Administration makes a determination on forgiveness.
While the PPP Loan currently has a two-year maturity, the amended law permits the borrower to request a five-year maturity from
its lender.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the years ended December&nbsp;31,
2020 and 2019, the Company recorded interest expense of $17,042 and $0, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.75in"><B>Note 8 &ndash;
Income Taxes</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The provision for income taxes consists of the following expenses (benefits):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: yellow"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">For The Years Ended</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">December 31,</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2020</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2019</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Deferred tax provision (benefit):</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.25in; width: 74%">Federal</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">(3,797,052</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">(4,999,920</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.25in; text-align: left; padding-bottom: 1pt">State and local</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(434,082</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">68,762</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(4,231,134</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(4,931,158</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Change in valuation allowance</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">4,231,134</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">4,931,158</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Provision for income taxes</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 97; Value: 8 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EYENOVIA,&nbsp;INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NOTES TO THE FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FOR THE YEARS ENDED DECEMBER 31, 2020
AND 2019</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Note 8 &ndash; Income Taxes &ndash; Continued</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The provision for income taxes differs from the United States Federal statutory rate as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">For The Years Ended</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">December 31,</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2020</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2019</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 74%; font: 10pt Times New Roman, Times, Serif; text-align: left">Federal statutory rate</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">(21.0</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">)%</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">21.0</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">State tax rate, net of federal benefit</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(0.1</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.1</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Permanent differences</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.5</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(0.2</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Research &amp; development tax credits</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(1.4</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">3.0</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Prior period adjustments and other</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.6</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(0.6</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Change in valuation allowance</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">21.4</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(23.3</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Effective income tax rate</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(0.0</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">0.0</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Deferred tax assets consist of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">For The Years Ended</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">December 31,</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2020</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2019</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 74%; font: 10pt Times New Roman, Times, Serif; text-align: left">Net operating loss carryforwards</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">12,972,865</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">9,479,512</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Stock-based compensation</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,385,554</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">943,370</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Intangible assets</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">409,705</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">328,773</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Research and development tax credits</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,861,938</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,584,753</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.25in; text-align: left">Deferred tax assets, gross</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">16,630,062</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">12,336,408</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Property and equipment</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(76,550</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(14,030</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.25in; text-align: left">Deferred tax assets, net before allowance</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">16,553,512</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">12,322,378</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Valuation allowance</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(16,553,512</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(12,322,378</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.25in; text-align: left; padding-bottom: 2.5pt">Deferred tax assets, net</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As of December 31, 2020, the Company had approximately $60,000,000 of domestic Federal net operating loss carryforwards ("NOLs") that
may be available to offset future Federal taxable income. Approximately $10,800,000 of those NOLs will expire during the years ranging
from 2034 to 2037. The remaining NOLs of approximately $49,200,000 have no expiration dates. Internal Revenue Code Section 382 limits
the utilization of approximately $35,000,000 of those NOLs to approximately $918,000 on an annual basis as a result of ownership changes
that occurred through July 15, 2019. As of December 31, 2020, the Company had (a) minimal state net operating loss carryforwards that
may be available to offset future state taxable income as it conducted most of its operations in Nevada which does not tax corporate income;
and (b) approximately $5,500,000 of New York City net operating loss carryforwards.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has assessed the likelihood that deferred
tax assets will be realized in accordance with the provisions of ASC 740 &ldquo;Income Taxes Accounting&rdquo; (&quot;ASC 740&quot;).
ASC 740 requires that such a review considers all available positive and negative evidence, including the scheduled reversal of deferred
tax liabilities, projected future taxable income, and tax planning strategies. ASC 740 requires that a valuation allowance be established
when it is &ldquo;more likely than not&rdquo; that all, or a portion of, deferred tax assets will not be realized. After the performance
of such reviews as of December 31, 2020 and 2019, management believes that uncertainty exists with respect to future realization of its
deferred tax assets and has, therefore, established a full valuation allowance as of those dates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 98; Value: 8 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Split-Segment; Name: 8 -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EYENOVIA,&nbsp;INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NOTES TO THE FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FOR THE YEARS ENDED DECEMBER 31, 2020
AND 2019</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Note 8 &ndash; Income Taxes &ndash; Continued</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Management has evaluated and concluded that there were no material
uncertain tax positions requiring recognition in the Company&rsquo;s consolidated financial statements as of December 31, 2020 and 2019.
The Company does not expect any significant changes in its unrecognized tax benefits within twelve months of the reporting date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">No tax audits were commenced or were in process during the years ended December 31, 2020 and 2019. No tax related interest or penalties
were incurred during the years ended December 31, 2020 and 2019. The Company's Federal, State and Local income tax returns beginning with
the year ended December 31, 2017 remain subject to examination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Note 9 &ndash; Commitments and Contingencies</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Operating Leases</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August&nbsp;8, 2018, the Company entered
into a lease agreement to lease approximately 3,800 square feet of office space in New York, NY. The monthly base rent ranges
from $19,633 to $22,486 per month over the term of the lease. The lease expires on September&nbsp;30, 2023. The security deposit
is approximately $119,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">On July&nbsp;17, 2020, the Company entered into a lease agreement
to lease approximately 3,000 square feet of office space in Redwood City, California (the &ldquo;Gross Industrial Lease&rdquo;).
The monthly base rent was for $7,500 per month over the term of the lease through August&nbsp;31, 2021 with a security deposit
of $7,500. On December&nbsp;1, 2020, the Company agreed to amend the terms of the Gross Industrial Lease for a base rent that
ranges from $7,500 to $7,957 per month over the term of the lease. The amended Gross Industrial Lease expires on August&nbsp;31,
2023.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Concurrent with the amendment to the Gross Industrial Lease
on December&nbsp;1, 2020, the Company entered into a lease agreement to lease approximately 1,500 square feet of additional office
space in Redwood City, California. The monthly base rent ranges from $3,000 to $3,183 per month over the term of the lease. The
lease expires on August&nbsp;31, 2023. The security deposit is $3,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Future minimum payments under this operating lease agreement
are as follows as:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 50%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: center">For the Year Ending</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December&nbsp;31,</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Minimum Lease
    Payments</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 49%; font-size: 10pt; text-align: center; padding-left: 5.4pt">2021</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 47%; font-size: 10pt; text-align: right">378,486</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: center; padding-left: 5.4pt">2022</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">389,212</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: center; padding-bottom: 1pt; padding-left: 5.4pt">2023</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">285,700</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: center; padding-bottom: 2.5pt; padding-left: 5.4pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">1,053,398</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">See Note 10 &ndash; Related Party Transactions
 &ndash; Lease Agreements for details of a lease agreement with a related party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Employment Agreements</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Effective February&nbsp;15, 2019, the
Company entered into at-will executive employment agreements with Tsontcho Ianchulev, its Chief Executive Officer and Chief Medical
Officer, John Gandolfo, its Chief Financial Officer, Jennifer Clasby, now its Vice President of Regulatory and Clinical, Luke
Clauson, its Vice President, Research and Development and Manufacturing (&ldquo;VP of R&amp;D&rdquo;), and Michael Rowe, now its
Chief Commercial Officer. Dr.&nbsp;Clasby and Mr.&nbsp;Rowe&rsquo;s employment agreements were amended on February&nbsp;1, 2021
to provide for their new roles at the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Each of the employment agreements provides
that if the executive&rsquo;s employment is terminated by the Company without &ldquo;Cause&rdquo; or the executive suffers an
 &ldquo;Involuntarily Termination&rdquo; (each as defined in the employment agreements), provided that the executive has signed
a full release of all claims, the executive will be entitled to receive: (i)&nbsp;severance pay equal to three months of his or
her then-current base salary (currently estimated at approximately $419,000 in the aggregate), and (ii)&nbsp;a reimbursement for
health insurance benefits under COBRA for the executive and his or her spouse and dependents for a period of three months or until
the executive becomes eligible for comparable insurance benefits from another employer, whichever is earlier.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 99; Value: 8 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EYENOVIA,&nbsp;INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NOTES TO THE FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FOR THE YEARS ENDED DECEMBER 31, 2020
AND 2019</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Note 9 &ndash; Commitments and Contingencies - Continued</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Employment Agreements - Continued</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Each of the employment agreements also
provides that if, within 12 months following any &ldquo;Corporate Transaction&rdquo; (as defined in the employment agreements)
of the Company, the executive&rsquo;s employment is terminated by the Company without Cause or the executive suffers an Involuntary
Termination, provided that the executive has signed a full release of all claims, the executive will be entitled to receive, in
lieu of what is described in the above paragraph: (i)&nbsp;severance pay equal to 12 months of his or her then-current base salary
(currently estimated at approximately $1,677,000 in the aggregate), and (ii)&nbsp;a reimbursement for health insurance benefits
under COBRA for the executive and his or her spouse and dependents for a period of 12 months or until the executive becomes eligible
for comparable insurance benefits from another employer, whichever is earlier.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Litigations, Claims and Assessments</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the normal course of business, the
Company may be involved in legal proceedings, claims and assessments arising in the ordinary course of business. The Company records
legal costs associated with loss contingencies as incurred and accrues for all probable and estimable settlements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Arctic Vision License Agreement</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August&nbsp;10, 2020, the Company entered into
the Arctic Vision License Agreement pursuant to which Arctic Vision may develop and commercialize MicroPine for the treatment of progressive
myopia and MicroLine for the treatment of presbyopia in Greater China (mainland China, Hong Kong, Macau and Taiwan) and South Korea.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under the terms of the Arctic Vision License Agreement,
the Company received a non-refundable, upfront payment of $4.0 million, before any payments to Senju. The Company has recorded this payment
as a deferred license fee until the payment is earned. The Company will consider payment earned once certain trial data has been fully
submitted to Arctic Vision, permitting Arctic Vision to obtain regulatory approval with the National Medical Products Administration.
The upfront payment had not been earned as of December&nbsp;31, 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, the Company may receive up to a total
of $41.75 million in additional payments, based on various development and regulatory milestones, including the initiation of clinical
research and approvals in Greater China and South Korea, and development costs. During December 2020, the Company satisfied a performance
obligation which resulted in the Company recognizing $2.0 million of milestone revenues, pursuant to the Arctic Vision License Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Arctic Vision also will purchase its supply of
MicroPine and MicroLine from the Company or, for such products not supplied by the Company, pay the Company a mid-single digit percentage
royalty on net sales of such products, subject to certain adjustments. No royalty payments were earned during the year ended December
31, 2020. The Company will pay a mid-double digit percentage of such payments, royalties, or net proceeds of such supply to Senju pursuant
to the Senju License Agreement. See Note 2 &ndash; Summary of Significant Accounting Policies and Note 10 &ndash; Related Party Transactions
for additional details.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Bausch License Agreement</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October&nbsp;9, 2020, the Company entered into
the &ldquo;Bausch License Agreement pursuant to which Bausch Health may develop and commercialize the Bausch Licensed Product in the Licensed
Territory.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with the Bausch License Agreement,
Bausch Health paid the Company a non-refundable, upfront payment of $10.0 million. The Company has recorded this payment as a deferred
license fee until the payment is earned. The Company will consider payment earned once certain trial data has been fully submitted to
Bausch Health and certain administrative functions are transferred to Bausch Health, permitting Bausch Health to assume supervisory oversight
of the ongoing MicroPine study (the CHAPERONE study). The upfront payment had not been earned as of December 31, 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Bausch Health could also pay the Company up to
an aggregate of approximately $35.0 million in additional payments, depending on the achievement of certain regulatory and launch-based
milestones. No milestone payments were earned during the year ended December 31, 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 100; Value: 8 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EYENOVIA,&nbsp;INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NOTES TO THE FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FOR THE YEARS ENDED DECEMBER 31, 2020
AND 2019</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Note 9 &ndash; Commitments and Contingencies
 &ndash; Continued</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under the terms of the Bausch License Agreement,
on a country-to-country basis and Bausch Licensed Product-by- Bausch Licensed Product basis, Bausch Health will pay the Company royalties
on a tiered basis (ranging from mid-single digit to mid-teen percentages) on gross profits from the sales of the Bausch Licensed Product
in the Licensed Territory, subject to certain adjustments in the event of generic entry, negative gross profits or patent expiration,
for a period of the later to occur of the 10th anniversary of the first commercial sale of a Bausch Licensed Product in such country
in the Licensed Territory or the expiration of the last valid patent claim for a Bausch Licensed Product in such country in the Licensed
Territory. No royalty payments were earned during the year ended December 31, 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Bausch Health may terminate the Bausch
License Agreement, with respect to the Bausch Licensed Product to either country in the Licensed Territory, at any time for convenience
upon 90 days&rsquo; written notice. Both parties have the right to terminate the Bausch License Agreement in the event of (i)&nbsp;an
uncured material breach after a 60-day period or (ii)&nbsp;a bankruptcy event. See Note 2 &ndash; Summary of Significant Accounting
Policies for additional details.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Note 10 &ndash; Related Party Transactions</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Consulting Agreements</U></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A company in which a member of the Company&rsquo;s
Board of Directors is part owner is a party to a consulting agreement with the Company dated July&nbsp;6, 2017 that provides for the payment
of $9,567 per month, and $250 per hour for any additional work, for advisory services performed by such director. The consulting agreement
was terminated on September&nbsp;1, 2020. The director remains on the Board. The Company incurred expenses of $76,536 and $213,521 for
the years ended December&nbsp;31, 2020 and 2019, respectively, related to the agreement which was included within general and administrative
expenses on the statements of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Lease Agreements</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&rsquo;s Vice President of
Research and Development and Manufacturing (&ldquo;VP of R&amp;D&rdquo;) owns a company that entered into a lease agreement with
the Company on September&nbsp;15, 2016 to lease 953 square feet of space located in Reno, Nevada with respect to its research
and development activities. The initial monthly base rent was $3,895 per month over the term of the lease and the security deposit
was $3,895. On September&nbsp;15, 2020, the Company amended the lease agreement to extend it until September&nbsp;14, 2022 and
increase the monthly base rent and security deposit to $5,404. The Company made $82,500 of leasehold improvements related to this
lease which are included on the balance sheet.&nbsp;The Company&rsquo;s rent expense for this space is recorded in Research and
Development on the income statement and amounted to $59,724 and $48,144 for the years ended December&nbsp;31, 2020 and 2019, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Research and Development Activities</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The VP of R&amp;D is the sole owner and President
of a company that performs contract engineering services for the Company. During the years ended December&nbsp;31, 2020 and 2019, the
Company recognized research and development expense of $1,024,430 and $851,746, respectively, related to services provided by such vendor.
The Company had a liability of $0 and $89,052 to the vendor as of December&nbsp;31, 2020 and 2019, respectively. The Company recognized
$239,460 and $186,160 of compensation expense related to the VP of R&amp;D during the years ended December&nbsp;31, 2020 and 2019, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Senju License Agreement</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During 2015, the Company entered into
an Exclusive License Agreement with Senju whereby the Company agreed to grant to Senju an exclusive, royalty-bearing license for
its microdose product candidates for Asia to sublicense, develop, make, have made, manufacture, use, import, market, sell, and
otherwise distribute the microdose product candidates. In consideration for the license, Senju agreed to pay to Eyenovia five
percent (5%) royalties on sales (net of certain manufacturing costs) for the term of the Exclusive License Agreement, subject
to certain adjustments upon the loss of patent coverage for the term of the license agreement. The agreement will continue in
full force and effect, on a country-by-country basis, until the latest to occur of: (i)&nbsp;the tenth (10th) anniversary of the
first commercial sale of such a product candidate in a country; or (ii)&nbsp;the expiration of the licensed patents in a country.
As of the date of this filing, there had been no commercial sales of a such a product in Asia, so no royalties had been earned.
Senju is owned by the family of a former member of the Company&rsquo;s Board of Directors and, together, they beneficially own
greater than 5% of the Company&rsquo;s common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 101; Value: 8 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EYENOVIA,&nbsp;INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NOTES TO THE FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FOR THE YEARS ENDED DECEMBER 31, 2020
AND 2019</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Note 10 &ndash; Related Party Transactions - Continued</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April&nbsp;8, 2020, Eyenovia entered
into an amendment (the &ldquo;License Amendment&rdquo;) to the Exclusive License Agreement. Pursuant to the License Amendment,
the Company can license to any third party the right to research, develop, commercialize, manufacture or use certain products
identified below (the &ldquo;Senju Licensed Products&rdquo;) previously licensed to Senju in China (including the People&rsquo;s
Republic of China, Hong Kong, Macao, and Taiwan) and South Korea (the &ldquo;Territory&rdquo;) if such a license is executed by
the Company by April&nbsp;8, 2021. The Senju Licensed Products are those using piezo-print technology in a microdose dispenser
with (i)&nbsp;atropine sulfate as its sole active ingredient to treat myopia in humans and (ii)&nbsp;pilocarpine as its sole active
ingredient to treat presbyopia in humans.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the License Amendment, the
Company must pay Senju (a)&nbsp;close to a mid-double digit percentage of revenue on any lump-sum payments the Company receives
from the third party, revenue (net of costs) obtained by the Company from contract research and/or development of the Senju Licensed
Product in the Territory, and revenue (net of costs) obtained by the Company from contract manufacture for the device of the Senju
Licensed Product in the Territory, the aggregate of which must be at least a high seven figure dollar amount minimum payment to
Senju; and (b)&nbsp;a lower-double digit percentage of any sales royalty revenue the Company receives from the third party. Unless
a third-party license is executed by the Company prior to April&nbsp;8, 2021 (in which case, subject to early termination the
License Amendment shall remain in effect for the duration of such license), the License Amendment terminates on April&nbsp;8,
2021, but may be terminated earlier by Senju upon the Company&rsquo;s material breach of the License Amendment, subject to a 60-day
cure period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Exclusive License Agreement was further
amended in a Letter Agreement by and between the Company and Senju on August&nbsp;10, 2020 (the &ldquo;Letter Agreement&rdquo;).
 &nbsp;Pursuant to the Letter Agreement, the Company will pay a mid-double digit percentage of certain payments, royalties, or
net proceeds received from Arctic Vision in connection with the Arctic Vision License Agreement to Senju. During the year ended
December&nbsp;31, 2020, the Company paid Senju $1.6 million in connection with the Arctic Vision License Agreement which was recorded
as deferred license costs in the Company&rsquo;s balance sheet and will be recognized as expense upon earning the related fee.
See Note 2- Summary of Significant Accounting Policies &ndash; Revenue Recognition and Note 9 &ndash; Commitments and Contingencies
for additional details.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 102; Value: 8 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EYENOVIA,&nbsp;INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NOTES TO THE FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FOR THE YEARS ENDED DECEMBER 31, 2020
AND 2019</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Note 11 &ndash; Stockholders&rsquo; Equity</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Authorized Capital</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company is authorized to issue 90,000,000
shares of common stock, par value of&thinsp;$0.0001 per share, and 6,000,000 shares of preferred stock, par value of&thinsp;$0.0001
per share. The holders of the Company&rsquo;s common stock are entitled to one vote per share. The Board of Directors is empowered,
without stockholder approval, to issue preferred stock with dividend, liquidation, redemption, voting or other rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Equity Incentive Plans</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April&nbsp;7, 2020, the Company&rsquo;s
Board of Directors approved the Company&rsquo;s Amended and Restated 2018 Omnibus Stock Incentive Plan (the &ldquo;Restated Plan&rdquo;),
which stockholders approved on June&nbsp;30, 2020. The Restated Plan makes certain changes to the Company&rsquo;s 2018 Omnibus
Stock Incentive Plan, as amended (the &ldquo;2018 Plan, as amended&rdquo;). The Restated Plan increases the number of shares of
Company&rsquo;s common stock reserved for issuance under the 2018 Plan, as amended to 2,950,000 shares. The Restated Plan requires
that all equity awards issued under the Restated Plan vest at least twelve months from the applicable grant date, subject to accelerated
vesting, and provides that no dividend or dividend equivalent will be paid on any unvested equity award, although dividends with
respect to unvested portions of equity may accrue and be paid when, and if, the awards later vest and the shares are actually
issued to the grantee. In addition, the Restated Plan sets an annual limit on the grant date fair value of awards to any non-employee
director, together with any cash fees paid during the year, of $150,000, subject to certain exceptions for a non-executive chair
of the Board. Finally, the Restated Plan makes several administrative changes to the 2018 Plan, as amended, including to clarify
that awards made under the Restated Plan are intended to be exempt from or comply with Section&nbsp;409(A)&nbsp;of the Internal
Revenue Code of 1986, as amended. As of December 31, 2020, the number of securities remaining available for future issuance under equity compensation plans was 518,186.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Warrants</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">A summary of the Warrant activity during the year ended December&nbsp;31,
2020 is presented below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center">Weighted</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center">Weighted</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center">Average</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center">Average</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center">Remaining</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center">Aggregate</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center">Number of</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center">Exercise</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center">Life</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center">Intrinsic</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Warrants</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Price</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">In Years</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Value</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">Outstanding January&nbsp;1, 2020</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 44%; font-size: 10pt">Granted</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 11%; font-size: 10pt; text-align: right">3,344,154</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 11%; font-size: 10pt; text-align: right">2.33</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 11%; font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 11%; font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">Exercised</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(1,332,841</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">2.19</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; padding-bottom: 1pt">Forfeited</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">Outstanding December&nbsp;31, 2020</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">2,011,313</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">2.43</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">3.8</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">7,215,147</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">Exercisable December&nbsp;31, 2020</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">2,011,313</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">2.43</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">3.8</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">7,215,147</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 103; Value: 8 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EYENOVIA,&nbsp;INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NOTES TO THE FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FOR THE YEARS ENDED DECEMBER 31, 2020
AND 2019</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Note 11 &ndash; Stockholders&rsquo; Equity - Continued</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Warrants &ndash; Continued</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table presents information
related to Warrants as of December&nbsp;31, 2020:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 65%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="6" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Warrants Outstanding</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Warrants Exercisable</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center">Weighted</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center">Outstanding</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center">Average</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center">Exercisable</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center">Exercise</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center">Number of</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center">Remaining Life</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center">Number of</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Price</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Warrants</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">In Years</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Warrants</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 23%; font-size: 10pt; text-align: right">2.0580</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 22%; font-size: 10pt; text-align: right">48,549</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 22%; font-size: 10pt; text-align: right">0.2</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 22%; font-size: 10pt; text-align: right">48,549</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">2.2700</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">144,256</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">0.2</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">144,256</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">2.4696</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">1,602,128</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">4.2</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">1,602,128</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">2.7240</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">216,380</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: right">4.2</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">216,380</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">2,011,313</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: right">3.8</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">2,011,313</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the year ended December&nbsp;31,
2020, Warrants for the purchase of 1,332,841 shares of the Company&rsquo;s common stock with exercise prices of either $2.058
or $2.4696 per share, respectively, were exercised for aggregate proceeds of approximately $2.8 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Public Offerings</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July&nbsp;15, 2019, the Company closed
an underwritten public offering of 4,388,490 shares of its common stock at a public offering price of $2.78 per share. The Company
granted the underwriters a 30-day over-allotment option to purchase up to an additional 658,273 shares of the Company&rsquo;s
common stock at the same price, which was exercised in full on July&nbsp;16, 2019. Including the over-allotment shares, the Company
issued a total of 5,046,763 shares in the underwritten public offering, and received gross proceeds of approximately $14.0 million
and net proceeds of approximately $13.0 million, after deducting underwriting discounts, commissions and other offering expenses,
which were recorded as a reduction of additional paid-in capital.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Securities Purchase Agreement</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On March 24, 2020, the Company closed on a private placement of approximately $6.0 million of Units. Each Unit consists of (i) one share
of the Company&rsquo;s common stock, (ii) a one-year warrant to purchase 0.5 of a share of common stock (&ldquo;Class A Warrant&rdquo;),
and (iii) a five-year warrant to purchase 0.75 of a share of common stock (&ldquo;Class B Warrant&rdquo;) (collectively, the Class A Warrants
and Class B Warrants, the &ldquo;Warrants&rdquo;). The Units were sold to the public at a price of $2.21425 per Unit and to certain directors
and executive officers at a price of $2.42625 per Unit. The Company generated approximately $5.3 million of net proceeds in the offering
after deducting placement agent fees and offering expenses. In the offering, the Company issued an aggregate of 2,675,293 shares of common
stock, Class A Warrants to purchase up to 1,337,659 shares of common stock, and Class B Warrants to purchase up to 2,006,495 shares of
common stock. The exercise price of the Class A Warrants issued to the public is $2.058 per share and the exercise price of the Class
A Warrants issued to the directors and officers is $2.27 per share. The exercise price of the Class B Warrants issued to the public is
$2.4696 per share and the exercise price of the Class B Warrants issued to the directors and officers is $2.724 per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In connection with the private placement, on March 23, 2020, the Company also entered into a Registration Rights Agreement with the investors.
Pursuant to the Registration Rights Agreement, the Company must file with the SEC, no later than 30 days following the date on which the
Company files its Form 10-K for the year ended December 31, 2019 with the SEC, a registration statement on Form S-3 covering the shares
of common stock issued in the offering and the shares of common stock underlying the Warrants. The Company timely filed the registration
statement on Form S-3 (Registration Statement No. 333-237790), which was declared and has remained effective with the SEC since May 13,
2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 104; Value: 8 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EYENOVIA,&nbsp;INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NOTES TO THE FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FOR THE YEARS ENDED DECEMBER 31, 2020
AND 2019</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Note 11 &ndash; Stockholders&rsquo; Equity - Continued</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Underwritten Public Offering</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August&nbsp;19, 2020, the Company entered
into an Underwriting Agreement (the &ldquo;Underwriting Agreement&rdquo;) with several underwriters (the &ldquo;Underwriters&rdquo;)
in connection with the public offering (the &ldquo;Offering&rdquo;) of 3,333,334 shares of the Company&rsquo;s common stock at
a price of $3.60 per share, less underwriting discounts and commissions. In addition, pursuant to the terms of the Underwriting
Agreement, the Company granted the Underwriters a 30-day option to purchase up to an additional 500,000 shares of the Company&rsquo;s
common stock at the same price. The Underwriting Agreement contains customary representations, warranties and covenants of the
Company and also provides for customary indemnification by the Company and the Underwriters against certain liabilities and customary
contribution provisions in respect of those liabilities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The closing of the Offering occurred on
August&nbsp;21, 2020. At closing, the Company issued 3,833,334 shares of common stock and received net proceeds of approximately
$12.5 million after deducting underwriting discounts and commissions and offering expenses of approximately $1.2 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Offering was made pursuant to the
Company&rsquo;s effective registration statement on Form&nbsp;S-3 (Registration Statement No.&nbsp;333-229365), including the
prospectus dated February&nbsp;12, 2019, as supplemented by the prospectus supplement dated August&nbsp;19, 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Stock-Based Compensation Expense</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company records stock-based compensation
expense related to stock options and restricted stock units (&ldquo;RSUs&rdquo;). For the years ended December&nbsp;31, 2020 and
2019, the Company recorded expense of $2,483,172 ($1,350,894 of which was included within research and development expenses and
$1,132,278 was included within general and administrative expenses on the statements of operations) and $2,511,944 ($1,459,055
of which was included within research and development expenses and $1,052,889 was included within general and administrative expenses
on the statements of operations), respectively. As of December&nbsp;31, 2020, there was $3,720,221 of unrecognized stock-based
compensation expense which will be recognized over a weighted average period of 2.0 years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Restricted Stock Units</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August&nbsp;16, 2019, the Company granted
to members of its Board of Directors an aggregate of 40,190 RSU under the 2018 Plan, as amended. The grants vest on the earlier
of (i)&nbsp;the one-year anniversary of the date of grant and (ii)&nbsp;the date of the 2020 annual stockholders meeting, subject
to the grantee remaining on the Board until then. The RSUs had a grant date fair value of $125,000, which were recognized over
the vesting period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September&nbsp;11, 2020, the Company
granted members of its Board of Directors an aggregate of 43,728 RSUs under the Restated Plan. Each RSU is subject to settlement
into one share of the Company&rsquo;s common stock. The RSUs vest on the earlier of (i)&nbsp;the one-year anniversary of the date
of grant and (ii)&nbsp;the date of the 2021 annual stockholders meeting, subject to the grantee remaining on the Board until then.
The RSUs had a grant date fair value of $150,000, which will be recognized over the vesting period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Stock Option Exercises</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the year ended December&nbsp;31,
2020, stock options for the purchase of an aggregate of 36,391 shares of the Company&rsquo;s common stock with exercise prices
ranging from $1.95 to $3.11 per share were exercised for aggregate proceeds of $82,161.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Stock Options</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January&nbsp;2, 2019, stock options
to purchase 180,000 and 133,686 shares of common stock with an exercise price of $1.24 and $1.95 per share, respectively, were
exercised for aggregate proceeds of $483,888. In connection with the exercise of the stock options, the Company remitted a portion
of an employee&rsquo;s payroll taxes of $62,193 to the Internal Revenue Service. The Company was reimbursed in full by the employee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January&nbsp;14, 2019, the Company
granted ten-year stock options to purchase an aggregate of 11,000 shares of common stock to its employees under the 2018 Plan.
The 11,000 shares vest over three years from the date of grant with one-third vesting on the one-year anniversary of the date
of grant and the balance vesting monthly over the remaining 24 months, subject to continued service to the Company. The stock
options have an exercise price of $2.74 per share, which represents the Company&rsquo;s closing stock price on the date of grant.
The stock options had a grant date value of $27,500, which the Company expects to recognize over the vesting period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February&nbsp;6, 2019, stock options
to purchase an aggregate of 320,001 shares of common stock with an exercise price of $1.24 per share were exercised on a cashless
basis, which resulted in the issuance of an aggregate of 236,466 shares of common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February&nbsp;13, 2019, the Board of
Directors of the Company approved the acceleration and immediate vesting of 124,210 stock options originally granted to Dr.&nbsp;Ianchulev
on July&nbsp;24, 2018 in connection with his employment. In connection with the acceleration and immediate vesting, the Company
recognized $609,322 of stock-based compensation expense during the year ended December&nbsp;31, 2019, which represents the remaining
unamortized grant date fair value of the award.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 105; Value: 8 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EYENOVIA,&nbsp;INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NOTES TO THE FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FOR THE YEARS ENDED DECEMBER 31, 2020
AND 2019</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Note 11 &ndash; Stockholders&rsquo; Equity - Continued</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Stock Options - Continued</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May&nbsp;14, 2019, stock options to
purchase 34,815 shares of common stock with an exercise price of $1.95 per share were exercised for aggregate proceeds of $67,889.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August&nbsp;16, 2019, the Company granted
ten-year stock options to purchase an aggregate of 681,572 shares of common stock to its employees, consultants and directors
under the 2018 Plan, as amended. Of the 681,572 shares, (i)&nbsp;636,287 vest over three years from the date of grant with one-third
vesting on the one-year anniversary of the date of grant and the balance vesting monthly over the remaining 24 months, subject
to continued service to the Company and (ii)&nbsp;45,285 vest on the earlier of the one-year anniversary of the date of grant
and the date of the 2020 annual stockholders meeting, subject to continued service to the Company. The stock options have an exercise
price of $3.11 per share, which represents the Company&rsquo;s closing stock price on the date of grant. The stock options had
a grant date value of $1,909,700, which the Company expects to recognize over the vesting period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January&nbsp;31, 2020, the Company
granted ten-year stock options to purchase 25,000 shares of common stock to its employees under the 2018 Plan, as amended. The
shares vest over three years from the date of grant with one-third vesting on the one-year anniversary of the date of grant and
the balance vesting monthly over the remaining 24 months. The stock options have an exercise price of $4.68 per share, which represents
the Company&rsquo;s closing stock price on the date of grant. The stock options had a grant date fair value of $103,400, which
the Company expects to recognize over the vesting period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May&nbsp;28, 2020, the Company granted
ten-year stock options to purchase 263,500 shares of common stock to its employees under the Restated Plan. The shares vest over
three years from the date of grant with one-third vesting on the one-year anniversary of the date of grant and the balance vesting
monthly over the remaining 24 months. The stock options have an exercise price of $2.89 per share, which represents the Company&rsquo;s
closing stock price on the date of grant. The stock options had a grant date fair value of $587,100, which the Company expects
to recognize over the vesting period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June&nbsp;3, 2020, the Company granted
ten-year stock options to purchase 764,419 shares of common stock to its executive officers under the Restated Plan. The shares
vest over three years from the date of grant with one-third vesting on the one-year anniversary of the date of grant and the balance
vesting monthly over the remaining 24 months. The stock options have an exercise price of $2.72 per share, which represents the
Company&rsquo;s closing stock price on the date of grant. The stock options had a grant date fair value of $1,603,600, which the
Company expects to recognize over the vesting period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July&nbsp;28, 2020, the Company granted
ten-year stock options to purchase 43,000 shares of common stock to an employee under the Restated Plan. The shares vest over
three years from the date of grant with one-third vesting on the one-year anniversary of the date of grant and the balance vesting
monthly over the remaining 24 months. The stock options have an exercise price of $3.71 per share, which represents the Company&rsquo;s
closing stock price on the date of grant. The stock options had a grant date fair value of $122,400, which the Company expects
to recognize over the vesting period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September&nbsp;8, 2020, the Company
granted ten-year stock options to purchase 45,000 shares of common stock to employees and consultants under the Restated Plan.
The shares vest over three years from the date of grant with one-third vesting on the one-year anniversary of the date of grant
and the balance vesting monthly over the remaining 24 months. The stock options have an exercise price of $3.48 per share, which
represents the Company&rsquo;s closing stock price on the date of grant. The stock options had a grant date fair value of $126,700,
which the Company expects to recognize over the vesting period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 106; Value: 8 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EYENOVIA,&nbsp;INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NOTES TO THE FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FOR THE YEARS ENDED DECEMBER 31, 2020
AND 2019</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Note 11 &ndash; Stockholders&rsquo; Equity
- Continued</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Stock Options - Continued</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September&nbsp;11,
2020, the Company granted ten-year stock options to purchase 58,920 shares of common stock under the Restated Plan to members
of its Board of Directors. The shares vest on the earlier of (i)&nbsp;the one-year anniversary of the date of grant and (ii)&nbsp;the
date of the 2021 annual stockholders meeting, subject to the grantee remaining on the Board until then. The stock options have
an exercise price of $3.43 per share, which represents the Company&rsquo;s closing stock price on the date of grant. The stock
options had a grant date fair value of $155,400, which the Company expects to recognize over the vesting period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On December&nbsp;23, 2020, the Company
granted ten-year stock options to purchase 50,000 shares of common stock to an employee under the Restated Plan. The shares vest
over three years from the date of grant with one-third vesting on the one-year anniversary of the date of grant and the balance
vesting monthly over the remaining 24 months. The stock options have an exercise price of $5.77 per share, which represents the
Company&rsquo;s closing stock price on the date of grant. The stock options had a grant date fair value of $218,700, which the
Company expects to recognize over the vesting period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In applying the Black-Scholes option pricing
model to stock options granted, the Company used the following approximate assumptions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 70%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-size: 10pt; font-weight: bold; text-align: center">For the Year Ended</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December&nbsp;31,</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2020</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2019</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Expected term (years)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">5.85 - 10.00</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">5.50 - 10.00</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Risk free interest rate</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">0.26% - 1.32</TD><TD STYLE="font-size: 10pt; text-align: left">%</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">1.42% - 2.53</TD><TD STYLE="font-size: 10pt; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Expected volatility</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">96% - 99</TD><TD STYLE="font-size: 10pt; text-align: left">%</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">134 - 139</TD><TD STYLE="font-size: 10pt; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 68%; font-size: 10pt; text-align: left">Expected dividends</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 13%; font-size: 10pt; text-align: right">0.00</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">%</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 13%; font-size: 10pt; text-align: right">0.00</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">%</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has computed the fair value of stock
options granted using the Black-Scholes option pricing model. Option forfeitures are accounted for at the time of occurrence. The expected
term used for options issued is the estimated period of time that options granted are expected to be outstanding. The Company utilizes
the &ldquo;simplified&rdquo; method to develop an estimate of the expected term of &ldquo;plain vanilla&rdquo; option grants. The Company
does not currently have a sufficient trading history to support its historical volatility calculations. Accordingly, the Company is utilizing
an expected volatility figure based on a review of the historical volatility of three comparable entities over a period of time equivalent
to the expected life of the instrument being valued. The risk-free interest rate was determined from the implied yields from U.S. Treasury
zero-coupon bonds with a remaining term consistent with the expected term of the instrument being valued. The Company has not declared
dividends, is currently in the development stage and has no plan to declare future dividends at this time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The weighted average estimated grant date
fair value of the stock options granted for the years ended December&nbsp;31, 2020 and 2019 was approximately $3.01 and $3.10
per share, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 107; Value: 8 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EYENOVIA,&nbsp;INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NOTES TO THE FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FOR THE YEARS ENDED DECEMBER 31, 2020
AND 2019</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Note 11 &ndash; Stockholders&rsquo; Equity - Continued</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Stock Options - Continued</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A summary of the option activity during
the year ended December&nbsp;31, 2020 is presented below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center">Weighted</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center">Weighted</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center">Average</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center">Average</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center">Remaining</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center">Aggregate</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center">Number of</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center">Exercise</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center">Life</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center">Intrinsic</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Options</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Price</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">In Years</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Value</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 40%; font-size: 10pt">Outstanding January&nbsp;1, 2020</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; font-size: 10pt; text-align: right">2,237,438</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 12%; font-size: 10pt; text-align: right">3.51</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">Granted</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">1,249,839</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">3.01</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">Exercised</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(36,391</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">2.26</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; padding-bottom: 1pt">Forfeited</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(23,181</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">4.59</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">Outstanding December&nbsp;31, 2020</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">3,427,705</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">3.37</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">8.0</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">9,843,341</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">Exercisable December&nbsp;31, 2020</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">1,768,292</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">3.48</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">6.8</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">5,013,118</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table presents information
related to stock options as of December&nbsp;31, 2020:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 60%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="6" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Options Outstanding</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Options Exercisable</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center">Weighted</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center">Outstanding</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center">Average</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center">Exercisable</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center">Exercise</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center">Number of</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center">Remaining Life</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center">Number of</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Price</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Options</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">In Years</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Options</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 22%; font-size: 10pt; text-align: right">1.24</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 22%; font-size: 10pt; text-align: right">260,000</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 21%; font-size: 10pt; text-align: right">4.2</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 21%; font-size: 10pt; text-align: right">260,000</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">1.95</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">673,544</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">6.5</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">673,544</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">2.72</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">764,419</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">2.74</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">6,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">8.0</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">3,833</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">2.89</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">263,500</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">3.11</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">659,849</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">8.6</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">318,432</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">3.43</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">58,920</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">3.48</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">45,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">3.71</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">43,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">4.00</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">2,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">7.9</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">1,390</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">4.68</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">25,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">5.10</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">6,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">7.7</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">4,500</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">5.19</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">16,500</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">7.7</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">12,375</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">5.25</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">26,668</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">5.8</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">26,668</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">5.77</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">50,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">6.20</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">300,387</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">7.6</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">270,476</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">6.30</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">60,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">7.5</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">48,333</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">$</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: right">8.72</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">166,918</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: right">7.3</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">148,741</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">3,427,705</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: right">6.8</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">1,768,292</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 108; Value: 8 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EYENOVIA,&nbsp;INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NOTES TO THE FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FOR THE YEARS ENDED DECEMBER 31, 2020
AND 2019</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Note 12 &ndash; Employee Benefit Plans</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>401(k)&nbsp;Plan</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In April&nbsp;2019, the Company adopted
the Eyenovia 401(k)&nbsp;Plan (the &ldquo;Plan&rdquo;), which went into effect in May&nbsp;2019. All Company employees are able
to participate in the Plan, subject to eligibility requirements as outlined in the Plan documents. Under the terms of the Plan,
eligible employees are able to defer a percentage of their pay every pay period up to annual limitations set by Congress and the
Internal Revenue Service under Section&nbsp;401(k)&nbsp;of the Internal Revenue Code. For 2019, the Company&rsquo;s Board of Directors
has approved a matching contribution equal to 100% of elective deferrals up to 4% of eligible earnings with the matching contribution
subject to certain vesting requirements as outlined in the Plan documents. For the years ended December&nbsp;31, 2020 and 2019,
the Company recorded expense of $138,785 and $71,285 associated with its matching contributions, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.75in"><B>Note
13 &ndash; Subsequent Events</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Management Option Grants</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Subsequent to December 31, 2020, the Company granted
options to its executive officers for a total of 652,899 shares, which grants are subject to stockholder approval of an amendment to the
Restated Plan to increase the share reserve thereunder at the 2021 Annual Meeting of Stockholders. The options, would have a ten year
term, vesting one-third on the one year anniversary of the date of grant and then in equal increments on each of the 24 one-month anniversaries
thereafter, subject to continued employment, and bear an exercise price of $6.01 per share for total possible consideration to the Company
of approximately $3.9 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Stock Warrant Exercises</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Subsequent to December&nbsp;31, 2020, the Company
issued an aggregate of 644,992 shares of common stock pursuant to the exercise of warrants for aggregate proceeds of $1,530,989 at exercise
prices ranging from $2.06 to $2.47.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 109; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.1
<SEQUENCE>2
<FILENAME>tm211152d1_ex4-1.htm
<DESCRIPTION>EXHIBIT 4.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit&nbsp;4.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>DESCRIPTION OF THE REGISTRANT&rsquo;S
SECURITIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>REGISTERED PURSUANT TO SECTION&nbsp;12
OF THE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES EXCHANGE ACT OF 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our authorized capital stock consists of
90,000,000 shares of common stock, $0.0001 par value per share, and 6,000,000 shares of undesignated preferred stock, par value
$0.0001 per share. The following description summarizes the material terms of our capital stock. Because it is only a summary,
it does not contain all the information that may be important to you. For a complete description of our capital stock, you should
refer to our amended and restated certificate of incorporation, as amended (our &ldquo;restated certificate&rdquo;), and our amended
and restated bylaws (our &ldquo;restated bylaws&rdquo;), which are included as exhibits to this Annual Report on Form&nbsp;10-K,
and to the provisions of applicable Delaware law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of December&nbsp;31, 2020, there were
24,978,585 shares of our common stock outstanding. Holders of our common stock are entitled to the following rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><I>Dividend Rights</I>. Subject to preferences that may apply to any shares of preferred stock outstanding at the time, the holders of outstanding shares of our common stock are entitled to receive dividends out of funds legally available at the times and in the amounts that our board of directors may determine. </TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><I>Voting Rights</I>. The holders of our common stock are entitled to one vote for each share of common stock held on all matters submitted to a vote of the stockholders, including the election of directors. Our restated certificate and restated bylaws do not provide for cumulative voting rights.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><I>No Preemptive or Similar Rights</I>. The holders of our common stock have no preemptive, conversion, or subscription rights, and there are no redemption provisions applicable to our common stock.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><I>Right to Receive Liquidation Distributions</I>. Upon our liquidation, dissolution or winding-up, the assets legally available for distribution to our stockholders would be distributable ratably among the holders of our common stock and any participating preferred stock outstanding at that time after payment of liquidation preferences, if any, on any outstanding shares of preferred stock and payment of other claims of creditors. </TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><I>Fully Paid and Non-Assessable</I>. All of the outstanding shares of our common stock are fully paid and non-assessable. </TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><I>Potential Adverse Effect of Future Preferred Stock</I>. The rights, preferences and privileges of the holders of common stock are subject to, and might be adversely affected by, the rights of the holders of shares of any series of our preferred stock that we may designate and issue in the future.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Preferred Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our board of directors is authorized, subject
to limitations prescribed by Delaware law, to issue up to 6,000,000 shares of preferred stock in one or more series, to establish
from time to time the number of shares to be included in each series, and to fix the designation, powers, preferences and rights
of the shares of each series and any of its qualifications, limitations or restrictions, in each case without further action by
our stockholders. Our board may authorize the issuance of preferred stock with voting or conversion rights that could adversely
affect the voting power or other rights of the holders of our common stock. The issuance of preferred stock, while providing flexibility
in connection with possible acquisitions and other corporate purposes, could, among other things, have the effect of delaying,
deferring, or preventing a change in our control or the removal of management and might adversely affect the market price of our
common stock and the voting and other rights of the holders of our common stock. As of December&nbsp;31, 2020, no shares of our
preferred stock were outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Stock Awards Available For Issuance</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of December&nbsp;31, 2020, the Company
has an aggregate of 518,186 shares of common stock available under our 2014 Equity Incentive Plan and Amended and Restated 2018
Omnibus Stock Incentive Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTAIN PROVISIONS OF DELAWARE LAW,</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>OUR RESTATED CERTIFICATE AND RESTATED
BYLAWS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The provisions of Delaware law, our restated
certificate, and our restated bylaws may have the effect of delaying, deferring, or discouraging another person from acquiring
control of our Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Delaware Law</B>. We are governed by
the provisions of Section&nbsp;203 of the Delaware General Corporation Law (&ldquo;DGCL&rdquo;). In general, Section&nbsp;203 prohibits
a public Delaware corporation from engaging in a &ldquo;business combination&rdquo; with an &ldquo;interested stockholder&rdquo;
for a period of three years after the date of the transaction in which the person became an interested stockholder unless:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify">prior to such time, the board of directors approved either the business combination or the transaction which resulted in the stockholder becoming an interested stockholder;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify">upon consummation of the transaction that resulted in the stockholder becoming an interested stockholder, the interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced, excluding shares owned by persons who are directors and also officers and by specified employee stock plans; or</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify">at or subsequent to the date of the transaction, the business combination is approved by the board of directors and authorized at an annual or special meeting of stockholders by the affirmative vote of at least 66 2/3% of the outstanding voting stock which is not owned by the interested stockholder.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A &ldquo;business combination&rdquo; includes
mergers, asset sales or other transactions resulting in a financial benefit to the stockholder. In general, an &ldquo;interested
stockholder&rdquo; is a person who, together with affiliates and associates, owns, or within three years did own, 15% or more of
the corporation&rsquo;s outstanding voting stock. These provisions may have the effect of delaying, deferring, or preventing a
change in our control. We expect the existence of this provision to have an anti-takeover effect with respect to transactions our
board of directors does not approve in advance. We also anticipate that DGCL Section&nbsp;203 may also discourage attempts that
might result in a premium over the market price for the shares of common stock held by stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Restated Certificate and Restated Bylaw
Provisions</B>. Various provisions of our restated certificate and restated bylaws could deter hostile takeovers or delay or prevent
changes in control of our management team, including the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Board of Directors Vacancies. Our restated
        certificate and restated bylaws authorize only our board fill vacant directorships. In addition, the number of directors constituting
        our board is permitted to be set only by a resolution adopted by a majority of our board. These provisions would prevent a stockholder
        from increasing the size of our board and then gaining control of our board by filling the resulting vacancies with its own nominees.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Stockholder Action; Special Meeting
of Stockholders. Under our restated certificate, our stockholders may no longer take action by written consent, and may only take
action at annual or special meetings of our stockholders. Our restated bylaws further provide that special meetings of our stockholders
may be called only our board, President, Chief Executive Officer or by such other person the board expressly authorizes to call
a special meeting.</P></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; width: 24px"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify">Our restated bylaws provide advance notice procedures for stockholders seeking to bring business before our annual meeting of stockholders. To be timely, a stockholder&rsquo;s notice must be delivered to, or mailed and received at, our principal executive offices not less than 90 days nor more than 120 days prior to the one-year anniversary of the previous year&rsquo;s annual meeting of stockholders; provided, that if no annual meeting of stockholders was held in the previous year or the date of the annual meeting of stockholders has been changed to be more than 30 calendar days earlier or 60 days later than such anniversary, notice by the stockholder, to be timely, must be received not earlier than the 120th day nor later to the 90th day prior to the date of such annual meeting or, if later, the 10th day following the date we publicly disclose the date of the annual meeting. Our restated bylaws also specify certain requirements regarding the form and content of a stockholder&rsquo;s notice. These provisions might preclude our stockholders from bringing matters before our annual meeting of stockholders.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify">Our restated bylaws provide advance notice procedures for stockholders to nominate candidates for election as directors at our annual meeting of stockholders. To be timely, a stockholder&rsquo;s notice must be delivered to, or mailed and received at, our principal executive offices not less than 60 days nor more than 90 days prior to the annual meeting of stockholders. Our restated bylaws also provide advance notice procedures for stockholders to nominate candidates for election as directors at a special meeting of stockholders. To be timely, a stockholder&rsquo;s notice must be delivered to, or mailed and received at, our principal executive offices not later than the close of business on the tenth business day following the date on which notice of such meeting is first given to stockholders. Our restated bylaws also specify certain requirements regarding the form and content of a stockholder&rsquo;s notice. These provisions might preclude our stockholders from making nominations for directors at our annual and/or a special meeting of stockholders.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify">Issuance of Undesignated Preferred Stock. Our board of directors has the authority, without further action by our stockholders, to issue up to 6,000,000 shares of undesignated preferred stock with rights and preferences, including voting rights, designated from time to time by our board. Our board may utilize these shares for a variety of corporate purposes, including future public offerings to raise additional capital, corporate acquisitions and employee benefits plans. The existence of authorized but unissued shares of preferred stock would enable our board to render more difficult or to discourage an attempt to obtain control of us by means of a merger, tender offer, proxy contest or other means. If we issue such shares without stockholder approval and in violation of limitations imposed by any stock exchange on which our stock may then be trading, our stock could be delisted.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Transfer Agent and Registrar</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The transfer agent and registrar for our
common stock is American Stock Transfer and Trust Company, LLC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Stock Exchange Listing</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our common stock is listed on the Nasdaq
Capital Market under the symbol &ldquo;EYEN&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>3
<FILENAME>tm211152d1_ex23-1.htm
<DESCRIPTION>EXHIBIT 23.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit&nbsp;23.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><U>Independent
Registered Public Accounting Firm&rsquo;s Consent</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We consent to the incorporation by reference in
the Registration Statements of Eyenovia,&nbsp;Inc. (the &ldquo;Company&rdquo;) on Forms S-3 (File No.&nbsp;333-229365 and File No.&nbsp;333-237790)
and Forms S-8 (File No.&nbsp;333-227049, File No.&nbsp;333-233278, File No.&nbsp;333-233280, and File No.&nbsp;333-246288) of our report,
which includes an explanatory paragraph as to the Company&rsquo;s ability to continue as a going concern, dated March&nbsp;30, 2021, with
respect to our audits of the financial statements of Eyenovia,&nbsp;Inc. as of December&nbsp;31, 2020 and 2019 and for each of the two
years in the period ended December&nbsp;31, 2020, which report is included in this Annual Report on Form&nbsp;10-K of Eyenovia,&nbsp;Inc.
for the year ended December&nbsp;31, 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">/s/ Marcum <FONT STYLE="font-variant: small-caps">LLP</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Marcum <FONT STYLE="font-variant: small-caps">LLP</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">New York, NY</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">March&nbsp;30, 2021</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>4
<FILENAME>tm211152d1_ex31-1.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit&nbsp;31.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATION OF THE PRINCIPAL EXECUTIVE
OFFICER<BR>
PURSUANT TO SECTION&nbsp;302 OF THE SARBANES-OXLEY ACT OF 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">I, Tsontcho Ianchulev, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt">1.</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">I have reviewed this annual report on Form&nbsp;10-K of Eyenovia,&nbsp;Inc. for the year ended December&nbsp;31, 2020;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px">2.</TD>
    <TD STYLE="text-align: justify">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px">3.</TD>
    <TD STYLE="text-align: justify">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px">4.</TD>
    <TD STYLE="text-align: justify">The registrant&rsquo;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&nbsp;13a-15(e)&nbsp;and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules&nbsp;13a-15(f)&nbsp;and 15d-15(f)) for the registrant and have:</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 43px">&nbsp;</TD>
    <TD STYLE="width: 24px">a)</TD>
    <TD STYLE="text-align: justify">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 43px">&nbsp;</TD>
    <TD STYLE="width: 24px">b)</TD>
    <TD STYLE="text-align: justify">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 43px">&nbsp;</TD>
    <TD STYLE="width: 24px">c)</TD>
    <TD STYLE="text-align: justify">Evaluated the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 43px">&nbsp;</TD>
    <TD STYLE="width: 24px">d)</TD>
    <TD STYLE="text-align: justify">Disclosed in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting; and</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px">5.</TD>
    <TD STYLE="text-align: justify">The registrant&rsquo;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors (or persons performing the equivalent functions):</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 43px">&nbsp;</TD>
    <TD STYLE="width: 24px">a)</TD>
    <TD STYLE="text-align: justify">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information; and</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 43px">&nbsp;</TD>
    <TD STYLE="width: 24px">b)</TD>
    <TD STYLE="text-align: justify">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s internal control over financial reporting.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Date: March&nbsp;30, 2021</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 50%; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">/s/ Tsontcho Ianchulev</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Name: Tsontcho Ianchulev</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Title Chief Executive Officer</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">(Principal Executive Officer)</FONT></TD></TR>
  </TABLE>





<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>5
<FILENAME>tm211152d1_ex31-2.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit&nbsp;31.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>CERTIFICATION OF
THE PRINCIPAL FINANCIAL OFFICER<BR>
PURSUANT TO SECTION&nbsp;302 OF THE SARBANES-OXLEY ACT OF 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">I, John Gandolfo, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt">1.</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">I have reviewed this annual report on Form&nbsp;10-K of Eyenovia,&nbsp;Inc. for the year ended December&nbsp;31, 2020;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt">2.</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt">3.</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt">4.</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">The registrant&rsquo;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&nbsp;13a-15(e)&nbsp;and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules&nbsp;13a-15(f)&nbsp;and 15d-15(f)) for the registrant and have:</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 46px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt">a)</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 46px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt">b)</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 46px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt">c)</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">Evaluated the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 46px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt">d)</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">Disclosed in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting; and</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt">5.</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">The registrant&rsquo;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors (or persons performing the equivalent functions):</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 46px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt">a)</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information; and</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 46px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt">b)</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s internal control over financial reporting.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Date: March&nbsp;30, 2021</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">/s/ John Gandolfo</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Name: John Gandolfo</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Title Chief Financial Officer</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 50%"><FONT STYLE="font-size: 10pt">(Principal Financial Officer)</FONT></TD></TR>
  </TABLE>


<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>6
<FILENAME>tm211152d1_ex32-1.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit&nbsp;32.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>CERTIFICATION OF THE PRINCIPAL EXECUTIVE
OFFICER<BR>
PURSUANT TO SECTION&nbsp;906 OF THE SARBANES-OXLEY ACT OF 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In connection with
the annual report of Eyenovia,&nbsp;Inc. (the &ldquo;Company&rdquo;) on Form&nbsp;10-K for the year ended December&nbsp;31, 2020,
as filed with the Securities and Exchange Commission on the date hereof (the &ldquo;Report&rdquo;),&nbsp;I, Tsontcho Ianchulev,
Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section&nbsp;1350, as adopted pursuant to Section&nbsp;906
of the Sarbanes-Oxley Act of 2002, that, to my knowledge:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The Report
fully complies with the requirements of Section&nbsp;13(a)&nbsp;or 15(d)&nbsp;of the Securities Exchange Act of 1934; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations
of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Date: March&nbsp;30, 2021</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">/s/ Tsontcho Ianchulev</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Name: Tsontcho Ianchulev</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Title Chief Executive Officer</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 50%"><FONT STYLE="font-size: 10pt">(Principal Executive Officer)</FONT></TD></TR>
  </TABLE>


<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>7
<FILENAME>tm211152d1_ex32-2.htm
<DESCRIPTION>EXHIBIT 32.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit&nbsp;32.2</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>CERTIFICATION OF THE PRINCIPAL FINANCIAL
OFFICER<BR>
PURSUANT TO SECTION&nbsp;906 OF THE SARBANES-OXLEY ACT OF 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In connection with
the annual report of Eyenovia,&nbsp;Inc. (the &ldquo;Company&rdquo;) on Form&nbsp;10-K for the year ended December&nbsp;31, 2020,
as filed with the Securities and Exchange Commission on the date hereof (the &ldquo;Report&rdquo;),&nbsp;I, John Gandolfo, Chief
Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section&nbsp;1350, as adopted pursuant to Section&nbsp;906 of
the Sarbanes-Oxley Act of 2002, that, to my knowledge:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The Report fully complies with the requirements of Section&nbsp;13(a)&nbsp;or 15(d)&nbsp;of the Securities Exchange Act of 1934;
and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The information
contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Date: March&nbsp;30, 2021</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">/s/ John Gandolfo</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Name: John Gandolfo</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Title Chief Financial Officer</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 50%"><FONT STYLE="font-size: 10pt">(Principal Financial Officer)</FONT></TD></TR>
  </TABLE>


<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>8
<FILENAME>eyen-20201231.xml
<DESCRIPTION>XBRL INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.9.3.5 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/31/2021 1:30:11 AM-->
<xbrl xmlns="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:eyen="http://www.eyenoviabio.com/20201231" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31">
  <link:schemaRef xlink:type="simple" xlink:href="eyen-20201231.xsd" />
  <!--Context Section-->
  <context id="Duration_1_2_2019_To_1_2_2019_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_StockOptionMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-02</startDate>
      <endDate>2019-01-02</endDate>
    </period>
  </context>
  <context id="Duration_3_24_2020_To_3_24_2020_us-gaap_StatementEquityComponentsAxis_eyen_ClassWarrantsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">eyen:ClassWarrantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-03-24</startDate>
      <endDate>2020-03-24</endDate>
    </period>
  </context>
  <context id="Duration_3_24_2020_To_3_24_2020_us-gaap_StatementEquityComponentsAxis_eyen_ClassBWarrantsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">eyen:ClassBWarrantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-03-24</startDate>
      <endDate>2020-03-24</endDate>
    </period>
  </context>
  <context id="Duration_7_15_2019_To_7_15_2019_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-07-15</startDate>
      <endDate>2019-07-15</endDate>
    </period>
  </context>
  <context id="Duration_2_1_2019_To_2_6_2019">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
    </entity>
    <period>
      <startDate>2019-02-01</startDate>
      <endDate>2019-02-06</endDate>
    </period>
  </context>
  <context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2020_srt_RangeAxis_srt_MinimumMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2020_srt_RangeAxis_srt_MaximumMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="As_Of_3_24_2020_us-gaap_StatementEquityComponentsAxis_eyen_ClassWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">eyen:ClassWarrantsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-03-24</instant>
    </period>
  </context>
  <context id="As_Of_3_24_2020_us-gaap_StatementEquityComponentsAxis_eyen_ClassBWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">eyen:ClassBWarrantsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-03-24</instant>
    </period>
  </context>
  <context id="As_Of_3_24_2020_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-03-24</instant>
    </period>
  </context>
  <context id="As_Of_7_15_2019_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-07-15</instant>
    </period>
  </context>
  <context id="As_Of_8_19_2020_us-gaap_SubsidiarySaleOfStockAxis_eyen_UnderwrittenPublicOfferingMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">eyen:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-08-19</instant>
    </period>
  </context>
  <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceTwoMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">eyen:ExercisePriceTwoMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceThreeMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">eyen:ExercisePriceThreeMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceTenMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">eyen:ExercisePriceTenMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceSixMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">eyen:ExercisePriceSixMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceSevenMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">eyen:ExercisePriceSevenMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceOneMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">eyen:ExercisePriceOneMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceNineMemberMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">eyen:ExercisePriceNineMemberMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceFourMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">eyen:ExercisePriceFourMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceFiveMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">eyen:ExercisePriceFiveMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceElevenMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">eyen:ExercisePriceElevenMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceEightMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">eyen:ExercisePriceEightMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePrice5.77Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">eyen:ExercisePrice5.77Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePrice4.68Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">eyen:ExercisePrice4.68Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePrice3.71Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">eyen:ExercisePrice3.71Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePrice3.48Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">eyen:ExercisePrice3.48Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePrice3.43Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">eyen:ExercisePrice3.43Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePrice2.89Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">eyen:ExercisePrice2.89Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePrice2.72Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">eyen:ExercisePrice2.72Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="As_Of_12_31_2020_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceTwoMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">eyen:ExercisePriceTwoMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2020_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceThreeMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">eyen:ExercisePriceThreeMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2020_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceTenMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">eyen:ExercisePriceTenMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2020_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceSixMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">eyen:ExercisePriceSixMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2020_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceSevenMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">eyen:ExercisePriceSevenMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2020_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceOneMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">eyen:ExercisePriceOneMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2020_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceNineMemberMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">eyen:ExercisePriceNineMemberMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2020_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceFourMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">eyen:ExercisePriceFourMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2020_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceFiveMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">eyen:ExercisePriceFiveMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2020_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceElevenMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">eyen:ExercisePriceElevenMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2020_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceEightMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">eyen:ExercisePriceEightMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2020_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePrice5.77Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">eyen:ExercisePrice5.77Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2020_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePrice4.68Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">eyen:ExercisePrice4.68Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2020_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePrice3.71Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">eyen:ExercisePrice3.71Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2020_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePrice3.48Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">eyen:ExercisePrice3.48Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2020_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePrice3.43Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">eyen:ExercisePrice3.43Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2020_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePrice2.89Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">eyen:ExercisePrice2.89Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2020_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePrice2.72Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">eyen:ExercisePrice2.72Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="Duration_2_6_2019_To_2_6_2019">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
    </entity>
    <period>
      <startDate>2019-02-06</startDate>
      <endDate>2019-02-06</endDate>
    </period>
  </context>
  <context id="Duration_1_2_2019_To_1_2_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-02</startDate>
      <endDate>2019-01-02</endDate>
    </period>
  </context>
  <context id="Duration_12_23_2020_To_12_23_2020_us-gaap_PlanNameAxis_eyen_EmployeesConsultantsAndDirectorsUnder2018PlanMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eyen:EmployeesConsultantsAndDirectorsUnder2018PlanMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-12-23</startDate>
      <endDate>2020-12-23</endDate>
    </period>
  </context>
  <context id="Duration_9_11_2020_To_9_11_2020_us-gaap_PlanNameAxis_eyen_EmployeesConsultantsAndDirectorsUnder2018PlanMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eyen:EmployeesConsultantsAndDirectorsUnder2018PlanMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-09-11</startDate>
      <endDate>2020-09-11</endDate>
    </period>
  </context>
  <context id="Duration_9_8_2020_To_9_8_2020_us-gaap_PlanNameAxis_eyen_EmployeesConsultantsAndDirectorsUnder2018PlanMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eyen:EmployeesConsultantsAndDirectorsUnder2018PlanMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-09-08</startDate>
      <endDate>2020-09-08</endDate>
    </period>
  </context>
  <context id="Duration_7_28_2020_To_7_28_2020_us-gaap_PlanNameAxis_eyen_EmployeesConsultantsAndDirectorsUnder2018PlanMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eyen:EmployeesConsultantsAndDirectorsUnder2018PlanMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-07-28</startDate>
      <endDate>2020-07-28</endDate>
    </period>
  </context>
  <context id="Duration_6_3_2020_To_6_3_2020_us-gaap_PlanNameAxis_eyen_EmployeesConsultantsAndDirectorsUnder2018PlanMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eyen:EmployeesConsultantsAndDirectorsUnder2018PlanMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-06-03</startDate>
      <endDate>2020-06-03</endDate>
    </period>
  </context>
  <context id="Duration_5_28_2020_To_5_28_2020_us-gaap_PlanNameAxis_eyen_EmployeesConsultantsAndDirectorsUnder2018PlanMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eyen:EmployeesConsultantsAndDirectorsUnder2018PlanMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-05-28</startDate>
      <endDate>2020-05-28</endDate>
    </period>
  </context>
  <context id="Duration_1_31_2020_To_1_31_2020_us-gaap_PlanNameAxis_eyen_EmployeesConsultantsAndDirectorsUnder2018PlanMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eyen:EmployeesConsultantsAndDirectorsUnder2018PlanMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-31</startDate>
      <endDate>2020-01-31</endDate>
    </period>
  </context>
  <context id="As_Of_12_31_2019_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_StockOptionMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="Duration_8_16_2019_To_8_16_2019_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-08-16</startDate>
      <endDate>2019-08-16</endDate>
    </period>
  </context>
  <context id="Duration_8_16_2019_To_8_16_2019_us-gaap_PlanNameAxis_eyen_EmployeesConsultantsAndDirectorsUnder2018PlanMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eyen:EmployeesConsultantsAndDirectorsUnder2018PlanMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-08-16</startDate>
      <endDate>2019-08-16</endDate>
    </period>
  </context>
  <context id="Duration_1_14_2019_To_1_14_2019_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-14</startDate>
      <endDate>2019-01-14</endDate>
    </period>
  </context>
  <context id="Duration_1_14_2019_To_1_14_2019_us-gaap_PlanNameAxis_eyen_EmployeesConsultantsAndDirectorsUnder2018PlanMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eyen:EmployeesConsultantsAndDirectorsUnder2018PlanMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-14</startDate>
      <endDate>2019-01-14</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_StockOptionMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="As_Of_12_31_2020_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_StockOptionMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="Duration_1_1_2019_To_12_31_2019_srt_RangeAxis_srt_MinimumMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2019_To_12_31_2019_srt_RangeAxis_srt_MaximumMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="Duration_9_11_2020_To_9_11_2020_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-09-11</startDate>
      <endDate>2020-09-11</endDate>
    </period>
  </context>
  <context id="Duration_8_16_2019_To_8_16_2019_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-08-16</startDate>
      <endDate>2019-08-16</endDate>
    </period>
  </context>
  <context id="Duration_12_23_2020_To_12_23_2020_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-12-23</startDate>
      <endDate>2020-12-23</endDate>
    </period>
  </context>
  <context id="Duration_9_8_2020_To_9_8_2020_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-09-08</startDate>
      <endDate>2020-09-08</endDate>
    </period>
  </context>
  <context id="Duration_7_28_2020_To_7_28_2020_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-07-28</startDate>
      <endDate>2020-07-28</endDate>
    </period>
  </context>
  <context id="Duration_6_3_2020_To_6_3_2020_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-06-03</startDate>
      <endDate>2020-06-03</endDate>
    </period>
  </context>
  <context id="Duration_5_28_2020_To_5_28_2020_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-05-28</startDate>
      <endDate>2020-05-28</endDate>
    </period>
  </context>
  <context id="Duration_1_31_2020_To_1_31_2020_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-31</startDate>
      <endDate>2020-01-31</endDate>
    </period>
  </context>
  <context id="Duration_12_23_2020_To_12_23_2020_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-12-23</startDate>
      <endDate>2020-12-23</endDate>
    </period>
  </context>
  <context id="Duration_12_23_2020_To_12_23_2020">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
    </entity>
    <period>
      <startDate>2020-12-23</startDate>
      <endDate>2020-12-23</endDate>
    </period>
  </context>
  <context id="Duration_9_8_2020_To_9_8_2020_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-09-08</startDate>
      <endDate>2020-09-08</endDate>
    </period>
  </context>
  <context id="Duration_9_8_2020_To_9_8_2020">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
    </entity>
    <period>
      <startDate>2020-09-08</startDate>
      <endDate>2020-09-08</endDate>
    </period>
  </context>
  <context id="Duration_7_28_2020_To_7_28_2020_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-07-28</startDate>
      <endDate>2020-07-28</endDate>
    </period>
  </context>
  <context id="Duration_7_28_2020_To_7_28_2020">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
    </entity>
    <period>
      <startDate>2020-07-28</startDate>
      <endDate>2020-07-28</endDate>
    </period>
  </context>
  <context id="Duration_6_3_2020_To_6_3_2020_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-06-03</startDate>
      <endDate>2020-06-03</endDate>
    </period>
  </context>
  <context id="Duration_6_3_2020_To_6_3_2020">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
    </entity>
    <period>
      <startDate>2020-06-03</startDate>
      <endDate>2020-06-03</endDate>
    </period>
  </context>
  <context id="Duration_5_28_2020_To_5_28_2020_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-05-28</startDate>
      <endDate>2020-05-28</endDate>
    </period>
  </context>
  <context id="Duration_5_28_2020_To_5_28_2020">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
    </entity>
    <period>
      <startDate>2020-05-28</startDate>
      <endDate>2020-05-28</endDate>
    </period>
  </context>
  <context id="Duration_1_31_2020_To_1_31_2020_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-31</startDate>
      <endDate>2020-01-31</endDate>
    </period>
  </context>
  <context id="Duration_1_31_2020_To_1_31_2020">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
    </entity>
    <period>
      <startDate>2020-01-31</startDate>
      <endDate>2020-01-31</endDate>
    </period>
  </context>
  <context id="Duration_8_16_2019_To_8_16_2019_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-08-16</startDate>
      <endDate>2019-08-16</endDate>
    </period>
  </context>
  <context id="Duration_1_14_2019_To_1_14_2019_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-14</startDate>
      <endDate>2019-01-14</endDate>
    </period>
  </context>
  <context id="Duration_1_14_2019_To_1_14_2019">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
    </entity>
    <period>
      <startDate>2019-01-14</startDate>
      <endDate>2019-01-14</endDate>
    </period>
  </context>
  <context id="Duration_2_1_2019_To_2_13_2019">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
    </entity>
    <period>
      <startDate>2019-02-01</startDate>
      <endDate>2019-02-13</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2019_To_12_31_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2019_To_12_31_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="As_Of_9_15_2020_us-gaap_RelatedPartyTransactionAxis_eyen_VicePresidentOfResearchAndDevelopmentMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">eyen:VicePresidentOfResearchAndDevelopmentMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-09-15</instant>
    </period>
  </context>
  <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_us-gaap_RelatedPartyTransactionAxis_eyen_ConsultingAgreementMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_eyen_CuraPartnersMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">eyen:ConsultingAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">eyen:CuraPartnersMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2019_To_12_31_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_us-gaap_RelatedPartyTransactionAxis_eyen_ConsultingAgreementMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_eyen_CuraPartnersMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">eyen:ConsultingAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">eyen:CuraPartnersMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2020_To_12_31_2020_srt_RangeAxis_srt_MinimumMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2020_To_12_31_2020_srt_RangeAxis_srt_MaximumMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2019_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2019_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="Duration_3_26_2021_To_3_26_2021_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2021-03-26</startDate>
      <endDate>2021-03-26</endDate>
    </period>
  </context>
  <context id="Duration_5_14_2019_To_5_14_2019">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
    </entity>
    <period>
      <startDate>2019-05-14</startDate>
      <endDate>2019-05-14</endDate>
    </period>
  </context>
  <context id="Duration_1_2_2019_To_1_2_2019">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
    </entity>
    <period>
      <startDate>2019-01-02</startDate>
      <endDate>2019-01-02</endDate>
    </period>
  </context>
  <context id="Duration_8_21_2020_To_8_21_2020_us-gaap_SubsidiarySaleOfStockAxis_eyen_UnderwrittenPublicOfferingMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">eyen:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-08-21</startDate>
      <endDate>2020-08-21</endDate>
    </period>
  </context>
  <context id="As_Of_12_31_2020_srt_StatementGeographicalAxis_stpr_NY">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NY</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_1_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_eyen_AdditionalOfficeSpaceMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">eyen:AdditionalOfficeSpaceMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-01</instant>
    </period>
  </context>
  <context id="As_Of_7_17_2020">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
    </entity>
    <period>
      <instant>2020-07-17</instant>
    </period>
  </context>
  <context id="As_Of_8_8_2018">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
    </entity>
    <period>
      <instant>2018-08-08</instant>
    </period>
  </context>
  <context id="As_Of_9_15_2016_us-gaap_RelatedPartyTransactionAxis_eyen_VicePresidentOfResearchAndDevelopmentMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">eyen:VicePresidentOfResearchAndDevelopmentMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-09-15</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2015_srt_OwnershipAxis_eyen_LicenseAgreementMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:OwnershipAxis">eyen:LicenseAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2020_us-gaap_DebtInstrumentAxis_eyen_PaycheckProtectionProgramLoanMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eyen:PaycheckProtectionProgramLoanMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2019_us-gaap_DebtInstrumentAxis_eyen_PaycheckProtectionProgramLoanMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eyen:PaycheckProtectionProgramLoanMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2020_us-gaap_RelatedPartyTransactionAxis_eyen_VicePresidentOfResearchAndDevelopmentMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">eyen:VicePresidentOfResearchAndDevelopmentMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="Duration_12_1_2020_To_12_1_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_eyen_AdditionalOfficeSpaceMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">eyen:AdditionalOfficeSpaceMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-12-01</startDate>
      <endDate>2020-12-01</endDate>
    </period>
  </context>
  <context id="Duration_12_1_2020_To_12_1_2020">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
    </entity>
    <period>
      <startDate>2020-12-01</startDate>
      <endDate>2020-12-01</endDate>
    </period>
  </context>
  <context id="Duration_8_1_2018_To_8_8_2018">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
    </entity>
    <period>
      <startDate>2018-08-01</startDate>
      <endDate>2018-08-08</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_RelatedPartyTransactionAxis_eyen_VicePresidentOfResearchAndDevelopmentMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">eyen:VicePresidentOfResearchAndDevelopmentMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2019_To_12_31_2019_us-gaap_RelatedPartyTransactionAxis_eyen_VicePresidentOfResearchAndDevelopmentMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">eyen:VicePresidentOfResearchAndDevelopmentMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="As_Of_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_RelatedPartyTransactionAxis_eyen_VicePresidentOfResearchAndDevelopmentMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">eyen:VicePresidentOfResearchAndDevelopmentMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_RelatedPartyTransactionAxis_eyen_VicePresidentOfResearchAndDevelopmentMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">eyen:VicePresidentOfResearchAndDevelopmentMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_FairValueByAssetClassAxis_us-gaap_PropertyPlantAndEquipmentMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2019_To_12_31_2019_us-gaap_FairValueByAssetClassAxis_us-gaap_PropertyPlantAndEquipmentMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="Duration_4_1_2019_To_4_30_2019">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
    </entity>
    <period>
      <startDate>2019-04-01</startDate>
      <endDate>2019-04-30</endDate>
    </period>
  </context>
  <context id="Duration_5_8_2020_To_5_8_2020_srt_RangeAxis_srt_MinimumMember_us-gaap_ShortTermDebtTypeAxis_eyen_PaycheckProtectionProgramLoanMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">eyen:PaycheckProtectionProgramLoanMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-05-08</startDate>
      <endDate>2020-05-08</endDate>
    </period>
  </context>
  <context id="Duration_5_8_2020_To_5_8_2020_srt_RangeAxis_srt_MaximumMember_us-gaap_ShortTermDebtTypeAxis_eyen_PaycheckProtectionProgramLoanMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">eyen:PaycheckProtectionProgramLoanMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-05-08</startDate>
      <endDate>2020-05-08</endDate>
    </period>
  </context>
  <context id="As_Of_2_24_2020_us-gaap_ShortTermDebtTypeAxis_us-gaap_NotesPayableOtherPayablesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-02-24</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2020_us-gaap_PlanNameAxis_eyen_OmnibusStockIncentivePlan2018Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eyen:OmnibusStockIncentivePlan2018Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="As_Of_4_7_2020_us-gaap_PlanNameAxis_eyen_OmnibusStockIncentivePlan2018Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eyen:OmnibusStockIncentivePlan2018Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-04-07</instant>
    </period>
  </context>
  <context id="As_Of_3_26_2021_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2021-03-26</instant>
    </period>
  </context>
  <context id="As_Of_3_26_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2021-03-26</instant>
    </period>
  </context>
  <context id="As_Of_3_26_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2021-03-26</instant>
    </period>
  </context>
  <context id="As_Of_3_24_2020_us-gaap_StatementEquityComponentsAxis_eyen_ClassWarrantsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">eyen:ClassWarrantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-03-24</instant>
    </period>
  </context>
  <context id="As_Of_3_24_2020_us-gaap_StatementEquityComponentsAxis_eyen_ClassBWarrantsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">eyen:ClassBWarrantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-03-24</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2018">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
    </entity>
    <period>
      <instant>2018-12-31</instant>
    </period>
  </context>
  <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_OptionIndexedToIssuersEquityTypeAxis_us-gaap_EmployeeStockOptionMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2019_To_12_31_2019_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2019_To_12_31_2019_us-gaap_OptionIndexedToIssuersEquityTypeAxis_us-gaap_EmployeeStockOptionMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="Duration_4_7_2020_To_4_7_2020_us-gaap_PlanNameAxis_eyen_OmnibusStockIncentivePlan2018Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eyen:OmnibusStockIncentivePlan2018Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-04-07</startDate>
      <endDate>2020-04-07</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_TypeOfArrangementAxis_eyen_ArcticVisionLicenseAgreementMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eyen:ArcticVisionLicenseAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2015_To_12_31_2015_us-gaap_RelatedPartyTransactionAxis_eyen_SenjuPharmaceuticalCoMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">eyen:SenjuPharmaceuticalCoMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="As_Of_1_2_2019">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
    </entity>
    <period>
      <instant>2019-01-02</instant>
    </period>
  </context>
  <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_eyen_CommonStockTwoMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">eyen:CommonStockTwoMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_eyen_CommonStockTwoMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">eyen:CommonStockTwoMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_eyen_CommonStockThreeMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">eyen:CommonStockThreeMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_eyen_CommonStockThreeMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">eyen:CommonStockThreeMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_eyen_CommonStockOneMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">eyen:CommonStockOneMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementClassOfStockAxis_eyen_CommonStockOneMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">eyen:CommonStockOneMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="Duration_5_8_2020_To_5_8_2020_us-gaap_ShortTermDebtTypeAxis_eyen_PaycheckProtectionProgramLoanMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">eyen:PaycheckProtectionProgramLoanMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-05-08</startDate>
      <endDate>2020-05-08</endDate>
    </period>
  </context>
  <context id="As_Of_5_8_2020_us-gaap_ShortTermDebtTypeAxis_eyen_PaycheckProtectionProgramLoanMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">eyen:PaycheckProtectionProgramLoanMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-05-08</instant>
    </period>
  </context>
  <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_RelatedPartyTransactionAxis_eyen_SenjuPharmaceuticalCoMember_us-gaap_TypeOfArrangementAxis_eyen_ArcticVisionLicenseAgreementMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">eyen:SenjuPharmaceuticalCoMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eyen:ArcticVisionLicenseAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="Duration_7_15_2019_To_7_15_2019_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-07-15</startDate>
      <endDate>2019-07-15</endDate>
    </period>
  </context>
  <context id="Duration_8_19_2020_To_8_19_2020_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-08-19</startDate>
      <endDate>2020-08-19</endDate>
    </period>
  </context>
  <context id="Duration_8_19_2020_To_8_19_2020_us-gaap_SubsidiarySaleOfStockAxis_eyen_UnderwrittenPublicOfferingMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">eyen:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-08-19</startDate>
      <endDate>2020-08-19</endDate>
    </period>
  </context>
  <context id="Duration_2_24_2020_To_2_24_2020_us-gaap_ShortTermDebtTypeAxis_us-gaap_NotesPayableOtherPayablesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-02-24</startDate>
      <endDate>2020-02-24</endDate>
    </period>
  </context>
  <context id="Duration_3_24_2020_To_3_24_2020">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
    </entity>
    <period>
      <startDate>2020-03-24</startDate>
      <endDate>2020-03-24</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_TypeOfArrangementAxis_eyen_BauschLicenseAgreementMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eyen:BauschLicenseAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="Duration_8_10_2020_To_8_10_2020_us-gaap_TypeOfArrangementAxis_eyen_ArcticVisionLicenseAgreementMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eyen:ArcticVisionLicenseAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-08-10</startDate>
      <endDate>2020-08-10</endDate>
    </period>
  </context>
  <context id="Duration_10_9_2020_To_10_9_2020_us-gaap_TypeOfArrangementAxis_eyen_BauschLicenseAgreementMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eyen:BauschLicenseAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-10-09</startDate>
      <endDate>2020-10-09</endDate>
    </period>
  </context>
  <context id="As_Of_10_9_2020_us-gaap_TypeOfArrangementAxis_eyen_BauschLicenseAgreementMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eyen:BauschLicenseAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-10-09</instant>
    </period>
  </context>
  <context id="As_Of_8_10_2020_us-gaap_TypeOfArrangementAxis_eyen_ArcticVisionLicenseAgreementMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eyen:ArcticVisionLicenseAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-08-10</instant>
    </period>
  </context>
  <context id="Duration_12_1_2020_To_12_1_2020_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_eyen_AdditionalOfficeSpaceMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">eyen:AdditionalOfficeSpaceMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-12-01</startDate>
      <endDate>2020-12-01</endDate>
    </period>
  </context>
  <context id="Duration_12_1_2020_To_12_1_2020_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_eyen_AdditionalOfficeSpaceMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">eyen:AdditionalOfficeSpaceMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-12-01</startDate>
      <endDate>2020-12-01</endDate>
    </period>
  </context>
  <context id="Duration_12_1_2020_To_12_1_2020_srt_RangeAxis_srt_MinimumMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-12-01</startDate>
      <endDate>2020-12-01</endDate>
    </period>
  </context>
  <context id="Duration_12_1_2020_To_12_1_2020_srt_RangeAxis_srt_MaximumMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-12-01</startDate>
      <endDate>2020-12-01</endDate>
    </period>
  </context>
  <context id="Duration_7_17_2020_To_7_17_2020">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
    </entity>
    <period>
      <startDate>2020-07-17</startDate>
      <endDate>2020-07-17</endDate>
    </period>
  </context>
  <context id="Duration_8_1_2018_To_8_8_2018_srt_RangeAxis_srt_MinimumMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-08-01</startDate>
      <endDate>2018-08-08</endDate>
    </period>
  </context>
  <context id="Duration_8_1_2018_To_8_8_2018_srt_RangeAxis_srt_MaximumMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-08-01</startDate>
      <endDate>2018-08-08</endDate>
    </period>
  </context>
  <context id="Duration_9_1_2016_To_9_15_2016_us-gaap_RelatedPartyTransactionAxis_eyen_VicePresidentOfResearchAndDevelopmentMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">eyen:VicePresidentOfResearchAndDevelopmentMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-09-01</startDate>
      <endDate>2016-09-15</endDate>
    </period>
  </context>
  <context id="Duration_3_24_2020_To_3_24_2020_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-03-24</startDate>
      <endDate>2020-03-24</endDate>
    </period>
  </context>
  <context id="Duration_7_15_2019_To_7_15_2019">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
    </entity>
    <period>
      <startDate>2019-07-15</startDate>
      <endDate>2019-07-15</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_RelatedPartyTransactionAxis_eyen_VicePresidentOfResearchAndDevelopmentMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">eyen:VicePresidentOfResearchAndDevelopmentMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2019_To_12_31_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_RelatedPartyTransactionAxis_eyen_VicePresidentOfResearchAndDevelopmentMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">eyen:VicePresidentOfResearchAndDevelopmentMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="Duration_7_6_2017_To_7_6_2017_us-gaap_RelatedPartyTransactionAxis_eyen_ConsultingAgreementMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_eyen_CuraPartnersMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">eyen:ConsultingAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">eyen:CuraPartnersMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-07-06</startDate>
      <endDate>2017-07-06</endDate>
    </period>
  </context>
  <context id="Duration_3_24_2020_To_3_24_2020_us-gaap_StatementEquityComponentsAxis_eyen_ClassWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">eyen:ClassWarrantsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-03-24</startDate>
      <endDate>2020-03-24</endDate>
    </period>
  </context>
  <context id="Duration_3_24_2020_To_3_24_2020_us-gaap_StatementEquityComponentsAxis_eyen_ClassBWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">eyen:ClassBWarrantsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-03-24</startDate>
      <endDate>2020-03-24</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_ClassOfWarrantOrRightAxis_eyen_WarrantsAtExercisePriceTwoMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">eyen:WarrantsAtExercisePriceTwoMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_ClassOfWarrantOrRightAxis_eyen_WarrantsAtExercisePriceThreeMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">eyen:WarrantsAtExercisePriceThreeMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_ClassOfWarrantOrRightAxis_eyen_WarrantsAtExercisePriceOneMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">eyen:WarrantsAtExercisePriceOneMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_ClassOfWarrantOrRightAxis_eyen_WarrantsAtExercisePriceFourMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">eyen:WarrantsAtExercisePriceFourMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="As_Of_12_31_2020_us-gaap_ClassOfWarrantOrRightAxis_eyen_WarrantsAtExercisePriceTwoMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">eyen:WarrantsAtExercisePriceTwoMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2020_us-gaap_ClassOfWarrantOrRightAxis_eyen_WarrantsAtExercisePriceThreeMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">eyen:WarrantsAtExercisePriceThreeMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2020_us-gaap_ClassOfWarrantOrRightAxis_eyen_WarrantsAtExercisePriceOneMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">eyen:WarrantsAtExercisePriceOneMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2020_us-gaap_ClassOfWarrantOrRightAxis_eyen_WarrantsAtExercisePriceFourMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">eyen:WarrantsAtExercisePriceFourMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="Duration_1_1_2019_To_12_31_2019">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="As_Of_12_31_2020">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2019">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="As_Of_6_30_2020">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
    </entity>
    <period>
      <instant>2020-06-30</instant>
    </period>
  </context>
  <context id="As_Of_3_29_2021">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
    </entity>
    <period>
      <instant>2021-03-29</instant>
    </period>
  </context>
  <context id="Duration_1_1_2020_To_12_31_2020">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <!--Unit Section-->
  <unit id="Unit15">
    <measure>utr:sqft</measure>
  </unit>
  <unit id="Unit14">
    <measure>xbrli:pure</measure>
  </unit>
  <unit id="Unit13">
    <divide>
      <unitNumerator>
        <measure>iso4217:USD</measure>
      </unitNumerator>
      <unitDenominator>
        <measure>xbrli:shares</measure>
      </unitDenominator>
    </divide>
  </unit>
  <unit id="Unit12">
    <measure>iso4217:USD</measure>
  </unit>
  <unit id="Unit1">
    <measure>xbrli:shares</measure>
  </unit>
  <!--Tuple Section-->
  <!--Element Section-->
  <dei:AmendmentFlag contextRef="Duration_1_1_2020_To_12_31_2020">false</dei:AmendmentFlag>
  <dei:CurrentFiscalYearEndDate contextRef="Duration_1_1_2020_To_12_31_2020">--12-31</dei:CurrentFiscalYearEndDate>
  <dei:DocumentFiscalPeriodFocus contextRef="Duration_1_1_2020_To_12_31_2020">FY</dei:DocumentFiscalPeriodFocus>
  <dei:DocumentFiscalYearFocus contextRef="Duration_1_1_2020_To_12_31_2020">2020</dei:DocumentFiscalYearFocus>
  <dei:DocumentPeriodEndDate contextRef="Duration_1_1_2020_To_12_31_2020">2020-12-31</dei:DocumentPeriodEndDate>
  <dei:DocumentType contextRef="Duration_1_1_2020_To_12_31_2020">10-K</dei:DocumentType>
  <dei:EntityCentralIndexKey contextRef="Duration_1_1_2020_To_12_31_2020">0001682639</dei:EntityCentralIndexKey>
  <dei:EntityCommonStockSharesOutstanding contextRef="As_Of_3_29_2021" unitRef="Unit1" decimals="0">25623577</dei:EntityCommonStockSharesOutstanding>
  <dei:EntityCurrentReportingStatus contextRef="Duration_1_1_2020_To_12_31_2020">Yes</dei:EntityCurrentReportingStatus>
  <dei:EntityEmergingGrowthCompany contextRef="Duration_1_1_2020_To_12_31_2020">true</dei:EntityEmergingGrowthCompany>
  <dei:EntityExTransitionPeriod contextRef="Duration_1_1_2020_To_12_31_2020">false</dei:EntityExTransitionPeriod>
  <dei:EntityFilerCategory contextRef="Duration_1_1_2020_To_12_31_2020">Non-accelerated Filer</dei:EntityFilerCategory>
  <dei:EntityIncorporationDateOfIncorporation contextRef="Duration_1_1_2020_To_12_31_2020">2014-03-12</dei:EntityIncorporationDateOfIncorporation>
  <dei:EntityIncorporationStateCountryCode contextRef="Duration_1_1_2020_To_12_31_2020">FL</dei:EntityIncorporationStateCountryCode>
  <dei:EntityInteractiveDataCurrent contextRef="Duration_1_1_2020_To_12_31_2020">Yes</dei:EntityInteractiveDataCurrent>
  <dei:EntityPublicFloat contextRef="As_Of_6_30_2020" unitRef="Unit12" decimals="0">32427910</dei:EntityPublicFloat>
  <dei:EntityRegistrantName contextRef="Duration_1_1_2020_To_12_31_2020">EYENOVIA, INC.</dei:EntityRegistrantName>
  <dei:EntityShellCompany contextRef="Duration_1_1_2020_To_12_31_2020">false</dei:EntityShellCompany>
  <dei:EntitySmallBusiness contextRef="Duration_1_1_2020_To_12_31_2020">true</dei:EntitySmallBusiness>
  <dei:EntityVoluntaryFilers contextRef="Duration_1_1_2020_To_12_31_2020">No</dei:EntityVoluntaryFilers>
  <dei:EntityWellKnownSeasonedIssuer contextRef="Duration_1_1_2020_To_12_31_2020">No</dei:EntityWellKnownSeasonedIssuer>
  <dei:Security12bTitle contextRef="Duration_1_1_2020_To_12_31_2020">Common Stock, $0.0001 Par Value</dei:Security12bTitle>
  <dei:SecurityExchangeName contextRef="Duration_1_1_2020_To_12_31_2020">NASDAQ</dei:SecurityExchangeName>
  <dei:TradingSymbol contextRef="Duration_1_1_2020_To_12_31_2020">EYEN</dei:TradingSymbol>
  <eyen:AccruedConsultingAndProfessionalServicesCurrent contextRef="As_Of_12_31_2019" unitRef="Unit12" decimals="0">97396</eyen:AccruedConsultingAndProfessionalServicesCurrent>
  <eyen:AccruedConsultingAndProfessionalServicesCurrent contextRef="As_Of_12_31_2020" unitRef="Unit12" decimals="0">235355</eyen:AccruedConsultingAndProfessionalServicesCurrent>
  <eyen:AccruedExpenseReimbursements contextRef="As_Of_12_31_2019" unitRef="Unit12" decimals="0">0</eyen:AccruedExpenseReimbursements>
  <eyen:AccruedExpenseReimbursements contextRef="As_Of_12_31_2020" unitRef="Unit12" decimals="0">5459</eyen:AccruedExpenseReimbursements>
  <eyen:AccruedExpensesAndOtherLiabilitiesCurrent contextRef="As_Of_12_31_2019" unitRef="Unit12" decimals="0">453430</eyen:AccruedExpensesAndOtherLiabilitiesCurrent>
  <eyen:AccruedExpensesAndOtherLiabilitiesCurrent contextRef="As_Of_12_31_2020" unitRef="Unit12" decimals="0">1480692</eyen:AccruedExpensesAndOtherLiabilitiesCurrent>
  <eyen:AccruedFranchiseTax contextRef="As_Of_12_31_2019" unitRef="Unit12" decimals="0">40995</eyen:AccruedFranchiseTax>
  <eyen:AccruedFranchiseTax contextRef="As_Of_12_31_2020" unitRef="Unit12" decimals="0">32480</eyen:AccruedFranchiseTax>
  <eyen:AccruedLicensingFees contextRef="As_Of_12_31_2019" unitRef="Unit12" decimals="0">0</eyen:AccruedLicensingFees>
  <eyen:AccruedLicensingFees contextRef="As_Of_12_31_2020" unitRef="Unit12" decimals="0">804447</eyen:AccruedLicensingFees>
  <eyen:AccruedPurchasesOfLeaseholdImprovements contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit12" decimals="0">42500</eyen:AccruedPurchasesOfLeaseholdImprovements>
  <eyen:AccruedPurchasesOfLeaseholdImprovements contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit12" decimals="0">0</eyen:AccruedPurchasesOfLeaseholdImprovements>
  <eyen:AccruedResearchAndDevelopmentExpensesCurrent contextRef="As_Of_12_31_2019" unitRef="Unit12" decimals="0">208175</eyen:AccruedResearchAndDevelopmentExpensesCurrent>
  <eyen:AccruedResearchAndDevelopmentExpensesCurrent contextRef="As_Of_12_31_2020" unitRef="Unit12" decimals="0">291256</eyen:AccruedResearchAndDevelopmentExpensesCurrent>
  <eyen:AccruedShippingAndPackagingFees contextRef="As_Of_12_31_2019" unitRef="Unit12" decimals="0">0</eyen:AccruedShippingAndPackagingFees>
  <eyen:AccruedShippingAndPackagingFees contextRef="As_Of_12_31_2020" unitRef="Unit12" decimals="0">56998</eyen:AccruedShippingAndPackagingFees>
  <eyen:AccruedTravelAndEntertainmentExpenses contextRef="As_Of_12_31_2019" unitRef="Unit12" decimals="0">7385</eyen:AccruedTravelAndEntertainmentExpenses>
  <eyen:AccruedTravelAndEntertainmentExpenses contextRef="As_Of_12_31_2020" unitRef="Unit12" decimals="0">0</eyen:AccruedTravelAndEntertainmentExpenses>
  <eyen:ClassOfWarrantOrRightExercisable contextRef="As_Of_12_31_2020" unitRef="Unit1" decimals="0">2011313</eyen:ClassOfWarrantOrRightExercisable>
  <eyen:ClassOfWarrantOrRightExercisable contextRef="As_Of_12_31_2020" unitRef="Unit1" decimals="0">2011313</eyen:ClassOfWarrantOrRightExercisable>
  <eyen:ClassOfWarrantOrRightExercisable contextRef="As_Of_12_31_2020_us-gaap_ClassOfWarrantOrRightAxis_eyen_WarrantsAtExercisePriceFourMember" unitRef="Unit1" decimals="0">216380</eyen:ClassOfWarrantOrRightExercisable>
  <eyen:ClassOfWarrantOrRightExercisable contextRef="As_Of_12_31_2020_us-gaap_ClassOfWarrantOrRightAxis_eyen_WarrantsAtExercisePriceOneMember" unitRef="Unit1" decimals="0">48549</eyen:ClassOfWarrantOrRightExercisable>
  <eyen:ClassOfWarrantOrRightExercisable contextRef="As_Of_12_31_2020_us-gaap_ClassOfWarrantOrRightAxis_eyen_WarrantsAtExercisePriceThreeMember" unitRef="Unit1" decimals="0">1602128</eyen:ClassOfWarrantOrRightExercisable>
  <eyen:ClassOfWarrantOrRightExercisable contextRef="As_Of_12_31_2020_us-gaap_ClassOfWarrantOrRightAxis_eyen_WarrantsAtExercisePriceTwoMember" unitRef="Unit1" decimals="0">144256</eyen:ClassOfWarrantOrRightExercisable>
  <eyen:ClassOfWarrantOrRightExercisableAggregateIntrinsicValue contextRef="As_Of_12_31_2020" unitRef="Unit12" decimals="0">7215147</eyen:ClassOfWarrantOrRightExercisableAggregateIntrinsicValue>
  <eyen:ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice contextRef="As_Of_12_31_2020" unitRef="Unit13" decimals="2">2.43</eyen:ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice>
  <eyen:ClassOfWarrantOrRightExercisableWeightedAverageRemainingLife contextRef="Duration_1_1_2020_To_12_31_2020">P3Y9M18D</eyen:ClassOfWarrantOrRightExercisableWeightedAverageRemainingLife>
  <eyen:ClassOfWarrantOrRightExercisableWeightedAverageRemainingLife contextRef="Duration_1_1_2020_To_12_31_2020">P3Y9M18D</eyen:ClassOfWarrantOrRightExercisableWeightedAverageRemainingLife>
  <eyen:ClassOfWarrantOrRightExercisableWeightedAverageRemainingLife contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_ClassOfWarrantOrRightAxis_eyen_WarrantsAtExercisePriceFourMember">P4Y2M12D</eyen:ClassOfWarrantOrRightExercisableWeightedAverageRemainingLife>
  <eyen:ClassOfWarrantOrRightExercisableWeightedAverageRemainingLife contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_ClassOfWarrantOrRightAxis_eyen_WarrantsAtExercisePriceOneMember">P2M12D</eyen:ClassOfWarrantOrRightExercisableWeightedAverageRemainingLife>
  <eyen:ClassOfWarrantOrRightExercisableWeightedAverageRemainingLife contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_ClassOfWarrantOrRightAxis_eyen_WarrantsAtExercisePriceThreeMember">P4Y2M12D</eyen:ClassOfWarrantOrRightExercisableWeightedAverageRemainingLife>
  <eyen:ClassOfWarrantOrRightExercisableWeightedAverageRemainingLife contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_ClassOfWarrantOrRightAxis_eyen_WarrantsAtExercisePriceTwoMember">P2M12D</eyen:ClassOfWarrantOrRightExercisableWeightedAverageRemainingLife>
  <eyen:ClassOfWarrantOrRightExercised contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit1" decimals="0">-1332841</eyen:ClassOfWarrantOrRightExercised>
  <eyen:ClassOfWarrantOrRightExercisedWeightedAverageExercisePrice contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit13" decimals="2">2.19</eyen:ClassOfWarrantOrRightExercisedWeightedAverageExercisePrice>
  <eyen:ClassOfWarrantOrRightGranted contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit1" decimals="0">3344154</eyen:ClassOfWarrantOrRightGranted>
  <eyen:ClassOfWarrantOrRightGrantedWeightedAverageExercisePrice contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit13" decimals="2">2.33</eyen:ClassOfWarrantOrRightGrantedWeightedAverageExercisePrice>
  <eyen:ClassOfWarrantOrRightNumberOfYearsSecuritiesCalledByWarrantsToPurchaseCommonStock contextRef="Duration_3_24_2020_To_3_24_2020_us-gaap_StatementEquityComponentsAxis_eyen_ClassBWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember">P5Y</eyen:ClassOfWarrantOrRightNumberOfYearsSecuritiesCalledByWarrantsToPurchaseCommonStock>
  <eyen:ClassOfWarrantOrRightNumberOfYearsSecuritiesCalledByWarrantsToPurchaseCommonStock contextRef="Duration_3_24_2020_To_3_24_2020_us-gaap_StatementEquityComponentsAxis_eyen_ClassWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember">P1Y</eyen:ClassOfWarrantOrRightNumberOfYearsSecuritiesCalledByWarrantsToPurchaseCommonStock>
  <eyen:ClassOfWarrantOrRightOutstandingAggregateIntrinsicValue contextRef="As_Of_12_31_2020" unitRef="Unit12" decimals="0">7215147</eyen:ClassOfWarrantOrRightOutstandingAggregateIntrinsicValue>
  <eyen:ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice contextRef="As_Of_12_31_2020" unitRef="Unit13" decimals="2">2.43</eyen:ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice>
  <eyen:ClassOfWarrantOrRightOutstandingWeightedAverageRemainingLife contextRef="Duration_1_1_2020_To_12_31_2020">P3Y9M18D</eyen:ClassOfWarrantOrRightOutstandingWeightedAverageRemainingLife>
  <eyen:ConsultingAgreementPaymentPerhour contextRef="Duration_7_6_2017_To_7_6_2017_us-gaap_RelatedPartyTransactionAxis_eyen_ConsultingAgreementMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_eyen_CuraPartnersMember" unitRef="Unit12" decimals="0">250</eyen:ConsultingAgreementPaymentPerhour>
  <eyen:ConsultingAgreementPaymentPermonth contextRef="Duration_7_6_2017_To_7_6_2017_us-gaap_RelatedPartyTransactionAxis_eyen_ConsultingAgreementMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_eyen_CuraPartnersMember" unitRef="Unit12" decimals="0">9567</eyen:ConsultingAgreementPaymentPermonth>
  <eyen:CostOfServicesEngineeringServices contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_RelatedPartyTransactionAxis_eyen_VicePresidentOfResearchAndDevelopmentMember" unitRef="Unit12" decimals="0">851746</eyen:CostOfServicesEngineeringServices>
  <eyen:CostOfServicesEngineeringServices contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_RelatedPartyTransactionAxis_eyen_VicePresidentOfResearchAndDevelopmentMember" unitRef="Unit12" decimals="0">1024430</eyen:CostOfServicesEngineeringServices>
  <eyen:CreditCardPayable contextRef="As_Of_12_31_2019" unitRef="Unit12" decimals="0">56979</eyen:CreditCardPayable>
  <eyen:CreditCardPayable contextRef="As_Of_12_31_2020" unitRef="Unit12" decimals="0">50002</eyen:CreditCardPayable>
  <eyen:DeferredIncomeTaxExpenseBenefitBeforeAdjustmentsForChangeInValuationAllowance contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit12" decimals="0">-4931158</eyen:DeferredIncomeTaxExpenseBenefitBeforeAdjustmentsForChangeInValuationAllowance>
  <eyen:DeferredIncomeTaxExpenseBenefitBeforeAdjustmentsForChangeInValuationAllowance contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit12" decimals="0">-4231134</eyen:DeferredIncomeTaxExpenseBenefitBeforeAdjustmentsForChangeInValuationAllowance>
  <eyen:DeferredLicenseCostsPolicyTextBlock contextRef="Duration_1_1_2020_To_12_31_2020">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt 0pt 8pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-size:10pt;text-decoration:underline;"&gt;Deferred License Costs&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 8pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-size:10pt;"&gt;The Company enters into license agreements which provides for payment of license costs in connection with the Company&amp;#x2019;s receipt of license fees. These payments are recorded as deferred license costs and will be recorded as an expense when the related license fee revenue is recognized. See Note 10 &amp;#x2013; Related Party Transactions for additional details.&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</eyen:DeferredLicenseCostsPolicyTextBlock>
  <eyen:DeferredLicenseFeePolicyTextBlock contextRef="Duration_1_1_2020_To_12_31_2020">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt 0pt 8pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-size:10pt;text-decoration:underline;"&gt;Deferred License Fee&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 8pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-size:10pt;"&gt;The Company enters into license agreements which provides for the receipt of non-refundable, upfront licensing payments. These payments are recorded as deferred license fees and will be earned and recognized as revenue upon the satisfaction of performance obligations. See Note 9 &amp;#x2013; Commitments and Contingencies for additional details.&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</eyen:DeferredLicenseFeePolicyTextBlock>
  <eyen:DeferredTaxAssetsLiabilityPropertyAndEquipment contextRef="As_Of_12_31_2019" unitRef="Unit12" decimals="0">14030</eyen:DeferredTaxAssetsLiabilityPropertyAndEquipment>
  <eyen:DeferredTaxAssetsLiabilityPropertyAndEquipment contextRef="As_Of_12_31_2020" unitRef="Unit12" decimals="0">76550</eyen:DeferredTaxAssetsLiabilityPropertyAndEquipment>
  <eyen:DeferredTaxAssetsNetBeforeValuationAllowance contextRef="As_Of_12_31_2019" unitRef="Unit12" decimals="0">12322378</eyen:DeferredTaxAssetsNetBeforeValuationAllowance>
  <eyen:DeferredTaxAssetsNetBeforeValuationAllowance contextRef="As_Of_12_31_2020" unitRef="Unit12" decimals="0">16553512</eyen:DeferredTaxAssetsNetBeforeValuationAllowance>
  <eyen:DisclosureOfAccruedCompensationTableTextBlock contextRef="Duration_1_1_2020_To_12_31_2020">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;As of December 31, 2020 and 2019, accrued compensation consisted of the following:&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:71.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:71.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="5" valign="bottom" style="width:26.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;December&amp;nbsp;31,&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:71.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:13.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;2020&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:11.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;2019&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:71.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Accrued bonus expenses&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 938,873&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 897,839&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:71.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Accrued payroll expenses&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 211,799&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 19,034&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:71.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Total accrued compensation&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 1,150,672&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 916,873&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt 0pt 8pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</eyen:DisclosureOfAccruedCompensationTableTextBlock>
  <eyen:EffectiveIncomeTaxRateReconciliationNetAtFederalStatutoryIncomeTaxRate contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit14" decimals="3">0.210</eyen:EffectiveIncomeTaxRateReconciliationNetAtFederalStatutoryIncomeTaxRate>
  <eyen:EffectiveIncomeTaxRateReconciliationNetAtFederalStatutoryIncomeTaxRate contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit14" decimals="3">-0.210</eyen:EffectiveIncomeTaxRateReconciliationNetAtFederalStatutoryIncomeTaxRate>
  <eyen:GrossProceedsOfStockValueIssuedDuringPeriod contextRef="Duration_7_15_2019_To_7_15_2019" unitRef="Unit12" decimals="-5">14000000</eyen:GrossProceedsOfStockValueIssuedDuringPeriod>
  <eyen:GrossProceedsOfStockValueIssuedDuringPeriod contextRef="Duration_3_24_2020_To_3_24_2020_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember" unitRef="Unit12" decimals="5">2.42625</eyen:GrossProceedsOfStockValueIssuedDuringPeriod>
  <eyen:IncreaseDecreaseInDeferredRent contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit12" decimals="0">3767</eyen:IncreaseDecreaseInDeferredRent>
  <eyen:IncreaseDecreaseInDeferredRent contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit12" decimals="0">1142</eyen:IncreaseDecreaseInDeferredRent>
  <eyen:IncreaseDecreaseInLicenseReceivable contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit12" decimals="0">0</eyen:IncreaseDecreaseInLicenseReceivable>
  <eyen:IncreaseDecreaseInLicenseReceivable contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit12" decimals="0">2966039</eyen:IncreaseDecreaseInLicenseReceivable>
  <eyen:LeaseholdImprovements contextRef="As_Of_12_31_2019" unitRef="Unit12" decimals="0">42500</eyen:LeaseholdImprovements>
  <eyen:LeaseholdImprovements contextRef="As_Of_12_31_2020" unitRef="Unit12" decimals="0">0</eyen:LeaseholdImprovements>
  <eyen:LeaseMonthlyBaseRent contextRef="Duration_9_1_2016_To_9_15_2016_us-gaap_RelatedPartyTransactionAxis_eyen_VicePresidentOfResearchAndDevelopmentMember" unitRef="Unit12" decimals="0">3895</eyen:LeaseMonthlyBaseRent>
  <eyen:LeaseMonthlyBaseRent contextRef="Duration_8_1_2018_To_8_8_2018_srt_RangeAxis_srt_MaximumMember" unitRef="Unit12" decimals="0">22486</eyen:LeaseMonthlyBaseRent>
  <eyen:LeaseMonthlyBaseRent contextRef="Duration_8_1_2018_To_8_8_2018_srt_RangeAxis_srt_MinimumMember" unitRef="Unit12" decimals="0">19633</eyen:LeaseMonthlyBaseRent>
  <eyen:LeaseMonthlyBaseRent contextRef="Duration_7_17_2020_To_7_17_2020" unitRef="Unit12" decimals="0">7500</eyen:LeaseMonthlyBaseRent>
  <eyen:LeaseMonthlyBaseRent contextRef="Duration_12_1_2020_To_12_1_2020_srt_RangeAxis_srt_MaximumMember" unitRef="Unit12" decimals="0">7957</eyen:LeaseMonthlyBaseRent>
  <eyen:LeaseMonthlyBaseRent contextRef="Duration_12_1_2020_To_12_1_2020_srt_RangeAxis_srt_MinimumMember" unitRef="Unit12" decimals="0">7500</eyen:LeaseMonthlyBaseRent>
  <eyen:LeaseMonthlyBaseRent contextRef="Duration_12_1_2020_To_12_1_2020_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_eyen_AdditionalOfficeSpaceMember" unitRef="Unit12" decimals="0">3183</eyen:LeaseMonthlyBaseRent>
  <eyen:LeaseMonthlyBaseRent contextRef="Duration_12_1_2020_To_12_1_2020_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_eyen_AdditionalOfficeSpaceMember" unitRef="Unit12" decimals="0">3000</eyen:LeaseMonthlyBaseRent>
  <eyen:LicenseAgreementsMaximumAdditionalPaymentsReceivable contextRef="As_Of_8_10_2020_us-gaap_TypeOfArrangementAxis_eyen_ArcticVisionLicenseAgreementMember" unitRef="Unit12" decimals="-4">41750000</eyen:LicenseAgreementsMaximumAdditionalPaymentsReceivable>
  <eyen:LicenseAgreementsMaximumAdditionalPaymentsReceivable contextRef="As_Of_10_9_2020_us-gaap_TypeOfArrangementAxis_eyen_BauschLicenseAgreementMember" unitRef="Unit12" decimals="-5">35000000</eyen:LicenseAgreementsMaximumAdditionalPaymentsReceivable>
  <eyen:LicenseAgreementsTerminationPeriodUponUncuredMaterialBreach contextRef="Duration_10_9_2020_To_10_9_2020_us-gaap_TypeOfArrangementAxis_eyen_BauschLicenseAgreementMember">P60D</eyen:LicenseAgreementsTerminationPeriodUponUncuredMaterialBreach>
  <eyen:LicenseAgreementsTerminationWrittenNoticePeriod contextRef="Duration_10_9_2020_To_10_9_2020_us-gaap_TypeOfArrangementAxis_eyen_BauschLicenseAgreementMember">P90D</eyen:LicenseAgreementsTerminationWrittenNoticePeriod>
  <eyen:LicenseAgreementsUpfrontPaymentsReceived contextRef="Duration_8_10_2020_To_8_10_2020_us-gaap_TypeOfArrangementAxis_eyen_ArcticVisionLicenseAgreementMember" unitRef="Unit12" decimals="-5">4000000</eyen:LicenseAgreementsUpfrontPaymentsReceived>
  <eyen:LicenseAgreementsUpfrontPaymentsReceived contextRef="Duration_10_9_2020_To_10_9_2020_us-gaap_TypeOfArrangementAxis_eyen_BauschLicenseAgreementMember" unitRef="Unit12" decimals="-5">10000000</eyen:LicenseAgreementsUpfrontPaymentsReceived>
  <eyen:LicenseReceivableCurrent contextRef="As_Of_12_31_2020" unitRef="Unit12" decimals="0">2966039</eyen:LicenseReceivableCurrent>
  <eyen:MilestoneRevenuePayments contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_TypeOfArrangementAxis_eyen_BauschLicenseAgreementMember" unitRef="Unit12" decimals="0">0</eyen:MilestoneRevenuePayments>
  <eyen:NetOperatingLossAnnualUtilizationLimitAsPerInternalRevenueCode contextRef="As_Of_12_31_2020" unitRef="Unit12" decimals="0">918000</eyen:NetOperatingLossAnnualUtilizationLimitAsPerInternalRevenueCode>
  <eyen:NetOperatingLossLimitForUtilizationAsPerInternalRevenueCode contextRef="As_Of_12_31_2020" unitRef="Unit12" decimals="0">35000000</eyen:NetOperatingLossLimitForUtilizationAsPerInternalRevenueCode>
  <eyen:NetProceedsFromIssuanceOfCommonStock contextRef="Duration_7_15_2019_To_7_15_2019" unitRef="Unit12" decimals="-5">13000000</eyen:NetProceedsFromIssuanceOfCommonStock>
  <eyen:NetProceedsFromIssuanceOfCommonStock contextRef="Duration_3_24_2020_To_3_24_2020" unitRef="Unit12" decimals="-5">5300000</eyen:NetProceedsFromIssuanceOfCommonStock>
  <eyen:NotesPayableDisclosureTextBlock contextRef="Duration_1_1_2020_To_12_31_2020">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-weight:bold;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Note&amp;nbsp;7&amp;nbsp;&amp;#x2013; Notes Payable&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;As of December 31, 2020 and 2019, notes payable consisted of the following:&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:41.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:06.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:05.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:06.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:41.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="8" valign="bottom" style="width:29.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;December&amp;nbsp;31,&amp;nbsp;2020&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="8" valign="bottom" style="width:25.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;December&amp;nbsp;31,&amp;nbsp;2019&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:41.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:07.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;Current&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:09.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;Non-Current&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:06.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;Current&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:09.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;Non-Current&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:06.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:41.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:07.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;Portion&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:09.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;Portion&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:08.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;Total&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:06.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;Portion&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:09.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;Portion&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:07.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;Total&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:41.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Paycheck Protection Program loan&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:06.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 97,539&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 365,814&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 463,353&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:05.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:06.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:41.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:06.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 97,539&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 365,814&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 463,353&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:05.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:06.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt 0pt 0pt 54pt;line-height:100%;text-indent: -54pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;On February 24, 2020, the Company issued a note payable (the &amp;#x201C;Note&amp;#x201D;) for the purchase of a directors&amp;#x2019; and officers&amp;#x2019; liability insurance policy. The Note was payable in nine monthly payments of $53,750 for an aggregate principal amount of $475,216. The Note accrues interest at a rate of 4.29% per year and matured on November 24, 2020. During the year ended December 31, 2020, the Company repaid the principal amount of the Note. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;On May 8, 2020, the Company received cash proceeds of $463,353 pursuant to a loan provided in connection with the Paycheck Protection Program under the CARES Act (the &amp;#x201C;PPP Loan&amp;#x201D;). The PPP Loan provides for monthly installment payments of $19,508 beginning in August 2021 with the remaining balance due on May 3, 2022, the maturity date. The PPP Loan bears interest at a fixed rate of 1.00% per annum. The Company will be applying for loan forgiveness on the PPP Loan. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Under the terms of the CARES Act, as amended by the Paycheck Protection Program Flexibility Act of 2020, the Company is eligible to apply for and receive forgiveness for all or a portion of its PPP Loan. Such forgiveness will be determined, subject to limitations, based on the use of the loan proceeds for certain permissible purposes as set forth in the PPP Loan, including, but not limited to, payroll costs and mortgage interest, rent or utility costs (collectively, &amp;#x201C;Qualifying Expenses&amp;#x201D;) incurred during the 24 weeks subsequent to funding, and on the maintenance of employee and compensation levels following the funding of the PPP Loan. The Company intends to use the proceeds of its PPP Loan for Qualifying Expenses. However, no assurance is provided that the Company will be able to obtain forgiveness of its PPP Loan in whole or in part. Any amounts that are not forgiven incur interest at 1.0% per annum and monthly repayments of principal and interest are deferred until six months after the Small Business Administration makes a determination on forgiveness. While the PPP Loan currently has a two-year maturity, the amended law permits the borrower to request a five-year maturity from its lender.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times New Roman,Times,serif;"&gt;During the years ended December 31, 2020 and 2019, the Company recorded interest expense of $17,042 and $0, respectively.&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</eyen:NotesPayableDisclosureTextBlock>
  <eyen:NumberOfCommonShares contextRef="Duration_3_24_2020_To_3_24_2020_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember" unitRef="Unit1" decimals="0">1</eyen:NumberOfCommonShares>
  <eyen:NumberOfMonthlyPayments contextRef="Duration_2_24_2020_To_2_24_2020_us-gaap_ShortTermDebtTypeAxis_us-gaap_NotesPayableOtherPayablesMember">P9M</eyen:NumberOfMonthlyPayments>
  <eyen:NumberOfSharesAgreedToBeIssued contextRef="Duration_8_19_2020_To_8_19_2020_us-gaap_SubsidiarySaleOfStockAxis_eyen_UnderwrittenPublicOfferingMember" unitRef="Unit1" decimals="0">3333334</eyen:NumberOfSharesAgreedToBeIssued>
  <eyen:NumberOfSharesAgreedToBeIssued contextRef="Duration_8_19_2020_To_8_19_2020_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember" unitRef="Unit1" decimals="0">500000</eyen:NumberOfSharesAgreedToBeIssued>
  <eyen:OperatingLossCarryForwardsExpirationTerm contextRef="Duration_1_1_2020_To_12_31_2020">2034 to 2037</eyen:OperatingLossCarryForwardsExpirationTerm>
  <eyen:OverAllotmentOptionPeriod contextRef="Duration_7_15_2019_To_7_15_2019_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember">P30D</eyen:OverAllotmentOptionPeriod>
  <eyen:OverAllotmentOptionPeriod contextRef="Duration_8_19_2020_To_8_19_2020_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember">P30D</eyen:OverAllotmentOptionPeriod>
  <eyen:PaymentsForLicenseCosts contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_RelatedPartyTransactionAxis_eyen_SenjuPharmaceuticalCoMember_us-gaap_TypeOfArrangementAxis_eyen_ArcticVisionLicenseAgreementMember" unitRef="Unit12" decimals="-5">1600000</eyen:PaymentsForLicenseCosts>
  <eyen:PaymentsForRepurchaseOfPublicOffering contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit12" decimals="0">256374</eyen:PaymentsForRepurchaseOfPublicOffering>
  <eyen:PaymentsForRepurchaseOfPublicOffering contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit12" decimals="0">329038</eyen:PaymentsForRepurchaseOfPublicOffering>
  <eyen:PayrollTaxesReceivable contextRef="As_Of_12_31_2019" unitRef="Unit12" decimals="0">95233</eyen:PayrollTaxesReceivable>
  <eyen:PayrollTaxesReceivable contextRef="As_Of_12_31_2020" unitRef="Unit12" decimals="0">151942</eyen:PayrollTaxesReceivable>
  <eyen:PercentageOfInterestOnAmountWhichIsNotForgiven contextRef="As_Of_5_8_2020_us-gaap_ShortTermDebtTypeAxis_eyen_PaycheckProtectionProgramLoanMember" unitRef="Unit14" decimals="3">0.010</eyen:PercentageOfInterestOnAmountWhichIsNotForgiven>
  <eyen:PercentageOfSuccessfulRateOfTraditionalEyeDrops contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit14" decimals="2">0.50</eyen:PercentageOfSuccessfulRateOfTraditionalEyeDrops>
  <eyen:PercentageOfSuccessRateOfOptejet contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit14" decimals="2">0.90</eyen:PercentageOfSuccessRateOfOptejet>
  <eyen:PeriodConsideredForUsageOfLoanProceedsFromFundingDate contextRef="Duration_5_8_2020_To_5_8_2020_us-gaap_ShortTermDebtTypeAxis_eyen_PaycheckProtectionProgramLoanMember">P168D</eyen:PeriodConsideredForUsageOfLoanProceedsFromFundingDate>
  <eyen:PrepaidConferenceExpenses contextRef="As_Of_12_31_2019" unitRef="Unit12" decimals="0">10600</eyen:PrepaidConferenceExpenses>
  <eyen:PrepaidConferenceExpenses contextRef="As_Of_12_31_2020" unitRef="Unit12" decimals="0">29403</eyen:PrepaidConferenceExpenses>
  <eyen:PrepaidDirectorFeesCurrent contextRef="As_Of_12_31_2019" unitRef="Unit12" decimals="0">0</eyen:PrepaidDirectorFeesCurrent>
  <eyen:PrepaidDirectorFeesCurrent contextRef="As_Of_12_31_2020" unitRef="Unit12" decimals="0">68250</eyen:PrepaidDirectorFeesCurrent>
  <eyen:PrepaidExpensesAndOtherCurrentAssetsDisclosureTextBlock contextRef="Duration_1_1_2020_To_12_31_2020">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-weight:bold;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Note&amp;nbsp;3&amp;nbsp;&amp;#x2013; Prepaid Expenses and Other Current Assets&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;As of December&amp;nbsp;31, 2020 and 2019, prepaid expenses and other current assets consisted of the following:&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="5" valign="bottom" style="width:24.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;December&amp;nbsp;31,&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;2020&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;2019&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Payroll tax receivable&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 151,942&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 95,233&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Prepaid insurance expenses&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 110,094&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 33,923&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Prepaid research and development expenses&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 17,978&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Prepaid licenses and subscriptions&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 57,051&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Prepaid patent expenses&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 12,404&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Prepaid conference expenses&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 29,403&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 10,600&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Prepaid board of directors expenses&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 68,250&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Prepaid rent and security deposit&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 25,004&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 2,463&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Other&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 11,734&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 24,079&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Total prepaid expenses and other current assets&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 453,478&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 196,680&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
			&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</eyen:PrepaidExpensesAndOtherCurrentAssetsDisclosureTextBlock>
  <eyen:PrepaidLicensesAndSubscriptions contextRef="As_Of_12_31_2019" unitRef="Unit12" decimals="0">0</eyen:PrepaidLicensesAndSubscriptions>
  <eyen:PrepaidLicensesAndSubscriptions contextRef="As_Of_12_31_2020" unitRef="Unit12" decimals="0">57051</eyen:PrepaidLicensesAndSubscriptions>
  <eyen:PrepaidPatentExpense contextRef="As_Of_12_31_2019" unitRef="Unit12" decimals="0">12404</eyen:PrepaidPatentExpense>
  <eyen:PrepaidPatentExpense contextRef="As_Of_12_31_2020" unitRef="Unit12" decimals="0">0</eyen:PrepaidPatentExpense>
  <eyen:PrepaidRentAndSecurityDeposit contextRef="As_Of_12_31_2019" unitRef="Unit12" decimals="0">2463</eyen:PrepaidRentAndSecurityDeposit>
  <eyen:PrepaidRentAndSecurityDeposit contextRef="As_Of_12_31_2020" unitRef="Unit12" decimals="0">25004</eyen:PrepaidRentAndSecurityDeposit>
  <eyen:PrepaidResearchAndDevelopmentExpenses contextRef="As_Of_12_31_2019" unitRef="Unit12" decimals="0">17978</eyen:PrepaidResearchAndDevelopmentExpenses>
  <eyen:PrepaidResearchAndDevelopmentExpenses contextRef="As_Of_12_31_2020" unitRef="Unit12" decimals="0">0</eyen:PrepaidResearchAndDevelopmentExpenses>
  <eyen:ProceedsFromPaycheckProtectionProgramLoan contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit12" decimals="0">0</eyen:ProceedsFromPaycheckProtectionProgramLoan>
  <eyen:ProceedsFromPaycheckProtectionProgramLoan contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit12" decimals="0">463353</eyen:ProceedsFromPaycheckProtectionProgramLoan>
  <eyen:ProceedsOfStockIssuedDuringPeriodGross contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementClassOfStockAxis_eyen_CommonStockOneMember" unitRef="Unit12" decimals="0">14030001</eyen:ProceedsOfStockIssuedDuringPeriodGross>
  <eyen:ProceedsOfStockIssuedDuringPeriodGross contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_eyen_CommonStockOneMember" unitRef="Unit12" decimals="0">14030001</eyen:ProceedsOfStockIssuedDuringPeriodGross>
  <eyen:ProceedsOfStockIssuedDuringPeriodGross contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_eyen_CommonStockThreeMember" unitRef="Unit12" decimals="0">13800002</eyen:ProceedsOfStockIssuedDuringPeriodGross>
  <eyen:ProceedsOfStockIssuedDuringPeriodGross contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_eyen_CommonStockThreeMember" unitRef="Unit12" decimals="0">13800002</eyen:ProceedsOfStockIssuedDuringPeriodGross>
  <eyen:ProceedsOfStockIssuedDuringPeriodGross contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_eyen_CommonStockTwoMember" unitRef="Unit12" decimals="0">5984931</eyen:ProceedsOfStockIssuedDuringPeriodGross>
  <eyen:ProceedsOfStockIssuedDuringPeriodGross contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_eyen_CommonStockTwoMember" unitRef="Unit12" decimals="0">5984931</eyen:ProceedsOfStockIssuedDuringPeriodGross>
  <eyen:PurchaseOfInsurancePremiumFinancedByShortTermNotePayable contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit12" decimals="0">0</eyen:PurchaseOfInsurancePremiumFinancedByShortTermNotePayable>
  <eyen:PurchaseOfInsurancePremiumFinancedByShortTermNotePayable contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit12" decimals="0">-475216</eyen:PurchaseOfInsurancePremiumFinancedByShortTermNotePayable>
  <eyen:RemittanceOfEmployeeSPayrollTaxes contextRef="As_Of_1_2_2019" unitRef="Unit12" decimals="0">62193</eyen:RemittanceOfEmployeeSPayrollTaxes>
  <eyen:RoyaltyPercentage contextRef="Duration_1_1_2015_To_12_31_2015_us-gaap_RelatedPartyTransactionAxis_eyen_SenjuPharmaceuticalCoMember" unitRef="Unit14" decimals="2">0.05</eyen:RoyaltyPercentage>
  <eyen:RoyaltyRevenuePayments contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_TypeOfArrangementAxis_eyen_ArcticVisionLicenseAgreementMember" unitRef="Unit12" decimals="0">0</eyen:RoyaltyRevenuePayments>
  <eyen:RoyaltyRevenuePayments contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_TypeOfArrangementAxis_eyen_BauschLicenseAgreementMember" unitRef="Unit12" decimals="0">0</eyen:RoyaltyRevenuePayments>
  <eyen:ScheduleOfNotesPayableTableTextBlock contextRef="Duration_1_1_2020_To_12_31_2020">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;As of December 31, 2020 and 2019, notes payable consisted of the following:&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:41.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:06.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:05.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:06.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:41.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="8" valign="bottom" style="width:29.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;December&amp;nbsp;31,&amp;nbsp;2020&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="8" valign="bottom" style="width:25.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;December&amp;nbsp;31,&amp;nbsp;2019&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:41.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:07.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;Current&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:09.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;Non-Current&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:06.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;Current&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:09.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;Non-Current&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:06.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:41.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:07.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;Portion&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:09.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;Portion&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:08.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;Total&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:06.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;Portion&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:09.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;Portion&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:07.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;Total&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:41.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Paycheck Protection Program loan&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:06.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 97,539&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 365,814&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 463,353&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:05.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:06.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:41.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:06.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 97,539&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 365,814&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 463,353&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:05.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:06.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt 0pt 0pt 54pt;line-height:100%;text-indent: -54pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</eyen:ScheduleOfNotesPayableTableTextBlock>
  <eyen:ShareBasedCompensationArrangementByShareBasedPaymentAwardCashFeePaid contextRef="Duration_4_7_2020_To_4_7_2020_us-gaap_PlanNameAxis_eyen_OmnibusStockIncentivePlan2018Member" unitRef="Unit12" decimals="0">150000</eyen:ShareBasedCompensationArrangementByShareBasedPaymentAwardCashFeePaid>
  <eyen:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodOnCashlessBasis contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit1" decimals="0">236466</eyen:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodOnCashlessBasis>
  <eyen:SmallBusinessAdministrationEconomicInjuryDisasterGrant contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit12" decimals="0">10000</eyen:SmallBusinessAdministrationEconomicInjuryDisasterGrant>
  <eyen:StockIssuedDuringPeriodSharesNewIssuesThree id="Item-0001" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit1" decimals="0">5046763</eyen:StockIssuedDuringPeriodSharesNewIssuesThree>
  <eyen:StockIssuedDuringPeriodSharesNewIssuesThree id="Item-0011" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit1" decimals="0">3833334</eyen:StockIssuedDuringPeriodSharesNewIssuesThree>
  <eyen:StockIssuedDuringPeriodSharesNewIssuesTwo id="Item-0006" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit1" decimals="0">2675293</eyen:StockIssuedDuringPeriodSharesNewIssuesTwo>
  <eyen:StockIssuedDuringPeriodSharesWarrantsExercised contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit1" decimals="0">1332841</eyen:StockIssuedDuringPeriodSharesWarrantsExercised>
  <eyen:StockIssuedDuringPeriodValueNewIssuesThree id="Item-0005" contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit12" decimals="0">12958575</eyen:StockIssuedDuringPeriodValueNewIssuesThree>
  <eyen:StockIssuedDuringPeriodValueNewIssuesThree id="Item-0003" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="Unit12" decimals="0">12958070</eyen:StockIssuedDuringPeriodValueNewIssuesThree>
  <eyen:StockIssuedDuringPeriodValueNewIssuesThree id="Item-0002" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit12" decimals="0">505</eyen:StockIssuedDuringPeriodValueNewIssuesThree>
  <eyen:StockIssuedDuringPeriodValueNewIssuesThree id="Item-0004" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="Unit12" decimals="0">0</eyen:StockIssuedDuringPeriodValueNewIssuesThree>
  <eyen:StockIssuedDuringPeriodValueNewIssuesThree id="Item-0015" contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit12" decimals="0">12495708</eyen:StockIssuedDuringPeriodValueNewIssuesThree>
  <eyen:StockIssuedDuringPeriodValueNewIssuesThree id="Item-0013" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="Unit12" decimals="0">12495325</eyen:StockIssuedDuringPeriodValueNewIssuesThree>
  <eyen:StockIssuedDuringPeriodValueNewIssuesThree id="Item-0012" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit12" decimals="0">383</eyen:StockIssuedDuringPeriodValueNewIssuesThree>
  <eyen:StockIssuedDuringPeriodValueNewIssuesThree id="Item-0014" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="Unit12" decimals="0">0</eyen:StockIssuedDuringPeriodValueNewIssuesThree>
  <eyen:StockIssuedDuringPeriodValueNewIssuesTwo id="Item-0010" contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit12" decimals="0">5451742</eyen:StockIssuedDuringPeriodValueNewIssuesTwo>
  <eyen:StockIssuedDuringPeriodValueNewIssuesTwo id="Item-0008" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="Unit12" decimals="0">5451475</eyen:StockIssuedDuringPeriodValueNewIssuesTwo>
  <eyen:StockIssuedDuringPeriodValueNewIssuesTwo id="Item-0007" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit12" decimals="0">267</eyen:StockIssuedDuringPeriodValueNewIssuesTwo>
  <eyen:StockIssuedDuringPeriodValueNewIssuesTwo id="Item-0009" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="Unit12" decimals="0">0</eyen:StockIssuedDuringPeriodValueNewIssuesTwo>
  <eyen:StockIssuedDuringPeriodValueStockOptionsExercisedOnCashlessBasis contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit12" decimals="0">0</eyen:StockIssuedDuringPeriodValueStockOptionsExercisedOnCashlessBasis>
  <eyen:StockIssuedDuringPeriodValueStockOptionsExercisedOnCashlessBasis contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="Unit12" decimals="0">-24</eyen:StockIssuedDuringPeriodValueStockOptionsExercisedOnCashlessBasis>
  <eyen:StockIssuedDuringPeriodValueStockOptionsExercisedOnCashlessBasis contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit12" decimals="0">24</eyen:StockIssuedDuringPeriodValueStockOptionsExercisedOnCashlessBasis>
  <eyen:StockIssuedDuringPeriodValueStockOptionsExercisedOnCashlessBasis contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="Unit12" decimals="0">0</eyen:StockIssuedDuringPeriodValueStockOptionsExercisedOnCashlessBasis>
  <eyen:StockIssuedDuringPeriodValueWarrantsExercised contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit12" decimals="0">2820362</eyen:StockIssuedDuringPeriodValueWarrantsExercised>
  <eyen:StockIssuedDuringPeriodValueWarrantsExercised contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="Unit12" decimals="0">2820228</eyen:StockIssuedDuringPeriodValueWarrantsExercised>
  <eyen:StockIssuedDuringPeriodValueWarrantsExercised contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit12" decimals="0">134</eyen:StockIssuedDuringPeriodValueWarrantsExercised>
  <eyen:StockIssuedDuringPeriodValueWarrantsExercised contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="Unit12" decimals="0">0</eyen:StockIssuedDuringPeriodValueWarrantsExercised>
  <us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock contextRef="Duration_1_1_2020_To_12_31_2020">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-weight:bold;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Note&amp;nbsp;5&amp;nbsp;&amp;#x2013; Accrued Expenses and Other Current Liabilities&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;As of December&amp;nbsp;31, 2020 and 2019, accrued expenses and other current liabilities consisted of the following:&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:71.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:71.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="5" valign="bottom" style="width:26.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;December&amp;nbsp;31,&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:71.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:13.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;2020&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:11.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;2019&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:71.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Accrued research and development expenses&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 291,256&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 208,175&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:71.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Accrued consulting and professional services&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 235,355&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 97,396&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:71.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Credit card payable&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 50,002&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 56,979&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:71.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Leasehold improvements&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 42,500&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:71.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Accrued franchise tax&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 32,480&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 40,995&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:71.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Accrued travel and entertainment expenses&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 7,385&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:71.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Accrued licensing fees&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 804,447&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:71.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Accrued interest&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 3,068&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:71.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Accrued expense reimbursements&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 5,459&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:71.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Accrued shipping and packaging fees&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 56,998&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:71.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Other&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 1,627&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:71.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Total accrued expenses and other current liabilities&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 1,480,692&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 453,430&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
			&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock>
  <us-gaap:AccountsPayableCurrent contextRef="As_Of_12_31_2019" unitRef="Unit12" decimals="0">1541358</us-gaap:AccountsPayableCurrent>
  <us-gaap:AccountsPayableCurrent contextRef="As_Of_12_31_2020" unitRef="Unit12" decimals="0">1461665</us-gaap:AccountsPayableCurrent>
  <us-gaap:AccruedBonusesCurrent contextRef="As_Of_12_31_2019" unitRef="Unit12" decimals="0">897839</us-gaap:AccruedBonusesCurrent>
  <us-gaap:AccruedBonusesCurrent contextRef="As_Of_12_31_2020" unitRef="Unit12" decimals="0">938873</us-gaap:AccruedBonusesCurrent>
  <us-gaap:AccruedLiabilitiesAndOtherLiabilities contextRef="As_Of_12_31_2019" unitRef="Unit12" decimals="0">453430</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
  <us-gaap:AccruedLiabilitiesAndOtherLiabilities contextRef="As_Of_12_31_2020" unitRef="Unit12" decimals="0">1480692</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
  <us-gaap:AccruedSalariesCurrent contextRef="As_Of_12_31_2019" unitRef="Unit12" decimals="0">19034</us-gaap:AccruedSalariesCurrent>
  <us-gaap:AccruedSalariesCurrent contextRef="As_Of_12_31_2020" unitRef="Unit12" decimals="0">211799</us-gaap:AccruedSalariesCurrent>
  <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="As_Of_12_31_2019" unitRef="Unit12" decimals="0">81491</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
  <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="As_Of_12_31_2020" unitRef="Unit12" decimals="0">176906</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
  <us-gaap:AdditionalPaidInCapital contextRef="As_Of_12_31_2019" unitRef="Unit12" decimals="0">69409949</us-gaap:AdditionalPaidInCapital>
  <us-gaap:AdditionalPaidInCapital contextRef="As_Of_12_31_2020" unitRef="Unit12" decimals="0">92742306</us-gaap:AdditionalPaidInCapital>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit12" decimals="0">2511944</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="Unit12" decimals="0">2511944</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit12" decimals="0">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit12" decimals="0">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="Unit12" decimals="0">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit12" decimals="0">2483172</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="Unit12" decimals="0">2483172</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit12" decimals="0">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit12" decimals="0">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="Unit12" decimals="0">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_eyen_CommonStockOneMember" unitRef="Unit12" decimals="0">1071426</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_eyen_CommonStockThreeMember" unitRef="Unit12" decimals="0">1304294</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_eyen_CommonStockTwoMember" unitRef="Unit12" decimals="0">533189</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit1" decimals="0">2297793</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_OptionIndexedToIssuersEquityTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="Unit1" decimals="0">2237438</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="Unit1" decimals="0">60355</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember" unitRef="Unit1" decimals="0">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit1" decimals="0">5543101</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_OptionIndexedToIssuersEquityTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="Unit1" decimals="0">3427705</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="Unit1" decimals="0">104083</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember" unitRef="Unit1" decimals="0">2011313</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:Assets contextRef="As_Of_12_31_2019" unitRef="Unit12" decimals="0">14697619</us-gaap:Assets>
  <us-gaap:Assets contextRef="As_Of_12_31_2020" unitRef="Unit12" decimals="0">33906760</us-gaap:Assets>
  <us-gaap:AssetsCurrent contextRef="As_Of_12_31_2019" unitRef="Unit12" decimals="0">14349281</us-gaap:AssetsCurrent>
  <us-gaap:AssetsCurrent contextRef="As_Of_12_31_2020" unitRef="Unit12" decimals="0">33391345</us-gaap:AssetsCurrent>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="As_Of_12_31_2019" unitRef="Unit12" decimals="0">14152601</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="As_Of_12_31_2020" unitRef="Unit12" decimals="0">28371828</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="Duration_1_1_2020_To_12_31_2020">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times New Roman,Times,serif;text-decoration:underline;"&gt;Cash and Cash Equivalents&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents in the financial statements.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The Company has cash deposits and U.S. treasury bills in financial institutions which, at times, may be in excess of Federal Deposit Insurance Corporation (&amp;#x201C;FDIC&amp;#x201D;) insurance limits. The Company has not experienced losses in such accounts and periodically evaluates the creditworthiness of its financial institutions. As of December&amp;nbsp;31, 2020 and 2019, the Company had cash and cash equivalent balances in excess of FDIC insurance limits of $28,121,828 and $13,902,601, respectively.&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="As_Of_12_31_2018" unitRef="Unit12" decimals="0">19728200</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="As_Of_12_31_2019" unitRef="Unit12" decimals="0">14152601</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="As_Of_12_31_2019" unitRef="Unit12" decimals="0">14152601</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="As_Of_12_31_2020" unitRef="Unit12" decimals="0">28371828</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit12" decimals="0">-5575599</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit12" decimals="0">14219227</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
  <us-gaap:CashUninsuredAmount contextRef="As_Of_12_31_2019" unitRef="Unit12" decimals="0">13902601</us-gaap:CashUninsuredAmount>
  <us-gaap:CashUninsuredAmount contextRef="As_Of_12_31_2020" unitRef="Unit12" decimals="0">28121828</us-gaap:CashUninsuredAmount>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="As_Of_3_24_2020_us-gaap_StatementEquityComponentsAxis_eyen_ClassBWarrantsMember" unitRef="Unit13" decimals="3">2.724</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="As_Of_3_24_2020_us-gaap_StatementEquityComponentsAxis_eyen_ClassWarrantsMember" unitRef="Unit13" decimals="2">2.27</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="As_Of_12_31_2020_us-gaap_ClassOfWarrantOrRightAxis_eyen_WarrantsAtExercisePriceFourMember" unitRef="Unit13" decimals="4">2.7240</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="As_Of_12_31_2020_us-gaap_ClassOfWarrantOrRightAxis_eyen_WarrantsAtExercisePriceOneMember" unitRef="Unit13" decimals="4">2.0580</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="As_Of_12_31_2020_us-gaap_ClassOfWarrantOrRightAxis_eyen_WarrantsAtExercisePriceOneMember" unitRef="Unit13" decimals="3">2.058</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="As_Of_12_31_2020_us-gaap_ClassOfWarrantOrRightAxis_eyen_WarrantsAtExercisePriceThreeMember" unitRef="Unit13" decimals="4">2.4696</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="As_Of_12_31_2020_us-gaap_ClassOfWarrantOrRightAxis_eyen_WarrantsAtExercisePriceThreeMember" unitRef="Unit13" decimals="4">2.4696</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="As_Of_12_31_2020_us-gaap_ClassOfWarrantOrRightAxis_eyen_WarrantsAtExercisePriceTwoMember" unitRef="Unit13" decimals="4">2.2700</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="As_Of_3_26_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" unitRef="Unit13" decimals="2">2.06</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="As_Of_3_26_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" unitRef="Unit13" decimals="2">2.47</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="As_Of_12_31_2020" unitRef="Unit1" decimals="0">1332841</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="As_Of_3_26_2021_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" unitRef="Unit1" decimals="0">644992</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="As_Of_12_31_2020" unitRef="Unit1" decimals="0">2011313</us-gaap:ClassOfWarrantOrRightOutstanding>
  <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="As_Of_12_31_2020" unitRef="Unit1" decimals="0">2011313</us-gaap:ClassOfWarrantOrRightOutstanding>
  <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="As_Of_12_31_2020_us-gaap_ClassOfWarrantOrRightAxis_eyen_WarrantsAtExercisePriceFourMember" unitRef="Unit1" decimals="0">216380</us-gaap:ClassOfWarrantOrRightOutstanding>
  <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="As_Of_12_31_2020_us-gaap_ClassOfWarrantOrRightAxis_eyen_WarrantsAtExercisePriceOneMember" unitRef="Unit1" decimals="0">48549</us-gaap:ClassOfWarrantOrRightOutstanding>
  <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="As_Of_12_31_2020_us-gaap_ClassOfWarrantOrRightAxis_eyen_WarrantsAtExercisePriceThreeMember" unitRef="Unit1" decimals="0">1602128</us-gaap:ClassOfWarrantOrRightOutstanding>
  <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="As_Of_12_31_2020_us-gaap_ClassOfWarrantOrRightAxis_eyen_WarrantsAtExercisePriceTwoMember" unitRef="Unit1" decimals="0">144256</us-gaap:ClassOfWarrantOrRightOutstanding>
  <us-gaap:CommitmentsAndContingencies xsi:nil="true" contextRef="As_Of_12_31_2019" unitRef="Unit12" />
  <us-gaap:CommitmentsAndContingencies xsi:nil="true" contextRef="As_Of_12_31_2020" unitRef="Unit12" />
  <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="Duration_1_1_2020_To_12_31_2020">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-weight:bold;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Note&amp;nbsp;9&amp;nbsp;&amp;#x2013; Commitments and Contingencies&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-decoration:underline;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Operating Leases&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;On August&amp;nbsp;8, 2018, the Company entered into a lease agreement to lease approximately 3,800 square feet of office space in New York, NY. The&amp;nbsp;monthly base rent ranges from $19,633 to $22,486 per&amp;nbsp;month over the term of the lease. The lease expires on September&amp;nbsp;30, 2023. The security deposit is approximately $119,000.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;On July 17, 2020, the Company entered into a lease agreement to lease approximately 3,000 square feet of office space in Redwood City, California (the &amp;#x201C;Gross Industrial Lease&amp;#x201D;). The monthly base rent was for $7,500 per month over the term of the lease through August 31, 2021 with a security deposit of $7,500. On December 1, 2020, the Company agreed to amend the terms of the Gross Industrial Lease for a base rent that ranges from $7,500 to $7,957 per month over the term of the lease. The amended Gross Industrial Lease expires on August 31, 2023. &amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Concurrent with the amendment to the Gross Industrial Lease on December 1, 2020, the Company entered into a lease agreement to lease approximately 1,500 square feet of additional office space in Redwood City, California. The monthly base rent ranges from $3,000 to $3,183 per month over the term of the lease. The lease expires on August 31, 2023. The security deposit is $3,000.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Future minimum payments under this operating lease agreement are as follows as:&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:74.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:21.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:74.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;For the Year Ending&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:21.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:74.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;December&amp;nbsp;31,&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:23.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;Minimum&amp;nbsp;Lease&amp;nbsp;Payments&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:74.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;2021&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:21.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 378,486&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:74.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;2022&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:21.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 389,212&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:74.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;2023&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:21.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 285,700&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:74.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:21.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 1,053,398&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;See Note&amp;nbsp;10&amp;nbsp;&amp;#x2013; Related Party Transactions&amp;nbsp;&amp;#x2013; Lease Agreements for details of a lease agreement with a related party.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-decoration:underline;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Employment Agreements&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;text-decoration:none;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;text-decoration:none;"&gt;Effective February 15, 2019, the Company entered into at-will executive employment agreements with Tsontcho Ianchulev, its Chief Executive Officer and Chief Medical Officer, John Gandolfo, its Chief Financial Officer, Jennifer Clasby, now its Vice President of Regulatory and Clinical, Luke Clauson, its Vice President, Research and Development and Manufacturing ("VP of R&amp;amp;D"), and Michael Rowe, now its Chief Commercial Officer. Dr. Clasby and Mr. Rowe&amp;#x2019;s employment agreements were amended on February 1, 2021 to provide for their new roles at the Company.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;text-decoration:none;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;text-decoration:none;"&gt;Each of the employment agreements provides that if the executive's employment is terminated by the Company without "Cause" or the executive suffers an "Involuntarily Termination" (each as defined in the employment agreements), provided that the executive has signed a full release of all claims, the executive will be entitled to receive: (i) severance pay equal to three months of his or her then-current base salary (currently estimated at approximately $419,000 in the aggregate), and (ii) a reimbursement for health insurance benefits under COBRA for the executive and his or her spouse and dependents for a period of three months or until the executive becomes eligible for comparable insurance benefits from another employer, whichever is earlier.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;text-decoration:none;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;text-decoration:none;"&gt;Each of the employment agreements also provides that if, within 12 months following any "Corporate Transaction" (as defined in the employment agreements) of the Company, the executive's employment is terminated by the Company without Cause or the executive suffers an Involuntary Termination, provided that the executive has signed a full release of all claims, the executive will be entitled to receive, in lieu of what is described in the above paragraph: (i) severance pay equal to 12 months of his or her then-current base salary (currently estimated at approximately $1,677,000 in the aggregate), and (ii) a reimbursement for health insurance benefits under COBRA for the executive and his or her spouse and dependents for a period of 12 months or until the executive becomes eligible for comparable insurance benefits from another employer, whichever is earlier.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-decoration:underline;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Litigations, Claims and Assessments&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;In the normal course of business, the Company may be involved in legal proceedings, claims and assessments arising in the ordinary course of business. The Company records legal costs associated with loss contingencies as incurred and accrues for all probable and estimable settlements.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;text-decoration:underline;"&gt;Arctic Vision License Agreement &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;On August 10, 2020, the Company entered into the &amp;#x201C;Arctic Vision License Agreement&amp;#x201D; pursuant to which Arctic Vision may develop and commercialize MicroPine for the treatment of progressive myopia and MicroLine for the treatment of presbyopia in Greater China (mainland China, Hong Kong, Macau and Taiwan) and South Korea.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Under the terms of the Arctic Vision License Agreement, the Company received a non-refundable, upfront payment of $4.0 million, before any payments to Senju. The Company has recorded this payment as a deferred license fee until the payment is earned. The Company will consider payment earned once certain trial data has been fully submitted to Arctic Vision, permitting Arctic Vision to obtain regulatory approval with the National Medical Products Administration. The upfront payment had not been earned as of December 31, 2020. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;In addition, the Company may receive up to a total of $41.75 million in additional payments, based on various development and regulatory milestones, including the initiation of clinical research and approvals in Greater China and South Korea, and development costs. During December 2020, the Company satisfied a performance obligation which resulted in the Company recognizing $2.0 million of milestone revenues, pursuant to the Arctic Vision License Agreement.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Arctic Vision also will purchase its supply of MicroPine and MicroLine from the Company or, for such products not supplied by the Company, pay the Company a mid-single digit percentage royalty on net sales of such products, subject to certain adjustments. No royalty payments were earned during the year ended December 31, 2020. The Company will pay a mid-double digit percentage of such payments, royalties, or net proceeds of such supply to Senju pursuant to the Senju License Agreement. See Note 2 &amp;#x2013; Summary of Significant Accounting Policies and Note 10 &amp;#x2013; Related Party Transactions for additional details. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;text-decoration:underline;"&gt;Bausch License Agreement&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;On October 9, 2020, the Company entered into the &amp;#x201C;Bausch License Agreement&amp;#x201D; pursuant to which Bausch Health may develop and commercialize the Bausch Licensed Product in the Licensed Territory. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;In connection with the Bausch License Agreement, Bausch Health paid the Company a non-refundable, upfront payment of $10.0 million. The Company has recorded this payment as a deferred license fee until the payment is earned. The Company will consider payment earned once certain trial data has been fully submitted to Bausch Health and certain administrative functions are transferred to Bausch Health, permitting Bausch Health to assume supervisory oversight of the ongoing MicroPine study (the CHAPERONE study). The upfront payment had not been earned as of December 31, 2020. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Bausch Health could also pay the Company up to an aggregate of approximately $35.0 million in additional payments, depending on the achievement of certain regulatory and launch-based milestones. No milestone payments were earned during the year ended December 31, 2020.Under the terms of the Bausch License Agreement, on a country-to-country basis and Bausch Licensed Product-by- Bausch Licensed Product basis, Bausch Health will pay the Company royalties on a tiered basis (ranging from mid-single digit to mid-teen percentages) on gross profits from the sales of the Bausch Licensed Product in the Licensed Territory, subject to certain adjustments in the event of generic entry, negative gross profits or patent expiration, for a period of the later to occur of the 10th anniversary of the first commercial sale of a Bausch Licensed Product in such country in the Licensed Territory or the expiration of the last valid patent claim for a Bausch Licensed Product in such country in the Licensed Territory. No royalty payments were earned during the year ended December 31, 2020. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Bausch Health may terminate the Bausch License Agreement, with respect to the Bausch Licensed Product to either country in the Licensed Territory, at any time for convenience upon 90 days&amp;#x2019; written notice. Both parties have the right to terminate the Bausch License Agreement in the event of (i) an uncured material breach after a 60-day period or (ii) a bankruptcy event. See Note 2 &amp;#x2013; Summary of Significant Accounting Policies for additional details.&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
  <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="As_Of_4_7_2020_us-gaap_PlanNameAxis_eyen_OmnibusStockIncentivePlan2018Member" unitRef="Unit1" decimals="0">2950000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
  <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="As_Of_12_31_2020_us-gaap_PlanNameAxis_eyen_OmnibusStockIncentivePlan2018Member" unitRef="Unit1" decimals="0">518186</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="As_Of_12_31_2019" unitRef="Unit13" decimals="4">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="As_Of_12_31_2020" unitRef="Unit13" decimals="4">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="As_Of_12_31_2020" unitRef="Unit13" decimals="4">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockSharesAuthorized contextRef="As_Of_12_31_2019" unitRef="Unit1" decimals="0">90000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesAuthorized contextRef="As_Of_12_31_2020" unitRef="Unit1" decimals="0">90000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesAuthorized contextRef="As_Of_12_31_2020" unitRef="Unit1" decimals="0">90000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesIssued contextRef="As_Of_12_31_2019" unitRef="Unit1" decimals="0">17100726</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesIssued contextRef="As_Of_12_31_2020" unitRef="Unit1" decimals="0">24978585</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesOutstanding contextRef="As_Of_12_31_2019" unitRef="Unit1" decimals="0">17100726</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:CommonStockSharesOutstanding contextRef="As_Of_12_31_2020" unitRef="Unit1" decimals="0">24978585</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:CommonStockValue contextRef="As_Of_12_31_2019" unitRef="Unit12" decimals="0">1710</us-gaap:CommonStockValue>
  <us-gaap:CommonStockValue contextRef="As_Of_12_31_2020" unitRef="Unit12" decimals="0">2498</us-gaap:CommonStockValue>
  <us-gaap:CompensationAndEmployeeBenefitPlansTextBlock contextRef="Duration_1_1_2020_To_12_31_2020">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-weight:bold;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Note&amp;nbsp;12&amp;nbsp;&amp;#x2013; Employee Benefit Plans&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;text-decoration:underline;"&gt;401(k) Plan&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;In April 2019, the Company adopted the Eyenovia 401(k) Plan (the &amp;#x201C;Plan&amp;#x201D;), which went into effect in May 2019. All Company employees are able to participate in the Plan, subject to eligibility requirements as outlined in the Plan documents. Under the terms of the Plan, eligible employees are able to defer a percentage of their pay every pay period up to annual limitations set by Congress and the Internal Revenue Service under Section 401(k) of the Internal Revenue Code. For 2019, the Company&amp;#x2019;s Board of Directors has approved a matching contribution equal to 100% of elective deferrals up to 4% of eligible earnings with the matching contribution subject to certain vesting requirements as outlined in the Plan documents. For the years ended December 31, 2020 and 2019, the Company recorded expense of $138,785 and $71,285 associated with its matching contributions, respectively.&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:CompensationAndEmployeeBenefitPlansTextBlock>
  <us-gaap:CompensationRelatedCostsGeneralTextBlock contextRef="Duration_1_1_2020_To_12_31_2020">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-weight:bold;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Note&amp;nbsp;6&amp;nbsp;&amp;#x2013; Accrued Compensation&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;As of December 31, 2020 and 2019, accrued compensation consisted of the following:&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:71.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:71.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="5" valign="bottom" style="width:26.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;December&amp;nbsp;31,&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:71.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:13.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;2020&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:11.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;2019&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:71.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Accrued bonus expenses&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 938,873&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 897,839&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:71.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Accrued payroll expenses&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 211,799&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 19,034&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:71.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Total accrued compensation&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 1,150,672&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 916,873&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
			&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:CompensationRelatedCostsGeneralTextBlock>
  <us-gaap:ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_TypeOfArrangementAxis_eyen_ArcticVisionLicenseAgreementMember" unitRef="Unit12" decimals="-5">2000000</us-gaap:ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized>
  <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="As_Of_12_31_2020" unitRef="Unit12" decimals="0">14000000</us-gaap:ContractWithCustomerLiabilityCurrent>
  <us-gaap:CostOfRevenue contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit12" decimals="0">800000</us-gaap:CostOfRevenue>
  <us-gaap:DebtInstrumentAnnualPrincipalPayment contextRef="As_Of_2_24_2020_us-gaap_ShortTermDebtTypeAxis_us-gaap_NotesPayableOtherPayablesMember" unitRef="Unit12" decimals="0">475216</us-gaap:DebtInstrumentAnnualPrincipalPayment>
  <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="As_Of_2_24_2020_us-gaap_ShortTermDebtTypeAxis_us-gaap_NotesPayableOtherPayablesMember" unitRef="Unit14" decimals="4">0.0429</us-gaap:DebtInstrumentInterestRateStatedPercentage>
  <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="As_Of_5_8_2020_us-gaap_ShortTermDebtTypeAxis_eyen_PaycheckProtectionProgramLoanMember" unitRef="Unit14" decimals="4">0.0100</us-gaap:DebtInstrumentInterestRateStatedPercentage>
  <us-gaap:DebtInstrumentPeriodicPayment contextRef="Duration_2_24_2020_To_2_24_2020_us-gaap_ShortTermDebtTypeAxis_us-gaap_NotesPayableOtherPayablesMember" unitRef="Unit12" decimals="0">53750</us-gaap:DebtInstrumentPeriodicPayment>
  <us-gaap:DebtInstrumentPeriodicPayment contextRef="Duration_5_8_2020_To_5_8_2020_us-gaap_ShortTermDebtTypeAxis_eyen_PaycheckProtectionProgramLoanMember" unitRef="Unit12" decimals="0">19508</us-gaap:DebtInstrumentPeriodicPayment>
  <us-gaap:DebtInstrumentTerm contextRef="Duration_5_8_2020_To_5_8_2020_srt_RangeAxis_srt_MaximumMember_us-gaap_ShortTermDebtTypeAxis_eyen_PaycheckProtectionProgramLoanMember">P5Y</us-gaap:DebtInstrumentTerm>
  <us-gaap:DebtInstrumentTerm contextRef="Duration_5_8_2020_To_5_8_2020_srt_RangeAxis_srt_MinimumMember_us-gaap_ShortTermDebtTypeAxis_eyen_PaycheckProtectionProgramLoanMember">P2Y</us-gaap:DebtInstrumentTerm>
  <us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock contextRef="Duration_1_1_2020_To_12_31_2020">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;As of December&amp;nbsp;31, 2020 and 2019, prepaid expenses and other current assets consisted of the following:&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="5" valign="bottom" style="width:24.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;December&amp;nbsp;31,&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;2020&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;2019&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Payroll tax receivable&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 151,942&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 95,233&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Prepaid insurance expenses&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 110,094&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 33,923&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Prepaid research and development expenses&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 17,978&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Prepaid licenses and subscriptions&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 57,051&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Prepaid patent expenses&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 12,404&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Prepaid conference expenses&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 29,403&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 10,600&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Prepaid board of directors expenses&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 68,250&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Prepaid rent and security deposit&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 25,004&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 2,463&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Other&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 11,734&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 24,079&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Total prepaid expenses and other current assets&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 453,478&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 196,680&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt 0pt 8pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock>
  <us-gaap:DeferredCostsCurrent contextRef="As_Of_12_31_2020" unitRef="Unit12" decimals="0">1600000</us-gaap:DeferredCostsCurrent>
  <us-gaap:DeferredFederalIncomeTaxExpenseBenefit contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit12" decimals="0">-4999920</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
  <us-gaap:DeferredFederalIncomeTaxExpenseBenefit contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit12" decimals="0">-3797052</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
  <us-gaap:DeferredRentCreditCurrent contextRef="As_Of_12_31_2020" unitRef="Unit12" decimals="0">7809</us-gaap:DeferredRentCreditCurrent>
  <us-gaap:DeferredRentCreditNoncurrent contextRef="As_Of_12_31_2019" unitRef="Unit12" decimals="0">45351</us-gaap:DeferredRentCreditNoncurrent>
  <us-gaap:DeferredRentCreditNoncurrent contextRef="As_Of_12_31_2020" unitRef="Unit12" decimals="0">38684</us-gaap:DeferredRentCreditNoncurrent>
  <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit12" decimals="0">68762</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
  <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit12" decimals="0">-434082</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
  <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets contextRef="As_Of_12_31_2019" unitRef="Unit12" decimals="0">328773</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
  <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets contextRef="As_Of_12_31_2020" unitRef="Unit12" decimals="0">409705</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
  <us-gaap:DeferredTaxAssetsGross contextRef="As_Of_12_31_2019" unitRef="Unit12" decimals="0">12336408</us-gaap:DeferredTaxAssetsGross>
  <us-gaap:DeferredTaxAssetsGross contextRef="As_Of_12_31_2020" unitRef="Unit12" decimals="0">16630062</us-gaap:DeferredTaxAssetsGross>
  <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment contextRef="As_Of_12_31_2019" unitRef="Unit12" decimals="0">1584753</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
  <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment contextRef="As_Of_12_31_2020" unitRef="Unit12" decimals="0">1861938</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
  <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="As_Of_12_31_2019" unitRef="Unit12" decimals="0">9479512</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
  <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="As_Of_12_31_2020" unitRef="Unit12" decimals="0">12972865</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
  <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration contextRef="As_Of_12_31_2020" unitRef="Unit12" decimals="0">49200000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration>
  <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration contextRef="As_Of_12_31_2020" unitRef="Unit12" decimals="0">10800000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration>
  <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="As_Of_12_31_2019" unitRef="Unit12" decimals="0">943370</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
  <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="As_Of_12_31_2020" unitRef="Unit12" decimals="0">1385554</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
  <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="As_Of_12_31_2019" unitRef="Unit12" decimals="0">12322378</us-gaap:DeferredTaxAssetsValuationAllowance>
  <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="As_Of_12_31_2020" unitRef="Unit12" decimals="0">16553512</us-gaap:DeferredTaxAssetsValuationAllowance>
  <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch contextRef="Duration_4_1_2019_To_4_30_2019" unitRef="Unit14" decimals="2">1.00</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch>
  <us-gaap:DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage contextRef="Duration_4_1_2019_To_4_30_2019" unitRef="Unit14" decimals="2">0.04</us-gaap:DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage>
  <us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit12" decimals="0">71285</us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount>
  <us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit12" decimals="0">138785</us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount>
  <us-gaap:DepreciationDepletionAndAmortization contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit12" decimals="0">15343</us-gaap:DepreciationDepletionAndAmortization>
  <us-gaap:DepreciationDepletionAndAmortization contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_FairValueByAssetClassAxis_us-gaap_PropertyPlantAndEquipmentMember" unitRef="Unit12" decimals="0">15343</us-gaap:DepreciationDepletionAndAmortization>
  <us-gaap:DepreciationDepletionAndAmortization contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit12" decimals="0">95415</us-gaap:DepreciationDepletionAndAmortization>
  <us-gaap:DepreciationDepletionAndAmortization contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_FairValueByAssetClassAxis_us-gaap_PropertyPlantAndEquipmentMember" unitRef="Unit12" decimals="0">95415</us-gaap:DepreciationDepletionAndAmortization>
  <us-gaap:DueToRelatedPartiesCurrentAndNoncurrent contextRef="As_Of_12_31_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_RelatedPartyTransactionAxis_eyen_VicePresidentOfResearchAndDevelopmentMember" unitRef="Unit12" decimals="0">89052</us-gaap:DueToRelatedPartiesCurrentAndNoncurrent>
  <us-gaap:DueToRelatedPartiesCurrentAndNoncurrent contextRef="As_Of_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_RelatedPartyTransactionAxis_eyen_VicePresidentOfResearchAndDevelopmentMember" unitRef="Unit12" decimals="0">0</us-gaap:DueToRelatedPartiesCurrentAndNoncurrent>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit13" decimals="2">-1.47</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit13" decimals="2">-0.94</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerSharePolicyTextBlock contextRef="Duration_1_1_2020_To_12_31_2020">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-decoration:underline;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Net Loss Per Common Share&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Basic net loss per common share is computed by dividing net loss by the weighted average number of common shares outstanding during the period. Diluted loss per share reflects the potential dilution that could occur if securities or other instruments to issue common stock were exercised or converted into common stock.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The following securities are excluded from the calculation of weighted average dilutive common shares because their inclusion would have been anti-dilutive:&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:72.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:72.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="3" valign="bottom" style="width:25.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;December&amp;nbsp;31,&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:72.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;2020&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;2019&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:72.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Warrants&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 2,011,313&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:72.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Options&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 3,427,705&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 2,237,438&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:72.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Restricted stock units&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 104,083&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 60,355&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:72.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Total potentially dilutive shares&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 5,543,101&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 2,297,793&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
  <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit14" decimals="3">0.233</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
  <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit14" decimals="3">-0.214</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
  <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit14" decimals="3">-0.002</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
  <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit14" decimals="3">0.005</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
  <us-gaap:EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit14" decimals="3">0.006</us-gaap:EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes>
  <us-gaap:EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit14" decimals="3">-0.006</us-gaap:EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes>
  <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit14" decimals="3">0.001</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
  <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit14" decimals="3">-0.001</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
  <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit14" decimals="3">0.030</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
  <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit14" decimals="3">-0.014</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
  <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="As_Of_12_31_2019" unitRef="Unit12" decimals="0">916873</us-gaap:EmployeeRelatedLiabilitiesCurrent>
  <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="As_Of_12_31_2020" unitRef="Unit12" decimals="0">1150672</us-gaap:EmployeeRelatedLiabilitiesCurrent>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="Duration_1_1_2020_To_12_31_2020">P2Y</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions contextRef="As_Of_12_31_2020" unitRef="Unit12" decimals="0">3720221</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
  <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="Duration_1_1_2020_To_12_31_2020">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-decoration:underline;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Fair Value of Financial Instruments&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The Company measures the fair value of financial assets and liabilities based on Accounting Standards Codification (&amp;#x201C;ASC&amp;#x201D;) Topic 820 &amp;#x201C;Fair Value Measurements and Disclosures&amp;#x201D; (&amp;#x201C;ASC 820&amp;#x201D;), which defines fair value, establishes a framework for measuring fair value, and expands disclosures about fair value measurements.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;ASC 820 defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 describes three levels of inputs that may be used to measure fair value:&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Level 1&amp;nbsp;&amp;#x2014; quoted prices in active markets for identical assets or liabilities;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Level 2&amp;nbsp;&amp;#x2014; quoted prices for similar assets and liabilities in active markets or inputs that are observable; and&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Level 3&amp;nbsp;&amp;#x2014; inputs that are unobservable (for example, cash flow modeling inputs based on assumptions).&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The carrying amounts of the Company&amp;#x2019;s financial instruments, such as cash and cash equivalents, accounts payable, accrued expenses and other current liabilities approximate fair values due to the short-term nature of these instruments.&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
  <us-gaap:GeneralAndAdministrativeExpense contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit12" decimals="0">7206095</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:GeneralAndAdministrativeExpense contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_FairValueByAssetClassAxis_us-gaap_PropertyPlantAndEquipmentMember" unitRef="Unit12" decimals="0">5581</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:GeneralAndAdministrativeExpense contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit12" decimals="0">7725408</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:GeneralAndAdministrativeExpense contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_FairValueByAssetClassAxis_us-gaap_PropertyPlantAndEquipmentMember" unitRef="Unit12" decimals="0">27820</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:GrossProfit contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit12" decimals="0">1200000</us-gaap:GrossProfit>
  <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="Duration_1_1_2020_To_12_31_2020">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-decoration:underline;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Impairment of Long-lived Assets&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The Company reviews for the impairment of long-lived assets whenever events or changes in circumstances indicate that the carrying amount of an asset might not be recoverable. An impairment would be recognized when estimated future cash flows expected to result from the use of the asset and its eventual disposition are less than its carrying amount. The Company did not record any impairment losses during the&amp;nbsp;years ended December&amp;nbsp;31, 2020 and 2019.&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
  <us-gaap:IncomeTaxDisclosureTextBlock contextRef="Duration_1_1_2020_To_12_31_2020">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-weight:bold;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Note&amp;nbsp;8&amp;nbsp;&amp;#x2013; Income Taxes&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The provision for income taxes consists of the following expenses (benefits):&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:74.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:74.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="5" valign="bottom" style="width:24.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;For&amp;nbsp;The&amp;nbsp;Years&amp;nbsp;Ended&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:74.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="5" valign="bottom" style="width:24.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;December&amp;nbsp;31,&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:74.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:11.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;2020&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:11.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;2019&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:74.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Deferred tax provision (benefit):&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:74.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt 6pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Federal&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; (3,797,052)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; (4,999,920)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:74.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt 6pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;State and local&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; (434,082)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 68,762&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:74.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; (4,231,134)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; (4,931,158)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:74.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Change in valuation allowance&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 4,231,134&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 4,931,158&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:74.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Provision for income taxes&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The provision for income taxes differs from the United States Federal statutory rate as follows:&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:74.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:74.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="3" valign="bottom" style="width:21.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;For&amp;nbsp;The&amp;nbsp;Years&amp;nbsp;Ended&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:74.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="3" valign="bottom" style="width:21.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;December&amp;nbsp;31,&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:74.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;2020&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;2019&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:74.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Federal statutory rate&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; (21.0)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;%&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 21.0&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:74.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;State tax rate, net of federal benefit&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; (0.1)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;%&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 0.1&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:74.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Permanent differences&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 0.5&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;%&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; (0.2)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:74.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Research &amp;amp; development tax credits&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; (1.4)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;%&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 3.0&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:74.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Prior period adjustments and other&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 0.6&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;%&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; (0.6)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:74.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Change in valuation allowance&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 21.4&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;%&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; (23.3)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:74.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Effective income tax rate&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;%&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Deferred tax assets consist of the following:&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:72.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:72.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="5" valign="bottom" style="width:26.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;For&amp;nbsp;The&amp;nbsp;Years&amp;nbsp;Ended&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:72.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="5" valign="bottom" style="width:26.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;December&amp;nbsp;31,&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:72.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;2020&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;2019&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:72.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Net operating loss carryforwards&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 12,972,865&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 9,479,512&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:72.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Stock-based compensation&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 1,385,554&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 943,370&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:72.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Intangible assets&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 409,705&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 328,773&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:72.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Research and development tax credits&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 1,861,938&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 1,584,753&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:72.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Deferred tax assets, gross&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 16,630,062&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 12,336,408&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:72.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Property and equipment&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; (76,550)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; (14,030)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:72.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Deferred tax assets, net before allowance&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 16,553,512&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 12,322,378&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:72.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Valuation allowance&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; (16,553,512)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; (12,322,378)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:72.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Deferred tax assets, net&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;As of December 31, 2020, the Company had approximately $60,000,000 of domestic federal net operating loss carryforwards ("NOLs") that may be available to offset future Federal taxable income. Approximately $10,800,000 of those NOLs will expire during the years ranging from 2034 to 2037. The remaining NOLs of approximately $49,200,000 have no expiration dates. Internal Revenue Code Section 382 limits the utilization of approximately $35,000,000 of those NOLs to approximately $918,000 on an annual basis as a result of ownership changes that occurred through July 15, 2019. As of December 31, 2020, the Company had (a) minimal state net operating loss carryforwards that may be available to offset future state taxable income as it conducted most of its operations in Nevada which does not tax corporate income; and (b) approximately $5,500,000 of New York City net operating loss carryforwards.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The Company has assessed the likelihood that deferred tax assets will be realized in accordance with the provisions of ASC 740 &amp;#x201C;&lt;/font&gt;&lt;font style="display:inline;font-style:italic;"&gt;Income Taxes&lt;/font&gt;&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;font style="display:inline;font-style:italic;"&gt;Accounting&lt;/font&gt;&lt;font style="display:inline;"&gt;&amp;#x201D; ("ASC 740"). ASC 740 requires that such a review considers all available positive and negative evidence, including the scheduled reversal of deferred tax liabilities, projected future taxable income, and tax planning strategies. ASC 740 requires that a valuation allowance be established when it is &amp;#x201C;more likely than not&amp;#x201D; that all, or a portion of, deferred tax assets will not be realized. After the performance of such reviews as of December 31, 2020 and 2019, management believes that uncertainty exists with respect to future realization of its deferred tax assets and has, therefore, established a full valuation allowance as of those dates.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Management has evaluated and concluded that there were no material uncertain tax positions requiring recognition in the Company&amp;#x2019;s consolidated financial statements as of December 31, 2020 and 2019. The Company does not expect any significant changes in its unrecognized tax benefits within twelve months of the reporting date.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;No tax audits were commenced or were in process during the years ended December 31, 2020 and 2019. No tax related interest or penalties were incurred during the years ended December 31, 2020 and 2019. The Company's Federal, State and Local income tax returns beginning with the year ended December 31, 2017 remain subject to examination.&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
  <us-gaap:IncomeTaxPolicyTextBlock contextRef="Duration_1_1_2020_To_12_31_2020">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-decoration:underline;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Income Taxes&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The Company is subject to Federal, New York State and City, and State of California income taxes and files tax returns in those jurisdictions.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of items that have been included or excluded in the consolidated financial statements or tax returns.&amp;nbsp;&amp;nbsp;Deferred tax assets and liabilities are determined on the basis of the difference between the tax basis of assets and liabilities and their respective financial reporting amounts (&amp;#x201C;temporary differences&amp;#x201D;) at enacted tax rates in effect for the years in which such temporary differences are expected to reverse. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The Company utilizes a recognition threshold and measurement process for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 8pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
			&lt;font style="display:inline;"&gt;The Company&amp;#x2019;s policy is to classify assessments, if any, for tax-related interest as interest expense and penalties as general and administrative expenses in the consolidated statements of operations.&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
  <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit12" decimals="0">31834</us-gaap:IncreaseDecreaseInAccountsPayable>
  <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit12" decimals="0">-79693</us-gaap:IncreaseDecreaseInAccountsPayable>
  <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit12" decimals="0">4769</us-gaap:IncreaseDecreaseInAccruedLiabilities>
  <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit12" decimals="0">233799</us-gaap:IncreaseDecreaseInAccruedLiabilities>
  <us-gaap:IncreaseDecreaseInContractWithCustomerLiability contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit12" decimals="0">0</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
  <us-gaap:IncreaseDecreaseInContractWithCustomerLiability contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit12" decimals="0">14000000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
  <us-gaap:IncreaseDecreaseInDeferredCharges contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit12" decimals="0">0</us-gaap:IncreaseDecreaseInDeferredCharges>
  <us-gaap:IncreaseDecreaseInDeferredCharges contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit12" decimals="0">1600000</us-gaap:IncreaseDecreaseInDeferredCharges>
  <us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit12" decimals="0">-266283</us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities>
  <us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit12" decimals="0">1000612</us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit12" decimals="0">63924</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit12" decimals="0">-218418</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:IncreaseDecreaseInSecurityDeposits contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit12" decimals="0">0</us-gaap:IncreaseDecreaseInSecurityDeposits>
  <us-gaap:IncreaseDecreaseInSecurityDeposits contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit12" decimals="0">-1235</us-gaap:IncreaseDecreaseInSecurityDeposits>
  <us-gaap:InterestExpense contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit12" decimals="0">17042</us-gaap:InterestExpense>
  <us-gaap:InterestExpenseDebt contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit12" decimals="0">0</us-gaap:InterestExpenseDebt>
  <us-gaap:InterestExpenseDebt contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit12" decimals="0">17042</us-gaap:InterestExpenseDebt>
  <us-gaap:InterestIncomeExpenseNonoperatingNet contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit12" decimals="0">151786</us-gaap:InterestIncomeExpenseNonoperatingNet>
  <us-gaap:InterestIncomeExpenseNonoperatingNet contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit12" decimals="0">26400</us-gaap:InterestIncomeExpenseNonoperatingNet>
  <us-gaap:InterestPaidCapitalized contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit12" decimals="0">0</us-gaap:InterestPaidCapitalized>
  <us-gaap:InterestPaidCapitalized contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit12" decimals="0">13974</us-gaap:InterestPaidCapitalized>
  <us-gaap:InterestPayableCurrent contextRef="As_Of_12_31_2019" unitRef="Unit12" decimals="0">0</us-gaap:InterestPayableCurrent>
  <us-gaap:InterestPayableCurrent contextRef="As_Of_12_31_2020" unitRef="Unit12" decimals="0">3068</us-gaap:InterestPayableCurrent>
  <us-gaap:LeaseAndRentalExpense contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_RelatedPartyTransactionAxis_eyen_VicePresidentOfResearchAndDevelopmentMember" unitRef="Unit12" decimals="0">48144</us-gaap:LeaseAndRentalExpense>
  <us-gaap:LeaseAndRentalExpense contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_RelatedPartyTransactionAxis_eyen_VicePresidentOfResearchAndDevelopmentMember" unitRef="Unit12" decimals="0">59724</us-gaap:LeaseAndRentalExpense>
  <us-gaap:LeaseExpirationDate1 contextRef="Duration_8_1_2018_To_8_8_2018">2023-09-30</us-gaap:LeaseExpirationDate1>
  <us-gaap:LeaseExpirationDate1 contextRef="Duration_12_1_2020_To_12_1_2020">2023-08-31</us-gaap:LeaseExpirationDate1>
  <us-gaap:LeaseExpirationDate1 contextRef="Duration_12_1_2020_To_12_1_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_eyen_AdditionalOfficeSpaceMember">2023-08-31</us-gaap:LeaseExpirationDate1>
  <us-gaap:LeaseholdImprovementsGross contextRef="As_Of_12_31_2020_us-gaap_RelatedPartyTransactionAxis_eyen_VicePresidentOfResearchAndDevelopmentMember" unitRef="Unit12" decimals="0">82500</us-gaap:LeaseholdImprovementsGross>
  <us-gaap:Liabilities contextRef="As_Of_12_31_2019" unitRef="Unit12" decimals="0">2957012</us-gaap:Liabilities>
  <us-gaap:Liabilities contextRef="As_Of_12_31_2020" unitRef="Unit12" decimals="0">18602875</us-gaap:Liabilities>
  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="As_Of_12_31_2019" unitRef="Unit12" decimals="0">14697619</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="As_Of_12_31_2020" unitRef="Unit12" decimals="0">33906760</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:LiabilitiesCurrent contextRef="As_Of_12_31_2019" unitRef="Unit12" decimals="0">2911661</us-gaap:LiabilitiesCurrent>
  <us-gaap:LiabilitiesCurrent contextRef="As_Of_12_31_2020" unitRef="Unit12" decimals="0">18198377</us-gaap:LiabilitiesCurrent>
  <us-gaap:LongTermNotesPayable contextRef="As_Of_12_31_2019" unitRef="Unit12" decimals="0">0</us-gaap:LongTermNotesPayable>
  <us-gaap:LongTermNotesPayable contextRef="As_Of_12_31_2019_us-gaap_DebtInstrumentAxis_eyen_PaycheckProtectionProgramLoanMember" unitRef="Unit12" decimals="0">0</us-gaap:LongTermNotesPayable>
  <us-gaap:LongTermNotesPayable contextRef="As_Of_12_31_2020" unitRef="Unit12" decimals="0">365814</us-gaap:LongTermNotesPayable>
  <us-gaap:LongTermNotesPayable contextRef="As_Of_12_31_2020" unitRef="Unit12" decimals="0">365814</us-gaap:LongTermNotesPayable>
  <us-gaap:LongTermNotesPayable contextRef="As_Of_12_31_2020_us-gaap_DebtInstrumentAxis_eyen_PaycheckProtectionProgramLoanMember" unitRef="Unit12" decimals="0">365814</us-gaap:LongTermNotesPayable>
  <us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners contextRef="As_Of_12_31_2015_srt_OwnershipAxis_eyen_LicenseAgreementMember" unitRef="Unit14" decimals="2">0.05</us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit12" decimals="0">13510352</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit12" decimals="0">20864760</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit12" decimals="0">-166643</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit12" decimals="0">-261257</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit12" decimals="0">-18919308</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit12" decimals="0">-6384276</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:NetIncomeLoss contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit12" decimals="0">-21156758</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit12" decimals="0">-21156758</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit12" decimals="0">-21156758</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="Unit12" decimals="0">0</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit12" decimals="0">0</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit12" decimals="0">0</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="Unit12" decimals="0">-21156758</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit12" decimals="0">-19769867</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit12" decimals="0">-19769867</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit12" decimals="0">-19769867</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="Unit12" decimals="0">0</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit12" decimals="0">0</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit12" decimals="0">0</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="Unit12" decimals="0">-19769867</us-gaap:NetIncomeLoss>
  <us-gaap:NetRentableArea contextRef="As_Of_9_15_2016_us-gaap_RelatedPartyTransactionAxis_eyen_VicePresidentOfResearchAndDevelopmentMember" unitRef="Unit15" decimals="0">953</us-gaap:NetRentableArea>
  <us-gaap:NetRentableArea contextRef="As_Of_8_8_2018" unitRef="Unit15" decimals="0">3800</us-gaap:NetRentableArea>
  <us-gaap:NetRentableArea contextRef="As_Of_7_17_2020" unitRef="Unit15" decimals="0">3000</us-gaap:NetRentableArea>
  <us-gaap:NetRentableArea contextRef="As_Of_12_1_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_eyen_AdditionalOfficeSpaceMember" unitRef="Unit15" decimals="0">1500</us-gaap:NetRentableArea>
  <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="Duration_1_1_2020_To_12_31_2020">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-decoration:underline;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Recently Adopted Accounting Pronouncements&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;In July 2017, the FASB issued Accounting Standards Update (&amp;#x201C;ASU&amp;#x201D;) 2017-11 &amp;#x201C;Earnings Per Share (Topic 260) and Derivatives and Hedging (Topic 815) - Accounting for Certain Financial Instruments with Down Round Features&amp;#x201D; (&amp;#x201C;ASU 2017-11&amp;#x201D;). Equity-linked instruments, such as warrants and convertible instruments may contain down round features that result in the strike price being reduced on the basis of the pricing of future equity offerings. Under ASU 2017-11, a down round feature will no longer require a freestanding equity-linked instrument (or embedded conversion option) to be classified as a liability that is remeasured at fair value through the income statement (i.e. marked-to-market). However, other features of the equity-linked instrument (or embedded conversion option) must still be evaluated to determine whether liability or equity classification is appropriate. Equity classified instruments are not marked-to-market. For earnings per share ("EPS") reporting, the ASU requires companies to recognize the effect of the down round feature only when it is triggered by treating it as a dividend and as a reduction of income available to common shareholders in basic EPS. The amendments in this ASU are effective for all entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. This standard, which the Company adopted on January 1, 2020, did not have a material impact on the Company&amp;#x2019;s financial position, results of operations, or cash flows.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;In March 2020, the FASB issued ASU 2020-03 &amp;#x201C;Codification Improvements to Financial Instruments&amp;#x201D; (&amp;#x201C;ASU 2020-03&amp;#x201D;). ASU 2020-03 improves and clarifies various financial instruments topics. ASU 2020-03 includes seven different issues that describe the areas of improvement and the related amendments to GAAP, intended to make the standards easier to understand and apply by eliminating inconsistencies and providing clarifications. The Company adopted ASU 2020-03 upon issuance, which did not have a material impact on the Company&amp;#x2019;s financial position, results of operations or cash flow.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-decoration:underline;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Recently Issued Accounting Pronouncements&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;In February&amp;nbsp;2016, the FASB issued ASU 2016&amp;#8209;02 &amp;#x201C;Leases (Topic 842)&amp;#x201D; (&amp;#x201C;ASU 2016&amp;#8209;02&amp;#x201D;). ASU 2016&amp;#8209;02 requires that a lessee recognize the assets and liabilities that arise from operating leases. A lessee should recognize in the statement of financial position a liability to make lease payments (the lease liability) and a right-of-use asset representing its right to use the underlying asset for the lease term. For leases with a term of 12&amp;nbsp;months or less, a lessee is permitted to make an accounting policy election by class of underlying asset not to recognize lease assets and lease liabilities. In transition, lessees and lessors are required to recognize and measure leases at the beginning of the earliest period presented using a modified retrospective approach. ASU 2016-02, as amended, is now effective for fiscal&amp;nbsp;years beginning after December&amp;nbsp;15, 2021, and interim periods within fiscal years beginning after December 15, 2022. The FASB issued ASU 2019-01 &amp;#x201C;Leases (Topic 842) Codification Improvements&amp;#x201D; in March 2019 and ASU 2018-10 &amp;#x201C;Codification Improvements to Topic 842, Leases&amp;#x201D; and ASU 2018-11 &amp;#x201C;Leases (Topic 842) Targeted Improvements&amp;#x201D; in July 2018, and ASU 2018-20 &amp;#x201C;Leases (Topic 842) - Narrow Scope Improvements for Lessors&amp;#x201D; in December 2018. ASU 2019-01, ASU 2018-10 and ASU 2018-20 provide certain amendments that affect narrow aspects of the guidance issued in ASU 2016-02. ASU 2018-11 allows all entities adopting ASU 2016-02 to choose an additional (and optional) transition method of adoption, under which an entity initially applies the new leases standard at the adoption date and recognizes a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption. The Company is currently evaluating ASU 2016-02 and its impact on its financial position, results of operations, and cash flows. The Company intends to adopt the ASU effective January 1, 2021 with no material impact.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;In August 2018, the FASB issued ASU No. 2018-13 &amp;#x201C;Fair Value Measurement (Topic 820): Disclosure Framework&amp;#x2014;Changes to the Disclosure Requirements for Fair Value Measurement&amp;#x201D; (&amp;#x201C;ASU 2018-13&amp;#x201D;). The amendments in ASU 2018-13 modify the disclosure requirements on fair value measurements based on the concepts in the FASB Concepts Statement, including the consideration of costs and benefits. The amendments on changes in unrealized gains and losses, the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements, and the narrative description of measurement uncertainty should be applied prospectively for only the most recent interim or annual period presented in the initial fiscal year of adoption. All other amendments should be applied retrospectively to all periods presented upon their effective date. The amendments are effective for fiscal years beginning after December 15, 2020. Early adoption is permitted, including adoption in an interim period. The Company is currently evaluating ASU 2018-13 and its impact on its financial position, results of operations and cash flows.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;In December 2019, the FASB issued ASU 2019-12, &amp;#x201C;Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes,&amp;#x201D; which is intended to simplify various aspects related to accounting for income taxes. ASU 2019-12 removes certain exceptions to the general principles in Topic 740 and also clarifies and amends existing guidance to improve consistent application. ASU 2019-12 is effective for fiscal years beginning after December 15, 2021. The Company is currently evaluating ASU 2019-12 and its impact financial position, results of operations, and cash flows.&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
  <us-gaap:NotesPayable contextRef="As_Of_12_31_2019" unitRef="Unit12" decimals="0">0</us-gaap:NotesPayable>
  <us-gaap:NotesPayable contextRef="As_Of_12_31_2019_us-gaap_DebtInstrumentAxis_eyen_PaycheckProtectionProgramLoanMember" unitRef="Unit12" decimals="0">0</us-gaap:NotesPayable>
  <us-gaap:NotesPayable contextRef="As_Of_12_31_2020" unitRef="Unit12" decimals="0">463353</us-gaap:NotesPayable>
  <us-gaap:NotesPayable contextRef="As_Of_12_31_2020_us-gaap_DebtInstrumentAxis_eyen_PaycheckProtectionProgramLoanMember" unitRef="Unit12" decimals="0">463353</us-gaap:NotesPayable>
  <us-gaap:NotesPayableCurrent contextRef="As_Of_12_31_2019" unitRef="Unit12" decimals="0">0</us-gaap:NotesPayableCurrent>
  <us-gaap:NotesPayableCurrent contextRef="As_Of_12_31_2019_us-gaap_DebtInstrumentAxis_eyen_PaycheckProtectionProgramLoanMember" unitRef="Unit12" decimals="0">0</us-gaap:NotesPayableCurrent>
  <us-gaap:NotesPayableCurrent contextRef="As_Of_12_31_2020" unitRef="Unit12" decimals="0">97539</us-gaap:NotesPayableCurrent>
  <us-gaap:NotesPayableCurrent contextRef="As_Of_12_31_2020_us-gaap_DebtInstrumentAxis_eyen_PaycheckProtectionProgramLoanMember" unitRef="Unit12" decimals="0">97539</us-gaap:NotesPayableCurrent>
  <us-gaap:OfficersCompensation contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_RelatedPartyTransactionAxis_eyen_VicePresidentOfResearchAndDevelopmentMember" unitRef="Unit12" decimals="0">186160</us-gaap:OfficersCompensation>
  <us-gaap:OfficersCompensation contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_RelatedPartyTransactionAxis_eyen_VicePresidentOfResearchAndDevelopmentMember" unitRef="Unit12" decimals="0">239460</us-gaap:OfficersCompensation>
  <us-gaap:OperatingExpenses contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit12" decimals="0">21308544</us-gaap:OperatingExpenses>
  <us-gaap:OperatingExpenses contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit12" decimals="0">20989225</us-gaap:OperatingExpenses>
  <us-gaap:OperatingIncomeLoss contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit12" decimals="0">-21308544</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingIncomeLoss contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit12" decimals="0">-19789225</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDue contextRef="As_Of_12_31_2020" unitRef="Unit12" decimals="0">1053398</us-gaap:OperatingLeasesFutureMinimumPaymentsDue>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent contextRef="As_Of_12_31_2020" unitRef="Unit12" decimals="0">378486</us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears contextRef="As_Of_12_31_2020" unitRef="Unit12" decimals="0">285700</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears contextRef="As_Of_12_31_2020" unitRef="Unit12" decimals="0">389212</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears>
  <us-gaap:OperatingLossCarryforwards contextRef="As_Of_12_31_2020" unitRef="Unit12" decimals="0">60000000</us-gaap:OperatingLossCarryforwards>
  <us-gaap:OperatingLossCarryforwards contextRef="As_Of_12_31_2020_srt_StatementGeographicalAxis_stpr_NY" unitRef="Unit12" decimals="0">5500000</us-gaap:OperatingLossCarryforwards>
  <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="Duration_1_1_2020_To_12_31_2020">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt 0pt 12pt;text-align:left;line-height:100%;font-family:Times New Roman,Times,serif;font-weight:bold;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Note&amp;nbsp;1&amp;nbsp;&amp;#x2013; Business Organization and Nature of Operations&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Eyenovia,&amp;nbsp;Inc. (&amp;#x201C;Eyenovia&amp;#x201D; or the &amp;#x201C;Company&amp;#x201D;) was organized as a corporation under the laws of the State of Florida on March&amp;nbsp;12, 2014 under the name, PGP Holdings V,&amp;nbsp;Inc. On May&amp;nbsp;5, 2014, PGP Holdings V,&amp;nbsp;Inc. changed its name to Eyenovia,&amp;nbsp;Inc. On October&amp;nbsp;6, 2014, Eyenovia,&amp;nbsp;Inc. reincorporated in the State of Delaware by merging into Eyenovia,&amp;nbsp;Inc., a Delaware corporation.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Eyenovia. Inc. (&amp;#x201C;Eyenovia&amp;#x201D; or the &amp;#x201C;Company&amp;#x201D;) is a clinical stage ophthalmic company developing a pipeline of advanced therapeutics based on its propriety array print (MAP&lt;/font&gt;&lt;font style="display:inline;font-size:5pt;top:-4pt;position:relative;line-height:100%"&gt;TM&lt;/font&gt;&lt;font style="display:inline;"&gt;) platform technology. Eyenovia aims to achieve clinical microdosing of next-generation formulations of novel and existing ophthalmic pharmaceutical agents using its high-precision targeted ocular delivery system, branded the Opejet&lt;/font&gt;&lt;font style="display:inline;font-size:5pt;top:-4pt;position:relative;line-height:100%"&gt;&amp;#xAE;&lt;/font&gt;&lt;font style="display:inline;"&gt;, which has the potential to replace conventional eye dropper delivery and improve safety, tolerability, patient compliance and topical delivery success for ophthalmic eye treatments. In the clinic, the Optejet has demonstrated the ability to horizontally deliver ophthalmic medication with a success rate significantly higher than that of traditional eye drops (~ 90% vs. ~ 50%). Using its proprietary delivery technology, Eyenovia is developing the next generation of smart ophthalmic therapies which target new indications or new combinations where there are currently no comparable drug therapies approved by the U.S. Food and Drug Administration (the &amp;#x201C;FDA&amp;#x201D;). Eyenovia&amp;#x2019;s microdose therapeutics follow the FDA-designated pharmaceutical registration and regulatory process. Its products are classified by the FDA as drugs, and not medical devices or drug-device combination products. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;text-decoration:underline;"&gt;Risks and Uncertainties&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 8pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-size:10pt;"&gt;Due to the COVID-19 pandemic, the company initially experienced delays in trial enrollment &lt;/font&gt;&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-size:10pt;"&gt;and initiation of its Phase III registration trial of its MicroPine drug candidate (the CHAPERONE study) &lt;/font&gt;&lt;font style="display:inline;font-size:10pt;"&gt;as a result of reduced clinical trial activities and operations at trial sites. However, the company has since been able to resume enrollment in that study.&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
  <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="As_Of_12_31_2019" unitRef="Unit12" decimals="0">0</us-gaap:OtherAccruedLiabilitiesCurrent>
  <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="As_Of_12_31_2020" unitRef="Unit12" decimals="0">1627</us-gaap:OtherAccruedLiabilitiesCurrent>
  <us-gaap:OtherAssets contextRef="As_Of_12_31_2019" unitRef="Unit12" decimals="0">24079</us-gaap:OtherAssets>
  <us-gaap:OtherAssets contextRef="As_Of_12_31_2020" unitRef="Unit12" decimals="0">11734</us-gaap:OtherAssets>
  <us-gaap:PaymentsOfDebtIssuanceCosts contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementClassOfStockAxis_eyen_CommonStockOneMember" unitRef="Unit12" decimals="0">815052</us-gaap:PaymentsOfDebtIssuanceCosts>
  <us-gaap:PaymentsOfDebtIssuanceCosts contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_eyen_CommonStockThreeMember" unitRef="Unit12" decimals="0">1066000</us-gaap:PaymentsOfDebtIssuanceCosts>
  <us-gaap:PaymentsOfDebtIssuanceCosts contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_eyen_CommonStockTwoMember" unitRef="Unit12" decimals="0">415795</us-gaap:PaymentsOfDebtIssuanceCosts>
  <us-gaap:PaymentsOfStockIssuanceCosts contextRef="Duration_8_21_2020_To_8_21_2020_us-gaap_SubsidiarySaleOfStockAxis_eyen_UnderwrittenPublicOfferingMember" unitRef="Unit12" decimals="-5">1200000</us-gaap:PaymentsOfStockIssuanceCosts>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit12" decimals="0">166643</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit12" decimals="0">261257</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="As_Of_12_31_2019" unitRef="Unit13" decimals="4">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="As_Of_12_31_2020" unitRef="Unit13" decimals="4">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="As_Of_12_31_2020" unitRef="Unit13" decimals="4">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockSharesAuthorized contextRef="As_Of_12_31_2019" unitRef="Unit1" decimals="0">6000000</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockSharesAuthorized contextRef="As_Of_12_31_2020" unitRef="Unit1" decimals="0">6000000</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockSharesAuthorized contextRef="As_Of_12_31_2020" unitRef="Unit1" decimals="0">6000000</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockSharesIssued contextRef="As_Of_12_31_2019" unitRef="Unit1" decimals="0">0</us-gaap:PreferredStockSharesIssued>
  <us-gaap:PreferredStockSharesIssued contextRef="As_Of_12_31_2020" unitRef="Unit1" decimals="0">0</us-gaap:PreferredStockSharesIssued>
  <us-gaap:PreferredStockSharesOutstanding contextRef="As_Of_12_31_2019" unitRef="Unit1" decimals="0">0</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:PreferredStockSharesOutstanding contextRef="As_Of_12_31_2020" unitRef="Unit1" decimals="0">0</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:PreferredStockValue contextRef="As_Of_12_31_2019" unitRef="Unit12" decimals="0">0</us-gaap:PreferredStockValue>
  <us-gaap:PreferredStockValue contextRef="As_Of_12_31_2020" unitRef="Unit12" decimals="0">0</us-gaap:PreferredStockValue>
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="As_Of_12_31_2019" unitRef="Unit12" decimals="0">196680</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="As_Of_12_31_2019" unitRef="Unit12" decimals="0">196680</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="As_Of_12_31_2020" unitRef="Unit12" decimals="0">453478</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="As_Of_12_31_2020" unitRef="Unit12" decimals="0">453478</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <us-gaap:PrepaidInsurance contextRef="As_Of_12_31_2019" unitRef="Unit12" decimals="0">33923</us-gaap:PrepaidInsurance>
  <us-gaap:PrepaidInsurance contextRef="As_Of_12_31_2020" unitRef="Unit12" decimals="0">110094</us-gaap:PrepaidInsurance>
  <us-gaap:ProceedsFromIssuanceInitialPublicOffering id="Item-0017" contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit12" decimals="0">13214949</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
  <us-gaap:ProceedsFromIssuanceInitialPublicOffering id="Item-0016" contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit12" decimals="0">0</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
  <us-gaap:ProceedsFromIssuanceOfCommonStock id="Item-0021" contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit12" decimals="0">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:ProceedsFromIssuanceOfCommonStock id="Item-0020" contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit12" decimals="0">12734002</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="Duration_8_21_2020_To_8_21_2020_us-gaap_SubsidiarySaleOfStockAxis_eyen_UnderwrittenPublicOfferingMember" unitRef="Unit12" decimals="-5">12500000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:ProceedsFromIssuanceOfPrivatePlacement id="Item-0019" contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit12" decimals="0">0</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
  <us-gaap:ProceedsFromIssuanceOfPrivatePlacement id="Item-0018" contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit12" decimals="0">5569136</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
  <us-gaap:ProceedsFromLongTermLinesOfCredit contextRef="Duration_5_8_2020_To_5_8_2020_us-gaap_ShortTermDebtTypeAxis_eyen_PaycheckProtectionProgramLoanMember" unitRef="Unit12" decimals="0">463353</us-gaap:ProceedsFromLongTermLinesOfCredit>
  <us-gaap:ProceedsFromStockOptionsExercised contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit12" decimals="0">551777</us-gaap:ProceedsFromStockOptionsExercised>
  <us-gaap:ProceedsFromStockOptionsExercised contextRef="Duration_1_2_2019_To_1_2_2019" unitRef="Unit12" decimals="0">483888</us-gaap:ProceedsFromStockOptionsExercised>
  <us-gaap:ProceedsFromStockOptionsExercised contextRef="Duration_5_14_2019_To_5_14_2019" unitRef="Unit12" decimals="0">67889</us-gaap:ProceedsFromStockOptionsExercised>
  <us-gaap:ProceedsFromStockOptionsExercised contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit12" decimals="0">82161</us-gaap:ProceedsFromStockOptionsExercised>
  <us-gaap:ProceedsFromStockOptionsExercised contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit12" decimals="0">82161</us-gaap:ProceedsFromStockOptionsExercised>
  <us-gaap:ProceedsFromWarrantExercises contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit12" decimals="0">0</us-gaap:ProceedsFromWarrantExercises>
  <us-gaap:ProceedsFromWarrantExercises contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit12" decimals="0">2820362</us-gaap:ProceedsFromWarrantExercises>
  <us-gaap:ProceedsFromWarrantExercises contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit12" decimals="-5">2800000</us-gaap:ProceedsFromWarrantExercises>
  <us-gaap:ProceedsFromWarrantExercises contextRef="Duration_3_26_2021_To_3_26_2021_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" unitRef="Unit12" decimals="0">1530989</us-gaap:ProceedsFromWarrantExercises>
  <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="Duration_1_1_2020_To_12_31_2020">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-weight:bold;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Note&amp;nbsp;4&amp;nbsp;&amp;#x2013; Property and Equipment, Net&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;As of December&amp;nbsp;31, 2020 and 2019, property and equipment consisted of the following:&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:72.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:72.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="5" valign="bottom" style="width:25.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;December&amp;nbsp;31,&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:72.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;2020&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:11.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;2019&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:72.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Equipment&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 435,521&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 229,529&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:72.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Leasehold improvements&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 137,765&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 82,500&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:72.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 573,286&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 312,029&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:72.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Less: accumulated depreciation and amortization&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; (176,906)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; (81,491)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:72.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Property and equipment, net&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 396,380&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 230,538&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Depreciation and amortization expense was $95,415 and $15,343 for the&amp;nbsp;years ended December&amp;nbsp;31, 2020 and 2019, respectively, of which $67,595 and $9,762 was included within research and development expenses and $27,820 and $5,581&amp;nbsp;was included in general and administrative expenses in the statements of operations for the&amp;nbsp;years ended December&amp;nbsp;31, 2020 and 2019, respectively.&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="As_Of_12_31_2019" unitRef="Unit12" decimals="0">312029</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="As_Of_12_31_2019_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember" unitRef="Unit12" decimals="0">229529</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="As_Of_12_31_2019_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember" unitRef="Unit12" decimals="0">82500</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="As_Of_12_31_2020" unitRef="Unit12" decimals="0">573286</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember" unitRef="Unit12" decimals="0">435521</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember" unitRef="Unit12" decimals="0">137765</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentNet contextRef="As_Of_12_31_2019" unitRef="Unit12" decimals="0">230538</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:PropertyPlantAndEquipmentNet contextRef="As_Of_12_31_2019" unitRef="Unit12" decimals="0">230538</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:PropertyPlantAndEquipmentNet contextRef="As_Of_12_31_2020" unitRef="Unit12" decimals="0">396380</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:PropertyPlantAndEquipmentNet contextRef="As_Of_12_31_2020" unitRef="Unit12" decimals="0">396380</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="Duration_1_1_2020_To_12_31_2020">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-decoration:underline;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Property and Equipment, Net&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Property and equipment are stated at cost, net of accumulated depreciation, which is recorded commencing at the in-service date using the straight-line method at rates sufficient to charge the cost of depreciable assets to operations over their estimated useful lives, which range from 1 to 10&amp;nbsp;years. Leasehold improvements are amortized over the lesser of (a)&amp;nbsp;the useful life of the asset; or (b)&amp;nbsp;the remaining lease term. Maintenance and repairs are charged to operations as incurred. The Company capitalizes costs attributable to the betterment of property and equipment when such betterment extends the useful life of the assets.&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
  <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="Duration_1_1_2020_To_12_31_2020">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;As of December&amp;nbsp;31, 2020 and 2019, property and equipment consisted of the following:&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:72.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:72.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="5" valign="bottom" style="width:25.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;December&amp;nbsp;31,&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:72.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;2020&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:11.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;2019&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:72.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Equipment&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 435,521&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 229,529&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:72.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Leasehold improvements&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 137,765&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 82,500&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:72.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 573,286&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 312,029&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:72.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Less: accumulated depreciation and amortization&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; (176,906)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; (81,491)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:72.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Property and equipment, net&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 396,380&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 230,538&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt 0pt 8pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
  <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="Duration_1_1_2020_To_12_31_2020_srt_RangeAxis_srt_MaximumMember">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
  <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="Duration_1_1_2020_To_12_31_2020_srt_RangeAxis_srt_MinimumMember">P1Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
  <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_us-gaap_RelatedPartyTransactionAxis_eyen_ConsultingAgreementMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_eyen_CuraPartnersMember" unitRef="Unit12" decimals="0">213521</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
  <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_us-gaap_RelatedPartyTransactionAxis_eyen_ConsultingAgreementMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_eyen_CuraPartnersMember" unitRef="Unit12" decimals="0">76536</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
  <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="Duration_1_1_2020_To_12_31_2020">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-weight:bold;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Note&amp;nbsp;10&amp;nbsp;&amp;#x2013; Related Party Transactions&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-decoration:underline;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Consulting Agreements&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;A company in which a member of the Company&amp;#x2019;s Board of Directors is part owner is a party to a consulting agreement with the Company dated July 6, 2017 that provides for the payment of $9,567 per month, and $250 per hour for any additional work, for advisory services performed by such director. The consulting agreement was terminated on September 1, 2020. The director remains on the Board. The Company incurred expenses of $76,536 and $213,521 for the years ended December 31, 2020 and 2019, respectively, related to the agreement which was included within general and administrative expenses on the statements of operations.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-decoration:underline;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Lease Agreements&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The Company&amp;#x2019;s Vice President of Research and Development and Manufacturing (&amp;#x201C;VP of R&amp;amp;D&amp;#x201D;) owns a company that entered into a lease agreement with the Company on September&amp;nbsp;15, 2016 to lease 953 square feet of space located in Reno, Nevada with respect to its research and development activities. The initial&amp;nbsp;monthly base rent was $3,895 per&amp;nbsp;month over the term of the lease and the security deposit was $3,895. On September&amp;nbsp;15, 2020, the Company amended the lease agreement to extend it until September&amp;nbsp;14, 2022 and increase the&amp;nbsp;monthly base rent and security deposit to $5,404. The Company made $82,500 of leasehold improvements related to this lease which are included on the balance sheet.&amp;nbsp;The Company&amp;#x2019;s rent expense for this space is recorded in Research and Development on the income statement and amounted to $59,724 and $48,144 for the&amp;nbsp;years ended December&amp;nbsp;31, 2020 and 2019, respectively.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-decoration:underline;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Research and Development Activities&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The VP of R&amp;amp;D is the sole owner and President of a company that performs contract engineering services for the Company. During the years ended December 31, 2020 and 2019, the Company recognized research and development expense of $1,024,430 and $851,746, respectively, related to services provided by such vendor. The Company had a liability of $0 and $89,052 to the vendor as of December 31, 2020 and 2019, respectively. The Company recognized $239,460 and $186,160 of compensation expense related to the VP of R&amp;amp;D during the years ended December 31, 2020 and 2019, respectively.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;text-align:left;line-height:100%;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;text-decoration:underline;"&gt;Senju License Agreement&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-align:left;line-height:100%;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;During 2015, the Company entered into an Exclusive License Agreement with Senju whereby the Company agreed to grant to Senju an exclusive, royalty-bearing license for its microdose product candidates for Asia to sublicense, develop, make, have made, manufacture, use, import, market, sell, and otherwise distribute the microdose product candidates. In consideration for the license, Senju agreed to pay to Eyenovia five percent (5%) royalties on sales (net of certain manufacturing costs) for the term of the Exclusive License Agreement, subject to certain adjustments upon the loss of patent coverage for the term of the license agreement. The agreement will continue in full force and effect, on a country-by-country basis, until the latest to occur of: (i) the tenth (10th) anniversary of the first commercial sale of such a product candidate in a country; or (ii) the expiration of the licensed patents in a country. As of the date of this filing, there had been no commercial sales of a such a product in Asia, so no royalties had been earned. Senju is owned by the family of a former member of the Company&amp;#x2019;s Board of Directors and, together, they beneficially own greater than 5% of the Company&amp;#x2019;s common stock.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;On April 8, 2020, Eyenovia entered into an amendment (the &amp;#x201C;License Amendment&amp;#x201D;) to the Exclusive License Agreement. Pursuant to the License Amendment, the Company can license to any third party the right to research, develop, commercialize, manufacture or use certain products identified below (the &amp;#x201C;Senju Licensed Products&amp;#x201D;) previously licensed to Senju in China (including the People&amp;#x2019;s Republic of China, Hong Kong, Macao, and Taiwan) and South Korea (the &amp;#x201C;Territory&amp;#x201D;) if such a license is executed by the Company by April 8, 2021. The Senju Licensed Products are those using piezo-print technology in a microdose dispenser with (i) atropine sulfate as its sole active ingredient to treat myopia in humans and (ii) pilocarpine as its sole active ingredient to treat presbyopia in humans.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Pursuant to the License Amendment, the Company must pay Senju (a) close to a mid-double digit percentage of revenue on any lump-sum payments the Company receives from the third party, revenue (net of costs) obtained by the Company from contract research and/or development of the Senju Licensed Product in the Territory, and revenue (net of costs) obtained by the Company from contract manufacture for the device of the Senju Licensed Product in the Territory, the aggregate of which must be at least a high seven figure dollar amount minimum payment to Senju; and (b) a lower-double digit percentage of any sales royalty revenue the Company receives from the third party. Unless a third-party license is executed by the Company prior to April 8, 2021 (in which case, subject to early termination the License Amendment shall remain in effect for the duration of such license), the License Amendment terminates on April 8, 2021, but may be terminated earlier by Senju upon the Company&amp;#x2019;s material breach of the License Amendment, subject to a 60-day cure period.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The Exclusive License Agreement was further amended in a Letter Agreement by and between the Company and Senju on August 10, 2020 (the &amp;#x201C;Letter Agreement&amp;#x201D;).&amp;nbsp;&amp;nbsp;Pursuant to the Letter Agreement, the Company will pay a mid-double digit percentage of certain payments, royalties, or net proceeds received from Arctic Vision in connection with the Arctic Vision License Agreement to Senju. During the year ended December 31, 2020, the Company paid Senju $1.6 million in connection with the Arctic Vision License Agreement which was recorded as deferred license costs in the Company&amp;#x2019;s balance sheet and will be recognized as expense upon earning the related fee. See Note 2- Summary of Significant Accounting Policies &amp;#x2013; Revenue Recognition and Note 9 &amp;#x2013; Commitments and Contingencies for additional details.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
			&lt;font style="display:inline;font-size:11pt;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
  <us-gaap:RepaymentsOfNotesPayable contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit12" decimals="0">0</us-gaap:RepaymentsOfNotesPayable>
  <us-gaap:RepaymentsOfNotesPayable contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit12" decimals="0">475216</us-gaap:RepaymentsOfNotesPayable>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit12" decimals="0">14102449</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_FairValueByAssetClassAxis_us-gaap_PropertyPlantAndEquipmentMember" unitRef="Unit12" decimals="0">9762</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit12" decimals="0">13263817</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_FairValueByAssetClassAxis_us-gaap_PropertyPlantAndEquipmentMember" unitRef="Unit12" decimals="0">67595</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="Duration_1_1_2020_To_12_31_2020">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-decoration:underline;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Research and Development&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 8pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
			&lt;font style="display:inline;"&gt;Research and development expenses are charged to operations as incurred. The Company records prepaid expenses on its balance sheet for the payment of research and development expenses in advance of services being provided.&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="As_Of_12_31_2019" unitRef="Unit12" decimals="0">-57671052</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="As_Of_12_31_2020" unitRef="Unit12" decimals="0">-77440919</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit12" decimals="0">2000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
  <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock contextRef="Duration_1_1_2020_To_12_31_2020">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;text-decoration:underline;"&gt;Revenue Recognition&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Our revenues are generated primarily through research, development and commercialization agreements. The terms of such agreements may contain multiple promised goods and services, which may include (i) licenses to our intellectual property, and (ii) in certain cases, payment in connection with the manufacturing and delivery of clinical supply materials. Payments to us under these arrangements typically include one or more of the following: non-refundable, upfront license fees; milestone payments; payments for clinical product supply, and royalties on future product sales.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;We analyze our arrangements to assess whether such arrangements involve joint operating activities. For collaboration arrangements that are deemed to be within the scope of ASC Topic 808, &amp;#x201C;Collaborative Arrangements&amp;#x201D; (&amp;#x201C;ASC 808&amp;#x201D;), we allocate the contract consideration between such joint operating activities and elements that are reflective of a vendor-customer relationship and, therefore, within the scope of ASC Topic 606, &amp;#x201C;Revenue from Contracts with Customers&amp;#x201D; (&amp;#x201C;ASC 606&amp;#x201D;). Our policy is to recognize amounts allocated to joint operating activities as a reduction in research and development expense.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Under ASC 606, we recognize revenue when our customers obtain control of promised goods or services, in an amount that reflects the consideration which we expect to receive in exchange for those goods or services. To determine revenue recognition for arrangements that we determine are within the scope of ASC 606, we perform the following five steps:&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;#x2022; &amp;nbsp;&lt;/font&gt;&lt;font style="display:inline;text-decoration:underline;"&gt;Step 1:&lt;/font&gt;&lt;font style="display:inline;"&gt; Identify the contract with the customer;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;#x2022; &amp;nbsp;&lt;/font&gt;&lt;font style="display:inline;text-decoration:underline;"&gt;Step 2:&lt;/font&gt;&lt;font style="display:inline;"&gt; Identify the performance obligations in the contract;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;#x2022; &amp;nbsp;&lt;/font&gt;&lt;font style="display:inline;text-decoration:underline;"&gt;Step 3:&lt;/font&gt;&lt;font style="display:inline;"&gt; Determine the transaction price;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;#x2022; &amp;nbsp;&lt;/font&gt;&lt;font style="display:inline;text-decoration:underline;"&gt;Step 4:&lt;/font&gt;&lt;font style="display:inline;"&gt; Allocate the transaction price to the performance obligations in the contract; and&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;#x2022; &amp;nbsp;&lt;/font&gt;&lt;font style="display:inline;text-decoration:underline;"&gt;Step 5:&lt;/font&gt;&lt;font style="display:inline;"&gt; Recognize revenue when the company satisfies a performance obligation.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;We must make significant judgments in our revenue recognition process, including identifying performance obligations in the contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price to each performance obligation. In addition, arrangements that include rights to additional goods or services that are exercisable at a customer&amp;#x2019;s discretion are generally considered discretionary purchase options. We assess if these options provide a material right to the customer and if so, they are considered performance obligations.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;For upfront license fees, we must consider how many performance obligations are in the contract and, if more than one, how to allocate the fee to those performance obligations upon satisfaction of the performance obligation(s). Milestone payments represent variable consideration that will be recognized when the performance obligation is achieved. Sales-based royalty payments derived from usage of intellectual property are recognized when those sales occur.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 8pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-size:10pt;"&gt;During 2020, the Company entered &lt;/font&gt;&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-size:10pt;"&gt;into a license agreement (the &amp;#x201C;Arctic Vision License Agreement&amp;#x201D;) with Arctic Vision (Hong Kong) Limited (&amp;#x201C;Arctic Vision&amp;#x201D;) and a license agreement (the &amp;#x201C;&lt;/font&gt;&lt;font style="display:inline;font-size:10pt;"&gt;Bausch License Agreement&amp;#x2019;) &lt;/font&gt;&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-size:10pt;"&gt;with Bausch Health Companies, Inc. (&amp;#x201C;Bausch Health&amp;#x201D;). &lt;/font&gt;&lt;font style="display:inline;font-size:10pt;"&gt;Each license has three revenue components: 1) an upfront license fee; 2) milestone payments and 3) royalty payments. See Note 9 &amp;#x2013; Commitments and Contingencies for additional details.&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
  <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="Duration_1_1_2020_To_12_31_2020">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;As of December&amp;nbsp;31, 2020 and 2019, accrued expenses and other current liabilities consisted of the following:&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:71.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:71.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="5" valign="bottom" style="width:26.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;December&amp;nbsp;31,&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:71.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:13.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;2020&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:11.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;2019&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:71.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Accrued research and development expenses&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 291,256&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 208,175&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:71.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Accrued consulting and professional services&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 235,355&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 97,396&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:71.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Credit card payable&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 50,002&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 56,979&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:71.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Leasehold improvements&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 42,500&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:71.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Accrued franchise tax&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 32,480&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 40,995&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:71.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Accrued travel and entertainment expenses&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 7,385&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:71.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Accrued licensing fees&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 804,447&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:71.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Accrued interest&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 3,068&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:71.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Accrued expense reimbursements&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 5,459&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:71.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Accrued shipping and packaging fees&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 56,998&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:71.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Other&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 1,627&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:71.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Total accrued expenses and other current liabilities&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 1,480,692&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 453,430&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt 0pt 8pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
  <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="Duration_1_1_2020_To_12_31_2020">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The following securities are excluded from the calculation of weighted average dilutive common shares because their inclusion would have been anti-dilutive:&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:72.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:72.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="3" valign="bottom" style="width:25.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;December&amp;nbsp;31,&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:72.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;2020&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;2019&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:72.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Warrants&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 2,011,313&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:72.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Options&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 3,427,705&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 2,237,438&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:72.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Restricted stock units&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 104,083&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 60,355&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:72.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Total potentially dilutive shares&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 5,543,101&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 2,297,793&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt 0pt 8pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
  <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock contextRef="Duration_1_1_2020_To_12_31_2020">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The provision for income taxes consists of the following expenses (benefits):&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:74.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:74.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="5" valign="bottom" style="width:24.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;For&amp;nbsp;The&amp;nbsp;Years&amp;nbsp;Ended&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:74.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="5" valign="bottom" style="width:24.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;December&amp;nbsp;31,&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:74.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:11.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;2020&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:11.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;2019&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:74.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Deferred tax provision (benefit):&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:74.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt 6pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Federal&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; (3,797,052)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; (4,999,920)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:74.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt 6pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;State and local&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; (434,082)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 68,762&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:74.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; (4,231,134)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; (4,931,158)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:74.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Change in valuation allowance&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 4,231,134&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 4,931,158&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:74.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Provision for income taxes&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
  <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="Duration_1_1_2020_To_12_31_2020">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Deferred tax assets consist of the following:&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:72.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:72.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="5" valign="bottom" style="width:26.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;For&amp;nbsp;The&amp;nbsp;Years&amp;nbsp;Ended&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:72.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="5" valign="bottom" style="width:26.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;December&amp;nbsp;31,&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:72.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;2020&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;2019&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:72.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Net operating loss carryforwards&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 12,972,865&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 9,479,512&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:72.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Stock-based compensation&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 1,385,554&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 943,370&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:72.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Intangible assets&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 409,705&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 328,773&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:72.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Research and development tax credits&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 1,861,938&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 1,584,753&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:72.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Deferred tax assets, gross&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 16,630,062&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 12,336,408&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:72.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Property and equipment&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; (76,550)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; (14,030)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:72.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Deferred tax assets, net before allowance&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 16,553,512&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 12,322,378&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:72.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Valuation allowance&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; (16,553,512)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; (12,322,378)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:72.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Deferred tax assets, net&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt 0pt 8pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
  <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="Duration_1_1_2020_To_12_31_2020">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The provision for income taxes differs from the United States Federal statutory rate as follows:&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:74.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:74.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="3" valign="bottom" style="width:21.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;For&amp;nbsp;The&amp;nbsp;Years&amp;nbsp;Ended&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:74.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="3" valign="bottom" style="width:21.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;December&amp;nbsp;31,&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:74.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;2020&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;2019&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:74.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Federal statutory rate&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; (21.0)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;%&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 21.0&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:74.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;State tax rate, net of federal benefit&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; (0.1)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;%&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 0.1&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:74.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Permanent differences&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 0.5&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;%&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; (0.2)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:74.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Research &amp;amp; development tax credits&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; (1.4)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;%&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 3.0&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:74.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Prior period adjustments and other&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 0.6&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;%&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; (0.6)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:74.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Change in valuation allowance&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 21.4&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;%&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; (23.3)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:74.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Effective income tax rate&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;%&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt 0pt 8pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
  <us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock contextRef="Duration_1_1_2020_To_12_31_2020">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Future minimum payments under this operating lease agreement are as follows as:&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:74.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:21.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:74.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;For the Year Ending&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:21.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:74.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;December&amp;nbsp;31,&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:23.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;Minimum&amp;nbsp;Lease&amp;nbsp;Payments&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:74.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;2021&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:21.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 378,486&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:74.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;2022&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:21.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 389,212&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:74.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;2023&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:21.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 285,700&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:74.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:21.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 1,053,398&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt 0pt 8pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock>
  <us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock contextRef="Duration_1_1_2020_To_12_31_2020">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The following table presents information related to stock options as of December 31, 2020:&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:02.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:20.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:18.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:25.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:18.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:02.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="3" valign="bottom" style="width:43.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;Options Outstanding&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="3" valign="bottom" style="width:48.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;Options&amp;nbsp;Exercisable&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:02.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:20.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:18.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:25.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;Weighted&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:18.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:02.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:20.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:18.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;Outstanding&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:25.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;Average&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:18.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;Exercisable&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:02.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:20.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;Exercise&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:18.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;Number&amp;nbsp;of&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:25.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;Remaining&amp;nbsp;Life&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:18.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;Number&amp;nbsp;of&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:02.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:20.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;Price&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:18.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;Options&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:25.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;In&amp;nbsp;Years&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:18.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;Options&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:02.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:20.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 1.24&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:18.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 260,000&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:25.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 4.2&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:18.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 260,000&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:02.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:20.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 1.95&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:18.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 673,544&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:25.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 6.5&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:18.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 673,544&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:02.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:20.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 2.72&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:18.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 764,419&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:25.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:18.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:02.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:20.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 2.74&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:18.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 6,000&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:25.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 8.0&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:18.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 3,833&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:02.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:20.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 2.89&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:18.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 263,500&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:25.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:18.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:02.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:20.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 3.11&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:18.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 659,849&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:25.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 8.6&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:18.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 318,432&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:02.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:20.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 3.43&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:18.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 58,920&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:25.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:18.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:02.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:20.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 3.48&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:18.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 45,000&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:25.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:18.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:02.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:20.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 3.71&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:18.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 43,000&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:25.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:18.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:02.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:20.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 4.00&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:18.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 2,000&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:25.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 7.9&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:18.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 1,390&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:02.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:20.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 4.68&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:18.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 25,000&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:25.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:18.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:02.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:20.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 5.10&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:18.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 6,000&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:25.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 7.7&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:18.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 4,500&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:02.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:20.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 5.19&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:18.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 16,500&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:25.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 7.7&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:18.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 12,375&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:02.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:20.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 5.25&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:18.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 26,668&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:25.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 5.8&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:18.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 26,668&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:02.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:20.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 5.77&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:18.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 50,000&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:25.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:18.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:02.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:20.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 6.20&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:18.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 300,387&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:25.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 7.6&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:18.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 270,476&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:02.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:20.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 6.30&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:18.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 60,000&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:25.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 7.5&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:18.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 48,333&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:02.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:20.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 8.72&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:18.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 166,918&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:25.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 7.3&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:18.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 148,741&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:02.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:20.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:18.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 3,427,705&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:25.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 6.8&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:18.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 1,768,292&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt 0pt 8pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock>
  <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="Duration_1_1_2020_To_12_31_2020">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;A summary of the option activity during the&amp;nbsp;year ended December 31, 2020 is presented below:&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:48.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:48.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;Weighted&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:48.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:08.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;Weighted&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;Average&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:48.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:08.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;Average&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;Remaining&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:13.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;Aggregate&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:48.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;Number&amp;nbsp;of&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:08.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;Exercise&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;Life&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:13.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;Intrinsic&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:48.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;Options&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:08.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;Price&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;In&amp;nbsp;Years&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:13.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;Value&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:48.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Outstanding January 1, 2020&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 2,237,438&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 3.51&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:48.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Granted&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 1,249,839&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 3.01&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:48.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Exercised&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; (36,391)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 2.26&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:48.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Forfeited&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; (23,181)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 4.59&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:48.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Outstanding December&amp;nbsp;31,&amp;nbsp;2020&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 3,427,705&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 3.37&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 8.0&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 9,843,341&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:48.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:48.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Exercisable December&amp;nbsp;31,&amp;nbsp;2020&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 1,768,292&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 3.48&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 6.8&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 5,013,118&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt 0pt 8pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
  <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="Duration_1_1_2020_To_12_31_2020">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;In applying the Black-Scholes option pricing model to stock options granted, the Company used the following approximate assumptions:&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:64.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:64.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="3" valign="bottom" style="width:32.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;For&amp;nbsp;the&amp;nbsp;Year Ended &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:64.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="3" valign="bottom" style="width:32.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;December&amp;nbsp;31,&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:64.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;2020&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;2019&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:64.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Expected term (years)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;5.85 - 10.00&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;5.50 - 10.00&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:64.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Risk free interest rate&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;0.26% - 1.32%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;1.42% - 2.53%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:64.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Expected volatility&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;96% - 99%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;134 - 139%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:64.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Expected dividends&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;0.00%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;0.00%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
  <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="Duration_1_1_2020_To_12_31_2020">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;A summary of the Warrant activity during the year ended December 31, 2020 is presented below:&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:58.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:05.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:58.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:05.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;Weighted&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:58.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:06.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;Weighted &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;Average&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:58.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:06.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;Average&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;Remaining&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:10.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;Aggregate&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:58.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;Number of&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:06.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;Exercise&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;Life&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:10.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;Intrinsic&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:58.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;Warrants&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:06.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;Price&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;In Years&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:10.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;Value&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:58.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Outstanding January 1, 2020&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:05.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:58.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Granted&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 3,344,154&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:05.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 2.33&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:58.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Exercised&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; (1,332,841)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:05.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 2.19&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:58.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Forfeited&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:05.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:58.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Outstanding December 31, 2020&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 2,011,313&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:05.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 2.43&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 3.8&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 7,215,147&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:58.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:05.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:58.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Exercisable December 31, 2020&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 2,011,313&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:05.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 2.43&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 3.8&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 7,215,147&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The following table presents information related to Warrants as of December 31, 2020:&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:22.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:22.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:22.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:22.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td colspan="3" valign="bottom" style="width:48.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;Warrants Outstanding&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="3" valign="bottom" style="width:48.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;Warrants Exercisable&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:22.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:22.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:22.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;Weighted&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:22.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:22.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:22.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;Outstanding&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:22.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;Average&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:22.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;Exercisable&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:22.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;Exercise&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:22.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;Number of&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:22.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;Remaining Life&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:22.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;Number of&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:22.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;Price&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:22.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;Warrants&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:22.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;In Years&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:22.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;Warrants&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:22.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;$2.0580 &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:22.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 48,549&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:22.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 0.2&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:22.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 48,549&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:22.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;$2.2700 &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:22.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 144,256&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:22.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 0.2&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:22.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 144,256&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:22.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;$2.4696 &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:22.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 1,602,128&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:22.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 4.2&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:22.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 1,602,128&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:22.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;$2.7240 &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:22.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 216,380&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:22.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 4.2&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:22.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 216,380&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:22.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:22.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 2,011,313&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:22.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 3.8&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:22.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 2,011,313&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
  <us-gaap:SecurityDeposit contextRef="As_Of_9_15_2016_us-gaap_RelatedPartyTransactionAxis_eyen_VicePresidentOfResearchAndDevelopmentMember" unitRef="Unit12" decimals="0">3895</us-gaap:SecurityDeposit>
  <us-gaap:SecurityDeposit contextRef="As_Of_8_8_2018" unitRef="Unit12" decimals="0">119000</us-gaap:SecurityDeposit>
  <us-gaap:SecurityDeposit contextRef="As_Of_12_31_2019" unitRef="Unit12" decimals="0">117800</us-gaap:SecurityDeposit>
  <us-gaap:SecurityDeposit contextRef="As_Of_7_17_2020" unitRef="Unit12" decimals="0">7500</us-gaap:SecurityDeposit>
  <us-gaap:SecurityDeposit contextRef="As_Of_9_15_2020_us-gaap_RelatedPartyTransactionAxis_eyen_VicePresidentOfResearchAndDevelopmentMember" unitRef="Unit12" decimals="0">5404</us-gaap:SecurityDeposit>
  <us-gaap:SecurityDeposit contextRef="As_Of_12_1_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_eyen_AdditionalOfficeSpaceMember" unitRef="Unit12" decimals="0">3000</us-gaap:SecurityDeposit>
  <us-gaap:SecurityDeposit contextRef="As_Of_12_31_2020" unitRef="Unit12" decimals="0">119035</us-gaap:SecurityDeposit>
  <us-gaap:SeveranceCosts1 contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit12" decimals="0">419000</us-gaap:SeveranceCosts1>
  <us-gaap:ShareBasedCompensation contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit12" decimals="0">2511944</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit12" decimals="0">2511944</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember" unitRef="Unit12" decimals="0">1052889</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="Unit12" decimals="0">1459055</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit12" decimals="0">2483172</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit12" decimals="0">2483172</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember" unitRef="Unit12" decimals="0">1132278</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="Unit12" decimals="0">1350894</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit12" decimals="0">609322</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber contextRef="Duration_2_1_2019_To_2_13_2019" unitRef="Unit1" decimals="0">124210</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="Duration_1_14_2019_To_1_14_2019">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="Duration_1_14_2019_To_1_14_2019_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember">P24M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="Duration_8_16_2019_To_8_16_2019_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember">P24M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="Duration_1_31_2020_To_1_31_2020">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="Duration_1_31_2020_To_1_31_2020_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember">P24M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="Duration_4_7_2020_To_4_7_2020_us-gaap_PlanNameAxis_eyen_OmnibusStockIncentivePlan2018Member">P12M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="Duration_5_28_2020_To_5_28_2020">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="Duration_5_28_2020_To_5_28_2020_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember">P24M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="Duration_6_3_2020_To_6_3_2020">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="Duration_6_3_2020_To_6_3_2020_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember">P24M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="Duration_7_28_2020_To_7_28_2020">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="Duration_7_28_2020_To_7_28_2020_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember">P24M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="Duration_9_8_2020_To_9_8_2020">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="Duration_9_8_2020_To_9_8_2020_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember">P24M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="Duration_12_23_2020_To_12_23_2020">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="Duration_12_23_2020_To_12_23_2020_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember">P24M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage contextRef="Duration_1_31_2020_To_1_31_2020_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember" unitRef="Unit14" decimals="4">0.0033</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage contextRef="Duration_5_28_2020_To_5_28_2020_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember" unitRef="Unit14" decimals="4">0.0033</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage contextRef="Duration_6_3_2020_To_6_3_2020_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember" unitRef="Unit14" decimals="4">0.0033</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage contextRef="Duration_7_28_2020_To_7_28_2020_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember" unitRef="Unit14" decimals="4">0.0033</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage contextRef="Duration_9_8_2020_To_9_8_2020_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember" unitRef="Unit14" decimals="4">0.0033</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage contextRef="Duration_12_23_2020_To_12_23_2020_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember" unitRef="Unit14" decimals="4">0.0033</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="Duration_8_16_2019_To_8_16_2019_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="Unit1" decimals="0">40190</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="Duration_9_11_2020_To_9_11_2020_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="Unit1" decimals="0">43728</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="Duration_8_16_2019_To_8_16_2019_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="Unit13" decimals="0">125000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="Duration_9_11_2020_To_9_11_2020_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="Unit13" decimals="0">150000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit14" decimals="4">0.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit14" decimals="4">0.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="Duration_1_1_2019_To_12_31_2019_srt_RangeAxis_srt_MaximumMember">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="Duration_1_1_2019_To_12_31_2019_srt_RangeAxis_srt_MinimumMember">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="Duration_1_1_2020_To_12_31_2020_srt_RangeAxis_srt_MaximumMember">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="Duration_1_1_2020_To_12_31_2020_srt_RangeAxis_srt_MinimumMember">P5Y10M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="Duration_1_1_2019_To_12_31_2019_srt_RangeAxis_srt_MaximumMember" unitRef="Unit14" decimals="2">1.39</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="Duration_1_1_2019_To_12_31_2019_srt_RangeAxis_srt_MinimumMember" unitRef="Unit14" decimals="2">1.34</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="Duration_1_1_2020_To_12_31_2020_srt_RangeAxis_srt_MaximumMember" unitRef="Unit14" decimals="2">0.99</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="Duration_1_1_2020_To_12_31_2020_srt_RangeAxis_srt_MinimumMember" unitRef="Unit14" decimals="2">0.96</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="Duration_1_1_2019_To_12_31_2019_srt_RangeAxis_srt_MaximumMember" unitRef="Unit14" decimals="4">0.0253</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="Duration_1_1_2019_To_12_31_2019_srt_RangeAxis_srt_MinimumMember" unitRef="Unit14" decimals="4">0.0142</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="Duration_1_1_2020_To_12_31_2020_srt_RangeAxis_srt_MaximumMember" unitRef="Unit14" decimals="4">0.0132</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="Duration_1_1_2020_To_12_31_2020_srt_RangeAxis_srt_MinimumMember" unitRef="Unit14" decimals="4">0.0026</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="As_Of_12_31_2020_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_StockOptionMember" unitRef="Unit12" decimals="0">5013118</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="As_Of_12_31_2020_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_StockOptionMember" unitRef="Unit1" decimals="0">1768292</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="As_Of_12_31_2020_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_StockOptionMember" unitRef="Unit13" decimals="2">3.48</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_StockOptionMember">P6Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="Duration_3_26_2021_To_3_26_2021_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" unitRef="Unit12" decimals="-5">3900000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_StockOptionMember" unitRef="Unit13" decimals="2">4.59</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_StockOptionMember" unitRef="Unit1" decimals="0">23181</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="Duration_1_14_2019_To_1_14_2019_us-gaap_PlanNameAxis_eyen_EmployeesConsultantsAndDirectorsUnder2018PlanMember" unitRef="Unit1" decimals="0">11000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="Duration_1_14_2019_To_1_14_2019_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember" unitRef="Unit1" decimals="0">11000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="Duration_8_16_2019_To_8_16_2019_us-gaap_PlanNameAxis_eyen_EmployeesConsultantsAndDirectorsUnder2018PlanMember" unitRef="Unit1" decimals="0">681572</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="Duration_8_16_2019_To_8_16_2019_us-gaap_PlanNameAxis_eyen_EmployeesConsultantsAndDirectorsUnder2018PlanMember" unitRef="Unit1" decimals="0">681572</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="Duration_8_16_2019_To_8_16_2019_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember" unitRef="Unit1" decimals="0">636287</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="Duration_8_16_2019_To_8_16_2019_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" unitRef="Unit1" decimals="0">45285</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_StockOptionMember" unitRef="Unit1" decimals="0">1249839</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="Duration_3_26_2021_To_3_26_2021_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" unitRef="Unit1" decimals="0">652899</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="As_Of_12_31_2020_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_StockOptionMember" unitRef="Unit12" decimals="0">9843341</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="As_Of_12_31_2019_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_StockOptionMember" unitRef="Unit1" decimals="0">2237438</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="As_Of_12_31_2020_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_StockOptionMember" unitRef="Unit1" decimals="0">3427705</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="As_Of_12_31_2019_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_StockOptionMember" unitRef="Unit13" decimals="2">3.51</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="As_Of_12_31_2020_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_StockOptionMember" unitRef="Unit13" decimals="2">3.37</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_StockOptionMember">P8Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="Duration_3_26_2021_To_3_26_2021_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 contextRef="Duration_1_14_2019_To_1_14_2019_us-gaap_PlanNameAxis_eyen_EmployeesConsultantsAndDirectorsUnder2018PlanMember" unitRef="Unit12" decimals="0">27500</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 contextRef="Duration_8_16_2019_To_8_16_2019_us-gaap_PlanNameAxis_eyen_EmployeesConsultantsAndDirectorsUnder2018PlanMember" unitRef="Unit12" decimals="0">1909700</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 contextRef="Duration_1_31_2020_To_1_31_2020_us-gaap_PlanNameAxis_eyen_EmployeesConsultantsAndDirectorsUnder2018PlanMember" unitRef="Unit12" decimals="0">103400</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 contextRef="Duration_5_28_2020_To_5_28_2020_us-gaap_PlanNameAxis_eyen_EmployeesConsultantsAndDirectorsUnder2018PlanMember" unitRef="Unit12" decimals="0">587100</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 contextRef="Duration_6_3_2020_To_6_3_2020_us-gaap_PlanNameAxis_eyen_EmployeesConsultantsAndDirectorsUnder2018PlanMember" unitRef="Unit12" decimals="0">1603600</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 contextRef="Duration_7_28_2020_To_7_28_2020_us-gaap_PlanNameAxis_eyen_EmployeesConsultantsAndDirectorsUnder2018PlanMember" unitRef="Unit12" decimals="0">122400</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 contextRef="Duration_9_8_2020_To_9_8_2020_us-gaap_PlanNameAxis_eyen_EmployeesConsultantsAndDirectorsUnder2018PlanMember" unitRef="Unit12" decimals="0">126700</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 contextRef="Duration_9_11_2020_To_9_11_2020_us-gaap_PlanNameAxis_eyen_EmployeesConsultantsAndDirectorsUnder2018PlanMember" unitRef="Unit12" decimals="0">155400</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 contextRef="Duration_12_23_2020_To_12_23_2020_us-gaap_PlanNameAxis_eyen_EmployeesConsultantsAndDirectorsUnder2018PlanMember" unitRef="Unit12" decimals="0">218700</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="Duration_1_2_2019_To_1_2_2019" unitRef="Unit13" decimals="2">1.24</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="Duration_1_2_2019_To_1_2_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit13" decimals="2">1.95</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="Duration_2_6_2019_To_2_6_2019" unitRef="Unit13" decimals="2">1.24</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="Duration_5_14_2019_To_5_14_2019" unitRef="Unit13" decimals="2">1.95</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_StockOptionMember" unitRef="Unit13" decimals="2">2.26</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="Duration_3_26_2021_To_3_26_2021_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" unitRef="Unit13" decimals="2">6.01</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit13" decimals="2">3.10</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="Duration_1_14_2019_To_1_14_2019_us-gaap_PlanNameAxis_eyen_EmployeesConsultantsAndDirectorsUnder2018PlanMember" unitRef="Unit13" decimals="2">2.74</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="Duration_8_16_2019_To_8_16_2019_us-gaap_PlanNameAxis_eyen_EmployeesConsultantsAndDirectorsUnder2018PlanMember" unitRef="Unit13" decimals="2">3.11</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit13" decimals="2">3.01</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_StockOptionMember" unitRef="Unit13" decimals="2">3.01</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="Duration_1_31_2020_To_1_31_2020_us-gaap_PlanNameAxis_eyen_EmployeesConsultantsAndDirectorsUnder2018PlanMember" unitRef="Unit13" decimals="2">4.68</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="Duration_5_28_2020_To_5_28_2020_us-gaap_PlanNameAxis_eyen_EmployeesConsultantsAndDirectorsUnder2018PlanMember" unitRef="Unit13" decimals="2">2.89</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="Duration_6_3_2020_To_6_3_2020_us-gaap_PlanNameAxis_eyen_EmployeesConsultantsAndDirectorsUnder2018PlanMember" unitRef="Unit13" decimals="2">2.72</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="Duration_7_28_2020_To_7_28_2020_us-gaap_PlanNameAxis_eyen_EmployeesConsultantsAndDirectorsUnder2018PlanMember" unitRef="Unit13" decimals="2">3.71</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="Duration_9_8_2020_To_9_8_2020_us-gaap_PlanNameAxis_eyen_EmployeesConsultantsAndDirectorsUnder2018PlanMember" unitRef="Unit13" decimals="2">3.48</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="Duration_9_11_2020_To_9_11_2020_us-gaap_PlanNameAxis_eyen_EmployeesConsultantsAndDirectorsUnder2018PlanMember" unitRef="Unit13" decimals="2">3.43</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="Duration_12_23_2020_To_12_23_2020_us-gaap_PlanNameAxis_eyen_EmployeesConsultantsAndDirectorsUnder2018PlanMember" unitRef="Unit13" decimals="2">5.77</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="Duration_1_1_2020_To_12_31_2020">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-decoration:underline;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Stock-Based Compensation&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The Company measures the cost of services received in exchange for an award of equity instruments based on the fair value of the award. The fair value of the award is measured on the grant date and the fair value amount is then recognized over the period during which services are required to be provided in exchange for the award, usually the vesting period. Upon the exercise of an option, the Company issues new shares of common stock out of the shares reserved for issuance under its equity plans.&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1 contextRef="As_Of_12_31_2020_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePrice2.72Member" unitRef="Unit13" decimals="2">2.72</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1 contextRef="As_Of_12_31_2020_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePrice2.89Member" unitRef="Unit13" decimals="2">2.89</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1 contextRef="As_Of_12_31_2020_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePrice3.43Member" unitRef="Unit13" decimals="2">3.43</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1 contextRef="As_Of_12_31_2020_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePrice3.48Member" unitRef="Unit13" decimals="2">3.48</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1 contextRef="As_Of_12_31_2020_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePrice3.71Member" unitRef="Unit13" decimals="2">3.71</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1 contextRef="As_Of_12_31_2020_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePrice4.68Member" unitRef="Unit13" decimals="2">4.68</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1 contextRef="As_Of_12_31_2020_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePrice5.77Member" unitRef="Unit13" decimals="2">5.77</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1 contextRef="As_Of_12_31_2020_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceEightMember" unitRef="Unit13" decimals="2">5.25</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1 contextRef="As_Of_12_31_2020_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceElevenMember" unitRef="Unit13" decimals="2">8.72</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1 contextRef="As_Of_12_31_2020_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceFiveMember" unitRef="Unit13" decimals="2">4.00</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1 contextRef="As_Of_12_31_2020_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceFourMember" unitRef="Unit13" decimals="2">3.11</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1 contextRef="As_Of_12_31_2020_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceNineMemberMember" unitRef="Unit13" decimals="2">6.20</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1 contextRef="As_Of_12_31_2020_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceOneMember" unitRef="Unit13" decimals="2">1.24</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1 contextRef="As_Of_12_31_2020_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceSevenMember" unitRef="Unit13" decimals="2">5.19</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1 contextRef="As_Of_12_31_2020_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceSixMember" unitRef="Unit13" decimals="2">5.10</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1 contextRef="As_Of_12_31_2020_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceTenMember" unitRef="Unit13" decimals="2">6.30</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1 contextRef="As_Of_12_31_2020_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceThreeMember" unitRef="Unit13" decimals="2">2.74</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1 contextRef="As_Of_12_31_2020_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceTwoMember" unitRef="Unit13" decimals="2">1.95</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions contextRef="As_Of_12_31_2020" unitRef="Unit1" decimals="0">1768292</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions contextRef="As_Of_12_31_2020_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePrice2.72Member" unitRef="Unit1" decimals="0">0</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions contextRef="As_Of_12_31_2020_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePrice2.89Member" unitRef="Unit1" decimals="0">0</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions contextRef="As_Of_12_31_2020_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePrice3.43Member" unitRef="Unit1" decimals="0">0</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions contextRef="As_Of_12_31_2020_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePrice3.48Member" unitRef="Unit1" decimals="0">0</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions contextRef="As_Of_12_31_2020_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePrice3.71Member" unitRef="Unit1" decimals="0">0</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions contextRef="As_Of_12_31_2020_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePrice4.68Member" unitRef="Unit1" decimals="0">0</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions contextRef="As_Of_12_31_2020_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePrice5.77Member" unitRef="Unit1" decimals="0">0</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions contextRef="As_Of_12_31_2020_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceEightMember" unitRef="Unit1" decimals="0">26668</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions contextRef="As_Of_12_31_2020_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceElevenMember" unitRef="Unit1" decimals="0">148741</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions contextRef="As_Of_12_31_2020_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceFiveMember" unitRef="Unit1" decimals="0">1390</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions contextRef="As_Of_12_31_2020_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceFourMember" unitRef="Unit1" decimals="0">318432</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions contextRef="As_Of_12_31_2020_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceNineMemberMember" unitRef="Unit1" decimals="0">270476</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions contextRef="As_Of_12_31_2020_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceOneMember" unitRef="Unit1" decimals="0">260000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions contextRef="As_Of_12_31_2020_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceSevenMember" unitRef="Unit1" decimals="0">12375</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions contextRef="As_Of_12_31_2020_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceSixMember" unitRef="Unit1" decimals="0">4500</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions contextRef="As_Of_12_31_2020_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceTenMember" unitRef="Unit1" decimals="0">48333</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions contextRef="As_Of_12_31_2020_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceThreeMember" unitRef="Unit1" decimals="0">3833</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions contextRef="As_Of_12_31_2020_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceTwoMember" unitRef="Unit1" decimals="0">673544</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions contextRef="As_Of_12_31_2020" unitRef="Unit1" decimals="0">3427705</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions contextRef="As_Of_12_31_2020_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePrice2.72Member" unitRef="Unit1" decimals="0">764419</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions contextRef="As_Of_12_31_2020_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePrice2.89Member" unitRef="Unit1" decimals="0">263500</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions contextRef="As_Of_12_31_2020_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePrice3.43Member" unitRef="Unit1" decimals="0">58920</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions contextRef="As_Of_12_31_2020_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePrice3.48Member" unitRef="Unit1" decimals="0">45000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions contextRef="As_Of_12_31_2020_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePrice3.71Member" unitRef="Unit1" decimals="0">43000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions contextRef="As_Of_12_31_2020_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePrice4.68Member" unitRef="Unit1" decimals="0">25000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions contextRef="As_Of_12_31_2020_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePrice5.77Member" unitRef="Unit1" decimals="0">50000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions contextRef="As_Of_12_31_2020_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceEightMember" unitRef="Unit1" decimals="0">26668</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions contextRef="As_Of_12_31_2020_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceElevenMember" unitRef="Unit1" decimals="0">166918</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions contextRef="As_Of_12_31_2020_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceFiveMember" unitRef="Unit1" decimals="0">2000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions contextRef="As_Of_12_31_2020_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceFourMember" unitRef="Unit1" decimals="0">659849</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions contextRef="As_Of_12_31_2020_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceNineMemberMember" unitRef="Unit1" decimals="0">300387</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions contextRef="As_Of_12_31_2020_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceOneMember" unitRef="Unit1" decimals="0">260000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions contextRef="As_Of_12_31_2020_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceSevenMember" unitRef="Unit1" decimals="0">16500</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions contextRef="As_Of_12_31_2020_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceSixMember" unitRef="Unit1" decimals="0">6000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions contextRef="As_Of_12_31_2020_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceTenMember" unitRef="Unit1" decimals="0">60000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions contextRef="As_Of_12_31_2020_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceThreeMember" unitRef="Unit1" decimals="0">6000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions contextRef="As_Of_12_31_2020_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceTwoMember" unitRef="Unit1" decimals="0">673544</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="Duration_1_1_2020_To_12_31_2020">P6Y9M18D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePrice2.72Member">P0Y</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePrice2.89Member">P0Y</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePrice3.43Member">P0Y</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePrice3.48Member">P0Y</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePrice3.71Member">P0Y</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePrice4.68Member">P0Y</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePrice5.77Member">P0Y</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceEightMember">P5Y9M18D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceElevenMember">P7Y3M18D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceFiveMember">P7Y10M24D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceFourMember">P8Y7M6D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceNineMemberMember">P7Y7M6D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceOneMember">P4Y2M12D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceSevenMember">P7Y8M12D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceSixMember">P7Y8M12D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceTenMember">P7Y6M</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceThreeMember">P8Y</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceTwoMember">P6Y6M</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharePrice contextRef="As_Of_8_19_2020_us-gaap_SubsidiarySaleOfStockAxis_eyen_UnderwrittenPublicOfferingMember" unitRef="Unit13" decimals="2">3.60</us-gaap:SharePrice>
  <us-gaap:SharesIssuedPricePerShare contextRef="As_Of_7_15_2019_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember" unitRef="Unit13" decimals="2">2.78</us-gaap:SharesIssuedPricePerShare>
  <us-gaap:SharesIssuedPricePerShare contextRef="As_Of_3_24_2020_us-gaap_StatementEquityComponentsAxis_eyen_ClassBWarrantsMember" unitRef="Unit13" decimals="4">2.4696</us-gaap:SharesIssuedPricePerShare>
  <us-gaap:SharesIssuedPricePerShare contextRef="As_Of_3_24_2020_us-gaap_StatementEquityComponentsAxis_eyen_ClassWarrantsMember" unitRef="Unit13" decimals="3">2.058</us-gaap:SharesIssuedPricePerShare>
  <us-gaap:SharesIssuedPricePerShare contextRef="As_Of_3_24_2020_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember" unitRef="Unit13" decimals="5">2.21425</us-gaap:SharesIssuedPricePerShare>
  <us-gaap:SharesIssuedPricePerShare contextRef="As_Of_3_24_2020_us-gaap_StatementEquityComponentsAxis_eyen_ClassBWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember" unitRef="Unit13" decimals="2">0.75</us-gaap:SharesIssuedPricePerShare>
  <us-gaap:SharesIssuedPricePerShare contextRef="As_Of_3_24_2020_us-gaap_StatementEquityComponentsAxis_eyen_ClassWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember" unitRef="Unit13" decimals="1">0.5</us-gaap:SharesIssuedPricePerShare>
  <us-gaap:SharesIssuedPricePerShare contextRef="As_Of_12_31_2020_srt_RangeAxis_srt_MaximumMember" unitRef="Unit13" decimals="2">3.11</us-gaap:SharesIssuedPricePerShare>
  <us-gaap:SharesIssuedPricePerShare contextRef="As_Of_12_31_2020_srt_RangeAxis_srt_MinimumMember" unitRef="Unit13" decimals="2">1.95</us-gaap:SharesIssuedPricePerShare>
  <us-gaap:SharesOutstanding contextRef="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit1" decimals="0">11468996</us-gaap:SharesOutstanding>
  <us-gaap:SharesOutstanding contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit1" decimals="0">17100726</us-gaap:SharesOutstanding>
  <us-gaap:SharesOutstanding contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit1" decimals="0">24978585</us-gaap:SharesOutstanding>
  <us-gaap:ShortTermBankLoansAndNotesPayable contextRef="As_Of_12_31_2020" unitRef="Unit12" decimals="0">97539</us-gaap:ShortTermBankLoansAndNotesPayable>
  <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="Duration_1_1_2020_To_12_31_2020">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-weight:bold;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Note&amp;nbsp;2&amp;nbsp;&amp;#x2013; Summary of Significant Accounting Policies&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-decoration:underline;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Use of Estimates&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Preparation of financial statements in conformity with accounting principles generally accepted in the United States of America (&amp;#x201C;U.S. GAAP&amp;#x201D;) requires management to make estimates, judgments and assumptions that affect the amounts reported in the financial statements and the amounts disclosed in the related notes to the financial statements. The Company bases its estimates and judgments on historical experience and on various other assumptions that it believes are reasonable under the circumstances. The amounts of assets and liabilities reported in the Company&amp;#x2019;s balance sheets and the amounts of expenses reported for each of the periods presented are affected by estimates and assumptions, which are used for, but not limited to, fair value calculations for equity securities, establishment of valuation allowances for deferred tax assets, stock-based compensation, the recoverability and useful lives of long-lived assets, the recovery of deferred costs and the deferral of revenues. Certain of the Company&amp;#x2019;s estimates could be affected by external conditions, including those unique to the Company and general economic conditions. It is reasonably possible that actual results could differ from those estimates.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;See Note 2 - Summary of Significant Accounting Policies&amp;#x2009;&amp;#x2014;&amp;#x2009;Stock-Based Compensation for additional discussion of the use of estimates in estimating the fair value of the Company&amp;#x2019;s common stock. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times New Roman,Times,serif;text-decoration:underline;"&gt;Cash and Cash Equivalents&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents in the financial statements.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The Company has cash deposits and U.S. treasury bills in financial institutions which, at times, may be in excess of Federal Deposit Insurance Corporation (&amp;#x201C;FDIC&amp;#x201D;) insurance limits. The Company has not experienced losses in such accounts and periodically evaluates the creditworthiness of its financial institutions. As of December&amp;nbsp;31, 2020 and 2019, the Company had cash and cash equivalent balances in excess of FDIC insurance limits of $28,121,828 and $13,902,601, respectively.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-decoration:underline;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Property and Equipment, Net&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Property and equipment are stated at cost, net of accumulated depreciation, which is recorded commencing at the in-service date using the straight-line method at rates sufficient to charge the cost of depreciable assets to operations over their estimated useful lives, which range from 1 to 10&amp;nbsp;years. Leasehold improvements are amortized over the lesser of (a)&amp;nbsp;the useful life of the asset; or (b)&amp;nbsp;the remaining lease term. Maintenance and repairs are charged to operations as incurred. The Company capitalizes costs attributable to the betterment of property and equipment when such betterment extends the useful life of the assets.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-decoration:underline;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Impairment of Long-lived Assets&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The Company reviews for the impairment of long-lived assets whenever events or changes in circumstances indicate that the carrying amount of an asset might not be recoverable. An impairment would be recognized when estimated future cash flows expected to result from the use of the asset and its eventual disposition are less than its carrying amount. The Company did not record any impairment losses during the&amp;nbsp;years ended December&amp;nbsp;31, 2020 and 2019.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-decoration:underline;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Preferred Stock&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The Company applies the accounting standards for distinguishing liabilities from equity when determining the classification and measurement of its preferred stock. Preferred shares subject to mandatory redemption are classified as liability instruments and are measured at fair value. Conditionally redeemable preferred shares (including preferred shares that feature redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company&amp;#x2019;s control) are classified as temporary equity. At all other times, preferred shares are classified as stockholders&amp;#x2019; equity.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-decoration:underline;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Fair Value of Financial Instruments&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The Company measures the fair value of financial assets and liabilities based on Accounting Standards Codification (&amp;#x201C;ASC&amp;#x201D;) Topic 820 &amp;#x201C;Fair Value Measurements and Disclosures&amp;#x201D; (&amp;#x201C;ASC 820&amp;#x201D;), which defines fair value, establishes a framework for measuring fair value, and expands disclosures about fair value measurements.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;ASC 820 defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 describes three levels of inputs that may be used to measure fair value:&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Level 1&amp;nbsp;&amp;#x2014; quoted prices in active markets for identical assets or liabilities;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Level 2&amp;nbsp;&amp;#x2014; quoted prices for similar assets and liabilities in active markets or inputs that are observable; and&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Level 3&amp;nbsp;&amp;#x2014; inputs that are unobservable (for example, cash flow modeling inputs based on assumptions).&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The carrying amounts of the Company&amp;#x2019;s financial instruments, such as cash and cash equivalents, accounts payable, accrued expenses and other current liabilities approximate fair values due to the short-term nature of these instruments.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-decoration:underline;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Income Taxes&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The Company is subject to Federal, New York State and City, and State of California income taxes and files tax returns in those jurisdictions.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of items that have been included or excluded in the consolidated financial statements or tax returns.&amp;nbsp;&amp;nbsp;Deferred tax assets and liabilities are determined on the basis of the difference between the tax basis of assets and liabilities and their respective financial reporting amounts (&amp;#x201C;temporary differences&amp;#x201D;) at enacted tax rates in effect for the years in which such temporary differences are expected to reverse. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The Company utilizes a recognition threshold and measurement process for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;text-decoration:none;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times New Roman,Times,serif;text-decoration:none;"&gt;The Company&amp;#x2019;s policy is to classify assessments, if any, for tax-related interest as interest expense and penalties as general and administrative expenses in the consolidated statements of operations.&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;text-decoration:underline;"&gt;Revenue Recognition&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Our revenues are generated primarily through research, development and commercialization agreements. The terms of such agreements may contain multiple promised goods and services, which may include (i) licenses to our intellectual property, and (ii) in certain cases, payment in connection with the manufacturing and delivery of clinical supply materials. Payments to us under these arrangements typically include one or more of the following: non-refundable, upfront license fees; milestone payments; payments for clinical product supply, and royalties on future product sales.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;We analyze our arrangements to assess whether such arrangements involve joint operating activities. For collaboration arrangements that are deemed to be within the scope of ASC Topic 808, &amp;#x201C;Collaborative Arrangements&amp;#x201D; (&amp;#x201C;ASC 808&amp;#x201D;), we allocate the contract consideration between such joint operating activities and elements that are reflective of a vendor-customer relationship and, therefore, within the scope of ASC Topic 606, &amp;#x201C;Revenue from Contracts with Customers&amp;#x201D; (&amp;#x201C;ASC 606&amp;#x201D;). Our policy is to recognize amounts allocated to joint operating activities as a reduction in research and development expense.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Under ASC 606, we recognize revenue when our customers obtain control of promised goods or services, in an amount that reflects the consideration which we expect to receive in exchange for those goods or services. To determine revenue recognition for arrangements that we determine are within the scope of ASC 606, we perform the following five steps:&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;#x2022; &amp;nbsp;&lt;/font&gt;&lt;font style="display:inline;text-decoration:underline;"&gt;Step 1:&lt;/font&gt;&lt;font style="display:inline;"&gt; Identify the contract with the customer;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;#x2022; &amp;nbsp;&lt;/font&gt;&lt;font style="display:inline;text-decoration:underline;"&gt;Step 2:&lt;/font&gt;&lt;font style="display:inline;"&gt; Identify the performance obligations in the contract;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;#x2022; &amp;nbsp;&lt;/font&gt;&lt;font style="display:inline;text-decoration:underline;"&gt;Step 3:&lt;/font&gt;&lt;font style="display:inline;"&gt; Determine the transaction price;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;#x2022; &amp;nbsp;&lt;/font&gt;&lt;font style="display:inline;text-decoration:underline;"&gt;Step 4:&lt;/font&gt;&lt;font style="display:inline;"&gt; Allocate the transaction price to the performance obligations in the contract; and&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;#x2022; &amp;nbsp;&lt;/font&gt;&lt;font style="display:inline;text-decoration:underline;"&gt;Step 5:&lt;/font&gt;&lt;font style="display:inline;"&gt; Recognize revenue when the company satisfies a performance obligation.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;We must make significant judgments in our revenue recognition process, including identifying performance obligations in the contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price to each performance obligation. In addition, arrangements that include rights to additional goods or services that are exercisable at a customer&amp;#x2019;s discretion are generally considered discretionary purchase options. We assess if these options provide a material right to the customer and if so, they are considered performance obligations.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;For upfront license fees, we must consider how many performance obligations are in the contract and, if more than one, how to allocate the fee to those performance obligations upon satisfaction of the performance obligation(s). Milestone payments represent variable consideration that will be recognized when the performance obligation is achieved. Sales-based royalty payments derived from usage of intellectual property are recognized when those sales occur.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 8pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-size:10pt;"&gt;During 2020, the Company entered &lt;/font&gt;&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-size:10pt;"&gt;into a license agreement (the &amp;#x201C;Arctic Vision License Agreement&amp;#x201D;) with Arctic Vision (Hong Kong) Limited (&amp;#x201C;Arctic Vision&amp;#x201D;) and a license agreement (the &amp;#x201C;&lt;/font&gt;&lt;font style="display:inline;font-size:10pt;"&gt;Bausch License Agreement&amp;#x2019;) &lt;/font&gt;&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-size:10pt;"&gt;with Bausch Health Companies, Inc. (&amp;#x201C;Bausch Health&amp;#x201D;). &lt;/font&gt;&lt;font style="display:inline;font-size:10pt;"&gt;Each license has three revenue components: 1) an upfront license fee; 2) milestone payments and 3) royalty payments. See Note 9 &amp;#x2013; Commitments and Contingencies for additional details.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 8pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-size:10pt;text-decoration:underline;"&gt;Deferred License Fee&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 8pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-size:10pt;"&gt;The Company enters into license agreements which provides for the receipt of non-refundable, upfront licensing payments. These payments are recorded as deferred license fees and will be earned and recognized as revenue upon the satisfaction of performance obligations. See Note 9 &amp;#x2013; Commitments and Contingencies for additional details.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 8pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-size:10pt;text-decoration:underline;"&gt;Deferred License Costs&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 8pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-size:10pt;"&gt;The Company enters into license agreements which provides for payment of license costs in connection with the Company&amp;#x2019;s receipt of license fees. These payments are recorded as deferred license costs and will be recorded as an expense when the related license fee revenue is recognized. See Note 10 &amp;#x2013; Related Party Transactions for additional details.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-decoration:underline;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Research and Development&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Research and development expenses are charged to operations as incurred. The Company records prepaid expenses on its balance sheet for the payment of research and development expenses in advance of services being provided.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-decoration:underline;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Stock-Based Compensation&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The Company measures the cost of services received in exchange for an award of equity instruments based on the fair value of the award. The fair value of the award is measured on the grant date and the fair value amount is then recognized over the period during which services are required to be provided in exchange for the award, usually the vesting period. Upon the exercise of an option, the Company issues new shares of common stock out of the shares reserved for issuance under its equity plans.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-decoration:underline;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Net Loss Per Common Share&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Basic net loss per common share is computed by dividing net loss by the weighted average number of common shares outstanding during the period. Diluted loss per share reflects the potential dilution that could occur if securities or other instruments to issue common stock were exercised or converted into common stock.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The following securities are excluded from the calculation of weighted average dilutive common shares because their inclusion would have been anti-dilutive:&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:72.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:72.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="3" valign="bottom" style="width:25.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;December&amp;nbsp;31,&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:72.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;2020&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;2019&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:72.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Warrants&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 2,011,313&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:72.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Options&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 3,427,705&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 2,237,438&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:72.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Restricted stock units&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 104,083&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 60,355&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:72.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Total potentially dilutive shares&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 5,543,101&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 2,297,793&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-decoration:underline;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Subsequent Events&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The Company has evaluated subsequent events through the date which the financial statements were issued. Based upon the evaluation, the Company did not identify any recognized or non-recognized subsequent events that would have required adjustment or disclosure in the financial statements, except as disclosed.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-decoration:underline;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Recently Adopted Accounting Pronouncements&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;In July 2017, the FASB issued Accounting Standards Update (&amp;#x201C;ASU&amp;#x201D;) 2017-11 &amp;#x201C;Earnings Per Share (Topic 260) and Derivatives and Hedging (Topic 815) - Accounting for Certain Financial Instruments with Down Round Features&amp;#x201D; (&amp;#x201C;ASU 2017-11&amp;#x201D;). Equity-linked instruments, such as warrants and convertible instruments may contain down round features that result in the strike price being reduced on the basis of the pricing of future equity offerings. Under ASU 2017-11, a down round feature will no longer require a freestanding equity-linked instrument (or embedded conversion option) to be classified as a liability that is remeasured at fair value through the income statement (i.e. marked-to-market). However, other features of the equity-linked instrument (or embedded conversion option) must still be evaluated to determine whether liability or equity classification is appropriate. Equity classified instruments are not marked-to-market. For earnings per share ("EPS") reporting, the ASU requires companies to recognize the effect of the down round feature only when it is triggered by treating it as a dividend and as a reduction of income available to common shareholders in basic EPS. The amendments in this ASU are effective for all entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. This standard, which the Company adopted on January 1, 2020, did not have a material impact on the Company&amp;#x2019;s financial position, results of operations, or cash flows.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;In March 2020, the FASB issued ASU 2020-03 &amp;#x201C;Codification Improvements to Financial Instruments&amp;#x201D; (&amp;#x201C;ASU 2020-03&amp;#x201D;). ASU 2020-03 improves and clarifies various financial instruments topics. ASU 2020-03 includes seven different issues that describe the areas of improvement and the related amendments to GAAP, intended to make the standards easier to understand and apply by eliminating inconsistencies and providing clarifications. The Company adopted ASU 2020-03 upon issuance, which did not have a material impact on the Company&amp;#x2019;s financial position, results of operations or cash flow.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-decoration:underline;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Recently Issued Accounting Pronouncements&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;In February&amp;nbsp;2016, the FASB issued ASU 2016&amp;#8209;02 &amp;#x201C;Leases (Topic 842)&amp;#x201D; (&amp;#x201C;ASU 2016&amp;#8209;02&amp;#x201D;). ASU 2016&amp;#8209;02 requires that a lessee recognize the assets and liabilities that arise from operating leases. A lessee should recognize in the statement of financial position a liability to make lease payments (the lease liability) and a right-of-use asset representing its right to use the underlying asset for the lease term. For leases with a term of 12&amp;nbsp;months or less, a lessee is permitted to make an accounting policy election by class of underlying asset not to recognize lease assets and lease liabilities. In transition, lessees and lessors are required to recognize and measure leases at the beginning of the earliest period presented using a modified retrospective approach. ASU 2016-02, as amended, is now effective for fiscal&amp;nbsp;years beginning after December&amp;nbsp;15, 2021, and interim periods within fiscal years beginning after December 15, 2022. The FASB issued ASU 2019-01 &amp;#x201C;Leases (Topic 842) Codification Improvements&amp;#x201D; in March 2019 and ASU 2018-10 &amp;#x201C;Codification Improvements to Topic 842, Leases&amp;#x201D; and ASU 2018-11 &amp;#x201C;Leases (Topic 842) Targeted Improvements&amp;#x201D; in July 2018, and ASU 2018-20 &amp;#x201C;Leases (Topic 842) - Narrow Scope Improvements for Lessors&amp;#x201D; in December 2018. ASU 2019-01, ASU 2018-10 and ASU 2018-20 provide certain amendments that affect narrow aspects of the guidance issued in ASU 2016-02. ASU 2018-11 allows all entities adopting ASU 2016-02 to choose an additional (and optional) transition method of adoption, under which an entity initially applies the new leases standard at the adoption date and recognizes a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption. The Company is currently evaluating ASU 2016-02 and its impact on its financial position, results of operations, and cash flows. The Company intends to adopt the ASU effective January 1, 2021 with no material impact.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;In August 2018, the FASB issued ASU No. 2018-13 &amp;#x201C;Fair Value Measurement (Topic 820): Disclosure Framework&amp;#x2014;Changes to the Disclosure Requirements for Fair Value Measurement&amp;#x201D; (&amp;#x201C;ASU 2018-13&amp;#x201D;). The amendments in ASU 2018-13 modify the disclosure requirements on fair value measurements based on the concepts in the FASB Concepts Statement, including the consideration of costs and benefits. The amendments on changes in unrealized gains and losses, the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements, and the narrative description of measurement uncertainty should be applied prospectively for only the most recent interim or annual period presented in the initial fiscal year of adoption. All other amendments should be applied retrospectively to all periods presented upon their effective date. The amendments are effective for fiscal years beginning after December 15, 2020. Early adoption is permitted, including adoption in an interim period. The Company is currently evaluating ASU 2018-13 and its impact on its financial position, results of operations and cash flows.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;In December 2019, the FASB issued ASU 2019-12, &amp;#x201C;Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes,&amp;#x201D; which is intended to simplify various aspects related to accounting for income taxes. ASU 2019-12 removes certain exceptions to the general principles in Topic 740 and also clarifies and amends existing guidance to improve consistent application. ASU 2019-12 is effective for fiscal years beginning after December 15, 2021. The Company is currently evaluating ASU 2019-12 and its impact financial position, results of operations, and cash flows.&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
  <us-gaap:StockholdersEquity contextRef="As_Of_12_31_2018" unitRef="Unit12" decimals="0">16875069</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="Unit12" decimals="0">53388216</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit12" decimals="0">1147</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="Unit12" decimals="0">-36514294</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="As_Of_12_31_2019" unitRef="Unit12" decimals="0">11740607</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="As_Of_12_31_2019" unitRef="Unit12" decimals="0">11740607</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="Unit12" decimals="0">69409949</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit12" decimals="0">1710</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="Unit12" decimals="0">-57671052</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="As_Of_12_31_2020" unitRef="Unit12" decimals="0">15303885</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="As_Of_12_31_2020" unitRef="Unit12" decimals="0">15303885</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="Unit12" decimals="0">92742306</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit12" decimals="0">2498</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="Unit12" decimals="0">-77440919</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="Duration_1_1_2020_To_12_31_2020">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-weight:bold;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Note&amp;nbsp;11&amp;nbsp;&amp;#x2013; Stockholders&amp;#x2019; Equity&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-decoration:underline;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Authorized Capital&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The Company is authorized to issue 90,000,000 shares of common stock, par value of&amp;#x2009;$0.0001 per share, and 6,000,000 shares of preferred stock, par value of&amp;#x2009;$0.0001 per share. The holders of the Company&amp;#x2019;s common stock are entitled to one vote per share. The Board of Directors is empowered, without stockholder approval, to issue preferred stock with dividend, liquidation, redemption, voting or other rights.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-decoration:underline;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Equity Incentive Plans&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;On April 7, 2020, the Company&amp;#x2019;s Board of Directors approved the Company&amp;#x2019;s Amended and Restated 2018 Omnibus Stock Incentive Plan (the &amp;#x201C;Restated Plan&amp;#x201D;), which stockholders approved on June 30, 2020. The Restated Plan makes certain changes to the Company&amp;#x2019;s 2018 Omnibus Stock Incentive Plan, as amended (the &amp;#x201C;2018 Plan, as amended&amp;#x201D;). The Restated Plan increases the number of shares of Company&amp;#x2019;s common stock reserved for issuance under the 2018 Plan, as amended to 2,950,000 shares. The Restated Plan requires that all equity awards issued under the Restated Plan vest at least twelve months from the applicable grant date, subject to accelerated vesting, and provides that no dividend or dividend equivalent will be paid on any unvested equity award, although dividends with respect to unvested portions of equity may accrue and be paid when, and if, the awards later vest and the shares are actually issued to the grantee. In addition, the Restated Plan sets an annual limit on the grant date fair value of awards to any non-employee director, together with any cash fees paid during the year, of $150,000, subject to certain exceptions for a non-executive chair of the Board. Finally, the Restated Plan makes several administrative changes to the 2018 Plan, as amended, including to clarify that awards made under the Restated Plan are intended to be exempt from or comply with Section 409(A) of the Internal Revenue Code of 1986, as amended. As of December 31, 2020, the number of securities remaining available for future issuance under equity compensation plans was 518,186.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;text-decoration:underline;"&gt;Warrants&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;A summary of the Warrant activity during the year ended December 31, 2020 is presented below:&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:58.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:05.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:58.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:05.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;Weighted&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:58.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:06.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;Weighted &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;Average&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:58.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:06.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;Average&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;Remaining&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:10.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;Aggregate&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:58.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;Number of&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:06.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;Exercise&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;Life&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:10.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;Intrinsic&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:58.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;Warrants&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:06.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;Price&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;In Years&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:10.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;Value&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:58.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Outstanding January 1, 2020&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:05.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:58.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Granted&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 3,344,154&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:05.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 2.33&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:58.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Exercised&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; (1,332,841)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:05.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 2.19&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:58.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Forfeited&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:05.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:58.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Outstanding December 31, 2020&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 2,011,313&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:05.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 2.43&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 3.8&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 7,215,147&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:58.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:05.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:58.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Exercisable December 31, 2020&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 2,011,313&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:05.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 2.43&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 3.8&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 7,215,147&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The following table presents information related to Warrants as of December 31, 2020:&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:22.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:22.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:22.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:22.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td colspan="3" valign="bottom" style="width:48.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;Warrants Outstanding&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="3" valign="bottom" style="width:48.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;Warrants Exercisable&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:22.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:22.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:22.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;Weighted&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:22.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:22.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:22.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;Outstanding&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:22.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;Average&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:22.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;Exercisable&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:22.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;Exercise&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:22.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;Number of&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:22.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;Remaining Life&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:22.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;Number of&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:22.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;Price&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:22.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;Warrants&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:22.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;In Years&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:22.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;Warrants&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:22.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;$2.0580 &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:22.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 48,549&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:22.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 0.2&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:22.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 48,549&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:22.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;$2.2700 &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:22.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 144,256&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:22.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 0.2&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:22.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 144,256&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:22.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;$2.4696 &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:22.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 1,602,128&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:22.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 4.2&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:22.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 1,602,128&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:22.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;$2.7240 &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:22.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 216,380&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:22.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 4.2&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:22.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 216,380&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:22.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:22.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 2,011,313&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:22.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 3.8&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:22.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 2,011,313&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;During the year ended December 31, 2020, Warrants for the purchase of 1,332,841 shares of the Company&amp;#x2019;s common stock with exercise prices of either $2.058 or $2.4696 per share, respectively, were exercised for aggregate proceeds of approximately $2.8 million. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;text-decoration:underline;"&gt;Public Offerings&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;On July 15, 2019, the Company closed an underwritten public offering of 4,388,490 shares of its common stock at a public offering price of $2.78 per share. The Company granted the underwriters a 30-day over-allotment option to purchase up to an additional 658,273 shares of the Company&amp;#x2019;s common stock at the same price, which was exercised in full on July 16, 2019. Including the over-allotment shares, the Company issued a total of 5,046,763 shares in the underwritten public offering, and received gross proceeds of approximately $14.0 million and net proceeds of approximately $13.0 million, after deducting underwriting discounts, commissions and other offering expenses, which were recorded as a reduction of additional paid-in capital.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;text-decoration:underline;"&gt;Securities Purchase Agreement&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;On March 24, 2020, the Company closed on a private placement of approximately $6.0 million of Units. Each Unit consists of (i) one share of the Company&amp;#x2019;s common stock, (ii) a one-year warrant to purchase 0.5 of a share of common stock (&amp;#x201C;Class A Warrant&amp;#x201D;), and (iii) a five-year warrant to purchase 0.75 of a share of common stock (&amp;#x201C;Class B Warrant&amp;#x201D;) (collectively, the Class A Warrants and Class B Warrants, the &amp;#x201C;Warrants&amp;#x201D;). The Units were sold to the public at a price of $2.21425 per Unit and to certain directors and executive officers at a price of $2.42625 per Unit. The Company generated approximately $5.3 million of net proceeds in the offering after deducting placement agent fees and offering expenses. In the offering, the Company issued an aggregate of 2,675,293 shares of common stock, Class A Warrants to purchase up to 1,337,659 shares of common stock, and Class B Warrants to purchase up to 2,006,495 shares of common stock. The exercise price of the Class A Warrants issued to the public is $2.058 per share and the exercise price of the Class A Warrants issued to the directors and officers is $2.27 per share. The exercise price of the Class B Warrants issued to the public is $2.4696 per share and the exercise price of the Class B Warrants issued to the directors and officers is $2.724 per share.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;In connection with the private placement, on March 23, 2020, the Company also entered into a Registration Rights Agreement with the investors. Pursuant to the Registration Rights Agreement, the Company must file with the SEC, no later than 30 days following the date on which the Company files its Form 10-K for the year ended December 31, 2019 with the SEC, a registration statement on Form S-3 covering the shares of common stock issued in the offering and the shares of common stock underlying the Warrants. The Company timely filed the registration statement on Form S-3 (Registration Statement No. 333-237790), which was declared and has remained effective with the SEC since May 13, 2020.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;text-decoration:underline;"&gt;Underwritten Public Offering&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;On August 19, 2020, the Company entered into an Underwriting Agreement (the &amp;#x201C;Underwriting Agreement&amp;#x201D;) with several underwriters (the &amp;#x201C;Underwriters&amp;#x201D;) in connection with the public offering (the &amp;#x201C;Offering&amp;#x201D;) of 3,333,334 shares of the Company&amp;#x2019;s common stock at a price of $3.60 per share, less underwriting discounts and commissions. In addition, pursuant to the terms of the Underwriting Agreement, the Company granted the Underwriters a 30-day option to purchase up to an additional 500,000 shares of the Company&amp;#x2019;s common stock at the same price. The Underwriting Agreement contains customary representations, warranties and covenants of the Company and also provides for customary indemnification by the Company and the Underwriters against certain liabilities and customary contribution provisions in respect of those liabilities.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The closing of the Offering occurred on August 21, 2020. At closing, the Company issued 3,833,334 shares of common stock and received net proceeds of approximately $12.5 million after deducting underwriting discounts and commissions and offering expenses of approximately $1.2 million.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The Offering was made pursuant to the Company&amp;#x2019;s effective registration statement on Form S-3 (Registration Statement No. 333-229365), including the prospectus dated February 12, 2019, as supplemented by the prospectus supplement dated August 19, 2020.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-decoration:underline;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Stock-Based Compensation Expense&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The Company records stock-based compensation expense related to stock options and restricted stock units (&amp;#x201C;RSUs&amp;#x201D;). For the&amp;nbsp;years ended December&amp;nbsp;31, 2020 and 2019, the Company recorded expense of $2,483,172 &amp;nbsp;($1,350,894 of which was included within research and development expenses and $1,132,278 was included within general and administrative expenses on the statements of operations) and $2,511,944 &amp;nbsp;($1,459,055 of which was included within research and development expenses and $1,052,889 was included within general and administrative expenses on the statements of operations), respectively. As of December&amp;nbsp;31, 2020, there was $3,720,221 of unrecognized stock-based compensation expense which will be recognized over a weighted average period of 2.0&amp;nbsp;years.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-decoration:underline;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Restricted Stock Units&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;On August 16, 2019, the Company granted to members of its Board of Directors an aggregate of 40,190 RSU under the 2018 Plan, as amended. The grants vest on the earlier of (i) the one-year anniversary of the date of grant and (ii) the date of the 2020 annual stockholders meeting, subject to the grantee remaining on the Board until then. The RSUs had a grant date fair value of $125,000, which were recognized over the vesting period.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;On September 11, 2020, the Company granted members of its Board of Directors an aggregate of 43,728 RSUs under the Restated Plan. Each RSU is subject to settlement into one share of the Company&amp;#x2019;s common stock. The RSUs vest on the earlier of (i) the one-year anniversary of the date of grant and (ii) the date of the 2021 annual stockholders meeting, subject to the grantee remaining on the Board until then. The RSUs had a grant date fair value of $150,000, which will be recognized over the vesting period.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;text-decoration:underline;"&gt;Stock Option Exercises&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;During the year ended December 31, 2020, stock options for the purchase of an aggregate of 36,391 shares of the Company&amp;#x2019;s common stock with exercise prices ranging from $1.95 to $3.11 per share were exercised for aggregate proceeds of $82,161.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;text-decoration:underline;"&gt;Stock Options&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;On January&amp;nbsp;2, 2019, stock options to purchase 180,000 and 133,686 shares of common stock with an exercise price of $1.24 and $1.95 per share, respectively, were exercised for aggregate proceeds of $483,888. In connection with the exercise of the stock options, the Company remitted a portion of an employee&amp;#x2019;s payroll taxes of $62,193 to the Internal Revenue Service.&amp;nbsp;&amp;nbsp;The Company was reimbursed in full by the employee.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;On January 14, 2019, the Company granted ten-year stock options to purchase an aggregate of 11,000 shares of common stock to its employees under the 2018 Plan. The 11,000 shares vest over three years from the date of grant with one-third vesting on the one-year anniversary of the date of grant and the balance vesting monthly over the remaining 24 months, subject to continued service to the Company. The stock options have an exercise price of $2.74 per share, which represents the Company&amp;#x2019;s closing stock price on the date of grant. The stock options had a grant date value of $27,500, which the Company expects to recognize over the vesting period.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;On February&amp;nbsp;6, 2019, stock options to purchase an aggregate of 320,001 shares of common stock with an exercise price of $1.24 per share were exercised on a cashless basis, which resulted in the issuance of an aggregate of 236,466 shares of common stock.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;On February&amp;nbsp;13, 2019, the Board of Directors of the Company approved the acceleration and immediate vesting of 124,210 stock options originally granted to Dr.&amp;nbsp;Ianchulev on July&amp;nbsp;24, 2018 in connection with his employment. In connection with the acceleration and immediate vesting, the Company recognized $609,322 of stock-based compensation expense during the year ended December 31, 2019, which represents the remaining unamortized grant date fair value of the award.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;On May 14, 2019, stock options to purchase 34,815 shares of common stock with an exercise price of $1.95 per share were exercised for aggregate proceeds of $67,889.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;On August 16, 2019, the Company granted ten-year stock options to purchase an aggregate of 681,572 shares of common stock to its employees, consultants and directors under the 2018 Plan, as amended.&amp;nbsp;&amp;nbsp;Of the 681,572 shares, (i) 636,287 vest over three years from the date of grant with one-third vesting on the one-year anniversary of the date of grant and the balance vesting monthly over the remaining 24 months, subject to continued service to the Company and (ii) 45,285 vest on the earlier of the one-year anniversary of the date of grant and the date of the 2020 annual stockholders meeting, subject to continued service to the Company. The stock options have an exercise price of $3.11 per share, which represents the Company&amp;#x2019;s closing stock price on the date of grant.&amp;nbsp;&amp;nbsp;The stock options had a grant date value of $1,909,700, which the Company expects to recognize over the vesting period.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;On January 31, 2020, the Company granted ten-year stock options to purchase 25,000 shares of common stock to its employees under the 2018 Plan, as amended. The shares vest over three years from the date of grant with one-third vesting on the one-year anniversary of the date of grant and the balance vesting monthly over the remaining 24 months. The stock options have an exercise price of $4.68 per share, which represents the Company&amp;#x2019;s closing stock price on the date of grant. The stock options had a grant date fair value of $103,400, which the Company expects to recognize over the vesting period. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;On May 28, 2020, the Company granted ten-year stock options to purchase 263,500 shares of common stock to its employees under the Restated Plan. The shares vest over three years from the date of grant with one-third vesting on the one-year anniversary of the date of grant and the balance vesting monthly over the remaining 24 months. The stock options have an exercise price of $2.89 per share, which represents the Company&amp;#x2019;s closing stock price on the date of grant. The stock options had a grant date fair value of $587,100, which the Company expects to recognize over the vesting period.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;On June 3, 2020, the Company granted ten-year stock options to purchase 764,419 shares of common stock to its executive officers under the Restated Plan. The shares vest over three years from the date of grant with one-third vesting on the one-year anniversary of the date of grant and the balance vesting monthly over the remaining 24 months. The stock options have an exercise price of $2.72 per share, which represents the Company&amp;#x2019;s closing stock price on the date of grant. The stock options had a grant date fair value of $1,603,600, which the Company expects to recognize over the vesting period.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;On July 28, 2020, the Company granted ten-year stock options to purchase 43,000 shares of common stock to an employee under the Restated Plan. The shares vest over three years from the date of grant with one-third vesting on the one-year anniversary of the date of grant and the balance vesting monthly over the remaining 24 months. The stock options have an exercise price of $3.71 per share, which represents the Company&amp;#x2019;s closing stock price on the date of grant. The stock options had a grant date fair value of $122,400, which the Company expects to recognize over the vesting period.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;On September 8, 2020, the Company granted ten-year stock options to purchase 45,000 shares of common stock to employees and consultants under the Restated Plan. The shares vest over three years from the date of grant with one-third vesting on the one-year anniversary of the date of grant and the balance vesting monthly over the remaining 24 months. The stock options have an exercise price of $3.48 per share, which represents the Company&amp;#x2019;s closing stock price on the date of grant. The stock options had a grant date fair value of $126,700, which the Company expects to recognize over the vesting period.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;text-decoration:underline;"&gt;Stock Options - Continued&lt;/font&gt;&lt;font style="display:inline;"&gt; On September 11, 2020, the Company granted ten-year stock options to purchase 58,920 shares of common stock under the Restated Plan to members of its Board of Directors. The shares vest on the earlier of (i) the one-year anniversary of the date of grant and (ii) the date of the 2021 annual stockholders meeting, subject to the grantee remaining on the Board until then. The stock options have an exercise price of $3.43 per share, which represents the Company&amp;#x2019;s closing stock price on the date of grant. The stock options had a grant date fair value of $155,400, which the Company expects to recognize over the vesting period.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;On December 23, 2020, the Company granted ten-year stock options to purchase 50,000 shares of common stock to an employee under the Restated Plan. The shares vest over three years from the date of grant with one-third vesting on the one-year anniversary of the date of grant and the balance vesting monthly over the remaining 24 months. The stock options have an exercise price of $5.77 per share, which represents the Company&amp;#x2019;s closing stock price on the date of grant. The stock options had a grant date fair value of $218,700, which the Company expects to recognize over the vesting period.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;In applying the Black-Scholes option pricing model to stock options granted, the Company used the following approximate assumptions:&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:64.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:64.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="3" valign="bottom" style="width:32.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;For&amp;nbsp;the&amp;nbsp;Year Ended &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:64.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="3" valign="bottom" style="width:32.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;December&amp;nbsp;31,&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:64.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;2020&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;2019&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:64.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Expected term (years)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;5.85 - 10.00&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;5.50 - 10.00&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:64.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Risk free interest rate&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;0.26% - 1.32%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;1.42% - 2.53%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:64.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Expected volatility&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;96% - 99%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;134 - 139%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:64.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Expected dividends&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;0.00%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;0.00%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The Company has computed the fair value of stock options granted using the Black-Scholes option pricing model. Option forfeitures are accounted for at the time of occurrence. The expected term used for options issued is the estimated period of time that options granted are expected to be outstanding. The Company utilizes the &amp;#x201C;simplified&amp;#x201D; method to develop an estimate of the expected term of &amp;#x201C;plain vanilla&amp;#x201D; option grants. The Company does not currently have a sufficient trading history to support its historical volatility calculations. Accordingly, the Company is utilizing an expected volatility figure based on a review of the historical volatility of three comparable entities over a period of time equivalent to the expected life of the instrument being valued. The risk-free interest rate was determined from the implied yields from U.S. Treasury zero-coupon bonds with a remaining term consistent with the expected term of the instrument being valued.&amp;nbsp;&amp;nbsp;The Company has not declared dividends, is currently in the development stage and has no plan to declare future dividends at this time.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The weighted average estimated grant date fair value of the stock options granted for the&amp;nbsp;years ended December&amp;nbsp;31, 2020 and 2019 was approximately $3.01 and $3.10 per share, respectively.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;A summary of the option activity during the&amp;nbsp;year ended December 31, 2020 is presented below:&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:48.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:48.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;Weighted&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:48.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:08.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;Weighted&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;Average&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:48.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:08.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;Average&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;Remaining&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:13.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;Aggregate&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:48.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;Number&amp;nbsp;of&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:08.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;Exercise&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;Life&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:13.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;Intrinsic&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:48.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;Options&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:08.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;Price&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;In&amp;nbsp;Years&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:13.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;Value&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:48.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Outstanding January 1, 2020&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 2,237,438&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 3.51&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:48.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Granted&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 1,249,839&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 3.01&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:48.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Exercised&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; (36,391)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 2.26&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:48.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Forfeited&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; (23,181)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 4.59&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:48.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Outstanding December&amp;nbsp;31,&amp;nbsp;2020&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 3,427,705&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 3.37&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 8.0&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 9,843,341&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:48.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:48.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Exercisable December&amp;nbsp;31,&amp;nbsp;2020&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 1,768,292&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 3.48&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 6.8&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 5,013,118&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The following table presents information related to stock options as of December 31, 2020:&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:02.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:20.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:18.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:25.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:18.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:02.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="3" valign="bottom" style="width:43.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;Options Outstanding&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="3" valign="bottom" style="width:48.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;Options&amp;nbsp;Exercisable&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:02.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:20.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:18.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:25.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;Weighted&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:18.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:02.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:20.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:18.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;Outstanding&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:25.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;Average&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:18.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;Exercisable&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:02.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:20.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;Exercise&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:18.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;Number&amp;nbsp;of&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:25.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;Remaining&amp;nbsp;Life&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:18.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;Number&amp;nbsp;of&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:02.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:20.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;Price&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:18.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;Options&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:25.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;In&amp;nbsp;Years&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:18.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;Options&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:02.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:20.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 1.24&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:18.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 260,000&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:25.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 4.2&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:18.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 260,000&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:02.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:20.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 1.95&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:18.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 673,544&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:25.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 6.5&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:18.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 673,544&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:02.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:20.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 2.72&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:18.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 764,419&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:25.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:18.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:02.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:20.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 2.74&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:18.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 6,000&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:25.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 8.0&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:18.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 3,833&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:02.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:20.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 2.89&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:18.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 263,500&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:25.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:18.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:02.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:20.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 3.11&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:18.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 659,849&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:25.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 8.6&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:18.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 318,432&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:02.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:20.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 3.43&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:18.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 58,920&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:25.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:18.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:02.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:20.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 3.48&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:18.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 45,000&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:25.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:18.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:02.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:20.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 3.71&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:18.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 43,000&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:25.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:18.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:02.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:20.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 4.00&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:18.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 2,000&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:25.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 7.9&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:18.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 1,390&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:02.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:20.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 4.68&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:18.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 25,000&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:25.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:18.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:02.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:20.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 5.10&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:18.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 6,000&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:25.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 7.7&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:18.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 4,500&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:02.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:20.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 5.19&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:18.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 16,500&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:25.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 7.7&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:18.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 12,375&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:02.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:20.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 5.25&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:18.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 26,668&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:25.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 5.8&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:18.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 26,668&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:02.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:20.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 5.77&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:18.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 50,000&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:25.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:18.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:02.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:20.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 6.20&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:18.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 300,387&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:25.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 7.6&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:18.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 270,476&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:02.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:20.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 6.30&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:18.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 60,000&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:25.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 7.5&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:18.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 48,333&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:02.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:20.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 8.72&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:18.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 166,918&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:25.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 7.3&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:18.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 148,741&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:02.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:20.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:18.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 3,427,705&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:25.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 6.8&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:18.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 1,768,292&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
			&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
  <us-gaap:StockholdersEquityNoteRedeemablePreferredStockIssuePolicy contextRef="Duration_1_1_2020_To_12_31_2020">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-decoration:underline;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Preferred Stock&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The Company applies the accounting standards for distinguishing liabilities from equity when determining the classification and measurement of its preferred stock. Preferred shares subject to mandatory redemption are classified as liability instruments and are measured at fair value. Conditionally redeemable preferred shares (including preferred shares that feature redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company&amp;#x2019;s control) are classified as temporary equity. At all other times, preferred shares are classified as stockholders&amp;#x2019; equity.&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:StockholdersEquityNoteRedeemablePreferredStockIssuePolicy>
  <us-gaap:StockIssued1 contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit12" decimals="0">24</us-gaap:StockIssued1>
  <us-gaap:StockIssued1 contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit12" decimals="0">0</us-gaap:StockIssued1>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="Duration_2_1_2019_To_2_6_2019" unitRef="Unit1" decimals="0">236466</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="Duration_7_15_2019_To_7_15_2019" unitRef="Unit1" decimals="0">5046763</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="Duration_7_15_2019_To_7_15_2019_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember" unitRef="Unit1" decimals="0">4388490</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="Duration_7_15_2019_To_7_15_2019_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember" unitRef="Unit1" decimals="0">658273</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="Duration_1_31_2020_To_1_31_2020_us-gaap_PlanNameAxis_eyen_EmployeesConsultantsAndDirectorsUnder2018PlanMember" unitRef="Unit1" decimals="0">25000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="Duration_3_24_2020_To_3_24_2020" unitRef="Unit1" decimals="0">2675293</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="Duration_3_24_2020_To_3_24_2020_us-gaap_StatementEquityComponentsAxis_eyen_ClassBWarrantsMember" unitRef="Unit1" decimals="0">2006495</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="Duration_3_24_2020_To_3_24_2020_us-gaap_StatementEquityComponentsAxis_eyen_ClassWarrantsMember" unitRef="Unit1" decimals="0">1337659</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="Duration_3_24_2020_To_3_24_2020_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember" unitRef="Unit1" decimals="-5">6000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="Duration_5_28_2020_To_5_28_2020_us-gaap_PlanNameAxis_eyen_EmployeesConsultantsAndDirectorsUnder2018PlanMember" unitRef="Unit1" decimals="0">263500</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="Duration_6_3_2020_To_6_3_2020_us-gaap_PlanNameAxis_eyen_EmployeesConsultantsAndDirectorsUnder2018PlanMember" unitRef="Unit1" decimals="0">764419</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="Duration_7_28_2020_To_7_28_2020_us-gaap_PlanNameAxis_eyen_EmployeesConsultantsAndDirectorsUnder2018PlanMember" unitRef="Unit1" decimals="0">43000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="Duration_8_21_2020_To_8_21_2020_us-gaap_SubsidiarySaleOfStockAxis_eyen_UnderwrittenPublicOfferingMember" unitRef="Unit1" decimals="0">3833334</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="Duration_9_8_2020_To_9_8_2020_us-gaap_PlanNameAxis_eyen_EmployeesConsultantsAndDirectorsUnder2018PlanMember" unitRef="Unit1" decimals="0">45000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="Duration_9_11_2020_To_9_11_2020_us-gaap_PlanNameAxis_eyen_EmployeesConsultantsAndDirectorsUnder2018PlanMember" unitRef="Unit1" decimals="0">58920</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="Duration_12_23_2020_To_12_23_2020_us-gaap_PlanNameAxis_eyen_EmployeesConsultantsAndDirectorsUnder2018PlanMember" unitRef="Unit1" decimals="0">50000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit1" decimals="0">348501</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="Duration_1_2_2019_To_1_2_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit1" decimals="0">133686</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="Duration_1_2_2019_To_1_2_2019_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_StockOptionMember" unitRef="Unit1" decimals="0">180000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="Duration_2_1_2019_To_2_6_2019" unitRef="Unit1" decimals="0">320001</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="Duration_5_14_2019_To_5_14_2019" unitRef="Unit1" decimals="0">34815</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit1" decimals="0">36391</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit1" decimals="0">36391</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_StockOptionMember" unitRef="Unit1" decimals="0">36391</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit12" decimals="0">551777</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="Unit12" decimals="0">551743</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit12" decimals="0">34</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="Unit12" decimals="0">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit12" decimals="0">82161</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="Unit12" decimals="0">82157</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit12" decimals="0">4</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="Unit12" decimals="0">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:SubsequentEventsPolicyPolicyTextBlock contextRef="Duration_1_1_2020_To_12_31_2020">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-decoration:underline;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Subsequent Events&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The Company has evaluated subsequent events through the date which the financial statements were issued. Based upon the evaluation, the Company did not identify any recognized or non-recognized subsequent events that would have required adjustment or disclosure in the financial statements, except as disclosed.&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:SubsequentEventsPolicyPolicyTextBlock>
  <us-gaap:SubsequentEventsTextBlock contextRef="Duration_1_1_2020_To_12_31_2020">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt 0pt 8pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-weight:bold;font-size:10pt;"&gt;Note&amp;nbsp;13&amp;nbsp;&amp;#x2013; Subsequent Events&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 8pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-size:10pt;text-decoration:underline;"&gt;Management Option Grants&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 8pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-size:10pt;"&gt;Subsequent to December 31, 2020, the Company granted options to its executive officers for a total of&amp;nbsp;&lt;/font&gt;&lt;font style="display:inline;font-size:10pt;"&gt;652,899 shares, which grants are subject to stockholder approval of an amendment to the Restated Plan to increase the share reserve thereunder at the 2021 Annual Meeting of Stockholders. The options, would have a ten year term, vesting one-third on the one year anniversary of the date of grant and then in equal increments on each of the 24 one-month anniversaries thereafter, subject to continued employment, and bear an exercise price of&amp;nbsp;$6.01, &amp;nbsp;per share for total possible consideration to the Company of approximately $3.9 million. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 8pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-size:10pt;text-decoration:underline;"&gt;Stock Warrant Exercises&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-size:10pt;"&gt;Subsequent to December 31, 2020, the Company issued an aggregate of 644,992 shares of common stock pursuant to the exercise of warrants for aggregate proceeds of $1,530,989 at exercise prices ranging from $2.06&amp;nbsp;to $2.47.&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
  <us-gaap:SupplementalUnemploymentBenefitsSalaryContinuation contextRef="As_Of_12_31_2020" unitRef="Unit12" decimals="0">1677000</us-gaap:SupplementalUnemploymentBenefitsSalaryContinuation>
  <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued contextRef="As_Of_12_31_2020" unitRef="Unit12" decimals="0">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
  <us-gaap:UseOfEstimates contextRef="Duration_1_1_2020_To_12_31_2020">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-decoration:underline;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Use of Estimates&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Preparation of financial statements in conformity with accounting principles generally accepted in the United States of America (&amp;#x201C;U.S. GAAP&amp;#x201D;) requires management to make estimates, judgments and assumptions that affect the amounts reported in the financial statements and the amounts disclosed in the related notes to the financial statements. The Company bases its estimates and judgments on historical experience and on various other assumptions that it believes are reasonable under the circumstances. The amounts of assets and liabilities reported in the Company&amp;#x2019;s balance sheets and the amounts of expenses reported for each of the periods presented are affected by estimates and assumptions, which are used for, but not limited to, fair value calculations for equity securities, establishment of valuation allowances for deferred tax assets, stock-based compensation, the recoverability and useful lives of long-lived assets, the recovery of deferred costs and the deferral of revenues. Certain of the Company&amp;#x2019;s estimates could be affected by external conditions, including those unique to the Company and general economic conditions. It is reasonably possible that actual results could differ from those estimates.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;See Note 2 - Summary of Significant Accounting Policies&amp;#x2009;&amp;#x2014;&amp;#x2009;Stock-Based Compensation for additional discussion of the use of estimates in estimating the fair value of the Company&amp;#x2019;s common stock. &lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:UseOfEstimates>
  <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit12" decimals="0">-4931158</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
  <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit12" decimals="0">-4231134</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit1" decimals="0">14349738</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="Duration_1_1_2020_To_12_31_2020" unitRef="Unit1" decimals="0">21054706</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:WorkersCompensationLiabilityCurrent contextRef="As_Of_12_31_2019" unitRef="Unit12" decimals="0">916873</us-gaap:WorkersCompensationLiabilityCurrent>
  <us-gaap:WorkersCompensationLiabilityCurrent contextRef="As_Of_12_31_2020" unitRef="Unit12" decimals="0">1150672</us-gaap:WorkersCompensationLiabilityCurrent>
  <!--Footnote Section-->
  <link:footnoteLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <link:loc xlink:type="locator" xlink:href="#Item-0001" xlink:label="Item-0001_lbl" />
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Item-0001_lbl" xlink:to="Footnote-01" order="1" />
    <link:loc xlink:type="locator" xlink:href="#Item-0011" xlink:label="Item-0011_lbl" />
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Item-0011_lbl" xlink:to="Footnote-03" order="1" />
    <link:loc xlink:type="locator" xlink:href="#Item-0006" xlink:label="Item-0006_lbl" />
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Item-0006_lbl" xlink:to="Footnote-02" order="1" />
    <link:loc xlink:type="locator" xlink:href="#Item-0005" xlink:label="Item-0005_lbl" />
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Item-0005_lbl" xlink:to="Footnote-01" order="1" />
    <link:loc xlink:type="locator" xlink:href="#Item-0003" xlink:label="Item-0003_lbl" />
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Item-0003_lbl" xlink:to="Footnote-01" order="1" />
    <link:loc xlink:type="locator" xlink:href="#Item-0002" xlink:label="Item-0002_lbl" />
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Item-0002_lbl" xlink:to="Footnote-01" order="1" />
    <link:loc xlink:type="locator" xlink:href="#Item-0004" xlink:label="Item-0004_lbl" />
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Item-0004_lbl" xlink:to="Footnote-01" order="1" />
    <link:loc xlink:type="locator" xlink:href="#Item-0015" xlink:label="Item-0015_lbl" />
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Item-0015_lbl" xlink:to="Footnote-03" order="1" />
    <link:loc xlink:type="locator" xlink:href="#Item-0013" xlink:label="Item-0013_lbl" />
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Item-0013_lbl" xlink:to="Footnote-03" order="1" />
    <link:loc xlink:type="locator" xlink:href="#Item-0012" xlink:label="Item-0012_lbl" />
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Item-0012_lbl" xlink:to="Footnote-03" order="1" />
    <link:loc xlink:type="locator" xlink:href="#Item-0014" xlink:label="Item-0014_lbl" />
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Item-0014_lbl" xlink:to="Footnote-03" order="1" />
    <link:loc xlink:type="locator" xlink:href="#Item-0010" xlink:label="Item-0010_lbl" />
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Item-0010_lbl" xlink:to="Footnote-02" order="1" />
    <link:loc xlink:type="locator" xlink:href="#Item-0008" xlink:label="Item-0008_lbl" />
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Item-0008_lbl" xlink:to="Footnote-02" order="1" />
    <link:loc xlink:type="locator" xlink:href="#Item-0007" xlink:label="Item-0007_lbl" />
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Item-0007_lbl" xlink:to="Footnote-02" order="1" />
    <link:loc xlink:type="locator" xlink:href="#Item-0009" xlink:label="Item-0009_lbl" />
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Item-0009_lbl" xlink:to="Footnote-02" order="1" />
    <link:loc xlink:type="locator" xlink:href="#Item-0017" xlink:label="Item-0017_lbl" />
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Item-0017_lbl" xlink:to="Footnote-04" order="1" />
    <link:loc xlink:type="locator" xlink:href="#Item-0016" xlink:label="Item-0016_lbl" />
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Item-0016_lbl" xlink:to="Footnote-04" order="1" />
    <link:loc xlink:type="locator" xlink:href="#Item-0021" xlink:label="Item-0021_lbl" />
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Item-0021_lbl" xlink:to="Footnote-06" order="1" />
    <link:loc xlink:type="locator" xlink:href="#Item-0020" xlink:label="Item-0020_lbl" />
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Item-0020_lbl" xlink:to="Footnote-06" order="1" />
    <link:loc xlink:type="locator" xlink:href="#Item-0019" xlink:label="Item-0019_lbl" />
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Item-0019_lbl" xlink:to="Footnote-05" order="1" />
    <link:loc xlink:type="locator" xlink:href="#Item-0018" xlink:label="Item-0018_lbl" />
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Item-0018_lbl" xlink:to="Footnote-05" order="1" />
    <link:footnote xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:label="Footnote-01" xml:lang="en-US">[1] Includes gross proceeds of $14,030,001, less total issuance costs of $1,071,426</link:footnote>
    <link:footnote xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:label="Footnote-03" xml:lang="en-US">[3] Includes gross proceeds of $13,800,002, less total issuance costs of $1,304,294.</link:footnote>
    <link:footnote xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:label="Footnote-02" xml:lang="en-US">[2] Includes gross proceeds of $5,984,931, less total issuance costs of $533,189.</link:footnote>
    <link:footnote xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:label="Footnote-04" xml:lang="en-US">Includes gross proceeds of $14,030,001, less issuance costs of $815,052 deducted directly from the offering proceeds.</link:footnote>
    <link:footnote xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:label="Footnote-06" xml:lang="en-US">Includes gross proceeds of $13,800,002, less issuance costs of $1,066,000 deducted directly from the offering proceeds.</link:footnote>
    <link:footnote xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:label="Footnote-05" xml:lang="en-US">Includes gross proceeds of $5,984,931, less issuance costs of $415,795 deducted directly from the private placement proceeds.</link:footnote>
  </link:footnoteLink>
</xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>9
<FILENAME>eyen-20201231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.9.3.5 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/31/2021 1:30:34 AM-->
<!--Modified on: 3/31/2021 1:30:34 AM-->
<schema xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:exch="http://xbrl.sec.gov/exch/2020-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:us-types="http://fasb.org/us-types/2020-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2020-01-31" xmlns:eyen="http://www.eyenoviabio.com/20201231" xmlns:sic="http://xbrl.sec.gov/sic/2020-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:country="http://xbrl.sec.gov/country/2020-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns="http://www.w3.org/2001/XMLSchema" targetNamespace="http://www.eyenoviabio.com/20201231" elementFormDefault="qualified" xmlns:srt-types="http://fasb.org/srt-types/2020-01-31">
  <annotation>
    <appinfo>
      <link:roleType roleURI="http://www.eyenoviabio.com/role/StatementBalanceSheets" id="StatementBalanceSheets">
        <link:definition>00100 - Statement - Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eyenoviabio.com/role/StatementStatementsOfOperations" id="StatementStatementsOfOperations">
        <link:definition>00200 - Statement - Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eyenoviabio.com/role/StatementStatementsOfCashFlows" id="StatementStatementsOfCashFlows">
        <link:definition>00400 - Statement - Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eyenoviabio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails" id="DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails">
        <link:definition>40301 - Disclosure - Prepaid Expenses and Other Current Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eyenoviabio.com/role/DisclosurePropertyAndEquipmentNetPropertyAndEquipmentDetails" id="DisclosurePropertyAndEquipmentNetPropertyAndEquipmentDetails">
        <link:definition>40401 - Disclosure - Property and Equipment, Net - Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eyenoviabio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails" id="DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails">
        <link:definition>40501 - Disclosure - Accrued Expenses and Other Current Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eyenoviabio.com/role/DisclosureAccruedCompensationDetails" id="DisclosureAccruedCompensationDetails">
        <link:definition>40601 - Disclosure - Accrued Compensation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eyenoviabio.com/role/DisclosureNotesPayableScheduleOfNotesPayableDetails" id="DisclosureNotesPayableScheduleOfNotesPayableDetails">
        <link:definition>40701 - Disclosure - Notes Payable - Schedule of notes payable (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eyenoviabio.com/role/DisclosureIncomeTaxesProvisionForIncomeTaxesDetails" id="DisclosureIncomeTaxesProvisionForIncomeTaxesDetails">
        <link:definition>40801 - Disclosure - Income Taxes - provision for income taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eyenoviabio.com/role/DisclosureIncomeTaxesDeferredTaxAssetsDetails" id="DisclosureIncomeTaxesDeferredTaxAssetsDetails">
        <link:definition>40803 - Disclosure - Income Taxes - Deferred tax assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eyenoviabio.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumPaymentsUnderOperatingLeaseAgreementDetails" id="DisclosureCommitmentsAndContingenciesFutureMinimumPaymentsUnderOperatingLeaseAgreementDetails">
        <link:definition>40901 - Disclosure - Commitments and Contingencies - Future Minimum Payments under Operating Lease Agreement (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eyenoviabio.com/role/StatementBalanceSheetsParenthetical" id="StatementBalanceSheetsParenthetical">
        <link:definition>00105 - Statement - Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eyenoviabio.com/role/StatementStatementsOfChangesInStockholdersEquity" id="StatementStatementsOfChangesInStockholdersEquity">
        <link:definition>00300 - Statement - Statements of Changes in Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eyenoviabio.com/role/StatementStatementsOfChangesInStockholdersEquityParenthetical" id="StatementStatementsOfChangesInStockholdersEquityParenthetical">
        <link:definition>00305 - Statement - Statements of Changes in Stockholders' Equity (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eyenoviabio.com/role/StatementStatementsOfCashFlowsParenthetical" id="StatementStatementsOfCashFlowsParenthetical">
        <link:definition>00405 - Statement - Statements of Cash Flows (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eyenoviabio.com/role/DisclosureBusinessOrganizationAndNatureOfOperationsDetails" id="DisclosureBusinessOrganizationAndNatureOfOperationsDetails">
        <link:definition>40101 - Disclosure - Business Organization and Nature of Operations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAntiDilutiveWeightedAverageDilutedCommonSharesDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesAntiDilutiveWeightedAverageDilutedCommonSharesDetails">
        <link:definition>40201 - Disclosure - Summary of Significant Accounting Policies - Anti-dilutive weighted average diluted common shares (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
        <link:definition>40202 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eyenoviabio.com/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetails" id="DisclosurePropertyAndEquipmentNetAdditionalInformationDetails">
        <link:definition>40402 - Disclosure - Property and Equipment, Net - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eyenoviabio.com/role/DisclosureNotesPayableAdditionalInformationDetails" id="DisclosureNotesPayableAdditionalInformationDetails">
        <link:definition>40702 - Disclosure - Notes Payable - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eyenoviabio.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxRateReconciliationDetails" id="DisclosureIncomeTaxesEffectiveIncomeTaxRateReconciliationDetails">
        <link:definition>40802 - Disclosure - Income Taxes - Effective income tax rate reconciliation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eyenoviabio.com/role/DisclosureIncomeTaxesAdditionalInformationDetails" id="DisclosureIncomeTaxesAdditionalInformationDetails">
        <link:definition>40804 - Disclosure - Income Taxes - Additional information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eyenoviabio.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" id="DisclosureCommitmentsAndContingenciesAdditionalInformationDetails">
        <link:definition>40902 - Disclosure - Commitments and Contingencies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eyenoviabio.com/role/DisclosureRelatedPartyTransactionsDetails" id="DisclosureRelatedPartyTransactionsDetails">
        <link:definition>41001 - Disclosure - Related Party Transactions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eyenoviabio.com/role/DisclosureStockholdersEquityAdditionalInformationRelatedToWarrantsDetails" id="DisclosureStockholdersEquityAdditionalInformationRelatedToWarrantsDetails">
        <link:definition>41102 - Disclosure - Stockholders' Equity - Additional information related to Warrants (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eyenoviabio.com/role/DisclosureStockholdersEquityBlackScholesOptionDetails" id="DisclosureStockholdersEquityBlackScholesOptionDetails">
        <link:definition>41103 - Disclosure - Stockholders' Equity - Black Scholes option (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eyenoviabio.com/role/DisclosureStockholdersEquitySummaryOfOptionActivityDetails" id="DisclosureStockholdersEquitySummaryOfOptionActivityDetails">
        <link:definition>41104 - Disclosure - Stockholders' Equity - Summary of option activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eyenoviabio.com/role/DisclosureStockholdersEquitySummaryOfInformationRelatedToStockOptionsDetails" id="DisclosureStockholdersEquitySummaryOfInformationRelatedToStockOptionsDetails">
        <link:definition>41105 - Disclosure - Stockholders' Equity - Summary of information related to stock options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eyenoviabio.com/role/DisclosureStockholdersEquityAdditionalInformationDetails" id="DisclosureStockholdersEquityAdditionalInformationDetails">
        <link:definition>41106 - Disclosure - Stockholders' Equity - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eyenoviabio.com/role/DisclosureEmployeeBenefitPlansDetails" id="DisclosureEmployeeBenefitPlansDetails">
        <link:definition>41201 - Disclosure - Employee Benefit Plans (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eyenoviabio.com/role/DisclosureSubsequentEventsDetails" id="DisclosureSubsequentEventsDetails">
        <link:definition>41301 - Disclosure - Subsequent Events (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eyenoviabio.com/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>00090 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eyenoviabio.com/role/DisclosureBusinessOrganizationAndNatureOfOperations" id="DisclosureBusinessOrganizationAndNatureOfOperations">
        <link:definition>10101 - Disclosure - Business Organization and Nature of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPolicies" id="DisclosureSummaryOfSignificantAccountingPolicies">
        <link:definition>10201 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eyenoviabio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssets" id="DisclosurePrepaidExpensesAndOtherCurrentAssets">
        <link:definition>10301 - Disclosure - Prepaid Expenses and Other Current Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eyenoviabio.com/role/DisclosurePropertyAndEquipmentNet" id="DisclosurePropertyAndEquipmentNet">
        <link:definition>10401 - Disclosure - Property and Equipment, Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eyenoviabio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities" id="DisclosureAccruedExpensesAndOtherCurrentLiabilities">
        <link:definition>10501 - Disclosure - Accrued Expenses and Other Current Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eyenoviabio.com/role/DisclosureAccruedCompensation" id="DisclosureAccruedCompensation">
        <link:definition>10601 - Disclosure - Accrued Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eyenoviabio.com/role/DisclosureNotesPayable" id="DisclosureNotesPayable">
        <link:definition>10701 - Disclosure - Notes Payable</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eyenoviabio.com/role/DisclosureIncomeTaxes" id="DisclosureIncomeTaxes">
        <link:definition>10801 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eyenoviabio.com/role/DisclosureCommitmentsAndContingencies" id="DisclosureCommitmentsAndContingencies">
        <link:definition>10901 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eyenoviabio.com/role/DisclosureRelatedPartyTransactions" id="DisclosureRelatedPartyTransactions">
        <link:definition>11001 - Disclosure - Related Party Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eyenoviabio.com/role/DisclosureStockholdersEquity" id="DisclosureStockholdersEquity">
        <link:definition>11101 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eyenoviabio.com/role/DisclosureEmployeeBenefitPlans" id="DisclosureEmployeeBenefitPlans">
        <link:definition>11201 - Disclosure - Employee Benefit Plans</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eyenoviabio.com/role/DisclosureSubsequentEvents" id="DisclosureSubsequentEvents">
        <link:definition>11301 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" id="DisclosureSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>20202 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" id="DisclosureSummaryOfSignificantAccountingPoliciesTables">
        <link:definition>30203 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eyenoviabio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsTables" id="DisclosurePrepaidExpensesAndOtherCurrentAssetsTables">
        <link:definition>30303 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eyenoviabio.com/role/DisclosurePropertyAndEquipmentNetTables" id="DisclosurePropertyAndEquipmentNetTables">
        <link:definition>30403 - Disclosure - Property and Equipment, Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eyenoviabio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables" id="DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables">
        <link:definition>30503 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eyenoviabio.com/role/DisclosureAccruedCompensationTables" id="DisclosureAccruedCompensationTables">
        <link:definition>30603 - Disclosure - Accrued Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eyenoviabio.com/role/DisclosureNotesPayableTables" id="DisclosureNotesPayableTables">
        <link:definition>30703 - Disclosure - Notes Payable (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eyenoviabio.com/role/DisclosureIncomeTaxesTables" id="DisclosureIncomeTaxesTables">
        <link:definition>30803 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eyenoviabio.com/role/DisclosureCommitmentsAndContingenciesTables" id="DisclosureCommitmentsAndContingenciesTables">
        <link:definition>30903 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eyenoviabio.com/role/DisclosureStockholdersEquityTables" id="DisclosureStockholdersEquityTables">
        <link:definition>31103 - Disclosure - Stockholders' Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eyenoviabio.com/role/DisclosureStockholdersEquityWarrantsActivityDetails" id="DisclosureStockholdersEquityWarrantsActivityDetails">
        <link:definition>41101 - Disclosure - Stockholders' Equity - Warrants Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="eyen-20201231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="eyen-20201231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="eyen-20201231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="eyen-20201231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
    </appinfo>
  </annotation>
  <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
  <import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <import namespace="http://xbrl.sec.gov/dei/2020-01-31" schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd" />
  <import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
  <import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
  <import namespace="http://fasb.org/us-roles/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd" />
  <import namespace="http://fasb.org/us-gaap/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd" />
  <import namespace="http://fasb.org/srt/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd" />
  <import namespace="http://xbrl.sec.gov/stpr/2018-01-31" schemaLocation="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd" />
  <element name="AccruedExpensesAndOtherLiabilitiesCurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="eyen_AccruedExpensesAndOtherLiabilitiesCurrent" substitutionGroup="xbrli:item" xbrli:balance="credit" />
  <element id="eyen_StockIssuedDuringPeriodValueStockOptionsExercisedOnCashlessBasis" name="StockIssuedDuringPeriodValueStockOptionsExercisedOnCashlessBasis" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodOnCashlessBasis" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="eyen_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodOnCashlessBasis" substitutionGroup="xbrli:item" />
  <element id="eyen_ProceedsOfStockIssuedDuringPeriodGross" name="ProceedsOfStockIssuedDuringPeriodGross" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <element name="IncreaseDecreaseInDeferredRent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="eyen_IncreaseDecreaseInDeferredRent" substitutionGroup="xbrli:item" xbrli:balance="debit" />
  <element id="eyen_PrepaidExpensesAndOtherCurrentAssetsDisclosureTextBlock" name="PrepaidExpensesAndOtherCurrentAssetsDisclosureTextBlock" nillable="true" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="eyen_DisclosureOfAccruedCompensationTableTextBlock" name="DisclosureOfAccruedCompensationTableTextBlock" nillable="true" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element name="PrepaidResearchAndDevelopmentExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="eyen_PrepaidResearchAndDevelopmentExpenses" substitutionGroup="xbrli:item" xbrli:balance="debit" />
  <element name="PrepaidPatentExpense" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="eyen_PrepaidPatentExpense" substitutionGroup="xbrli:item" xbrli:balance="debit" />
  <element name="PrepaidRentAndSecurityDeposit" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="eyen_PrepaidRentAndSecurityDeposit" substitutionGroup="xbrli:item" xbrli:balance="debit" />
  <element name="PrepaidConferenceExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="eyen_PrepaidConferenceExpenses" substitutionGroup="xbrli:item" xbrli:balance="debit" />
  <element name="PayrollTaxesReceivable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="eyen_PayrollTaxesReceivable" substitutionGroup="xbrli:item" xbrli:balance="debit" />
  <element name="AccruedResearchAndDevelopmentExpensesCurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="eyen_AccruedResearchAndDevelopmentExpensesCurrent" substitutionGroup="xbrli:item" xbrli:balance="credit" />
  <element id="eyen_CreditCardPayable" name="CreditCardPayable" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <element name="CuraPartnersMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="eyen_CuraPartnersMember" substitutionGroup="xbrli:item" />
  <element name="ConsultingAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="eyen_ConsultingAgreementMember" substitutionGroup="xbrli:item" />
  <element name="VicePresidentOfResearchAndDevelopmentMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="eyen_VicePresidentOfResearchAndDevelopmentMember" substitutionGroup="xbrli:item" />
  <element name="SenjuPharmaceuticalCoMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="eyen_SenjuPharmaceuticalCoMember" substitutionGroup="xbrli:item" />
  <element name="CostOfServicesEngineeringServices" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="eyen_CostOfServicesEngineeringServices" substitutionGroup="xbrli:item" xbrli:balance="debit" />
  <element id="eyen_ConsultingAgreementPaymentPerhour" name="ConsultingAgreementPaymentPerhour" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <element name="LeaseMonthlyBaseRent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="eyen_LeaseMonthlyBaseRent" substitutionGroup="xbrli:item" xbrli:balance="debit" />
  <element name="RoyaltyPercentage" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="eyen_RoyaltyPercentage" substitutionGroup="xbrli:item" />
  <element name="ExercisePriceOneMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="eyen_ExercisePriceOneMember" substitutionGroup="xbrli:item" />
  <element name="ExercisePriceTwoMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="eyen_ExercisePriceTwoMember" substitutionGroup="xbrli:item" />
  <element name="ExercisePriceThreeMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="eyen_ExercisePriceThreeMember" substitutionGroup="xbrli:item" />
  <element name="ExercisePriceFourMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="eyen_ExercisePriceFourMember" substitutionGroup="xbrli:item" />
  <element name="ExercisePriceFiveMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="eyen_ExercisePriceFiveMember" substitutionGroup="xbrli:item" />
  <element name="ExercisePriceSixMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="eyen_ExercisePriceSixMember" substitutionGroup="xbrli:item" />
  <element name="ExercisePriceSevenMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="eyen_ExercisePriceSevenMember" substitutionGroup="xbrli:item" />
  <element name="ExercisePriceEightMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="eyen_ExercisePriceEightMember" substitutionGroup="xbrli:item" />
  <element name="ExercisePriceNineMemberMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="eyen_ExercisePriceNineMemberMember" substitutionGroup="xbrli:item" />
  <element name="ExercisePriceTenMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="eyen_ExercisePriceTenMember" substitutionGroup="xbrli:item" />
  <element id="eyen_AccruedFranchiseTax" name="AccruedFranchiseTax" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <element id="eyen_NetProceedsFromIssuanceOfCommonStock" name="NetProceedsFromIssuanceOfCommonStock" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <element id="eyen_GrossProceedsOfStockValueIssuedDuringPeriod" name="GrossProceedsOfStockValueIssuedDuringPeriod" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <element id="eyen_AccruedTravelAndEntertainmentExpenses" name="AccruedTravelAndEntertainmentExpenses" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <element id="eyen_StockIssuedDuringPeriodValueNewIssuesTwo" name="StockIssuedDuringPeriodValueNewIssuesTwo" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <element id="eyen_StockIssuedDuringPeriodSharesNewIssuesTwo" name="StockIssuedDuringPeriodSharesNewIssuesTwo" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="eyen_CommonStockOneMember" name="CommonStockOneMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="eyen_CommonStockTwoMember" name="CommonStockTwoMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="eyen_OperatingLossCarryForwardsExpirationTerm" name="OperatingLossCarryForwardsExpirationTerm" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="eyen_ConsultingAgreementPaymentPermonth" name="ConsultingAgreementPaymentPermonth" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <element id="eyen_EmployeesConsultantsAndDirectorsUnder2018PlanMember" name="EmployeesConsultantsAndDirectorsUnder2018PlanMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="eyen_LicenseAgreementMember" name="LicenseAgreementMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="eyen_OmnibusStockIncentivePlan2018Member" name="OmnibusStockIncentivePlan2018Member" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="eyen_PaymentsForRepurchaseOfPublicOffering" name="PaymentsForRepurchaseOfPublicOffering" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <element id="eyen_ExercisePriceElevenMember" name="ExercisePriceElevenMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="eyen_AccruedPurchasesOfLeaseholdImprovements" name="AccruedPurchasesOfLeaseholdImprovements" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <element id="eyen_CommonStockThreeMember" name="CommonStockThreeMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="eyen_StockIssuedDuringPeriodValueNewIssuesThree" name="StockIssuedDuringPeriodValueNewIssuesThree" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <element id="eyen_StockIssuedDuringPeriodSharesNewIssuesThree" name="StockIssuedDuringPeriodSharesNewIssuesThree" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="eyen_PercentageOfSuccessfulRateOfTraditionalEyeDrops" name="PercentageOfSuccessfulRateOfTraditionalEyeDrops" nillable="true" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="eyen_LeaseholdImprovements" name="LeaseholdImprovements" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <element id="eyen_NetOperatingLossLimitForUtilizationAsPerInternalRevenueCode" name="NetOperatingLossLimitForUtilizationAsPerInternalRevenueCode" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <element id="eyen_NetOperatingLossAnnualUtilizationLimitAsPerInternalRevenueCode" name="NetOperatingLossAnnualUtilizationLimitAsPerInternalRevenueCode" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <element id="eyen_RemittanceOfEmployeeSPayrollTaxes" name="RemittanceOfEmployeeSPayrollTaxes" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <element id="eyen_DeferredTaxAssetsLiabilityPropertyAndEquipment" name="DeferredTaxAssetsLiabilityPropertyAndEquipment" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <element id="eyen_DeferredIncomeTaxExpenseBenefitBeforeAdjustmentsForChangeInValuationAllowance" name="DeferredIncomeTaxExpenseBenefitBeforeAdjustmentsForChangeInValuationAllowance" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <element id="eyen_ClassWarrantsMember" name="ClassWarrantsMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="eyen_ClassBWarrantsMember" name="ClassBWarrantsMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="eyen_ExercisePrice4.68Member" name="ExercisePrice4.68Member" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="eyen_NumberOfMonthlyPayments" name="NumberOfMonthlyPayments" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="eyen_PurchaseOfInsurancePremiumFinancedByShortTermNotePayable" name="PurchaseOfInsurancePremiumFinancedByShortTermNotePayable" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <element id="eyen_PercentageOfSuccessRateOfOptejet" name="PercentageOfSuccessRateOfOptejet" nillable="true" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="eyen_PaycheckProtectionProgramLoanMember" name="PaycheckProtectionProgramLoanMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="eyen_ExercisePrice2.72Member" name="ExercisePrice2.72Member" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="eyen_ExercisePrice2.89Member" name="ExercisePrice2.89Member" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="eyen_SmallBusinessAdministrationEconomicInjuryDisasterGrant" name="SmallBusinessAdministrationEconomicInjuryDisasterGrant" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <element id="eyen_StockIssuedDuringPeriodValueWarrantsExercised" name="StockIssuedDuringPeriodValueWarrantsExercised" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <element id="eyen_StockIssuedDuringPeriodSharesWarrantsExercised" name="StockIssuedDuringPeriodSharesWarrantsExercised" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="eyen_ProceedsFromPaycheckProtectionProgramLoan" name="ProceedsFromPaycheckProtectionProgramLoan" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <element id="eyen_NotesPayableDisclosureTextBlock" name="NotesPayableDisclosureTextBlock" nillable="true" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="eyen_ScheduleOfNotesPayableTableTextBlock" name="ScheduleOfNotesPayableTableTextBlock" nillable="true" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="eyen_PeriodConsideredForUsageOfLoanProceedsFromFundingDate" name="PeriodConsideredForUsageOfLoanProceedsFromFundingDate" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="eyen_PercentageOfInterestOnAmountWhichIsNotForgiven" name="PercentageOfInterestOnAmountWhichIsNotForgiven" nillable="true" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" />
  <element id="eyen_ShareBasedCompensationArrangementByShareBasedPaymentAwardCashFeePaid" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardCashFeePaid" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <element id="eyen_PrepaidDirectorFeesCurrent" name="PrepaidDirectorFeesCurrent" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <element id="eyen_BauschLicenseAgreementMember" name="BauschLicenseAgreementMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="eyen_LicenseAgreementsUpfrontPaymentsReceived" name="LicenseAgreementsUpfrontPaymentsReceived" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <element id="eyen_ArcticVisionLicenseAgreementMember" name="ArcticVisionLicenseAgreementMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="eyen_LicenseAgreementsMaximumAdditionalPaymentsReceivable" name="LicenseAgreementsMaximumAdditionalPaymentsReceivable" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <element id="eyen_PaymentsForLicenseCosts" name="PaymentsForLicenseCosts" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <element id="eyen_LicenseAgreementsTerminationWrittenNoticePeriod" name="LicenseAgreementsTerminationWrittenNoticePeriod" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="eyen_LicenseAgreementsTerminationPeriodUponUncuredMaterialBreach" name="LicenseAgreementsTerminationPeriodUponUncuredMaterialBreach" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="eyen_ClassOfWarrantsOrRightsOutstandingRollforward" name="ClassOfWarrantsOrRightsOutstandingRollforward" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="eyen_ClassOfWarrantOrRightGranted" name="ClassOfWarrantOrRightGranted" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="eyen_ClassOfWarrantOrRightExercised" name="ClassOfWarrantOrRightExercised" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="eyen_ClassOfWarrantOrRightExercisable" name="ClassOfWarrantOrRightExercisable" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" />
  <element id="eyen_ClassOfWarrantsOrRightsWeightedAverageExercisePriceRollforward" name="ClassOfWarrantsOrRightsWeightedAverageExercisePriceRollforward" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="eyen_ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice" name="ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice" nillable="true" type="num:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" />
  <element id="eyen_ClassOfWarrantOrRightGrantedWeightedAverageExercisePrice" name="ClassOfWarrantOrRightGrantedWeightedAverageExercisePrice" nillable="true" type="num:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="eyen_ClassOfWarrantOrRightExercisedWeightedAverageExercisePrice" name="ClassOfWarrantOrRightExercisedWeightedAverageExercisePrice" nillable="true" type="num:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="eyen_ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice" name="ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice" nillable="true" type="num:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" />
  <element id="eyen_ClassOfWarrantOrRightOutstandingWeightedAverageRemainingLife" name="ClassOfWarrantOrRightOutstandingWeightedAverageRemainingLife" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="eyen_ClassOfWarrantOrRightExercisableWeightedAverageRemainingLife" name="ClassOfWarrantOrRightExercisableWeightedAverageRemainingLife" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="eyen_ClassOfWarrantOrRightOutstandingAggregateIntrinsicValue" name="ClassOfWarrantOrRightOutstandingAggregateIntrinsicValue" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <element id="eyen_ClassOfWarrantOrRightExercisableAggregateIntrinsicValue" name="ClassOfWarrantOrRightExercisableAggregateIntrinsicValue" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <element id="eyen_WarrantsAtExercisePriceOneMember" name="WarrantsAtExercisePriceOneMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="eyen_WarrantsAtExercisePriceTwoMember" name="WarrantsAtExercisePriceTwoMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="eyen_WarrantsAtExercisePriceThreeMember" name="WarrantsAtExercisePriceThreeMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="eyen_WarrantsAtExercisePriceFourMember" name="WarrantsAtExercisePriceFourMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="eyen_UnderwrittenPublicOfferingMember" name="UnderwrittenPublicOfferingMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="eyen_NumberOfSharesAgreedToBeIssued" name="NumberOfSharesAgreedToBeIssued" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="eyen_OverAllotmentOptionPeriod" name="OverAllotmentOptionPeriod" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="eyen_ExercisePrice3.43Member" name="ExercisePrice3.43Member" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="eyen_ExercisePrice3.48Member" name="ExercisePrice3.48Member" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="eyen_ExercisePrice3.71Member" name="ExercisePrice3.71Member" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="eyen_ExercisePrice5.77Member" name="ExercisePrice5.77Member" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="eyen_LicenseReceivableCurrent" name="LicenseReceivableCurrent" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <element id="eyen_IncreaseDecreaseInLicenseReceivable" name="IncreaseDecreaseInLicenseReceivable" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <element id="eyen_PrepaidLicensesAndSubscriptions" name="PrepaidLicensesAndSubscriptions" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <element id="eyen_AdditionalOfficeSpaceMember" name="AdditionalOfficeSpaceMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="eyen_AccruedExpenseReimbursements" name="AccruedExpenseReimbursements" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <element id="eyen_AccruedShippingAndPackagingFees" name="AccruedShippingAndPackagingFees" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <element id="eyen_AccruedLicensingFees" name="AccruedLicensingFees" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <element id="eyen_AccruedConsultingAndProfessionalServicesCurrent" name="AccruedConsultingAndProfessionalServicesCurrent" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <element id="eyen_DeferredTaxAssetsNetBeforeValuationAllowance" name="DeferredTaxAssetsNetBeforeValuationAllowance" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <element id="eyen_MilestoneRevenuePayments" name="MilestoneRevenuePayments" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <element id="eyen_RoyaltyRevenuePayments" name="RoyaltyRevenuePayments" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <element id="eyen_ClassOfWarrantOrRightNumberOfYearsSecuritiesCalledByWarrantsToPurchaseCommonStock" name="ClassOfWarrantOrRightNumberOfYearsSecuritiesCalledByWarrantsToPurchaseCommonStock" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="eyen_NumberOfCommonShares" name="NumberOfCommonShares" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="eyen_EffectiveIncomeTaxRateReconciliationNetAtFederalStatutoryIncomeTaxRate" name="EffectiveIncomeTaxRateReconciliationNetAtFederalStatutoryIncomeTaxRate" nillable="true" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="eyen_DeferredLicenseFeePolicyTextBlock" name="DeferredLicenseFeePolicyTextBlock" nillable="true" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="eyen_DeferredLicenseCostsPolicyTextBlock" name="DeferredLicenseCostsPolicyTextBlock" nillable="true" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>10
<FILENAME>eyen-20201231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.9.3.5 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/31/2021 1:30:34 AM-->
<!--Modified on: 3/31/2021 1:30:34 AM-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="eyen-20201231.xsd#StatementBalanceSheets" roleURI="http://www.eyenoviabio.com/role/StatementBalanceSheets" />
  <roleRef xlink:type="simple" xlink:href="eyen-20201231.xsd#StatementStatementsOfOperations" roleURI="http://www.eyenoviabio.com/role/StatementStatementsOfOperations" />
  <roleRef xlink:type="simple" xlink:href="eyen-20201231.xsd#StatementStatementsOfCashFlows" roleURI="http://www.eyenoviabio.com/role/StatementStatementsOfCashFlows" />
  <roleRef xlink:type="simple" xlink:href="eyen-20201231.xsd#DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails" roleURI="http://www.eyenoviabio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails" />
  <roleRef xlink:type="simple" xlink:href="eyen-20201231.xsd#DisclosurePropertyAndEquipmentNetPropertyAndEquipmentDetails" roleURI="http://www.eyenoviabio.com/role/DisclosurePropertyAndEquipmentNetPropertyAndEquipmentDetails" />
  <roleRef xlink:type="simple" xlink:href="eyen-20201231.xsd#DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails" roleURI="http://www.eyenoviabio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails" />
  <roleRef xlink:type="simple" xlink:href="eyen-20201231.xsd#DisclosureAccruedCompensationDetails" roleURI="http://www.eyenoviabio.com/role/DisclosureAccruedCompensationDetails" />
  <roleRef xlink:type="simple" xlink:href="eyen-20201231.xsd#DisclosureNotesPayableScheduleOfNotesPayableDetails" roleURI="http://www.eyenoviabio.com/role/DisclosureNotesPayableScheduleOfNotesPayableDetails" />
  <roleRef xlink:type="simple" xlink:href="eyen-20201231.xsd#DisclosureIncomeTaxesProvisionForIncomeTaxesDetails" roleURI="http://www.eyenoviabio.com/role/DisclosureIncomeTaxesProvisionForIncomeTaxesDetails" />
  <roleRef xlink:type="simple" xlink:href="eyen-20201231.xsd#DisclosureIncomeTaxesDeferredTaxAssetsDetails" roleURI="http://www.eyenoviabio.com/role/DisclosureIncomeTaxesDeferredTaxAssetsDetails" />
  <roleRef xlink:type="simple" xlink:href="eyen-20201231.xsd#DisclosureCommitmentsAndContingenciesFutureMinimumPaymentsUnderOperatingLeaseAgreementDetails" roleURI="http://www.eyenoviabio.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumPaymentsUnderOperatingLeaseAgreementDetails" />
  <calculationLink xlink:role="http://www.eyenoviabio.com/role/StatementBalanceSheets" xlink:type="extended" xlink:title="00100 - Statement - Balance Sheets">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_637527510329799968" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent_637527510329799968" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_637527510329819955" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_637527510329799968" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_637527510329819955" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCostsCurrent" xlink:label="us-gaap_DeferredCostsCurrent_637527510329819955" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_637527510329799968" xlink:to="us-gaap_DeferredCostsCurrent_637527510329819955" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_LicenseReceivableCurrent" xlink:label="eyen_LicenseReceivableCurrent_637527510329819955" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_637527510329799968" xlink:to="eyen_LicenseReceivableCurrent_637527510329819955" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_637527510329819955" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_637527510329799968" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_637527510329819955" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_637527510329819955" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_637527510329819955" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SecurityDeposit" xlink:label="us-gaap_SecurityDeposit_637527510329819955" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="us-gaap_SecurityDeposit_637527510329819955" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_637527510329929880" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities_637527510329929880" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_637527510329929880" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_637527510329929880" xlink:to="us-gaap_LiabilitiesCurrent_637527510329929880" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_637527510329929880" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_637527510329929880" xlink:to="us-gaap_AccountsPayableCurrent_637527510329929880" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WorkersCompensationLiabilityCurrent" xlink:label="us-gaap_WorkersCompensationLiabilityCurrent_637527510329929880" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_637527510329929880" xlink:to="us-gaap_WorkersCompensationLiabilityCurrent_637527510329929880" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_AccruedExpensesAndOtherLiabilitiesCurrent" xlink:label="eyen_AccruedExpensesAndOtherLiabilitiesCurrent_637527510329929880" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_637527510329929880" xlink:to="eyen_AccruedExpensesAndOtherLiabilitiesCurrent_637527510329929880" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRentCreditCurrent" xlink:label="us-gaap_DeferredRentCreditCurrent_637527510329929880" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_637527510329929880" xlink:to="us-gaap_DeferredRentCreditCurrent_637527510329929880" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_637527510329929880" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_637527510329929880" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent_637527510329929880" order="5" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermBankLoansAndNotesPayable" xlink:label="us-gaap_ShortTermBankLoansAndNotesPayable_637527510329929880" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_637527510329929880" xlink:to="us-gaap_ShortTermBankLoansAndNotesPayable_637527510329929880" order="6" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="us-gaap_DeferredRentCreditNoncurrent_637527510329929880" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_637527510329929880" xlink:to="us-gaap_DeferredRentCreditNoncurrent_637527510329929880" order="2" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermNotesPayable" xlink:label="us-gaap_LongTermNotesPayable_637527510329929880" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_637527510329929880" xlink:to="us-gaap_LongTermNotesPayable_637527510329929880" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_637527510329929880" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity_637527510329929880" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue_637527510329929880" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_637527510329929880" xlink:to="us-gaap_PreferredStockValue_637527510329929880" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_637527510329929880" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_637527510329929880" xlink:to="us-gaap_CommonStockValue_637527510329929880" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital_637527510329939888" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_637527510329929880" xlink:to="us-gaap_AdditionalPaidInCapital_637527510329939888" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_637527510329939888" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_637527510329929880" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_637527510329939888" order="4" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.eyenoviabio.com/role/StatementStatementsOfOperations" xlink:type="extended" xlink:title="00200 - Statement - Statements of Operations">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_637527510329939888" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_637527510329939888" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrossProfit" xlink:label="us-gaap_GrossProfit_637527510329939888" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_637527510329939888" xlink:to="us-gaap_GrossProfit_637527510329939888" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_637527510329939888" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_GrossProfit_637527510329939888" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_637527510329939888" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfRevenue" xlink:label="us-gaap_CostOfRevenue_637527510329939888" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_GrossProfit_637527510329939888" xlink:to="us-gaap_CostOfRevenue_637527510329939888" order="2" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses_637527510329939888" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_637527510329939888" xlink:to="us-gaap_OperatingExpenses_637527510329939888" order="2" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_637527510329939888" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses_637527510329939888" xlink:to="us-gaap_ResearchAndDevelopmentExpense_637527510329939888" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense_637527510329939888" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses_637527510329939888" xlink:to="us-gaap_GeneralAndAdministrativeExpense_637527510329939888" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_SmallBusinessAdministrationEconomicInjuryDisasterGrant" xlink:label="eyen_SmallBusinessAdministrationEconomicInjuryDisasterGrant_637527510329939888" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="eyen_SmallBusinessAdministrationEconomicInjuryDisasterGrant_637527510329939888" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet_637527510329939888" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet_637527510329939888" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense_637527510329939888" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="us-gaap_InterestExpense_637527510329939888" order="4" use="optional" weight="-1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.eyenoviabio.com/role/StatementStatementsOfCashFlows" xlink:type="extended" xlink:title="00400 - Statement - Statements of Cash Flows">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_637527510329949878" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_637527510329949878" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_637527510329949878" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637527510329949878" xlink:to="us-gaap_NetIncomeLoss_637527510329949878" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization_637527510329949878" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637527510329949878" xlink:to="us-gaap_DepreciationDepletionAndAmortization_637527510329949878" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_637527510329949878" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637527510329949878" xlink:to="us-gaap_ShareBasedCompensation_637527510329949878" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_637527510329949878" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637527510329949878" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_637527510329949878" order="4" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_IncreaseDecreaseInLicenseReceivable" xlink:label="eyen_IncreaseDecreaseInLicenseReceivable_637527510329949878" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637527510329949878" xlink:to="eyen_IncreaseDecreaseInLicenseReceivable_637527510329949878" order="5" use="optional" weight="-1" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_637527510329949878" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637527510329949878" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_637527510329949878" order="6" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_637527510329949878" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637527510329949878" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_637527510329949878" order="7" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_637527510329949878" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637527510329949878" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_637527510329949878" order="8" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredCharges" xlink:label="us-gaap_IncreaseDecreaseInDeferredCharges_637527510329949878" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637527510329949878" xlink:to="us-gaap_IncreaseDecreaseInDeferredCharges_637527510329949878" order="9" use="optional" weight="-1" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_637527510329949878" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637527510329949878" xlink:to="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_637527510329949878" order="10" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInSecurityDeposits" xlink:label="us-gaap_IncreaseDecreaseInSecurityDeposits_637527510329949878" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637527510329949878" xlink:to="us-gaap_IncreaseDecreaseInSecurityDeposits_637527510329949878" order="11" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_IncreaseDecreaseInDeferredRent" xlink:label="eyen_IncreaseDecreaseInDeferredRent_637527510329949878" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637527510329949878" xlink:to="eyen_IncreaseDecreaseInDeferredRent_637527510329949878" order="12" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_637527510329949878" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_637527510329949878" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_637527510329949878" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_637527510329949878" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_637527510329949878" order="1" use="optional" weight="-1" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_637527510329949878" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_637527510329949878" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_ProceedsFromPaycheckProtectionProgramLoan" xlink:label="eyen_ProceedsFromPaycheckProtectionProgramLoan_637527510329959859" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_637527510329949878" xlink:to="eyen_ProceedsFromPaycheckProtectionProgramLoan_637527510329959859" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises_637527510329959859" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_637527510329949878" xlink:to="us-gaap_ProceedsFromWarrantExercises_637527510329959859" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_637527510329959859" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_637527510329949878" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_637527510329959859" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_637527510329959859" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_637527510329949878" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_637527510329959859" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="us-gaap_RepaymentsOfNotesPayable_637527510329959859" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_637527510329949878" xlink:to="us-gaap_RepaymentsOfNotesPayable_637527510329959859" order="5" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_637527510329959859" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_637527510329949878" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_637527510329959859" order="6" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_637527510329959859" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_637527510329949878" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_637527510329959859" order="7" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_PaymentsForRepurchaseOfPublicOffering" xlink:label="eyen_PaymentsForRepurchaseOfPublicOffering_637527510329959859" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_637527510329949878" xlink:to="eyen_PaymentsForRepurchaseOfPublicOffering_637527510329959859" order="8" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_637527510329959859" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_637527510329949878" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_637527510329959859" order="9" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.eyenoviabio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails" xlink:type="extended" xlink:title="40301 - Disclosure - Prepaid Expenses and Other Current Assets (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidInsurance" xlink:label="us-gaap_PrepaidInsurance_637527510329969851" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidInsurance_637527510329969851" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_PayrollTaxesReceivable" xlink:label="eyen_PayrollTaxesReceivable_637527510329969851" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="eyen_PayrollTaxesReceivable_637527510329969851" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_PrepaidDirectorFeesCurrent" xlink:label="eyen_PrepaidDirectorFeesCurrent_637527510329969851" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="eyen_PrepaidDirectorFeesCurrent_637527510329969851" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_PrepaidConferenceExpenses" xlink:label="eyen_PrepaidConferenceExpenses_637527510329969851" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="eyen_PrepaidConferenceExpenses_637527510329969851" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_PrepaidResearchAndDevelopmentExpenses" xlink:label="eyen_PrepaidResearchAndDevelopmentExpenses_637527510329969851" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="eyen_PrepaidResearchAndDevelopmentExpenses_637527510329969851" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_PrepaidLicensesAndSubscriptions" xlink:label="eyen_PrepaidLicensesAndSubscriptions_637527510329969851" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="eyen_PrepaidLicensesAndSubscriptions_637527510329969851" order="6" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_PrepaidPatentExpense" xlink:label="eyen_PrepaidPatentExpense_637527510329969851" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="eyen_PrepaidPatentExpense_637527510329969851" order="7" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_PrepaidRentAndSecurityDeposit" xlink:label="eyen_PrepaidRentAndSecurityDeposit_637527510329969851" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="eyen_PrepaidRentAndSecurityDeposit_637527510329969851" order="8" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssets" xlink:label="us-gaap_OtherAssets_637527510329969851" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_OtherAssets_637527510329969851" order="9" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.eyenoviabio.com/role/DisclosurePropertyAndEquipmentNetPropertyAndEquipmentDetails" xlink:type="extended" xlink:title="40401 - Disclosure - Property and Equipment, Net - Property and Equipment (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_637026734627435437" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_637527510329969851" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet_637026734627435437" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_637527510329969851" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_637527510329969851" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet_637026734627435437" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_637527510329969851" order="2" use="optional" weight="-1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.eyenoviabio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:type="extended" xlink:title="40501 - Disclosure - Accrued Expenses and Other Current Liabilities (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_AccruedResearchAndDevelopmentExpensesCurrent" xlink:label="eyen_AccruedResearchAndDevelopmentExpensesCurrent_637527510329979846" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="eyen_AccruedResearchAndDevelopmentExpensesCurrent_637527510329979846" order="1" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_AccruedConsultingAndProfessionalServicesCurrent" xlink:label="eyen_AccruedConsultingAndProfessionalServicesCurrent_637527510329979846" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="eyen_AccruedConsultingAndProfessionalServicesCurrent_637527510329979846" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_AccruedLicensingFees" xlink:label="eyen_AccruedLicensingFees_637527510329979846" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="eyen_AccruedLicensingFees_637527510329979846" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_AccruedExpenseReimbursements" xlink:label="eyen_AccruedExpenseReimbursements_637527510329979846" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="eyen_AccruedExpenseReimbursements_637527510329979846" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_AccruedShippingAndPackagingFees" xlink:label="eyen_AccruedShippingAndPackagingFees_637527510329979846" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="eyen_AccruedShippingAndPackagingFees_637527510329979846" order="5" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:label="us-gaap_InterestPayableCurrent_637527510329979846" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="us-gaap_InterestPayableCurrent_637527510329979846" order="6" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_LeaseholdImprovements" xlink:label="eyen_LeaseholdImprovements_637527510329979846" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="eyen_LeaseholdImprovements_637527510329979846" order="7" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_CreditCardPayable" xlink:label="eyen_CreditCardPayable_637527510329979846" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="eyen_CreditCardPayable_637527510329979846" order="8" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_AccruedFranchiseTax" xlink:label="eyen_AccruedFranchiseTax_637527510329979846" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="eyen_AccruedFranchiseTax_637527510329979846" order="9" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_AccruedTravelAndEntertainmentExpenses" xlink:label="eyen_AccruedTravelAndEntertainmentExpenses_637527510329979846" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="eyen_AccruedTravelAndEntertainmentExpenses_637527510329979846" order="10" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_637527510329979846" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_637527510329979846" order="11" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.eyenoviabio.com/role/DisclosureAccruedCompensationDetails" xlink:type="extended" xlink:title="40601 - Disclosure - Accrued Compensation (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedBonusesCurrent" xlink:label="us-gaap_AccruedBonusesCurrent_637527510329989857" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_AccruedBonusesCurrent_637527510329989857" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedSalariesCurrent" xlink:label="us-gaap_AccruedSalariesCurrent_637527510329989857" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_AccruedSalariesCurrent_637527510329989857" order="2" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.eyenoviabio.com/role/DisclosureNotesPayableScheduleOfNotesPayableDetails" xlink:type="extended" xlink:title="40701 - Disclosure - Notes Payable - Schedule of notes payable (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayable" xlink:label="us-gaap_NotesPayable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="us-gaap_NotesPayableCurrent_637527510329989857" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NotesPayable" xlink:to="us-gaap_NotesPayableCurrent_637527510329989857" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermNotesPayable" xlink:label="us-gaap_LongTermNotesPayable_637527510329989857" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NotesPayable" xlink:to="us-gaap_LongTermNotesPayable_637527510329989857" order="2" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.eyenoviabio.com/role/DisclosureIncomeTaxesProvisionForIncomeTaxesDetails" xlink:type="extended" xlink:title="40801 - Disclosure - Income Taxes - provision for income taxes (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_637026734627435437" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_DeferredIncomeTaxExpenseBenefitBeforeAdjustmentsForChangeInValuationAllowance" xlink:label="eyen_DeferredIncomeTaxExpenseBenefitBeforeAdjustmentsForChangeInValuationAllowance_637527510330019841" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit_637026734627435437" xlink:to="eyen_DeferredIncomeTaxExpenseBenefitBeforeAdjustmentsForChangeInValuationAllowance_637527510330019841" order="1" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_637527510330019841" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="eyen_DeferredIncomeTaxExpenseBenefitBeforeAdjustmentsForChangeInValuationAllowance_637527510330019841" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_637527510330019841" order="1" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_637527510330019841" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="eyen_DeferredIncomeTaxExpenseBenefitBeforeAdjustmentsForChangeInValuationAllowance_637527510330019841" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_637527510330019841" order="2" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_637527510330019841" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit_637026734627435437" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_637527510330019841" order="2" use="optional" weight="-1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.eyenoviabio.com/role/DisclosureIncomeTaxesDeferredTaxAssetsDetails" xlink:type="extended" xlink:title="40803 - Disclosure - Income Taxes - Deferred tax assets (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_637527510330029832" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_637527510330029832" order="1" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_DeferredTaxAssetsNetBeforeValuationAllowance" xlink:label="eyen_DeferredTaxAssetsNetBeforeValuationAllowance_637527510330029832" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="eyen_DeferredTaxAssetsNetBeforeValuationAllowance_637527510330029832" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_DeferredTaxAssetsLiabilityPropertyAndEquipment" xlink:label="eyen_DeferredTaxAssetsLiabilityPropertyAndEquipment_637527510330029832" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="eyen_DeferredTaxAssetsNetBeforeValuationAllowance_637527510330029832" xlink:to="eyen_DeferredTaxAssetsLiabilityPropertyAndEquipment_637527510330029832" order="1" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross_637527510330029832" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="eyen_DeferredTaxAssetsNetBeforeValuationAllowance_637527510330029832" xlink:to="us-gaap_DeferredTaxAssetsGross_637527510330029832" order="2" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_637527510330029832" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_637527510330029832" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_637527510330029832" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_637527510330029832" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_637527510330029832" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_637527510330029832" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_637527510330029832" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_637527510330029832" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_637527510330029832" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_637527510330029832" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_637527510330029832" xlink:to="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_637527510330029832" order="4" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.eyenoviabio.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumPaymentsUnderOperatingLeaseAgreementDetails" xlink:type="extended" xlink:title="40901 - Disclosure - Commitments and Contingencies - Future Minimum Payments under Operating Lease Agreement (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_637026734627591739" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_637527510330029832" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_637026734627591739" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_637527510330029832" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_637527510330029832" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_637026734627591739" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_637527510330029832" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_637527510330029832" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_637026734627591739" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_637527510330029832" order="3" use="optional" weight="1" />
  </calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>11
<FILENAME>eyen-20201231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.9.3.5 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/31/2021 1:30:34 AM-->
<!--Modified on: 3/31/2021 1:30:34 AM-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd#eedm" roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" />
  <roleRef xlink:type="simple" xlink:href="eyen-20201231.xsd#StatementStatementsOfChangesInStockholdersEquity" roleURI="http://www.eyenoviabio.com/role/StatementStatementsOfChangesInStockholdersEquity" />
  <roleRef xlink:type="simple" xlink:href="eyen-20201231.xsd#StatementStatementsOfChangesInStockholdersEquityParenthetical" roleURI="http://www.eyenoviabio.com/role/StatementStatementsOfChangesInStockholdersEquityParenthetical" />
  <roleRef xlink:type="simple" xlink:href="eyen-20201231.xsd#StatementStatementsOfCashFlowsParenthetical" roleURI="http://www.eyenoviabio.com/role/StatementStatementsOfCashFlowsParenthetical" />
  <roleRef xlink:type="simple" xlink:href="eyen-20201231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesAntiDilutiveWeightedAverageDilutedCommonSharesDetails" roleURI="http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAntiDilutiveWeightedAverageDilutedCommonSharesDetails" />
  <roleRef xlink:type="simple" xlink:href="eyen-20201231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" roleURI="http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" />
  <roleRef xlink:type="simple" xlink:href="eyen-20201231.xsd#DisclosurePropertyAndEquipmentNetPropertyAndEquipmentDetails" roleURI="http://www.eyenoviabio.com/role/DisclosurePropertyAndEquipmentNetPropertyAndEquipmentDetails" />
  <roleRef xlink:type="simple" xlink:href="eyen-20201231.xsd#DisclosurePropertyAndEquipmentNetAdditionalInformationDetails" roleURI="http://www.eyenoviabio.com/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetails" />
  <roleRef xlink:type="simple" xlink:href="eyen-20201231.xsd#DisclosureNotesPayableScheduleOfNotesPayableDetails" roleURI="http://www.eyenoviabio.com/role/DisclosureNotesPayableScheduleOfNotesPayableDetails" />
  <roleRef xlink:type="simple" xlink:href="eyen-20201231.xsd#DisclosureNotesPayableAdditionalInformationDetails" roleURI="http://www.eyenoviabio.com/role/DisclosureNotesPayableAdditionalInformationDetails" />
  <roleRef xlink:type="simple" xlink:href="eyen-20201231.xsd#DisclosureIncomeTaxesAdditionalInformationDetails" roleURI="http://www.eyenoviabio.com/role/DisclosureIncomeTaxesAdditionalInformationDetails" />
  <roleRef xlink:type="simple" xlink:href="eyen-20201231.xsd#DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" roleURI="http://www.eyenoviabio.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" />
  <roleRef xlink:type="simple" xlink:href="eyen-20201231.xsd#DisclosureRelatedPartyTransactionsDetails" roleURI="http://www.eyenoviabio.com/role/DisclosureRelatedPartyTransactionsDetails" />
  <roleRef xlink:type="simple" xlink:href="eyen-20201231.xsd#DisclosureStockholdersEquityAdditionalInformationRelatedToWarrantsDetails" roleURI="http://www.eyenoviabio.com/role/DisclosureStockholdersEquityAdditionalInformationRelatedToWarrantsDetails" />
  <roleRef xlink:type="simple" xlink:href="eyen-20201231.xsd#DisclosureStockholdersEquityBlackScholesOptionDetails" roleURI="http://www.eyenoviabio.com/role/DisclosureStockholdersEquityBlackScholesOptionDetails" />
  <roleRef xlink:type="simple" xlink:href="eyen-20201231.xsd#DisclosureStockholdersEquitySummaryOfOptionActivityDetails" roleURI="http://www.eyenoviabio.com/role/DisclosureStockholdersEquitySummaryOfOptionActivityDetails" />
  <roleRef xlink:type="simple" xlink:href="eyen-20201231.xsd#DisclosureStockholdersEquitySummaryOfInformationRelatedToStockOptionsDetails" roleURI="http://www.eyenoviabio.com/role/DisclosureStockholdersEquitySummaryOfInformationRelatedToStockOptionsDetails" />
  <roleRef xlink:type="simple" xlink:href="eyen-20201231.xsd#DisclosureStockholdersEquityAdditionalInformationDetails" roleURI="http://www.eyenoviabio.com/role/DisclosureStockholdersEquityAdditionalInformationDetails" />
  <roleRef xlink:type="simple" xlink:href="eyen-20201231.xsd#DisclosureSubsequentEventsDetails" roleURI="http://www.eyenoviabio.com/role/DisclosureSubsequentEventsDetails" />
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" />
  <definitionLink xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="extended" xlink:title="Extensible Enumeration Domain Members" />
  <definitionLink xlink:role="http://www.eyenoviabio.com/role/StatementStatementsOfChangesInStockholdersEquity" xlink:type="extended" xlink:title="00300 - Statement - Statements of Changes in Stockholders' Equity">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_637527510330429588" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_637527510330429588" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_StockIssuedDuringPeriodValueNewIssuesTwo" xlink:label="eyen_StockIssuedDuringPeriodValueNewIssuesTwo" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="eyen_StockIssuedDuringPeriodValueNewIssuesTwo" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_StockIssuedDuringPeriodSharesNewIssuesTwo" xlink:label="eyen_StockIssuedDuringPeriodSharesNewIssuesTwo" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="eyen_StockIssuedDuringPeriodSharesNewIssuesTwo" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_StockIssuedDuringPeriodValueNewIssuesThree" xlink:label="eyen_StockIssuedDuringPeriodValueNewIssuesThree" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="eyen_StockIssuedDuringPeriodValueNewIssuesThree" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_StockIssuedDuringPeriodSharesNewIssuesThree" xlink:label="eyen_StockIssuedDuringPeriodSharesNewIssuesThree" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="eyen_StockIssuedDuringPeriodSharesNewIssuesThree" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_StockIssuedDuringPeriodValueStockOptionsExercisedOnCashlessBasis" xlink:label="eyen_StockIssuedDuringPeriodValueStockOptionsExercisedOnCashlessBasis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_StatementLineItems" xlink:to="eyen_StockIssuedDuringPeriodValueStockOptionsExercisedOnCashlessBasis" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodOnCashlessBasis" xlink:label="eyen_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodOnCashlessBasis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_StatementLineItems" xlink:to="eyen_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodOnCashlessBasis" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_StockIssuedDuringPeriodValueWarrantsExercised" xlink:label="eyen_StockIssuedDuringPeriodValueWarrantsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_StatementLineItems" xlink:to="eyen_StockIssuedDuringPeriodValueWarrantsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:label="eyen_StockIssuedDuringPeriodSharesWarrantsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_StatementLineItems" xlink:to="eyen_StockIssuedDuringPeriodSharesWarrantsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.eyenoviabio.com/role/StatementStatementsOfChangesInStockholdersEquityParenthetical" xlink:type="extended" xlink:title="00305 - Statement - Statements of Changes in Stockholders' Equity (Parenthetical)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_CommonStockOneMember" xlink:label="eyen_CommonStockOneMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="eyen_CommonStockOneMember" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_CommonStockTwoMember" xlink:label="eyen_CommonStockTwoMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EquityComponentDomain" xlink:to="eyen_CommonStockTwoMember" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_CommonStockThreeMember" xlink:label="eyen_CommonStockThreeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_EquityComponentDomain" xlink:to="eyen_CommonStockThreeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_ProceedsOfStockIssuedDuringPeriodGross" xlink:label="eyen_ProceedsOfStockIssuedDuringPeriodGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="eyen_ProceedsOfStockIssuedDuringPeriodGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.eyenoviabio.com/role/StatementStatementsOfCashFlowsParenthetical" xlink:type="extended" xlink:title="00405 - Statement - Statements of Cash Flows (Parenthetical)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_637527510330489552" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_637527510330489552" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_CommonStockOneMember" xlink:label="eyen_CommonStockOneMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="eyen_CommonStockOneMember" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_CommonStockTwoMember" xlink:label="eyen_CommonStockTwoMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="eyen_CommonStockTwoMember" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_CommonStockThreeMember" xlink:label="eyen_CommonStockThreeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="eyen_CommonStockThreeMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_ProceedsOfStockIssuedDuringPeriodGross" xlink:label="eyen_ProceedsOfStockIssuedDuringPeriodGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="eyen_ProceedsOfStockIssuedDuringPeriodGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAntiDilutiveWeightedAverageDilutedCommonSharesDetails" xlink:type="extended" xlink:title="40201 - Disclosure - Summary of Significant Accounting Policies - Anti-dilutive weighted average diluted common shares (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_WarrantMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_OptionIndexedToIssuersEquityTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:to="us-gaap_OptionIndexedToIssuersEquityTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeDomain_637527510330499545" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:to="us-gaap_OptionIndexedToIssuersEquityTypeDomain_637527510330499545" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:to="us-gaap_EmployeeStockOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637527510330499545" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637527510330499545" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="extended" xlink:title="40202 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember_637527510330509540" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_637527510330509540" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637527510330509540" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637527510330509540" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_BauschLicenseAgreementMember" xlink:label="eyen_BauschLicenseAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="eyen_BauschLicenseAgreementMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_ArcticVisionLicenseAgreementMember" xlink:label="eyen_ArcticVisionLicenseAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="eyen_ArcticVisionLicenseAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashUninsuredAmount" xlink:label="us-gaap_CashUninsuredAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashUninsuredAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_LicenseAgreementsTerminationWrittenNoticePeriod" xlink:label="eyen_LicenseAgreementsTerminationWrittenNoticePeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_StatementLineItems" xlink:to="eyen_LicenseAgreementsTerminationWrittenNoticePeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_LicenseAgreementsTerminationPeriodUponUncuredMaterialBreach" xlink:label="eyen_LicenseAgreementsTerminationPeriodUponUncuredMaterialBreach" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_StatementLineItems" xlink:to="eyen_LicenseAgreementsTerminationPeriodUponUncuredMaterialBreach" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_LicenseAgreementsUpfrontPaymentsReceived" xlink:label="eyen_LicenseAgreementsUpfrontPaymentsReceived" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_StatementLineItems" xlink:to="eyen_LicenseAgreementsUpfrontPaymentsReceived" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_LicenseAgreementsMaximumAdditionalPaymentsReceivable" xlink:label="eyen_LicenseAgreementsMaximumAdditionalPaymentsReceivable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_StatementLineItems" xlink:to="eyen_LicenseAgreementsMaximumAdditionalPaymentsReceivable" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:label="us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.eyenoviabio.com/role/DisclosurePropertyAndEquipmentNetPropertyAndEquipmentDetails" xlink:type="extended" xlink:title="40401 - Disclosure - Property and Equipment, Net - Property and Equipment (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_637527510330529527" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_637527510330529527" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_EquipmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.eyenoviabio.com/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetails" xlink:type="extended" xlink:title="40402 - Disclosure - Property and Equipment, Net - Additional Information (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FairValueByAssetClassAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_637527510330539521" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_637527510330539521" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentMember" xlink:label="us-gaap_PropertyPlantAndEquipmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DepreciationDepletionAndAmortization" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_GeneralAndAdministrativeExpense" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.eyenoviabio.com/role/DisclosureNotesPayableScheduleOfNotesPayableDetails" xlink:type="extended" xlink:title="40701 - Disclosure - Notes Payable - Schedule of notes payable (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_637527510330549514" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain_637527510330549514" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_PaycheckProtectionProgramLoanMember" xlink:label="eyen_PaycheckProtectionProgramLoanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="eyen_PaycheckProtectionProgramLoanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="us-gaap_NotesPayableCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NotesPayableCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermNotesPayable" xlink:label="us-gaap_LongTermNotesPayable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LongTermNotesPayable" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayable" xlink:label="us-gaap_NotesPayable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NotesPayable" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.eyenoviabio.com/role/DisclosureNotesPayableAdditionalInformationDetails" xlink:type="extended" xlink:title="40702 - Disclosure - Notes Payable - Additional Information (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="us-gaap_ScheduleOfShortTermDebtTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="us-gaap_ShortTermDebtTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShortTermDebtTable" xlink:to="us-gaap_ShortTermDebtTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="us-gaap_ShortTermDebtTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="us-gaap_ShortTermDebtTypeDomain_637527510330549514" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain_637527510330549514" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayableOtherPayablesMember" xlink:label="us-gaap_NotesPayableOtherPayablesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="us-gaap_NotesPayableOtherPayablesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_PaycheckProtectionProgramLoanMember" xlink:label="eyen_PaycheckProtectionProgramLoanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="eyen_PaycheckProtectionProgramLoanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfShortTermDebtTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="us-gaap_ShortTermDebtLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_ScheduleOfShortTermDebtTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_NumberOfMonthlyPayments" xlink:label="eyen_NumberOfMonthlyPayments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="eyen_NumberOfMonthlyPayments" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentPeriodicPayment" xlink:label="us-gaap_DebtInstrumentPeriodicPayment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_DebtInstrumentPeriodicPayment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAnnualPrincipalPayment" xlink:label="us-gaap_DebtInstrumentAnnualPrincipalPayment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_DebtInstrumentAnnualPrincipalPayment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="us-gaap_RepaymentsOfNotesPayable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_RepaymentsOfNotesPayable" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromLongTermLinesOfCredit" xlink:label="us-gaap_ProceedsFromLongTermLinesOfCredit" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_ProceedsFromLongTermLinesOfCredit" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_PeriodConsideredForUsageOfLoanProceedsFromFundingDate" xlink:label="eyen_PeriodConsideredForUsageOfLoanProceedsFromFundingDate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="eyen_PeriodConsideredForUsageOfLoanProceedsFromFundingDate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_PercentageOfInterestOnAmountWhichIsNotForgiven" xlink:label="eyen_PercentageOfInterestOnAmountWhichIsNotForgiven" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="eyen_PercentageOfInterestOnAmountWhichIsNotForgiven" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="us-gaap_DebtInstrumentTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_DebtInstrumentTerm" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_InterestExpenseDebt" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.eyenoviabio.com/role/DisclosureIncomeTaxesAdditionalInformationDetails" xlink:type="extended" xlink:title="40804 - Disclosure - Income Taxes - Additional information (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="srt_StatementGeographicalAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_637527510330579497" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain_637527510330579497" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_NY" xlink:label="stpr_NY" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_SegmentGeographicalDomain" xlink:to="stpr_NY" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_NetOperatingLossLimitForUtilizationAsPerInternalRevenueCode" xlink:label="eyen_NetOperatingLossLimitForUtilizationAsPerInternalRevenueCode" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="eyen_NetOperatingLossLimitForUtilizationAsPerInternalRevenueCode" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_NetOperatingLossAnnualUtilizationLimitAsPerInternalRevenueCode" xlink:label="eyen_NetOperatingLossAnnualUtilizationLimitAsPerInternalRevenueCode" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="eyen_NetOperatingLossAnnualUtilizationLimitAsPerInternalRevenueCode" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_OperatingLossCarryForwardsExpirationTerm" xlink:label="eyen_OperatingLossCarryForwardsExpirationTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="eyen_OperatingLossCarryForwardsExpirationTerm" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.eyenoviabio.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:type="extended" xlink:title="40902 - Disclosure - Commitments and Contingencies - Additional Information (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_ArcticVisionLicenseAgreementMember" xlink:label="eyen_ArcticVisionLicenseAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="eyen_ArcticVisionLicenseAgreementMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_BauschLicenseAgreementMember" xlink:label="eyen_BauschLicenseAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="eyen_BauschLicenseAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_AdditionalOfficeSpaceMember" xlink:label="eyen_AdditionalOfficeSpaceMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="eyen_AdditionalOfficeSpaceMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetRentableArea" xlink:label="us-gaap_NetRentableArea" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetRentableArea" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_LeaseMonthlyBaseRent" xlink:label="eyen_LeaseMonthlyBaseRent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="eyen_LeaseMonthlyBaseRent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseExpirationDate1" xlink:label="us-gaap_LeaseExpirationDate1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LeaseExpirationDate1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SecurityDeposit" xlink:label="us-gaap_SecurityDeposit" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SecurityDeposit" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_LicenseAgreementsUpfrontPaymentsReceived" xlink:label="eyen_LicenseAgreementsUpfrontPaymentsReceived" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="eyen_LicenseAgreementsUpfrontPaymentsReceived" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_LicenseAgreementsMaximumAdditionalPaymentsReceivable" xlink:label="eyen_LicenseAgreementsMaximumAdditionalPaymentsReceivable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="eyen_LicenseAgreementsMaximumAdditionalPaymentsReceivable" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_LicenseAgreementsTerminationWrittenNoticePeriod" xlink:label="eyen_LicenseAgreementsTerminationWrittenNoticePeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_StatementLineItems" xlink:to="eyen_LicenseAgreementsTerminationWrittenNoticePeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_LicenseAgreementsTerminationPeriodUponUncuredMaterialBreach" xlink:label="eyen_LicenseAgreementsTerminationPeriodUponUncuredMaterialBreach" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_StatementLineItems" xlink:to="eyen_LicenseAgreementsTerminationPeriodUponUncuredMaterialBreach" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeveranceCosts1" xlink:label="us-gaap_SeveranceCosts1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SeveranceCosts1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalUnemploymentBenefitsSalaryContinuation" xlink:label="us-gaap_SupplementalUnemploymentBenefitsSalaryContinuation" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SupplementalUnemploymentBenefitsSalaryContinuation" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized" xlink:label="us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_RoyaltyRevenuePayments" xlink:label="eyen_RoyaltyRevenuePayments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_StatementLineItems" xlink:to="eyen_RoyaltyRevenuePayments" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_MilestoneRevenuePayments" xlink:label="eyen_MilestoneRevenuePayments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_StatementLineItems" xlink:to="eyen_MilestoneRevenuePayments" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.eyenoviabio.com/role/DisclosureRelatedPartyTransactionsDetails" xlink:type="extended" xlink:title="41001 - Disclosure - Related Party Transactions (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_637527510330619472" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_637527510330619472" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_CuraPartnersMember" xlink:label="eyen_CuraPartnersMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="eyen_CuraPartnersMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeStatementLocationAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_637527510330619472" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_637527510330619472" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain_637527510330629466" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain_637527510330629466" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_ConsultingAgreementMember" xlink:label="eyen_ConsultingAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="eyen_ConsultingAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_VicePresidentOfResearchAndDevelopmentMember" xlink:label="eyen_VicePresidentOfResearchAndDevelopmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="eyen_VicePresidentOfResearchAndDevelopmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_SenjuPharmaceuticalCoMember" xlink:label="eyen_SenjuPharmaceuticalCoMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="eyen_SenjuPharmaceuticalCoMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipAxis" xlink:label="srt_OwnershipAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_StatementTable" xlink:to="srt_OwnershipAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipDomain" xlink:label="srt_OwnershipDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipDomain" xlink:label="srt_OwnershipDomain_637527510330629466" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain_637527510330629466" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_LicenseAgreementMember" xlink:label="eyen_LicenseAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_OwnershipDomain" xlink:to="eyen_LicenseAgreementMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="5" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_ArcticVisionLicenseAgreementMember" xlink:label="eyen_ArcticVisionLicenseAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="eyen_ArcticVisionLicenseAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="6" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_ClassWarrantsMember" xlink:label="eyen_ClassWarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="eyen_ClassWarrantsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_ClassBWarrantsMember" xlink:label="eyen_ClassBWarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EquityComponentDomain" xlink:to="eyen_ClassBWarrantsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="7" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_637527510330649455" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_637527510330649455" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_ConsultingAgreementPaymentPermonth" xlink:label="eyen_ConsultingAgreementPaymentPermonth" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="eyen_ConsultingAgreementPaymentPermonth" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_ConsultingAgreementPaymentPerhour" xlink:label="eyen_ConsultingAgreementPaymentPerhour" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="eyen_ConsultingAgreementPaymentPerhour" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_CostOfServicesEngineeringServices" xlink:label="eyen_CostOfServicesEngineeringServices" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="eyen_CostOfServicesEngineeringServices" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetRentableArea" xlink:label="us-gaap_NetRentableArea" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetRentableArea" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_LeaseMonthlyBaseRent" xlink:label="eyen_LeaseMonthlyBaseRent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="eyen_LeaseMonthlyBaseRent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="us-gaap_LeaseAndRentalExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LeaseAndRentalExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SecurityDeposit" xlink:label="us-gaap_SecurityDeposit" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SecurityDeposit" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OfficersCompensation" xlink:label="us-gaap_OfficersCompensation" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OfficersCompensation" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsGross" xlink:label="us-gaap_LeaseholdImprovementsGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LeaseholdImprovementsGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:label="us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_RoyaltyPercentage" xlink:label="eyen_RoyaltyPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_StatementLineItems" xlink:to="eyen_RoyaltyPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_PaymentsForLicenseCosts" xlink:label="eyen_PaymentsForLicenseCosts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_StatementLineItems" xlink:to="eyen_PaymentsForLicenseCosts" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="18" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_GrossProceedsOfStockValueIssuedDuringPeriod" xlink:label="eyen_GrossProceedsOfStockValueIssuedDuringPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="19" xlink:from="us-gaap_StatementLineItems" xlink:to="eyen_GrossProceedsOfStockValueIssuedDuringPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_NetProceedsFromIssuanceOfCommonStock" xlink:label="eyen_NetProceedsFromIssuanceOfCommonStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="20" xlink:from="us-gaap_StatementLineItems" xlink:to="eyen_NetProceedsFromIssuanceOfCommonStock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="21" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.eyenoviabio.com/role/DisclosureStockholdersEquityAdditionalInformationRelatedToWarrantsDetails" xlink:type="extended" xlink:title="41102 - Disclosure - Stockholders' Equity - Additional information related to Warrants (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_637527510330709422" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_637527510330709422" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_WarrantsAtExercisePriceOneMember" xlink:label="eyen_WarrantsAtExercisePriceOneMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="eyen_WarrantsAtExercisePriceOneMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_WarrantsAtExercisePriceTwoMember" xlink:label="eyen_WarrantsAtExercisePriceTwoMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="eyen_WarrantsAtExercisePriceTwoMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_WarrantsAtExercisePriceThreeMember" xlink:label="eyen_WarrantsAtExercisePriceThreeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="eyen_WarrantsAtExercisePriceThreeMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_WarrantsAtExercisePriceFourMember" xlink:label="eyen_WarrantsAtExercisePriceFourMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="eyen_WarrantsAtExercisePriceFourMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_ClassOfWarrantOrRightExercisableWeightedAverageRemainingLife" xlink:label="eyen_ClassOfWarrantOrRightExercisableWeightedAverageRemainingLife" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="eyen_ClassOfWarrantOrRightExercisableWeightedAverageRemainingLife" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_ClassOfWarrantOrRightExercisable" xlink:label="eyen_ClassOfWarrantOrRightExercisable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="eyen_ClassOfWarrantOrRightExercisable" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_ClassOfWarrantOrRightExercised" xlink:label="eyen_ClassOfWarrantOrRightExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="eyen_ClassOfWarrantOrRightExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ProceedsFromWarrantExercises" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.eyenoviabio.com/role/DisclosureStockholdersEquityBlackScholesOptionDetails" xlink:type="extended" xlink:title="41103 - Disclosure - Stockholders' Equity - Black Scholes option (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.eyenoviabio.com/role/DisclosureStockholdersEquitySummaryOfOptionActivityDetails" xlink:type="extended" xlink:title="41104 - Disclosure - Stockholders' Equity - Summary of option activity (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DerivativeInstrumentRiskAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="us-gaap_DerivativeContractTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="us-gaap_DerivativeContractTypeDomain_637527510330729412" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain_637527510330729412" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockOptionMember" xlink:label="us-gaap_StockOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="us-gaap_StockOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.eyenoviabio.com/role/DisclosureStockholdersEquitySummaryOfInformationRelatedToStockOptionsDetails" xlink:type="extended" xlink:title="41105 - Disclosure - Stockholders' Equity - Summary of information related to stock options (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_637527510330749403" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_637527510330749403" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_ExercisePriceOneMember" xlink:label="eyen_ExercisePriceOneMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="eyen_ExercisePriceOneMember" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_ExercisePriceTwoMember" xlink:label="eyen_ExercisePriceTwoMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="eyen_ExercisePriceTwoMember" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_ExercisePrice2.72Member" xlink:label="eyen_ExercisePrice2.72Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="eyen_ExercisePrice2.72Member" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_ExercisePriceThreeMember" xlink:label="eyen_ExercisePriceThreeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="eyen_ExercisePriceThreeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_ExercisePrice2.89Member" xlink:label="eyen_ExercisePrice2.89Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="eyen_ExercisePrice2.89Member" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_ExercisePriceFourMember" xlink:label="eyen_ExercisePriceFourMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="eyen_ExercisePriceFourMember" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_ExercisePrice3.43Member" xlink:label="eyen_ExercisePrice3.43Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="eyen_ExercisePrice3.43Member" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_ExercisePrice3.48Member" xlink:label="eyen_ExercisePrice3.48Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="eyen_ExercisePrice3.48Member" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_ExercisePrice3.71Member" xlink:label="eyen_ExercisePrice3.71Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="eyen_ExercisePrice3.71Member" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_ExercisePriceFiveMember" xlink:label="eyen_ExercisePriceFiveMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="eyen_ExercisePriceFiveMember" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_ExercisePrice4.68Member" xlink:label="eyen_ExercisePrice4.68Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="eyen_ExercisePrice4.68Member" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_ExercisePriceSixMember" xlink:label="eyen_ExercisePriceSixMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="eyen_ExercisePriceSixMember" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_ExercisePriceSevenMember" xlink:label="eyen_ExercisePriceSevenMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="eyen_ExercisePriceSevenMember" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_ExercisePriceEightMember" xlink:label="eyen_ExercisePriceEightMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="eyen_ExercisePriceEightMember" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_ExercisePrice5.77Member" xlink:label="eyen_ExercisePrice5.77Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="eyen_ExercisePrice5.77Member" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_ExercisePriceNineMemberMember" xlink:label="eyen_ExercisePriceNineMemberMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="eyen_ExercisePriceNineMemberMember" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_ExercisePriceTenMember" xlink:label="eyen_ExercisePriceTenMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="eyen_ExercisePriceTenMember" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_ExercisePriceElevenMember" xlink:label="eyen_ExercisePriceElevenMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="18" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="eyen_ExercisePriceElevenMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.eyenoviabio.com/role/DisclosureStockholdersEquityAdditionalInformationDetails" xlink:type="extended" xlink:title="41106 - Disclosure - Stockholders' Equity - Additional Information (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_WarrantsAtExercisePriceOneMember" xlink:label="eyen_WarrantsAtExercisePriceOneMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="eyen_WarrantsAtExercisePriceOneMember" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_WarrantsAtExercisePriceThreeMember" xlink:label="eyen_WarrantsAtExercisePriceThreeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="eyen_WarrantsAtExercisePriceThreeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_637527510330769383" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_637527510330769383" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_EmployeesConsultantsAndDirectorsUnder2018PlanMember" xlink:label="eyen_EmployeesConsultantsAndDirectorsUnder2018PlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PlanNameDomain" xlink:to="eyen_EmployeesConsultantsAndDirectorsUnder2018PlanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_OmnibusStockIncentivePlan2018Member" xlink:label="eyen_OmnibusStockIncentivePlan2018Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PlanNameDomain" xlink:to="eyen_OmnibusStockIncentivePlan2018Member" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_VestingAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain_637527510330779387" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain_637527510330779387" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="5" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_UnderwrittenPublicOfferingMember" xlink:label="eyen_UnderwrittenPublicOfferingMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="eyen_UnderwrittenPublicOfferingMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="6" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_WarrantMember" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_ClassWarrantsMember" xlink:label="eyen_ClassWarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_WarrantMember" xlink:to="eyen_ClassWarrantsMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_ClassBWarrantsMember" xlink:label="eyen_ClassBWarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_WarrantMember" xlink:to="eyen_ClassBWarrantsMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="7" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="8" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeStatementLocationAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_ShareBasedCompensationArrangementByShareBasedPaymentAwardCashFeePaid" xlink:label="eyen_ShareBasedCompensationArrangementByShareBasedPaymentAwardCashFeePaid" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="eyen_ShareBasedCompensationArrangementByShareBasedPaymentAwardCashFeePaid" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_NumberOfCommonShares" xlink:label="eyen_NumberOfCommonShares" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_StatementLineItems" xlink:to="eyen_NumberOfCommonShares" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_ClassOfWarrantOrRightNumberOfYearsSecuritiesCalledByWarrantsToPurchaseCommonStock" xlink:label="eyen_ClassOfWarrantOrRightNumberOfYearsSecuritiesCalledByWarrantsToPurchaseCommonStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_StatementLineItems" xlink:to="eyen_ClassOfWarrantOrRightNumberOfYearsSecuritiesCalledByWarrantsToPurchaseCommonStock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_GrossProceedsOfStockValueIssuedDuringPeriod" xlink:label="eyen_GrossProceedsOfStockValueIssuedDuringPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_StatementLineItems" xlink:to="eyen_GrossProceedsOfStockValueIssuedDuringPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_NetProceedsFromIssuanceOfCommonStock" xlink:label="eyen_NetProceedsFromIssuanceOfCommonStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_StatementLineItems" xlink:to="eyen_NetProceedsFromIssuanceOfCommonStock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_NumberOfSharesAgreedToBeIssued" xlink:label="eyen_NumberOfSharesAgreedToBeIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_StatementLineItems" xlink:to="eyen_NumberOfSharesAgreedToBeIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_OverAllotmentOptionPeriod" xlink:label="eyen_OverAllotmentOptionPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="us-gaap_StatementLineItems" xlink:to="eyen_OverAllotmentOptionPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="18" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="19" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="20" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensation" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="21" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="22" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="23" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="24" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="25" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="26" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="27" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="28" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="29" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="30" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="31" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromWarrantExercises" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_RemittanceOfEmployeeSPayrollTaxes" xlink:label="eyen_RemittanceOfEmployeeSPayrollTaxes" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="32" xlink:from="us-gaap_StatementLineItems" xlink:to="eyen_RemittanceOfEmployeeSPayrollTaxes" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="33" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="34" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="35" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="36" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="37" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.eyenoviabio.com/role/DisclosureSubsequentEventsDetails" xlink:type="extended" xlink:title="41301 - Disclosure - Subsequent Events (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_EmployeesConsultantsAndDirectorsUnder2018PlanMember" xlink:label="eyen_EmployeesConsultantsAndDirectorsUnder2018PlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PlanNameDomain" xlink:to="eyen_EmployeesConsultantsAndDirectorsUnder2018PlanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_637527510330899304" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_637527510330899304" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromWarrantExercises" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" priority="1" use="optional" />
  </definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>12
<FILENAME>eyen-20201231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.9.3.5 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/31/2021 1:30:34 AM-->
<!--Modified on: 3/31/2021 1:30:34 AM-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
  <labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Document and Entity Information</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Entity Ex Transition Period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Balance Sheets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Stock options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Stock option activity</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">Assets [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">Assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Assets, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current Assets:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCostsCurrent" xlink:label="us-gaap_DeferredCostsCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCostsCurrent" xlink:to="us-gaap_DeferredCostsCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCostsCurrent_lbl" xml:lang="en-US">Deferred Costs, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredCostsCurrent_lbl" xml:lang="en-US">Deferred license costs</label>
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_LicenseReceivableCurrent" xlink:label="eyen_LicenseReceivableCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_LicenseReceivableCurrent" xlink:to="eyen_LicenseReceivableCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_LicenseReceivableCurrent_lbl" xml:lang="en-US">The amount of license receivable classified as current.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_LicenseReceivableCurrent_lbl" xml:lang="en-US">License Receivable, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="eyen_LicenseReceivableCurrent_lbl" xml:lang="en-US">License receivable</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Prepaid Expense and Other Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Total prepaid expenses and other current assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Prepaid expenses and other current assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total Current Assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property, Plant and Equipment, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property and equipment, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property and equipment, net</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SecurityDeposit" xlink:label="us-gaap_SecurityDeposit" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SecurityDeposit" xlink:to="us-gaap_SecurityDeposit_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SecurityDeposit_lbl" xml:lang="en-US">Security Deposit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SecurityDeposit_lbl" xml:lang="en-US">Security deposit</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total Assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">Liabilities and Equity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">Liabilities and Stockholders' Equity</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Liabilities, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current Liabilities:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts Payable, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts payable</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WorkersCompensationLiabilityCurrent" xlink:label="us-gaap_WorkersCompensationLiabilityCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WorkersCompensationLiabilityCurrent" xlink:to="us-gaap_WorkersCompensationLiabilityCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WorkersCompensationLiabilityCurrent_lbl" xml:lang="en-US">Workers' Compensation Liability, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WorkersCompensationLiabilityCurrent_lbl" xml:lang="en-US">Accrued compensation</label>
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_AccruedExpensesAndOtherLiabilitiesCurrent" xlink:label="eyen_AccruedExpensesAndOtherLiabilitiesCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_AccruedExpensesAndOtherLiabilitiesCurrent" xlink:to="eyen_AccruedExpensesAndOtherLiabilitiesCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_AccruedExpensesAndOtherLiabilitiesCurrent_lbl" xml:lang="en-US">Carrying value as of the balance sheet date of obligations incurred and payable, of accrued expenses and other current liabilities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_AccruedExpensesAndOtherLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued expenses and other liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="eyen_AccruedExpensesAndOtherLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued expenses and other current liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRentCreditCurrent" xlink:label="us-gaap_DeferredRentCreditCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRentCreditCurrent" xlink:to="us-gaap_DeferredRentCreditCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRentCreditCurrent_lbl" xml:lang="en-US">Deferred Rent Credit, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredRentCreditCurrent_lbl" xml:lang="en-US">Deferred rent - current portion</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xml:lang="en-US">Contract with Customer, Liability, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xml:lang="en-US">Deferred license fee</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermBankLoansAndNotesPayable" xlink:label="us-gaap_ShortTermBankLoansAndNotesPayable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermBankLoansAndNotesPayable" xlink:to="us-gaap_ShortTermBankLoansAndNotesPayable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermBankLoansAndNotesPayable_lbl" xml:lang="en-US">Short-term Bank Loans and Notes Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShortTermBankLoansAndNotesPayable_lbl" xml:lang="en-US">Notes payable - current portion</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total Current Liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="us-gaap_DeferredRentCreditNoncurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRentCreditNoncurrent" xlink:to="us-gaap_DeferredRentCreditNoncurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRentCreditNoncurrent_lbl" xml:lang="en-US">Deferred Rent Credit, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredRentCreditNoncurrent_lbl" xml:lang="en-US">Deferred rent - non-current portion</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermNotesPayable" xlink:label="us-gaap_LongTermNotesPayable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermNotesPayable" xlink:to="us-gaap_LongTermNotesPayable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermNotesPayable_lbl" xml:lang="en-US">Notes Payable, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermNotesPayable_lbl" xml:lang="en-US">Notes payable - non-current portion</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LongTermNotesPayable_lbl" xml:lang="en-US">Non-Current Portion</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Total Liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments and Contingencies.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments and contingencies (Note 9)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Stockholders' Equity:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Preferred Stock, Value, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Preferred stock, $0.0001 par value, 6,000,000 shares authorized;0 shares issued and outstanding as of December 31, 2020 and 2019 respectively</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common Stock, Value, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common stock, $0.0001 par value, 90,000,000 shares authorized; 24,978,585 and 17,100,726 shares issued and outstanding as of December 31, 2020 and 2019, respectively</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">Additional Paid in Capital</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">Additional paid-in capital</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Stockholders' Equity Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total Stockholders' Equity</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Liabilities and Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total Liabilities and Stockholders' Equity</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred Stock, Shares Authorized</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Preferred Stock, Shares Issued</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred Stock, Shares Outstanding</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common Stock, Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, shares authorized</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common Stock, Shares, Issued</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common Stock, Shares, Outstanding</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Statements of Operations</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenuesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenuesAbstract_lbl" xml:lang="en-US">Revenues [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenuesAbstract_lbl" xml:lang="en-US">Operating Income</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xml:lang="en-US">Revenue</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfRevenue" xlink:label="us-gaap_CostOfRevenue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfRevenue" xlink:to="us-gaap_CostOfRevenue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfRevenue_lbl" xml:lang="en-US">Cost of Revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_CostOfRevenue_lbl" xml:lang="en-US">Cost of revenue</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrossProfit" xlink:label="us-gaap_GrossProfit" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_GrossProfit_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GrossProfit_lbl" xml:lang="en-US">Gross Profit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_GrossProfit_lbl" xml:lang="en-US">Gross Profit</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Operating Expenses [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Operating Expenses:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and Development Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and Administrative Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative expenses</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Operating Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Total Operating Expenses</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Operating Income (Loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Loss From Operations</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US">Other Income (Expense):</label>
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_SmallBusinessAdministrationEconomicInjuryDisasterGrant" xlink:label="eyen_SmallBusinessAdministrationEconomicInjuryDisasterGrant" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_SmallBusinessAdministrationEconomicInjuryDisasterGrant" xlink:to="eyen_SmallBusinessAdministrationEconomicInjuryDisasterGrant_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_SmallBusinessAdministrationEconomicInjuryDisasterGrant_lbl" xml:lang="en-US">Amount of small business administration economic injury disaster grant.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_SmallBusinessAdministrationEconomicInjuryDisasterGrant_lbl" xml:lang="en-US">Small Business Administration Economic Injury Disaster Grant</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="eyen_SmallBusinessAdministrationEconomicInjuryDisasterGrant_lbl" xml:lang="en-US">Small Business Administration Economic Injury Disaster Grant</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpense_lbl" xml:lang="en-US">Interest Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestExpense_lbl" xml:lang="en-US">Interest expense</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet_lbl" xml:lang="en-US">Interest Income (Expense), Nonoperating, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet_lbl" xml:lang="en-US">Interest income</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net Income (Loss) Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net Loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDilutedAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedAbstract_lbl" xml:lang="en-US">Earnings Per Share, Basic and Diluted [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedAbstract_lbl" xml:lang="en-US">Net Loss Per Share</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xml:lang="en-US">Earnings Per Share, Basic and Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xml:lang="en-US">- Basic and Diluted</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_lbl" xml:lang="en-US">Earnings Per Share, Basic and Diluted, Other Disclosures [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_lbl" xml:lang="en-US">Weighted Average Number of Common Shares Outstanding</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic and Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xml:lang="en-US">- Basic and Diluted</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US">Statements of Changes in Stockholders' Equity</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Shares, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Balance (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Balance (in shares)</label>
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_StockIssuedDuringPeriodValueNewIssuesTwo" xlink:label="eyen_StockIssuedDuringPeriodValueNewIssuesTwo" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_StockIssuedDuringPeriodValueNewIssuesTwo" xlink:to="eyen_StockIssuedDuringPeriodValueNewIssuesTwo_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_StockIssuedDuringPeriodValueNewIssuesTwo_lbl" xml:lang="en-US">Stock issuance of common stock two value on public offering.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_StockIssuedDuringPeriodValueNewIssuesTwo_lbl" xml:lang="en-US">Stock Issued During Period Value New Issues Two</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="eyen_StockIssuedDuringPeriodValueNewIssuesTwo_lbl" xml:lang="en-US">Issuance of common stock and warrants in private placement</label>
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_StockIssuedDuringPeriodSharesNewIssuesTwo" xlink:label="eyen_StockIssuedDuringPeriodSharesNewIssuesTwo" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_StockIssuedDuringPeriodSharesNewIssuesTwo" xlink:to="eyen_StockIssuedDuringPeriodSharesNewIssuesTwo_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_StockIssuedDuringPeriodSharesNewIssuesTwo_lbl" xml:lang="en-US">Stock issuance of common stock one shares on public offering</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_StockIssuedDuringPeriodSharesNewIssuesTwo_lbl" xml:lang="en-US">Stock Issued During Period Shares New Issues Two</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="eyen_StockIssuedDuringPeriodSharesNewIssuesTwo_lbl" xml:lang="en-US">Issuance of common stock and warrants in private placement(in shares)</label>
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_StockIssuedDuringPeriodValueNewIssuesThree" xlink:label="eyen_StockIssuedDuringPeriodValueNewIssuesThree" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_StockIssuedDuringPeriodValueNewIssuesThree" xlink:to="eyen_StockIssuedDuringPeriodValueNewIssuesThree_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_StockIssuedDuringPeriodValueNewIssuesThree_lbl" xml:lang="en-US">This represents Stock Issued During Period Value New Issues three.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_StockIssuedDuringPeriodValueNewIssuesThree_lbl" xml:lang="en-US">Stock Issued During Period Value New Issues Three</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="eyen_StockIssuedDuringPeriodValueNewIssuesThree_lbl" xml:lang="en-US">Issuance of common stock in public offering</label>
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_StockIssuedDuringPeriodSharesNewIssuesThree" xlink:label="eyen_StockIssuedDuringPeriodSharesNewIssuesThree" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_StockIssuedDuringPeriodSharesNewIssuesThree" xlink:to="eyen_StockIssuedDuringPeriodSharesNewIssuesThree_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_StockIssuedDuringPeriodSharesNewIssuesThree_lbl" xml:lang="en-US">This represents common stock issued during period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_StockIssuedDuringPeriodSharesNewIssuesThree_lbl" xml:lang="en-US">Stock Issued During Period Shares New Issues Three</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="eyen_StockIssuedDuringPeriodSharesNewIssuesThree_lbl" xml:lang="en-US">Issuance of common stock in public offering (in shares)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Aggregate number of shares issued including over-allotment option (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Issuance of common stock (in shares)</label>
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_StockIssuedDuringPeriodValueStockOptionsExercisedOnCashlessBasis" xlink:label="eyen_StockIssuedDuringPeriodValueStockOptionsExercisedOnCashlessBasis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_StockIssuedDuringPeriodValueStockOptionsExercisedOnCashlessBasis" xlink:to="eyen_StockIssuedDuringPeriodValueStockOptionsExercisedOnCashlessBasis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_StockIssuedDuringPeriodValueStockOptionsExercisedOnCashlessBasis_lbl" xml:lang="en-US">Value of stock issued as a result of the exercise of stock options on cashless basis.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_StockIssuedDuringPeriodValueStockOptionsExercisedOnCashlessBasis_lbl" xml:lang="en-US">Exercise of stock options on a cashless basis</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="eyen_StockIssuedDuringPeriodValueStockOptionsExercisedOnCashlessBasis_lbl" xml:lang="en-US">Exercise of stock options on a cashless basis</label>
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodOnCashlessBasis" xlink:label="eyen_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodOnCashlessBasis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodOnCashlessBasis" xlink:to="eyen_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodOnCashlessBasis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodOnCashlessBasis_lbl" xml:lang="en-US">Number of share options (or share units) exercised on cashless basis during the current period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodOnCashlessBasis_lbl" xml:lang="en-US">Share based Compensation Arrangement by Share based Payment Award Options Exercises in Period On Cashless Basis</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="eyen_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodOnCashlessBasis_lbl" xml:lang="en-US">Exercise of stock options on a cashless basis (in shares)</label>
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_StockIssuedDuringPeriodValueWarrantsExercised" xlink:label="eyen_StockIssuedDuringPeriodValueWarrantsExercised" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_StockIssuedDuringPeriodValueWarrantsExercised" xlink:to="eyen_StockIssuedDuringPeriodValueWarrantsExercised_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_StockIssuedDuringPeriodValueWarrantsExercised_lbl" xml:lang="en-US">Value of stock issued as a result of the exercise of warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_StockIssuedDuringPeriodValueWarrantsExercised_lbl" xml:lang="en-US">Stock Issued During Period, Value, Warrants Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="eyen_StockIssuedDuringPeriodValueWarrantsExercised_lbl" xml:lang="en-US">Exercise of stock warrants</label>
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:label="eyen_StockIssuedDuringPeriodSharesWarrantsExercised" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:to="eyen_StockIssuedDuringPeriodSharesWarrantsExercised_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_StockIssuedDuringPeriodSharesWarrantsExercised_lbl" xml:lang="en-US">Number of shares issued as a result of the exercise of warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_StockIssuedDuringPeriodSharesWarrantsExercised_lbl" xml:lang="en-US">Stock Issued During Period, Shares, Warrants Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="eyen_StockIssuedDuringPeriodSharesWarrantsExercised_lbl" xml:lang="en-US">Exercise of stock warrants (in shares)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US">Exercise of stock options</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Number of Options Exercised | Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Exercise of stock options (in shares)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US">Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US">Stock-based compensation</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US">Equity Component [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US">Equity Component [Domain]</label>
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_CommonStockOneMember" xlink:label="eyen_CommonStockOneMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_CommonStockOneMember" xlink:to="eyen_CommonStockOneMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_CommonStockOneMember_lbl" xml:lang="en-US">Common Stock One</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_CommonStockOneMember_lbl" xml:lang="en-US">Common Stock One [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="eyen_CommonStockOneMember_lbl" xml:lang="en-US">Common Stock One [Member]</label>
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_CommonStockTwoMember" xlink:label="eyen_CommonStockTwoMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_CommonStockTwoMember" xlink:to="eyen_CommonStockTwoMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_CommonStockTwoMember_lbl" xml:lang="en-US">Common Stock Two</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_CommonStockTwoMember_lbl" xml:lang="en-US">Common Stock Two [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="eyen_CommonStockTwoMember_lbl" xml:lang="en-US">Common Stock Two [Member]</label>
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_ProceedsOfStockIssuedDuringPeriodGross" xlink:label="eyen_ProceedsOfStockIssuedDuringPeriodGross" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_ProceedsOfStockIssuedDuringPeriodGross" xlink:to="eyen_ProceedsOfStockIssuedDuringPeriodGross_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_ProceedsOfStockIssuedDuringPeriodGross_lbl" xml:lang="en-US">It represents issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_ProceedsOfStockIssuedDuringPeriodGross_lbl" xml:lang="en-US">Proceeds Of Stock Issued During Period Gross</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" xml:lang="en-US">Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statements of Cash Flows</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Cash Flows From Operating Activities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xml:lang="en-US">Depreciation, Depletion and Amortization</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xml:lang="en-US">Depreciation of property and equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xml:lang="en-US">Depreciation and amortization expense</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Share-based Compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Stock-based compensation</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in operating assets and liabilities:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US">Prepaid expenses and other current assets</label>
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_IncreaseDecreaseInLicenseReceivable" xlink:label="eyen_IncreaseDecreaseInLicenseReceivable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_IncreaseDecreaseInLicenseReceivable" xlink:to="eyen_IncreaseDecreaseInLicenseReceivable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_IncreaseDecreaseInLicenseReceivable_lbl" xml:lang="en-US">The amount of increase or decrease in license receivable.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_IncreaseDecreaseInLicenseReceivable_lbl" xml:lang="en-US">Increase Decrease in License Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="eyen_IncreaseDecreaseInLicenseReceivable_lbl" xml:lang="en-US">License receivable</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredCharges" xlink:label="us-gaap_IncreaseDecreaseInDeferredCharges" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredCharges" xlink:to="us-gaap_IncreaseDecreaseInDeferredCharges_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInDeferredCharges_lbl" xml:lang="en-US">Increase (Decrease) in Deferred Charges</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInDeferredCharges_lbl" xml:lang="en-US">Deferred license costs</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US">Accounts payable</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xml:lang="en-US">Accrued compensation</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">Increase (Decrease) in Other Accounts Payable and Accrued Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">Accrued expenses and other current liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xml:lang="en-US">Deferred license fee</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInSecurityDeposits" xlink:label="us-gaap_IncreaseDecreaseInSecurityDeposits" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInSecurityDeposits" xlink:to="us-gaap_IncreaseDecreaseInSecurityDeposits_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInSecurityDeposits_lbl" xml:lang="en-US">Increase (Decrease) in Security Deposits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInSecurityDeposits_lbl" xml:lang="en-US">Security deposit</label>
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_IncreaseDecreaseInDeferredRent" xlink:label="eyen_IncreaseDecreaseInDeferredRent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_IncreaseDecreaseInDeferredRent" xlink:to="eyen_IncreaseDecreaseInDeferredRent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_IncreaseDecreaseInDeferredRent_lbl" xml:lang="en-US">Amount of increase (decrease) of deferred rent that provides economic benefits in future periods.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_IncreaseDecreaseInDeferredRent_lbl" xml:lang="en-US">Increase Decrease in Deferred Rent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="eyen_IncreaseDecreaseInDeferredRent_lbl" xml:lang="en-US">Deferred rent</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Cash used in operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net Cash Used In Operating Activities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Cash Flows From Investing Activities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchases of property and equipment</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net Cash Used In Investing Activities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Cash Flows From Financing Activities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xml:lang="en-US">Proceeds from Issuance Initial Public Offering</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xml:lang="en-US">Proceeds from sale of common stock in public offering</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xml:lang="en-US">Proceeds from sale of common stock and warrants in private placement</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Proceeds from Issuance of Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Proceeds from sale of common stock in public offering</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xml:lang="en-US">Proceeds from Warrant Exercises</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xml:lang="en-US">Proceeds from exercise of stock warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xml:lang="en-US">Proceeds from exercise of warrants</label>
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_ProceedsFromPaycheckProtectionProgramLoan" xlink:label="eyen_ProceedsFromPaycheckProtectionProgramLoan" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_ProceedsFromPaycheckProtectionProgramLoan" xlink:to="eyen_ProceedsFromPaycheckProtectionProgramLoan_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_ProceedsFromPaycheckProtectionProgramLoan_lbl" xml:lang="en-US">The cash inflow from paycheck protection program loan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_ProceedsFromPaycheckProtectionProgramLoan_lbl" xml:lang="en-US">Proceeds from Paycheck Protection Program Loan</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="eyen_ProceedsFromPaycheckProtectionProgramLoan_lbl" xml:lang="en-US">Proceeds from PPP 7(a) Loan</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="us-gaap_RepaymentsOfNotesPayable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfNotesPayable" xlink:to="us-gaap_RepaymentsOfNotesPayable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfNotesPayable_lbl" xml:lang="en-US">Repayments of Notes Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfNotesPayable_lbl" xml:lang="en-US">Repayments of notes payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RepaymentsOfNotesPayable_lbl" xml:lang="en-US">Repayments of loan</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US">Payments of Stock Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US">Payment of private placement issuance costs</label>
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_PaymentsForRepurchaseOfPublicOffering" xlink:label="eyen_PaymentsForRepurchaseOfPublicOffering" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_PaymentsForRepurchaseOfPublicOffering" xlink:to="eyen_PaymentsForRepurchaseOfPublicOffering_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_PaymentsForRepurchaseOfPublicOffering_lbl" xml:lang="en-US">The cash outflow associated with the repurchase of amount received from entity's offering of stock to the public.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_PaymentsForRepurchaseOfPublicOffering_lbl" xml:lang="en-US">Payments for Repurchase of Public Offering</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="eyen_PaymentsForRepurchaseOfPublicOffering_lbl" xml:lang="en-US">Payment of public offering issuance costs</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US">Proceeds from Stock Options Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US">Proceeds from Stock Options Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US">Proceeds from exercise of stock options</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net Cash Provided By Financing Activities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US">Net Increase (Decrease) in Cash and Cash Equivalents</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Cash and cash equivalents - End of Year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Cash and cash equivalents - Beginning of Year</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">Supplemental Disclosure of Cash Flow Information:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPaidCapitalized" xlink:label="us-gaap_InterestPaidCapitalized" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidCapitalized" xlink:to="us-gaap_InterestPaidCapitalized_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaidCapitalized_lbl" xml:lang="en-US">Interest Paid, Capitalized, Investing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestPaidCapitalized_lbl" xml:lang="en-US">Interest</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xml:lang="en-US">Noncash Investing and Financing Items [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xml:lang="en-US">Supplemental Disclosure of Non-Cash Investing and Financing Activities</label>
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_PurchaseOfInsurancePremiumFinancedByShortTermNotePayable" xlink:label="eyen_PurchaseOfInsurancePremiumFinancedByShortTermNotePayable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_PurchaseOfInsurancePremiumFinancedByShortTermNotePayable" xlink:to="eyen_PurchaseOfInsurancePremiumFinancedByShortTermNotePayable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_PurchaseOfInsurancePremiumFinancedByShortTermNotePayable_lbl" xml:lang="en-US">The amount of purchase of insurance premium financed by short term notes payable.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_PurchaseOfInsurancePremiumFinancedByShortTermNotePayable_lbl" xml:lang="en-US">Purchase Of Insurance Premium Financed By Short Term Note Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="eyen_PurchaseOfInsurancePremiumFinancedByShortTermNotePayable_lbl" xml:lang="en-US">Purchase of insurance premium financed by note payable</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssued1" xlink:label="us-gaap_StockIssued1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssued1" xlink:to="us-gaap_StockIssued1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssued1_lbl" xml:lang="en-US">Stock Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssued1_lbl" xml:lang="en-US">Exercise of stock options on a cashless basis</label>
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_AccruedPurchasesOfLeaseholdImprovements" xlink:label="eyen_AccruedPurchasesOfLeaseholdImprovements" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_AccruedPurchasesOfLeaseholdImprovements" xlink:to="eyen_AccruedPurchasesOfLeaseholdImprovements_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_AccruedPurchasesOfLeaseholdImprovements_lbl" xml:lang="en-US">This represents accrued purchases of leasehold improvements.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_AccruedPurchasesOfLeaseholdImprovements_lbl" xml:lang="en-US">Accrued Purchases of Leasehold Improvements</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="eyen_AccruedPurchasesOfLeaseholdImprovements_lbl" xml:lang="en-US">Accrued purchases of leasehold improvements</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US">Class of Stock [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockDomain_lbl" xml:lang="en-US">Class Of Stock [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfStockDomain_lbl" xml:lang="en-US">Class of Stock [Domain]</label>
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_CommonStockThreeMember" xlink:label="eyen_CommonStockThreeMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_CommonStockThreeMember" xlink:to="eyen_CommonStockThreeMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_CommonStockThreeMember_lbl" xml:lang="en-US">This represents common stock three member.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_CommonStockThreeMember_lbl" xml:lang="en-US">Common Stock Three [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="eyen_CommonStockThreeMember_lbl" xml:lang="en-US">Common Stock Three [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfDebtIssuanceCosts" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts_lbl" xml:lang="en-US">Payments of Debt Issuance Costs</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US">Business Organization and Nature of Operations</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US">Business Organization and Nature of Operations</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Summary of Significant Accounting Policies</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Significant Accounting Policies [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Summary of Significant Accounting Policies</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsAbstract" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsAbstract_lbl" xml:lang="en-US">Prepaid Expenses and Other Current Assets</label>
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_PrepaidExpensesAndOtherCurrentAssetsDisclosureTextBlock" xlink:label="eyen_PrepaidExpensesAndOtherCurrentAssetsDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_PrepaidExpensesAndOtherCurrentAssetsDisclosureTextBlock" xlink:to="eyen_PrepaidExpensesAndOtherCurrentAssetsDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_PrepaidExpensesAndOtherCurrentAssetsDisclosureTextBlock_lbl" xml:lang="en-US">The entire disclosure of prepaid expenses and other current assets.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_PrepaidExpensesAndOtherCurrentAssetsDisclosureTextBlock_lbl" xml:lang="en-US">Prepaid Expenses and Other Current Assets Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="eyen_PrepaidExpensesAndOtherCurrentAssetsDisclosureTextBlock_lbl" xml:lang="en-US">Prepaid Expenses and Other Current Assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xml:lang="en-US">Property and Equipment, Net</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US">Property and Equipment, Net</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xml:lang="en-US">Accrued Expenses and Other Current Liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xml:lang="en-US">Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xml:lang="en-US">Accrued Expenses and Other Current Liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationRelatedCostsAbstract" xlink:label="us-gaap_CompensationRelatedCostsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationRelatedCostsAbstract" xlink:to="us-gaap_CompensationRelatedCostsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationRelatedCostsAbstract_lbl" xml:lang="en-US">Accrued Compensation</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationRelatedCostsGeneralTextBlock" xlink:label="us-gaap_CompensationRelatedCostsGeneralTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationRelatedCostsGeneralTextBlock" xlink:to="us-gaap_CompensationRelatedCostsGeneralTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationRelatedCostsGeneralTextBlock_lbl" xml:lang="en-US">Compensation Related Costs, General [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CompensationRelatedCostsGeneralTextBlock_lbl" xml:lang="en-US">Accrued Compensation</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayableAbstract" xlink:label="us-gaap_NotesPayableAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayableAbstract" xlink:to="us-gaap_NotesPayableAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesPayableAbstract_lbl" xml:lang="en-US">Notes Payable</label>
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_NotesPayableDisclosureTextBlock" xlink:label="eyen_NotesPayableDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_NotesPayableDisclosureTextBlock" xlink:to="eyen_NotesPayableDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_NotesPayableDisclosureTextBlock_lbl" xml:lang="en-US">The entire disclosure of notes payable.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_NotesPayableDisclosureTextBlock_lbl" xml:lang="en-US">Notes Payable Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="eyen_NotesPayableDisclosureTextBlock_lbl" xml:lang="en-US">Notes Payable</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US">Income Taxes</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">Income Tax Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">Income Taxes</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">Commitments and Contingencies</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US">Related Party Transactions</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US">Related Party Transactions</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US">Stockholders' Equity</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">Stockholders' Equity</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xml:lang="en-US">Employee Benefit Plans</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:to="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_lbl" xml:lang="en-US">Compensation and Employee Benefit Plans [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_lbl" xml:lang="en-US">Employee Benefit Plans</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">Subsequent Events</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">Subsequent Events [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">Subsequent Events</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of Estimates</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">Cash and Cash Equivalents</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US">Property and Equipment, Net</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xml:lang="en-US">Impairment of Long-lived Assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy" xlink:label="us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy" xlink:to="us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy_lbl" xml:lang="en-US">Stockholders' Equity Note, Redeemable Preferred Stock, Issue, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy_lbl" xml:lang="en-US">Preferred Stock</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xml:lang="en-US">Fair Value of Financial Instruments</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US">Income Taxes</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xml:lang="en-US">Revenue Recognition</label>
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_DeferredLicenseFeePolicyTextBlock" xlink:label="eyen_DeferredLicenseFeePolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_DeferredLicenseFeePolicyTextBlock" xlink:to="eyen_DeferredLicenseFeePolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_DeferredLicenseFeePolicyTextBlock_lbl" xml:lang="en-US">Disclosure of accounting policy for deferral license fee.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_DeferredLicenseFeePolicyTextBlock_lbl" xml:lang="en-US">Deferred License Fee [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="eyen_DeferredLicenseFeePolicyTextBlock_lbl" xml:lang="en-US">Deferred License Fee</label>
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_DeferredLicenseCostsPolicyTextBlock" xlink:label="eyen_DeferredLicenseCostsPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_DeferredLicenseCostsPolicyTextBlock" xlink:to="eyen_DeferredLicenseCostsPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_DeferredLicenseCostsPolicyTextBlock_lbl" xml:lang="en-US">Disclosure of accounting policy for deferral license costs.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_DeferredLicenseCostsPolicyTextBlock_lbl" xml:lang="en-US">Deferred License Costs [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="eyen_DeferredLicenseCostsPolicyTextBlock_lbl" xml:lang="en-US">Deferred License Costs</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and Development</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US">Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US">Stock-Based Compensation</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Net Loss Per Common Share</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsPolicyPolicyTextBlock" xlink:label="us-gaap_SubsequentEventsPolicyPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsPolicyPolicyTextBlock" xlink:to="us-gaap_SubsequentEventsPolicyPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Subsequent Events, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Subsequent Events</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Recently Adopted Accounting Pronouncements</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US">Schedule of anti-dilutive weighted average diluted common shares</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_lbl" xml:lang="en-US">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_lbl" xml:lang="en-US">Schedule of prepaid expenses and other current assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US">Schedule of property and equipment</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of accrued expenses and other current liabilities</label>
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_DisclosureOfAccruedCompensationTableTextBlock" xlink:label="eyen_DisclosureOfAccruedCompensationTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_DisclosureOfAccruedCompensationTableTextBlock" xlink:to="eyen_DisclosureOfAccruedCompensationTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_DisclosureOfAccruedCompensationTableTextBlock_lbl" xml:lang="en-US">Tabular disclosure of accrued compensation.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_DisclosureOfAccruedCompensationTableTextBlock_lbl" xml:lang="en-US">Disclosure of Accrued compensation [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="eyen_DisclosureOfAccruedCompensationTableTextBlock_lbl" xml:lang="en-US">Schedule of accrued compensation</label>
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_ScheduleOfNotesPayableTableTextBlock" xlink:label="eyen_ScheduleOfNotesPayableTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_ScheduleOfNotesPayableTableTextBlock" xlink:to="eyen_ScheduleOfNotesPayableTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_ScheduleOfNotesPayableTableTextBlock_lbl" xml:lang="en-US">Tabular disclosure of notes payable.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_ScheduleOfNotesPayableTableTextBlock_lbl" xml:lang="en-US">Schedule of Notes Payable [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="eyen_ScheduleOfNotesPayableTableTextBlock_lbl" xml:lang="en-US">Schedule of notes payable</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xml:lang="en-US">Schedule of provision for income taxes</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US">Schedule of effective income tax rate reconciliation</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of deferred tax assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:to="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl" xml:lang="en-US">Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl" xml:lang="en-US">Schedule of future minimum operating lease payments</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xml:lang="en-US">Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xml:lang="en-US">Summary of the Warrant activity and related information</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US">Schedule of Black-Scholes option pricing model to stock options granted</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">Share-based Compensation, Stock Options, Activity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of the stock option activity</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_lbl" xml:lang="en-US">Schedule Of Share Based Compensation Shares Outstanding Under Stock Option Plans By Exercise Price Range Table Text Block</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_lbl" xml:lang="en-US">Schedule of information related to stock options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationDateOfIncorporation" xlink:label="dei_EntityIncorporationDateOfIncorporation" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationDateOfIncorporation" xlink:to="dei_EntityIncorporationDateOfIncorporation_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationDateOfIncorporation_lbl" xml:lang="en-US">Entity Incorporation, Date of Incorporation</label>
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_PercentageOfSuccessRateOfOptejet" xlink:label="eyen_PercentageOfSuccessRateOfOptejet" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_PercentageOfSuccessRateOfOptejet" xlink:to="eyen_PercentageOfSuccessRateOfOptejet_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_PercentageOfSuccessRateOfOptejet_lbl" xml:lang="en-US">This refers percentage of success rate.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_PercentageOfSuccessRateOfOptejet_lbl" xml:lang="en-US">Percentage Of Success Rate Of Optejet</label>
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_PercentageOfSuccessfulRateOfTraditionalEyeDrops" xlink:label="eyen_PercentageOfSuccessfulRateOfTraditionalEyeDrops" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_PercentageOfSuccessfulRateOfTraditionalEyeDrops" xlink:to="eyen_PercentageOfSuccessfulRateOfTraditionalEyeDrops_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_PercentageOfSuccessfulRateOfTraditionalEyeDrops_lbl" xml:lang="en-US">This represents successful percentage rate.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_PercentageOfSuccessfulRateOfTraditionalEyeDrops_lbl" xml:lang="en-US">Percentage of Successful Rate of Traditional Eye Drops</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Total potentially dilutive shares</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashUninsuredAmount" xlink:label="us-gaap_CashUninsuredAmount" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashUninsuredAmount" xlink:to="us-gaap_CashUninsuredAmount_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashUninsuredAmount_lbl" xml:lang="en-US">Cash, Uninsured Amount</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US">Property, Plant and Equipment, Useful Life</label>
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_LicenseAgreementsTerminationWrittenNoticePeriod" xlink:label="eyen_LicenseAgreementsTerminationWrittenNoticePeriod" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_LicenseAgreementsTerminationWrittenNoticePeriod" xlink:to="eyen_LicenseAgreementsTerminationWrittenNoticePeriod_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_LicenseAgreementsTerminationWrittenNoticePeriod_lbl" xml:lang="en-US">Period for providing written notice for termination of license agreement by the counterparty, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_LicenseAgreementsTerminationWrittenNoticePeriod_lbl" xml:lang="en-US">License Agreements, Termination, Written Notice Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="eyen_LicenseAgreementsTerminationWrittenNoticePeriod_lbl" xml:lang="en-US">Written notice period for termination of agreement</label>
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_LicenseAgreementsTerminationPeriodUponUncuredMaterialBreach" xlink:label="eyen_LicenseAgreementsTerminationPeriodUponUncuredMaterialBreach" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_LicenseAgreementsTerminationPeriodUponUncuredMaterialBreach" xlink:to="eyen_LicenseAgreementsTerminationPeriodUponUncuredMaterialBreach_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_LicenseAgreementsTerminationPeriodUponUncuredMaterialBreach_lbl" xml:lang="en-US">Period after which the license agreement can be terminated by either of the party in the event of uncured material breach, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_LicenseAgreementsTerminationPeriodUponUncuredMaterialBreach_lbl" xml:lang="en-US">License Agreements, Termination Period Upon Uncured Material Breach</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="eyen_LicenseAgreementsTerminationPeriodUponUncuredMaterialBreach_lbl" xml:lang="en-US">Termination period upon uncured material breach</label>
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_LicenseAgreementsUpfrontPaymentsReceived" xlink:label="eyen_LicenseAgreementsUpfrontPaymentsReceived" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_LicenseAgreementsUpfrontPaymentsReceived" xlink:to="eyen_LicenseAgreementsUpfrontPaymentsReceived_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_LicenseAgreementsUpfrontPaymentsReceived_lbl" xml:lang="en-US">Amount of upfront payments received by the entity, pursuant to a license agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_LicenseAgreementsUpfrontPaymentsReceived_lbl" xml:lang="en-US">License Agreements, Upfront Payments Received</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="eyen_LicenseAgreementsUpfrontPaymentsReceived_lbl" xml:lang="en-US">Upfront payment received</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="eyen_LicenseAgreementsUpfrontPaymentsReceived_lbl" xml:lang="en-US">Upfront payment received</label>
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_LicenseAgreementsMaximumAdditionalPaymentsReceivable" xlink:label="eyen_LicenseAgreementsMaximumAdditionalPaymentsReceivable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_LicenseAgreementsMaximumAdditionalPaymentsReceivable" xlink:to="eyen_LicenseAgreementsMaximumAdditionalPaymentsReceivable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_LicenseAgreementsMaximumAdditionalPaymentsReceivable_lbl" xml:lang="en-US">Maximum amount of additional payments receivable by the company pursuant to a license agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_LicenseAgreementsMaximumAdditionalPaymentsReceivable_lbl" xml:lang="en-US">License Agreements, Maximum Additional Payments Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="eyen_LicenseAgreementsMaximumAdditionalPaymentsReceivable_lbl" xml:lang="en-US">Maximum additional payments receivable</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:label="us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:to="us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_lbl" xml:lang="en-US">Due to Related Parties</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_lbl" xml:lang="en-US">Due to related party</label>
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_PayrollTaxesReceivable" xlink:label="eyen_PayrollTaxesReceivable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_PayrollTaxesReceivable" xlink:to="eyen_PayrollTaxesReceivable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_PayrollTaxesReceivable_lbl" xml:lang="en-US">Amount of Payroll Taxes Receivable.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_PayrollTaxesReceivable_lbl" xml:lang="en-US">Payroll Taxes Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="eyen_PayrollTaxesReceivable_lbl" xml:lang="en-US">Payroll tax receivable</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidInsurance" xlink:label="us-gaap_PrepaidInsurance" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidInsurance" xlink:to="us-gaap_PrepaidInsurance_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidInsurance_lbl" xml:lang="en-US">Prepaid Insurance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PrepaidInsurance_lbl" xml:lang="en-US">Prepaid insurance expenses</label>
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_PrepaidResearchAndDevelopmentExpenses" xlink:label="eyen_PrepaidResearchAndDevelopmentExpenses" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_PrepaidResearchAndDevelopmentExpenses" xlink:to="eyen_PrepaidResearchAndDevelopmentExpenses_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_PrepaidResearchAndDevelopmentExpenses_lbl" xml:lang="en-US">Amount of asset related to consideration paid in advance for research and development expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_PrepaidResearchAndDevelopmentExpenses_lbl" xml:lang="en-US">Prepaid research and development expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="eyen_PrepaidResearchAndDevelopmentExpenses_lbl" xml:lang="en-US">Prepaid research and development expenses</label>
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_PrepaidLicensesAndSubscriptions" xlink:label="eyen_PrepaidLicensesAndSubscriptions" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_PrepaidLicensesAndSubscriptions" xlink:to="eyen_PrepaidLicensesAndSubscriptions_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_PrepaidLicensesAndSubscriptions_lbl" xml:lang="en-US">The amount of prepaid licenses and subscriptions, current.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_PrepaidLicensesAndSubscriptions_lbl" xml:lang="en-US">Prepaid Licenses and Subscriptions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="eyen_PrepaidLicensesAndSubscriptions_lbl" xml:lang="en-US">Prepaid licenses and subscriptions</label>
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_PrepaidPatentExpense" xlink:label="eyen_PrepaidPatentExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_PrepaidPatentExpense" xlink:to="eyen_PrepaidPatentExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_PrepaidPatentExpense_lbl" xml:lang="en-US">Amount of asset related to consideration paid in advance for patent expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_PrepaidPatentExpense_lbl" xml:lang="en-US">Prepaid Patent Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="eyen_PrepaidPatentExpense_lbl" xml:lang="en-US">Prepaid patent expenses</label>
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_PrepaidConferenceExpenses" xlink:label="eyen_PrepaidConferenceExpenses" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_PrepaidConferenceExpenses" xlink:to="eyen_PrepaidConferenceExpenses_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_PrepaidConferenceExpenses_lbl" xml:lang="en-US">Amount of assets related to prepaid conference expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_PrepaidConferenceExpenses_lbl" xml:lang="en-US">Prepaid conference Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="eyen_PrepaidConferenceExpenses_lbl" xml:lang="en-US">Prepaid conference expenses</label>
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_PrepaidDirectorFeesCurrent" xlink:label="eyen_PrepaidDirectorFeesCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_PrepaidDirectorFeesCurrent" xlink:to="eyen_PrepaidDirectorFeesCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_PrepaidDirectorFeesCurrent_lbl" xml:lang="en-US">Carrying value as of the balance sheet date of director fees prepaid, classified as current.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_PrepaidDirectorFeesCurrent_lbl" xml:lang="en-US">Prepaid Director Fees, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="eyen_PrepaidDirectorFeesCurrent_lbl" xml:lang="en-US">Prepaid board of director expenses</label>
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_PrepaidRentAndSecurityDeposit" xlink:label="eyen_PrepaidRentAndSecurityDeposit" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_PrepaidRentAndSecurityDeposit" xlink:to="eyen_PrepaidRentAndSecurityDeposit_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_PrepaidRentAndSecurityDeposit_lbl" xml:lang="en-US">Amount of asset related to consideration paid in advance for rent and security deposits that provides economic benefits within a future period of one year or the normal operating cycle.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_PrepaidRentAndSecurityDeposit_lbl" xml:lang="en-US">Prepaid Rent and Security Deposit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="eyen_PrepaidRentAndSecurityDeposit_lbl" xml:lang="en-US">Prepaid rent and security deposit</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssets" xlink:label="us-gaap_OtherAssets" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssets" xlink:to="us-gaap_OtherAssets_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssets_lbl" xml:lang="en-US">Other Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherAssets_lbl" xml:lang="en-US">Other</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xml:lang="en-US">Property Plant And Equipment Type [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquipmentMember" xlink:to="us-gaap_EquipmentMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquipmentMember_lbl" xml:lang="en-US">Equipment [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquipmentMember_lbl" xml:lang="en-US">Equipment [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xml:lang="en-US">Leasehold Improvements [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xml:lang="en-US">Leasehold Improvements [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US">Property, Plant and Equipment, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US">Property and equipment, gross</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US">Less: accumulated depreciation and amortization</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueByAssetClassAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByAssetClassAxis_lbl" xml:lang="en-US">Asset Class [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" xml:lang="en-US">Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation By Asset Class [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" xml:lang="en-US">Asset Class [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentMember" xlink:label="us-gaap_PropertyPlantAndEquipmentMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentMember" xlink:to="us-gaap_PropertyPlantAndEquipmentMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentMember_lbl" xml:lang="en-US">Property Plant And Equipment [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentMember_lbl" xml:lang="en-US">Property, Plant and Equipment [Member]</label>
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_AccruedResearchAndDevelopmentExpensesCurrent" xlink:label="eyen_AccruedResearchAndDevelopmentExpensesCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_AccruedResearchAndDevelopmentExpensesCurrent" xlink:to="eyen_AccruedResearchAndDevelopmentExpensesCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_AccruedResearchAndDevelopmentExpensesCurrent_lbl" xml:lang="en-US">Amount of accrued research and development expenses paid by the entity.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_AccruedResearchAndDevelopmentExpensesCurrent_lbl" xml:lang="en-US">Accrued research and development expenses, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="eyen_AccruedResearchAndDevelopmentExpensesCurrent_lbl" xml:lang="en-US">Accrued research and development expenses</label>
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_AccruedConsultingAndProfessionalServicesCurrent" xlink:label="eyen_AccruedConsultingAndProfessionalServicesCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_AccruedConsultingAndProfessionalServicesCurrent" xlink:to="eyen_AccruedConsultingAndProfessionalServicesCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_AccruedConsultingAndProfessionalServicesCurrent_lbl" xml:lang="en-US">Carrying value as of the balance sheet date of obligations incurred through that date and payable for consulting and professional service, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_AccruedConsultingAndProfessionalServicesCurrent_lbl" xml:lang="en-US">Accrued Consulting and Professional Services, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="eyen_AccruedConsultingAndProfessionalServicesCurrent_lbl" xml:lang="en-US">Accrued consulting and professional services</label>
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_CreditCardPayable" xlink:label="eyen_CreditCardPayable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_CreditCardPayable" xlink:to="eyen_CreditCardPayable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_CreditCardPayable_lbl" xml:lang="en-US">Amount of credit card expenses payable by the entity.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_CreditCardPayable_lbl" xml:lang="en-US">Credit Card payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="eyen_CreditCardPayable_lbl" xml:lang="en-US">Credit card payable</label>
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_LeaseholdImprovements" xlink:label="eyen_LeaseholdImprovements" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_LeaseholdImprovements" xlink:to="eyen_LeaseholdImprovements_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_LeaseholdImprovements_lbl" xml:lang="en-US">This represents accrued purchases balances of Leasehold improvements.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_LeaseholdImprovements_lbl" xml:lang="en-US">Leasehold Improvements</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="eyen_LeaseholdImprovements_lbl" xml:lang="en-US">Leasehold improvements</label>
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_AccruedFranchiseTax" xlink:label="eyen_AccruedFranchiseTax" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_AccruedFranchiseTax" xlink:to="eyen_AccruedFranchiseTax_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_AccruedFranchiseTax_lbl" xml:lang="en-US">Amount of accrued franchise tax expenses paid by the entity.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_AccruedFranchiseTax_lbl" xml:lang="en-US">Accrued Franchise Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="eyen_AccruedFranchiseTax_lbl" xml:lang="en-US">Accrued franchise tax</label>
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_AccruedTravelAndEntertainmentExpenses" xlink:label="eyen_AccruedTravelAndEntertainmentExpenses" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_AccruedTravelAndEntertainmentExpenses" xlink:to="eyen_AccruedTravelAndEntertainmentExpenses_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_AccruedTravelAndEntertainmentExpenses_lbl" xml:lang="en-US">Amount of accrued travel and entertainment expenses paid by the entity.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_AccruedTravelAndEntertainmentExpenses_lbl" xml:lang="en-US">Accrued Travel And Entertainment Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="eyen_AccruedTravelAndEntertainmentExpenses_lbl" xml:lang="en-US">Accrued travel and entertainment expenses</label>
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_AccruedLicensingFees" xlink:label="eyen_AccruedLicensingFees" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_AccruedLicensingFees" xlink:to="eyen_AccruedLicensingFees_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_AccruedLicensingFees_lbl" xml:lang="en-US">The amount of accrued licensing fees, current.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_AccruedLicensingFees_lbl" xml:lang="en-US">Accrued Licensing Fees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="eyen_AccruedLicensingFees_lbl" xml:lang="en-US">Accrued licensing fees</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:label="us-gaap_InterestPayableCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPayableCurrent" xlink:to="us-gaap_InterestPayableCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPayableCurrent_lbl" xml:lang="en-US">Interest Payable, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestPayableCurrent_lbl" xml:lang="en-US">Accrued interest</label>
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_AccruedExpenseReimbursements" xlink:label="eyen_AccruedExpenseReimbursements" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_AccruedExpenseReimbursements" xlink:to="eyen_AccruedExpenseReimbursements_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_AccruedExpenseReimbursements_lbl" xml:lang="en-US">Carrying value as of the balance sheet date of obligations incurred through that date and payable for expense reimbursements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_AccruedExpenseReimbursements_lbl" xml:lang="en-US">Accrued Expense Reimbursements</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="eyen_AccruedExpenseReimbursements_lbl" xml:lang="en-US">Accrued expense reimbursements</label>
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_AccruedShippingAndPackagingFees" xlink:label="eyen_AccruedShippingAndPackagingFees" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_AccruedShippingAndPackagingFees" xlink:to="eyen_AccruedShippingAndPackagingFees_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_AccruedShippingAndPackagingFees_lbl" xml:lang="en-US">Carrying value as of the balance sheet date of obligations incurred through that date and payable for shipping and packaging fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_AccruedShippingAndPackagingFees_lbl" xml:lang="en-US">Accrued Shipping and Packaging Fees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="eyen_AccruedShippingAndPackagingFees_lbl" xml:lang="en-US">Accrued shipping and packaging fees</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Other Accrued Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Other</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl" xml:lang="en-US">Accrued Liabilities and Other Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl" xml:lang="en-US">Total accrued expenses and other current liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedBonusesCurrent" xlink:label="us-gaap_AccruedBonusesCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedBonusesCurrent" xlink:to="us-gaap_AccruedBonusesCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedBonusesCurrent_lbl" xml:lang="en-US">Accrued Bonuses, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccruedBonusesCurrent_lbl" xml:lang="en-US">Accrued bonus expenses</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedSalariesCurrent" xlink:label="us-gaap_AccruedSalariesCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedSalariesCurrent" xlink:to="us-gaap_AccruedSalariesCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedSalariesCurrent_lbl" xml:lang="en-US">Accrued Salaries, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccruedSalariesCurrent_lbl" xml:lang="en-US">Accrued payroll expenses</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US">Employee-related Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US">Total accrued compensation</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="us-gaap_NotesPayableCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayableCurrent" xlink:to="us-gaap_NotesPayableCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesPayableCurrent_lbl" xml:lang="en-US">Notes Payable, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NotesPayableCurrent_lbl" xml:lang="en-US">Current Portion</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayable" xlink:label="us-gaap_NotesPayable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayable" xlink:to="us-gaap_NotesPayable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesPayable_lbl" xml:lang="en-US">Notes Payable.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NotesPayable_lbl" xml:lang="en-US">Total</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="us-gaap_ScheduleOfShortTermDebtTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShortTermDebtTable" xlink:to="us-gaap_ScheduleOfShortTermDebtTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShortTermDebtTable_lbl" xml:lang="en-US">Schedule of Short-term Debt [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="us-gaap_ShortTermDebtLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_ShortTermDebtLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermDebtLineItems_lbl" xml:lang="en-US">Short-term Debt [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShortTermDebtLineItems_lbl" xml:lang="en-US">Notes Payable</label>
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_NumberOfMonthlyPayments" xlink:label="eyen_NumberOfMonthlyPayments" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_NumberOfMonthlyPayments" xlink:to="eyen_NumberOfMonthlyPayments_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_NumberOfMonthlyPayments_lbl" xml:lang="en-US">Number of monthly payments.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_NumberOfMonthlyPayments_lbl" xml:lang="en-US">Number Of Monthly Payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="eyen_NumberOfMonthlyPayments_lbl" xml:lang="en-US">Number of monthly payments</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentPeriodicPayment" xlink:label="us-gaap_DebtInstrumentPeriodicPayment" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentPeriodicPayment" xlink:to="us-gaap_DebtInstrumentPeriodicPayment_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentPeriodicPayment_lbl" xml:lang="en-US">Debt Instrument, Periodic Payment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentPeriodicPayment_lbl" xml:lang="en-US">Debt Instrument, Periodic Payment</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAnnualPrincipalPayment" xlink:label="us-gaap_DebtInstrumentAnnualPrincipalPayment" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAnnualPrincipalPayment" xlink:to="us-gaap_DebtInstrumentAnnualPrincipalPayment_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentAnnualPrincipalPayment_lbl" xml:lang="en-US">Debt Instrument, Annual Principal Payment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentAnnualPrincipalPayment_lbl" xml:lang="en-US">Aggregate principal payments</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US">Interest rate (as a percent)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromLongTermLinesOfCredit" xlink:label="us-gaap_ProceedsFromLongTermLinesOfCredit" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromLongTermLinesOfCredit" xlink:to="us-gaap_ProceedsFromLongTermLinesOfCredit_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromLongTermLinesOfCredit_lbl" xml:lang="en-US">Proceeds from Long-term Lines of Credit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromLongTermLinesOfCredit_lbl" xml:lang="en-US">Cash proceeds from loan</label>
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_PeriodConsideredForUsageOfLoanProceedsFromFundingDate" xlink:label="eyen_PeriodConsideredForUsageOfLoanProceedsFromFundingDate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_PeriodConsideredForUsageOfLoanProceedsFromFundingDate" xlink:to="eyen_PeriodConsideredForUsageOfLoanProceedsFromFundingDate_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_PeriodConsideredForUsageOfLoanProceedsFromFundingDate_lbl" xml:lang="en-US">Period allowed to use loan proceeds for the requirements subsequent to the date of funding.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_PeriodConsideredForUsageOfLoanProceedsFromFundingDate_lbl" xml:lang="en-US">Period Considered for Usage of Loan Proceeds from Funding Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="eyen_PeriodConsideredForUsageOfLoanProceedsFromFundingDate_lbl" xml:lang="en-US">Period for usage of loan proceeds</label>
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_PercentageOfInterestOnAmountWhichIsNotForgiven" xlink:label="eyen_PercentageOfInterestOnAmountWhichIsNotForgiven" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_PercentageOfInterestOnAmountWhichIsNotForgiven" xlink:to="eyen_PercentageOfInterestOnAmountWhichIsNotForgiven_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_PercentageOfInterestOnAmountWhichIsNotForgiven_lbl" xml:lang="en-US">Percentage of interest on amount which is not forgiven.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_PercentageOfInterestOnAmountWhichIsNotForgiven_lbl" xml:lang="en-US">Percentage of Interest on Amount which is Not Forgiven</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="eyen_PercentageOfInterestOnAmountWhichIsNotForgiven_lbl" xml:lang="en-US">Interest rate on non forgiven amount</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="us-gaap_DebtInstrumentTerm" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTerm" xlink:to="us-gaap_DebtInstrumentTerm_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentTerm_lbl" xml:lang="en-US">Debt Instrument, Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentTerm_lbl" xml:lang="en-US">Maturity term</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseDebt" xlink:to="us-gaap_InterestExpenseDebt_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpenseDebt_lbl" xml:lang="en-US">Interest Expense, Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestExpenseDebt_lbl" xml:lang="en-US">Interest expense</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xml:lang="en-US">Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xml:lang="en-US">Deferred tax provision (benefit):</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Deferred Federal Income Tax Expense (Benefit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Federal</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Deferred State and Local Income Tax Expense (Benefit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">State and local</label>
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_DeferredIncomeTaxExpenseBenefitBeforeAdjustmentsForChangeInValuationAllowance" xlink:label="eyen_DeferredIncomeTaxExpenseBenefitBeforeAdjustmentsForChangeInValuationAllowance" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_DeferredIncomeTaxExpenseBenefitBeforeAdjustmentsForChangeInValuationAllowance" xlink:to="eyen_DeferredIncomeTaxExpenseBenefitBeforeAdjustmentsForChangeInValuationAllowance_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_DeferredIncomeTaxExpenseBenefitBeforeAdjustmentsForChangeInValuationAllowance_lbl" xml:lang="en-US">Amount of deferred income tax expense (benefit) before adjustments for change in valuation allowance.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_DeferredIncomeTaxExpenseBenefitBeforeAdjustmentsForChangeInValuationAllowance_lbl" xml:lang="en-US">Deferred Income Tax Expense (Benefit) Before Adjustments for Change in Valuation Allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="eyen_DeferredIncomeTaxExpenseBenefitBeforeAdjustmentsForChangeInValuationAllowance_lbl" xml:lang="en-US">Total</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xml:lang="en-US">Change in valuation allowance</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Income Tax Expense (Benefit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Provision for income taxes</label>
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_EffectiveIncomeTaxRateReconciliationNetAtFederalStatutoryIncomeTaxRate" xlink:label="eyen_EffectiveIncomeTaxRateReconciliationNetAtFederalStatutoryIncomeTaxRate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_EffectiveIncomeTaxRateReconciliationNetAtFederalStatutoryIncomeTaxRate" xlink:to="eyen_EffectiveIncomeTaxRateReconciliationNetAtFederalStatutoryIncomeTaxRate_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_EffectiveIncomeTaxRateReconciliationNetAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the federal statutory income tax rates to pretax income (loss) from continuing operations applicable to federal income tax expense (benefit), net of federal tax expense (benefit).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_EffectiveIncomeTaxRateReconciliationNetAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation net at Federal Statutory Income Tax Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="eyen_EffectiveIncomeTaxRateReconciliationNetAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">Federal statutory rate</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US">State tax rate, net of federal benefit</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xml:lang="en-US">Permanent differences</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl" xml:lang="en-US">Research &amp; development tax credits</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Prior Year Income Taxes, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes_lbl" xml:lang="en-US">Prior period adjustments and other</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Change in valuation allowance</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract_lbl" xml:lang="en-US">Deferred Tax Assets, Net [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract_lbl" xml:lang="en-US">Deferred Tax Assets:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US">Net operating loss carryforwards</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xml:lang="en-US">Stock-based compensation expense</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:to="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl" xml:lang="en-US">Deferred Tax Assets, Goodwill and Intangible Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl" xml:lang="en-US">Intangibles</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xml:lang="en-US">Deferred Tax Assets, in Process Research and Development</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xml:lang="en-US">Research and development tax credits</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US">Deferred Tax Assets, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US">Deferred tax assets</label>
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_DeferredTaxAssetsLiabilityPropertyAndEquipment" xlink:label="eyen_DeferredTaxAssetsLiabilityPropertyAndEquipment" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_DeferredTaxAssetsLiabilityPropertyAndEquipment" xlink:to="eyen_DeferredTaxAssetsLiabilityPropertyAndEquipment_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_DeferredTaxAssetsLiabilityPropertyAndEquipment_lbl" xml:lang="en-US">Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property and equipment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_DeferredTaxAssetsLiabilityPropertyAndEquipment_lbl" xml:lang="en-US">Deferred Tax Assets (liability), Property and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="eyen_DeferredTaxAssetsLiabilityPropertyAndEquipment_lbl" xml:lang="en-US">Property and equipment</label>
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_DeferredTaxAssetsNetBeforeValuationAllowance" xlink:label="eyen_DeferredTaxAssetsNetBeforeValuationAllowance" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_DeferredTaxAssetsNetBeforeValuationAllowance" xlink:to="eyen_DeferredTaxAssetsNetBeforeValuationAllowance_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_DeferredTaxAssetsNetBeforeValuationAllowance_lbl" xml:lang="en-US">Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_DeferredTaxAssetsNetBeforeValuationAllowance_lbl" xml:lang="en-US">Deferred Tax Assets, Net Before Valuation Allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="eyen_DeferredTaxAssetsNetBeforeValuationAllowance_lbl" xml:lang="en-US">Deferred tax assets, net before allowance</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Valuation allowance</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US">Deferred tax assets, net</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US">Operating Loss Carryforwards</label>
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_NetOperatingLossLimitForUtilizationAsPerInternalRevenueCode" xlink:label="eyen_NetOperatingLossLimitForUtilizationAsPerInternalRevenueCode" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_NetOperatingLossLimitForUtilizationAsPerInternalRevenueCode" xlink:to="eyen_NetOperatingLossLimitForUtilizationAsPerInternalRevenueCode_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_NetOperatingLossLimitForUtilizationAsPerInternalRevenueCode_lbl" xml:lang="en-US">This represents amount of net operating loss limit of usage determined by the Internal revenue code.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_NetOperatingLossLimitForUtilizationAsPerInternalRevenueCode_lbl" xml:lang="en-US">Net Operating Loss Limit for Utilization as per Internal Revenue Code</label>
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_NetOperatingLossAnnualUtilizationLimitAsPerInternalRevenueCode" xlink:label="eyen_NetOperatingLossAnnualUtilizationLimitAsPerInternalRevenueCode" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_NetOperatingLossAnnualUtilizationLimitAsPerInternalRevenueCode" xlink:to="eyen_NetOperatingLossAnnualUtilizationLimitAsPerInternalRevenueCode_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_NetOperatingLossAnnualUtilizationLimitAsPerInternalRevenueCode_lbl" xml:lang="en-US">This represents Annual utilization limit.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_NetOperatingLossAnnualUtilizationLimitAsPerInternalRevenueCode_lbl" xml:lang="en-US">Net Operating Loss Annual Utilization Limit as per Internal Revenue Code</label>
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_OperatingLossCarryForwardsExpirationTerm" xlink:label="eyen_OperatingLossCarryForwardsExpirationTerm" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_OperatingLossCarryForwardsExpirationTerm" xlink:to="eyen_OperatingLossCarryForwardsExpirationTerm_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_OperatingLossCarryForwardsExpirationTerm_lbl" xml:lang="en-US">The expiry term of carryforward operating losses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_OperatingLossCarryForwardsExpirationTerm_lbl" xml:lang="en-US">Operating Loss Carry forwards Expiration Term</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_lbl" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, Not Subject to Expiration</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_lbl" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl" xml:lang="en-US">Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl" xml:lang="en-US">Tax related interest or penalties were incurred</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_lbl" xml:lang="en-US">Operating Leases, Future Minimum Payments Due, Next Twelve Months</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_lbl" xml:lang="en-US">2021</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_lbl" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Two Years</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_lbl" xml:lang="en-US">2022</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_lbl" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Three Years</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_lbl" xml:lang="en-US">2023</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl" xml:lang="en-US">Operating Leases, Future Minimum Payments Due</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl" xml:lang="en-US">Minimum Lease Payments</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetRentableArea" xlink:label="us-gaap_NetRentableArea" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetRentableArea" xlink:to="us-gaap_NetRentableArea_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetRentableArea_lbl" xml:lang="en-US">Net Rentable Area</label>
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_LeaseMonthlyBaseRent" xlink:label="eyen_LeaseMonthlyBaseRent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_LeaseMonthlyBaseRent" xlink:to="eyen_LeaseMonthlyBaseRent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_LeaseMonthlyBaseRent_lbl" xml:lang="en-US">The base rent per month for lease.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_LeaseMonthlyBaseRent_lbl" xml:lang="en-US">Lease, Monthly Base Rent</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseExpirationDate1" xlink:label="us-gaap_LeaseExpirationDate1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseExpirationDate1" xlink:to="us-gaap_LeaseExpirationDate1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseExpirationDate1_lbl" xml:lang="en-US">Lease Expiration Date</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeveranceCosts1" xlink:label="us-gaap_SeveranceCosts1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeveranceCosts1" xlink:to="us-gaap_SeveranceCosts1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeveranceCosts1_lbl" xml:lang="en-US">Severance Costs</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalUnemploymentBenefitsSalaryContinuation" xlink:label="us-gaap_SupplementalUnemploymentBenefitsSalaryContinuation" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalUnemploymentBenefitsSalaryContinuation" xlink:to="us-gaap_SupplementalUnemploymentBenefitsSalaryContinuation_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalUnemploymentBenefitsSalaryContinuation_lbl" xml:lang="en-US">Supplemental Unemployment Benefits, Salary Continuation</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized" xlink:label="us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized" xlink:to="us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized_lbl" xml:lang="en-US">Contract with Customer, Liability, Change in Timeframe, Performance Obligation Satisfied, Revenue Recognized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized_lbl" xml:lang="en-US">Recognizing milestone revenues</label>
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_RoyaltyRevenuePayments" xlink:label="eyen_RoyaltyRevenuePayments" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_RoyaltyRevenuePayments" xlink:to="eyen_RoyaltyRevenuePayments_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_RoyaltyRevenuePayments_lbl" xml:lang="en-US">Amount of royalty revenue payment earned during period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_RoyaltyRevenuePayments_lbl" xml:lang="en-US">Royalty Revenue Payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="eyen_RoyaltyRevenuePayments_lbl" xml:lang="en-US">Royalty payments earned</label>
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_MilestoneRevenuePayments" xlink:label="eyen_MilestoneRevenuePayments" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_MilestoneRevenuePayments" xlink:to="eyen_MilestoneRevenuePayments_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_MilestoneRevenuePayments_lbl" xml:lang="en-US">Amount of milestone revenue payment earned during period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_MilestoneRevenuePayments_lbl" xml:lang="en-US">Milestone Revenue Payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="eyen_MilestoneRevenuePayments_lbl" xml:lang="en-US">Milestone payments earned</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:to="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_lbl" xml:lang="en-US">Related Party Transaction, Expenses from Transactions with Related Party</label>
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_ConsultingAgreementPaymentPermonth" xlink:label="eyen_ConsultingAgreementPaymentPermonth" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_ConsultingAgreementPaymentPermonth" xlink:to="eyen_ConsultingAgreementPaymentPermonth_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_ConsultingAgreementPaymentPermonth_lbl" xml:lang="en-US">It represents monthly consulting fee expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_ConsultingAgreementPaymentPermonth_lbl" xml:lang="en-US">Consulting agreement payment, Permonth</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="eyen_ConsultingAgreementPaymentPermonth_lbl" xml:lang="en-US">Consulting agreement payment, Per month</label>
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_ConsultingAgreementPaymentPerhour" xlink:label="eyen_ConsultingAgreementPaymentPerhour" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_ConsultingAgreementPaymentPerhour" xlink:to="eyen_ConsultingAgreementPaymentPerhour_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_ConsultingAgreementPaymentPerhour_lbl" xml:lang="en-US">It represents hourly consulting fee expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_ConsultingAgreementPaymentPerhour_lbl" xml:lang="en-US">Consulting agreement payment, Per hour</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="eyen_ConsultingAgreementPaymentPerhour_lbl" xml:lang="en-US">Consulting agreement payment, Per hour</label>
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_CostOfServicesEngineeringServices" xlink:label="eyen_CostOfServicesEngineeringServices" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_CostOfServicesEngineeringServices" xlink:to="eyen_CostOfServicesEngineeringServices_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_CostOfServicesEngineeringServices_lbl" xml:lang="en-US">Represent the cost of services engineering services.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_CostOfServicesEngineeringServices_lbl" xml:lang="en-US">Cost Of Services Engineering Services</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="us-gaap_LeaseAndRentalExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseAndRentalExpense" xlink:to="us-gaap_LeaseAndRentalExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseAndRentalExpense_lbl" xml:lang="en-US">Operating Leases, Rent Expense</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OfficersCompensation" xlink:label="us-gaap_OfficersCompensation" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OfficersCompensation" xlink:to="us-gaap_OfficersCompensation_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OfficersCompensation_lbl" xml:lang="en-US">Salary and Wage, Officer, Excluding Cost of Good and Service Sold</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OfficersCompensation_lbl" xml:lang="en-US">Officers' Compensation</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsGross" xlink:label="us-gaap_LeaseholdImprovementsGross" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsGross" xlink:to="us-gaap_LeaseholdImprovementsGross_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseholdImprovementsGross_lbl" xml:lang="en-US">Leasehold Improvements, Gross</label>
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_RoyaltyPercentage" xlink:label="eyen_RoyaltyPercentage" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_RoyaltyPercentage" xlink:to="eyen_RoyaltyPercentage_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_RoyaltyPercentage_lbl" xml:lang="en-US">It represents the percentage rate of royalty.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_RoyaltyPercentage_lbl" xml:lang="en-US">Royalty Percentage</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_lbl" xml:lang="en-US">Minority Interest Ownership Percentage In Company</label>
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_PaymentsForLicenseCosts" xlink:label="eyen_PaymentsForLicenseCosts" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_PaymentsForLicenseCosts" xlink:to="eyen_PaymentsForLicenseCosts_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_PaymentsForLicenseCosts_lbl" xml:lang="en-US">Amount of payments made for license costs.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_PaymentsForLicenseCosts_lbl" xml:lang="en-US">Payments For License Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="eyen_PaymentsForLicenseCosts_lbl" xml:lang="en-US">License costs paid</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US">Shares Issued, Price Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US">Shares Issued, Price Per Share</label>
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_GrossProceedsOfStockValueIssuedDuringPeriod" xlink:label="eyen_GrossProceedsOfStockValueIssuedDuringPeriod" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_GrossProceedsOfStockValueIssuedDuringPeriod" xlink:to="eyen_GrossProceedsOfStockValueIssuedDuringPeriod_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_GrossProceedsOfStockValueIssuedDuringPeriod_lbl" xml:lang="en-US">Equity impact of the value of new stock issued during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_GrossProceedsOfStockValueIssuedDuringPeriod_lbl" xml:lang="en-US">Gross Proceeds Of Stock Value Issued During Period</label>
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_NetProceedsFromIssuanceOfCommonStock" xlink:label="eyen_NetProceedsFromIssuanceOfCommonStock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_NetProceedsFromIssuanceOfCommonStock" xlink:to="eyen_NetProceedsFromIssuanceOfCommonStock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_NetProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">The cash inflow from issuance of common stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_NetProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Net Proceeds From Issuance Of Common Stock</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US">Exercise price of warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US">Exercise Price of Warrants Outstanding</label>
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_ClassOfWarrantsOrRightsOutstandingRollforward" xlink:label="eyen_ClassOfWarrantsOrRightsOutstandingRollforward" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_ClassOfWarrantsOrRightsOutstandingRollforward" xlink:to="eyen_ClassOfWarrantsOrRightsOutstandingRollforward_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_ClassOfWarrantsOrRightsOutstandingRollforward_lbl" xml:lang="en-US">A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_ClassOfWarrantsOrRightsOutstandingRollforward_lbl" xml:lang="en-US">Class Of Warrants Or Rights Outstanding [Rollforward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="eyen_ClassOfWarrantsOrRightsOutstandingRollforward_lbl" xml:lang="en-US">Number of Warrants</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US">Class of Warrant or Right, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US">Outstanding at ending balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US">Outstanding at beginning balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US">Outstanding Number of Warrants</label>
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_ClassOfWarrantOrRightGranted" xlink:label="eyen_ClassOfWarrantOrRightGranted" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_ClassOfWarrantOrRightGranted" xlink:to="eyen_ClassOfWarrantOrRightGranted_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_ClassOfWarrantOrRightGranted_lbl" xml:lang="en-US">Number of warrants or rights granted during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_ClassOfWarrantOrRightGranted_lbl" xml:lang="en-US">Class of Warrant or Right, Granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="eyen_ClassOfWarrantOrRightGranted_lbl" xml:lang="en-US">Granted</label>
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_ClassOfWarrantOrRightExercised" xlink:label="eyen_ClassOfWarrantOrRightExercised" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_ClassOfWarrantOrRightExercised" xlink:to="eyen_ClassOfWarrantOrRightExercised_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_ClassOfWarrantOrRightExercised_lbl" xml:lang="en-US">Number of warrants or rights exercised during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_ClassOfWarrantOrRightExercised_lbl" xml:lang="en-US">Class of Warrant or Right, Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="eyen_ClassOfWarrantOrRightExercised_lbl" xml:lang="en-US">Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="eyen_ClassOfWarrantOrRightExercised_lbl" xml:lang="en-US">Number of warrants exercised</label>
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_ClassOfWarrantOrRightExercisable" xlink:label="eyen_ClassOfWarrantOrRightExercisable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_ClassOfWarrantOrRightExercisable" xlink:to="eyen_ClassOfWarrantOrRightExercisable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_ClassOfWarrantOrRightExercisable_lbl" xml:lang="en-US">Number of warrants or rights exercisable.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_ClassOfWarrantOrRightExercisable_lbl" xml:lang="en-US">Class of Warrant or Right, Exercisable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="eyen_ClassOfWarrantOrRightExercisable_lbl" xml:lang="en-US">Exercisable Number of warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="eyen_ClassOfWarrantOrRightExercisable_lbl" xml:lang="en-US">Exercisable Number of Warrants</label>
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_ClassOfWarrantsOrRightsWeightedAverageExercisePriceRollforward" xlink:label="eyen_ClassOfWarrantsOrRightsWeightedAverageExercisePriceRollforward" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_ClassOfWarrantsOrRightsWeightedAverageExercisePriceRollforward" xlink:to="eyen_ClassOfWarrantsOrRightsWeightedAverageExercisePriceRollforward_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_ClassOfWarrantsOrRightsWeightedAverageExercisePriceRollforward_lbl" xml:lang="en-US">A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_ClassOfWarrantsOrRightsWeightedAverageExercisePriceRollforward_lbl" xml:lang="en-US">Class Of Warrants Or Rights, Weighted Average Exercise Price [Rollforward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="eyen_ClassOfWarrantsOrRightsWeightedAverageExercisePriceRollforward_lbl" xml:lang="en-US">Weighted Average Exercise Price</label>
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice" xlink:label="eyen_ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice" xlink:to="eyen_ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price of warrants or rights outstanding.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Class of Warrant or Right, Outstanding, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="eyen_ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Outstanding at ending balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="eyen_ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Outstanding at beginning balance</label>
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_ClassOfWarrantOrRightGrantedWeightedAverageExercisePrice" xlink:label="eyen_ClassOfWarrantOrRightGrantedWeightedAverageExercisePrice" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_ClassOfWarrantOrRightGrantedWeightedAverageExercisePrice" xlink:to="eyen_ClassOfWarrantOrRightGrantedWeightedAverageExercisePrice_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_ClassOfWarrantOrRightGrantedWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price of warrants or rights granted during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_ClassOfWarrantOrRightGrantedWeightedAverageExercisePrice_lbl" xml:lang="en-US">Class of Warrant or Right, Granted, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="eyen_ClassOfWarrantOrRightGrantedWeightedAverageExercisePrice_lbl" xml:lang="en-US">Granted</label>
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_ClassOfWarrantOrRightExercisedWeightedAverageExercisePrice" xlink:label="eyen_ClassOfWarrantOrRightExercisedWeightedAverageExercisePrice" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_ClassOfWarrantOrRightExercisedWeightedAverageExercisePrice" xlink:to="eyen_ClassOfWarrantOrRightExercisedWeightedAverageExercisePrice_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_ClassOfWarrantOrRightExercisedWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price of warrants or rights exercised during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_ClassOfWarrantOrRightExercisedWeightedAverageExercisePrice_lbl" xml:lang="en-US">Class of Warrant or Right, Exercised, , Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="eyen_ClassOfWarrantOrRightExercisedWeightedAverageExercisePrice_lbl" xml:lang="en-US">Exercised</label>
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice" xlink:label="eyen_ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice" xlink:to="eyen_ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price of warrants or rights exercisable.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Class of Warrant or Right, Exercisable, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="eyen_ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Exercisable</label>
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_ClassOfWarrantOrRightOutstandingWeightedAverageRemainingLife" xlink:label="eyen_ClassOfWarrantOrRightOutstandingWeightedAverageRemainingLife" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_ClassOfWarrantOrRightOutstandingWeightedAverageRemainingLife" xlink:to="eyen_ClassOfWarrantOrRightOutstandingWeightedAverageRemainingLife_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_ClassOfWarrantOrRightOutstandingWeightedAverageRemainingLife_lbl" xml:lang="en-US">Weighted average remaining life of warrants or rights outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_ClassOfWarrantOrRightOutstandingWeightedAverageRemainingLife_lbl" xml:lang="en-US">Class of Warrant or Right, Outstanding, Weighted Average Remaining Life</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="eyen_ClassOfWarrantOrRightOutstandingWeightedAverageRemainingLife_lbl" xml:lang="en-US">Weighted Average Remaining Life, Outstanding</label>
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_ClassOfWarrantOrRightExercisableWeightedAverageRemainingLife" xlink:label="eyen_ClassOfWarrantOrRightExercisableWeightedAverageRemainingLife" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_ClassOfWarrantOrRightExercisableWeightedAverageRemainingLife" xlink:to="eyen_ClassOfWarrantOrRightExercisableWeightedAverageRemainingLife_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_ClassOfWarrantOrRightExercisableWeightedAverageRemainingLife_lbl" xml:lang="en-US">Weighted average remaining life of warrants or rights exercisable, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_ClassOfWarrantOrRightExercisableWeightedAverageRemainingLife_lbl" xml:lang="en-US">Class of Warrant or Right, Exercisable, Weighted Average Remaining Life</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="eyen_ClassOfWarrantOrRightExercisableWeightedAverageRemainingLife_lbl" xml:lang="en-US">Weighted Average Remaining Life, Exercisable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="eyen_ClassOfWarrantOrRightExercisableWeightedAverageRemainingLife_lbl" xml:lang="en-US">Weighted Average Remaining Life, Exercisable</label>
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_ClassOfWarrantOrRightOutstandingAggregateIntrinsicValue" xlink:label="eyen_ClassOfWarrantOrRightOutstandingAggregateIntrinsicValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_ClassOfWarrantOrRightOutstandingAggregateIntrinsicValue" xlink:to="eyen_ClassOfWarrantOrRightOutstandingAggregateIntrinsicValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_ClassOfWarrantOrRightOutstandingAggregateIntrinsicValue_lbl" xml:lang="en-US">Aggregate intrinsic value of warrants or rights outstanding.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_ClassOfWarrantOrRightOutstandingAggregateIntrinsicValue_lbl" xml:lang="en-US">Class of Warrant or Right, Outstanding, Aggregate Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="eyen_ClassOfWarrantOrRightOutstandingAggregateIntrinsicValue_lbl" xml:lang="en-US">Aggregate Intrinsic Value, Outstanding</label>
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_ClassOfWarrantOrRightExercisableAggregateIntrinsicValue" xlink:label="eyen_ClassOfWarrantOrRightExercisableAggregateIntrinsicValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_ClassOfWarrantOrRightExercisableAggregateIntrinsicValue" xlink:to="eyen_ClassOfWarrantOrRightExercisableAggregateIntrinsicValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_ClassOfWarrantOrRightExercisableAggregateIntrinsicValue_lbl" xml:lang="en-US">Aggregate intrinsic value of warrants or rights exercisable.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_ClassOfWarrantOrRightExercisableAggregateIntrinsicValue_lbl" xml:lang="en-US">Class of Warrant or Right, Exercisable, Aggregate Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="eyen_ClassOfWarrantOrRightExercisableAggregateIntrinsicValue_lbl" xml:lang="en-US">Aggregate Intrinsic Value, Exercisable</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightTable_lbl" xml:lang="en-US">Class of Warrant or Right [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xml:lang="en-US">Class of Warrant or Right [Line Items]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Range [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeMember_lbl" xml:lang="en-US">Range [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_RangeMember_lbl" xml:lang="en-US">Range [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Expected term (years)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US">Risk free interest rate</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Expected volatility</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Expected dividends</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Number of Options Outstanding | Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Number of Options Outstanding | Shares</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Number of Options Granted</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US">Number of Options Forfeited | Shares</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US">Number of Options Exercisable | Shares</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Outstanding | $ / Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Outstanding | $ / Shares</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Granted | $ / Shares</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Exercise price per share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Exercised</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Forfeited | $ / Shares</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Exercisable | $ / Shares</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Term of the options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Weighted Average Remaining Life In Years, Outstanding</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Weighted Average Remaining Life In Years, Exercisable</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US">Aggregate Intrinsic Value, Outstanding | $</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US">Aggregate Intrinsic Value, Exercisable</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_lbl" xml:lang="en-US">Exercise Price Range [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_lbl" xml:lang="en-US">Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_lbl" xml:lang="en-US">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Domain]</label>
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_ExercisePriceOneMember" xlink:label="eyen_ExercisePriceOneMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_ExercisePriceOneMember" xlink:to="eyen_ExercisePriceOneMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_ExercisePriceOneMember_lbl" xml:lang="en-US">Exercise Price One</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_ExercisePriceOneMember_lbl" xml:lang="en-US">Exercise Price One [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="eyen_ExercisePriceOneMember_lbl" xml:lang="en-US">Exercise Price 1.24 [Member]</label>
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_ExercisePriceTwoMember" xlink:label="eyen_ExercisePriceTwoMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_ExercisePriceTwoMember" xlink:to="eyen_ExercisePriceTwoMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_ExercisePriceTwoMember_lbl" xml:lang="en-US">Exercise Price Two</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_ExercisePriceTwoMember_lbl" xml:lang="en-US">Exercise Price Two [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="eyen_ExercisePriceTwoMember_lbl" xml:lang="en-US">Exercise Price 1.95 [Member]</label>
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_ExercisePrice2.72Member" xlink:label="eyen_ExercisePrice2.72Member" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_ExercisePrice2.72Member" xlink:to="eyen_ExercisePrice2.72Member_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_ExercisePrice2.72Member_lbl" xml:lang="en-US">representing information pertaining to</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_ExercisePrice2.72Member_lbl" xml:lang="en-US">Exercise Price2.72 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="eyen_ExercisePrice2.72Member_lbl" xml:lang="en-US">Exercise Price 2.72 [Member]</label>
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_ExercisePriceThreeMember" xlink:label="eyen_ExercisePriceThreeMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_ExercisePriceThreeMember" xlink:to="eyen_ExercisePriceThreeMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_ExercisePriceThreeMember_lbl" xml:lang="en-US">Exercise Price Three</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_ExercisePriceThreeMember_lbl" xml:lang="en-US">Exercise Price Three [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="eyen_ExercisePriceThreeMember_lbl" xml:lang="en-US">Exercise Price 2.74 [Member]</label>
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_ExercisePrice2.89Member" xlink:label="eyen_ExercisePrice2.89Member" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_ExercisePrice2.89Member" xlink:to="eyen_ExercisePrice2.89Member_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_ExercisePrice2.89Member_lbl" xml:lang="en-US">representing information pertaining to</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_ExercisePrice2.89Member_lbl" xml:lang="en-US">Exercise Price2.89 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="eyen_ExercisePrice2.89Member_lbl" xml:lang="en-US">Exercise Price 2.89 [Member]</label>
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_ExercisePriceFourMember" xlink:label="eyen_ExercisePriceFourMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_ExercisePriceFourMember" xlink:to="eyen_ExercisePriceFourMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_ExercisePriceFourMember_lbl" xml:lang="en-US">Exercise Price Four</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_ExercisePriceFourMember_lbl" xml:lang="en-US">Exercise Price Four [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="eyen_ExercisePriceFourMember_lbl" xml:lang="en-US">Exercise Price 3.11 [Member]</label>
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_ExercisePrice3.43Member" xlink:label="eyen_ExercisePrice3.43Member" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_ExercisePrice3.43Member" xlink:to="eyen_ExercisePrice3.43Member_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_ExercisePrice3.43Member_lbl" xml:lang="en-US">Represents the information pertaining to Exercise price 3.43 Member.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_ExercisePrice3.43Member_lbl" xml:lang="en-US">Exercise Price3.43 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="eyen_ExercisePrice3.43Member_lbl" xml:lang="en-US">Exercise price 3.43 [Member]</label>
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_ExercisePrice3.48Member" xlink:label="eyen_ExercisePrice3.48Member" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_ExercisePrice3.48Member" xlink:to="eyen_ExercisePrice3.48Member_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_ExercisePrice3.48Member_lbl" xml:lang="en-US">Represents the information pertaining to Exercise price 3.48 Member.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_ExercisePrice3.48Member_lbl" xml:lang="en-US">Exercise Price3.48 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="eyen_ExercisePrice3.48Member_lbl" xml:lang="en-US">Exercise price 3.48 [Member]</label>
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_ExercisePrice3.71Member" xlink:label="eyen_ExercisePrice3.71Member" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_ExercisePrice3.71Member" xlink:to="eyen_ExercisePrice3.71Member_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_ExercisePrice3.71Member_lbl" xml:lang="en-US">Represents the information pertaining to Exercise Price 3.71 Member.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_ExercisePrice3.71Member_lbl" xml:lang="en-US">Exercise Price3.71 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="eyen_ExercisePrice3.71Member_lbl" xml:lang="en-US">Exercise price 3.71 [Member]</label>
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_ExercisePriceFiveMember" xlink:label="eyen_ExercisePriceFiveMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_ExercisePriceFiveMember" xlink:to="eyen_ExercisePriceFiveMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_ExercisePriceFiveMember_lbl" xml:lang="en-US">Exercise Price Five</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_ExercisePriceFiveMember_lbl" xml:lang="en-US">Exercise Price Five [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="eyen_ExercisePriceFiveMember_lbl" xml:lang="en-US">Exercise Price 4.00 [Member]</label>
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_ExercisePrice4.68Member" xlink:label="eyen_ExercisePrice4.68Member" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_ExercisePrice4.68Member" xlink:to="eyen_ExercisePrice4.68Member_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_ExercisePrice4.68Member_lbl" xml:lang="en-US">Exercise price 4.68 [ Member ]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_ExercisePrice4.68Member_lbl" xml:lang="en-US">Exercise Price4.68 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="eyen_ExercisePrice4.68Member_lbl" xml:lang="en-US">Exercise price 4.68 [Member]</label>
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_ExercisePriceSixMember" xlink:label="eyen_ExercisePriceSixMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_ExercisePriceSixMember" xlink:to="eyen_ExercisePriceSixMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_ExercisePriceSixMember_lbl" xml:lang="en-US">Exercise Price Six</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_ExercisePriceSixMember_lbl" xml:lang="en-US">Exercise Price Six [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="eyen_ExercisePriceSixMember_lbl" xml:lang="en-US">Exercise Price 5.10 [Member]</label>
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_ExercisePriceSevenMember" xlink:label="eyen_ExercisePriceSevenMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_ExercisePriceSevenMember" xlink:to="eyen_ExercisePriceSevenMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_ExercisePriceSevenMember_lbl" xml:lang="en-US">Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_ExercisePriceSevenMember_lbl" xml:lang="en-US">Exercise Price Seven [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="eyen_ExercisePriceSevenMember_lbl" xml:lang="en-US">Exercise Price 5.19 [Member]</label>
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_ExercisePriceEightMember" xlink:label="eyen_ExercisePriceEightMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_ExercisePriceEightMember" xlink:to="eyen_ExercisePriceEightMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_ExercisePriceEightMember_lbl" xml:lang="en-US">Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_ExercisePriceEightMember_lbl" xml:lang="en-US">Exercise Price Eight [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="eyen_ExercisePriceEightMember_lbl" xml:lang="en-US">Exercise Price 5.25 [Member]</label>
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_ExercisePrice5.77Member" xlink:label="eyen_ExercisePrice5.77Member" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_ExercisePrice5.77Member" xlink:to="eyen_ExercisePrice5.77Member_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_ExercisePrice5.77Member_lbl" xml:lang="en-US">Represents the information pertaining to its exercise price 5.77 member.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_ExercisePrice5.77Member_lbl" xml:lang="en-US">Exercise Price5.77 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="eyen_ExercisePrice5.77Member_lbl" xml:lang="en-US">Exercise Price 5.77 [Member]</label>
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_ExercisePriceNineMemberMember" xlink:label="eyen_ExercisePriceNineMemberMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_ExercisePriceNineMemberMember" xlink:to="eyen_ExercisePriceNineMemberMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_ExercisePriceNineMemberMember_lbl" xml:lang="en-US">Exercise Price Nine Member [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="eyen_ExercisePriceNineMemberMember_lbl" xml:lang="en-US">Exercise Price 6.20 [Member]</label>
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_ExercisePriceTenMember" xlink:label="eyen_ExercisePriceTenMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_ExercisePriceTenMember" xlink:to="eyen_ExercisePriceTenMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_ExercisePriceTenMember_lbl" xml:lang="en-US">Exercise Price Ten</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_ExercisePriceTenMember_lbl" xml:lang="en-US">Exercise Price Ten [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="eyen_ExercisePriceTenMember_lbl" xml:lang="en-US">Exercise Price 6.30 [Member]</label>
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_ExercisePriceElevenMember" xlink:label="eyen_ExercisePriceElevenMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_ExercisePriceElevenMember" xlink:to="eyen_ExercisePriceElevenMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_ExercisePriceElevenMember_lbl" xml:lang="en-US">Exercise Price Eleven.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_ExercisePriceElevenMember_lbl" xml:lang="en-US">Exercise Price Eleven [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="eyen_ExercisePriceElevenMember_lbl" xml:lang="en-US">Exercise Price 8.72 [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_lbl" xml:lang="en-US">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Exercisable Options, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_lbl" xml:lang="en-US">Options Outstanding, Outstanding Exercise Price</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_lbl" xml:lang="en-US">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Number of Outstanding Options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_lbl" xml:lang="en-US">Options Outstanding, Outstanding Number of Options</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Options Exercisable, Weighted Average Remaining Life In Years</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_lbl" xml:lang="en-US">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Number of Exercisable Options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_lbl" xml:lang="en-US">Options Exercisable, Exercisable Number of Options</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US">Common stock reserved for issuance</label>
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_ShareBasedCompensationArrangementByShareBasedPaymentAwardCashFeePaid" xlink:label="eyen_ShareBasedCompensationArrangementByShareBasedPaymentAwardCashFeePaid" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_ShareBasedCompensationArrangementByShareBasedPaymentAwardCashFeePaid" xlink:to="eyen_ShareBasedCompensationArrangementByShareBasedPaymentAwardCashFeePaid_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_ShareBasedCompensationArrangementByShareBasedPaymentAwardCashFeePaid_lbl" xml:lang="en-US">Amount of cash fees paid subject to certain exceptions for a non-executive chair of the Board.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_ShareBasedCompensationArrangementByShareBasedPaymentAwardCashFeePaid_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Cash Fee Paid</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="eyen_ShareBasedCompensationArrangementByShareBasedPaymentAwardCashFeePaid_lbl" xml:lang="en-US">Cash fee paid</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</label>
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_NumberOfCommonShares" xlink:label="eyen_NumberOfCommonShares" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_NumberOfCommonShares" xlink:to="eyen_NumberOfCommonShares_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_NumberOfCommonShares_lbl" xml:lang="en-US">Information about number of share of common stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_NumberOfCommonShares_lbl" xml:lang="en-US">Number of Common Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="eyen_NumberOfCommonShares_lbl" xml:lang="en-US">Number of common shares</label>
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_ClassOfWarrantOrRightNumberOfYearsSecuritiesCalledByWarrantsToPurchaseCommonStock" xlink:label="eyen_ClassOfWarrantOrRightNumberOfYearsSecuritiesCalledByWarrantsToPurchaseCommonStock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_ClassOfWarrantOrRightNumberOfYearsSecuritiesCalledByWarrantsToPurchaseCommonStock" xlink:to="eyen_ClassOfWarrantOrRightNumberOfYearsSecuritiesCalledByWarrantsToPurchaseCommonStock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_ClassOfWarrantOrRightNumberOfYearsSecuritiesCalledByWarrantsToPurchaseCommonStock_lbl" xml:lang="en-US">Information about number of years warrant to purchase share of common stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_ClassOfWarrantOrRightNumberOfYearsSecuritiesCalledByWarrantsToPurchaseCommonStock_lbl" xml:lang="en-US">Class Of Warrant Or Right Number Of Years Securities Called By Warrants to Purchase Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="eyen_ClassOfWarrantOrRightNumberOfYearsSecuritiesCalledByWarrantsToPurchaseCommonStock_lbl" xml:lang="en-US">Warrant to purchase common stock in period</label>
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_NumberOfSharesAgreedToBeIssued" xlink:label="eyen_NumberOfSharesAgreedToBeIssued" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_NumberOfSharesAgreedToBeIssued" xlink:to="eyen_NumberOfSharesAgreedToBeIssued_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_NumberOfSharesAgreedToBeIssued_lbl" xml:lang="en-US">Number of shares agreed to be issued by the company.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_NumberOfSharesAgreedToBeIssued_lbl" xml:lang="en-US">Number Of Shares Agreed To Be Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="eyen_NumberOfSharesAgreedToBeIssued_lbl" xml:lang="en-US">Number of shares agreed to be issued (in shares)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US">Share Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US">Price per share (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_OverAllotmentOptionPeriod" xlink:label="eyen_OverAllotmentOptionPeriod" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_OverAllotmentOptionPeriod" xlink:to="eyen_OverAllotmentOptionPeriod_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_OverAllotmentOptionPeriod_lbl" xml:lang="en-US">Period during which the underwriters can exercise their overallotment option, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_OverAllotmentOptionPeriod_lbl" xml:lang="en-US">Over-Allotment Option Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="eyen_OverAllotmentOptionPeriod_lbl" xml:lang="en-US">Over-allotment option period</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xml:lang="en-US">Unrecognized stock - based compensation expense</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US">Weighted average period of recognition</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US">Number of awards granted</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" xml:lang="en-US">Share based Compensation Arrangement by Share based Payment Award Options Grants in Period Grant Date Fair Value</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award Accelerated Compensation Cost</label>
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_RemittanceOfEmployeeSPayrollTaxes" xlink:label="eyen_RemittanceOfEmployeeSPayrollTaxes" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_RemittanceOfEmployeeSPayrollTaxes" xlink:to="eyen_RemittanceOfEmployeeSPayrollTaxes_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_RemittanceOfEmployeeSPayrollTaxes_lbl" xml:lang="en-US">This represents company remitted portion of employee's payroll taxes to internal revenue service.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_RemittanceOfEmployeeSPayrollTaxes_lbl" xml:lang="en-US">Remittance of employee's Payroll Taxes</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US">Warrants for purchase of common stock</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Accelerated Vesting, Number</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanTable" xlink:label="us-gaap_DefinedContributionPlanTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanTable" xlink:to="us-gaap_DefinedContributionPlanTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanTable_lbl" xml:lang="en-US">Defined Contribution Plan [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:label="us-gaap_DefinedContributionPlanDisclosureLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanDisclosureLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanDisclosureLineItems_lbl" xml:lang="en-US">Defined Contribution Plan Disclosure [Line Items]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_lbl" xml:lang="en-US">Defined Contribution Plan, Employer Matching Contribution, Percent of Match</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage" xlink:label="us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage" xlink:to="us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage_lbl" xml:lang="en-US">Defined Contribution Plan, Employers Matching Contribution, Annual Vesting Percentage</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount" xlink:to="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount_lbl" xml:lang="en-US">Defined Contribution Plan, Maximum Annual Contributions Per Employee, Amount</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US">Subsequent Event Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xml:lang="en-US">Subsequent Event Type [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xml:lang="en-US">Subsequent Event Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US">Subsequent Event [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US">Subsequent Event [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xml:lang="en-US">Total exercise price</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid In Capital [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-in Capital [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Retained Earnings [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Accumulated Deficit [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US">Warrant [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US">Warrants</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:to="us-gaap_OptionIndexedToIssuersEquityTypeAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeAxis_lbl" xml:lang="en-US">Option Indexed to Issuer's Equity, Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:to="us-gaap_OptionIndexedToIssuersEquityTypeDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeDomain_lbl" xml:lang="en-US">Option Indexed To Issuers Equity Type [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeDomain_lbl" xml:lang="en-US">Option Indexed to Issuer's Equity, Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US">Employee Stock Option [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US">Options</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US">Award Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xml:lang="en-US">Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xml:lang="en-US">Equity Award [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xml:lang="en-US">Restricted Stock Units R S U [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xml:lang="en-US">Restricted stock units</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xml:lang="en-US">Arrangements And Nonarrangement Transactions [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</label>
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_BauschLicenseAgreementMember" xlink:label="eyen_BauschLicenseAgreementMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_BauschLicenseAgreementMember" xlink:to="eyen_BauschLicenseAgreementMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_BauschLicenseAgreementMember_lbl" xml:lang="en-US">This member stands for Bausch License Agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_BauschLicenseAgreementMember_lbl" xml:lang="en-US">Bausch License Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="eyen_BauschLicenseAgreementMember_lbl" xml:lang="en-US">Bausch License Agreement</label>
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_ArcticVisionLicenseAgreementMember" xlink:label="eyen_ArcticVisionLicenseAgreementMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_ArcticVisionLicenseAgreementMember" xlink:to="eyen_ArcticVisionLicenseAgreementMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_ArcticVisionLicenseAgreementMember_lbl" xml:lang="en-US">This member stands for Arctic Vision License Agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_ArcticVisionLicenseAgreementMember_lbl" xml:lang="en-US">Arctic Vision License Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="eyen_ArcticVisionLicenseAgreementMember_lbl" xml:lang="en-US">Arctic Vision License Agreement</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xml:lang="en-US">Debt Instrument [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_DebtInstrumentNameDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xml:lang="en-US">Debt Instrument Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xml:lang="en-US">Debt Instrument, Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_PaycheckProtectionProgramLoanMember" xlink:label="eyen_PaycheckProtectionProgramLoanMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_PaycheckProtectionProgramLoanMember" xlink:to="eyen_PaycheckProtectionProgramLoanMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_PaycheckProtectionProgramLoanMember_lbl" xml:lang="en-US">Represents the information pertaining to Paycheck Protection Program Loan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_PaycheckProtectionProgramLoanMember_lbl" xml:lang="en-US">Paycheck Protection Program Loan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="eyen_PaycheckProtectionProgramLoanMember_lbl" xml:lang="en-US">Paycheck Protection Program loan</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="us-gaap_ShortTermDebtTypeAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermDebtTypeAxis_lbl" xml:lang="en-US">Short-term Debt, Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="us-gaap_ShortTermDebtTypeDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="us-gaap_ShortTermDebtTypeDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermDebtTypeDomain_lbl" xml:lang="en-US">Short Term Debt Type [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShortTermDebtTypeDomain_lbl" xml:lang="en-US">Short-term Debt, Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayableOtherPayablesMember" xlink:label="us-gaap_NotesPayableOtherPayablesMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayableOtherPayablesMember" xlink:to="us-gaap_NotesPayableOtherPayablesMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesPayableOtherPayablesMember_lbl" xml:lang="en-US">Notes Payable Other Payables [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NotesPayableOtherPayablesMember_lbl" xml:lang="en-US">Notes payable</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementGeographicalAxis_lbl" xml:lang="en-US">Geographical [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_SegmentGeographicalDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_SegmentGeographicalDomain_lbl" xml:lang="en-US">Segment Geographical [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_SegmentGeographicalDomain_lbl" xml:lang="en-US">Geographical [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_NY" xlink:label="stpr_NY" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="stpr_NY" xlink:to="stpr_NY_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="stpr_NY_lbl" xml:lang="en-US">N [Y]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="stpr_NY_lbl" xml:lang="en-US">New York City</label>
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_AdditionalOfficeSpaceMember" xlink:label="eyen_AdditionalOfficeSpaceMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_AdditionalOfficeSpaceMember" xlink:to="eyen_AdditionalOfficeSpaceMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_AdditionalOfficeSpaceMember_lbl" xml:lang="en-US">Represents the information pertaining to Additional office Space.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_AdditionalOfficeSpaceMember_lbl" xml:lang="en-US">Additional Office Space [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="eyen_AdditionalOfficeSpaceMember_lbl" xml:lang="en-US">Additional Office Space</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US">Related Party [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyDomain_lbl" xml:lang="en-US">Related Party [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyDomain_lbl" xml:lang="en-US">Related Party [Domain]</label>
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_CuraPartnersMember" xlink:label="eyen_CuraPartnersMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_CuraPartnersMember" xlink:to="eyen_CuraPartnersMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_CuraPartnersMember_lbl" xml:lang="en-US">Cura Partners [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="eyen_CuraPartnersMember_lbl" xml:lang="en-US">Cura Partners [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US">Income Statement Location [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US">Income Statement Location [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US">Income Statement Location [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US">Research And Development Expense [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US">Research and Development Expense [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US">General And Administrative Expense [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US">General and Administrative Expense [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionAxis_lbl" xml:lang="en-US">Related Party Transaction [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="us-gaap_RelatedPartyTransactionDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionDomain_lbl" xml:lang="en-US">Related Party Transaction [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionDomain_lbl" xml:lang="en-US">Related Party Transaction [Domain]</label>
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_ConsultingAgreementMember" xlink:label="eyen_ConsultingAgreementMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_ConsultingAgreementMember" xlink:to="eyen_ConsultingAgreementMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_ConsultingAgreementMember_lbl" xml:lang="en-US">Consulting Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="eyen_ConsultingAgreementMember_lbl" xml:lang="en-US">Consulting Agreement [Member]</label>
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_VicePresidentOfResearchAndDevelopmentMember" xlink:label="eyen_VicePresidentOfResearchAndDevelopmentMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_VicePresidentOfResearchAndDevelopmentMember" xlink:to="eyen_VicePresidentOfResearchAndDevelopmentMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_VicePresidentOfResearchAndDevelopmentMember_lbl" xml:lang="en-US">Vice President Of Research And Development [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="eyen_VicePresidentOfResearchAndDevelopmentMember_lbl" xml:lang="en-US">Vice President of Research and Development [Member]</label>
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_SenjuPharmaceuticalCoMember" xlink:label="eyen_SenjuPharmaceuticalCoMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_SenjuPharmaceuticalCoMember" xlink:to="eyen_SenjuPharmaceuticalCoMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_SenjuPharmaceuticalCoMember_lbl" xml:lang="en-US">Senju Pharmaceutical Co [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="eyen_SenjuPharmaceuticalCoMember_lbl" xml:lang="en-US">Senju Pharmaceutical Co [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipAxis" xlink:label="srt_OwnershipAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_OwnershipAxis_lbl" xml:lang="en-US">Ownership [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipDomain" xlink:label="srt_OwnershipDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_OwnershipDomain" xlink:to="srt_OwnershipDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_OwnershipDomain_lbl" xml:lang="en-US">Ownership [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_OwnershipDomain_lbl" xml:lang="en-US">Ownership [Domain]</label>
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_LicenseAgreementMember" xlink:label="eyen_LicenseAgreementMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_LicenseAgreementMember" xlink:to="eyen_LicenseAgreementMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_LicenseAgreementMember_lbl" xml:lang="en-US">This member stands for license agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_LicenseAgreementMember_lbl" xml:lang="en-US">License Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="eyen_LicenseAgreementMember_lbl" xml:lang="en-US">License Agreement</label>
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_ClassWarrantsMember" xlink:label="eyen_ClassWarrantsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_ClassWarrantsMember" xlink:to="eyen_ClassWarrantsMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_ClassWarrantsMember_lbl" xml:lang="en-US">Class A Warrants Member</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_ClassWarrantsMember_lbl" xml:lang="en-US">Class Warrants [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="eyen_ClassWarrantsMember_lbl" xml:lang="en-US">Class A Warrants [Member]</label>
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_ClassBWarrantsMember" xlink:label="eyen_ClassBWarrantsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_ClassBWarrantsMember" xlink:to="eyen_ClassBWarrantsMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_ClassBWarrantsMember_lbl" xml:lang="en-US">Class B Warrants [Member ]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_ClassBWarrantsMember_lbl" xml:lang="en-US">Class B Warrants [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="eyen_ClassBWarrantsMember_lbl" xml:lang="en-US">Class B Warrants [Member ]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US">Sale of Stock [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xml:lang="en-US">Sale Of Stock Name Of Transaction [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xml:lang="en-US">Sale of Stock [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IPOMember_lbl" xml:lang="en-US">I P O [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IPOMember_lbl" xml:lang="en-US">IPO [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xml:lang="en-US">Class of Warrant or Right [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_lbl" xml:lang="en-US">Class Of Warrant Or Right [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_lbl" xml:lang="en-US">Class of Warrant or Right [Domain]</label>
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_WarrantsAtExercisePriceOneMember" xlink:label="eyen_WarrantsAtExercisePriceOneMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_WarrantsAtExercisePriceOneMember" xlink:to="eyen_WarrantsAtExercisePriceOneMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_WarrantsAtExercisePriceOneMember_lbl" xml:lang="en-US">This member stands for warrants with the first exercise price.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_WarrantsAtExercisePriceOneMember_lbl" xml:lang="en-US">Warrants At Exercise Price One [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="eyen_WarrantsAtExercisePriceOneMember_lbl" xml:lang="en-US">Warrants at exercise price of $2.0580</label>
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_WarrantsAtExercisePriceTwoMember" xlink:label="eyen_WarrantsAtExercisePriceTwoMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_WarrantsAtExercisePriceTwoMember" xlink:to="eyen_WarrantsAtExercisePriceTwoMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_WarrantsAtExercisePriceTwoMember_lbl" xml:lang="en-US">This member stands for warrants with the second exercise price.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_WarrantsAtExercisePriceTwoMember_lbl" xml:lang="en-US">Warrants At Exercise Price Two [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="eyen_WarrantsAtExercisePriceTwoMember_lbl" xml:lang="en-US">Warrants at exercise price of $2.2700</label>
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_WarrantsAtExercisePriceThreeMember" xlink:label="eyen_WarrantsAtExercisePriceThreeMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_WarrantsAtExercisePriceThreeMember" xlink:to="eyen_WarrantsAtExercisePriceThreeMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_WarrantsAtExercisePriceThreeMember_lbl" xml:lang="en-US">This member stands for warrants with the third exercise price.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_WarrantsAtExercisePriceThreeMember_lbl" xml:lang="en-US">Warrants At Exercise Price Three [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="eyen_WarrantsAtExercisePriceThreeMember_lbl" xml:lang="en-US">Warrants at exercise price of $2.4696</label>
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_WarrantsAtExercisePriceFourMember" xlink:label="eyen_WarrantsAtExercisePriceFourMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_WarrantsAtExercisePriceFourMember" xlink:to="eyen_WarrantsAtExercisePriceFourMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_WarrantsAtExercisePriceFourMember_lbl" xml:lang="en-US">This member stands for warrants with the fourth exercise price.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_WarrantsAtExercisePriceFourMember_lbl" xml:lang="en-US">Warrants At Exercise Price Four [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="eyen_WarrantsAtExercisePriceFourMember_lbl" xml:lang="en-US">Warrants at exercise price of $2.7240</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeInstrumentRiskAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeInstrumentRiskAxis_lbl" xml:lang="en-US">Derivative Instrument [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="us-gaap_DerivativeContractTypeDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="us-gaap_DerivativeContractTypeDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeContractTypeDomain_lbl" xml:lang="en-US">Derivative Contract Type [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DerivativeContractTypeDomain_lbl" xml:lang="en-US">Derivative Contract [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockOptionMember" xlink:label="us-gaap_StockOptionMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionMember" xlink:to="us-gaap_StockOptionMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockOptionMember_lbl" xml:lang="en-US">Stock Option [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockOptionMember_lbl" xml:lang="en-US">Stock Options [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US">Plan Name [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameDomain_lbl" xml:lang="en-US">Plan Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PlanNameDomain_lbl" xml:lang="en-US">Plan Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_EmployeesConsultantsAndDirectorsUnder2018PlanMember" xlink:label="eyen_EmployeesConsultantsAndDirectorsUnder2018PlanMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_EmployeesConsultantsAndDirectorsUnder2018PlanMember" xlink:to="eyen_EmployeesConsultantsAndDirectorsUnder2018PlanMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_EmployeesConsultantsAndDirectorsUnder2018PlanMember_lbl" xml:lang="en-US">This member stands for employees consultants and directors under the 2018 plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_EmployeesConsultantsAndDirectorsUnder2018PlanMember_lbl" xml:lang="en-US">Employees Consultants And Directors Under2018 Plan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="eyen_EmployeesConsultantsAndDirectorsUnder2018PlanMember_lbl" xml:lang="en-US">Employees Consultants and Directors Under the 2018 Plan [Member]</label>
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_OmnibusStockIncentivePlan2018Member" xlink:label="eyen_OmnibusStockIncentivePlan2018Member" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_OmnibusStockIncentivePlan2018Member" xlink:to="eyen_OmnibusStockIncentivePlan2018Member_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_OmnibusStockIncentivePlan2018Member_lbl" xml:lang="en-US">The member stands for omnibus stock incentive plan 2018.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_OmnibusStockIncentivePlan2018Member_lbl" xml:lang="en-US">Omnibus Stock Incentive Plan2018 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="eyen_OmnibusStockIncentivePlan2018Member_lbl" xml:lang="en-US">Omnibus Stock Incentive Plan 2018 [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VestingAxis_lbl" xml:lang="en-US">Vesting [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_VestingDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VestingDomain_lbl" xml:lang="en-US">Vesting [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_VestingDomain_lbl" xml:lang="en-US">Vesting [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" xml:lang="en-US">Share Based Compensation Award Tranche One [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" xml:lang="en-US">Share-based Compensation Award, Tranche One [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_lbl" xml:lang="en-US">Share Based Compensation Award Tranche Two [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_lbl" xml:lang="en-US">Share-based Compensation Award, Tranche Two [Member]</label>
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_UnderwrittenPublicOfferingMember" xlink:label="eyen_UnderwrittenPublicOfferingMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_UnderwrittenPublicOfferingMember" xlink:to="eyen_UnderwrittenPublicOfferingMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_UnderwrittenPublicOfferingMember_lbl" xml:lang="en-US">This member stands for underwritten public offering.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_UnderwrittenPublicOfferingMember_lbl" xml:lang="en-US">Underwritten Public Offering [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="eyen_UnderwrittenPublicOfferingMember_lbl" xml:lang="en-US">Underwritten Public Offering</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OverAllotmentOptionMember" xlink:to="us-gaap_OverAllotmentOptionMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OverAllotmentOptionMember_lbl" xml:lang="en-US">Over Allotment Option [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OverAllotmentOptionMember_lbl" xml:lang="en-US">Over Allotment Option</label>
  </labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>13
<FILENAME>eyen-20201231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.9.3.5 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/31/2021 1:30:34 AM-->
<!--Modified on: 3/31/2021 1:30:34 AM-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="eyen-20201231.xsd#DocumentDocumentAndEntityInformation" roleURI="http://www.eyenoviabio.com/role/DocumentDocumentAndEntityInformation" />
  <roleRef xlink:type="simple" xlink:href="eyen-20201231.xsd#StatementBalanceSheets" roleURI="http://www.eyenoviabio.com/role/StatementBalanceSheets" />
  <roleRef xlink:type="simple" xlink:href="eyen-20201231.xsd#StatementBalanceSheetsParenthetical" roleURI="http://www.eyenoviabio.com/role/StatementBalanceSheetsParenthetical" />
  <roleRef xlink:type="simple" xlink:href="eyen-20201231.xsd#StatementStatementsOfOperations" roleURI="http://www.eyenoviabio.com/role/StatementStatementsOfOperations" />
  <roleRef xlink:type="simple" xlink:href="eyen-20201231.xsd#StatementStatementsOfChangesInStockholdersEquity" roleURI="http://www.eyenoviabio.com/role/StatementStatementsOfChangesInStockholdersEquity" />
  <roleRef xlink:type="simple" xlink:href="eyen-20201231.xsd#StatementStatementsOfChangesInStockholdersEquityParenthetical" roleURI="http://www.eyenoviabio.com/role/StatementStatementsOfChangesInStockholdersEquityParenthetical" />
  <roleRef xlink:type="simple" xlink:href="eyen-20201231.xsd#StatementStatementsOfCashFlows" roleURI="http://www.eyenoviabio.com/role/StatementStatementsOfCashFlows" />
  <roleRef xlink:type="simple" xlink:href="eyen-20201231.xsd#StatementStatementsOfCashFlowsParenthetical" roleURI="http://www.eyenoviabio.com/role/StatementStatementsOfCashFlowsParenthetical" />
  <roleRef xlink:type="simple" xlink:href="eyen-20201231.xsd#DisclosureBusinessOrganizationAndNatureOfOperations" roleURI="http://www.eyenoviabio.com/role/DisclosureBusinessOrganizationAndNatureOfOperations" />
  <roleRef xlink:type="simple" xlink:href="eyen-20201231.xsd#DisclosureSummaryOfSignificantAccountingPolicies" roleURI="http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPolicies" />
  <roleRef xlink:type="simple" xlink:href="eyen-20201231.xsd#DisclosurePrepaidExpensesAndOtherCurrentAssets" roleURI="http://www.eyenoviabio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssets" />
  <roleRef xlink:type="simple" xlink:href="eyen-20201231.xsd#DisclosurePropertyAndEquipmentNet" roleURI="http://www.eyenoviabio.com/role/DisclosurePropertyAndEquipmentNet" />
  <roleRef xlink:type="simple" xlink:href="eyen-20201231.xsd#DisclosureAccruedExpensesAndOtherCurrentLiabilities" roleURI="http://www.eyenoviabio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities" />
  <roleRef xlink:type="simple" xlink:href="eyen-20201231.xsd#DisclosureAccruedCompensation" roleURI="http://www.eyenoviabio.com/role/DisclosureAccruedCompensation" />
  <roleRef xlink:type="simple" xlink:href="eyen-20201231.xsd#DisclosureNotesPayable" roleURI="http://www.eyenoviabio.com/role/DisclosureNotesPayable" />
  <roleRef xlink:type="simple" xlink:href="eyen-20201231.xsd#DisclosureIncomeTaxes" roleURI="http://www.eyenoviabio.com/role/DisclosureIncomeTaxes" />
  <roleRef xlink:type="simple" xlink:href="eyen-20201231.xsd#DisclosureCommitmentsAndContingencies" roleURI="http://www.eyenoviabio.com/role/DisclosureCommitmentsAndContingencies" />
  <roleRef xlink:type="simple" xlink:href="eyen-20201231.xsd#DisclosureRelatedPartyTransactions" roleURI="http://www.eyenoviabio.com/role/DisclosureRelatedPartyTransactions" />
  <roleRef xlink:type="simple" xlink:href="eyen-20201231.xsd#DisclosureStockholdersEquity" roleURI="http://www.eyenoviabio.com/role/DisclosureStockholdersEquity" />
  <roleRef xlink:type="simple" xlink:href="eyen-20201231.xsd#DisclosureEmployeeBenefitPlans" roleURI="http://www.eyenoviabio.com/role/DisclosureEmployeeBenefitPlans" />
  <roleRef xlink:type="simple" xlink:href="eyen-20201231.xsd#DisclosureSubsequentEvents" roleURI="http://www.eyenoviabio.com/role/DisclosureSubsequentEvents" />
  <roleRef xlink:type="simple" xlink:href="eyen-20201231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" />
  <roleRef xlink:type="simple" xlink:href="eyen-20201231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesTables" roleURI="http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" />
  <roleRef xlink:type="simple" xlink:href="eyen-20201231.xsd#DisclosurePrepaidExpensesAndOtherCurrentAssetsTables" roleURI="http://www.eyenoviabio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsTables" />
  <roleRef xlink:type="simple" xlink:href="eyen-20201231.xsd#DisclosurePropertyAndEquipmentNetTables" roleURI="http://www.eyenoviabio.com/role/DisclosurePropertyAndEquipmentNetTables" />
  <roleRef xlink:type="simple" xlink:href="eyen-20201231.xsd#DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables" roleURI="http://www.eyenoviabio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables" />
  <roleRef xlink:type="simple" xlink:href="eyen-20201231.xsd#DisclosureAccruedCompensationTables" roleURI="http://www.eyenoviabio.com/role/DisclosureAccruedCompensationTables" />
  <roleRef xlink:type="simple" xlink:href="eyen-20201231.xsd#DisclosureNotesPayableTables" roleURI="http://www.eyenoviabio.com/role/DisclosureNotesPayableTables" />
  <roleRef xlink:type="simple" xlink:href="eyen-20201231.xsd#DisclosureIncomeTaxesTables" roleURI="http://www.eyenoviabio.com/role/DisclosureIncomeTaxesTables" />
  <roleRef xlink:type="simple" xlink:href="eyen-20201231.xsd#DisclosureCommitmentsAndContingenciesTables" roleURI="http://www.eyenoviabio.com/role/DisclosureCommitmentsAndContingenciesTables" />
  <roleRef xlink:type="simple" xlink:href="eyen-20201231.xsd#DisclosureStockholdersEquityTables" roleURI="http://www.eyenoviabio.com/role/DisclosureStockholdersEquityTables" />
  <roleRef xlink:type="simple" xlink:href="eyen-20201231.xsd#DisclosureBusinessOrganizationAndNatureOfOperationsDetails" roleURI="http://www.eyenoviabio.com/role/DisclosureBusinessOrganizationAndNatureOfOperationsDetails" />
  <roleRef xlink:type="simple" xlink:href="eyen-20201231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesAntiDilutiveWeightedAverageDilutedCommonSharesDetails" roleURI="http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAntiDilutiveWeightedAverageDilutedCommonSharesDetails" />
  <roleRef xlink:type="simple" xlink:href="eyen-20201231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" roleURI="http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" />
  <roleRef xlink:type="simple" xlink:href="eyen-20201231.xsd#DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails" roleURI="http://www.eyenoviabio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails" />
  <roleRef xlink:type="simple" xlink:href="eyen-20201231.xsd#DisclosurePropertyAndEquipmentNetPropertyAndEquipmentDetails" roleURI="http://www.eyenoviabio.com/role/DisclosurePropertyAndEquipmentNetPropertyAndEquipmentDetails" />
  <roleRef xlink:type="simple" xlink:href="eyen-20201231.xsd#DisclosurePropertyAndEquipmentNetAdditionalInformationDetails" roleURI="http://www.eyenoviabio.com/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetails" />
  <roleRef xlink:type="simple" xlink:href="eyen-20201231.xsd#DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails" roleURI="http://www.eyenoviabio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails" />
  <roleRef xlink:type="simple" xlink:href="eyen-20201231.xsd#DisclosureAccruedCompensationDetails" roleURI="http://www.eyenoviabio.com/role/DisclosureAccruedCompensationDetails" />
  <roleRef xlink:type="simple" xlink:href="eyen-20201231.xsd#DisclosureNotesPayableScheduleOfNotesPayableDetails" roleURI="http://www.eyenoviabio.com/role/DisclosureNotesPayableScheduleOfNotesPayableDetails" />
  <roleRef xlink:type="simple" xlink:href="eyen-20201231.xsd#DisclosureNotesPayableAdditionalInformationDetails" roleURI="http://www.eyenoviabio.com/role/DisclosureNotesPayableAdditionalInformationDetails" />
  <roleRef xlink:type="simple" xlink:href="eyen-20201231.xsd#DisclosureIncomeTaxesProvisionForIncomeTaxesDetails" roleURI="http://www.eyenoviabio.com/role/DisclosureIncomeTaxesProvisionForIncomeTaxesDetails" />
  <roleRef xlink:type="simple" xlink:href="eyen-20201231.xsd#DisclosureIncomeTaxesEffectiveIncomeTaxRateReconciliationDetails" roleURI="http://www.eyenoviabio.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxRateReconciliationDetails" />
  <roleRef xlink:type="simple" xlink:href="eyen-20201231.xsd#DisclosureIncomeTaxesDeferredTaxAssetsDetails" roleURI="http://www.eyenoviabio.com/role/DisclosureIncomeTaxesDeferredTaxAssetsDetails" />
  <roleRef xlink:type="simple" xlink:href="eyen-20201231.xsd#DisclosureIncomeTaxesAdditionalInformationDetails" roleURI="http://www.eyenoviabio.com/role/DisclosureIncomeTaxesAdditionalInformationDetails" />
  <roleRef xlink:type="simple" xlink:href="eyen-20201231.xsd#DisclosureCommitmentsAndContingenciesFutureMinimumPaymentsUnderOperatingLeaseAgreementDetails" roleURI="http://www.eyenoviabio.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumPaymentsUnderOperatingLeaseAgreementDetails" />
  <roleRef xlink:type="simple" xlink:href="eyen-20201231.xsd#DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" roleURI="http://www.eyenoviabio.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" />
  <roleRef xlink:type="simple" xlink:href="eyen-20201231.xsd#DisclosureRelatedPartyTransactionsDetails" roleURI="http://www.eyenoviabio.com/role/DisclosureRelatedPartyTransactionsDetails" />
  <roleRef xlink:type="simple" xlink:href="eyen-20201231.xsd#DisclosureStockholdersEquityWarrantsActivityDetails" roleURI="http://www.eyenoviabio.com/role/DisclosureStockholdersEquityWarrantsActivityDetails" />
  <roleRef xlink:type="simple" xlink:href="eyen-20201231.xsd#DisclosureStockholdersEquityAdditionalInformationRelatedToWarrantsDetails" roleURI="http://www.eyenoviabio.com/role/DisclosureStockholdersEquityAdditionalInformationRelatedToWarrantsDetails" />
  <roleRef xlink:type="simple" xlink:href="eyen-20201231.xsd#DisclosureStockholdersEquityBlackScholesOptionDetails" roleURI="http://www.eyenoviabio.com/role/DisclosureStockholdersEquityBlackScholesOptionDetails" />
  <roleRef xlink:type="simple" xlink:href="eyen-20201231.xsd#DisclosureStockholdersEquitySummaryOfOptionActivityDetails" roleURI="http://www.eyenoviabio.com/role/DisclosureStockholdersEquitySummaryOfOptionActivityDetails" />
  <roleRef xlink:type="simple" xlink:href="eyen-20201231.xsd#DisclosureStockholdersEquitySummaryOfInformationRelatedToStockOptionsDetails" roleURI="http://www.eyenoviabio.com/role/DisclosureStockholdersEquitySummaryOfInformationRelatedToStockOptionsDetails" />
  <roleRef xlink:type="simple" xlink:href="eyen-20201231.xsd#DisclosureStockholdersEquityAdditionalInformationDetails" roleURI="http://www.eyenoviabio.com/role/DisclosureStockholdersEquityAdditionalInformationDetails" />
  <roleRef xlink:type="simple" xlink:href="eyen-20201231.xsd#DisclosureEmployeeBenefitPlansDetails" roleURI="http://www.eyenoviabio.com/role/DisclosureEmployeeBenefitPlansDetails" />
  <roleRef xlink:type="simple" xlink:href="eyen-20201231.xsd#DisclosureSubsequentEventsDetails" roleURI="http://www.eyenoviabio.com/role/DisclosureSubsequentEventsDetails" />
  <presentationLink xlink:role="http://www.eyenoviabio.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="00090 - Document - Document and Entity Information">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType_637527510331209110" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType_637527510331209110" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate_637527510331249087" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate_637527510331249087" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName_637527510331249087" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName_637527510331249087" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus_637527510331249087" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus_637527510331249087" order="4" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent_637527510331249087" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent_637527510331249087" order="5" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory_637527510331249087" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFilerCategory_637527510331249087" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness_637527510331249087" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntitySmallBusiness_637527510331249087" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany_637527510331249087" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany_637527510331249087" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod_637527510331249087" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityExTransitionPeriod_637527510331249087" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany_637527510331249087" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityShellCompany_637527510331249087" order="10" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle_637527510331249087" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle_637527510331249087" order="11" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol_637527510331249087" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol_637527510331249087" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName_637527510331249087" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName_637527510331249087" order="13" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding_637527510331249087" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding_637527510331249087" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey_637527510331249087" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey_637527510331249087" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate_637527510331249087" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate_637527510331249087" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus_637527510331259080" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus_637527510331259080" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus_637527510331259080" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus_637527510331259080" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag_637527510331259080" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag_637527510331259080" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers_637527510331259080" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityVoluntaryFilers_637527510331259080" order="20" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat_637527510331259080" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityPublicFloat_637527510331259080" order="21" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer_637527510331259080" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityWellKnownSeasonedIssuer_637527510331259080" order="22" use="optional" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.eyenoviabio.com/role/StatementBalanceSheets" xlink:type="extended" xlink:title="00100 - Statement - Balance Sheets">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_29" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract_637527510331259080" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_29" xlink:to="us-gaap_AssetsAbstract_637527510331259080" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract_637527510331259080" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_637527510331259080" xlink:to="us-gaap_AssetsCurrentAbstract_637527510331259080" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_637527510331259080" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637527510331259080" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_637527510331259080" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCostsCurrent" xlink:label="us-gaap_DeferredCostsCurrent_637527510331259080" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637527510331259080" xlink:to="us-gaap_DeferredCostsCurrent_637527510331259080" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_LicenseReceivableCurrent" xlink:label="eyen_LicenseReceivableCurrent_637527510331259080" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637527510331259080" xlink:to="eyen_LicenseReceivableCurrent_637527510331259080" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_637527510331259080" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637527510331259080" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_637527510331259080" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_637527510331259080" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637527510331259080" xlink:to="us-gaap_AssetsCurrent_637527510331259080" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_637527510331259080" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_637527510331259080" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_637527510331259080" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SecurityDeposit" xlink:label="us-gaap_SecurityDeposit_637527510331259080" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_637527510331259080" xlink:to="us-gaap_SecurityDeposit_637527510331259080" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets_637527510331269074" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_637527510331259080" xlink:to="us-gaap_Assets_637527510331269074" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637527510331269074" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_29" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637527510331269074" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract_637527510331269074" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637527510331269074" xlink:to="us-gaap_LiabilitiesCurrentAbstract_637527510331269074" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_637527510331269074" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_637527510331269074" xlink:to="us-gaap_AccountsPayableCurrent_637527510331269074" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WorkersCompensationLiabilityCurrent" xlink:label="us-gaap_WorkersCompensationLiabilityCurrent_637527510331269074" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_637527510331269074" xlink:to="us-gaap_WorkersCompensationLiabilityCurrent_637527510331269074" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_AccruedExpensesAndOtherLiabilitiesCurrent" xlink:label="eyen_AccruedExpensesAndOtherLiabilitiesCurrent_637527510331269074" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_637527510331269074" xlink:to="eyen_AccruedExpensesAndOtherLiabilitiesCurrent_637527510331269074" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRentCreditCurrent" xlink:label="us-gaap_DeferredRentCreditCurrent_637527510331269074" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_637527510331269074" xlink:to="us-gaap_DeferredRentCreditCurrent_637527510331269074" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_637527510331269074" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_637527510331269074" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent_637527510331269074" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermBankLoansAndNotesPayable" xlink:label="us-gaap_ShortTermBankLoansAndNotesPayable_637527510331269074" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_637527510331269074" xlink:to="us-gaap_ShortTermBankLoansAndNotesPayable_637527510331269074" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_637527510331269074" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_637527510331269074" xlink:to="us-gaap_LiabilitiesCurrent_637527510331269074" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="us-gaap_DeferredRentCreditNoncurrent_637527510331269074" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637527510331269074" xlink:to="us-gaap_DeferredRentCreditNoncurrent_637527510331269074" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermNotesPayable" xlink:label="us-gaap_LongTermNotesPayable_637527510331269074" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637527510331269074" xlink:to="us-gaap_LongTermNotesPayable_637527510331269074" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_637527510331269074" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637527510331269074" xlink:to="us-gaap_Liabilities_637527510331269074" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies_637527510331269074" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_29" xlink:to="us-gaap_CommitmentsAndContingencies_637527510331269074" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract_637527510331269074" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_29" xlink:to="us-gaap_StockholdersEquityAbstract_637527510331269074" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue_637527510331269074" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_637527510331269074" xlink:to="us-gaap_PreferredStockValue_637527510331269074" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_637527510331279067" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_637527510331269074" xlink:to="us-gaap_CommonStockValue_637527510331279067" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital_637527510331279067" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_637527510331269074" xlink:to="us-gaap_AdditionalPaidInCapital_637527510331279067" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_637527510331279067" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_637527510331269074" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_637527510331279067" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_637527510331279067" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_637527510331269074" xlink:to="us-gaap_StockholdersEquity_637527510331279067" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_637527510331279067" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_29" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_637527510331279067" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.eyenoviabio.com/role/StatementBalanceSheetsParenthetical" xlink:type="extended" xlink:title="00105 - Statement - Balance Sheets (Parenthetical)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_98" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_637527510331279067" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_98" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_637527510331279067" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized_637527510331279067" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_98" xlink:to="us-gaap_PreferredStockSharesAuthorized_637527510331279067" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued_637527510331279067" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_98" xlink:to="us-gaap_PreferredStockSharesIssued_637527510331279067" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding_637527510331279067" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_98" xlink:to="us-gaap_PreferredStockSharesOutstanding_637527510331279067" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_637527510331279067" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_98" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_637527510331279067" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized_637527510331279067" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_98" xlink:to="us-gaap_CommonStockSharesAuthorized_637527510331279067" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued_637527510331279067" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_98" xlink:to="us-gaap_CommonStockSharesIssued_637527510331279067" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding_637527510331279067" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_98" xlink:to="us-gaap_CommonStockSharesOutstanding_637527510331279067" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>
  <presentationLink xlink:role="http://www.eyenoviabio.com/role/StatementStatementsOfOperations" xlink:type="extended" xlink:title="00200 - Statement - Statements of Operations">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_143" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract_637527510331289062" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_143" xlink:to="us-gaap_RevenuesAbstract_637527510331289062" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_637527510331289062" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract_637527510331289062" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_637527510331289062" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfRevenue" xlink:label="us-gaap_CostOfRevenue_637527510331289062" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract_637527510331289062" xlink:to="us-gaap_CostOfRevenue_637527510331289062" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrossProfit" xlink:label="us-gaap_GrossProfit_637527510331289062" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract_637527510331289062" xlink:to="us-gaap_GrossProfit_637527510331289062" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract_637527510331289062" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_143" xlink:to="us-gaap_OperatingExpensesAbstract_637527510331289062" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_637527510331289062" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_637527510331289062" xlink:to="us-gaap_ResearchAndDevelopmentExpense_637527510331289062" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense_637527510331289062" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_637527510331289062" xlink:to="us-gaap_GeneralAndAdministrativeExpense_637527510331289062" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses_637527510331289062" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_637527510331289062" xlink:to="us-gaap_OperatingExpenses_637527510331289062" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_637527510331289062" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_143" xlink:to="us-gaap_OperatingIncomeLoss_637527510331289062" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_637527510331289062" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_143" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_637527510331289062" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_SmallBusinessAdministrationEconomicInjuryDisasterGrant" xlink:label="eyen_SmallBusinessAdministrationEconomicInjuryDisasterGrant_637527510331289062" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract_637527510331289062" xlink:to="eyen_SmallBusinessAdministrationEconomicInjuryDisasterGrant_637527510331289062" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense_637527510331289062" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract_637527510331289062" xlink:to="us-gaap_InterestExpense_637527510331289062" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet_637527510331289062" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract_637527510331289062" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet_637527510331289062" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_637527510331289062" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_143" xlink:to="us-gaap_NetIncomeLoss_637527510331289062" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedAbstract_637527510331289062" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_143" xlink:to="us-gaap_EarningsPerShareBasicAndDilutedAbstract_637527510331289062" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_637527510331299055" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedAbstract_637527510331289062" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_637527510331299055" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_637527510331299055" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_143" xlink:to="us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_637527510331299055" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_637527510331299055" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_637527510331299055" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_637527510331299055" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.eyenoviabio.com/role/StatementStatementsOfChangesInStockholdersEquity" xlink:type="extended" xlink:title="00300 - Statement - Statements of Changes in Stockholders' Equity">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_364255" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637527510331299055" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_364255" xlink:to="us-gaap_StatementTable_637527510331299055" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_637527510331299055" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637527510331299055" xlink:to="us-gaap_StatementEquityComponentsAxis_637527510331299055" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_637527510331299055" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637527510331299055" xlink:to="us-gaap_CommonStockMember_637527510331299055" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember_637527510331299055" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637527510331299055" xlink:to="us-gaap_AdditionalPaidInCapitalMember_637527510331299055" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember_637527510331299055" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637527510331299055" xlink:to="us-gaap_RetainedEarningsMember_637527510331299055" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_637527510331299055" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637527510331299055" xlink:to="us-gaap_EquityComponentDomain_637527510331299055" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637527510331299055" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637527510331299055" xlink:to="us-gaap_StatementLineItems_637527510331299055" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_637527510331299055" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637527510331299055" xlink:to="us-gaap_StockholdersEquity_637527510331299055" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_637527510331299055" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637527510331299055" xlink:to="us-gaap_SharesOutstanding_637527510331299055" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_StockIssuedDuringPeriodValueNewIssuesTwo" xlink:label="eyen_StockIssuedDuringPeriodValueNewIssuesTwo_637527510331299055" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637527510331299055" xlink:to="eyen_StockIssuedDuringPeriodValueNewIssuesTwo_637527510331299055" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_StockIssuedDuringPeriodSharesNewIssuesTwo" xlink:label="eyen_StockIssuedDuringPeriodSharesNewIssuesTwo_637527510331299055" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637527510331299055" xlink:to="eyen_StockIssuedDuringPeriodSharesNewIssuesTwo_637527510331299055" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_StockIssuedDuringPeriodValueNewIssuesThree" xlink:label="eyen_StockIssuedDuringPeriodValueNewIssuesThree_637527510331299055" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637527510331299055" xlink:to="eyen_StockIssuedDuringPeriodValueNewIssuesThree_637527510331299055" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_StockIssuedDuringPeriodSharesNewIssuesThree" xlink:label="eyen_StockIssuedDuringPeriodSharesNewIssuesThree_637527510331299055" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637527510331299055" xlink:to="eyen_StockIssuedDuringPeriodSharesNewIssuesThree_637527510331299055" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_637527510331309050" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637527510331299055" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_637527510331309050" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_StockIssuedDuringPeriodValueStockOptionsExercisedOnCashlessBasis" xlink:label="eyen_StockIssuedDuringPeriodValueStockOptionsExercisedOnCashlessBasis_637527510331309050" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637527510331299055" xlink:to="eyen_StockIssuedDuringPeriodValueStockOptionsExercisedOnCashlessBasis_637527510331309050" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodOnCashlessBasis" xlink:label="eyen_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodOnCashlessBasis_637527510331309050" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637527510331299055" xlink:to="eyen_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodOnCashlessBasis_637527510331309050" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_StockIssuedDuringPeriodValueWarrantsExercised" xlink:label="eyen_StockIssuedDuringPeriodValueWarrantsExercised_637527510331309050" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637527510331299055" xlink:to="eyen_StockIssuedDuringPeriodValueWarrantsExercised_637527510331309050" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:label="eyen_StockIssuedDuringPeriodSharesWarrantsExercised_637527510331309050" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637527510331299055" xlink:to="eyen_StockIssuedDuringPeriodSharesWarrantsExercised_637527510331309050" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_637527510331309050" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637527510331299055" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_637527510331309050" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_637527510331309050" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637527510331299055" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_637527510331309050" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_637527510331309050" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637527510331299055" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_637527510331309050" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_637527510331309050" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637527510331299055" xlink:to="us-gaap_NetIncomeLoss_637527510331309050" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_637527510331309050" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637527510331299055" xlink:to="us-gaap_StockholdersEquity_637527510331309050" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_637527510331309050" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637527510331299055" xlink:to="us-gaap_SharesOutstanding_637527510331309050" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.eyenoviabio.com/role/StatementStatementsOfChangesInStockholdersEquityParenthetical" xlink:type="extended" xlink:title="00305 - Statement - Statements of Changes in Stockholders' Equity (Parenthetical)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_364366" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637527510331309050" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_364366" xlink:to="us-gaap_StatementTable_637527510331309050" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_637527510331319043" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637527510331309050" xlink:to="us-gaap_StatementEquityComponentsAxis_637527510331319043" order="1" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_637527510331319043" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637527510331319043" xlink:to="us-gaap_EquityComponentDomain_637527510331319043" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_CommonStockOneMember" xlink:label="eyen_CommonStockOneMember_637527510331319043" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain_637527510331319043" xlink:to="eyen_CommonStockOneMember_637527510331319043" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_CommonStockTwoMember" xlink:label="eyen_CommonStockTwoMember_637527510331319043" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain_637527510331319043" xlink:to="eyen_CommonStockTwoMember_637527510331319043" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_CommonStockThreeMember" xlink:label="eyen_CommonStockThreeMember_637527510331319043" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain_637527510331319043" xlink:to="eyen_CommonStockThreeMember_637527510331319043" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637527510331319043" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637527510331309050" xlink:to="us-gaap_StatementLineItems_637527510331319043" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_ProceedsOfStockIssuedDuringPeriodGross" xlink:label="eyen_ProceedsOfStockIssuedDuringPeriodGross_637527510331319043" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637527510331319043" xlink:to="eyen_ProceedsOfStockIssuedDuringPeriodGross_637527510331319043" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_637527510331319043" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637527510331319043" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_637527510331319043" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>
  <presentationLink xlink:role="http://www.eyenoviabio.com/role/StatementStatementsOfCashFlows" xlink:type="extended" xlink:title="00400 - Statement - Statements of Cash Flows">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_247" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_637527510331319043" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_247" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_637527510331319043" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_637527510331319043" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_637527510331319043" xlink:to="us-gaap_NetIncomeLoss_637527510331319043" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637527510331319043" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_637527510331319043" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637527510331319043" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization_637527510331319043" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637527510331319043" xlink:to="us-gaap_DepreciationDepletionAndAmortization_637527510331319043" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_637527510331319043" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637527510331319043" xlink:to="us-gaap_ShareBasedCompensation_637527510331319043" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637527510331319043" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637527510331319043" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637527510331319043" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_637527510331319043" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637527510331319043" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_637527510331319043" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_IncreaseDecreaseInLicenseReceivable" xlink:label="eyen_IncreaseDecreaseInLicenseReceivable_637527510331319043" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637527510331319043" xlink:to="eyen_IncreaseDecreaseInLicenseReceivable_637527510331319043" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredCharges" xlink:label="us-gaap_IncreaseDecreaseInDeferredCharges_637527510331319043" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637527510331319043" xlink:to="us-gaap_IncreaseDecreaseInDeferredCharges_637527510331319043" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_637527510331319043" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637527510331319043" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_637527510331319043" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_637527510331319043" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637527510331319043" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_637527510331319043" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_637527510331329038" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637527510331319043" xlink:to="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_637527510331329038" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_637527510331329038" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637527510331319043" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_637527510331329038" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInSecurityDeposits" xlink:label="us-gaap_IncreaseDecreaseInSecurityDeposits_637527510331329038" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637527510331319043" xlink:to="us-gaap_IncreaseDecreaseInSecurityDeposits_637527510331329038" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_IncreaseDecreaseInDeferredRent" xlink:label="eyen_IncreaseDecreaseInDeferredRent_637527510331329038" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637527510331319043" xlink:to="eyen_IncreaseDecreaseInDeferredRent_637527510331329038" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_637527510331329038" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_637527510331319043" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_637527510331329038" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637527510331329038" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_247" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637527510331329038" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_637527510331329038" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637527510331329038" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_637527510331329038" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_637527510331329038" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637527510331329038" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_637527510331329038" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637527510331329038" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_247" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637527510331329038" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_637527510331329038" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637527510331329038" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_637527510331329038" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_637527510331329038" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637527510331329038" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_637527510331329038" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_637527510331329038" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637527510331329038" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_637527510331329038" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises_637527510331329038" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637527510331329038" xlink:to="us-gaap_ProceedsFromWarrantExercises_637527510331329038" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_ProceedsFromPaycheckProtectionProgramLoan" xlink:label="eyen_ProceedsFromPaycheckProtectionProgramLoan_637527510331329038" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637527510331329038" xlink:to="eyen_ProceedsFromPaycheckProtectionProgramLoan_637527510331329038" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="us-gaap_RepaymentsOfNotesPayable_637527510331329038" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637527510331329038" xlink:to="us-gaap_RepaymentsOfNotesPayable_637527510331329038" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_637527510331339032" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637527510331329038" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_637527510331339032" order="7" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_PaymentsForRepurchaseOfPublicOffering" xlink:label="eyen_PaymentsForRepurchaseOfPublicOffering_637527510331339032" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637527510331329038" xlink:to="eyen_PaymentsForRepurchaseOfPublicOffering_637527510331339032" order="8" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_637527510331339032" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637527510331329038" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_637527510331339032" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_637527510331339032" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637527510331329038" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_637527510331339032" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_637527510331339032" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_247" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_637527510331339032" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_637527510331339032" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_247" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_637527510331339032" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6375275103313390321" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_247" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6375275103313390321" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_637527510331339032" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_247" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_637527510331339032" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPaidCapitalized" xlink:label="us-gaap_InterestPaidCapitalized_637527510331339032" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract_637527510331339032" xlink:to="us-gaap_InterestPaidCapitalized_637527510331339032" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_637527510331339032" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_247" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_637527510331339032" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_PurchaseOfInsurancePremiumFinancedByShortTermNotePayable" xlink:label="eyen_PurchaseOfInsurancePremiumFinancedByShortTermNotePayable_637527510331349045" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract_637527510331339032" xlink:to="eyen_PurchaseOfInsurancePremiumFinancedByShortTermNotePayable_637527510331349045" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssued1" xlink:label="us-gaap_StockIssued1_637527510331349045" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract_637527510331339032" xlink:to="us-gaap_StockIssued1_637527510331349045" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_AccruedPurchasesOfLeaseholdImprovements" xlink:label="eyen_AccruedPurchasesOfLeaseholdImprovements_637527510331349045" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract_637527510331339032" xlink:to="eyen_AccruedPurchasesOfLeaseholdImprovements_637527510331349045" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.eyenoviabio.com/role/StatementStatementsOfCashFlowsParenthetical" xlink:type="extended" xlink:title="00405 - Statement - Statements of Cash Flows (Parenthetical)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_277" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637527510331349045" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_277" xlink:to="us-gaap_StatementTable_637527510331349045" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_637527510331349045" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637527510331349045" xlink:to="us-gaap_StatementClassOfStockAxis_637527510331349045" order="1" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_637527510331349045" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_637527510331349045" xlink:to="us-gaap_ClassOfStockDomain_637527510331349045" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_CommonStockOneMember" xlink:label="eyen_CommonStockOneMember_637527510331349045" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_637527510331349045" xlink:to="eyen_CommonStockOneMember_637527510331349045" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_CommonStockTwoMember" xlink:label="eyen_CommonStockTwoMember_637527510331349045" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_637527510331349045" xlink:to="eyen_CommonStockTwoMember_637527510331349045" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_CommonStockThreeMember" xlink:label="eyen_CommonStockThreeMember_637527510331349045" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_637527510331349045" xlink:to="eyen_CommonStockThreeMember_637527510331349045" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637527510331349045" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637527510331349045" xlink:to="us-gaap_StatementLineItems_637527510331349045" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_ProceedsOfStockIssuedDuringPeriodGross" xlink:label="eyen_ProceedsOfStockIssuedDuringPeriodGross_637527510331349045" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637527510331349045" xlink:to="eyen_ProceedsOfStockIssuedDuringPeriodGross_637527510331349045" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts_637527510331349045" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637527510331349045" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts_637527510331349045" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>
  <presentationLink xlink:role="http://www.eyenoviabio.com/role/DisclosureBusinessOrganizationAndNatureOfOperations" xlink:type="extended" xlink:title="10101 - Disclosure - Business Organization and Nature of Operations">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_285" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_637527510331359039" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_285" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_637527510331359039" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPolicies" xlink:type="extended" xlink:title="10201 - Disclosure - Summary of Significant Accounting Policies">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_637527510331359039" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_637527510331359039" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.eyenoviabio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssets" xlink:type="extended" xlink:title="10301 - Disclosure - Prepaid Expenses and Other Current Assets">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsAbstract" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsAbstract_5" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_PrepaidExpensesAndOtherCurrentAssetsDisclosureTextBlock" xlink:label="eyen_PrepaidExpensesAndOtherCurrentAssetsDisclosureTextBlock_637527510331359039" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsAbstract_5" xlink:to="eyen_PrepaidExpensesAndOtherCurrentAssetsDisclosureTextBlock_637527510331359039" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.eyenoviabio.com/role/DisclosurePropertyAndEquipmentNet" xlink:type="extended" xlink:title="10401 - Disclosure - Property and Equipment, Net">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_637026734627243880" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_637527510331359039" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract_637026734627243880" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_637527510331359039" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.eyenoviabio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities" xlink:type="extended" xlink:title="10501 - Disclosure - Accrued Expenses and Other Current Liabilities">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_8" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_637527510331359039" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_8" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_637527510331359039" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.eyenoviabio.com/role/DisclosureAccruedCompensation" xlink:type="extended" xlink:title="10601 - Disclosure - Accrued Compensation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationRelatedCostsAbstract" xlink:label="loc_us-gaap_CompensationRelatedCostsAbstract_368361" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationRelatedCostsGeneralTextBlock" xlink:label="us-gaap_CompensationRelatedCostsGeneralTextBlock_637527510331359039" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationRelatedCostsAbstract_368361" xlink:to="us-gaap_CompensationRelatedCostsGeneralTextBlock_637527510331359039" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.eyenoviabio.com/role/DisclosureNotesPayable" xlink:type="extended" xlink:title="10701 - Disclosure - Notes Payable">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayableAbstract" xlink:label="us-gaap_NotesPayableAbstract" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_NotesPayableDisclosureTextBlock" xlink:label="eyen_NotesPayableDisclosureTextBlock_637527510331369032" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NotesPayableAbstract" xlink:to="eyen_NotesPayableDisclosureTextBlock_637527510331369032" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.eyenoviabio.com/role/DisclosureIncomeTaxes" xlink:type="extended" xlink:title="10801 - Disclosure - Income Taxes">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_637026734627253889" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_637527510331369032" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637026734627253889" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_637527510331369032" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.eyenoviabio.com/role/DisclosureCommitmentsAndContingencies" xlink:type="extended" xlink:title="10901 - Disclosure - Commitments and Contingencies">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_11" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_637527510331369032" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_11" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_637527510331369032" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.eyenoviabio.com/role/DisclosureRelatedPartyTransactions" xlink:type="extended" xlink:title="11001 - Disclosure - Related Party Transactions">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_14" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_637527510331369032" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_14" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_637527510331369032" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.eyenoviabio.com/role/DisclosureStockholdersEquity" xlink:type="extended" xlink:title="11101 - Disclosure - Stockholders' Equity">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_17" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_637527510331369032" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_17" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_637527510331369032" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.eyenoviabio.com/role/DisclosureEmployeeBenefitPlans" xlink:type="extended" xlink:title="11201 - Disclosure - Employee Benefit Plans">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_637527510331369032" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_637527510331369032" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.eyenoviabio.com/role/DisclosureSubsequentEvents" xlink:type="extended" xlink:title="11301 - Disclosure - Subsequent Events">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_20" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock_637527510331379024" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_20" xlink:to="us-gaap_SubsequentEventsTextBlock_637527510331379024" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended" xlink:title="20202 - Disclosure - Summary of Significant Accounting Policies (Policies)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_23" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates_637527510331379024" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_23" xlink:to="us-gaap_UseOfEstimates_637527510331379024" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_637527510331379024" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_23" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_637527510331379024" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_637527510331379024" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_23" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_637527510331379024" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_637527510331379024" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_23" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_637527510331379024" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy" xlink:label="us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy_637527510331379024" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_23" xlink:to="us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy_637527510331379024" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_637527510331379024" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_23" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_637527510331379024" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_637527510331379024" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_23" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_637527510331379024" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_637527510331379024" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_23" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_637527510331379024" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_DeferredLicenseFeePolicyTextBlock" xlink:label="eyen_DeferredLicenseFeePolicyTextBlock_637527510331379024" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_23" xlink:to="eyen_DeferredLicenseFeePolicyTextBlock_637527510331379024" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_DeferredLicenseCostsPolicyTextBlock" xlink:label="eyen_DeferredLicenseCostsPolicyTextBlock_637527510331379024" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_23" xlink:to="eyen_DeferredLicenseCostsPolicyTextBlock_637527510331379024" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_637527510331379024" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_23" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_637527510331379024" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_637527510331379024" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_23" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_637527510331379024" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_637527510331379024" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_23" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_637527510331379024" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsPolicyPolicyTextBlock" xlink:label="us-gaap_SubsequentEventsPolicyPolicyTextBlock_637527510331379024" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_23" xlink:to="us-gaap_SubsequentEventsPolicyPolicyTextBlock_637527510331379024" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_637527510331389018" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_23" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_637527510331389018" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" xlink:type="extended" xlink:title="30203 - Disclosure - Summary of Significant Accounting Policies (Tables)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_59" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_637527510331389018" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_59" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_637527510331389018" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.eyenoviabio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsTables" xlink:type="extended" xlink:title="30303 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsAbstract" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsAbstract_62" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_637527510331389018" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsAbstract_62" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_637527510331389018" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.eyenoviabio.com/role/DisclosurePropertyAndEquipmentNetTables" xlink:type="extended" xlink:title="30403 - Disclosure - Property and Equipment, Net (Tables)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_637026734627283917" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_637527510331389018" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract_637026734627283917" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_637527510331389018" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.eyenoviabio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:type="extended" xlink:title="30503 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_65" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_637527510331389018" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_65" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_637527510331389018" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.eyenoviabio.com/role/DisclosureAccruedCompensationTables" xlink:type="extended" xlink:title="30603 - Disclosure - Accrued Compensation (Tables)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationRelatedCostsAbstract" xlink:label="loc_us-gaap_CompensationRelatedCostsAbstract_368364" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_DisclosureOfAccruedCompensationTableTextBlock" xlink:label="eyen_DisclosureOfAccruedCompensationTableTextBlock_637527510331399015" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationRelatedCostsAbstract_368364" xlink:to="eyen_DisclosureOfAccruedCompensationTableTextBlock_637527510331399015" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.eyenoviabio.com/role/DisclosureNotesPayableTables" xlink:type="extended" xlink:title="30703 - Disclosure - Notes Payable (Tables)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayableAbstract" xlink:label="us-gaap_NotesPayableAbstract" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_ScheduleOfNotesPayableTableTextBlock" xlink:label="eyen_ScheduleOfNotesPayableTableTextBlock_637527510331409110" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NotesPayableAbstract" xlink:to="eyen_ScheduleOfNotesPayableTableTextBlock_637527510331409110" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.eyenoviabio.com/role/DisclosureIncomeTaxesTables" xlink:type="extended" xlink:title="30803 - Disclosure - Income Taxes (Tables)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_637026734627293926" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_637527510331418981" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637026734627293926" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_637527510331418981" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_637527510331418981" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637026734627293926" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_637527510331418981" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_637527510331418981" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637026734627293926" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_637527510331418981" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.eyenoviabio.com/role/DisclosureCommitmentsAndContingenciesTables" xlink:type="extended" xlink:title="30903 - Disclosure - Commitments and Contingencies (Tables)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_637026734627293926" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_637527510331418981" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_637026734627293926" xlink:to="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_637527510331418981" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.eyenoviabio.com/role/DisclosureStockholdersEquityTables" xlink:type="extended" xlink:title="31103 - Disclosure - Stockholders' Equity (Tables)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_224653" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_637527510331418981" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_224653" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_637527510331418981" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_637527510331418981" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_224653" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_637527510331418981" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_637527510331418981" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_224653" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_637527510331418981" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_637527510331418981" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_224653" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_637527510331418981" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.eyenoviabio.com/role/DisclosureBusinessOrganizationAndNatureOfOperationsDetails" xlink:type="extended" xlink:title="40101 - Disclosure - Business Organization and Nature of Operations (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_225484" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode_637527510331418981" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_225484" xlink:to="dei_EntityIncorporationStateCountryCode_637527510331418981" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationDateOfIncorporation" xlink:label="dei_EntityIncorporationDateOfIncorporation_637527510331428976" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_225484" xlink:to="dei_EntityIncorporationDateOfIncorporation_637527510331428976" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_PercentageOfSuccessRateOfOptejet" xlink:label="eyen_PercentageOfSuccessRateOfOptejet_637527510331428976" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_225484" xlink:to="eyen_PercentageOfSuccessRateOfOptejet_637527510331428976" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_PercentageOfSuccessfulRateOfTraditionalEyeDrops" xlink:label="eyen_PercentageOfSuccessfulRateOfTraditionalEyeDrops_637527510331428976" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_225484" xlink:to="eyen_PercentageOfSuccessfulRateOfTraditionalEyeDrops_637527510331428976" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>
  <presentationLink xlink:role="http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAntiDilutiveWeightedAverageDilutedCommonSharesDetails" xlink:type="extended" xlink:title="40201 - Disclosure - Summary of Significant Accounting Policies - Anti-dilutive weighted average diluted common shares (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_68" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637527510331428976" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_68" xlink:to="us-gaap_StatementTable_637527510331428976" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_637527510331428976" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637527510331428976" xlink:to="us-gaap_StatementEquityComponentsAxis_637527510331428976" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_637527510331428976" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637527510331428976" xlink:to="us-gaap_EquityComponentDomain_637527510331428976" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember_637527510331428976" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain_637527510331428976" xlink:to="us-gaap_WarrantMember_637527510331428976" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeAxis_637527510331428976" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637527510331428976" xlink:to="us-gaap_OptionIndexedToIssuersEquityTypeAxis_637527510331428976" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeDomain_637527510331428976" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OptionIndexedToIssuersEquityTypeAxis_637527510331428976" xlink:to="us-gaap_OptionIndexedToIssuersEquityTypeDomain_637527510331428976" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_637527510331428976" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OptionIndexedToIssuersEquityTypeDomain_637527510331428976" xlink:to="us-gaap_EmployeeStockOptionMember_637527510331428976" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_637527510331428976" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637527510331428976" xlink:to="us-gaap_AwardTypeAxis_637527510331428976" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637527510331428976" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_637527510331428976" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637527510331428976" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_637527510331428976" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637527510331428976" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_637527510331428976" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637527510331428976" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637527510331428976" xlink:to="us-gaap_StatementLineItems_637527510331428976" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_637527510331428976" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637527510331428976" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_637527510331428976" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="extended" xlink:title="40202 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_83" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637527510331428976" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_83" xlink:to="us-gaap_StatementTable_637527510331428976" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_637527510331438969" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637527510331428976" xlink:to="srt_RangeAxis_637527510331438969" order="1" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember_637527510331438969" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_637527510331438969" xlink:to="srt_RangeMember_637527510331438969" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_637527510331438969" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637527510331438969" xlink:to="srt_MaximumMember_637527510331438969" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_637527510331438969" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637527510331438969" xlink:to="srt_MinimumMember_637527510331438969" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_637527510331438969" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637527510331428976" xlink:to="us-gaap_TypeOfArrangementAxis_637527510331438969" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637527510331438969" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_637527510331438969" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637527510331438969" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_BauschLicenseAgreementMember" xlink:label="eyen_BauschLicenseAgreementMember_637527510331438969" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637527510331438969" xlink:to="eyen_BauschLicenseAgreementMember_637527510331438969" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_ArcticVisionLicenseAgreementMember" xlink:label="eyen_ArcticVisionLicenseAgreementMember_637527510331438969" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637527510331438969" xlink:to="eyen_ArcticVisionLicenseAgreementMember_637527510331438969" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637527510331438969" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637527510331428976" xlink:to="us-gaap_StatementLineItems_637527510331438969" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_637527510331438969" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637527510331438969" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_637527510331438969" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_637527510331438969" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637527510331438969" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_637527510331438969" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_637527510331438969" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637527510331438969" xlink:to="us-gaap_NetIncomeLoss_637527510331438969" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_637527510331438969" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637527510331438969" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_637527510331438969" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashUninsuredAmount" xlink:label="us-gaap_CashUninsuredAmount_637527510331438969" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637527510331438969" xlink:to="us-gaap_CashUninsuredAmount_637527510331438969" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_637527510331438969" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637527510331438969" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_637527510331438969" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_LicenseAgreementsTerminationWrittenNoticePeriod" xlink:label="eyen_LicenseAgreementsTerminationWrittenNoticePeriod_637527510331438969" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637527510331438969" xlink:to="eyen_LicenseAgreementsTerminationWrittenNoticePeriod_637527510331438969" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_LicenseAgreementsTerminationPeriodUponUncuredMaterialBreach" xlink:label="eyen_LicenseAgreementsTerminationPeriodUponUncuredMaterialBreach_637527510331448965" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637527510331438969" xlink:to="eyen_LicenseAgreementsTerminationPeriodUponUncuredMaterialBreach_637527510331448965" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_LicenseAgreementsUpfrontPaymentsReceived" xlink:label="eyen_LicenseAgreementsUpfrontPaymentsReceived_637527510331448965" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637527510331438969" xlink:to="eyen_LicenseAgreementsUpfrontPaymentsReceived_637527510331448965" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_LicenseAgreementsMaximumAdditionalPaymentsReceivable" xlink:label="eyen_LicenseAgreementsMaximumAdditionalPaymentsReceivable_637527510331448965" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637527510331438969" xlink:to="eyen_LicenseAgreementsMaximumAdditionalPaymentsReceivable_637527510331448965" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_637527510331448965" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637527510331438969" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_637527510331448965" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:label="us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_637527510331448965" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637527510331438969" xlink:to="us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_637527510331448965" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.eyenoviabio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails" xlink:type="extended" xlink:title="40301 - Disclosure - Prepaid Expenses and Other Current Assets (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsAbstract" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsAbstract_116" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_PayrollTaxesReceivable" xlink:label="eyen_PayrollTaxesReceivable_637527510331448965" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsAbstract_116" xlink:to="eyen_PayrollTaxesReceivable_637527510331448965" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidInsurance" xlink:label="us-gaap_PrepaidInsurance_637527510331448965" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsAbstract_116" xlink:to="us-gaap_PrepaidInsurance_637527510331448965" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_PrepaidResearchAndDevelopmentExpenses" xlink:label="eyen_PrepaidResearchAndDevelopmentExpenses_637527510331448965" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsAbstract_116" xlink:to="eyen_PrepaidResearchAndDevelopmentExpenses_637527510331448965" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_PrepaidLicensesAndSubscriptions" xlink:label="eyen_PrepaidLicensesAndSubscriptions_637527510331448965" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsAbstract_116" xlink:to="eyen_PrepaidLicensesAndSubscriptions_637527510331448965" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_PrepaidPatentExpense" xlink:label="eyen_PrepaidPatentExpense_637527510331448965" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsAbstract_116" xlink:to="eyen_PrepaidPatentExpense_637527510331448965" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_PrepaidConferenceExpenses" xlink:label="eyen_PrepaidConferenceExpenses_637527510331448965" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsAbstract_116" xlink:to="eyen_PrepaidConferenceExpenses_637527510331448965" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_PrepaidDirectorFeesCurrent" xlink:label="eyen_PrepaidDirectorFeesCurrent_637527510331448965" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsAbstract_116" xlink:to="eyen_PrepaidDirectorFeesCurrent_637527510331448965" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_PrepaidRentAndSecurityDeposit" xlink:label="eyen_PrepaidRentAndSecurityDeposit_637527510331458957" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsAbstract_116" xlink:to="eyen_PrepaidRentAndSecurityDeposit_637527510331458957" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssets" xlink:label="us-gaap_OtherAssets_637527510331458957" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsAbstract_116" xlink:to="us-gaap_OtherAssets_637527510331458957" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_637527510331458957" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsAbstract_116" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_637527510331458957" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.eyenoviabio.com/role/DisclosurePropertyAndEquipmentNetPropertyAndEquipmentDetails" xlink:type="extended" xlink:title="40401 - Disclosure - Property and Equipment, Net - Property and Equipment (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_637026734627414064" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637527510331458957" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract_637026734627414064" xlink:to="us-gaap_StatementTable_637527510331458957" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_637527510331458957" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637527510331458957" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_637527510331458957" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_637527510331458957" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_637527510331458957" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_637527510331458957" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember_637527510331458957" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_637527510331458957" xlink:to="us-gaap_EquipmentMember_637527510331458957" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember_637527510331458957" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_637527510331458957" xlink:to="us-gaap_LeaseholdImprovementsMember_637527510331458957" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637527510331458957" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637527510331458957" xlink:to="us-gaap_StatementLineItems_637527510331458957" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_637527510331458957" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637527510331458957" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_637527510331458957" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_637527510331458957" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637527510331458957" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_637527510331458957" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_637527510331458957" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637527510331458957" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_637527510331458957" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.eyenoviabio.com/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetails" xlink:type="extended" xlink:title="40402 - Disclosure - Property and Equipment, Net - Additional Information (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_637026734627435437" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637527510331458957" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract_637026734627435437" xlink:to="us-gaap_StatementTable_637527510331458957" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis_637527510331458957" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637527510331458957" xlink:to="us-gaap_FairValueByAssetClassAxis_637527510331458957" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_637527510331458957" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis_637527510331458957" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_637527510331458957" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentMember" xlink:label="us-gaap_PropertyPlantAndEquipmentMember_637527510331458957" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_637527510331458957" xlink:to="us-gaap_PropertyPlantAndEquipmentMember_637527510331458957" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637527510331468966" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637527510331458957" xlink:to="us-gaap_StatementLineItems_637527510331468966" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization_637527510331468966" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637527510331468966" xlink:to="us-gaap_DepreciationDepletionAndAmortization_637527510331468966" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_637527510331468966" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637527510331468966" xlink:to="us-gaap_ResearchAndDevelopmentExpense_637527510331468966" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense_637527510331468966" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637527510331468966" xlink:to="us-gaap_GeneralAndAdministrativeExpense_637527510331468966" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.eyenoviabio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:type="extended" xlink:title="40501 - Disclosure - Accrued Expenses and Other Current Liabilities (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_122" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_AccruedResearchAndDevelopmentExpensesCurrent" xlink:label="eyen_AccruedResearchAndDevelopmentExpensesCurrent_637527510331468966" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_122" xlink:to="eyen_AccruedResearchAndDevelopmentExpensesCurrent_637527510331468966" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_AccruedConsultingAndProfessionalServicesCurrent" xlink:label="eyen_AccruedConsultingAndProfessionalServicesCurrent_637527510331468966" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_122" xlink:to="eyen_AccruedConsultingAndProfessionalServicesCurrent_637527510331468966" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_CreditCardPayable" xlink:label="eyen_CreditCardPayable_637527510331468966" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_122" xlink:to="eyen_CreditCardPayable_637527510331468966" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_LeaseholdImprovements" xlink:label="eyen_LeaseholdImprovements_637527510331468966" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_122" xlink:to="eyen_LeaseholdImprovements_637527510331468966" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_AccruedFranchiseTax" xlink:label="eyen_AccruedFranchiseTax_637527510331468966" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_122" xlink:to="eyen_AccruedFranchiseTax_637527510331468966" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_AccruedTravelAndEntertainmentExpenses" xlink:label="eyen_AccruedTravelAndEntertainmentExpenses_637527510331468966" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_122" xlink:to="eyen_AccruedTravelAndEntertainmentExpenses_637527510331468966" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_AccruedLicensingFees" xlink:label="eyen_AccruedLicensingFees_637527510331468966" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_122" xlink:to="eyen_AccruedLicensingFees_637527510331468966" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:label="us-gaap_InterestPayableCurrent_637527510331468966" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_122" xlink:to="us-gaap_InterestPayableCurrent_637527510331468966" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_AccruedExpenseReimbursements" xlink:label="eyen_AccruedExpenseReimbursements_637527510331468966" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_122" xlink:to="eyen_AccruedExpenseReimbursements_637527510331468966" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_AccruedShippingAndPackagingFees" xlink:label="eyen_AccruedShippingAndPackagingFees_637527510331468966" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_122" xlink:to="eyen_AccruedShippingAndPackagingFees_637527510331468966" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_637527510331468966" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_122" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_637527510331468966" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities_637527510331468966" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_122" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities_637527510331468966" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.eyenoviabio.com/role/DisclosureAccruedCompensationDetails" xlink:type="extended" xlink:title="40601 - Disclosure - Accrued Compensation (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationRelatedCostsAbstract" xlink:label="loc_us-gaap_CompensationRelatedCostsAbstract_368367" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedBonusesCurrent" xlink:label="us-gaap_AccruedBonusesCurrent_637527510331478954" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationRelatedCostsAbstract_368367" xlink:to="us-gaap_AccruedBonusesCurrent_637527510331478954" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedSalariesCurrent" xlink:label="us-gaap_AccruedSalariesCurrent_637527510331478954" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationRelatedCostsAbstract_368367" xlink:to="us-gaap_AccruedSalariesCurrent_637527510331478954" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_637527510331478954" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationRelatedCostsAbstract_368367" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_637527510331478954" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.eyenoviabio.com/role/DisclosureNotesPayableScheduleOfNotesPayableDetails" xlink:type="extended" xlink:title="40701 - Disclosure - Notes Payable - Schedule of notes payable (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayableAbstract" xlink:label="us-gaap_NotesPayableAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637527510331478954" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NotesPayableAbstract" xlink:to="us-gaap_StatementTable_637527510331478954" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_637527510331478954" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637527510331478954" xlink:to="us-gaap_DebtInstrumentAxis_637527510331478954" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_637527510331478954" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_637527510331478954" xlink:to="us-gaap_DebtInstrumentNameDomain_637527510331478954" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_PaycheckProtectionProgramLoanMember" xlink:label="eyen_PaycheckProtectionProgramLoanMember_637527510331478954" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_637527510331478954" xlink:to="eyen_PaycheckProtectionProgramLoanMember_637527510331478954" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637527510331478954" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637527510331478954" xlink:to="us-gaap_StatementLineItems_637527510331478954" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="us-gaap_NotesPayableCurrent_637527510331478954" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637527510331478954" xlink:to="us-gaap_NotesPayableCurrent_637527510331478954" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermNotesPayable" xlink:label="us-gaap_LongTermNotesPayable_637527510331478954" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637527510331478954" xlink:to="us-gaap_LongTermNotesPayable_637527510331478954" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayable" xlink:label="us-gaap_NotesPayable_637527510331478954" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637527510331478954" xlink:to="us-gaap_NotesPayable_637527510331478954" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="5" />
  </presentationLink>
  <presentationLink xlink:role="http://www.eyenoviabio.com/role/DisclosureNotesPayableAdditionalInformationDetails" xlink:type="extended" xlink:title="40702 - Disclosure - Notes Payable - Additional Information (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayableAbstract" xlink:label="us-gaap_NotesPayableAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="us-gaap_ScheduleOfShortTermDebtTable_637527510331478954" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NotesPayableAbstract" xlink:to="us-gaap_ScheduleOfShortTermDebtTable_637527510331478954" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="us-gaap_ShortTermDebtTypeAxis_637527510331478954" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShortTermDebtTable_637527510331478954" xlink:to="us-gaap_ShortTermDebtTypeAxis_637527510331478954" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="us-gaap_ShortTermDebtTypeDomain_637527510331478954" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeAxis_637527510331478954" xlink:to="us-gaap_ShortTermDebtTypeDomain_637527510331478954" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayableOtherPayablesMember" xlink:label="us-gaap_NotesPayableOtherPayablesMember_637527510331478954" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeDomain_637527510331478954" xlink:to="us-gaap_NotesPayableOtherPayablesMember_637527510331478954" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_PaycheckProtectionProgramLoanMember" xlink:label="eyen_PaycheckProtectionProgramLoanMember_637527510331488962" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeDomain_637527510331478954" xlink:to="eyen_PaycheckProtectionProgramLoanMember_637527510331488962" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_637527510331488962" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShortTermDebtTable_637527510331478954" xlink:to="srt_RangeAxis_637527510331488962" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember_637527510331488962" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_637527510331488962" xlink:to="srt_RangeMember_637527510331488962" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_637527510331488962" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637527510331488962" xlink:to="srt_MinimumMember_637527510331488962" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_637527510331488962" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637527510331488962" xlink:to="srt_MaximumMember_637527510331488962" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="us-gaap_ShortTermDebtLineItems_637527510331488962" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShortTermDebtTable_637527510331478954" xlink:to="us-gaap_ShortTermDebtLineItems_637527510331488962" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_NumberOfMonthlyPayments" xlink:label="eyen_NumberOfMonthlyPayments_637527510331488962" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtLineItems_637527510331488962" xlink:to="eyen_NumberOfMonthlyPayments_637527510331488962" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentPeriodicPayment" xlink:label="us-gaap_DebtInstrumentPeriodicPayment_637527510331488962" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtLineItems_637527510331488962" xlink:to="us-gaap_DebtInstrumentPeriodicPayment_637527510331488962" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAnnualPrincipalPayment" xlink:label="us-gaap_DebtInstrumentAnnualPrincipalPayment_637527510331488962" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtLineItems_637527510331488962" xlink:to="us-gaap_DebtInstrumentAnnualPrincipalPayment_637527510331488962" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_637527510331488962" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtLineItems_637527510331488962" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_637527510331488962" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="us-gaap_RepaymentsOfNotesPayable_637527510331488962" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtLineItems_637527510331488962" xlink:to="us-gaap_RepaymentsOfNotesPayable_637527510331488962" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromLongTermLinesOfCredit" xlink:label="us-gaap_ProceedsFromLongTermLinesOfCredit_637527510331488962" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtLineItems_637527510331488962" xlink:to="us-gaap_ProceedsFromLongTermLinesOfCredit_637527510331488962" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_PeriodConsideredForUsageOfLoanProceedsFromFundingDate" xlink:label="eyen_PeriodConsideredForUsageOfLoanProceedsFromFundingDate_637527510331488962" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtLineItems_637527510331488962" xlink:to="eyen_PeriodConsideredForUsageOfLoanProceedsFromFundingDate_637527510331488962" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_PercentageOfInterestOnAmountWhichIsNotForgiven" xlink:label="eyen_PercentageOfInterestOnAmountWhichIsNotForgiven_637527510331488962" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtLineItems_637527510331488962" xlink:to="eyen_PercentageOfInterestOnAmountWhichIsNotForgiven_637527510331488962" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="us-gaap_DebtInstrumentTerm_637527510331488962" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtLineItems_637527510331488962" xlink:to="us-gaap_DebtInstrumentTerm_637527510331488962" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt_637527510331488962" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtLineItems_637527510331488962" xlink:to="us-gaap_InterestExpenseDebt_637527510331488962" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.eyenoviabio.com/role/DisclosureIncomeTaxesProvisionForIncomeTaxesDetails" xlink:type="extended" xlink:title="40801 - Disclosure - Income Taxes - provision for income taxes (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_637026734627435437" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_637527510331498953" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637026734627435437" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_637527510331498953" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_637527510331498953" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_637527510331498953" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_637527510331498953" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_637527510331498953" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_637527510331498953" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_637527510331498953" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_DeferredIncomeTaxExpenseBenefitBeforeAdjustmentsForChangeInValuationAllowance" xlink:label="eyen_DeferredIncomeTaxExpenseBenefitBeforeAdjustmentsForChangeInValuationAllowance_637527510331498953" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_637527510331498953" xlink:to="eyen_DeferredIncomeTaxExpenseBenefitBeforeAdjustmentsForChangeInValuationAllowance_637527510331498953" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_637527510331498953" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637026734627435437" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_637527510331498953" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_637527510331498953" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637026734627435437" xlink:to="us-gaap_IncomeTaxExpenseBenefit_637527510331498953" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.eyenoviabio.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxRateReconciliationDetails" xlink:type="extended" xlink:title="40802 - Disclosure - Income Taxes - Effective income tax rate reconciliation (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_637026734627435437" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_EffectiveIncomeTaxRateReconciliationNetAtFederalStatutoryIncomeTaxRate" xlink:label="eyen_EffectiveIncomeTaxRateReconciliationNetAtFederalStatutoryIncomeTaxRate_637527510331498953" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637026734627435437" xlink:to="eyen_EffectiveIncomeTaxRateReconciliationNetAtFederalStatutoryIncomeTaxRate_637527510331498953" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_637527510331498953" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637026734627435437" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_637527510331498953" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_637527510331498953" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637026734627435437" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_637527510331498953" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_637527510331498953" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637026734627435437" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_637527510331498953" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes_637527510331498953" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637026734627435437" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes_637527510331498953" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_637527510331498953" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637026734627435437" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_637527510331498953" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.eyenoviabio.com/role/DisclosureIncomeTaxesDeferredTaxAssetsDetails" xlink:type="extended" xlink:title="40803 - Disclosure - Income Taxes - Deferred tax assets (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_637026734627435437" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract_637527510331498953" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637026734627435437" xlink:to="us-gaap_DeferredTaxAssetsNetAbstract_637527510331498953" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_637527510331498953" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract_637527510331498953" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_637527510331498953" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_637527510331498953" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract_637527510331498953" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_637527510331498953" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_637527510331498953" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract_637527510331498953" xlink:to="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_637527510331498953" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_637527510331508947" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract_637527510331498953" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_637527510331508947" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross_637527510331508947" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract_637527510331498953" xlink:to="us-gaap_DeferredTaxAssetsGross_637527510331508947" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_DeferredTaxAssetsLiabilityPropertyAndEquipment" xlink:label="eyen_DeferredTaxAssetsLiabilityPropertyAndEquipment_637527510331508947" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract_637527510331498953" xlink:to="eyen_DeferredTaxAssetsLiabilityPropertyAndEquipment_637527510331508947" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_DeferredTaxAssetsNetBeforeValuationAllowance" xlink:label="eyen_DeferredTaxAssetsNetBeforeValuationAllowance_637527510331508947" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract_637527510331498953" xlink:to="eyen_DeferredTaxAssetsNetBeforeValuationAllowance_637527510331508947" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_637527510331508947" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract_637527510331498953" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_637527510331508947" order="8" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet_637527510331508947" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract_637527510331498953" xlink:to="us-gaap_DeferredTaxAssetsNet_637527510331508947" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.eyenoviabio.com/role/DisclosureIncomeTaxesAdditionalInformationDetails" xlink:type="extended" xlink:title="40804 - Disclosure - Income Taxes - Additional information (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_637026734627435437" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637527510331508947" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637026734627435437" xlink:to="us-gaap_StatementTable_637527510331508947" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis_637527510331508947" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637527510331508947" xlink:to="srt_StatementGeographicalAxis_637527510331508947" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_637527510331508947" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis_637527510331508947" xlink:to="srt_SegmentGeographicalDomain_637527510331508947" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_NY" xlink:label="stpr_NY_637527510331508947" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain_637527510331508947" xlink:to="stpr_NY_637527510331508947" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637527510331508947" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637527510331508947" xlink:to="us-gaap_StatementLineItems_637527510331508947" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards_637527510331508947" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637527510331508947" xlink:to="us-gaap_OperatingLossCarryforwards_637527510331508947" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_NetOperatingLossLimitForUtilizationAsPerInternalRevenueCode" xlink:label="eyen_NetOperatingLossLimitForUtilizationAsPerInternalRevenueCode_637527510331508947" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637527510331508947" xlink:to="eyen_NetOperatingLossLimitForUtilizationAsPerInternalRevenueCode_637527510331508947" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_NetOperatingLossAnnualUtilizationLimitAsPerInternalRevenueCode" xlink:label="eyen_NetOperatingLossAnnualUtilizationLimitAsPerInternalRevenueCode_637527510331508947" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637527510331508947" xlink:to="eyen_NetOperatingLossAnnualUtilizationLimitAsPerInternalRevenueCode_637527510331508947" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_OperatingLossCarryForwardsExpirationTerm" xlink:label="eyen_OperatingLossCarryForwardsExpirationTerm_637527510331508947" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637527510331508947" xlink:to="eyen_OperatingLossCarryForwardsExpirationTerm_637527510331508947" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_637527510331508947" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637527510331508947" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_637527510331508947" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_637527510331518933" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637527510331508947" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_637527510331518933" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_637527510331518933" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637527510331508947" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_637527510331518933" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.eyenoviabio.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumPaymentsUnderOperatingLeaseAgreementDetails" xlink:type="extended" xlink:title="40901 - Disclosure - Commitments and Contingencies - Future Minimum Payments under Operating Lease Agreement (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_637026734627591739" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_637527510331518933" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_637026734627591739" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_637527510331518933" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_637527510331518933" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_637026734627591739" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_637527510331518933" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_637527510331518933" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_637026734627591739" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_637527510331518933" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_637527510331518933" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_637026734627591739" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_637527510331518933" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.eyenoviabio.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:type="extended" xlink:title="40902 - Disclosure - Commitments and Contingencies - Additional Information (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_637026734627591739" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637527510331518933" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_637026734627591739" xlink:to="us-gaap_StatementTable_637527510331518933" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_637527510331518933" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637527510331518933" xlink:to="srt_RangeAxis_637527510331518933" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember_637527510331518933" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_637527510331518933" xlink:to="srt_RangeMember_637527510331518933" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_637527510331518933" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637527510331518933" xlink:to="srt_MinimumMember_637527510331518933" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_637527510331518933" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637527510331518933" xlink:to="srt_MaximumMember_637527510331518933" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_637527510331518933" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637527510331518933" xlink:to="us-gaap_TypeOfArrangementAxis_637527510331518933" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637527510331518933" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_637527510331518933" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637527510331518933" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_ArcticVisionLicenseAgreementMember" xlink:label="eyen_ArcticVisionLicenseAgreementMember_637527510331518933" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637527510331518933" xlink:to="eyen_ArcticVisionLicenseAgreementMember_637527510331518933" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_BauschLicenseAgreementMember" xlink:label="eyen_BauschLicenseAgreementMember_637527510331518933" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637527510331518933" xlink:to="eyen_BauschLicenseAgreementMember_637527510331518933" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_637527510331528924" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637527510331518933" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_637527510331528924" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_637527510331528924" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_637527510331528924" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_637527510331528924" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_AdditionalOfficeSpaceMember" xlink:label="eyen_AdditionalOfficeSpaceMember_637527510331528924" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_637527510331528924" xlink:to="eyen_AdditionalOfficeSpaceMember_637527510331528924" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637527510331528924" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637527510331518933" xlink:to="us-gaap_StatementLineItems_637527510331528924" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetRentableArea" xlink:label="us-gaap_NetRentableArea_637527510331528924" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637527510331528924" xlink:to="us-gaap_NetRentableArea_637527510331528924" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_LeaseMonthlyBaseRent" xlink:label="eyen_LeaseMonthlyBaseRent_637527510331528924" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637527510331528924" xlink:to="eyen_LeaseMonthlyBaseRent_637527510331528924" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseExpirationDate1" xlink:label="us-gaap_LeaseExpirationDate1_637527510331528924" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637527510331528924" xlink:to="us-gaap_LeaseExpirationDate1_637527510331528924" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SecurityDeposit" xlink:label="us-gaap_SecurityDeposit_637527510331528924" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637527510331528924" xlink:to="us-gaap_SecurityDeposit_637527510331528924" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_LicenseAgreementsUpfrontPaymentsReceived" xlink:label="eyen_LicenseAgreementsUpfrontPaymentsReceived_637527510331528924" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637527510331528924" xlink:to="eyen_LicenseAgreementsUpfrontPaymentsReceived_637527510331528924" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_LicenseAgreementsMaximumAdditionalPaymentsReceivable" xlink:label="eyen_LicenseAgreementsMaximumAdditionalPaymentsReceivable_637527510331528924" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637527510331528924" xlink:to="eyen_LicenseAgreementsMaximumAdditionalPaymentsReceivable_637527510331528924" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_LicenseAgreementsTerminationWrittenNoticePeriod" xlink:label="eyen_LicenseAgreementsTerminationWrittenNoticePeriod_637527510331528924" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637527510331528924" xlink:to="eyen_LicenseAgreementsTerminationWrittenNoticePeriod_637527510331528924" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_LicenseAgreementsTerminationPeriodUponUncuredMaterialBreach" xlink:label="eyen_LicenseAgreementsTerminationPeriodUponUncuredMaterialBreach_637527510331528924" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637527510331528924" xlink:to="eyen_LicenseAgreementsTerminationPeriodUponUncuredMaterialBreach_637527510331528924" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeveranceCosts1" xlink:label="us-gaap_SeveranceCosts1_637527510331528924" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637527510331528924" xlink:to="us-gaap_SeveranceCosts1_637527510331528924" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalUnemploymentBenefitsSalaryContinuation" xlink:label="us-gaap_SupplementalUnemploymentBenefitsSalaryContinuation_637527510331528924" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637527510331528924" xlink:to="us-gaap_SupplementalUnemploymentBenefitsSalaryContinuation_637527510331528924" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized" xlink:label="us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized_637527510331528924" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637527510331528924" xlink:to="us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized_637527510331528924" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_RoyaltyRevenuePayments" xlink:label="eyen_RoyaltyRevenuePayments_637527510331528924" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637527510331528924" xlink:to="eyen_RoyaltyRevenuePayments_637527510331528924" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_MilestoneRevenuePayments" xlink:label="eyen_MilestoneRevenuePayments_637527510331538918" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637527510331528924" xlink:to="eyen_MilestoneRevenuePayments_637527510331538918" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.eyenoviabio.com/role/DisclosureRelatedPartyTransactionsDetails" xlink:type="extended" xlink:title="41001 - Disclosure - Related Party Transactions (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_161" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637527510331538918" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_161" xlink:to="us-gaap_StatementTable_637527510331538918" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_637527510331538918" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637527510331538918" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_637527510331538918" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_637527510331538918" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_637527510331538918" xlink:to="us-gaap_RelatedPartyDomain_637527510331538918" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_CuraPartnersMember" xlink:label="eyen_CuraPartnersMember_637527510331538918" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain_637527510331538918" xlink:to="eyen_CuraPartnersMember_637527510331538918" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis_637527510331538918" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637527510331538918" xlink:to="us-gaap_IncomeStatementLocationAxis_637527510331538918" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_637527510331538918" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis_637527510331538918" xlink:to="us-gaap_IncomeStatementLocationDomain_637527510331538918" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_637527510331538918" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_637527510331538918" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_637527510331538918" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_637527510331538918" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_637527510331538918" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_637527510331538918" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis_637527510331538918" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637527510331538918" xlink:to="us-gaap_RelatedPartyTransactionAxis_637527510331538918" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain_637527510331538918" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis_637527510331538918" xlink:to="us-gaap_RelatedPartyTransactionDomain_637527510331538918" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_ConsultingAgreementMember" xlink:label="eyen_ConsultingAgreementMember_637527510331538918" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain_637527510331538918" xlink:to="eyen_ConsultingAgreementMember_637527510331538918" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_VicePresidentOfResearchAndDevelopmentMember" xlink:label="eyen_VicePresidentOfResearchAndDevelopmentMember_637527510331538918" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain_637527510331538918" xlink:to="eyen_VicePresidentOfResearchAndDevelopmentMember_637527510331538918" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_SenjuPharmaceuticalCoMember" xlink:label="eyen_SenjuPharmaceuticalCoMember_637527510331538918" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain_637527510331538918" xlink:to="eyen_SenjuPharmaceuticalCoMember_637527510331538918" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipAxis" xlink:label="srt_OwnershipAxis_637527510331538918" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637527510331538918" xlink:to="srt_OwnershipAxis_637527510331538918" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipDomain" xlink:label="srt_OwnershipDomain_637527510331548923" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis_637527510331538918" xlink:to="srt_OwnershipDomain_637527510331548923" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_LicenseAgreementMember" xlink:label="eyen_LicenseAgreementMember_637527510331548923" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipDomain_637527510331548923" xlink:to="eyen_LicenseAgreementMember_637527510331548923" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_637527510331548923" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637527510331538918" xlink:to="us-gaap_TypeOfArrangementAxis_637527510331548923" order="5" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637527510331548923" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_637527510331548923" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637527510331548923" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_ArcticVisionLicenseAgreementMember" xlink:label="eyen_ArcticVisionLicenseAgreementMember_637527510331548923" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637527510331548923" xlink:to="eyen_ArcticVisionLicenseAgreementMember_637527510331548923" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_637527510331548923" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637527510331538918" xlink:to="us-gaap_StatementEquityComponentsAxis_637527510331548923" order="6" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_637527510331548923" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637527510331548923" xlink:to="us-gaap_EquityComponentDomain_637527510331548923" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_ClassWarrantsMember" xlink:label="eyen_ClassWarrantsMember_637527510331548923" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain_637527510331548923" xlink:to="eyen_ClassWarrantsMember_637527510331548923" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_ClassBWarrantsMember" xlink:label="eyen_ClassBWarrantsMember_637527510331548923" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain_637527510331548923" xlink:to="eyen_ClassBWarrantsMember_637527510331548923" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_637527510331548923" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637527510331538918" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_637527510331548923" order="7" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_637527510331548923" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_637527510331548923" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_637527510331548923" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember_637527510331548923" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_637527510331548923" xlink:to="us-gaap_IPOMember_637527510331548923" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637527510331548923" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637527510331538918" xlink:to="us-gaap_StatementLineItems_637527510331548923" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_637527510331548923" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637527510331548923" xlink:to="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_637527510331548923" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_ConsultingAgreementPaymentPermonth" xlink:label="eyen_ConsultingAgreementPaymentPermonth_637527510331558916" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637527510331548923" xlink:to="eyen_ConsultingAgreementPaymentPermonth_637527510331558916" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_ConsultingAgreementPaymentPerhour" xlink:label="eyen_ConsultingAgreementPaymentPerhour_637527510331558916" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637527510331548923" xlink:to="eyen_ConsultingAgreementPaymentPerhour_637527510331558916" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_CostOfServicesEngineeringServices" xlink:label="eyen_CostOfServicesEngineeringServices_637527510331558916" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637527510331548923" xlink:to="eyen_CostOfServicesEngineeringServices_637527510331558916" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetRentableArea" xlink:label="us-gaap_NetRentableArea_637527510331558916" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637527510331548923" xlink:to="us-gaap_NetRentableArea_637527510331558916" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_LeaseMonthlyBaseRent" xlink:label="eyen_LeaseMonthlyBaseRent_637527510331558916" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637527510331548923" xlink:to="eyen_LeaseMonthlyBaseRent_637527510331558916" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="us-gaap_LeaseAndRentalExpense_637527510331558916" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637527510331548923" xlink:to="us-gaap_LeaseAndRentalExpense_637527510331558916" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SecurityDeposit" xlink:label="us-gaap_SecurityDeposit_637527510331558916" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637527510331548923" xlink:to="us-gaap_SecurityDeposit_637527510331558916" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OfficersCompensation" xlink:label="us-gaap_OfficersCompensation_637527510331558916" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637527510331548923" xlink:to="us-gaap_OfficersCompensation_637527510331558916" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsGross" xlink:label="us-gaap_LeaseholdImprovementsGross_637527510331558916" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637527510331548923" xlink:to="us-gaap_LeaseholdImprovementsGross_637527510331558916" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:label="us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_637527510331558916" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637527510331548923" xlink:to="us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_637527510331558916" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_637527510331558916" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637527510331548923" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_637527510331558916" order="12" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_RoyaltyPercentage" xlink:label="eyen_RoyaltyPercentage_637527510331568909" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637527510331548923" xlink:to="eyen_RoyaltyPercentage_637527510331568909" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_637527510331568909" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637527510331548923" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_637527510331568909" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_PaymentsForLicenseCosts" xlink:label="eyen_PaymentsForLicenseCosts_637527510331568909" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637527510331548923" xlink:to="eyen_PaymentsForLicenseCosts_637527510331568909" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_637527510331568909" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637527510331548923" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_637527510331568909" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare_637527510331568909" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637527510331548923" xlink:to="us-gaap_SharesIssuedPricePerShare_637527510331568909" order="17" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_GrossProceedsOfStockValueIssuedDuringPeriod" xlink:label="eyen_GrossProceedsOfStockValueIssuedDuringPeriod_637527510331568909" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637527510331548923" xlink:to="eyen_GrossProceedsOfStockValueIssuedDuringPeriod_637527510331568909" order="18" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_NetProceedsFromIssuanceOfCommonStock" xlink:label="eyen_NetProceedsFromIssuanceOfCommonStock_637527510331568909" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637527510331548923" xlink:to="eyen_NetProceedsFromIssuanceOfCommonStock_637527510331568909" order="19" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_637527510331568909" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637527510331548923" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_637527510331568909" order="20" use="optional" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.eyenoviabio.com/role/DisclosureStockholdersEquityWarrantsActivityDetails" xlink:type="extended" xlink:title="41101 - Disclosure - Stockholders' Equity - Warrants Activity (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_ClassOfWarrantsOrRightsOutstandingRollforward" xlink:label="eyen_ClassOfWarrantsOrRightsOutstandingRollforward_637527510331578903" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="eyen_ClassOfWarrantsOrRightsOutstandingRollforward_637527510331578903" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_637527510331578903" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eyen_ClassOfWarrantsOrRightsOutstandingRollforward_637527510331578903" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_637527510331578903" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_ClassOfWarrantOrRightGranted" xlink:label="eyen_ClassOfWarrantOrRightGranted_637527510331578903" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eyen_ClassOfWarrantsOrRightsOutstandingRollforward_637527510331578903" xlink:to="eyen_ClassOfWarrantOrRightGranted_637527510331578903" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_ClassOfWarrantOrRightExercised" xlink:label="eyen_ClassOfWarrantOrRightExercised_637527510331578903" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eyen_ClassOfWarrantsOrRightsOutstandingRollforward_637527510331578903" xlink:to="eyen_ClassOfWarrantOrRightExercised_637527510331578903" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_6375275103315789031" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eyen_ClassOfWarrantsOrRightsOutstandingRollforward_637527510331578903" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_6375275103315789031" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_ClassOfWarrantOrRightExercisable" xlink:label="eyen_ClassOfWarrantOrRightExercisable_637527510331578903" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eyen_ClassOfWarrantsOrRightsOutstandingRollforward_637527510331578903" xlink:to="eyen_ClassOfWarrantOrRightExercisable_637527510331578903" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_ClassOfWarrantsOrRightsWeightedAverageExercisePriceRollforward" xlink:label="eyen_ClassOfWarrantsOrRightsWeightedAverageExercisePriceRollforward_637527510331578903" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="eyen_ClassOfWarrantsOrRightsWeightedAverageExercisePriceRollforward_637527510331578903" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice" xlink:label="eyen_ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice_637527510331578903" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eyen_ClassOfWarrantsOrRightsWeightedAverageExercisePriceRollforward_637527510331578903" xlink:to="eyen_ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice_637527510331578903" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_ClassOfWarrantOrRightGrantedWeightedAverageExercisePrice" xlink:label="eyen_ClassOfWarrantOrRightGrantedWeightedAverageExercisePrice_637527510331578903" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eyen_ClassOfWarrantsOrRightsWeightedAverageExercisePriceRollforward_637527510331578903" xlink:to="eyen_ClassOfWarrantOrRightGrantedWeightedAverageExercisePrice_637527510331578903" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_ClassOfWarrantOrRightExercisedWeightedAverageExercisePrice" xlink:label="eyen_ClassOfWarrantOrRightExercisedWeightedAverageExercisePrice_637527510331578903" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eyen_ClassOfWarrantsOrRightsWeightedAverageExercisePriceRollforward_637527510331578903" xlink:to="eyen_ClassOfWarrantOrRightExercisedWeightedAverageExercisePrice_637527510331578903" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice" xlink:label="eyen_ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice_6375275103315789031" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eyen_ClassOfWarrantsOrRightsWeightedAverageExercisePriceRollforward_637527510331578903" xlink:to="eyen_ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice_6375275103315789031" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice" xlink:label="eyen_ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice_637527510331578903" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eyen_ClassOfWarrantsOrRightsWeightedAverageExercisePriceRollforward_637527510331578903" xlink:to="eyen_ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice_637527510331578903" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_ClassOfWarrantOrRightOutstandingWeightedAverageRemainingLife" xlink:label="eyen_ClassOfWarrantOrRightOutstandingWeightedAverageRemainingLife_637527510331578903" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="eyen_ClassOfWarrantOrRightOutstandingWeightedAverageRemainingLife_637527510331578903" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_ClassOfWarrantOrRightExercisableWeightedAverageRemainingLife" xlink:label="eyen_ClassOfWarrantOrRightExercisableWeightedAverageRemainingLife_637527510331578903" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="eyen_ClassOfWarrantOrRightExercisableWeightedAverageRemainingLife_637527510331578903" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_ClassOfWarrantOrRightOutstandingAggregateIntrinsicValue" xlink:label="eyen_ClassOfWarrantOrRightOutstandingAggregateIntrinsicValue_637527510331578903" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="eyen_ClassOfWarrantOrRightOutstandingAggregateIntrinsicValue_637527510331578903" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_ClassOfWarrantOrRightExercisableAggregateIntrinsicValue" xlink:label="eyen_ClassOfWarrantOrRightExercisableAggregateIntrinsicValue_637527510331578903" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="eyen_ClassOfWarrantOrRightExercisableAggregateIntrinsicValue_637527510331578903" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.eyenoviabio.com/role/DisclosureStockholdersEquityAdditionalInformationRelatedToWarrantsDetails" xlink:type="extended" xlink:title="41102 - Disclosure - Stockholders' Equity - Additional information related to Warrants (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable_637527510331588898" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightTable_637527510331588898" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_637527510331588898" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable_637527510331588898" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_637527510331588898" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_637527510331588898" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_637527510331588898" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_637527510331588898" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_WarrantsAtExercisePriceOneMember" xlink:label="eyen_WarrantsAtExercisePriceOneMember_637527510331588898" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_637527510331588898" xlink:to="eyen_WarrantsAtExercisePriceOneMember_637527510331588898" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_WarrantsAtExercisePriceTwoMember" xlink:label="eyen_WarrantsAtExercisePriceTwoMember_637527510331588898" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_637527510331588898" xlink:to="eyen_WarrantsAtExercisePriceTwoMember_637527510331588898" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_WarrantsAtExercisePriceThreeMember" xlink:label="eyen_WarrantsAtExercisePriceThreeMember_637527510331588898" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_637527510331588898" xlink:to="eyen_WarrantsAtExercisePriceThreeMember_637527510331588898" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_WarrantsAtExercisePriceFourMember" xlink:label="eyen_WarrantsAtExercisePriceFourMember_637527510331588898" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_637527510331588898" xlink:to="eyen_WarrantsAtExercisePriceFourMember_637527510331588898" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_637527510331588898" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable_637527510331588898" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems_637527510331588898" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_637527510331588898" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_637527510331588898" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_637527510331588898" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_637527510331588898" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_637527510331588898" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_637527510331588898" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_ClassOfWarrantOrRightExercisableWeightedAverageRemainingLife" xlink:label="eyen_ClassOfWarrantOrRightExercisableWeightedAverageRemainingLife_637527510331588898" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_637527510331588898" xlink:to="eyen_ClassOfWarrantOrRightExercisableWeightedAverageRemainingLife_637527510331588898" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_ClassOfWarrantOrRightExercisable" xlink:label="eyen_ClassOfWarrantOrRightExercisable_637527510331588898" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_637527510331588898" xlink:to="eyen_ClassOfWarrantOrRightExercisable_637527510331588898" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_ClassOfWarrantOrRightExercised" xlink:label="eyen_ClassOfWarrantOrRightExercised_637527510331588898" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_637527510331588898" xlink:to="eyen_ClassOfWarrantOrRightExercised_637527510331588898" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises_637527510331588898" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_637527510331588898" xlink:to="us-gaap_ProceedsFromWarrantExercises_637527510331588898" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
  </presentationLink>
  <presentationLink xlink:role="http://www.eyenoviabio.com/role/DisclosureStockholdersEquityBlackScholesOptionDetails" xlink:type="extended" xlink:title="41103 - Disclosure - Stockholders' Equity - Black Scholes option (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_224669" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637527510331598892" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_224669" xlink:to="us-gaap_StatementTable_637527510331598892" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_637527510331598892" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637527510331598892" xlink:to="srt_RangeAxis_637527510331598892" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember_637527510331598892" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_637527510331598892" xlink:to="srt_RangeMember_637527510331598892" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_637527510331598892" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637527510331598892" xlink:to="srt_MinimumMember_637527510331598892" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_637527510331598892" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637527510331598892" xlink:to="srt_MaximumMember_637527510331598892" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637527510331598892" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637527510331598892" xlink:to="us-gaap_StatementLineItems_637527510331598892" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_637527510331598892" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637527510331598892" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_637527510331598892" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_637527510331598892" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637527510331598892" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_637527510331598892" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_637527510331598892" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637527510331598892" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_637527510331598892" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_637527510331598892" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637527510331598892" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_637527510331598892" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.eyenoviabio.com/role/DisclosureStockholdersEquitySummaryOfOptionActivityDetails" xlink:type="extended" xlink:title="41104 - Disclosure - Stockholders' Equity - Summary of option activity (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_224721" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637527510331608865" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_224721" xlink:to="us-gaap_StatementTable_637527510331608865" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="us-gaap_DerivativeInstrumentRiskAxis_637527510331608865" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637527510331608865" xlink:to="us-gaap_DerivativeInstrumentRiskAxis_637527510331608865" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="us-gaap_DerivativeContractTypeDomain_637527510331608865" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentRiskAxis_637527510331608865" xlink:to="us-gaap_DerivativeContractTypeDomain_637527510331608865" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockOptionMember" xlink:label="us-gaap_StockOptionMember_637527510331608865" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeContractTypeDomain_637527510331608865" xlink:to="us-gaap_StockOptionMember_637527510331608865" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637527510331608865" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637527510331608865" xlink:to="us-gaap_StatementLineItems_637527510331608865" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_637527510331608865" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637527510331608865" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_637527510331608865" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_637527510331608865" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637527510331608865" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_637527510331608865" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_637527510331608865" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637527510331608865" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_637527510331608865" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_637527510331608865" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637527510331608865" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_637527510331608865" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6375275103316088651" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637527510331608865" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6375275103316088651" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_637527510331608865" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637527510331608865" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_637527510331608865" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_637527510331608865" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637527510331608865" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_637527510331608865" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_637527510331608865" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637527510331608865" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_637527510331608865" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_637527510331608865" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637527510331608865" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_637527510331608865" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_637527510331608865" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637527510331608865" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_637527510331608865" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_637527510331618858" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637527510331608865" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_637527510331618858" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_637527510331618858" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637527510331608865" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_637527510331618858" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_637527510331618858" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637527510331608865" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_637527510331618858" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_637527510331618858" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637527510331608865" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_637527510331618858" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_637527510331638855" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637527510331608865" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_637527510331638855" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_637527510331638855" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637527510331608865" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_637527510331638855" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.eyenoviabio.com/role/DisclosureStockholdersEquitySummaryOfInformationRelatedToStockOptionsDetails" xlink:type="extended" xlink:title="41105 - Disclosure - Stockholders' Equity - Summary of information related to stock options (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_225356" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637527510331638855" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_225356" xlink:to="us-gaap_StatementTable_637527510331638855" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_637527510331638855" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637527510331638855" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_637527510331638855" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_637527510331638855" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_637527510331638855" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_637527510331638855" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_ExercisePriceOneMember" xlink:label="eyen_ExercisePriceOneMember_637527510331638855" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_637527510331638855" xlink:to="eyen_ExercisePriceOneMember_637527510331638855" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_ExercisePriceTwoMember" xlink:label="eyen_ExercisePriceTwoMember_637527510331638855" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_637527510331638855" xlink:to="eyen_ExercisePriceTwoMember_637527510331638855" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_ExercisePrice2.72Member" xlink:label="eyen_ExercisePrice2.72Member_637527510331638855" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_637527510331638855" xlink:to="eyen_ExercisePrice2.72Member_637527510331638855" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_ExercisePriceThreeMember" xlink:label="eyen_ExercisePriceThreeMember_637527510331638855" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_637527510331638855" xlink:to="eyen_ExercisePriceThreeMember_637527510331638855" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_ExercisePrice2.89Member" xlink:label="eyen_ExercisePrice2.89Member_637527510331648848" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_637527510331638855" xlink:to="eyen_ExercisePrice2.89Member_637527510331648848" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_ExercisePriceFourMember" xlink:label="eyen_ExercisePriceFourMember_637527510331648848" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_637527510331638855" xlink:to="eyen_ExercisePriceFourMember_637527510331648848" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_ExercisePrice3.43Member" xlink:label="eyen_ExercisePrice3.43Member_637527510331648848" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_637527510331638855" xlink:to="eyen_ExercisePrice3.43Member_637527510331648848" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_ExercisePrice3.48Member" xlink:label="eyen_ExercisePrice3.48Member_637527510331648848" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_637527510331638855" xlink:to="eyen_ExercisePrice3.48Member_637527510331648848" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_ExercisePrice3.71Member" xlink:label="eyen_ExercisePrice3.71Member_637527510331648848" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_637527510331638855" xlink:to="eyen_ExercisePrice3.71Member_637527510331648848" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_ExercisePriceFiveMember" xlink:label="eyen_ExercisePriceFiveMember_637527510331648848" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_637527510331638855" xlink:to="eyen_ExercisePriceFiveMember_637527510331648848" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_ExercisePrice4.68Member" xlink:label="eyen_ExercisePrice4.68Member_637527510331648848" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_637527510331638855" xlink:to="eyen_ExercisePrice4.68Member_637527510331648848" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_ExercisePriceSixMember" xlink:label="eyen_ExercisePriceSixMember_637527510331648848" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_637527510331638855" xlink:to="eyen_ExercisePriceSixMember_637527510331648848" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_ExercisePriceSevenMember" xlink:label="eyen_ExercisePriceSevenMember_637527510331648848" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_637527510331638855" xlink:to="eyen_ExercisePriceSevenMember_637527510331648848" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_ExercisePriceEightMember" xlink:label="eyen_ExercisePriceEightMember_637527510331648848" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_637527510331638855" xlink:to="eyen_ExercisePriceEightMember_637527510331648848" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_ExercisePrice5.77Member" xlink:label="eyen_ExercisePrice5.77Member_637527510331648848" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_637527510331638855" xlink:to="eyen_ExercisePrice5.77Member_637527510331648848" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_ExercisePriceNineMemberMember" xlink:label="eyen_ExercisePriceNineMemberMember_637527510331648848" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_637527510331638855" xlink:to="eyen_ExercisePriceNineMemberMember_637527510331648848" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_ExercisePriceTenMember" xlink:label="eyen_ExercisePriceTenMember_637527510331658847" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_637527510331638855" xlink:to="eyen_ExercisePriceTenMember_637527510331658847" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_ExercisePriceElevenMember" xlink:label="eyen_ExercisePriceElevenMember_637527510331658847" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_637527510331638855" xlink:to="eyen_ExercisePriceElevenMember_637527510331658847" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637527510331658847" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637527510331638855" xlink:to="us-gaap_StatementLineItems_637527510331658847" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_637527510331658847" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637527510331658847" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_637527510331658847" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_637527510331658847" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637527510331658847" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_637527510331658847" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_637527510331658847" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637527510331658847" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_637527510331658847" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_637527510331658847" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637527510331658847" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_637527510331658847" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.eyenoviabio.com/role/DisclosureStockholdersEquityAdditionalInformationDetails" xlink:type="extended" xlink:title="41106 - Disclosure - Stockholders' Equity - Additional Information (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_202" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637527510331658847" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_202" xlink:to="us-gaap_StatementTable_637527510331658847" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_637527510331658847" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637527510331658847" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_637527510331658847" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_637527510331658847" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_637527510331658847" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_637527510331658847" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_WarrantsAtExercisePriceOneMember" xlink:label="eyen_WarrantsAtExercisePriceOneMember_637527510331658847" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_637527510331658847" xlink:to="eyen_WarrantsAtExercisePriceOneMember_637527510331658847" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_WarrantsAtExercisePriceThreeMember" xlink:label="eyen_WarrantsAtExercisePriceThreeMember_637527510331658847" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_637527510331658847" xlink:to="eyen_WarrantsAtExercisePriceThreeMember_637527510331658847" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_637527510331668840" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637527510331658847" xlink:to="us-gaap_PlanNameAxis_637527510331668840" order="2" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_637527510331668840" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis_637527510331668840" xlink:to="us-gaap_PlanNameDomain_637527510331668840" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_EmployeesConsultantsAndDirectorsUnder2018PlanMember" xlink:label="eyen_EmployeesConsultantsAndDirectorsUnder2018PlanMember_637527510331668840" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_637527510331668840" xlink:to="eyen_EmployeesConsultantsAndDirectorsUnder2018PlanMember_637527510331668840" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_OmnibusStockIncentivePlan2018Member" xlink:label="eyen_OmnibusStockIncentivePlan2018Member_637527510331668840" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_637527510331668840" xlink:to="eyen_OmnibusStockIncentivePlan2018Member_637527510331668840" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_637527510331668840" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637527510331658847" xlink:to="srt_RangeAxis_637527510331668840" order="3" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember_637527510331668840" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_637527510331668840" xlink:to="srt_RangeMember_637527510331668840" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_637527510331668840" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637527510331668840" xlink:to="srt_MinimumMember_637527510331668840" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_637527510331668840" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637527510331668840" xlink:to="srt_MaximumMember_637527510331668840" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis_637527510331668840" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637527510331658847" xlink:to="us-gaap_VestingAxis_637527510331668840" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain_637527510331668840" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis_637527510331668840" xlink:to="us-gaap_VestingDomain_637527510331668840" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember_637527510331668840" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain_637527510331668840" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember_637527510331668840" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_637527510331668840" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain_637527510331668840" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_637527510331668840" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_637527510331668840" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637527510331658847" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_637527510331668840" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_637527510331668840" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_637527510331668840" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_637527510331668840" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember_637527510331668840" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_637527510331668840" xlink:to="us-gaap_IPOMember_637527510331668840" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_UnderwrittenPublicOfferingMember" xlink:label="eyen_UnderwrittenPublicOfferingMember_637527510331668840" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_637527510331668840" xlink:to="eyen_UnderwrittenPublicOfferingMember_637527510331668840" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember_637527510331668840" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_637527510331668840" xlink:to="us-gaap_OverAllotmentOptionMember_637527510331668840" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_637527510331678833" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637527510331658847" xlink:to="us-gaap_StatementEquityComponentsAxis_637527510331678833" order="6" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_637527510331678833" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637527510331678833" xlink:to="us-gaap_EquityComponentDomain_637527510331678833" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember_637527510331678833" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain_637527510331678833" xlink:to="us-gaap_WarrantMember_637527510331678833" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_ClassWarrantsMember" xlink:label="eyen_ClassWarrantsMember_637527510331678833" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WarrantMember_637527510331678833" xlink:to="eyen_ClassWarrantsMember_637527510331678833" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_ClassBWarrantsMember" xlink:label="eyen_ClassBWarrantsMember_637527510331678833" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WarrantMember_637527510331678833" xlink:to="eyen_ClassBWarrantsMember_637527510331678833" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_637527510331678833" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain_637527510331678833" xlink:to="us-gaap_CommonStockMember_637527510331678833" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_637527510331678833" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637527510331658847" xlink:to="us-gaap_AwardTypeAxis_637527510331678833" order="7" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637527510331678833" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_637527510331678833" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637527510331678833" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_637527510331678833" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637527510331678833" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_637527510331678833" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis_637527510331678833" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637527510331658847" xlink:to="us-gaap_IncomeStatementLocationAxis_637527510331678833" order="8" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_637527510331678833" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis_637527510331678833" xlink:to="us-gaap_IncomeStatementLocationDomain_637527510331678833" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_637527510331678833" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_637527510331678833" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_637527510331678833" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_637527510331678833" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_637527510331678833" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_637527510331678833" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637527510331688827" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637527510331658847" xlink:to="us-gaap_StatementLineItems_637527510331688827" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized_637527510331688827" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637527510331688827" xlink:to="us-gaap_CommonStockSharesAuthorized_637527510331688827" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_637527510331688827" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637527510331688827" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_637527510331688827" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized_637527510331688827" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637527510331688827" xlink:to="us-gaap_PreferredStockSharesAuthorized_637527510331688827" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_637527510331688827" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637527510331688827" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_637527510331688827" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_637527510331688827" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637527510331688827" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_637527510331688827" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_ShareBasedCompensationArrangementByShareBasedPaymentAwardCashFeePaid" xlink:label="eyen_ShareBasedCompensationArrangementByShareBasedPaymentAwardCashFeePaid_637527510331688827" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637527510331688827" xlink:to="eyen_ShareBasedCompensationArrangementByShareBasedPaymentAwardCashFeePaid_637527510331688827" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_637527510331688827" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637527510331688827" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_637527510331688827" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="2" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_NumberOfCommonShares" xlink:label="eyen_NumberOfCommonShares_637527510331688827" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637527510331688827" xlink:to="eyen_NumberOfCommonShares_637527510331688827" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_637527510331688827" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637527510331688827" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_637527510331688827" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare_637527510331698821" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637527510331688827" xlink:to="us-gaap_SharesIssuedPricePerShare_637527510331698821" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_ClassOfWarrantOrRightNumberOfYearsSecuritiesCalledByWarrantsToPurchaseCommonStock" xlink:label="eyen_ClassOfWarrantOrRightNumberOfYearsSecuritiesCalledByWarrantsToPurchaseCommonStock_637527510331698821" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637527510331688827" xlink:to="eyen_ClassOfWarrantOrRightNumberOfYearsSecuritiesCalledByWarrantsToPurchaseCommonStock_637527510331698821" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_GrossProceedsOfStockValueIssuedDuringPeriod" xlink:label="eyen_GrossProceedsOfStockValueIssuedDuringPeriod_637527510331698821" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637527510331688827" xlink:to="eyen_GrossProceedsOfStockValueIssuedDuringPeriod_637527510331698821" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="2" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_NetProceedsFromIssuanceOfCommonStock" xlink:label="eyen_NetProceedsFromIssuanceOfCommonStock_637527510331698821" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637527510331688827" xlink:to="eyen_NetProceedsFromIssuanceOfCommonStock_637527510331698821" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="2" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_NumberOfSharesAgreedToBeIssued" xlink:label="eyen_NumberOfSharesAgreedToBeIssued_637527510331698821" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637527510331688827" xlink:to="eyen_NumberOfSharesAgreedToBeIssued_637527510331698821" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice_637527510331698821" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637527510331688827" xlink:to="us-gaap_SharePrice_637527510331698821" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_OverAllotmentOptionPeriod" xlink:label="eyen_OverAllotmentOptionPeriod_637527510331698821" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637527510331688827" xlink:to="eyen_OverAllotmentOptionPeriod_637527510331698821" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_637527510331698821" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637527510331688827" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_637527510331698821" order="17" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_637527510331698821" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637527510331688827" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_637527510331698821" order="18" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_637527510331708815" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637527510331688827" xlink:to="us-gaap_ShareBasedCompensation_637527510331708815" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_637527510331708815" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637527510331688827" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_637527510331708815" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_637527510331708815" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637527510331688827" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_637527510331708815" order="21" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_637527510331708815" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637527510331688827" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_637527510331708815" order="22" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_637527510331708815" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637527510331688827" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_637527510331708815" order="23" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_637527510331708815" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637527510331688827" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_637527510331708815" order="24" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_637527510331708815" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637527510331688827" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_637527510331708815" order="25" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_637527510331718809" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637527510331688827" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_637527510331718809" order="26" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_637527510331718809" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637527510331688827" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_637527510331718809" order="27" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost_637527510331718809" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637527510331688827" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost_637527510331718809" order="28" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_637527510331718809" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637527510331688827" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_637527510331718809" order="29" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises_637527510331718809" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637527510331688827" xlink:to="us-gaap_ProceedsFromWarrantExercises_637527510331718809" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_RemittanceOfEmployeeSPayrollTaxes" xlink:label="eyen_RemittanceOfEmployeeSPayrollTaxes_637527510331718809" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637527510331688827" xlink:to="eyen_RemittanceOfEmployeeSPayrollTaxes_637527510331718809" order="31" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_637527510331718809" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637527510331688827" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_637527510331718809" order="32" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_637527510331728803" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637527510331688827" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_637527510331728803" order="33" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_637527510331728803" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637527510331688827" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_637527510331728803" order="34" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber_637527510331728803" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637527510331688827" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber_637527510331728803" order="35" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_637527510331728803" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637527510331688827" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_637527510331728803" order="36" use="optional" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.eyenoviabio.com/role/DisclosureEmployeeBenefitPlansDetails" xlink:type="extended" xlink:title="41201 - Disclosure - Employee Benefit Plans (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_637527510331728803" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_637527510331728803" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage" xlink:label="us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage_637527510331728803" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage_637527510331728803" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount_637527510331738797" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount_637527510331738797" order="3" use="optional" />
  </presentationLink>
  <presentationLink xlink:role="http://www.eyenoviabio.com/role/DisclosureSubsequentEventsDetails" xlink:type="extended" xlink:title="41301 - Disclosure - Subsequent Events (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_233" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637527510331738797" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_233" xlink:to="us-gaap_StatementTable_637527510331738797" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_637527510331738797" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637527510331738797" xlink:to="us-gaap_PlanNameAxis_637527510331738797" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_637527510331738797" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis_637527510331738797" xlink:to="us-gaap_PlanNameDomain_637527510331738797" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="eyen-20201231.xsd#eyen_EmployeesConsultantsAndDirectorsUnder2018PlanMember" xlink:label="eyen_EmployeesConsultantsAndDirectorsUnder2018PlanMember_637527510331738797" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_637527510331738797" xlink:to="eyen_EmployeesConsultantsAndDirectorsUnder2018PlanMember_637527510331738797" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis_637527510331738797" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637527510331738797" xlink:to="us-gaap_SubsequentEventTypeAxis_637527510331738797" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_637527510331738797" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis_637527510331738797" xlink:to="us-gaap_SubsequentEventTypeDomain_637527510331738797" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember_637527510331738797" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain_637527510331738797" xlink:to="us-gaap_SubsequentEventMember_637527510331738797" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_637527510331738797" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637527510331738797" xlink:to="srt_RangeAxis_637527510331738797" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember_637527510331738797" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_637527510331738797" xlink:to="srt_RangeMember_637527510331738797" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_637527510331738797" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637527510331738797" xlink:to="srt_MaximumMember_637527510331738797" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_637527510331738797" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637527510331738797" xlink:to="srt_MinimumMember_637527510331738797" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637527510331738797" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637527510331738797" xlink:to="us-gaap_StatementLineItems_637527510331738797" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare_637527510331738797" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637527510331738797" xlink:to="us-gaap_SharesIssuedPricePerShare_637527510331738797" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_637527510331738797" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637527510331738797" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_637527510331738797" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_637527510331738797" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637527510331738797" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_637527510331738797" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises_637527510331738797" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637527510331738797" xlink:to="us-gaap_ProceedsFromWarrantExercises_637527510331738797" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_637527510331738797" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637527510331738797" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_637527510331738797" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_637527510331748790" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637527510331738797" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_637527510331748790" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_637527510331748790" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637527510331738797" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_637527510331748790" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_637527510331748790" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637527510331738797" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_637527510331748790" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_637527510331748790" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637527510331738797" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_637527510331748790" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>tm211152d1_10ksp1img001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm211152d1_10ksp1img001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" $2 &D# 2(  A$! Q$!_\0
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M66AR:-NWBD,@2VP.WY4K6N14U% #M,79>Q?[PK!N'!N[CD?ZUJZ"S_X^X_\
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KOGRH\_[HHHJH?$8U/A8ME;QIG"(/HM6EZT454B:.Q)11169TA1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>tm211152d1_10ksp1img002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm211152d1_10ksp1img002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" ". @4# 2(  A$! Q$!_\0
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M_$EMYT(5;I1D <;_ *UYEI>H7G@[6 IWALX,;4 >JZ5J+Z/=(\'&#@#UKO\
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MAL>U 'PY_P %%OB-=>"=#+64H$^Y7A)[,&S7U;^Q]\;%^.?[/7AWQ(67[3-
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MGM46O>'+;Q/9K%<)EB#L<#[A]:Y[2-6\P DX'UKH+#4 0.IH&W8\IUOP_?\
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MSVK]QO\ @X#@L?#_ ,='\1:@N\6^F110QD]3S7XL^.1>>/\ 6I)(;<B-FR%
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MX8Z0^I>(;*** REI@"/2@#])?^">&CVMO\3_  <FS#.\)QZ\5^OD>J G!XP
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MFWH!P0\)WL7^IN+F-AW$I%-BUKQ7X9?=!=?:XQ]Y9OFS^-=G=:;+))D97^M
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M+7;<R0G<H.,XH O;Z*2B@!@'-/I=E!7 K,NXE% &:",4 ]= HHHH):L%%%%
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<&CGP[X<M[-F#M&@RPZ'B@#80;UHI =HHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>tm211152d1_10ksp1img003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm211152d1_10ksp1img003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" ") ?8# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MN-/XB?PKM_#^G1'4;%X[^W^R6L9-Q"(^96]J4Z;@W&#V.ANI-ISP\+R_O?\
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MLI<L<*KKM+0Z+X7Z'>^.[?P3HVJ:K8-"NJ7-U>_:IP84&6\HLQ_B&16A\=/
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M.WMXQ%#$ JJO050&+\/OAQ8> +)UMEDDN)3F:>5BS2MW/-=$!@4M% !1110
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MJ?P1I_\ PU[\3O!?@UC:> M3^%K7GB:'3+CRK72-2%RJVDT14[8;ADW'*\G
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M$!8)YAR=A?!P"%+<URS^,?@#H_QKU+2]+\#V>I:GI%[:RZGJNFZ7YUO97EV
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MP!L+P8&2,@GF@#Z-\"77@OXY^'M:NM/TBSU+1M>?R[RYFLPL&L #:&R1^\
M&#T]*X?X)_%SX*^%?BC<^!O PT33M9O+NYLWCLK;:E[=6H!N(?,ZL\08$J3Q
MFO)O@1\*?CMI,VNV'@?7[;P;X1ABTF+1[/Q7I[7ILVBM]EY'"JLK!"^ "QQD
M$BN#_9Y_9(^)'P\_X*97?Q _L"SL]-UK5-1CURT,).FP0-&AAU*S8L=ES.X(
MD7TQF@#ZL7XX_#2V_:>U3X/316EGXZ\2:4=>N+*2U"+K-J,1M)O'#E?ND'FO
M.F_:F_9_^!_B'QA_9FEV]K/\'GM]&U6?3=-)71VNF!CMT(Z[F<$@>M<#^W9\
M$/&WC+]HP_$+X<:'-<^/OAS#976BRS1&.WU&-W:.[M?,[@QONV^JUXK\0OV7
M/&/ASPI^TII5AX4\0ZC?>+M3\-7EO<Q63L-5GB>)[MU;NJD,,^@H ^SF_:#^
M&OP,\?Z]H'AGPW=7&OM$OB#Q+;:!IN^2P25-XN+HKQO8#IRQQTJCJG_!4KX5
MZ%?31WUWKMK!::;:ZO=W3Z5-Y-C:W)*PRS'&4!(P<]*\]_9_TO7_ -E+]LKX
MSWOB#PSK^L>'OBO=6&N:'J^GZ<;@ADM5A>RG"\QE67Y<\?,:\:_;$_94^(_Q
MW_:<^)NO^'-%\06FGKX6T0OX?.(=/\8Q03/)<Z8\@Z,4(VD?Q<&@#[>^)?[8
M/AGX?^)K'0K6#4_%'B"^TX:RNFZ-#]HN(['_ )^6&0 G(QW/85G^"/V\OA]\
M2?$7@;3=!U&XU67XAPW,VD/!$=A^S?\ 'PDA_@>,Y!![BOG[X<6FL_ S]MWQ
M#\9+KP3XIE\%?$KP/INFV=I;:>TU]H-W9;@;*2$995;(PP^4D'->2_LW? CQ
MQ^RY\<OA?XQ\2^%?$8M-2UOQ7XDU&RTNP:[7P]'J.TV\#!.Y"\J,X)- 'WC\
M5_VNO"OP:^)=AX3U==6;5]3TNXUBVCM;-IO-MX"HD(QU(+*,>]<?X3_X*3>
M_&7B'6--M-/\7BYT&0P:B9-(D5+.00^=L<]CLYYK@H;SQ+\7_P#@H#\'_'4O
M@GQ#HNB6OAC6K2Z>ZMO^/5I)(_)$G]TN$W8]Q4GP-\&Z]HWC?]JZ>^T#5X+?
MQ1JSW&D/):DB_7[ (@8QW^;B@#T/P?\ \%"O!?C;P3#XCLK#Q7_8=UILVJVU
M\^ER+!<01*7<JQ_V0W7TIWPK_P""B_PR^+&G7MQ;ZO>:9]AT(^)VCU.S>V:7
M3 "?M4>>'C&,$CH?K7RM^RQX%U7X>?L?6OAR32/C#J'BN?P%>Z->:;J=L_\
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M$_"CR1FGT4 (5X_"F"/-244 ,*;10$R*?10 P18H\O:/I3Z* &!<TY5VTM%
M#6CW4GE?I3Z* &;"3UXH,>6/-/HH ;L]S13J* /./VE/@@GQT\#0623"VO\
M3+V+4;*1ONB6,Y /L:;HEGXH\7)%8ZU91V%NBC[0PD#><1Z#T/6O1E[_ $JO
M%]YOK2LKW GM+=;2U2)/N(H5?I4E(GW:6F 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
..444 %%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>tm211152d1_10ksp1img004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm211152d1_10ksp1img004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" "] @4# 2(  A$! Q$!_\0
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M  2DL7M=!\:KM_Y>+3_T&6BLWA9IV)]K$_KBI-U!Y%,/!KB-!^<TM-48IV:
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M^E>V? NPM="U6[LX+T26SQJT7R[22>^*Y+Q=I=GH^BPV*V6G&/4XDCX;A.^
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M0U.6&>[4?.\:X4UL 8%(APM*#D461C>^HM%%%, HHHH **** "BBB@ HHHH
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M#MP"YSR1USGC\*V_ /BCQ+HVB0>+8-"B:P\/W*0WXC 23RV(RI]<]*Z+QO\
M!O2IOBKH&@QZC:Z#X-\:7)NX+I7W_9F/SMO7IW(_"N'$9BXU/>=TG:[W/;PF
M6Q<(0G"5WK\2^'^;T1Y[XK^'K:;XPL]&@FU.?4=9M%N[>%03L#+NKSF:$67A
M4*JZFDT5TPOYRA"( < >F<U]D_LL^#1=?M8:Y;7FKZ=/9^%M-EEM]1/S-<Q;
M"JD#T&!7->$O@<OBSX0^.-:U_7-'T;1I9A'!<)EB9A+N&4]P>M8+,X0<HR=[
M>IUQR2K6H0JN2]_FY;S35H[O9GS1-J]E<:]IIMGOW7!4KM8LV!S6MX?FCM)=
M3U PZK+I$9P^86(B)[FO<? ?[-*>*/&>E?;_ !CH%IJABD&D6MOS]N.TX+'M
MGCBO4?@3\(VU/X(_$SPY+=Z0_BNVB688.8"J9.-WKQ58S,8PI-1T?NOY.YCE
M?#\JKI3@X^^IZ<T;Z6MLEYGRSI.@I>:CH&C7$]W:3Z_<(;:>3Y0P/& ?3VJ[
M+\,)=7;Q;;Z;/,?^$84R7Y;M\WRE1W[_ )UZ3XD\.:5XE_9,TKQBVJ06OB7P
MO?R6ZZ20 >9, [NOO5'Q3X?C\+:!X6T[PRL5[XH\>2?:-95)MT8;'RIGTQVK
M%9BY2E.,VDO(?]A48227*Y\M])+5WMR^JT9XS<G3TO;=VO+RU74[7:V]2,G.
M.E5K5IC%.MKJ.Z>R7RV4C:-G<UZ?X\LO$'B7Q]K*0Z!9W=MX6LX_M*HH"6IC
M&'.>_-</<6,K:#_:G]E0[-?F^RQ3K(!YK=",9XYKT89C%1NIW3/.K93*5:7/
M!RN^5:JS:6MK=@CNIK2.WN(]1M9[>6,B(H2I9AUZ5ZI\"?VW/''P/G4:)K.^
M"?AH9I-ZJ1V ->?:7\-]?_M"UT&+P?<SZAI4?VZ.-&W"*(]>G]:MZ]\.&LO#
M]KJ5UX1U2"PENRMQ=C[T3=E&.@KGQ%;#U?<KP4_4TPN Q6%G2G@IRCS<VU]+
M:GW5\"O^"Q4]W>V]OXSTA2DQ"&YM"/DYZD=J^W_ 'QE\-_$:PAFTG5[&[$Z!
MP(Y@67/8CUK\$)_"5Q9&]O+.+6]+AT^<I()HF9#&QV]>YYS72^$_'FL_"^Z\
MS3?$5[931!7B7<T88<?-CTKY;,^$<#B%SX67*^Q]]E'B/FN7Q_VVFZM/NK77
MWG[\1S#?CMZ^M/W[37YX?L5_\%0TTS06TKQ_J!O98Y L-]"-WR^XK[2^&?[1
M/A+XPVPDT36;>=L<QE@'_+K7YUC<GQF%DU.-XKJ?M>1\5X#-*2G0FN9]'N=[
MYHII.34*2@'U^HJ93NKS(R4E>)]$I/9JPA.!2%]PI9N#4>*95Q>WX5^<?_!U
M/_RAN\9_]A/3_P#T>*_1P=#]*_.3_@ZF_P"4-GC3_L)Z=_Z/%,F6Y_*!'PPK
MI]#N9+.WBDB=HI%X#(<$5S$1R5KIM+4?84^M>E@?XB,YV<>6>QZ'X*^(']E^
M&)H)IKCSY&RK[SEC7;>"O',VJ+)%/*Y^7_6,_4>E>6>&I;.*V/V@?-CY<]JW
M/#=TI@;!QSE2/2OIX7CN?$9KET')RIGH&JI!=2I-$H$BGJ>];F@PM::?.DO[
MMIU^0KZUQ&GZA).P1?FSWKO-$MY5M%\S\S70M4?'UO<33.5U"S?Q%?21RA8D
MMH' CE'F([G^( ]#6+X#^'\5GJ.YSO9CGA>#7HZP+9ZT)3"LT;+M88]:=;^%
M;:UOX9(6>-F/S(>U1[-7N;T\WE"@XW-#1O#$<, .U1GCI4MSHF'^1=P'!P*Z
M?3M(CN=/CV?P-R?6ND\.^"5N86?C&1GWK9-K8\6FJM:;<9'G5EI%Q:S*55\Y
M]*^@OV=_$,NFW\*ONX SD5F)X7T^TVE^2%Z 5/H7BJUT36D"8'..*SG[VC/5
MR^BJ%6\I:GZ-_LL>/HO/ME<XX'6ON?PQJ=MJ7AZ']W]X !P.M?EA^S9X_5I+
M-D?.X#.3[U^D/P=U^WU?PE9"*8>8FW<H[&OSWB3#M5>:)^Y\+8M5,*H7V+'B
M+P86>_,7[N5_NL#@DUYY>(VD7BMOV7<;??\ XA_C7NUYI4FHB>8#YEYQ7G'C
M/P-]KNNH6;EA7@X6NV_>/JYSIRA?J<WXP\56GB34+!Y;>]GCMH]MR@<A)?PZ
M"L^U\2)J^L6^EZ?;6/AO2B^&EQNDYZ?-U%275A!::5(K73)+G:3MXQ]:Q-5T
M<)Y(4K,KQ@@XZFO75F>15HJ]Y;G06]M!X#\4I&+2]\67L^4;[42T"9/#*/IW
MJ/4O%/\ 9ES<V>K+;:6CRF,+8*K2(G4YK(>WU6#PY]K^WRP@7'V?$?\ K1\N
M00?3_"L=]&N(]1N)\&]DM\,\BKR^?[WO6\::W9R-6?NG3:IXRTC3(-+GT>27
M43;NT;FZ=<-&3W7M6#KEC%X@@O+B;43=E9,A8R%>/G 4#ICZ53U2.WN9%\FU
MM[<",131!,-(Q[BDG>233W4/;L^X6P61=LL6TY[55.E%.YD^9RYCCKNU>69U
MW/)+"Y.T<LJ>C'I4=YH%S:W/EW*D,P!;GL1GK747<GVR^N$MBB^8OD3F,<M4
M']C>7)&/M.\[27$@RW%>C":Y;'GSHMU+HYJVL66Y$MJC0^7@+\N>GK79>&O!
ML_B*\CDF +,=Q.W&?PINFZ/YH<!LMP?N\UZW\+O!_E 3.A^Z.HKDQ6(C3IM=
M3T<!E_M:B<D2'X77&F?"F\U)=ODVZ$,I'6OR*_X*I>.UTW0K\$JGFL0!CJ*_
M8WXX^/Y_!OP2U*T$:A+@8!STK^?K_@KI\48KK738"<EV;A<]*WX8FY-UIGA\
M81GI0@<S_P $JY/MUG\0)%Z->VO_ *#-14'_  2:G$6A>.1C_EYM#_X[+177
M649S<K[GH8.<84(P:V1_7%1117CDV%3K3B14+OM''6JUW<%",MY:]R:)3L["
M=DKMV+D[8C-<)\7/CGX;^"'AW^T/$6I06,7.-[_.?H.IKB?C?^W?\/\ X';X
M-2UN&:^!*"&!@[*WH1VK\I_^"C7[2FI?M4?%NVO])U7[%H\4&Q(KAPK1D'[P
M7/-?4Y)PS6Q]50KQ<8/J?G_%?'.%RW#R>&DI37;H?3_[<_\ P52T?QI\+=1\
M/>"KJ:WNIV"RW,A\L"(]<?6OSQU.\?Q!>RM>ZW--(S9VVSYD;V-=#\/=<\!^
M'+6VE\2Z.WB2>3=&KM?,B,<]?+^M;G@-="\+^&M=\4Z9HKM-'J*I%<K&7@M@
M.0I7')/ K]0P&!P>5TK8=+3JS\&S3-:N=5OK&,KMV7PJ+T5TCB='^'FF:C\0
M;W[/%JM]+I$!NGL7/S 9&21U/6O7/'TOB+5/@/X;U#3O GV:WMXY(HKFSL,R
ME <;G[@C/2KGQ1\9_P#"EOBCX*^)5WI,FD:CXEMX/-_=;8[@LV&7&,<CH#7K
M=U^TMJ?@/]MS2?#SSC3- \1R1W$L$N/(A@>,'=C[H]Q7#F.9SK+G]K%V[/3T
M/3P>6TX3G2K.I>$E'2-D[J]_3NSY:;X@Z_I>C^'O%)M;B#3[&=5AU-8 D$LD
M9QM/HV:]Q^!G[2WB[2/CC=>%M?%Q;CX@6#_9Y;AMRN9$/E[?QXK)U;XZ^$/$
MO[2.L>&_$AAE\#?;II)8;>+-LC#.THHZ$G'(KE;#XRZ'_P -(Z9XBNM+U"]T
M;P_=&2R ;]XJ(,1J,]NE0\4IPM-IV5ST,/A%"I[11J_%:U^G\WH>G_ KP-#\
M7_!?Q-\"^*(T@USP7(=0TVV>3"0.H.YA_.LSX#? '0O%'P2UCXK:QXFCTS7(
M0^G6T:N/+.?E_>#K\WK7EOC;]L?4]+^-VL>*]#\/2/-K1EAGA<?>1QCYL5Y<
M_B37E^%USI$>E36LEZ[N$W,4$C'Y3CVI4ZO[_P!G&I974K_+87]GU94;/"/5
MN'Q?9>TV?H1\,OV:[3PS^S=JFC^)-9T6T\0^/'272U23=%+L^Y_WUFN,\5_\
M$Y]2U'2M'T[6_'F@:7XKTR>2Z6PFD^62)^@%?)>D?M$?%.Y\/Z+8ZTEO=:MH
M$*VVCR0@D0LO*LU5+?QC\</$OQ/O_$GC]4U.>YC$,#0/M$2CI@5Y^'KU:E:'
M/5LY<TGIM9Z?>=<L+STZTUA+RIQ]G%<SUC;WGZ=4?;/P'_8.U;PCK7BC6M9\
M:>''@DTE].'V*7/D._"AB.GXU#J'[ /B75_V8]<L)?%N@+>:AJ,-S9RK-BW5
M(ST;L2:_/[X?ZM\</ WC75[KS[MO"^I3O)/9+.3YX_A)]Q3_ !UXI^//C_5(
M[;3GU&U\)6TJ3-I1N6"R$'DXZTEB:]6E.2JI.ZZ+8Z*>6T,)RTHX)>S5+W;O
MJ]U9=7O\C[7\ ?\ !/'Q!J?Q3\*:A<^._#,T.GR/NBM)=LH.PC"\^M>P_LW_
M +'.H^$/$/CG3+[Q/I=Y<:Q9R6EH+>0EX0<G+CVK\Q_C+??%J^N-(OO#B:CH
M%WIJ$;HYF5B?IFM6?X]_&2R\*0?8+K4=/\5SQA9[\2-OD]>>^:O'9A-U^2==
M+1?9[$Y9@%2>#J3P$=)I/WK-)WU?K?\  ^MG_P""9]_XF\-:GIFK_$_PQ926
M4F^(Q2X;(;+;QZA<UV?P4_8ILO@_XPT3Q?XD\9Z,_A/29_-TV9'R]XP&!^N:
M^ _#/B?XG:;X#U-=2LM0OM8O3(#,68F5F[UM?"SX@_%6V^'-CHWBK?=:-II/
M]FPMUAR<D,36=/,O:1L\2E&3U]W8YH98J%&4_P"SUS1J3:?-W:_R/NW2O@+;
M_#[XUZII_CCQ1IUII'Q#BGBTY+9L/,LYRI8^@XKSSX#?L^>'KW]I#Q'X%\2W
M=I=:7X(MGO-/O(I/D:3!VEAW(KYMO/B=\8?BKX[TW6?%BZ;J<&CP?8]-2V=4
M,$(X7.#][IS5'P7K7Q&\'_$'Q'?+HBSVNNHMOYQN#YJ*O)_,<4HX^BXQ;KKF
MD[6L]$G:_P"II5PM>,ZJCATE#WX:_:DO>7XGT7^SK\3-3\'_  B^+WC>6XS%
MHMO+IUL^2992SD+@^F*YB[^*7BWP[^R;IEQJ,4X_X3C5$_L^W>3)?R^6)],Y
M&*M>'/C1J=G^S/X@\$)\/YI)->NEFDN!,!N (/3VJ]+\1=+N_P!EQM%UG1KA
MO$>B3F;1DE0[+9>,X([\5M4Q4%.7+-.VWF3A\O\ 81HPG2GS*,YRL]%?H.U2
M?XAGQ/I'A)]%NKR>VM?.N=.BB\QH@[ J\C]&_H*Z[]I7X;>)/'GCJ7PW>^&K
M***PT6.?[5:6H"1JL98AW[-QC%1_#K]IK7T_9;\574$LT>N6US$WG/@WC19Y
M4-C.VJGB;XTZ_8_LGQ:Y<7-YY'BS4S974\A+73*!P@&,XZ_E713Q%13NIQMS
M<M_E<EPBL*_949+]VY[76WP^I\W:?X;TM?"VG/IRZI;M]K82W4;,_EL,83 _
M'\Z[GX'?&_4/A3\0-*U.R\0/OM+HAHRVTR@=0:]FMO#6K_ F/P?H6E:!<O8^
M(84U"YW6I)WN=H ?!QE<'\:\V\6>(?!_P;^(/B^#7/"4%_*97$5O=@J]LS'.
M\-WSGM7HO'1K+V5;E:\CYV65+#26(A&<)M*5[::J_0_1?X-?\%5/!/C1;>TU
MHOI=U( BNQW(Q]2:^J/"?B"S\4:%:ZA87*W%K*FY64@A@:_GJ\3ZA9ZAJW_$
MDN/["58A,%WF02*>> >G>OOC]@W_ (*0:;\'/A5I?ASQ'--JGE+O%S$0VU#T
MS7QN>\*PBO:8'7R/T?A3Q)<Y_5<SEHMG9H_2Z4Y--KSGX.?M)^%OCI8K/X?U
M:*YD'+6QXD'X5W,=XQG^;(&,8-? SHU*<^2JK'[+@\12Q5-5</)23+B_Q?2O
MSC_X.J/^4-WC/_L)Z=_Z/%?HRSL5/;BOSC_X.GP5_P"".?C/=_T%-._]'BLD
M[[&M[KF9_*-$,-S72^'I?.BC3WZUSA/-:_A>XPX7OO!Q[5ZF!:]HC&J_W/J=
M?JNBF1-R\,.11X:O9K/4-AY7/05M0J9[!90-P"\UF6FJV\T[97RRIQGUKZ5S
M]VY\U2JQGS1>YV&F2DW(D4\J<]:[/0->GE1%D88SZUYMIFIPQH"&.?K78^'=
M5AN8_0@<UOS**21\?CL(W)N2/4="^S+*CW"&2/&?DZUT.I6FCZKI=U%9V%P;
MD1>;')N^Z17FNFZG-';.R$LBICV%=#X6\7/I-[$]Q$_D2*=VP_,U7?2Y\\Z,
M87B:7@_Q$;6]\IP0#QSWKU31]0$%@I3HPKP+7O$UO8WHD5PB,Y95W<I]:[GP
M?\38)M% R=PZ$FFM2J:G0C=(V_'/Q"N]$G(7E?6O/)OB?+)K 8OM8MZ]*;\6
M_'40LV;S5!VDU\ZWOQ3NCJ;.&^ZWKUK*I4C'<];+,MJXR3G&Y^H7[,'Q@L(-
M(LE-V?M.0#STK]+_ -D/XJK<V]O"[[XV(RV>M?SW_L^?'XV&M0-+(5(< _-Q
M7ZJ_L9?'UM3CL'CN$V[UW &O'S3#?6,,Y0W/M>',;/ XCV.(T/UUT*Z%U9SD
M<@C(P>M5-4TBWU&W0"+]Z20#7(?!?Q\OB"T"EU!" ]>V*]':V4-'M(Y&Y37Y
MC5O2ERO<_5%.TN=+0\J\2^!XUTG[,;<OMD)8J.E<1XKT!+*\MHXA(J1\X-?1
M$.GK)"Y<#YSAJY+Q+X0COR[&(D>@7K753KVW9M&<)_'N>.>'+&:61HY"CVT^
MXN2>5XXJ$VMWI45_Y$X6)V">6GWF'9C77K\/9M"@D>6V=T8[HU0\]>]5;[PK
M)=:SYB6C1R$(9,YVX%>C3Q-UJP=".\3%M+>VM[%KVZ%NMQ!&0P8_OF<GY2%Z
M5DVWAN;4-%("PB?4YF<RS#:ZD=<8[UTOB#09-5LA'<O#&KL<!.'8BFZ)X8WZ
M?*$\S9!'N0/R1*3@X_"M57CO<PEA6]CB-'T(:='<I>[K>+YC%)&F[SV'8FM:
MT\+3:O#%<^28YY"=N$R"N.,UV/AWX0EC$EV&F7EQST)KT#0_AM'!)#LC,>.-
MI/:N6MCHQUN32P<8SO,\_P# _P - UPLEQ%B3OQBO3=*T1+)5C0?*>!BMG3?
M"ZVLS$Q8!'!]:J^+]2A\(>'YKZ>00K C%5(ZG%>75Q+JSC'N=7M%%MPV1\E_
M\%(/BXO@_P *SVBRJJP1DR9..*_G)_;>^+DOQ*^*E_-_!;R,L; YR*_3G_@L
M'^UP4M]0A%UO^T,R#:W.,\5^,_B[6?[2U"ZG+%M[DG=Z5^B86@\/@^7J?GE:
MK/&9GS_91]=_\$E]1=] \;]/^/FT_P#09J*A_P""1LRGP]XXX_Y>;3_T&:BO
M,YY'JSIQ<F[G]@(;-!.*8[@)U%0W-Z+:/).><<=A[UR\K2NM2G**5V[%;6YX
MK9%ED<(J@DEFV@ 5XS\7OVT_ 'A/39[%_$=G%=.'B+*^XQ-C&?SKF?\ @HQX
MGU;Q/\!-9TSP;<_\3M$W824*7&.5!SUZ5^//A7PU\1/&OQLLO"VLV$WA*6^.
MZ:]OV&-@(W,#D@U]1DF4X2M:IC)N+[)'YKQ7Q+F-*3P^7PA)/1MRT,OXQW7C
M;QE\<]>D6Y@.E3WK.EXSAGN5+=<=N*^G/"&@? "U^&AL]9L;J_\ $VG[)[EY
M9.;W(&50YX%<+\1/V=/#'AOQ+/8VWBC4=002"2>8R ("!R%/I7D?BOPC:Q:[
M.^FS7-Q)$IA1WE^38?3U-?HLL;2KTHTX*2Y?EH?EO]FX^E-U:\Z-Y>?4ZC3]
M7\%67BSQ?<6F@6C^'IH]EFDDFY].?G[I[UU_P(_:_P!3_9\^"]_H=GI>A75I
M?7?VE#<PK-L/8G/>O#3\*I(='$<DTD4(;<V"?F^H[U3/PSEN+<#]ZMOYH9G+
MG!QTXK;EH^R4%!R6[NSGE+'*?MYUXJS4;1MJGT]-#V;XV_M5:W\;?"5H/$FI
MVNHP1RJ;:S$2A(2.FT8R,5S6N^)T\4307FHZB\MS"JQ*7?E5Q@*#U&*Q?"WP
M_L=-<:E?#SDC)(P#M7'M4S:M9^)-2']DVD3>6WSL1D'_ .O2PV&HSER+#JTM
M32MB,:Z=257&:QFI;?87V2Q<6ND:1HTR^9'%*YX.=S.3_6K6G:Q;Z':&2XF:
M*,J"LDF/O8XKGE\36=[KK60MQ+<H^T?+]T_6MF/0D.J;M1 D:,_NXY!E3^%4
MN7V7M'15EHR*U*K6KU/9XMIU;<GIU7H;FFL\&C#5+N[WQW#Y3;& 0/>M[PG:
MKKVGM?,DQB@0K"7'##UK'CU0K8,)(4V'Y63'RH.V!6E9^*(=;BCMK601?9A\
MP0XP/I7'+"KD5#V7Q:K76Q=)X?FGC_K#Y%'V;5]GLG]Y8^&&J:<WB9U$:!H(
M^9&'W/K3/%WCP'Q'+;EGF9V^3GY1[BJ=_P"+K*%98X77>XVLZ(!D^]97B'64
ML4MYI[<9*A0_ _'-535.=>>)]CI&-B*F&C+#4,/]8?/%Z._Q)N]F^OD;7B/X
MH6>BC[.)F&%&]5'>LOP1\5#<PZA?&XEB2 ;5:7H?I7.)?OX@CN_[-M8W=$9V
ME<!N@KQV/X@'Q)K7]GQS20W/F^6R*,*YSZ5A"%.5"GS4M9LZ(5J53,,35E5E
M\-G'7W+6M)?UU/J?P7X[M?%\TTIN/,1,/YS#@L3T%%Q\1X#XV-BI$SJP5-R@
MHH[Y->#?$;5=3^'?ARVLM1NTM$G&Z)HN,XYP<5<^&-]K'C32KV\MY!A4!\T'
MDUV_5VJ[C3II2L>>ZU.>51KU<0Y0C.SF]WVT\CWOXK^*CH,:7#7A6W.-OE ?
M(?;%9$'B&VUO0)[C[5YO[HL(",EQZ_6OFX^.]5D\7P:9'?O,IDVO%(V5SFNU
M\0^*I_AWXSTZUG4)#J,9^<'H?\*Y8RJ_5^?D5HO4]AX&"Q]W6;C4@N57?GJ>
MO_"S1X_'<,D^E*!Y,)RFW&#WQ4?A/Q<#XN_LZ=F6ZBN#&Z[<C&,5C?#SQ;=6
MND7,NGN+1U;&].D@%9CZE)?>*C<,QCFGF^8Q]<UO)8B&(<7!>_'3;L<4(4U2
M]E'$N]&3;_KT.]\9>/'\*>-8K;S73,8$04<2$UN^/?B"^A:5ILLAC$,_^M,B
M!L$=!T[FO.H89+37([B^+W:6KAU9^6C45Z-X2\8)KU^C1V\&H1;MR17$8(([
MUY\<+%.[I?P]ST:,U.G*?UIVK+ECWL'CO7(_#7PWT_55M8[63466&XDC'!4^
MHINH?$2ZT7X4V.HO<V\UO!= Q6\J92-N?G [<=_>N]\2>,_"=_)%I-S:Q"7"
MCR2-RH36)XTT/0O#UHEKJ"0+87!Q'&O.\=>GI7-0NJ2A*@K.IS?A8ZI0:O*&
M+O"G!QGTU>SMW.ITC_@H#XL\'_#[3[RZFLM147"Q6[7$090O90<<8KBOBA\<
M-'\??%.Q\:>(=&TO5);\@R684)$608!]Z74=?TWPQX56WGTZUO-#D(,4,D?"
MG_9]ZELK[X>>--(MFOXH+06C;8T(\O83[5K>G"7/*BTK]")0Q=H1AC$VH1;O
MV6GY%;X<^.?A1XE^(MXGB_P;IUX+Z8.UU%(473H^Z*HQD8KF/VM(_AMXMTG[
M1\+;,>%IK61;=8BQVW2@\$9KM?$/P/\ "%PR>(8I;$PJ@C4M)M!]L9KE]2^#
M'@BVLDBGAN8#>R":)EG)!(/8]A3P^-H*I[3EJ:/H1B\%BZU+V?M:;;_F26C[
M&I_P2V^,FH?!;XLWVJ>,M1CM=/CA\J,(V1(3Z^E?JS\,/VI_!/Q?>.WTG6[*
M2]4<PM( Q/MZU^7M]^RUX-\2_#W6I=#\2W&G>)8(O/A@N)E,,X49V_6O)_V4
M_"_Q8\7_ !%TF\L-)>SM(+T*U_YHCC55;!(&>>E<6=8+ 8Y.I%3A+S1Z7#F:
MYGDW+2AR5(-ZM/;R/WE^U8A 9<-[=Q7YT?\ !U/*/^'._C+_ +"FG?\ H\5]
MR> O'UGK.G0P&\@:Y@B2)P),Y8#G'XU\)_\ !TM+]I_X) >-(SA"NJ:>>O7]
M\*_-IX:5*6B/W?#5H5Z?-!K:[LS^4X]:N:-)Y5SFJ;<-Q3HI?+-:P?)+F1#2
ME'EZ'M'@*Z$ND.IP<*<5R/B/3FLM3?:>'))S2^ /$7D_*<\?K5KQO*T]U&X4
M@$5]-&?/13B>#2I^RQLHO9F9;:I]A W?SKHM#\6)$"=^TX_.N09?,;'!)( !
MJ36K;_A'KH17!'*@@@USK&)NW8[L1@XU79H]2TKXG3#2S;$[89N"QJ_J_B:\
ML=*65)A."-L9#XVFO()-3^T6PCW-Y?;%7;;Q!"VARV<WG[O^6>'Z>]="QL;6
MD>-7X;IN2DMSL9-9MM;T62%=0BMKQ&'F^8V2Y/I7/7?Q%UC2&81S3^5&?++
M84^]<I=7T5Y&T8W+*  Y[M^-:_A_08?$MRNE_:)M\D331B-2Y9@,[?TKBK8U
MK5'J4LHH1CRU%<L:AX^N/$%M^]FE<@8.>E<QK"F8@J"N >E:;>&)K"U5K9;J
MX"X\]#"08#[TQH0PVGAN<J1\R_45E4JRJQL=>&A2I2O25C/\-^('TF]1@[#:
MV>#7VI^Q)^UJ?#M];6;W!0AQEF/4U\0ZEIHA?<@)Y]*O^$/%<WAS5(Y4E=&5
M@<@XQBHPN)E2GR5-CFS/*HXG_:8NTD?TU?L1?M4Z?/I$YO[IY'DC B.[C-?9
M'PO^)D/BJW@_> _P]:_G3_85_;2EM)X+"YGD)8A5^;.VOU7_ &<OVF/M2VG^
MD <#^+&:X\XRA5G[>D=W#_$7.OJ=56?F?HI82 9W X#G)[&KES#%,1MQ\PVX
MQZUYU\/_ !^?$_AJR^SNDDTSX8;N:ZJ+Q&UK<".4;'CY;(KX>I2<9M36I]34
MP<YR4H?F7I[%9=.V%5S&<!L<XK/U'PNT\AD"QEF4* 1VK1M-4BNX<[E^8]JO
M_;(G3[IW#H<TE)HP=>K3?(T<A/\ #NRD:,M;+YD9)W8]:MV_@&&T4^6%![C;
MWKJAL=%)Z\'IUJ9Y%DPCXC!]N:'-V)69-:6,2Q\+1(Y9E!P._:M2/3H8K<-C
M+ XW$]*?<"-+K*O\N,=>]1R7\8@V$]^<5C%\SUU,9UIU]-AMP1&[ MA N1[U
M\2?\%,?VPK3X=>#[FR6[2-$1MYST;'2O?/VH/VG]'^!?ABZDGGBENVB;R$$@
M&PCN:_GH_P""G'[<MS\8/$=U;VU^S6KS/YA5LC.:^JX>R?VM;ZU45DMCQ<US
M!4J"P])^\]SYN_;4_:"G^,GCV[?S2\43$A<\=:^<-4OOM$^%R!CG/K6YXGOY
MKEI9&/SN3\W]ZN;=-N,\GUKZ#'UW-Z,PP5#V=)7W/M?_ ()&-L\.>-^O_'S:
M=/\ =FHI/^"2/_(O>-_^OBS_ /09J*\Z\3T#^O\ ,ZJ6!4<=S7PC_P %=/VE
M/&7PKTO2;3PJ]Z+&Y5VNIM/0N^X=%..E?5_QP^(=WX3TG;;K&1(O.:^'YI]9
MU;]I>WUF;69I+)(F9]+DB#VTIZ9.3^->UD.&C[7VEKI=#X;BK,J,J'U5.2;Z
MH^)O _QB\??M!ZOJ%OHG]MW4UC;F6X:\E: 0$_WMWXURWB/Q#KTWB.RM=0@D
MN+JW7$I%P7P1Z&OJ;X]? M_&_P :-2O;+7+CP^-6PEQ!8VX6-U'08R*XOPO^
MR;;/XIO\ZW/NLU 1OLPYQZ_-7Z''.,1+WJ48Q6UK=C\J7"^"2M4E*4M[MGD+
M>'?$UGX2N;V_N+>#[:_R0R2<HG8BLDP7-W>:?H^FE+A)-K3W#<%,')QZU]%>
M&OV6X/$T5Y<ZCK,UWY!(2-K<;5Q_P*J/A#]E^WNM-N=0&K/&]N7"JMJ,=3_M
M5G4S+$U)SE6M\/ZHQKY-E].E!)/XOT9XS\1;">.Y2(7T*63<2EN'X]*Y+Q%X
MRM[:R6WBOD^S1L"VX_.<5[?HW[(T'Q">\N;_ %ZZ)ASM5;< #_QZN:\.?L!Z
M-XI\:S?:M:NF2$9"?9QC_P!"K.&.F^2/>,OT%+*<OY74E'X91_4\;O\ XL2-
MH,D=M<;$G<JN[D 5GZ5\68/#-F8-'1!/*,3,PZMZU[CXR_8<TB;6+*PCU66"
M%[CRSLMAG'_?5:7CC_@GMH'P]O(([35;A_,B#LTEN"<_]]5A#.JM/#JO'[.A
MT2R3+7-X;D^.\OD^GX'B'PYO5N!/>WEQ''=,V]2M2>)?BY;^'TNI991<7GWH
MF)QTKWKPQ^P7H\'@>34_[8N6G+#@VXP.?]ZN5C_8'T3QC\1XXKG5K@1F(Y M
MQSS_ +U5/,ZO.L+TGJ98;#Y?*E+'\GO4+I'@-U^TC?ZY!$BR+&H/S,#UK3\/
M_%V*PCDGBN/(DFZNW?\ "O8?$7[ 'A_PIKT]O!J,I5&.TM;#Y>/]ZNETW_@F
MWX;_ .$-AU%]7NY+@#=S;C&?INK*CG=:=655_P#+E-(VQ&6Y;AX4H.G>-?5K
MI<\+'C.U@TQ9Y+I1(QW'!QNS7+_$OXOW&K:1)&ERTB1)V/W*^CH_V&]'\6:_
MIT4VJ2QHC$$);#YOK\U6=4_X)]^'=$U2[@749I$D X:W''_CU<]/'U(8&5=O
MXFST)95EL\SIY?.%W9.+[6UT/AG3/VL]5^&]J]G:EI?/#(6W8ZUYY8?&C4W\
M3"\WB.:";?P>6)YZU^A>D_\ !+7P9KGA[4;B:^G,JL=K?9Q\O/\ O5@M_P $
MUO"-P\<'VED_>J"XM1D_^/5GB,?4A3PD%NV>SEN'P%66.E3C::TD^K]3Y+\?
M_'?5OB[<Z9%>;(X[0, @;+,:]+^&/CB]\,>"6@L[@1"=0K9/W2>U?1/B'_@F
M7X.T&ZT]X;N;<V2V8!S_ ./5U/AS_@G[X<U!!%_:$Z1JO"K ,?\ H5=SQU59
M@Z:>NFIY4\+ET\F6-E3]VF]5W/@_QO?ZMX<U^'5+:=994ER1Z]ZR?BE\?O$/
MQ'OK)I%\EK1=B@'&37WG+_P3U\,SV\B2W\\O[U^3".,=/XJHZQ_P3*\(6WAH
M74=]<+,91EO(!S_X]7GK$5*D<10B[)/_ ".NK3RZG]7QD86E6^%_RGR7\,/V
MC]0TC0Y=)>Y99)%P=SYQ]#7=>#OBA)=VJO\ :E6XA?))/'YU[CX<_P"":?A*
M^UR-OMLT><9"VXY_\>K2NO\ @G_X?\.^+;BVBU.<V\B'Y#;CC_QZJ_M*M6PW
MUJ^L-%Z&]7)<#0S267TX_P :-V_D><>$/C%'?7DR3R>9A?F?<-K5T6A^*KKP
M?JD4_G^;9RKN1XS]S)Z5WG_#O/0=.\'FZ@U>Y1V'(^SCG_QZNL\*?L?:=/I(
MMFU24HT0Q_HXX_\ 'JV^LS?+K_&W/&CEF6N52FH66&V_X!Y4FLW>O^,C>VUR
MJQ2!2Y<<G%=OXOTF\^(T%G=6]Q'#=6(*-GGS$^E=)HG[+UKH6KRP+JDDBJ/E
MWVXX_P#'JZ-?V?Q8WUF8M7D4'JHMA@\_[U;3QE5-T_Y3FQ6%RR>%AB.1VQ,U
M==N4\YURVE\2>"(-'>[BLK^RD$L<CGAB*YOQ!X'CU[2XPU]$FLV\@(E/$3_4
M5] _$_\ 9UMM7L8MU_Y;[?OK;#)_\>K%\+?LUV^K>'7MY=48X;A_LPS_ .A4
ML/C<;*%/DDEJ=>,R_*'7J^S@](I?(\<U7P9K^L>'(M/34;477V@2KEOD?':N
MDUKX+:QKNEZ#Y%["+NV)%S'(^%Y_NUZEX0_9T@BM9K=]4DE2)\H6@&5/M\U:
M/AGX0.FK7,4FJ--Y;X4M;C*_^/5M*OF-I+G6Y$,MP-1QARN[C;]3PCQ5^SQX
MN\.Z_?"TNH[JTOH5\N;S#^X;'( JYX3^ ?Q+N$TJUL(UP&(*17?EGG\:^A-'
M\$WD*30/JOFIG W6P^7_ ,>J:W\#7%CI,S1ZFZ.C?(Z0A64^QS45<QQD*:YF
MF8RX=RV4'-.47+WE9[:GRS:?M >/_AOXXET)T\76^HZ9*8I4ME>1<]B"!R*]
M;_X+1?$O7?B1_P &_FNW?BA'35Y-2L,+,-D^P3#!93S7NOP.CF^'VM:G?O)#
MJLUVF6-U #@COFOC+_@MA\/=5^+7P)\<3W7B:]M[*6ZLR+!(LP)A@1@;O6O)
MSO&?7**YX)275'T^0X+#Y/C*-:G5G+VRL[OMH?@D1M-)7KC?LQ+N_P"0TW_@
M(/\ XJD_X9B7_H--_P" @_\ BJ^'M;0_796OH>:Z!JCVMV?FP,\5WMU<C7-,
M1E^8HM7E_9D56_Y#3?\ @(/_ (NNW^'O[.FV)PVLEALZ&T'_ ,57J8&LVG3[
M'!BZ.GUCJCP'4KIXKIOX2IXJE<ZA-=R;IG,A[%N:]T\8_LM1;W==99?FZ"T'
M_P 77/']F%?^@V__ ("#_P"*KAQ'NSO$[(OFC&1Y9%?O#T?'M2OJLS3!]W(Z
M5ZHO[+R,!G6F_P# 0?\ Q=,'[,*[S_Q.VX_Z=!_\76*G)[LH\K2\=;IWSRX^
M8U?T"YN=-N5O+.XD@FA.Y)$/(KTAOV7D4;O[;?\ \!!_\53E_9IV*V-;9>,\
M6@_^+JU)[ <YX*^(FM^%=7-_;ZA%:SEC(QF4/YS 'J#QS5S68IQK<U_?[[&>
M^MC=GSH,+*S?W0.U:\?[.(^R/NUC=R.3:#_XNNN\-_LW-J,2RWNOW-ZI0HJ2
MP9$8'3'SUV4YVN<U2"C:43R;27@UNW93Y?V@8!3-5[[P8[(Q6-M^<*H&2QKV
M^_\ V<M(TOX8S*LC?VJ+]=FH*NUE7!.W;G!_.N]\$?L\65Y\';34Y[O?J!U$
M6YF$&/EQZ;JZ:$X58N,EKW//Q=25-^U3/ESP-XOU'X9:]%/B9/*.XYXQ7Z"_
ML=?MWZ?J4-K:W=\MO<#:!YCXR:\;US]C_3[^6Y=]5F+'C_CW'_Q5<9XK_8ZM
MO#:"XL]?NHI$&01;CC_QZMXWI1Y9.Z/)G.ABJGM*=U+N?N3^S;\=]5N?(FT^
M]-TL?SJ()/,/3T%?3GA_X_+?-:?VC-MDNUVL7&"&].:_#?\ X(PZ=XKUK]O/
MP#X(G\;:LFA^(;QH;H0)LEVB-C\K%CCD#M7[N_$/P?H'PU^.'AGX>WFE?\)%
M8:E;FZ6[O)MMQ X;'!4#/XU\[F>'IS;DD?8Y3B:E""3;9W>@:\-1M8# ,AF
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MF=CWC_@D@N?#WCC_ *^;/_T&:BO3O^"5W[/RZ+H'C,#53)ON+3_EV QA9?\
(:]Z*YB+L_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>tm211152d1_10ksp1img005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm211152d1_10ksp1img005.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" #R 54# 2(  A$! Q$!_\0
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M<T >6_"'_DXKXK_]=M,_]):]3KRSX0_\G$_%?_KMIG_I+7J= !1110 4444
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M/U+[9XR-OJT-KJ*V=[!K=ZXO[N=T,5Q-&<+%B(-'L7(7.1S7G'PY_P""M/Q
MM=->+7M)\':W>Z=>-%-#927$-YJ@DN9D06D>TJPA1%:0D_=;/'%?;/[-7CGQ
M#\4?@KX=\1>*+'2M.U?6[5;V2UT^1Y(($D&Y%W. Q8 \\=:H.MCY#G_X)T?&
M+5];\,7$_C>R5=#DGN[+=JUY<MX<=A.J1PA^+D?O%_>2_,NSBEG_ ."??QVD
MT.W@T[XA0Z-/]CU"W(.LW=W#8+,B!1"7&\R,ZNQD8G8)" .*^^]O/2C%"TN!
MYS^RS\,M;^$/P+T#P_XAU"YU/5M.B99[B>[-VS9<D#S2H+  X&1G@5U7Q/\
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M)H ]F_M._*_\@SM_SW6O-C=SS_ME:5YUMY'_ !2-QSO#;O\ 2X_2O6PNQ._
MKRO4)@/VS-)!( /A"Y(_"[CHVU [C5_%UCI]\8)9F611ROD,_P#(5\O>&O\
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M5$08"J  ![5)YR_WE_.CSE_O+^= =;CJ*;YR_P!Y?SH\Y?[R_G0 ZL+XG_\
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M3A-6FKBNSY1_X*-_%O6?A-\"+>/1/$D<&G:]?C2M4OI[+[9)I]I)%)O<=AT
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MN)TN%126VKM!&T]/6O:[8.+1/,QYFWYL<C..<5-39/NT >7_ +&7_)O&C?\
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M7\?31/KFCZ%K+6X(B-[;13^6#R0-P.*N:)I6D^#-(%II5KIVGVL662WME2)
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M6/M\/_/:'_OL4?;X?^>T/_?8JO\ \(QIW_/E;?\ ?L4?\(QIW_/E;?\ ?L4
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MBV\]SUEA7@*#E5FE.:^&UW;MZG;?\$5X?VGO GCOXQW7Q/U'2_&_]H:O$_\
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MZJ$;*32VT,!QC !$2JO;KC-=<D2Q] !]*SO^$4M_^>EY_P"!#_XT?\(I;_\
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M6?E@ DA@/+^]R>?IZ5'!^S#XH@L].@_X6_XV*Z;()$8PVNZ7 (PY\OYA@]*
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@**#..Y)1110:!1110 4444 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>tm211152d1_10ksp1img006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm211152d1_10ksp1img006.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" %6 ;H# 2(  A$! Q$!_\0
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M_H9] _\  ^+_ .*K*_X9C^'?_0D^&/\ P71?X4?\,Q_#O_H2?#'_ (+HO\*
M-7_A<GA'_H9] _\  ^+_ .*H_P"%R>$?^AGT#_P/B_\ BJRO^&8_AW_T)/AC
M_P %T7^%'_#,?P[_ .A)\,?^"Z+_  H U?\ A<GA'_H9] _\#XO_ (JC_A<G
MA'_H9] _\#XO_BJRO^&8_AW_ -"3X8_\%T7^%'_#,?P[_P"A)\,?^"Z+_"@#
M5_X7)X1_Z&?0/_ ^+_XJC_A<GA'_ *&?0/\ P/B_^*K*_P"&8_AW_P!"3X8_
M\%T7^%'_  S'\._^A)\,?^"Z+_"@#5_X7)X1_P"AGT#_ ,#XO_BJ/^%R>$?^
MAGT#_P #XO\ XJLK_AF/X=_]"3X8_P#!=%_A1_PS'\._^A)\,?\ @NB_PH U
M?^%R>$?^AGT#_P #XO\ XJC_ (7)X1_Z&?0/_ ^+_P"*K*_X9C^'?_0D^&/_
M  71?X4?\,Q_#O\ Z$GPQ_X+HO\ "@#5/QC\),/^1GT#_P #XO\ XJO+K?Q7
MI?BG]NO2VTS4K#45C\'7 =K:X679FY3&=I.*[MOV9/AXHX\$^&/_  71?X5Y
MQH/PUT#X=?MUZ<NA:+IFD)<>#IS*MI;K$),7*8S@<XY_.@#W.]U&WMI,23PJ
M^/XF KY_^//_  44^'OP!^)*>&-8?5KJ\C2.:]GL+3SX=+C<_*\K \9]L\<U
M[GKG@G2]?NO/N[*UGEV[=TB9.*\.^-?_  31^&GQW^(,7B'4;?5+&XV)#?0:
M==&"WU2-#E4F4 YQTXP2#BO*QJQG+_LD8WO]JYW8-83GOBTVK=#W'2/%6F:E
MI<%Q#?6TD%S&LL;^8,,K#(/Y5Q7[57Q@T#X%_L^>(_%?B+2_[=T'28%>ZL56
M-Q<JS*BKA_EQDCD\5TEG\(O#NG645O%I%BD,"+&B",#8H& *YC]J3X!6O[2O
M[/6O?#]K\:-!KULMNMRL*R"':ZN/D;[P^7D'UKMHN;TJ;G+44%_#V/%?AC^V
M3\"_&7@C71X@\.Z#X+L/#.II;W%C>VEM<6\D\D?F*\1@#(YV$YQRO<5Z'I/[
M0?P#D\4745EK7@3^T[?3OM,\L4<0V6GEAB&DQC:(RI*YZ'I7A>K_ /!&N'Q)
M:WDDGQ ^SZCJ<X:_M].T:.RTN1%MS;@BVC88E .=^?F.,@BH[;_@AWH$MG_9
M]UXZU/\ LF31?['G2TL8[:>\_<B(&8J=KJNT,!MSGOBN@S/4!^V1\$].O](T
MSPY9Z#JMEJ,<\J2V-K##;V;1R1!U<, 48^8C $<UT1_:U_9^\0^']8\SQ+X*
MO=/TA4@O(WA1@%9R%54*YD7>"!M!&:\A\,?\$:="T.R'F>+9A=R!UN7M=/2*
M.49AP=I9CD"$?,3U)J;XG_\ !'+PQX^T#PS ?$UU:W'A"QBM=/D:V5H7ECN&
MG5Y$!&\$N01FBX'K/QK\=_"W7?V6[&^\FVUKP?JM[9VVCVVC;4,]T9AY"P8P
M%D5QGVVFN<\/?MG^&/&'B!(+7X>:]>>$]5UO^QI/$AMX#;W-Y$=AE:-CYCQJ
MRD>=CC!QQ5J;]A(^%/V:?!/@OPWJ=I]L\%>(;;Q##--!Y5O=.DS/*A1<[5*N
M^/0@5RWB#_@E;#K]_9Z4_CK44\!6&LRZW9Z.+&/[7I\DDAFD@BN@0RPLY)((
MS@XS0!Z1J/[8?P*NM-UBZN/%GA*>+3[I(;UFQ(7F^:-,+M)D/RLH*@]#BN;\
M<?$3]FOXL65KX>U'5/!%S_PF,$$R")4B>^B5M\>]PO&3'PK$9VXQQ7!?!S_@
MCGX<^$/BK3[V/Q(]TFB7MM/I\7V!%=H87DD$<K$G>29#\PQC P.M4;3_ ((F
M^%[/QZFLP^)IWBN'2:^CFL5D:1HY)'C,1R G^LP>#TXQF@#TFW_:W_9_U.$P
M"[\&2>'/#<:7%K=_9HFMHIVD9-L,87<7W*>4!S@^E=7X(\7_  [^/GQAL+>S
MLA=7G@^WC\1:'.O%G>170:/[7&!@,P(9<D94GWKRO5/^"76G:9=^#]3T?QG-
MH^N>!K"TL-)N6LHI8!)"\K;Y(S@-N\UACKD9KU#X'?LR:M\-/C2?$VIZ]'K$
M-AX9A\/VDGDK!-.WG--/-(B (@+D!54< 4 =!^VFK)^ROXQ#=?LD?/K^]2O3
M?#W_ " +'_KWC_\ 017)?M!> +OXL_!K7/#MG)%#<ZK"L4<DGW5(=6R?P%=?
MI,?V/2K:(D$Q1*A([X % %JBBB@ HHHH 0_>%>0?L[#=\7/C /\ J88O_26.
MO7S]X5Y!^SJ?^+N?&'U'B&+_ -)8Z ,#]HV]^)'A?XF>$X/#WC6TTW3/%NL#
M33;2:.D[VJ^4[[E<GDY7OZU[7X6TZ_TO0[6'4KW^T;^*/;-<K$(Q,WKM' KY
MJ_;+\0?$>P^-_P *H])T[PC/I\GB@)8/=7,R2LWV64GS0JD >F*]L\4?%W_A
M4_@*RU/Q@GD73?)<)IEM+=QQOU.T*-VW'<T =[17GGP2_:5\,?M"1M/X7N-0
MNK1(Q*)I]/EMXY5)(^5G49Y]*]"8X';\: %HKRO]H']J.U_9UMEN]5\->*M2
MTW$8>\TNR%Q%$[N$5"<@Y)8=J[+X:>/)/B'X?^WR:-K&AG>5^S:E"(IL>N 3
MP: .BHHHH **** "BBD)P* %HI VZEH **** "BBFNVU: '4R239Z?C43WJJ
MV-R9QD@L/EKF_BK\-=)^+7A)K/5#>-;Q9F1K2[>W<,%.#N0@T =(]\L499_D
M5>I;C%>=M^V+\,$ULZ:?&^@"_#^7]G^T?O-V[;TQZ\5QO[ /PHTS0?@EHWB)
M9]8N]6U:"1;J:]U*:Y\S;,ZCAV(' '059_X1#2F_;N=?[+T[ \'"3_CV3[WV
ML\].M 'N<4@FC5AR& (-.KRO]HG]H^[_ &>=+;49/!OB'Q!I4,:M-<:;Y)$)
M9P@!#,#U(KK?ACXZU#QYX?%[J'A[4_#4S2%5M+]HS*5'\7R$C% '3T4V5]B9
M_D*\%^-/Q@^*_@;XO>&M"T73O!%QIWBV[GMK.>\DN!);^7$9,R!1C)QCCUH
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M_P#!2&#XA^)CH\7A+Q%JVHV5Y)#JTUC;*D.A1FX:&+SPS98Y4[MF>F:B:;V
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MO^"QGA[1)=?T_P .>%]<U;7-.19[))9(TBOX_M$<$C@@DICS,@-R<=JUI/\
M@KKX=M=2FB/P_P#'QMK7SY);Y;>(VZPP3K#<RD[\[8W8#IDC)%#5P/!/&/CW
M]H;XG^+OAQ9>)++Q:C6=SIFI6UG;:*%L]557F,DU],O^H?Y8LQ@X^8\<UI?\
M-&?M'I\.-<O4N/&MQ/;3V,UY#<>&O*N4NVGD%S86>%(:+R]F)&& >_->QVW_
M  67^&VIWOB&+3])\5:C'I8F%J\%JK#5GCF6&18@3\K;W&-^ <<=*Z_X%?\
M!0*3X\_M&VG@>U\%:[H\*:;>SZG-J)19M-N[:98FA902#G<#N!QS[4(#B_V,
MOBU\<_'/[5GB6W\?I=Z5X5MTF%OI<^FN@BC!002)/M"%B"=X#'YLXZ5]B?:&
M]/\ QS->??M;:_?>"_V=/%&IZ7=SV.H6=NC031.0T),B [?P)%>A:"HFT.S=
M@&9H$))'4E13 O4444 %%9OB[5/[#\.7M[L,ALX)+@(#R^Q2V/QQC\:_,_X4
M?\%)/BQ\3=0T'2-2URW\,W_Q*G@ETRYN-/@>#0K5YI5=T97(+#RP@68 Y)H
M_4$_>%>0?LZ?\E>^,'_8PQ?^DD=9G['/[06M_%K]E>V\6:Y;'5]5M)KRTG.F
M0_\ (3-O.\(EB0\?/LW8!QSQ6?\ LD_$<^*_'OQ:OSH.OZ:TGB*(&WO+?RYD
M(M8^HSQ0!H_M8+_Q=OX(?]C?_P"VDU>O>+1CPOJG_7I+_P"@-7AW[5NO%_BS
M\$6^QWW'BX\;.G^B2^]=S\>(M=\4?#Z_30]5U3PQ<PP33/.MA'<^<HC;Y-KG
M ^HH J_L1DO^RKX()))_L_J?]YJ]5(S7R_\ \$T8O$^D_LN^$;_6O$&J>(;:
M\TU?(MCID4"VF';.&0Y.?>OH5_&4? ^S78YQR /ZT ><?MX?+^S9J>/^?VP'
M_DW%7KUH,6R?[H_E7S'_ ,%&OVC/"_@/X%7FEZQ=S:=?W-Q93Q026SON0746
M3E01^!->U?#GXV:-\2_#D6I:"+[4; _NQ,ENR#<.",-@_I0!V]%91\2\'_0-
M0X'_ #S_ /KURNJ?M+^#/#^H/9W^NZ=97L9*O;SW422J1R05+9H Z?Q-XWTG
MP=$DFK:KI^E12ML22[N$B5SZ#<13?#'CS1O&CR?V1K&F:J(<>:;2Y28)GIG:
M37"?'H:-\0/@QKUQ>:$FKP)I-S/;236R3*/W+893_45E?LH0:-X)_9Y\(W-C
MH:Z8LFBVTUU+#:K%NQ'DLY_K0![1(VT=^O:O OVR=!U^PM]%U?1/''BCP^=0
MUJQTN6WLIHU@$<LF'8!E.&QWKN;#]J;P-JVIPV5IXCT>ZN[AQ''%#?P.\C'H
M H?))]!7)?MB>)//\"^&LV5_\GB[2QS%C_EM]: /6/ /AB7P=X;BT^;5=2UJ
M2$G-Y?R!YY<\_,0 /TK7<D&N-^),>K>*_#MQ9:+J.J>&+\L"FH164<[1C/\
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M=?%37CJ7B;P1X8UW46B$!N;[3XYY2@Z+N89QR:YD?!'6L?\ )1?B=C&>MO\
M_$4A^"6M9_Y*)\3OSM__ (W2<8O=$RA&6Z/5O#OA>P\-:-;Z?I]E;65C:1B*
M""*,+'"@& J@= !VJ'QY\/='^)G@W4?#^O6%OJ>C:M ;>[M9ES',A[&O+_\
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M65CYVHZ?'$)YEC#D7<7"[B,\>E>Q^(/'NE^!O"<FK:E.8K"VB61Y$C:7*D
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MR_J*<,1BJ.(D\7./L]+6N85?JTL/!48_O%?FUW['*_LB,8_$'QB(&<>.[S(
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M_C'_ -C.G_I+%7LU>,_LS#;\6?C&/^IG3_TEBKV4'(H 6BBB@ HHHH ****
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MW@"NO_9?79^T1\=">^OV?/\ VY1_XT\ Y3YJDNLG^&A.);C0A1+'[7(QXO\
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MS6%^Q@H'[)_P\X_Y@5K_ .BQ75?%QO\ BTWB?_L$W7_HEJY;]C Y_9/^'O\
MV K7_P!%B@#F_ B_\9\_$'_L5]*/_D2:N5_X*+?L_P"@?$?P%8ZKJ3:Q]H76
M]+M]EOJ4T$(3[4@SL5@N>>O6NL\"G_C/CX@_]BOI?_HR:KW[;?S?!JTQ_P!#
M!I?3M_I<= '3P6%C\ /AR4L;3Q!JMI9MN6"-Y+^]DW'H"Q+$>Q/%>'?\$[?B
M\GBOPQKNEOX;\5Z>TGB75KD7-]IYBM\&X/R[B>OM7T7XXU36=&\.33^']*@U
MC5 1Y=M-<_9UD]<N00/RKR+]D;PO\2OA^FH:1XK\+:3IVG7FJ7NIB]M-7%P5
M\Z0NJ>7M!XSC.:757V#TW/DW3?VH]*^"/_!0^\LETS4+KP98:K=:3%>P$8M[
M^[V PA.ZB3C=[U[[^WO\ =+^/O[-OB+4/'C?V9'H%A<WFEB"Z\F2RE\M@&:;
MC)8<%>G->2?''_@DEX"\9_\ !1SPWXHNM7\8067BQ[KQ#J&@VVI&*P?4+8(8
MYP%^9>2#@'J*\S_X.$?V2?%WBG]D[P]I'A/Q-XWOVO-=6%M/O;_=83ED(432
M\.@S]W)(SUKYM8.5*C5_M&2=.[:[)7Z]_+L?1XC%X6K6I3PK=.2BE*756[>I
M]K_L.^$-'^ WP-\&^#].@6WTJ73(+G3Y-^[[2TB!Y-['[S[B3GOFF?LUOO\
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MRG%3G*-&-^3XFMK>IU'_  7T^)?A;X;>$O!>M^(?$>DK_9SSQ+H.H[VAU+S
M!YH5<_,F,\CH3R*^O_\ @GMI5GH_[(/@2VT_Q%%XKL?[-26'589"\5TKY;Y"
M<G:N=H!]*^0?^"GO_!+Q?VMOV:KSQ-\3=>GL=;\((U[81:&H"0M*R)(LDC@F
M4E3QT QQ7W+^RC\"M!_9K_9]\)>"/#%M+:Z%X?TZ*WM4D?>Y&W)9CW)))/UK
MGP>!C'$3QCC:4SLQ^-@\#2P=*7P2E==->MS _9C_ .2J_&/_ +&9/_26*O9Z
M\9_9E_Y*O\8_^QG3_P!)8J]FKU3PPHHHH **** "BBB@#QO]O22UC_8Z^(1O
M])N->M5TB7S+&%BCR\C#!@"1M.&R <;:^(O^"2MQ:2?M66PL]#NVT4Z#>G1M
M0GO9I[ACYR&YN[@,B@FXDR$;KMBZ5]P_MS>(;_PO^R9X^U#3M8AT"]MM*D,5
M_,<);=B2V#M)!QD],Y[5\G_\$F/A%\3O"WQ/BU+6M*U7PYX4MM+N+81ZEXCB
MU:35TDF$MLT>TDA45FRY(SNQCB@#]"W?R8Z\;\5?M]_#'PGJWBK3WU]K[4O!
MMY;:=J5G86SW,XNK@$QP1JOWY,*25'3!S7KNM:;_ &OI%S:^=)!]HB:+S8SA
MXLC&Y?<=1[BOAC1?^"1WB'X0^.;_ ,1>#OB#+J=Q:W]AJFE6VO1AXY9X/-$K
M7,D8#.SB4X?KQS0!]F_"7XLZ%\;O 6G^)O#E[]OTC459H9=A1LJ2K*RGE65@
M00>A!KA?V=&Q\7OC#_V,,/\ Z21TW]F+]F9O@_\ LYQ>#-:U$:E=7TMU=ZC<
M6FZ!3+<S--((B#N50SD YSQ7._LE?"O3/!OC[XM:;:2ZHUM#XABVF>_FF?FU
MCZLS$G\Z /?S\PZ]?0UROQ@\5:5X1\!:O<:KJ-EIL,EG/$CW4ZQ*[&-L %B!
MFM?_ (0NU_OW?_@2_P#C7DO[8&@:AI_PHE30_ 9^(=]=EK<6,]P-L 9& E&_
MN"128(\+_P""4?C/3+7P/IFG:;?V.H-<Z#;WC0P3K(P<EP<@'C)3O74>$_B-
MXZ/_  4$UJZD^&]W%'-X3M+9S_:D!\J(7<G[TGO]*\D_8?\ A[XF^%WB'P=I
M7BSX8K\/)[/03I[W<,Z_Z>XF+<[>A57)%?2.E?L#V5A\1F\5#XB_$^35)8T@
ME+:N"DL"N76)ALY7)->7EUJ=>K1[/\+$45^[2['0_MV/G]FC4N,$WMAD>_VN
M*O5]0UVR\/:,;R_NH+.UA0-)-,X1(Q[D\"OG7]OGQ#I^C?"2X\.Q:?XIU#5;
MR>TN(TL;2XNEV)<QLQ9D! . 3BO5O" \-_&WPAYYLM1GTZ5O)DMM5MI8MY'9
MHY,9%>J6>;_L)_$OP]K+?$6SL]<TJ[NKCQMJ4L4,-TCR2)\GS!0<D5I?M MG
M]L;X&?\ 775__245B?L6?!'PMI3^/;FRT6QLKNU\8ZC%%-#$L<L2?)\JL!D"
MN-_:1^,7AW0OVQOA/%)I_C*7^QKG58[AXM,N)%):W &Q@,.,^E 'NG[6?@C5
M_''P2U^+2_$MWX<$>F7;3FWMHYOM*>2WR'?]T>XK"_87\ ZMX)_9X\(_VGXI
MOO$,,VCVOV:.XMHHA:*(QP"HR?QK*_:]T[Q#J7P6-WX037/LUU9S-J/DS113
MBU,1)W"?OCL.:Q_V);;7M*^!<6H>*$\0G0;/2X9M*%S+#+<-;+%G[L'.[';O
M0!T_PH4_\-T_%SWTG1L'_@$M<[^WQXC\<66F>'(-'\+:;J6E#Q/ICI<S:F()
M6D$O"[=IP,]Z\<^!/[<O@GQ+^VWXRE3P]\3K>U\86^E:=IT\VA7<41DC$BMN
M<\*N2.37N?[6/@GQKXP32]*\,>#?[:LM/U:SU1KN;71!Y@A?<R!6!.?>@#U[
M1O&\^B^"X]1\9II7A>Y)(F1KY6MXB<X'FMM!)KR/_@GM\0_#_B3X/7EEI^N:
M1>WB:[JLK06UY'+*J?:Y/F*J2<<CGW%=GK/P+T3]I#X9?V9\2/!UO);74HDG
MT>\NOM<093\K;A@&LWX3?L"_!_\ 9^\2R:QX)\!:)X6U22%H&N-.C:)VC)R5
MZ]S0!YE\1?V<K[4OVX_"5R/B'XU@DGT+4I8Q%<Q!8!YD1\M04/R5Y/\ \%2/
MB[J'P(^("^'-+L8KW4_B?HGV>UOKZ?R+:VFM/OLY_B=D?H.N*]<\=?$I+?\
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M9_9/\9R:V-0D71]'N+JV6VO9+=?-"Y1FV$9PP!'IBM?XC^%[8?M>?#9<W/\
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MK/<JWA=M+>*,\F,R&-<[22,9H6H'T>1D4C1[J=10 W;M85Y#^SI_R5[XP?\
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M<UJ^9/\ @IY^T7I?PE_9V\1:!>:9K^IW_BO2;FVL5TVS-Q\^  &V].M?0O\
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M/WV9B26/4FN._9MMXXOBS\7E6-$4>(HL!5 '_'K'7L1^\*\@_9T_Y*]\8/\
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M-ZR2!63<I[Y/8U] _%?XL>'O@-^S4GC.XUK5?%.F:)L9-4AC^V7-SO?9\VP
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M?_@E?XHU/5/C@MA;^.;#5] T_0?).E_\)S/X@G#J5"NBNBJJ+@C.2>:^C?\
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M:1IE[;%;N*T@$:-&H.?E'& ,X KT.H+E!)P<$>AKUY6<6GU-5;9GY0?L@?\
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M,(JL7RZ/IZF%3#\U55XO5'O?A[QC?ZUI%O<PV$3QS*",7 &/;I4\NMZG_P!
MV/I_S\BOR_UW_@K+K?PK_:D/PWU'Q#XGTB:.YN+:[M$\/6LGDW8D152)F;)B
M.XD<9.X>E?J1IDS/X=MI9BYE^SJ\A==K9V@G(' /M6>#Q#E0O-KFC=/Y&ZDF
MN9'C7P:U'4/$G[1OQ$UJ.P28636^E(?/')1=[8/U(KV)-8U<-SHX_P# E:\T
M_8S@:Y\"ZMK$F0WB#7+R\7W3S"B_HHKVBHR>'+A4^[;^]F&&UAS/J8C:SJQ'
M_(('_@0M<S\4/BM+\-O#C7^I:-J$D,N8 ME&]W)D@X^5%)Q7H-(5#&O4-K)G
MR;^RC=6/Q9^ .B^%]6\)Z[:ZCHL+RL;ZSFL)+4F5R#'*RC#<@\'OS7Q-<?M-
M?M"^#_\ @I)]IU[X:^*KOPO<VP\+QVMUY2XT_P"T8BOWN =N1+\V?3KS7[ W
MPPC[,[@,@#OZ=:^9O$$'C?Q=^T%>:IJGPMOY_#5]H?\ 84F=5MBW_'P7\W;G
M.W&#ZYKFKX:-6#2T9S8C#RJ<KC*S3OIU79GM_@OQKJFJZ&@;3D^TVS>3.//4
M#<.,_0UL'7-5(_Y!:?\ @0*_/O\ ;W_:8^*?[!US#%I'C[P-X>T^>V3[!_;]
MFUU/K&)40 8/#QJV#Z@9KZW_ &1?'WB#Q7\$TUOQ?XX\'>,C=3.\>KZ @AL%
MBX^0DG&0<C.:YLOJMP]E4>L-_,Z(34S._:!UC4=>^)G@#0#8I_I.I_;)$$XX
M2$%B?Y5ZS::GJOF?\@D':3@_:5ZUY#9>+M,\??MK+%;ZGI]R/#7A\E1%<(XD
MDG?MACR%!KWJVZ^AQR*PRF+<JM1]9?D2E[[9F'6=6'_,('_@2M5[RYU/4(I8
MWTQHO,C*;EN5RN>X]ZZ&D(S7LFGD?/N@_L<6_ASXC/XI@U7X@2ZK.(TF:7Q#
ME)8T8LL97;R@)/%?*?\ P7!^ ?QG^-%KX8E\%:1I5AX>TF[A>YO8]6,.H75V
MTB_9HRH7!C63#=>M?I<%Q7@/[:%WXEU_P]#H.A>"];\0E-1L=0:YM7A6%4BN
M$D=?G93N"J?SI.-W=[F-:@JL>2]NQRG[/7C?XI>)/V>= UK6$\/Z9XXDA33-
M9E60W=M'/&=GF,ORD-Q\P]\UT?[*?Q.^*WQ-L;[5O$DOABXT^TU*[TP6UC;/
M#(YAD*"3<S'@XSC'>N(_:C3QMI'P;\2^(_ ^G:MX8O?%,)M[RREEBBFL+GI'
M> _,@4C ?';GK7C'_!$OQI\2_'OB_P 3WNMGQ#;^"[2:YTX6FIZM!=>9JD<O
M^DSH$7)0MP#G'?%>+3G.AB/8_8>M^S+A;E]G)^\C[(_:G\7:GHO[/?BJ1K!(
M?,L7@#&<'E_D'\ZW_A=#J?AWX>:%8KI*G[)80Q8^T 8P@%<_^V/_ *;\(8=/
MQN;5=7L;-5/\6Z9<C\@:]3LHO*MT0=$X'Y5O3IWQLJGDE\B5?VC\B@-9U9?^
M80/_  )6C^VM6_Z!'_DPM;*\?G2UZBV-3";4]49L_P!D'Z?:5Q6#\1_!MO\
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M%?[-4A4M[J_"YS1E3PS4'HGLC]UK77-9* /I<<A  +). &/J!4RZOJKL"=)
MP?\ GX6K6A7,-QIT;6Y0P%0$*G(Q@=*N*/GKV(24HJ2ZG38\8_97FEN/B?\
M&)IH_*<^)DRF[./]%B[U[77C/[,QW?%?XQ_]C,G_ *2Q5[-5 %%%% !1110
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MJ.% (!''4=JV:]5;'2M@HHHI@)CFH;B/+?7UJ>FR)O% 'X>?MB?!KQ'\0/\
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M,?OXF0_A]EBKV:O//@3\"'^#1\07%SK]]XCU+Q+J']HWEW=1)$2X0(%"IP
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MG%>'?\$K_C[\:/CGX[UR;Q3>W^M^%&>9KBXOHX#;6\ORB-+26(Y96.YBC@%
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MM_B9\1_CKX#OM2^(ZW&M>'+-OM=AJ.N16[W$5T)'+B-XB5=(XPN'P"#D4=;
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MZJ=0K!L9KW;XTW_PV^$OPM@^$?Q,\<^+=?M/$VUIKN\5I[E+%IE54NKB)<+
MS$1[GZ@G-=1H/P#\ ?L?3WWC71?$^K^'/ VC6S'5/#JWQO-'5L*$:.%MS12
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M?X0?#&\_X*(_'?2?''CE;M[!?M%_;AUCDT^#2BQVVR7ELX>*781YD4X/1L4
M?27ABZT']D_Q!;RZ/K&M_$KQS\78A>PR3/$MW=6=M!E9D155&VAEZX+EAS7S
M_P#L3:);V>O^-O%7Q%FU2VLO"=Q/X@\33:N,V]U.27C:6TN5WVTZ !0T+%6V
MBO8+K0OV:?VJ/B-HM[>ZXL/BF^LET?PS"-1>QN=/A@=E5K+81Y>]D)']\*.*
MZ'XS0_"[P7\.!\(/BMX[U76[7[,FKZA=:M,/-N+-)P(X+J5%^97;Y N,N%-
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MREY7%?7B=*H>&]-DTG2H8))?/>.-5>8J%,[8Y<@< GJ:T ,4 +1110 4444
M%%%% !1110 4444 %(SA.M#MM%>8_M%_M+:=\!;71(/[(U7Q/XA\271M=(T3
M2T5KN^95W.PW$!45>68D 4 >:_ML?M3?"GX8>-?#7AWXEVOAW5=$N;M'NI+V
M6.7^Q9F^6"66!N3$Q)7>,[<\\52^+=]\)/V-?A7#IZ>#=7OO!'Q,U$65U:Z!
M!)J%LGF1%P_E*25B*K_RSXKY4_9\\!?$7]I?]N?5KS5XM;&F1W+KXNTW7[6W
MGAL87\PQ6QAE!=&V% CQ':V&.:^@?BU^V)X7_87\2>%O!.A:9>Z_X0\)PK::
MU!:6LU]J&B(Y_=SK( RE8\D.I(8+TZ4 >C?"WX9_!/XOZG9_$SX=:5I%UK'A
MY#%#<Z,SV$CND>%MKA%V@D# (D4XSFOG>\_9&^(_BZQNE^,/@"/Q>OC'5Y-0
M;6O"^L>3JWA<3':EO-$^$GBB7;RN1P>*^F?C%I)^,'P9LE^%7CC2_ VN^+[B
MWU/3-8LHH6-^@97<[",2[DX.1GBJ3_&?QG^S#\-=9U3XNW6A^(K2P>*UT>]T
M&!H[_7I)6"I";8_*LS,0!M8@\T 8?[0WC+X>?L/?LP:/X6UFPT_6?"T:I;W6
MF7<\<<]Q:*09ITB/$I3AFC7\!78_ 3P=\'_#_AZ?XI?#V+0[#1?$.FK<2W^F
MRF*PF@'S"1HP=BL.Y"@C&#7PY\7;OXL_M*_MV:;!::5XO\(ZJ'CGM]'UJ*WE
MM++3!Y8>5XI-T4J$[]YC.X,4!Z5T?[4_Q5TSP[\!/%GASX4>&_&NC> IO$DS
MZSXGT\>1I$]R?EFAA93NA@:;9EU79G/.* /:?@EXE^ /[=GC3Q#8S^'/#EO\
M0-"U(7]Z+>Z0WLV,".\AN8B&>-U5>AXZ$5T'[4O[3OP;\+?&KPKX'^)=GX:U
M"Q:0P6]]J$T4Z:3>.NR-)H6Y42(2!)R,FO$?@!X=NOV>O WP]O/&OA;7?&'Q
MEFN+ZZ\+Z;I=M9Q:I%IOE*A>\DAV1R(,YRY/)7'->;?LE>$/$?Q0^+_C[Q+\
M2)-6;P#IEM=_\)HGB2VMYO(G\HDP1K(#- Z[@5V'&W&* /MOXI^%?AS^RO\
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MP#^V3XXOOA=X]T>6VAU2\_M/0[^"VN-/L/$\0)(A9L*6F4#YXR2' R,@5?\
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MJBB@#*\$?\$Z%\%ZAX7F/B*.<^&O$^L^(R?L8!F_M"%H1'UZIG.>^*\6NO\
M@AK'I-Y$]KXLTN>&_P!/M-/UDW^F-.Y%M(TBO;@2*B[E;:0X8#&1110!ZI^S
MK_P35U3X$_M5_P#">KXLT]--MA=#^S],T]K0ZD+C&W[2 YC)CQPRJ">IK[!H
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
,@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>tm211152d1_10ksp1img007.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm211152d1_10ksp1img007.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" #C 3D# 2(  A$! Q$!_\0
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M_P"Q7M/_ $"O?Z\ _P""5O\ RCG^#?\ V*]I_P"@5[_0 R1]IZU#//L4Y?:
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M5-^"_P 6[/QC/I'B^!XO L,ESJ3RQ&-?)0D&2//WUR, BO9OA7\3-/\ C%X
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MTXPJ2:48WV)ERV;9^!G[6=K$G[&7QN/EQY3XJZ?&AVC*K]I;@'T]J_?7]GE
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MH8QZK0 ?\$JV+?\ !.?X.$@@_P#"+VF1C'\%?0)&:\ _X)7<_P#!.CX-]?\
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M]Z_,C4KCPKI<O[%]W\3ET\> F\"ZA&C:F/\ 0/M1@8*#VW=AFG?LY?L#:?\
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M'_!"3_@AWX:TW]CWPSXJ^-MC)XNUO6,:AI>GWE])+9Z9;,,HHBSMR>M><_\
M!2']K#]FZT_X)2:Q\(/@U<?9Y%FMC%&+=DDNW5P7GD8\L[=R:_57_@GY>07/
M[%7PPBCDB=X?#UJKJC;BA""NO%8"OA4H5J;C?OU)4XR5XGIGP^^$OACX5Z-'
M8>&] TG0[2,#;'96J0@?D*WRF&)]>,TT3;2%/?H?6LSQ5XST[P3H\NH:K?6>
MFV4"EY)KJ41H@'7DUR6D](C-%CM/RX7)[CK7.^//'6E^ _#U[J6MZC::;8VL
M3N\D\BQ@ #W/)]J^6/B#_P %1[OXI^)9O#'P&\)WGQ"UM"8VU,HT.EVC="6D
M(PV/:L"7_@E[XE_:?TR[U'X_^/=2UZXNHR\>BZ5*8+#3SUX Y8CISZ5Z-++(
MI*6-FHQNO-O5=#.4IO2FC\<OVI?B5\2?C2WQ6^&GPST"#Q%X=^(.OG4+B2.)
MI+I!'+NC9,<;3QG-?I;^PA^WG^UYHOPRLO#_ (K^  O1I=E!9:=+;2_9\)&@
M3,A;@G %9'_!$?\ 9>T+1_VD_BEK,=Q>)+X'U-]-LD=ODF@.1\Z]#TK]2H-<
MT]80GVJVSTV^8,FOJ>+,9@H8^:IT>=VC>5_(X\#2JRA)Q;W]3Y$?XI_MF>/K
MS.G>!_ 7A*TD[WUV9Y8Q[@5'<_LK?M3?$N7=K/QOTS0(7/SQ:1IO*#ZMWK[/
M4H\&Y<%6Y&WI2V*!E8Y;.<9S7RW]JRBN6%."_P"W5?[SK=-WM9V[W_0^,G_X
M)'7GBMPWC#XT?$O7W/\ K%CN_L\;#N,+3_&?_!$WX1W_ ,/-4LK*'5VUFYMV
M6'4;_4);AH7QG=@G%?:07 ]?7-9_B+4H-)TZ22XEA@CV-\\KA%Z'N:(YOCN9
M.$ON)="%G<_)3_@A)^RY-I/[1_Q$U-M5AFT_PE=2Z-<V,MNKK?G<0K8(.,$?
MK7ZX:/I5KIL9%O;6]L3RPBC" _D*_.O_ ((A:O9P?%OX\AKRW_TKQ-(T)>50
MTB[VQM]?PK]&X#@9]?45Z_&F(K5<UDZV]H_^DF>7J*H>Z3T4U6R:=7RYUGF/
M[7'CN+X8?LU^./$$^EQ:W%I>CW$SV$JYCN5$9RCC^Z>]?A/^RW^TKJVC_&OX
M<Q3_  W^#7A70Y?$]G>6<-@3+=#[6>)8E.=Y&<'^[7[O_M1^/+;X9_L\>,O$
M%WIBZS!IFD3SRZ>R;A=*$)\MAZ&OP_\ V<?VM-.\3?M%^ -?\0>!_A+J]];:
M[:6.EZ9I"C[7I=I<G,>Q1U>(GYO2E3^.P'] =N=T"'U4'I4E,@;?"AQC*@X/
M:GTP"O O^"I/_*/7XN_]BW<_^@U[[7@7_!4G_E'K\7?^Q;N?_0: &_\ !*W_
M )1S_!O_ +%>T_\ 0*]_KP#_ ()6_P#*.?X-_P#8KVG_ *!7O] "8YJ"^TN'
M4K=XIXTFC?JCJ&4_@>*L44 06VG164 CA188P-H6,!5'X#BI2FZG44 <IXZ^
M"/A7XG:QH^H:_HECJM]X?F^T:=/<1AWLY/[Z'L:F^*7PB\.?&SP3>^'/%>DV
MFNZ'J"A;FRNT\R*8>X-=+10!XA\*?^";OP-^!WCFU\2^$OAKX8T'7;+/D7MI
M:A)8\C'!^E>M>*_!NF^-_#=WI&JVL5_IM_$8+BWE&4E0]5([BM6B@#RWQ[^Q
M;\+?BA\.--\(>(/ ^@:IX;T<@V-C/;*T=GC^YW7\*U?$7[-/@?Q'\)8? UQX
M<T[_ (1*W$:Q:5'$([= A!7Y1Z$5WM% 'DOC/]B+X6?$7XGZ#XPUGP7H][XA
M\-(D>G7;Q8:W5!A  .#M[9Z5ZND6S'H!C%/IKMM0D#- "GI65XF\86'@S0;O
M5-6N[;3M/L(FN+FXN) D<$:C)9F/ JG\1?BAHOPC\&ZCXA\2ZE::/HFDQ&:Z
MN[B38D:@9SG] .M? ITSQG_P6N\>+/=C5?!W[-&CW&%MSF&Z\<.C?>/=;?C\
M<T )XG^)_C7_ (+*^/[OPKX'DU'PA^SOI-T;?6/$0!BN?%S _-;VYZK"?[W>
MOLK0/V2OA[X:^"EG\/H/"VE'PEIT:K#I[PAHR5Z.WJWJQY-=IX!^'6B_"SP;
M8:!X?TZVTK2-,A%O;6MN@1(D'0 "KFH:A'IEG--*Z10PH6D=VP(Q[U+FXRCR
MMWNMA22<7S;'X4_#O_@C7X3_ ."D7[4GQCT>Y\5:WX)T_P )ZP\-I!I4:[=A
M8C'(K]%?^"=/_!,O3/\ @EIIVN7MW\6O%?BS2+BV6)4\07(2VT]$Y^3T_.OC
MW]D#]L#5_A'^UU\;;#X?^$[SQUXD\6:U(VF1P'_1T4,?G=^R\U]5^&OV!?B#
M^U5JL>N_M">,;B:V#"6+PGHDA@L;<?W9&',GN#7W'%%"O/%J>-GRP45Z_)'!
MA:J5*\%N=#\5O^"I/_"2>)Y?"GP1\+WWQ*\1;C$;R$$:9:$G!9I>AQ[&L[PU
M_P $YO%_[1>JV^O_ +0'C2]UY=PFA\-:9(T&FVQ/.Q@.7QTR3S7U-\,?@[X9
M^#?AB+2_"NBZ?HVGQ* (K: 1Y[9/<_C77VT?EQ #TKYEYC"FK82-D_M=3KC"
M3^-I^ASWP\^%/A_X2^'HM)\-Z18Z/IT"A4@MH511CZ5'\1/'6B_#/P]/J.NZ
MI9Z39$%//N7"+N(X&:ZH#%>8?M1_LI^$OVOOA^WACQC!=7&F>:)@+>=H6##W
M%<-/EG64J[_4T>W+W/SP_P""7GC#P]XK\6?M$: WBVRT.Y\5ZS)#IMU%< 2O
MN)&^//7K7':;^Q]XP_X;LE^$(^*OBY8(--34UU 3'S)"3TQT K[#\$?\$/O@
M1\.?&FEZ]8Z5JZWVBW2W=L[7[D>8#D9&>?QK@].D _X+?7Q *H/#<8W X!'I
M4\8SPV*Q-.K0D]91OTZ'Z)X78JOAJ..HQBI*-&<DVD[-..I]Q_#'P>_@3P!I
MFCRWT^IRV$*PO=3',DQ ^\?>NAAB\L$=.:@M2=K;NN>GI5I6PHS1;E]U'YW[
M1U?WLMV+M]S7CO[:?[*5O^U_\*$\+76OZSX=B6Y6Z^U:=)LE)7C:?8YKV('-
M1SQB0C/OCBKI5'3FJD=T*44U8_/GX1?\$)/"WP;^).F^(-+^(GC$365VMW)#
MNV1W+ Y._'4&OO.'5DM L>^)F "Y+\$ 5@?&_P !ZA\1/ACK&BZ7JDVCW^HV
M[0QWL1P\)/0BORO\(_L\_%75?VS=4^%TOQ>\4*=*M$O1<"X+%P3TQTK'-\]Q
M%:K">(O*4M+^B/K>%>$(9I0Q%2->%/V*YW%WNX[:?>?L!!-YA.,<8Z5+N/I7
M/_#G0[CPYX.TRQN;E[R>TMDAEG?[TS* -Q]S714X2;BFSY:45";@G>W4\V_:
MIU+5=)_9P\;7>B6L5[JUOH]P]K;RP^<MRXC.(V3^+/I7Y/?\$U/BS\$M-^+?
M@O4M4_98\::!\6]3F$=YJQT8BQM)R<&>/LHSD\=,U^L'[5-OXFN/V</&R^#G
M=?$\FCW TUE'SB7RSC';=FOR&^#_ .TCXS^+FH?LX^ O!^E?%BR^*G@36&7Q
M3>:K%LLI('8FY\UOX@>=OH,4Z:UN2?N DNY ?49I/-()Z>U9VL:T=$\-W-]]
MGFNC:6S3F&%<R2D#.U1ZFOC+_@G7_P %+O&O[97[7?Q>\%^(?!Q\&:7X(6!]
M+M+SB]D1SCS)!V##FF!]OK+N7..V<8YKP/\ X*D/_P :\OB\?^I;NO\ T&OD
M#]KK_@L5\3_A'^TCXUA\(^&= OOAK\*-1L-,\1O=RG[;>R74@3,/^[NR:]F_
MX*G_ +;_ ,+-*_8A^)GAG4_&_A[3?%&I^%GDATJ>[5;EC+&&0;<YYR* /6?^
M"5XQ_P $Z?@Y_P!BO:?^@5[_ %\__P#!*R02_P#!.?X-E3D'PO:=#G^"OH"@
M HHHH **** "BBB@ HHHH ***1CM%  QVK7&?'+X\>%_V=OAOJ?BOQAJMKH^
MA:7&7GGF;&[C(5!_$QZ8%9/[3W[4WA#]D?X3:AXO\:ZA'8Z=9+A(E.Z:\D/W
M8HEZNQ..!7R!\&_V</&7_!3OXD:=\5OC?8W6B_#G3)1=>$? C-A9QG*75\O&
M7/!"D<5-[.[ RO OPT\<?\%D?B/8^-?B!9:CX2_9[TBX\_P]X8ES%<^*2K?+
M<W2\8CXX4U^A.B^';'PCH]I8:9;16.GV4:QP6UN@1(E48"@#H*DLK"#1[)(8
M(XXK>!0L4:*   ,< >WI7SQ^UW_P44T/]G[5;?PAX>L;GQG\2-5_=V.AZ:/,
M9&/1IF&0BC@G-:X;#U\14Y*4;_U^7<.AZ_\ &S]H#PM^SUX+N=>\6:M:Z5I]
MNF1YKX>4_P!U%ZL?I7QMK,GQ9_X*KK/%9'4OA7\&W)07#J8]4UM?[RCC:OO7
M6_!W]@?Q!\<?&=K\1_VA;Z/7]=B;S=-\/0L?[+T=>H&W.'D'J17T%^T=^T5X
M/_8[^%<GB?Q;.=.T&V9+5#;P;RC-T 4=J]'FAA:D:>'_ 'E:^K7PQMV[LPFI
M23OL?F#_ ,$JOV2;K0_VI_BW-X7U^ZL]9\ --I.F&4Y@N]S$9F'<\5U>I?%'
M]JW3/VIH_AC_ ,)AH?\ ;EU"UW$RP?N53/'%<U_P3-_X*"?#?X5_M<_%6_UG
M5+N"U^(NM[M'/V9F$NYB03QQUKZ&URY-W_P6HT21=WER^'_-C8="&Y_E4^)'
MUJ>.IU:LK?"K]'W\C]$\+<50C1QD*M"$TJ4I+F5[2CLU]Y]H?!VP\0Z7X TJ
M#Q5=0WFNQ0*M]+']QY,<D#TS76F8JG SCIS51)\\ IR>1_7-<7\3?VD?!GP8
MLKB?Q'KFGZ>(@25>8;W]@HYS^%>5*4(-\SV/AH>TQ=6]*-Y/I%?Y'?)<MM.5
MJG)X@CA:;S"D2P#<[.< #ZU\GW__  4.\0_%R_?3_A'X"U76WD^5=1OU-O9C
MWW-U'TJ#_AD'XL_M#72S?$SQY<:1I[<'1]!;R4QW#/G+5SNO&<K4ES,]^GP[
M.$?:9C6A079N\GZ16J?K9'I7QR_;W^'?PPM+BSEU=M2U60>7'9::#/,['H %
MZ5^5FBGXD>(/^"BLFM:3I?B::_#?VBME+/Y=V]GNR$;T7T%?KC\'?V-?A]\$
MK0#1?#UM'=1D,UY,/-GD8=RS9-?+>AQ&/_@M[>>5^[+>&ER .U>3FV'Q$W3O
MHN9'Z+X=YUE^!HYC# T_:+V$[RJNR>L=$HZZ^;/2M._X*6ZIX=F\CQ+\)/'6
ME"'B25(/.4#UR*Z;P[_P5/\ A3J\_E7>H:AH\@^\M[:/%M^N17T,UBEP&,@1
MMPQ]RL'7O@YX7\1IMO\ 0=)O-PSF6U1L_I7L.C6C\,KGYS_:&23=IX:4?\-1
M6^YQ;_$YOP=^V?\ #'QJ0NG^,]#F=NBFX"D?7-=U9^-=*UI4-GJ%E=;QQY4R
MM_6O(O%W_!.OX2^+)7F?P?IL-P_62W4Q%?IM(K@[[_@E/X1MKIIM%\0>+O#C
M#H+34GV_D2:B^(CK:X>PR.JG:O.#[.%U_P"!)_H?3\]TC$[G7:,'!<<5^?\
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MGTI0,4M% !367)IU% %>6V;.5V_C34L K9[D<\]ZM44$\L2)(B/[OX4>2?\
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M$;P;\/OVH/A#XBTNSN=%M_ASX&U"/XE77V.1/L]QYAQYYQEW_,F@#]BOC/\
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M>_;7_;Y\3>/?B9<_!']GX6^I^/&39K_B-\'3/!\##YI97^[Y@&?ESG(KQSX
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M_@#-_P#$T?\ #]#]F;_HH"_^ ,W_ ,37T)_PS5\._P#H1O"O_@JA_P#B:/\
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M(=B-T0.%8#%?I#X\_P"";GP=^(WQ9TGQEJ7@G1_[8T>VFM83#:I''(LPPQ(
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M.!4E,@&(_3V]*?0 5G^)=)77='N+-GD1;J)HB\3;9(PPQN4]B/6M"F2KNP*
M/QK^$W[,-]#^W[\9+SX;>._'$_AKX0:+/#(FL:T9+74-8GB;$98G 5"<\].*
MN?\ !%>X\4_L]_MFVWP_^+\GB:X^(WBG0)=:M+L>(/[1TZ]@WDEB =JG!X]J
M_2;X??L/?#_X;^&_'FDV6ER-9?$>[EOM;1Y,_:)9!AL'J.*XO]D+_@E=\*/V
M,O'MYXE\+6>IWFNW$+6T5WJEXUR]E;LV3%%N^ZN?2@#Z3MF!Z=2,_AVS4U0V
MH7;E00,8P1TQ4U !1110 4444 %%%% "8S2T44 %%%% !1110 FT>E!0$=!^
M5+10 4444 %9/C&:_@\-:@^E)#+J:0.UHDS;8WE .P,?3.*UJ:_ H _+C0/^
M"C'[8>I_MS?\*/N/ /PVBU^UL%UBZF&H'R!:%\;E[[MM>U_#O_@K[X0\%0^*
MG^+OB3PUHG]G>(&T33ETYFG>>1%RRD =<]*?H_[)OC:U_P""V6K_ !9:P2/P
M3=>#%TQ+T-EFGW?=Q7Q]H_\ P2B^+4W[46G:QJ/A.UNM!7XKS^(YUE8.CV3#
MAR#P: /M[P__ ,%R/V:O$^J:9:VOQ"M_-U6\73U\RUD18+@G CE)&$8G&,UU
MD7_!5;X%-\<D^'T?CBS/B(W'V( QM]F6?C$)F^[O/89K\]?BC_P2*^)6N? +
MX[Z39>#],CU;QC\4K36]&DC55<:>C*6<'&5P >/:O,?A_P#\$5OC-X0^/A\)
M:OX8U/7?#MSXRA\1G7TU5$L(4!#Y9"OF&08QD'M0!^KG_!1S]LV?]C?X'V.I
M:/91ZIXH\3:I;Z)H=FS<2SS. &]P!DU@?$G_ (*[?!3]G37Y/"OQ!\;VNG^,
M-&MX&UBU@MWD%H[J"68@85?<UY+_ ,%PO ]UH?A3X&>-P)IM'^'?C:PN=42)
M3(PB)"%\>WK7CW[1?_!-WX@?&CXO?M>^*+#PUIVIVGQ8\)VEMX4NY K-,ZHO
M3/0T ?3GC#_@L9\)O&GPV\:S?#;QEI&J^)_#&F#4XXKZ-X;>>/@;P2/F7W%2
MW'_!9KX*?#3PSI<'C[QGI]CXH;2[;4=2MK&"29+=)E!5\@<)[FOBGXZ_\$G/
MBMJVG^&H] \)V4'V/X/)X9O/*VQ[M1+*2IQU/O73?"[_ ()7?$?2[GXWW6L^
M$=.N[CQ-\*;+PUHSR[7+7L<.UE&>F#WH ^NM&_X*,M>?MZ^$_A\5L+SP%\3?
M#1UCPCK5LV?M<JX+(WX$XKZ\'2OR(^!_P<\0^'/VMOV,OA9>61A\3?"OP=-J
M'B4Q-N%BF"@C9NV2:_7=6W+D<CVH 6BBB@!-HSG'-&.:6B@ HHHH **** $Q
M1BEHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** &
MN@V]*8O"CZ444 +2*,(!VQTHHH Q?&GA#2_'/A6[TS6+"UU+3[@CS;>XC#QR
M8.1D&K^B:?#I>BVMO;Q)#!;JL<4:C"HH' 'M110!;C7>>>:>5&1QWS110!SF
MF?#G0K'X@:AXABTFQ37+V$03WPB'GRQCHI;K@>E=(O"BBB@!:*** "BBB@ H
1HHH **** "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>tm211152d1_10ksp1img008.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm211152d1_10ksp1img008.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0 B17AI9@  34T *@    @  0$2  ,
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MU]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$! 0$! 0
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M\$K_ /@A:OQ*_9^LKKXT:[\4-)BM/%][J[> 9M4\K1I"ER7AE: 9X. V<\T
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M?&3_ (+4_"/X++XL^W0>*M4'A+Q3#X/N/[,T]KAKG4I%W"&(#[V.AQWJ5O\
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M ^NOVY?^"D_PU_X)]1>%)/B#J%U;MXTU1=*T^*VB\QU<D*9&&>(P6&6KR_\
M:6_X+=_#C]E'XI0^$M?\&_%2\N-0N$M=-O-/\.RS6FKRNF\+;O\ \M"0> N:
M^8_^"EW[&?[0/_!0K]M[QU_PC'ACPU;>!_!OA!_#VDW/BM)##>7-P-\UQ9B,
MY$BD *QK1U;X9_&/XT_!+]B237O!.NKXD^'/C".U\3I)'N:SAMT,*W+Y.=K
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MCO'EU-:_%:U^!\FDV\&D+\2%C;65O%/*1L"9#"N2/F/:OTVMB3",]>A/K]*
M)J*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_P#A=6__ ,:H_P"&S?VK/^C4;7_PNK?_ .-5]E44 ?&O_#9O[5G_ $:C:_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M?VEML:S@G=NSG<!RN.:^CXM1%S$CQ_,L@5E.>H//\J /C?\ 83_Y2<?M9?\
M80TC_P!)!7VE7Q7^PFVW_@II^U?GJU]I#8]/]%%?:E !1110 4444 <'^U#_
M ,FV?$#_ +%Z_P#_ $G>O)_^"/G_ "C2^#__ & E_P#1CUZQ^U#_ ,FV?$#_
M +%Z_P#_ $G>O)_^"/G_ "C2^#__ & E_P#1CT ?2@Z44#I10 4444 %%%%
M!7%_&[]H#P;^SAX377O'/B32?"VB>8(3?:A-Y40<]%SZFNTK\L?^#O-=_P#P
M2D8?]3-9?^ST ?7@_P""OW[,A;_DMWP_Z9P=1 /\J=_P][_9C_Z+=\/_ /P9
M+7\5/V9<#@-GDY%-^RI_=7\J">8_M8/_  5]_9C'_-;OA_\ ^#(?X4T_\%>_
MV96X7XW> &9N !J(Y-?Q5K!&/X$_*KWAR%1XDTWY4_X^X1]W_;6@.8_M0UK_
M (*N_LY>%]2:SU/XQ>";"[15<PW%[Y;JK $$@CN"#58?\%??V8R?^2X?#_\
M\&(K^5G_ (+5VT<?[?NO*L4:J-'THX5 !G[%'VKY/\A?[J?]\T%']J__  ][
M_9C_ .BW?#__ ,&2T'_@K[^S&1_R6[X?_P#@R'^%?Q3_ &2/^XOY4-:H!]Q>
M/:@5T?W'? G]M[X3_M.Z[=Z;\/?B!X9\87UB@EN(--NO->&,\;C^->M5_-[_
M ,&6$:_\->?%C"J-OAR'&.W[X5_2%0,**** "BBB@ HHHH AE_U,W^[_ $KY
M!_X(H_\ )M?C;_LHFO?^E-?7TO\ J9O]W^E?(/\ P11_Y-K\;?\ 91->_P#2
MF@#[$'2B@=** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!K-M'\
MJCDGV]%W9_3ZTZ8%DXX/KZ5\@_M[?M;?&W]E[Q9_:/AKPM\)6^'XC0'6O%?B
M8Z8[3MG,87OT[4 ?5VA^+-/\2S74=A?6=Z]C,8+@03+(8''57 ^ZWL:TG^9?
MQKXI_P""+":WKW@3XI^,?$&J>"=1U#QYXSN-9:/PMJW]IV-EO0?NA+ZC'2OM
M=EW4 >:?M(Z=XRU'P7%_PA<>E7E_!<JUW87[>6-0MB"LD0DP2C$'(8#MCO7R
M1\*_V#_B=^SYJ<OBOPII7A\7VK+JE@?"\FJ2-!HEK>.70QW!4F0HY+,"/85^
M@'E\?XTC0[J /@#0?^"=/Q#^&7@/7/A[HDFAZKX=^(PL7UK5IIF2?2IXB3<E
M(\8D5P2$.1R.:^E_VF/V)O#G[5'A[0-+US7O&FCP^'A^Z?0-;FTV2;Y57]XT
M1!;[OZU[3Y6'!STI0",?KQUH _/G_@DK\#--_9V_;E_:D\)Z3J&N:I96.I:4
MZW.KWSWMV^;4'#2OEF_$U^A%?%O["?\ RDX_:R_["&D?^D@K[2H **** "BB
MB@#@_P!J'_DVSX@?]B]?_P#I.]>3_P#!'S_E&E\'_P#L!+_Z,>O6/VH?^3;/
MB!_V+U__ .D[UY/_ ,$?/^4:7P?_ .P$O_HQZ /I0=**!THH **** "BBB@
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M ,&5W_)W7Q:_[%R'_P!'BOZ0*_F__P"#*[_D[KXM?]BY#_Z/%?T@5!H%%%%
M!1110 4444 0R_ZF;_=_I7R#_P $4?\ DVOQM_V437O_ $IKZ^E_U,W^[_2O
MD'_@BC_R;7XV_P"RB:]_Z4T ?8@Z44#I10 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M^CQ7](%9F@4444 %%%% !1110!#+_J9O]W^E?(/_  11_P"3:_&W_91->_\
M2FOKV9\QR8]"#[<5\@?\$5&V_LV^-?\ LHFO?C_I)H ^QATHIJ_U-.H ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M4:7P?_[ 2_\ HQZ]8_:A_P"3;/B!_P!B]?\ _I.]>3_\$?/^4:7P?_[ 2_\
MHQZ /I0=**!THH **** "BBB@ K\L_\ @[S_ .44C?\ 8S6/_L]?J97Y9_\
M!WG_ ,HI&_[&:Q_]GIQW _EG/W5_'^=%!^ZOX_SHJS,****7*@"BBBCE0!2/
M]VEI'^[3 _:7_@RN_P"3NOBU_P!BY#_Z/%?T@5_-_P#\&5W_ "=U\6O^Q<A_
M]'BOZ0*S- HHHH **** "BBB@"&Y3?$W^Z1].*\#_P""=_[,NN?LL?"+Q%X?
MU^YM+FZU;Q3J>M0O;/N58;B;>@/ P<=17T$!BF^6* '*,"BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MKO\ D[KXM?\ 8N0_^CQ7](%?S?\ _!E=_P G=?%K_L7(?_1XK^D"LS0****
M*MYJEMIT+233Q01K]YI'"J/J35$^.='!_P"0OIG_ (%)_C7PW_P<A7MUI_\
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M=^PG_P I./VLO^PAI'_I(*^TJ^+?V$N?^"FW[6?_ &$-(&?^W05]I4 %%%%
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M:[K\3T,D:6+5ET/Z HON4ZFP_<IU?@)]T%%%% !1110 4444 %%%% !1110
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MV:_ NH_$"#Q5<>$M#;Q)!CR=0^Q)YT94  @XZXZ9Z5WEE'Y417^Z<#K5BB@
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MQ/OO_0TKY6?JM?5/_!!S_E+=HW_8GWW_ *&E?,\>?\BB?^*)WY/_ +Y'T/Z
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MT^%<AS_PLGP,/^XY;_\ Q="DNNA3IS2NT>FL0:<!@5Y>/VLOA4I_Y*5X'_\
M!Y;_ /Q==!X#^,OA+XG7$\/AKQ-H?B![50\W]GWT=QY(/0D(3571#C)?$CL*
M*CAS@YXY]<C\*DH *_+/_@[S_P"44C?]C-8_^SU^IE?EG_P=Y_\ **1O^QFL
M?_9Z<=P/Y9S]U?Q_G10?NK^/\Z*LS"BBB@ HHHH *1_NTM(_W: /VE_X,KO^
M3NOBU_V+D/\ Z/%?T@5_-_\ \&5W_)W7Q:_[%R'_ -'BOZ0*S- HHHH _/\
M_P"#E#_E%CXF_P"PUIO_ */K\4X?^/=?]T5^UG_!RA_RBQ\3?]AK3?\ T?7X
MIP_\>Z_[HK]<\+?]WQ'^)'RG$?Q0"BBBOU@^:"BBB@ HHHH 1^JU]4_\$'/^
M4MVC?]B???\ H:5\K/U6OJG_ ((.?\I;M&_[$^^_]#2OBN//^11/_%$]3)O]
M[CZ'] ,/W:?3(?NT^OP ^]EN%%%% @HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M .#O/_E%(W_8S6/_ +/3CN!_+.?NK^/\Z*#]U?Q_G15F84444 %%%% !2/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%173%(&8$ CN17R5_P44G^*'B'QEX'TWP%J&K6
M.DVMO>ZMKZ:7K46EWLL44>4 9@Q(X/ 'XT ?7!?!IU?FG_PUAXG^*O@/QU\2
M-#\:^)-'M_AHFCKH6CW,XVZFLG$QNU'^N9V!4-C&1D5]>_M*?MBK^S+X:\/:
MA<^"O'7C :Z.8_#FF_:WM2$4YD&1M!SQ0!XY^PG_ ,I./VLO^PAI'_I(*^RY
MO]8?PK\__P#@DK\9$^/G[;W[4/BJ+0]?\.+?:CI2"PUBU^S7<>+8#+)DXK]
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MLCP\+PK1P[YZ<O>3O'3;1K]3VWQ9\5]#\0>!;UYKK2VAFT."QMK2&W*7HN4
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MP ^]EN%%%% @HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MU?Q_G10?NK^/\Z*LS"BBB@ HHHH *1_NTM(_W: /VE_X,KO^3NOBU_V+D/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MOC]\</$FAW,JS2V5[JZ/$[J<JQ&WJ#7G?_$+A\(P /\ A9'Q6&.!_P 3-?\
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MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB@MB@ HH#9HH ****
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M@ HHII?#4 .HHHH **3<*6@ HHI-PH 6BDW"EH **** "BBB@ HHHH ****
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MQ?\ !&;XQWNBZQI/A>+P.^AZKX[U?7?[-,HMOLUI=P;(6A;RV$>UN60+SZT
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M_"FN7>G:MX@TJQU+3=-.JW5O-.(Y;>TZ-.P_N>I]J_.'QA_P1/\ &_B/PO\
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M$WXN_$GP1IOA+61X!\!V?@/PQJ6@:;KGAZ1OMOC"2X/[N2\^5=J'^($MR<T
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M*W\?IXWTO0_#]WJMQHT+ZI*()'N86*L@3KVS]*^/G_X)-_&I/C,NFF/P3<>
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M\*O&>DW?Q*@\=>(XO%MMXFEUG4)6LK) KFP\Y&.V( _=;Z5?_P""//Q#OO\
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M+6I^)M6\6M:%+*Y\/3P% BW0^9MV[;Y?;%=A\4OV;?&7[!/BR[\1?"'0]?\
M$.GZ3JD=C]KU:Q;47$Z0$1LENF-R*I2)7ZC>Q/2@#]8I"$0<[5^O?^M)*^QO
ME//^3S7#^#?$WB+QI^S_ *=JFMZ3<:'XFU#1//N[&$AGLKAHCN12>K ]!7XT
M?L_?#[]H?3H/CUH]CIWQ6U66]\+7DR:OJ3W%G.MW]HW)$(78I)*RC >+' H
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M64#E_>OV6\!?#Z;X:_L^Z5X<)N?$%UHVBI9NUS,3+J,B1;7#,?XG((S_ +5
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M:J\DZ3O('W*3\B*K;O6@#]B&.'.TMT.X8Y--P7P&8,,$,I7.01W/:OR3MO\
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MC)/'');RR#YE;N<<YH ^]$E$:_>&<#&>"<^W:FR'SD95QC[I'MWX/XU\L?\
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M_C[]G/\ 9F\*>)/A;)HT5WXEU"%99-0:(7$=J\>_,$4C(LDG^R6% 'MW@_\
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MJR:=>"YM;BW2+SO- 4D;HW R1ZU\L_\ !7+XN_$WP9^V-\=-%M_B))I_A?\
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ME_MW?'3]M+7=*.I?$K4(;C6HM15;!OA[)'ID3Q&58\7^[80"JG(ZFNN^#O\
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MN36R1Z9\.X;A-%T&.-5T^WDF&QI2@ZD(6 '09KO'^"'A,_#U/"/_  C>C_\
M"+QX"Z6;=?LH .X?)C'#<UUU% '-^)_AIHOC?1(--UC2=/U.QMY8IHK:YA5X
MXGCY1@/48&/2N2M/V/?AEI?BRXURV\ ^$X=6OIWN+F\73XQ-+(ZE'=FQR64X
M->HT4 >5^&_V-OA?X/M;Z#2? /A73X-2GCN;E(K!,2R(<HS#'\)Y [&MBX_9
MW\&3SO))X1\/S.]Z=3+/:*2UUMV^:>/OXXW>E=Y10!YQ\.?V5OA[\(_$']K^
M&O!?AO0]4VR*;JSLTBE(<[F&X#H3SBNGTOP!I.B>)]2UBUTRQM]3U8K]MNHX
M56:[V#";V')P.!FN@HH \I\8?L5_"?XA>+9O$&N?#GP?JVNW#B66^N-.C>>1
MQT)8C.1BNP\5_"O0O'7A^/2=:T?3=4TNW>.2*UNX!+$C1D&-@IX!4@8KIJ*
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M P>V*V]<^'VD>(]>TW5+[2[.[U#179]/N)8E:6R9AAC&W49'%;]% ' _%?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
F4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>tm211152d1_10ksp1img009.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm211152d1_10ksp1img009.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" "> =0# 2(  A$! Q$!_\0
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M=*@O;8[K>[C$L;$8W*>E9RIRA\9O1Q=&J[4I7+Z?=I:;'3J@Z0HHHH ****
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M(KXASBON#X-_\DK\/?\ 7E%_Z"*\3.OAA\S[3@S^-4]$=.GW:6D P*6O"/T
M**** "BBB@ I'^[2TC_=H \I_:__ .2/R_\ 7S%_.ODZOK']K_\ Y(_+_P!?
M,7\Z^3J^BR;^!\S\VXN_WN/H% Z44#I7LGRG40CG\*^W?@8<_"30?^O1:^(S
M][_/I7VW\"O^20Z!_P!>BUX6<;(^SX+^.H=;1117@GZ"%%%% !1110 4444
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MH%*/NFDI1]TUZQ\IU$/WO\^E?;?P*_Y)#H'_ %Z+7Q(?O?Y]*^V/@:[)\)-
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MC1H^SDM3XK/,@K8O$>UI/0^3:!TKZS_X9)\'?\^MQ_W^:@?LC^#_ /GUN/\
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MIW9K+\0?\$YOAEXDEB=]'O[/][,]T+34)8/[12602R0S[3B2(R -M;@8XZT
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M18;6WT:\TYK.WBALKFSU*:&ZL3%-),C12@Y1@\K_ #=?FQTH'MHCS6'_ (+
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MDL1TKS[0?^"H?@WQ1#8WMEX=\4S:*/L<6N:H+>,0>&Y[J5H88KCY\D^8I#%
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M4? WC&QT+PU9^$O$/C6*[AEUFUWRO;&Z=7N=D;-L42E/F  R3GK0!XC\3?\
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M84M[@_+]VZ::/:,?+\QYQ6)X>_X+>^+_ (G:=;>&-$^$:P_$J]GO3'#>ZO\
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(B@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>tm211152d1_10ksp1img010.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm211152d1_10ksp1img010.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" #$ 10# 2(  A$! Q$!_\0
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M^,-[I=UXN\'>%?%-QH4CRZ=+J^E07KV#NNUS$958H67@[<9XKJNM% '*Z/\
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MZ=X_TGP7/X#O8+'S)-*NO#4^JW.LR3@F8&*>/&])/)6.%P06.0^7;SM^-O\
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M=/B5\1?'6G:;HOPADS?:XN@Q-=2W4-E(L]UI<<-Y))]F,D8CBOI2Z%<@P."
M0=M1BY2Y5N)Z*Y^@N<"C/^>U?-/P?_;K\1^/_A_\;M5U#X;W\>J_":>[6RTK
M3II+H^($BCF>)8IO+"-*_E<HFYDWJ&4$@'F/@E^VU\3_ (O_ !@FGE\)Z?%X
M*T+PCK6HS0Z9'<W#^)]0M+N**![&XEBC_<2(7"AD#,X;JJ@F>MOZ[CZ'UZ&V
MT#@U\,>'/^"M7CC4OAS\.M6O?@K=PZO\3+R^T[2-*M]4^T2RW5HL=U)&VV/Y
M,V(O' 8!O.LRA W@UO?"C_@IMXR\?6_P?GU3X3R:);_$G7+K2;YH]2-Y+IB(
MT"PRK%&A8AC,1(6 $1A??A3N#LPZ7/LD# ZFC'';V]Z^1?B=^W]X^^''[6&O
M>";/X<2:YX<TO5;*!]4:6:$K:S/HL#&$+ RR.LFJR.=S@;;63GT\J_;O_P""
M@_Q=^#/QD^*FC?#S7O#>H6W@[3["5M/N/"-U)=:;),\&!;R[_+O78.WF%O+B
MC$T*JS2!P%;6P'Z'X_G0.:^6_$G[='CKP7XN\!Z%>?#66XOO%/@"3Q-=K#-+
MYUKJR64UP=.,*HS1KOA\OS'XS(%X;:'\F@_X*T^/M=\<^%KS3/AR)_#.L0-;
MRV)6Z%Y=W!GT9-UK(8-K/$NH73-'(%4I92MO&TBA*[L%M+GWYG_(I<X_^M7P
M1\%?^"NOCKXB?#G6]5F^$ER(=&T'1[^#59[_ &6]Y)>FR5[N2..)I!9(+MY#
M+&C_ "6DW&>FIX:_X*;?$:V^)"6>M> M$OM!U7QK8:#:3Z2]\9[33[G3K"=;
MH12VZS7*M/=2@.L:A5@;>J@%@^5MV);Y=&?<8'&?>@]>WYT,-I]LT X%(H<A
M"K]XBBA3Q_GFB@!K#D_SH_\ U4,,'^7M0O)XY_"D F*4O0PQV_2CJ<]*8"8X
M]?K2D[2,?K0/_P!6:".?UH ^5_VT_P#E(/\ L9\_\S9XF_\ 47U&OJCH*^5O
MVU!C_@H1^QGG_H:_$O\ ZB^HUW/_  4R\>ZW\+/^">?QK\2>&M4O-%\0:)X+
MU.\T[4+5]L]E.EN[))&><,IP0?4"@7FST*Y_9[\ ZA:Z)#/X%\'S0^&+U]2T
M>.31K=ETFZ=S(\]N"F(I6=BQ=,,6)).>:^<_%OPW^-7A?XN_VEX,_9R_9CN+
M3PY<W:>&M9N_$LUEJEO;SRO+(P$>DO\ 9WE>21Y%CD(+2,26))/ANA_LS:KJ
MNEV;I^T1^TG+)<6L4PS\0YEWF0?+Q]G.,E9?IL]#4Y_9@U(1I)_PT/\ M)B)
M\N&_X6)-RG^LW ?9_P#GC\^/7CWKY[_6;!_WON_X)\?_ *\9;M:7W+_,WG^.
MOQ]U;]JW5_A,W[./[.P\5R: GCZ^N1XXNUM;M)[AK'S'<:5O>X)M@"67[BI\
MW&!ZIX"^''QE\5_%G2+KQ[^SQ^S7;:2]D^@ZCK%GXEGU+5+;2I%99;:)9=*C
M\R)@Q!A:148,<]:^<3^PMIUC\3+KQD?C?^T&GBPZ9_8MQJP\?S&[^Q12F8VY
M;[/RBRS(V!U,I]*W3^ROK9D,:_M!?M)&494*?B/-]X?)@G[-_P ]LIGTY]J7
M^LV#\_N_X(?Z\9;VE]R_S/O:Q_9\\!:3K&J:A:^!O"%M?ZWIZ:1J5S%HUNLN
MH62H$2VF<)F2$( HC8E0 !C K9\$>!-#^&/A6ST+PWHND^'M#TY/+M-.TRTC
MM+6U7.2$BC 51DDX [U^;/CO]G;6-&\!ZQ?V?[1'[2!N8-.N+BT)^(DQ#N('
MDBX^S]_+D/ML]^/N']@/QKJWQ)_84^"WB+7KZ?5=;U_P+HFH:C>SG,MY<2V$
M+R2N>[,S%B?4FO2P&94<7S.E?3OYGLY3G>&S%2>'O[MKW5M_^&/6J#QV_*C.
M*,<^H_G7H'L!F@<?_KHS_G-#=/Q]* /CO]L__@HEXM_9M^.6IZ!H]CX-N;/0
MK/1IX=$U$W']O>,&U"YF@D;3=CJFRT6,22923(5\F(88\I\-/^"O.JZ;^S-X
MW\=>*;+P;XQ?PS'H+V$WA"XFMK#4+C4[19FT]GD:XV7-NV0^&(Q)'D(20/NJ
M:RAN+B.:2&)Y8-PCD9 S1[AAL'J,CKZU#!H5C:Z?]BBL;.*T)W&!(5$1.<YV
MXQG(STHZ6!61\1W'_!77P[>^+[;6&^%-TFI7-LMCX=UB[U*VB$D,]YI\-PMS
M.5_T*W$ES:LS$LK&+L0N:_Q+_P""JGC3PM^SQ\)?%\=AX"T*\\;?#6Y\?WG]
MMM<&TU6Z@BM7&AZ:4D4F[F^T-L+&0X08CDR<?<[:/9M"4-I:%"I0KY2X(."1
MC'3@?D*=)IUO+%"C6\#I;NLD2F,$1,O0J.@([$=*;M96 ^,_V6_^"HVK?$^?
MXO7/C2Q\-Z;#\/-%G\0PZ=I7G27%I:Q37*&*YN-\B>=MB0,C102HXD'DL@5S
MS3?\%VM/B\!VVJ/\(O&<M_<Z=<ZNMG;7*SQ?9+6]FTZZF,XCP%BOEMHR& ;9
M=I)M 4K7W@FG6T,D[+;VX-V<SD1 &?C'S<?-QQS20Z5:16ODI:VJP[&C,:Q*
M%*G[RXQC![BD!\6>/O\ @I[H^F:+>>/]1^#TS7W@GPII.LVEQJ6HP+>6USK,
MLT*Z?"RQR%24M)6:93M9=@Q\QQB^(/\ @N]H^EQW,MG\,?$>HQ2V,=WID2:I
M +R<M/9P?Z3 %)M(BUUE97)5U0$??%?=ITFT>V,)M;5H654*>4NTJOW01C&!
MV':N5T3]GKP5X<^(>K^*[3P[8+XAUZW%I?7CAI6EARK>4%<E40E$)5  2JDY
MP*':^@*QX;\//^"B]]\4OVQ_#_PUL/"/]C:5>Z7=7E]-J=XG]J)+'IVG7J*M
MLC'9$!?B,RL65WBD"D;<G+_8K_X*E2_M3>.M%\/7O@:]TC^U+">5-52[1HI;
MF"RL+V6(6_+HOE7\8#%VRR,,=Z^LUL8!>"<01>?L">:(QOVCMG&<<]*2WTVW
MM2IB@@C(SC9$%*\ 'H/0#\AZ4=PTM8^(K?\ X+?Z*OPH\*^*KOX:^*=/A\5>
M*#H4%E<748NGM?\ 12;R-0IWLOVR%6A8HP8. 6P"TT__  5ANO$GBOP=;R_#
MVQO?!/C.V6'4EAUR&ZO=-6ZU/2M/MC,B_*K_ /$T'G6K 21[&^8@?-]I_P!B
M614+]BM-JRF8#R5P)#U;I]X^O7FGC2+6(_+:6RY8N<1*,L6#$].I8 _49HTO
M<%MJ?*_BG_@HYH'P ^(7CCX?1^ IM'TKX61Z+;6K0W44%K<65U=V=DTL2HAC
MA@MOM:$AG# 1-E$!5CY9J/\ P6[NA=Z_+;^"[5M+.FPWNB31WZSW,;-:3W#-
M<P!E9K<BW<"="JAGC0Y+9K[[?2K:5YRUM;LUVH2<M&I\X#@!N/F R>#ZUA?$
M'X/^%_BGX1O-!\0:%I^I:/J,:Q7-K)'M6>-'60(VW!*;D4E2<'&""*6K146D
M]4?+'A?_ (+"6'B_PZM_#\-]>TA;OQC-X5LI=>U6UTJTE6*&XF>XEGD.V!]M
MLZK#( 6D>-0WS9'N/[$7[0>K_M1?L]6'C'7-&T_P_J=SJFJ6$MA9WC7:0+:Z
MA<6J;G95(<K"K,"."?0UZD^D6KJX^RVQ627SW'E*0\@(PY&.6R!SUXJ:*W2V
M!$<:1[V+L$4 %B>2?4GUIDCPV.__ ->BE49'8?C11J C$@G]:^)/^"WR:OJ_
MP4\"0:7=_%--'TSQA;:AXOA^&&O_ -F^+ETD6MTFZVC$B&=//:#>G)V;F494
M$?;1_'\Z_*/_ (.#/V?M%^.]SK6FZ1^R%X^^*?Q-O-$TY=,^(VE6,,EGIL27
MOF/:-(9T<,(EF& A'[\<]<)ZV&C)_P""77PN^+VB_M=^%_%GAG4?VI9_A3K_
M (HU:VN;7XH>*?[36'08='C,3WEJ[NUM<OJ<G^CD$.\2/O7 R?URSG'ZBOD[
M_@DEX=\"^'/A-XJC\"?LW^*/V:[&36$>YTC7+:&"75Y/)4"Y0132@@* G)'*
M]*\P_:,_;[\;Z)^TGK^E:1\0+WPUX)\):TFAZEKEC\(;G7?#>B73^4%@U/5'
MO8CYF9H@YMXA'#YJAWR"17D2MKGVG\=F\9CX0Z]_PKV?P[:^,?LQ_LR?7TFD
MT^W?(S)*D7SN%7<P0$;F !(!)K\E?B+_ ,%#/CW<_L?_ +.WCFX^(7B>QT:#
MX<ZGXV^)>J>&)_#D&M7ZQ7UO DR6>H(?,BC3SB4MT!8NJAMV ?V"\'0:R?!]
MC%XG.DS:W]G":@VFQR)9R2XPYC60EU0]E8DC.,G&:\TU[_@G]\$/%6@>"=*U
M/X4^!-2T[X<-O\,6]UI,4R:+\P;$(8':I8!BO()4$C(%%[*WI^H=#YK^.7[0
M6I?%?_@J1^R?H\GPY\=>'-%TKQ)XBGT_Q+JR6B:=X@1O"]_@VZQSO,"0V[$L
M<> I[\5[9_P5P&?^"7GQ_P"O_(AZOT_Z]GKG_P!M7_E(1^QE_P!C7XF_]1?4
M:Z'_ (*WY_X=>_'_ /[$/5O_ $F>DQ=#@- CNSX?L?/\S_CRC$GDBYZ[$W[<
M'VBVX[B7L35KR;H%/OB7)+9^U;=_F9]?N^?S_P!<N!\M9_A2*,:#IICM&MO]
M M]A> ?NOE^4']Y_!E\_]=DJT8(S;Q?Z$^Q5(6/R!N1=N/+/[W[WEY@S_?-?
MC?4_F_J3O!?EG$?!W?NMPNR/XMF[!_Z[;L<<Q8J-[=VSN6\\G!!Q]KW[?+QQ
M@_>\G X_Y:Y(^:H;F"#-QNL)9=QDW[;<?OON;L?O?XL1X_ZX/ZU/Y>V<X5%;
M)Q(;8;0=V=W^MZ>9^^_W#2%H8?Q:BN_^%4^*3+O(_L>^,^S[3S_HS;]G..HB
MVY["3N37M?\ P3,/_&N'X >O_"N?#_\ Z;8*\,^*<2#X5^(B+1X3_8UWLW0#
M]QBUEV[OWO\  "X/!YF3TKW/_@F8?^-<'P _[)SX?'/;_B6V]?:\)?#5^7ZG
MZ9X??!7_ .W?_;CV\<5\U?\ !3W]HWXD_LO_  >\,^)/ %MX5-I+XMT72M?N
MM7:62>"TO-3M+0K:PJNUY7\]LN[J$"Y <GCZ5ZG_  K#^(GPR\/_ !<\.+I'
MB;2+'6],6[MKY;:[CWQB>WF2>"3']Y)8T=3V*CTK[!;IGZ,[VT/F#]GS]IWX
ME^,?^"A7C;P/>>*/!OC3P'X:MK\ZS)H^D/:0>#[[[5"-,TL7CRM]MO7M7D>Y
M0(HA81\C>%/QW\*?^"R_Q_\ C5I5I-;QP:&?&<\6K6UO%X(_M&\\/:)]OU.S
M>XLHDO2VI;9K6U@D61(9E+S2B,QKD?='CK_@F]\&OAG_ ,);X^\%? +P=XD^
M(M^SZK]G65-/FUV^^U1W8WW,F41VN(XY/,8'YD!KY^USX0^,_$UKXIAO_P#@
MG#\.[E/&]]'J>N;_ (B:+G4;E'9TE<_9\A@[R-\N.9)#U=LK6R0]#UC]@?\
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M3LGV*VD8[E^SF>P!;@)Y6.OW_P#0OJ.>.:=+<W>9C'Y,V&;RM^H >=UV;O\
M1SC?^^W=<?9HNN>&S7(1I-VI2K&%8F87J[T7R@=^/L_WA#BZ_P"NI(Z4!\C
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M^%_A/XF2WCCL]+U:[\:>)?"U_IUHDAF2"XMK O!>[)6<ABT>X-M*@9IO=/\
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M%G_!0YRG[?O[.V"3(?#OC!8D+E5GD)T8+&Y"MA6. QQT->_FO^YU/0^NS_\
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M.A^F*_1>&_\ <EZL_9."_P#D61]6(O)K\UOV2V!^,G[30=H9L?&C6P(2D98
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M: <4 .0D#I10HW#CCZT4 -)VGM],T=10_4_6@#ITH$#=:/\ /-!X_P *.]
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MI0%S_@!1C SS0 '%'2D_SUZT9_#\.M QWF$]\T;CZFFD?_K-+R1ZT +NX_\
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MS\/[EDNCI^BW&C(LA5%)66VN96DP03(=P*CY:V?@I;?#OX+^./ VOO\ #O\
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KRV/4?THHH!B'^E)YF?3THHH$//W33=V7_K110/H.CDR@.!SSTHHHH)/_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>tm211152d1_10ksp1img011.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm211152d1_10ksp1img011.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" #/ B<# 2(  A$! Q$!_\0
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M5Q\7/$'PZE\4:;X6U+4],DM-*TNWU+[1'I,,YN&GE6X2/8)RJ!'?G%?3%_\
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MP)XGM_&W@C1M9M+NTU&TU>Q@O8+NT!$%TDD:NLD>>=C!@1GG!%3TN!K4444
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M\1:/XCUV?Q-+J#V>J3:;&(8-DMM,L]A,D0&RXM=KJ5Y#;FKS[]E+_@AMX?\
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M.F>*/B!X?U.ZUJPL/['N9M-UJ[TP:UIOF^<=/OE@D07-KYH#^7)D9SC@D'Z
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M)T^VO-2BU=I '6U;[1%Y)Q=Q^8=EFUN7#L4I)-KS#OY'Z'8H/2OG#_@F_P"
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M#D%KKJ2/8@WMTL.^1492V"1@;@,D$D"J=%S_ ':ZZ&%=1E2E&6B:_0^;H?\
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M_P!ES_KR\8_^D-G7T;=>)=.LH())M0L8H[GF%WN$59?]TD\]1T]:^<OVF?\
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MA5\-(XPF!=MX;T8B(8*;L>5V0"XY&,2!>V*^8EQ93CO3?WGP=/C^C/X:+_\
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MB%JOP@\2Z$EUXY\,:KX)MI_&>OF\\+VECJFH+<7* Q 2%XYO,:(^9OWD*SD
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M_P#L6-U6SN+J683&*1?W:P<J<9W?+N;"GQ3]B+_@KQ\1_C7^V3+\&OBQ\'M
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ML)'F2'_1X("/*S<,!7I=E8PIK\"QVT!B&J:6(MG@YVC,36V;/9$YWF(R9-G
M_P"\DES+>?)BOV_"+GHP]%^7]>A\[B::E5GZO\_Z]3B?VCWGF_9'^()NI9OL
MJ?#V3"7&L*]K&DAFDME>-!YN'QOM4^_=_-=7?**!_1;\./\ DGN@_P#8.M__
M $4M?SK_ !XMG'[*GQ E2.=)A\/-58/#HZVLPS)*MVPNF^09DP+N8_ZZ7;#:
M_NR:_HH^'/\ R3W0?^P=;_\ HI:^3XH_B4UY?J?3<.?!47G^ALFEI",BA>E?
M*'T@F>32B@=*\G^)_P"V!X?^%G[3GP]^%5YIOB*YUSXB17UQ:WL&GO\ V;8I
M:VLMPPEN" AD=87"Q(6DXW%0N"6DWL!ZP*3M7@/PX_X*-^!?B%^S9\3OBO)9
M>)M!\)_"K4M7T_5AJVG-:WTHTU0TLJ6[XD4."-BR!'.1E5S7+>'_ /@K!X2U
M+1?!7]I>"_B#H7B'Q=\0%^'%UHMSI\<TGAS4SY;$WES"\EJD>R:!EVRLS^:
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M](;7;B33=*T[6M3:&UMW>6V6*_@GMW=T#QEBF?F/S $FJ^P&TSP7_@@S\,-
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M:[4J0RK;V_[T$8*_?Q\X"Q^G[DYXQ4-OXITAY-XUS3=OE>8)Q<VN2OE^=O\
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ME2W[SGRV+S'VNE]*_/\ DMJ?C*KN4N2YT_\ P1*S_P .J/@KG&[^PVR5Z?\
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MV^V*?C!I8:W 4^=_Q+M3^7#$+STY.*R28&BFQ;6]SNF<DA-/_P!-)8$R</\
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MTCGG[LR52MK2T,NW_A%(O^/<C[*(]-R!Y.SR^),]/]!],C^[\U-N5@DL9/\
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MV<<D>H27$Q3$L-Q+<Q*A7,84XX?+?K1^U1\"-4_:?_9]TG0-+\=ZGX3CDO\
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M/Q'\$FQU30_#WBG0[CPW%)<>(X=0GTR^D2Z,^JQRPV\4C6K--;*(2#+F61@
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M$P+#^+_2)N:^8O\ @O8MR/VQ/V:GM/[1$L6B^+Y"]B(8YHE$6G;F^TR_+9(
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MPL+>*;3RGXSM)V9 R?*[_NU4]>*_**F'JIZ1?W'X#A\%7G\=-_<S0L98)/\
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MI(_CG^TL()O-E_X6]J1%J]RL2%_L&G[$YC8XE.X,<\>4N!UKZA_X>M_LR_\
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M;_P33^$.A>(_C1\,M"UG3=&,=U8ZAXCM8+FU;[1*=LB,X93@@X//(]:^>/\
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M^@'H^1_TY1?X4G_"NO#W_0"T;_P!B_\ B:V"*.E3<HQ_^%<^'_\ H Z-_P"
M,7_Q-'_"N?#W_0!T;_P"B_\ B:V.E'0_Q=/6G<#'_P"%<^'O^@#HO_@#%_\
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M?X0_]$J^&W_A,V7_ ,:KT;&?IWI0<T7 \X_X8V^$/_1*OAM_X3-E_P#&J/\
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KP*<5)!I%7B@!:0TM% "=:0THZTGWFH 7M2T4@7)H 6DI:* $S12T4 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>tm211152d1_10ksp2img001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm211152d1_10ksp2img001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" "- *P# 2(  A$! Q$!_\0
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MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]_***0G%
M"TUZ7<*9,W'3- #6D"^_TIHG1W S5=[K9NP.G6N$^-OQ^T#X'>$I=5UNYCM(
MU!V9;YG/H!7/B\13P]-SJZ(WPF&JXJHJ-!<TGVU.[O+U(U))7"\G)QBO%_CQ
M^W?X#^!220ZCJL<M[&<&"##OW_PKX-_:B_X*;^+?BM+>:?X6EDTC3"VT39^>
M0<].]?*OB6^O=8GDO[ZXGNKTC)ED;<9*_,\]\1,/2?LL/%MG[QPKX%8_%0CB
M<>^6+Z=3[K^*/_!<6-;N>V\.>&I)F. DUQ+L&/7%>(^)O^"JGQ9\=32&#48-
M-AW85(4Y ^M?,5K9#4M7,[VTKDCMQ6W9>?:V+!+,I\W!/6OB<?QAC*\+QE8_
M8LH\)\CP<HJM"[/7M7_;,^*MPGFKXRU5';G"28 JSI?_  4#^+O@F&.XD\2W
M%_%G.V;YLUY+97S786.165AZBIK]M\)C=,HHXSWKP\/Q+FD9Z3/J9^'60RT]
MC^!]:?"C_@L]XKCN5M]9T:WU",8#2K)Y;#\*^D?A#_P50\&^-M82RU'[3I$\
MN%!E'[K)_P!JORACOTTT[UCP<\UMZ5JK/(&VE4(R 3D_A7M4^.,TI:S=T?(9
MQX(Y/BDY8=<C/W;\*^-;#Q=IRW-A>07,,JY5T<$&MJ"7*?YYK\4/AE^U'XU^
M"=[#=:!JURMM;#_CVG?S(Y/;VK[Y_8T_X*:>'_C[#;:1KCG2O$1 CV2G]U,>
M!\IZ9]J_4.&^-L'F--4VN67F?SOQAX2YKDDOK$5ST^Z5SZZ^TX;[OY5.>!6?
M97L<D6Y6#+G&:N_:%>($=,^E?=1E&7PNY^6/27*]R>BD5PU+5 %%%% !37%.
MJ.X;:M  .:@NKH0$?,!QDC\A_6HY'( YQC)->2_M<_M,Z+^S#\++_6M7NBDS
MQ/':0H-SS2[?E ]LXS]165:O"C!U*CLC?#82IBZJP]%7D^QQW[;?[:^D_LQZ
M+]F^T^=KVH*QM+=03@#JQ.,8Y_2OS'^.W[1'B'X_Z@T_B'47FMV<O';L<1Q_
M0"N&BU;Q?^TWX_U36O$;W5S//<,UL9R<Q(>0BCL!7JGA;]E62]L4>:+/&&,C
M<#Z5_/W%G$^*Q-=TJ,M#^O?#_@S*<CPD:^-2E5>OFCR6"Z6%]T<T;%5P!V'M
M71>'OAOJ'B:)9@OVE6.X(HZ5W>K_ +/%IHI*J+0[>NULG\JT+#QI'\+XK>$V
MTH0C 9%ZU^?NE6;O)ZL_6YYZITU'#:6V*/@O]F6^O+J*86VT.>03C%=U\1OV
M?+;1?"GVB.%!*B_,0>AKL?A)\<[%W@6XBE@7!W/)TQ5[]H/]HCPGX8\-D2W4
M>&&<#!S7=_9]25._,?"5L[S2>.C3<7:_8^/-5TPRSM$SGS >-HP15+^S[RRB
MVR,KH!\K,<$UB^._C<GBSQ5--IW^CVA!"GCYJQVU?4=<2$27$F^(Y1@>#40R
M^M%79^J87$25&/.M3L4TRUUBVVQLKS#.1G&#6>+\Z:/*ZR1<,.N*H6?#)]J5
MK>\F.P2(V%)]ZWK#P_\ 9[:1)OFO V[?V85$DX*\MCI]N]F5)O$1DLMG^JW<
M'WKF=%U6\TUTNK:[FBN[6\0Q21G8T?S#!S782: L<*F122YXKG9=-CL=:\G9
MA96$B#^]@YK? XWDEST'8TJ8#"XNGR8I<T>Q^B__  3K_P""C1U)+/PAXSO6
MGU&1]L-ZWW)1P%!]Z_06RO8[RW1HV!1\>U?@-;I/9S6TML[VLUNP>.6,8*G.
M>M?I/_P3-_;NM/B38IX0\0:@3XDML"+SN&NH\8&*_9>"N+UB7]3J_%W/Y \7
MO#*& JO,\N7N=4NA]PQ(5IP;-007'/S'%2(P+U^I;JZ/YY)**** "H[@_+4E
M17+@#K0%[:E#4+Q+2#S7;:D66<GTQ7XZ?MW?M76O[3O[7*:2LTESX0T/;912
MKGRQ*6^9OQPOY5^AW_!1[]H*#]GW]G'6[\W/D7E[;O:VH!Y:1AQBOQ@\.Z[/
M?:!J<,:1R7$CB?SL?,64D@Y]\_I7YOQWF[HT8T(]3]Q\(N$?K4JF9U-H;?/3
M]3](OAW\'?#VD>&[1O*MO.1!\Y7EA7-?%B>))C;:?*(W7HBG[U>?_ ']J2$_
M"Z./7F\N^C0)SU(' KG/&7Q6TJ]UQ;VVO#NW=,\&OR&K5I7YGN?KV59)CYXV
M<IW<5MV.Y\-> =1LVDNKB&.82#<I;J33_B3X$CU3P8L@BA^W'_5@\;3S7%>)
M/VH8['0P(Y0SIP-I]J\G^(O[6E_+HL?EF0SJ?E _&N5S4Y<L>I]1@\AS-U54
MM:**OQABU:TLWMQ>264L8&]E?&>M?/\ XC\47VMSBTO+B6Y2$\[F)W5I>./'
M_B#QUJ4L]Q,ZQMU4'%8%C;):EOE<OC)+'-?18&A&,/?1]W0PL(Q7M8JY+8:=
M%/.5C1PN,X!^[75^&_"R2Q+*\MRB9XVO67H=CY=ON((,G?VKL=)5?[.\E""?
M:N;,:L+6IG;RI*YMV'@BTURT16ED>0$E"S=/0UU'A4_9;8:3JJ'[1_RQG[-Z
M"J_AK1C%;Q-S]SM6Y>>'9+ZV#%]LL7S(X[&O@L5CN:HX,XZE1-V(I_#\L;1Q
MR_=7D>PK"\3>$_W*W04^;:Y91CJ!S7J7P?\ "UW\59#I8M))KN+HV/O5Z/;?
MLB:I$URNIV_E6ZH589Y4$5XG]H^QJ:'SE;BC!X.O[&I+4^<=/5;G1!=G;Y<:
M[F)'%>,>&?B=K/PR_:@TSQ;83W,']CW<<RJIQB//S+]",U]1:Y\)9+7PQ<Z?
M;P3+Y+%9,]AGO7EFL_"*WBL+G?9O)/(<;L\XKZGAOB"&&Q/MC?&K#9O@Y85_
M;/VX_9J_:!T?]HCX5:=XCTF<20W<8W#KL8#Y@?<5Z5 ,OFOS8_X(O?$O_A7E
MSK'@.[D=8IIOM5F)#]T%>5%?I/:GC_/%?U9P_FL,PP:K0/X0XRX?GDN;5,)+
M;H3T445[1\N%070 ?<1VP#[U/5>];*D'L-U#O;0+KJ?DQ_P7S^*EYJ7Q+\)>
M%8YBUG;V[W=Q$&ZEONG'X&OA#PI=W+WLL=MYJAU .SGC ZU]"_\ !93Q[-KG
M[=5S;+\\>F645N<<\\MC]:\V^%/AM]9D7[-''B7 E/<5^$\88I2KRYNA_<?A
M9EM+!\/1F_M%KP+J<FK,;#S99'V[1CFK^K?!_P 11IY^QA;ENI)SBNWF\#6G
MPUUR"Y,2+!)%F1Y!C;^-=E'X]T?Q1X:^R6MS&9&XR!_6OA)<CC<^T^O>QOR+
M0^;=9$^E/Y$KR80]#ZUG1Z5/>YR"ZYW<?P_6O2/BMX)2VO7:'<KM@%AWJ;X!
M_#&3QY\0;>PA$[/(0K=PW3M1!IKW-SZEYU1I83V]3:*N>/:SX1O6@E$<<OKC
M%8]CI\D*3L\K;D7!4K7UO^TG\#/$GPOE*Z)HLMRMRN'D*]/IQ7SK>^#==32K
MJYO;(VR1G][YA_I7KX;%SA'EF>#'.*6.M4H/0K>$K3RHP9U$T<@PI!^[70OH
M/V*TD=5:,XR,GI7.^'9([R]6"VBN9Y\#$=LA9A7J_P ,O@UXM^,NL#2].\/:
MN[9 WRQ-L('//'M7%B,#7JS7LNIIC\]P^"H-UFM%</!%Q=76CQ>5M<E<>N*]
M&\%>&-2UF+!1<>I' K[A^#?_  3C\+0_"VP7Q#HP35S /-$3XP:\\^*_P)T_
MX7S75CIT(MTC!(.[-?)<:9+B\KH1K3CN?EF'\6,#F.)E@L,K274YKX*>%3\.
M[2#4;1(7N\[I!ZCTKZ-\#./&.D27ETJJ]ZOEM$1T.,"O / 'AC4+RT@FLF>0
M(V'B/?FO>O"\LGA/2D6(,BR1ECE<X;':OPR>?OV[BS\TXRJ*I7]I&?OGFFL>
M!K#0?#&L2ZGY5LSS.5W  GKCK7@NO>"M,DT*]NX)4>0L=I; "U[+\?KK5M;N
M9[O454:?'PD:'&\^]?.'B+Q!-JMW):1*;.VSP,_>-?3Y-F#Q,_</O."J.*JX
M?VGM&:O[+VDZOX!^/NB:RT4WD&[5)9@<!E/2OUXT.X^TV4;_ -X9-?D)I/Q,
MD\.&S6\GC"Q,LGR$9RIXK]8OA+K2:_X*TZ[B.8I[=74GOG-?U_X4XR;PGL&?
MEGC5@:D<73Q51;G44445^PGX<%5-2&5/^[5NJU[\WR]BII--II!U7J?@+_P4
MGG:Y_;K\9F4XQ=Q* 1SC8*[[]CWX;66HZ3<71Y<GNW0<Y-<3_P %=]$G\+_M
MU>(I0/+&H)%.-W\7RXKF?V;?BCKEAI-_!]JAM8"FP.QP><]*_ >+:4_;2N?V
MYPC6G/(*5*GNTCT?]JKQ.=):.WMO+U!+=BJ+NZGC(]ZR/A^M_?Z=IM\VGPVE
MJ\@60)V]Z\Z\3^%=2NI/,:]>3=+Y@?=G.>M=K_PL#4O#?PN6*'R3Y(R&D_B-
M?(QI^Z?:X;#5E2]F]V>G>*/!X\:7\EM8(S"(J2ZG.:^D/V3_ -FF/1##JD=N
M5NXP,,QQSD<UXC^R7-/XM\(F[FV0W4R[L@<8%?27B'QWJ?P]^#8U+2R9[J(8
M*COUS_*KPD5&7,S\[XSS6M*'U#"O?1FA\9/ VL^)M>O+5KV"&UBP57 Y&.1F
MOD']L[]F*PMO"KW4.LS:;*67S TG[N3FNN\4?M?W6J7L(O[@Q-=D)*,X*&E^
M./PA7XS?# W6GZR;Z*- QC!W<USRQLYUK0Z')D6"Q^5<E/%NT&TSSG]@#X9:
MGX%^*8N[O^SM5TF9"%<*"PSP#FOTA^$?Q"T:Q\7FRMHK.*Y2%G,:8^; )[5\
M%_""^U3X-^ <Q:84@BCV/*_7)XKVJT\9CX;_  C_ .$IMEC?7+J LLC-]T-\
MN/UKW*&8U*4?:=M?N/+XYRV>8XE0ISOS*Q]>S_M)0:=NCO&A21LA45<\"OG7
M]K+QY'XJ0SZ1B::Y(4[.M?-FD_M(>(O$=['-J ?S"")#'U*GTKM? 'CN/7O&
M,4=R)8X80/O]Z_/N->*ZF.A[-]#SLL\._P"RJBQ<NQZW^R?9ZB;)_ML<GS-C
M+=J]M\010I;+&K('BP!DCDFN+M]=M/ W@&74+/RMH7>!_$2!FN)3XHIXD6WO
MS)(?/; 3/ /:OY\QE6DJ<Y2AJSYK&X*IF.*EB(_9.I^,VG1#P9=>9'YDF,XQ
MG'%?!WQ4N[O3]1<1?+EC@^@K[F\9^*I(_"%T+V*,"10%(;D@BOB/XYR3G69C
M'&!;DG!ZFOH^!*7[T_5O#!5(*=.H>5W>L7$][$)+B1AO'\Z_<#]D^3S/@7X;
M)+$_8X^O^[7XFZ?X=?6;VW\DR8BE4M\O4DU^X_P!TK^Q/A3H=MC'EVR#I_LU
M_9?A53]ZHSY7Z1%:G['"4T=O1117[8?RV%0W(Y_"IJ@N3C=_NT6OH)]S\8/^
M#@7P>=-_:5\/:CY;*-2TW"R#H=C#/_H5?-7P>\"KJ\%JYN?.M@^'C7MGUK]2
M_P#@MM^S4/C+^S]%KL,;->>$V>\!"YQ&1\W\A7Y6?LY>/K+X>:S<75P)I(-R
MC:%P.@_QK\;XXPO+6MW/ZP\*,]I8C*XTGO$]<^,7PD;3X86L99?)\C(.,]NE
M>(ZIH7B&ZN;2S1;BYCDF550)[]Z^K?$WQQT/7M$M&B&Q'C!.?X:YS3OBGIFE
M:JLL%OYA7D/7YGA\5[)RB?L&%EB)P;@?3?[-O@>/P5X&L!,D7F"V"O;E<')Q
M6Y\2];F\(>&/(6R8V<K]<9 8@\?SKGOV??B!9^,(%FE9-^W&UFQBO8/%_AZ/
MQ#X!V_:(/+B;SMH.[.,]OQKOBG6CS(_%<XJ5,/F2E5[GYO?'*Q:Z\27A=_LL
MD;;HU*XZU]9?\$OOAP][\/[_ /M.YCFL)22BD\ ]Z\8_;)^%EQK-W+J-A%Y:
M$ ,Q&U2 #WK9_P""?OQ9O_"$!T5I(ELYBR2,6SBL<!4C3JOG5V?H/$_/F?#\
M5@MUN?=OAKX:^ ]:MK_27:UG_>$,I.><5\G_ +2O@J\\8^)U\-Z6XM[32YBE
MO&O2?_/6O2]9\ :WXK\*W.IZ#<M'-;RL/-C_ (U':OG3PM\;=;N/C2_VJRE\
M_2;F1+DK]Z0#%<6:8RI*A90LK_@?FO"66XF-2IC8U_:3BG:'9]#L]+_9;\0^
M"/"Z7D]K+=3NVW8O\ JIHG@#4]&UH3SP7'F.?F39VKZC\/?&.[^)7A R1VZ6
MD"J%1 >0>Y-<?J&OV=EKL:O=1N\8W,"^=M?EO$>%:CS4^IZN$XGS*LIT,33U
M$\#^'M7\2^#KB"[AN 0,0@I^585OX/'AC41:3([BQB\PJ5P <YKUWP9\;+!;
MJ.UAB$KD!=V?E'U]JZ'4/A!-\0?M+31Q"*]&\2(_7VKYJEPG5QU/FPGQ]3X:
MIQ%/"U9QQ</<N?+GQ'\3OK-VZF3$+ ($#]*^>?&GFZ;?W4;3<(VY0WI7VA\<
MO@+9?#-I;QKFV_T>(MLE^]T[5\;_ !2L3XAU&2>T7]PQ^8GI7KY%EE?!5_98
M@_9^ LTP^*C?#[%S]ES34\8_$O0].MOG\^_3S$;V:OV<\,VHLM+MXATC397Y
MD?\ !*OX"3>*OBW)XDNTEB32<I&53]W)7Z@VGRD"O[%\+\N^K8"57^<_!_''
M.88O.8X>GM3+-%%%?IY^,!3)20.!3Z9*>?PH Y?XC>$8?&_@_4=)NEW0:G ]
MM)[*P.3BOYZ_VN?@K>?LJ_M!ZGX:O5NYH8)A/:S^7M62)V)'UQBOZ,@P=AD<
M]!7Q=_P5H_8,3]J#X?Q>(])VVGB+PW;R3)M7)N4^7<I_[X&/J:^:XFRNGBZ3
M?VC]"\.^)GD^/]G/X)'Y/^'?&43VOE/&[>9C:M=)X4\%WNK:JLB.\$.,E3WK
MS[19+GP]K7V>X0I-%*5DCD7!0CBOI/X.W^F7#P->X12O7UK^?,WPWL*K@?VS
MA,QC+#/$05TT:7PW\2OX;O(+!H9!#(-IE_NU[Y\-?BJMM=-IK2//'(I3=Z#B
MLG1/!'AW6S;S1/" HW'!ZUIS>"K/0)VO+;B,<[@:Y,/+V*UZGYWGE>AC9\KA
M9G0^,? EGXQT]3--)Y84A86'!SWKP[1_V']5T3XG0ZAH6HO=:3=29>-#S"Q[
M5Z=\3/'4VF>!/-M'.ZWQWZUB? +]HBZTGPS+% @>[BG,KIGYF'>NKZY3/)HX
M7,J."E]4V/L[X">"+7X??#.VTFXG!;:9) YYYKY4^*BZ+X.^.&K7$6F+$))G
M/G _ZT_+780^/-8\<^'KK729K7R1A4W'@=^*^>/''Q<&I:]))>21@V[?ZT_Q
M5QYOF*G14% ^8X2X=Q;QU6LIWD[W1Z]>?$?5-1\'726-I]FC(($@^\![5XIX
MAEN+.3?+=-NDR?F/>G:I^T_-?Z:;+3XDC0+M+^M<'XH^(PUQK?35P)&YD<'D
M9]*_/L5ED\1-3>Q^LY%PU5IRE*K3W/J_]E3P+/XXT"0VMZ\ER_S%1R%8=*^X
M?@_H5_I?@>V@OV4SH"F=N.*^+/\ @G'\4M#\(2)HS2>7.?XY&^^QK[0G^*-G
MH]I*TTT9$0W<'^&OU[@59?@USU9G\T^)<,6LREAU3]Q;'F?[5_[/-E\3[];^
M\:2)+>,@E'^\,&OA;XQ^"[+2+S[+H$]S\W[A(\_>8G&:^P/VJ?VF8+'P;>1V
M3CYD.#N]C7C_ .PS\![SXU>*D\6:TACM+.?,<3+_ *TYR#7G3P5/-L^;P$-#
MZ+A7$XC*,J^NXW2%M#Z<_87^!;_!3X/VMM<GSKJ[_?2EAW*U[Q9?=%5;.W6T
M@"(F!&,<"KMMRWTK^F\!A(83#PP],_"\PQ]3'8R>+J=2:BBBNXY IDG6GTF,
MT 1%0!T%4[ZR6]38RJR,"CJ1P5(Y_I5]Q3"OS=*F4%)68TVG<_*G_@KA_P $
M_6\-ZC%X[\)Z1,T$H9[^*!<;'..=HKXW^'_B*YM;7[.S%6CZ"3[P;TQ7] GB
MWPQ:>,=.DL+V"*YMYP0T4@R'%? G[=?_  29CUF*3Q'\,;&VL]90EY;$MMCN
M!WQC@&OS/C#A&6(7MJ&Y^]>'GB9#"TU@LQ>FQ\=_#3XG:EHVI[;B3]UG YKU
MB^^+SZCX6:*&5<E3WKYQU/[5X0\07&DZS;76G:I8/LFCD0@;N^">HK17Q 5M
M!L,V#QE'P/R%?B6,R_%4JCA/H?TO0AEF8.-6B]T>A6?Q;GN[2?3[B92KY4Y.
M<5QLGCB;X?Z\=0L;A/,SA5)X8=ZPD$HNMXM\*>LC/G)]ZSKG1))[N1II5DRW
MR(J [?I7/A;4Y7GT/;PN58=1<);'U[\!OVFEU/PO)#?>03*I\U1T''I7F^O^
M"+;7_$6H2SDM9R2F2&,=%S7GO@OQ$W@K2W&XM)(1SM XSZU>T7QN-3UR[O+R
M:9+39LCC1R"QHQ%6$W<^<P_#L,#BY5Z.S,?Q?9MX>N[E=/4S;!\J*,BN;\)D
MV$\EU>9^TN3P>=E=>?$%WJ]P;/3K80O.2%E*\GZFN/O?#FK1^*O[-D!EO'.6
M<' Q54J*G$^JI8I0@[]CK/!7CB;0_&%E>QW$L061264D8P:^YM)UVX\;?#6U
MU9-1DEN4C_> O\K(!SD?2OG[X9?LL?:?A(=9UK3V6Z@4D*C'YACKCO7MG[%?
MP(\1?$W3%2>T>R\.!VCW,S*]TN<' _AP*[<KRNM7J>RH4S\5\0<TR:O%5[KG
MAN<MX9^$FL_M*_'BVL(UN_\ A%H2K7$T0^0D$97-?HM\.? ^G_#[0K;3-.@B
MMX+>,( JX+8]:J?"OX-:/\)-$2TTNRB@R0SX R3W)XZUV41S)QZXXK^@N%N%
MZ>6T_:V]\_F+BSBBIFE14Z7\.!8@'6I H7H,4 8I:^R/D@HHHH **** #&:3
M%+10 QH%)Z"JTUHA?D#I@#UJY4<XZ4;[AUNMSPO]HO\ 8/\ A[^T583#6=!M
M?M[@E+R(!)HS@\A@,GKTK\]/C1_P2!^(/P=\0W%YX2D7Q%HTN?+MVDVS(.O?
MCMC\:_7O:&8<=*;/:QR1@%> >U?.YKPQAL;=M69]CP_QSFV4S4J4[I=S\!/%
MO@_Q9\.K]EUWPQJ>G)$VUP\+%#_P+I2V.I6,Z_(4C)PQ1F^8?A7[L^*OA5X?
M\96CPZGI5G>QR?>6:,,#7CWC3_@F;\(O'-ZTUUX<6%WZFV<Q?RK\_P ?X:0E
M*]*1^OY9X]U81MC*=WY'Y'W$^GRIS(@XY Q67%X@TNQF8KYCA#G##C-?J]+_
M ,$?_@NS_P#((U ?2\>K6F?\$G_@SHURDBZ!-*4.0)+EF!^M>+3\,J_/[TU8
M]NM](#">S_@L_(\ZCXA\5:ZO]D+?1[0-BP1L=QZ5[]^QI^Q;X_\ ''Q6TS5=
M<\..=+\S]]<7<AW;?4 U^IG@+]F#P/\ #Z%(],T"QA"]"8PQ'XUWMCX;L].3
M]S!'$!T"C KZK+O#NA37OL^(SSQMQ.-I.G@X<B:L>?\ ASX Z'INFQ6\]C"Z
MQ*,)G(S]*[3PUX5LO#EJ(+*&.WBSG8B "M5H5QTIL1PXQZU]U@,KP>$@HTXZ
HGXOB<?C,1-RJSNF2"U ;.!3U@13PH'X4^BO8./;8**** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>tm211152d1_10ksp2img002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm211152d1_10ksp2img002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" "V <8# 2(  A$! Q$!_\0
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M"<!E'6O6HU8R6C/D,1E\XJY]J?\ $1+^TE_T4'Q7_P"#)O\ "H/^(BG]I/\
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M55#CIGIBIX;1KJ/)Y]:\V>.N[1/=P^7P:U1]5_\ #[3X^N?^1]\1_P#@<?\
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M).?CYXB_[%]O_2F&B@P/WL_X.IL?\,E>$AW.H7N/?]PM?S),X59/]ZOZ;/\
M@ZEY_92\'?\ 81O/_1"U_,UIU@^I71AB0L9I"O3W[5FY\FIK"E*I-([W]GGX
M13_$OQA;LN1;VQ!D!'##K7VW\.]$L;?;:8$<=N<)COCK^M>;_L[_  \A^'W@
MV+8I-S,@W9&",UZ_I>@F*Q^T1IAL9VBOC<WS!J9^H\+Y-.:YR'Q5'C4@L(]L
M#TJFMA)$XVGYNM:6FVK7]Q))(#E5(&:BL_#%Y<S*RY&21FO!>*@XN3/OZ>7U
ME))E[2YVC8.T?&WDXJQ96*ZQ>GS9Q':]6W'@_2NT\/\ P/DU?PQ'+-?!47YB
MN.6KP3]LGQA+\,-/T[3].BG:2:7S0$4C=CCG\J\VA*CB9N'8]R=;ZI!=STG6
M?&5AX)TB69IO*M4&$.>9#Z5ROP_UG6?'_B$W3Q)I^C*<AW7YY!6%^SIX:'Q=
MF76?$;3/:HNU+$G&&'M7L[6\'DI;VEOY4"G"J1C ]J6)A&E)I,[LJKRQ,[-:
M#EN-(M8]W9CMW8QN-12O81NLL1YSS4?BK1H+=(=L3?,1C'2N=O+6Y=\0I\H8
MUPW]IN?7>QITF=#=^)+>($[165?:HEY"6Q6<FG7._#CK6K;:;Y,>UL?2CFN;
M)PGT,6X#26_!/6LF;21/(=P[=<5OZK-)9\(JXZFL2]\2I"O0;\X^M=='8\['
M<D59%,Z&L513Q&-2HC/UIK:Y+(264CC@54@O)KR8]5^M=R:L><Y4^7E:U&.S
MHQ_=MBF.%B.]U;'>IKRRNC( AR32-HLSX,N<=ZT4['/]6?Q1*5WKMLHVA"??
MTK-O(8IVW(.M;&HV=M:1_P +$=<5CR78G<B,<CI751E='A5O:<SB5908CCI6
M9J>I-&VP#=6G=VTSG+<"H'L%AP>.?6NJ)X^*P[>YFQS!E^=/SJ-Y$D!_A9>!
M5C5XVV\;5K,AA:%B3DUZ%&-]3YC&THK1G)_%7P+_ ,)5I#/M'FQC.X#FOGJ]
MM38S;6'(?)%?5MUF>7:1\CK@BO"?C?X(?PWK[7$:_N;CH,<"O:P]76Q\+G.$
M7+S11YWJK#[$?I6#'S%]#6UJ?SVS8YQP?:L_0M/FUV_ALXURTCX.!7MV<871
M\6XMR2/3_P!G+X1MXSUD7DHW1Q," 1Z5],74*Z;;A$3;%& H'TXKGOA%X?C\
M >$(8F"+-LR3W/%;%UJ!OK?//(KPL1SR9[V#2B1S72[,_KZU=TO2_M\:R#E>
M_M6? F0HQNXX%;^@#"B/:44CJ:\R<G&]V?381KJ7=D6BZ89<C?C\ZR;/?J]P
MS-T)XI?$,+SW'E;]P[!:-)9K3:&X[&N164;GN0E!QT-:SQ8X6M?3[9;ANGO6
M-=A!LDW9[D ]*OSZU:Z3IANI98X[7;\[%L&N6=.4_A.NG7L^5FS<'-LP4=!V
MK%M8 ]V1)G:>0:Y.3Q5JOQ#U*.VT/,=@I!>9A]\>U=Q%I$L%G&B$R-&NTG'.
M:QQ"@M]SLA2YW<1+"&RGWCC)X]Z?K,(N%4CL.E,^RF9_WIV[.@JU&D-Q;DLW
M*^]3"44M#T724;,J7=U';Z<HXSBLJ\U426NVM1X;>=2-P/TK$U6*&/*J,_2M
M<+1BW>1RU# U2ZVMA:S"\EZR*IPQ.![UHW%OM9MO)/0&I]%@^QF*20<A\XQ7
MJ+E2Y8G@8F[E9&AX=^"=UKDL4EPSI'G)S7>?\(EH?A9H[9K/[3+CCCK4-]\:
MK6TLXH BIL4!L\'ZU8M?$-Q\1+JW?3D5=AQNQGFO,KXBK3D84W2<E">Y+<^"
M-%N;1M]KY,\IPH Z>U<-XS^ FHQV[W=G&/(4$YQ7M/A3P(^DW7VG49"X!WN'
MX!^E7/B/\6-*?P?/8Z7:MYX4J6 K*&8U7)(K$*G!.Q\>7]G<6):(D^9WXK)<
MR1M\_4]:Z+QVVI6]\\]Q;/&KGAB.*YV>Z:< G%?48",ZL>9GSF/J72(Y9]B'
M-5)+A%)'7/44^=BZ'O47V?C)KTJ,9PEKL<D]8:%6_5;JT:(QY&*\5^(7AQ_#
M^L,X'[J<XZ>M>Y-#QQUKE_B9X<'B#1<H@+Q G('<5VIH\?$4UL>A?\$B J_'
MWQ&">GA]O_2F&BIO^"0BM%^T-XI5L9&@L!]/M$-%:'!RVT/WB_X.J7V_LG^#
MAZZE>?\ HA:_GD_9<^'X\7>.!/(O[BV<ECU'6OZ(_P#@Z;"']DKPHS#E=1N\
M?]^17X@?L7>&8=)\)/=NB[KAL GW)KSL?7Y*;/:R*C"KB$F?1'P]\&17$J2X
MW0( ,8ZUW&H6T6F6GEQQ#D>E4_ 0^QP18 V C(]:V[Z&.._0S9VL<X]J_*LQ
MQ,YR?J?T9PS@Z=-%#P5X8@O(YC<HPZD8%:.B>!Y[Z=S$\45NI(!8C.:[_P )
M:UH&F0A'CC;<O/3BL74-4L;CQ*@C#)9[_FV&OG)5*L4^;8^OKX2E-7CN>]?L
M\?"+2[CPHQNKJ&XN?*)",/:N)\0?LBVGQ&\3/=3V%I<P6CD-OA)VCVKUC]E*
MRTK7?&5L%E\N(+MVN?O"OIF[^#MG=V,ZV5Q;QQ7 _>!!@XKY&OF=:C7M'9L_
M/\UQ4J.(4);'YU>/O@EH/PW5+;3C;6L8^;"1\,?K7$WOP_DDM?M,5Q'DMN**
M.PKZ;_:+^%A\/ZY-!%&9[4'"N1G%>!:KX-NM)N25G9D!)P#7L4<?5J;GZ%D-
M!2I>T74XKQ'I4\^W;&05QCOFL,VUS;QL'0!MQVC'->HF..XC574!Q^9KGM3T
MCR;QIMN53D@BO5H8AI69[4:<)*S..71+AE$C#:N>XJCXA!MI5VMAL<UU>HW#
MWR/M7"#H *P-6M$O$#2 @CBMJ-6YJL.XW4=C!:83QG>5R?>L'4+:*"Z)P&QS
MBMZ^A@MU)STKG[J>*25B.>,5ZU!W1\]CZ4UJ5Y-1BS_JU]*I7MQ^]_= ?\![
M5;6".<=1GZU"D:6DKMP0#75/X3Q:U22A=DL+^0 [G&/6G:AJL;VQ 9>G8U@>
M(]9>=MD?%9Z7TWEXVL3]*ZZ3CRZG*\QE O28N)N"<FE73C9GS,+^-,TB.6:4
M%@!6AJDRPP8."<5O&:3]TN,75?.S(NY);L-P@ K,N+E@"K8X'!K9E=5L3ZM^
ME<[?PN7;%=:E<\;'+V5VC(U>=R_6HK-7EJ>ZLGF:DMK9X3SQ7?1E9'R>(A*I
M*Z'PVZQ3?-S7(_&;1$\2^&YV55,EOTQUKM9[5%7=DUDWVGBZLYD/_+7]:ZZ-
M3WT>5F&!?L[2ZGR%KB&+3F4?(4?YL\9KMOV7O!W_  D/C(W+@-'!R#VK$^+^
MB?V)XBGMD4E2^<@5[?\ LM>%5T#P+-?RQX:Y.(R!UKZ>I.]%'Y9B_P!W7Y#N
M]6?:NT?P\8K-^U2(=HS@U:OI3D_6J]JGGR],UYDIJ,=32FY2GH='X/TT73QL
M_0$]:U[JXB,_DQ*P*':6 XKG;::?3%^7HU:6E2S2@N1][G)KRJU*$G='TF&]
MHDC1A\-[I/.64.YYVYS5U?#EO?$JS[9QR #U-5]'DDDG\L9#D]:]"\*_#%_$
M5K\AQ.W?TKR,145-:GT.%IRW9Y'X]MKOPSX=O;QF+F!,+$!S7F_PK^V?$S5[
M:SU7[=!;Y+&,(WS#/%?84GP$CNX]ES)YDW&8V'!IFL_#.RT"X@2UM(8Y< 92
M/D5STLXA&%CT?8<U1'"Z/X8LO#%JD4"^6J#"ICYOQI]WKOV5MJ18R.W.:Z76
MO"K6K9\LNW<^]4K#P8^L7D<:IMW'!K@JX^$G<]U/D2.6^V++<YEXS^59NMZU
M%9 HC??]#7H_C'X4+X0A2ZNY%\H\XS7#^)M$TNY*/ XY'//0UZ5*=.=.YY68
M9C*.D3DV\1O9380AMWO3+C6/-&Z3C/<=J?%H:K=="1R13"JB\:(IP>.:]&G&
M'+H<'UZ;AS,H7=]"XW!QQ[T^RU7@;6ZGD8S576/"\HF9U8*G7&:LZ';P6Z_O
M77Y?]JNGV;Y-#PL1F,N?0H>)"U_="1H#\O'!QFOJ']A'X=Q>*](G5RL=YNW(
MC^E?-&MMN<RV[*VT_=SUK9^#7[0NM?#OQU'- DK*GR^4F>GK7'CL)4=/F1PQ
MQ4W54F?17[8-W=^#A';J=JQ*0QB'7KZ5S7P=O- \7>%EN))8H[B'[_F$?-^%
M<!\1?B_KWQV\3.@!MX(LE]RG_/>LAX(?#$7V9;DQE_F9@>*XL#@'9RF=53%W
MT9H?'@VVL:L\2R6H@7[JJ,9Q7AFLZ9_9]RQC$@B<\;AC%>O0Z(NL-YT$D<X!
MY+'FJ7C[P#Y_AC<)8]PR=J_XU]#@ZWLUR(=2E"<+GD+0L@'<-Z4LG&,U.UFU
MO* 3G8,5#,-QKVYS]Q(\^<>2+L5Y7 ;BH1;^:_E'[K\<]*DECPU3>:JA.,MD
M<^E.F>+-<YWG_!,+0'T3]I_Q*H3AO#C'D?\ 3U#17=_\$W]!6;]H76KCNWAP
MJ?\ P(BHKL.5TIW/V/\ ^#I. WG[+'A"-?XM1NU./^N*U^._P9\.)X>\$Z=$
M!@,@8^U?M'_P<GV?]I? 7P+!MRLFJW(/_?I:_(6V@73[**-!A50 #TKYW-:M
MU[,^HX=I6E[0[7PIXJ"D)_=.*[VYN$UO25"?ZX#@^E>(6LDEA.'3O7<>$_&S
M:7;?O>N.:_/\;@_?/U[)LS]G(T+V:;3[D[F96Z9S6EX>U]["X$CXE4D9![5R
MNL>(QK-T''3-7GOA]AQT+#&:XJE"#@XL^\PV8.HSZ_\ @/X^L;!+>6U2,RE.
M3G[IKT[XB_M9^'?A3X-C^UZVEAJ,X.$>?&:^ =%^+=Y\.X,6TFX/@D^E<5^U
MKITG[3'A"&6VW_VI;_<VL1[GI]:\*GPS3Q%7GGL>%GF7*O/VT=T?9>M_M,V_
MQ/TYX].U:#4."9&CDW8/I7E5SXKN(-3D:59/+)X]J^6_A+'XG_9RT&UFBLDO
M+1UQ<>7G=&>^:]X\$_&'1_BCHZ&*YC%ST:)CAA]:WQF1K#N]$]SAS&SIQ4)G
M<6UPNK2+,C+A>PJ/75_=\#KUS5.SU73M#C(3(?TSD9K+USQ@\I^YE#TKR8T*
ML7RL^WC!2?-$9(P*N N,=Q7):Y=L)< 9YKKUUZW?1WPG[PBN$U[4FAB<XPV>
MM>GA4U*S,<5C/=.?U^Z,992N,]ZY"X$D<[8;AJZ>ZNI+NU;<,DG%<W*<W!W+
MC;\M?04XWU/E<;B)S5D4761)<;V_ U?TZSF=?N\'N:;>:9*;,O&,U9T5G:%-
MS$$=JZ[65CFI22CRS+)\)L^)77CZ4D&B)')]P5KR:FZ0!,EO:JLEP7;)3'O6
M/-;0U^K4W[Q6EL4B7A0/>LB_M!.3[5MW+^:=OK67K.G26L>\?=ZFNFA*YG).
M_N&;<:>/)_"LJ[M=AP._%:DUU^ZY'&*P]<NV"_N\CTKT8'SN.A)WYB"]TUH.
M0:I^04^\:2&&[NF/[PT[^Q9!]]ZZN:QX4XVL-W1B+YCFJLMB]S*BIT]:MG3_
M "35AKY=/MN$_P"6=-5K'+BX1DES'SO^T;H9M/%EJ$3_ (^#@U[IX.T=-$\"
M:;;H,+'%N(_"O/?C/9+XB\5:&^S[\HKU6Y7RM.BB7M$!^E?38>ISTD?C>>48
MK%>Z<WJDA9ZO^$])DO;D$+\O>FM:^9*M=AX%M5MD8;>M<]?8>"A'F]XMP>$8
MKB,%L<#@5M:7X"\VS+1+DXX%/MM/!N5.['M7;>']/+6 5/7\Z^<QF*Y=#[W"
MX&G*FF<'I^ARV%V5DBP2< @=*]3^"&A3IXAC2=Y"DA P.*DNM$AM?++IE^I-
M=/\ #OQ UUJRQP6@/DGAL=:\'$XF4X-(ZH48P?NGH'Q(\"CPE!;W-G;ES<Q\
M[C]VCX7?!)?%=\;N[?Y-N5![&MF2\U/XIVKV6TQFS7Y2%SFNK\+37>G^&XK*
MRM&-TAVRRE<#%?'5,744N4T^M<FAXK\5OA1_85Q.L95_FR"*\^T;PY<:=JBE
M_D7.<U[I\>-!?3K)KH39G;&Y!ZUX?XMOM3>%&V?NP<L?:NK#1E-ZGHTOWL2A
M\?+3[1X?1MY=%'ZUXHNF-=A1$KLS^W2O7[W7?[3>*"9E,./NFH-L.D:-*L=K
M$2Y^5\<K7TM!^QA8\7'4.6[.5TSX8G3]+^UWTJ0IC(!ZFO./$$"R:ZX0[(=W
M#^M;OQ4U_5;2588I))T;^#/W:XBPEEN[:7[8'C56Y]J^BPGOJY\Q4Q')%HQ?
M'6NW&G7)C1RR8X8=ZY>/6[AE/[P\UM^(&^TRM'$"8AT8]JP+FV:W*C&1G[WK
M7TN&IKDU/!KXQMV1=TW6;GSU^<D9KO?A]:M9:JE[\A?T:N TLF*XCRN1GFNP
M@^VMM>W7$(K#,.7EY(FN YYN[/1D^(5K!<7#ND$&5P^!C-8OB6*W\1QI=6\D
M8C49('>O-_'%[-I9_><>9WK:^&OBV#RH;:0E@QR1CK6'U>:IW#VMJO*S6TR&
MZU:X"0(8H0<,4.,UT'B/68=#\.2VD@+/MZ]:ZV&QT[5=&:. &V? YVXKE_B<
MFF:'X86#/G3L.7]#7GT:DXU+,^GJ<GU?0\9<F5G_ -MB1[51DM',IK7M8REL
M=W+EB?PIJ':3E< 5] I^XCQ[7T,H0[3R.?I31"WS< <5<O)US4"R%C7='X#S
M7#DJ6/HK_@F% +CXU:Z6Z_V(P_\ (\5%3_\ !+7CXTZUOZ_V ?\ THBHKJCL
M<5;XV?M+_P '"NF?VA\$O!B?]1*X/_D-:_&[4('MFE [,17[._\ !?\ NO(^
M#'@\;<YO[C_T6M?C5X@LV>Y>7H,YKY#-_P"*C[/AFASX=+S(+._=,#;G/>C5
M[.]8(T0PI/2I=/OHXX(R_P![/-=G;WUE=Z6JG[X(S7@8FI;0_2\'@M3G] M_
M,M,2-@CJ*TF@2YCVQOR!6=/>I#J#I$.<'FFC[5IRK</^\1N,>E>)*IJ?7X2A
MR),6Z\-7.H-AG_=YPWTK1\,Z"_A:_CYWP3'A:TM :.\A4L_WFRR^@KJH?"7]
MI0@-'B(#*&N2KB)+2&Y[=#"QG-2GL:,&E6UG:&61?,5QS'MR*\P\>?L_VFO7
MO]I:'=?V1JF[,87Y$D/^U7<6VH-HNH"WN-WD]%;L*ZC3+6!G7S%A56YWGJ:X
M'CJL'=GN3RN$E>F>6_":V\8IJ@TWQ!8IA3_KT;(8#O7H]SH=NDC9YV< >M;E
MYJ4EE#MMDWCHK5GB&2,_O1EWY8>E>=B<6ZTN9FV$A4H+D9SFIZ;N3=%\IS]W
MTK*U/PVMW'F7[V*]"%A%)%]SDUEZWH7^BN5;GTK6EBKRN$XQ^&>YYQ+X?,2-
MM&<\8KD]2\/2"_V[.^:]>_LY!8 /%@Y^8^HK)UG2U@T]Y-N,'Y/I7JTL99V/
M-KX--:'FMY;B!?)W8)[4W2?#_GG(?[E;4WA.:]F\XG&_I4HT233(\;^O%>C]
M9YM#RGA;.QF/;O$A^;.VH[>1;I\/VK;M=#:.W=R=V1TK#=L3O\GW32-:=&*5
MI"RV\*<^E,GF@N(MIJ*XO/.!^4\>E4#JD3,5*OGWK>D5>G#4?<VUJ$/TYKG=
M82R4DU?U>0R)\O2N;ULY6O4PWQ'SF88BG*[[$<LT6?DIAWXJ&SA\KYST[U:N
M;N%8?PKJE\9XDL13G RKP3@;TK,O)IP:N7FNYK/FU+'\%>A3C=H^:Q=2-_=,
M34[1+GQ-HB/_ ,]17HNMP>0G'05YS)/Y_BO1-W_/45Z=J\"3PNWHU>]3C:)^
M2YU*^).=B_X^A76^&)L"N=,7F2-]16SI#>0Q^>N6KV'@OB1U-N_[P-Z5U_A?
MQ<NG1 >U>?0:NL1VO^=68V\Y<H[[?:O!Q6#YS[W!XFT$CU^#QE97&B3;O]=G
M ^M6O .HWF@2O<K\S2_=%>.V%^'?:K\IZUTGASQM+HU_%F7*J>!7E8O \L+G
MI6YE<^H?@;X^U'PIJDDUW9AQ.?XNE?0OASXBPW.GN]S96L<9YX3)KY)\'>-_
M^$D@A>*1(I8^F>]>LM\1EB\(DF[@B\O (9\9-?#X[!2G+E1/LBC^TSXRM]>D
MC2RBPOF8<B/M7D?C:6V2PBMC)M\U0<8Q7H+>-M(N[2<W8LI">0$DY^M>5^.M
M?L-6O)M@*"(_N\G.*6%PU3#2L>METM.4YBP\ 6UWKI N,87I6!X^7_A'9&BB
MD\S/0^AJ34=<_LI_M"SYRV'%<[XO\4QZ@J-[_+[BOJ\)3G)79Y>9]22RT^U.
MFO=:HN6[5YEX^7[5*?+&U&;CZ5V-YXKS^[(RN*XCQ?J#Q;I$&$!KZ?"86ZL?
M!XBLM8LY&XA^RVKH_P#RT8@-_=JSIG@P1V7F22[E7YL^M0_8I/$-Y\H+'NN<
M9K8T_P /7%E((I08XV[;LU[52LZ4>5'F4:%.3YB9O"]L-":\93LB&01WJ31O
M&(E6"T2%O)<\DUNO-9CPO+8[^,9-<[X%TU;S4_L]O\Y#?*/?->9><HR;/4I3
MA#$611^(6BOJET(UAPPY3W%4_#_AEM!D66YB\I^U>[V7@!;UHPR?Z3&N[\:X
MSXAFV@AV2!5GA;#%JTH8^ZY!/+[U/:C[+74DTL//?($0#Y!]XUQ'CK6#KU[\
MF\0+]W/>DN]/M[E%F5R2>PZ5!]F/0=*VH86S=0]._+!(QF7RQBJTMM.YS_#W
MKH3:1+RW6H;R( ?+TKTI?"CBJG.R:8S$$]*=(B1)BKESUJ(0;^:[5_#/.C\9
M[_\ \$Q-G_"XM<_[ K?^CXJ*G_X)H0)_PN+6_P#L#-_Z/BHKJI_"<%?XV?LG
M_P '$^H_8O@OX#P=OF:K=)G_ +9+7Y':JYDM "<_*.?7BOU3_P"#FW4?[(_9
MX\"W/_/'5+LG_ORM?DQH\YU[POI]PI^1X5D<Y]J^:S7#\T^<^@X?Q/+24/,H
MRJL<A%7O#1,FI;=YVCL>E9^J6SM<%H^1GG%5I]2:WPJ':P[U\S6ASZ'Z?@L7
M[-G;-Y4\NS<H8'M6U!:0S:1Y6\%@2:\ZTS4)#=@.XS75Z?&]QC#_ %YKR:M#
MD=SZO!8Z[N6+&\_X1G40[#S(<Y(KT*R\>PW]I&L#84\-[5YWJZ1QV)3S 6SF
MJ.BV<Y;*.?O9X-<&)H\R3/H\'CE*?*>R7FG6^K:8^6'"[E;WJCX&OEUFZ%A,
MV&B;@_WJY^R\47"6(M-A)Z4VRM-0T:Y^V)&PYR37#/#0L[GT$JL[*QZ](BV:
M88KE!CFJ4C1SSAB4_.N4M==G\0P;?/PY^\.]6K>W\ITA9V/]XFO$=!1=T=2;
M:NS?N-3CA& 8ZRM2OF:)O+9<]\5)'I=O+-MR367K%EY-VL<8/7GGM6E,T0D>
M6MB6?>>P]ZSG5]18PLN*W;2P2V"!U^\<<55US29;:]$D!^2NQ2NN4TC"Z,[5
M=,46J1(0'45SFN::]KL4G.:V]8DEA?S6/3@USE[=QZE=C$S<'!'85M2INYQ8
MJA'XF6!<0Z?:?/SFL*_6"4M@;=W>KFJH(AEGS&N,'UK-U.%+U 8SSV ->Q15
MG8\2<J:8QO#*-$6$G;-<EKR_V?<E0-_O78H9+:#&,\5S>O2B2;E,'Z5M0_BG
MG8Y*4+Q.<GOFQPIK-U4-*,GKVK;OXO)7=BLFZN5U L0#\H(KUZ/\0^;K1M Y
MA=6EMPJXZL15F2%[J'BHM5MF#\C"CD&F66J;3L[UZD879\M6J<K:,754>UEI
M(ILU9U9':Z+,/SJJ!^Z>O0HT]3Y_%RY?>.7\7:TFC^*M(7/_ "\"O:YX_M%L
MJ_\ /2/?7S+\<]:^P^--,*,-J2#=[5]+>'-1BU'PUI]XOSI)"%R/I7I2C:*/
MSK&RYJSD9,DGDB@:AY7-%_:/,QV].U9]W$\!'6L^6,OB-*%[^Z=/IL9U*%6#
M]LU?6YEL;<J.>*Y+3M1GB90IP,=JZW1I!=VV9?X17'5A%;'O8=U"KI4TJ79E
M;H3716$"(V\J23S6<JP7(.7"[>@%7-,UB*%?*)#8XKSJB334CZ#"NH=!IFN7
M.F1^=:7@A*_P$]:Y_P"*7Q(UOQCX,O;6VNY;&[B0[3_>IEWIYN[G>CX]JM7/
MA]I[/>W)VD5P4\'2OSR/4_>.-CQ?X4>+O%7@JZ34-;N+^YM5;:[(20![BOI'
MPQXGLO%.FI<0W<5Q'.-QP<-']16!X8L[:+3#:W$$+QR')##K6/\ $/X3F2Y%
MWX=N/L5P "+>,_(YJ<5AJ-65XG3@L)4I:G2>(+>$7!6,,4_O$_>]ZSKW28;V
M.-0O-8O@[QO?6VH1:+XCL)89E&%=5X?WKN5LDM+O<494497CK7/S0IKE1I6P
M$ZJLSEH_AW<SV4FX>7\VY&]JY[Q5X7>33A&1N^8 G%>SZEJJZIX8\N(;;CH#
MC&*Y_P 5^#Y+;P6LQ==Y8%JUPV/:7*CY/&9*^<\>\/\ P\FLKX2J"$+5L>(]
M%D*+M'(/-=TNV>S2-0 44'IUK,N<"0R2H"J= :ZOKDY:,G#9(W!G">(]&BTO
M2^&_TB1>E9O@"*3PMXAMY\YWMD^U3^-M7.H:M@)M4' ]J=HVDM-L9I1U]>E=
MLY7A8\;&8)JI;L>LQ>-+B_U$20KE@,<5Y?\ &%Y;_6;>.5=KS-FO1/!/B+2_
M"M@\DTJ2R 8P>:XCQ/K$?C;Q*UQ&O"'Y>.E8X2FU+0]-PY:21A0Z+Y%E&I'W
M34SV CCSLKI+323/MCQUJ36K&.W@$>/F4<BNV%><)-,*E.T$S@IH-TY&W%0:
MA:$1''I6EJ,BQ3G"D'-565KFO1H3YU<X*ISES;.&IBGRSBMF[T\@5FW5H5;(
MKT*>QY&)/??^"9T+K\9=</KHS?\ H^*BK_\ P3/(?XMZR&XQHS?^CXJ*[J?P
MGBNKJ?J?_P '3TAA_91\)@=]0O&SZ$0"OQX_9E\:'Q1\&X2Q)>-%B//I7[#?
M\'4Z;_V1?"V.HU"\/_D!:_"?]A;X@*\E_H=PRK$V6C#=C[5X^8T&T>EE5?DJ
M(^CO*5;//\6*YK4K<*3(>&;MZ5NZI=?9H,J"..E<AJ^JR7%SC&!7RJH3YF?H
MM/&^ZB2T\T78()Y/&37::'=2Z:AWR<NO /-<5;/M"&NBMKXWFPJW*C')XKEQ
M>'=U<^BRK&Z#=5O[C[2#DLN3DUT'P]U%YQ_C61K.I106H^3)[G'>E\*WSQS_
M +OY,\\<5YU>G)1LCW\%C?\ :4=_J5Z^GW\;X'/H*[+1[^34M&VR#Y'[FN!U
MR[,.C1S/@N._6MKPYXJ^VZ5&BR;<#D9KQITJCD?HOUN&ER:\B?PG=?:86RF\
M%AFM33_%J:K;-.&0,"<BJ&J[=0L#"QR6':JV@>"T.G2(K$,PSUKFK4FHV9[%
M*M&2LCI_#\\TJM,6R#TP:FN4:\N-W/'>L*/4KCPE8!"I90.I[U+I7BL:LI(;
M8Q[ XKS_ &,^A5:7+9&[''L&6;[G//>H[B^:_4XPN!535G>"%&+$KUZ]:KZ?
M>+ F7^;=TS3=&IH:O$0C"S,S5XIF9]YRG-8Z6JI92G:/RK5U_P 3Q1WGE^6=
MI]!6->:H(X^%PC=0:]C#Q<5:1Y=6LJETCF]:U3S,1YXSTK,EO9+>1?))/XU9
M\4QK;R^:N-K^G:L:ZO\ R2I''KCO7IT5=V/DL5BE&5C6_P"$@>V@;S,[R./:
ML+4=7^U.Q+#/:N@B>WO](8L$R%ZXKA=:M3]N/EL0H/8UT86C:H37QB]E8N^<
M;U"I(Z8K&UFQFMS^Z!V]\=Z \MM*NW=C(S[BIY];,OR#CUKT^7ED>)7J/DLC
M OYO-4H^1_2L5V6VE^5\GZ5UNK0K)!N"C..N*Y.YMY6N#C ^E=M(^.S&,TN8
MD$YU#[PJ.YB2 #_8^][U+:J+?JWZUE?$?6HM \'W5UG;-_!C@FO4P^Y\KC:T
MG2M(^?/C-X@^W>)YF09VOQ[5])?LR^*O[?\ A);JS!GA. !VKY,\2W)N[A92
M23(<OD]*]?\ V)?'2VNN7ND2N/+QF($\$_2O<G3YJ5^Q^>UZG[T^AY!\AK,E
MA^T29;H*U;A71^5_"JUQ&OE'G\J\KI8]##5K$$5M&C \?E6UILL2)R>M<W,&
M"\,WMS5C3 _FJ69B/<UR3/J<)7C;4U+VVQ.Y0]LBKNG61:'<!EP.1BFV\2LH
M^E:.E_Z-+G*X/KWKBF?0X>K3=D2^'KL!3Y_#<\&NFT2U?4X' *[.PK"GLXI5
M#?*K'T%6-+O)-&EW*[E3[UP5KV]T]NC.FJB-XZ/"+?RI5*XY#**=HT)TJX D
M;>C'Y&(QBH(?%'VN4;ABK&K7B7]HI63!0_E7E+VD5<^@YZ<K)'60:'9Z@_G7
M%K%<2*!B1^2*M:CI=K(=RQKM48(Q7/\ A3Q]%I,'ES9F=CA2>:U;WQ+-?0$;
M?O=*\NK3JRE<Z(*FD4KNP4Y$8"Y]JP_%-K=RZ88?-0I_=S6M(99B%W%<]\TR
M[T*(P8>0NS>^:[L/*4%[QR5LNA4]XY+1K4VX3<=W8U4\8Z:EU!E&V@=0.*Z+
M2=,VZ@Z&(N@Q_6IO$>CVKP[5BVD]016V'KWD<$<%!1:/*KOPA:RHKELYJ!]"
MCBA8)D8%=;/X?C28@Y ':LW5;%+<<,>O->O3J75CQ*F I\S..@TS$[;F8@\=
M:TK/3$LT^4;2:LOIWF2;H\#!HEBD:0<\ =!7;1W/#Q$80G8GLKF:"96 /!ZU
M)KDV?WK#[W%5Q?E%],"H'U,OU^;'0-SBNLRQ%1<J,N]M!/)NV?I5.>TV*<<5
MIWVH/,IVA0.X'>H94#0Y/%=^&V/)JRAT,"[DV#FJ=[;'[WM6I?6 FSBJ7E.R
MG?\ *B<DUZ-(\+$GL/\ P3P\21Z+\?-8BDX\S0IGQ]+J$45P?[!6N?V[^UGX
MAMT8%;3P],.O_3W!178>)+<_9W_@ZG.W]DKPGCOJ%YG_ +\+7\VOPJ\8/X,\
M:65W&Q79/A^<97-?TD?\'5<PA_9&\*DC/^GWF/\ OPM?S)F7?!(5X?>?YT3I
M\\&=="?)J?HW#K%IXIT&#4HBLBS1#Y5Z;L8KF=7M/(^\OS^U>9?L/_% ZA"?
M#^H2;^?W18].]>VZ]HC^=)E2"&(&?3M7S->/LYGTN#Q5X:G(K<G@8Q6E;:A]
MD@ '/.:KWU@R/S4%QF* 8KAK6;N?2Y;B=#0U'63/;C^56_"^J,MVK,/E''-<
MXS.TRCI[5N6<WV6TST]Z\ZK'FT1]#@,1:?,==J7BA+ZW\G.0!T/:H= UC[$[
MC=CT&:Y#2;T7FH$;SUJ]J-TMM<H >>]>?.C;0^P^O<\8M,]#T;Q06<!VY9N.
M:[#PYJRR(?FPVXBO*]#D6::-MV E;QUI;&XCV2<$YXKR<51GT1]/D^:1<K2/
M1M:B;4K3:=K#'?M7,KX:FM)?,B(&WG IVF^*VDPA?(/J:UI9?+@\S>%#>]>;
M"G*]F?25,91DK19B:QXW=+;R9%<,G&:;-XG/V&$K[4S51:W7F%F#-C.#WK)O
M=(DTVTWJV_S!\H_NBNRG"/VCS*]=):%NZU 7K>9W]Z@NP;RV)X.*YLZO/"Q2
M13C/6HY_%ITX;4R<UV>S3T1XW]HNG/R+VHP_VA R,N .E<UJ6EO#)\W*UIQ^
M)WN4^[EQ5/5=::8!2H&W[U;T:#CH<V+G2FN9&?%J!MU:/<<'C&:B\I2^Y@,'
MUJO=P&5B0VPD\>U07UQ<6L87<&]Z]*E39Y]6=.,+L?=/&LF.@]!65?E$E_=Y
MSGK5&]U"99>>@ZTHO#(@-=G)U9X%7-(0=D/OI[B&,$C*&DM8H+ILE,?A6M;0
MI?V !P#BJHT_[-N)X X ]:WI5%>QY.-YJB]IT,S4=(B1MRC(KQ']HWQA]IU!
M-)@8 0_>(->S^-/%MOX+\-27%V0,?=!ZFOE'Q'J4OB+6+J[=LM/)F+)ZKZ&O
M>P5+WKGP.;XE*/*8>LH/LDGS89.G^U5GX4^('\#>-].O=V,N-_/:J&KQLUKN
M/WAW]*RX6-P?-)P5Z5[WL]&CX9ZNY^A&AZU!XET:WO8R&25/X3T-4KI&1R,9
MR:\:_8X^+GVNQ.A7CAW!_=9/(KW;4;<Q2<\L*\JK"S-*4K,R'@P0*N6D"JM1
MS\L3WIUMR":\RM8^DPT]"P;P1 #/(XK1M";F!&5_J,USNI$QC=R*-%U*8S;5
M)KC=%[GM8;%*]CM[$AU_>&IY+R*/"!LXK BEF:'K4*2RK/SS7%4IGK_6;13.
MRTN)+F4G@\5IZ'I\<T[)(Y'S5B>&I\1DD8.<5>GNGLM0^7H3Q7GSBUJCZ;"8
MA>S-^^\-PQQ[X<;UY ]:DTKQ&MN2EPI^7OVJ2WN8WL 9V*L>F*I:C,KVI38.
M3E6[UR.[?O'6L27YKY+AO-5@!Z>E2VZQR6\DN2&&,&N;73Y#$2CDG/2MC2[Y
MK>Q9;E/DQR:B<5RV1U+%>Z7-,+Y8C'S=_6JNI0N9R32Z=J4,H/ED!>V33=1D
M:&$F1AZ@T4J1RSK]#!U6 EB>]<Y>VYN)&4KVR#6_<3M+)G?D>E9U]=J)]I45
MZ5*#/(Q%6QSAMFM0PJK'(4D_2M+7KI=GR\'.*QUD8?-S7KT*>A\]BE=\P^ZN
M!&-I0'-0FT#1EQQ[5(TBRH2_7MFJS7A1"OY&N^G3ZGB8BJRI<1^4Q(XJ%YF=
M>:FEFW/C-,D^X:[J:6QY=2IJ4IB0..M<]\0O%*>%?"]T\S#<RD#UZ5TS(&'-
M?.O[3OCQ;W4AIMM-NVM\XS7;2ILYL777(>O_ /!)36FUG]IKQ5=2D[Y/#SG)
M/7-U#16?_P $A=Q^/OB(X&1X>8?A]IAHKJ/$YKZG[R?\'5JAOV0_"G_81N__
M $0M?S*[!OD&.-QK^F[_ (.H81/^R3X31FQG4;LY]O)6OYF=)TRYUR\>*SM9
M[R9V(C2$;B?>B#Z%]"]X+\7ZAX,UV#4+)OWD#!MH."PS7W?\(?B;8_%WP+%?
M02*UU;@+<Q$\DU^?Z0/;7'SKY&)#!*'X:,^]=]\ _C+<?"#X@Q/NS9;MKQC[
MLOO7G8_!^XYK<]'"U[343[4US0-R[U'7GZ5A7^GXCV@<BO0/"VH:=\1?"R:E
MITOFI(-\@!^X3U%8>M:*+>Y^5"58]<U\PE):5#Z6CB$I)(XA(R]\ 1G ZT_6
M]0,(2&/JPYQ6M%I#?;)R4VJ@R#ZUC/8222M,>@/ I\D'JCZ"&)M:Q-X=C6RN
MBS]6Z&K6KC?=QGKZUDR2/)<*3T6M4PF18V/>L*L(GTV$QJ<5$U]/G\M#\V.!
M4PO/.N$ ZYK'U"?[%$&!QTS5K3[DR31..0.IK@J4+ZH]BAB;2T.MM9C$H.>1
MSUJ_J'B,M;(K'@<CFN5O=0DD'R_A1=W$C6Z[N2.17EU,+[Q[%/&M*US5EU?,
MJG/?\ZU4\0QS1*K']:X=II3$#TYIT<LI(.<FJA@XO5G-_:$WU.FUXQ/%E<5R
M4MO_ *7GWK4CO&=?WC8%5-3$:VC&-OFS79'#J+LC.57GUDR&V8Q76['!J/4X
MMSEU&7/;UJ)-=$4"@+N(JE=Z\\SX";3Z^E=:I'%6K<LM'H)>+*PY4#%5;AI;
MFVP.M22!IY [2XJK<3K:-\KY[_6MH*QPXG&IJQG7>F2=^IJ(6SQ *.<5=9FF
MRQ/TJ2)65<@<G]:[+I;GSE=^]S#;:Z,4>!Q5FYNX8XFEN'")$N1FA8(D;YB4
M^4L21P*\._:$^-@M(9=-LVR3\I9>]5AL%*I54EL>7C\[]E2Y$<I^T5\3V\9^
M(&M8'_<V_&!T-><1-Y9S][WIC2&XN [DL[=3GK3D_=R8'%?7T*'LUJ? XO%R
MJ:LJ:L<6^.U980>56OJ\?[K[OZU%X:\&ZSXS>6/2M*OK]XCRMO"7 %=D.MSR
MTFGJ0^#/%D_@?Q5:ZE%D".09"GH*^YOACXVMOBAX4AN[:1#/M_>#/(..:^%]
M=\':IX8O_LVI6-UI\LB%]MRA4G![5V?P/^,UY\)?$R/'O-A<. 4/.T'ZUR8B
MGS+0I.S/L%[-BS MEL]ZB5&ML[C5W3=6L_&'ANVO[3+B4 L4/"_6H;B!1%C(
M;'&1WKQ)TK2U/1P^(:,V^N1.NWTJ+2&^S7/7Z47:K"_"\^N:BBEWS#M[UI9<
MIZ&'Q/OG26NH9;:W2IF380>U8YD98DY^IJ[+J&+- G7O7!5@GLCV*F-3M%&_
MHUZ8WQVZUI:A?/(H8#)]:YS1M0\O!-:5SJBW$?R\=J\ZK1OL>]A\P7L['1Z-
MK+W<0#G[ORC-7(9]TC!V[]*XZTNVMC]X@GFK]O?-*2=QKEEA;K4[88Y'66!@
MCN.6Z^]:6K7$#6H\L\XZ5R-M.5A$F>:T-/U%=P,AW#I7+]6M([Y8Q620MQHR
M7)#QRE,=%![UFZWJEQ91[927'0&M.50&9XC\HY ]*RM39;\,).,=_6M8TM3&
M>)T*$>IQO:9Z'/K6?=W'G\A\'/6I9M+B2(X?]:P[V*2%_D8L/2O4HTERGBXG
M%OHR6^C\Q#E\FJZ 10]><U5D>8'G@>M0F;<W)SQ7=2A8\>KC9M6"\E52>_M5
M&6Y8'VJ6<*.G7ZU6N;WR#@K^-=BW/+JUI/2P_)/S9H>;]W[TD6V5-Q) ]JQ_
M&GBVV\#Z0]W>'RWVDQ+ZFNZE%'F5FT<_\<OB;!X'\/2K"^;J8;44'D5\HZC=
MS:UJ,UU<L=[L6&>M;GQ&^(-Q\0/$4]U+E45BJ#U%<XWSMD]:]&E:*LSR:E5O
M1GU?_P $AA_Q?GQ#_P!B^W_I3#12_P#!(;_DO'B'_L7V_P#2F&B@:V/WD_X.
MJ)67]D7PJ0F__3[P8';]R.:_,_\ X(-?LLV-KX?USXHZYI6G:S8Z>PM[6WO)
M%C21GX/)]*_4'_@Y]\+:EXK_ &5_"\&F6-[?2+?W>]+>(R$ P@#I7X'V/C_X
MY:#\![#P'IOA_P 16.CV<Q=3!:2(S-D\L0.:+&B.Q_X+)_LCR?LX?M.RW6GP
MVRZ-XM3[=&8CF&!V56*J1P<=*^06D.S+?(5. ?:OHCXU^+?C;^T%X!T#P[XA
M\+ZW=Q>'/^/>X>SD,S?4XYXKR[_AFWQ\[MO\'^(FX'6QD_PHW5B;M.Z.D_9R
M_:DU#X->)H%D+S:6V!)"3D-7W9X0U[2?BWX<34=(GCE,B^88LC*'N*_.R+]F
MWX@+G_BC?$7H#]B?_"O2/@+8?%SX+:U'/;>$?$<EFI^=&LY#D?E7C9EERE'F
M@ST,'BI<WOL^Q-;\+O#8;C'M8G)%<IK>A^664<#TKU#X9WNL?&SPNCR^&M8T
MZ\6,%Q):. 3^53ZU\#->G=MNAZFW'46[<_I7SD*,H/EDCZ>&,A9:G@MQIQ6;
M!&15Z7]S;IQTKT>_^ ?B13D>']4/_;NW^%4;SX)>)GC _P"$>U;CTMF_PK3Z
MO/L>CA<SA'5R/.?$,X: #':HK'4VBMA^E=GJ_P #O%DB?\BWK'_@,W^%9O\
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M=3\ /VCKKX>3):7,CR6#D(0>@KZMT+4[7Q7I$=U8R1/#(H; /W<U\56W[/\
MXXC0J?"/B+:3G'V&3C]*].^"<WQ(^&M^(9O"?B.73F;!'V&0D#\JXJ]"Y46S
MWV[LF\PX^<>OI4:62''-=-X2\+ZSX\TX7$>@:U;_ "Y=6LW!S^57?^%2:\%8
MC0=6.#P?LC_X5S>P9O1J-2.36+Y .H%.R85 KIYOA;X@B; T+5A];5_\*8?A
M9K[MSH6L?A:O_A64\-H>FZMI7,FWE\N(>]2Q2Y:M*;X;>(HL8T'5_P#P%?\
MPIR?#GQ$G_,!U;/_ %ZO_A7/+"71Z%''16A3N;@[EQV&*N:;<84Y[U*OP]\1
M2]="U7T_X]7_ ,*L)\/_ !#&/^0'JO3_ )]F_P *R>#=CICF";M<;+J7EV&,
MTZRU'S[0@';[FFS_  _\1RJ!_8>J8'_3L_\ A5J/X?\ B);8+_86J\^EJ_\
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M+;!BJ ]*ZKXH^&OB3\1=7F8^%/$?V;<<*+*0#^5<BO[/?CGRMA\(>(MN<_\
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M_P!\T#X!>$!_S K'_OBBBJ]C#L/VL^XI^ ?A%NNAV1_X!2'X!>#R/^0#8_\
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:]H5PTMGX8TZVD<%69 <D<''7VHHHH"Q__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>tm211152d1_10ksp2img003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm211152d1_10ksp2img003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" %; >P# 2(  A$! Q$!_\0
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M%(/AI^U+;ZM_PCVJ(C:+<M:SQR2#(*G!->LM\9_#3N,:K;!6!*MO'.*_-?\
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M6\:&.+W/;K0![C\./V?/A5X4\=(EA);WNKQJ#$$FW,@_ XKWB*&*"V5 !\G
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M,/H?2HYF\CJ,_2@"P#FEJO9S^;GCBK&: "BBB@ HHHH **** "BBB@ HHHH
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M16SXM_9J^.W['\R7WP[\01_$#PG9H=WA_5E78(_]_!8G&>,54\$?MP_!KXH
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MN>)+C2/$=H^EQ,_EW]H8][#MG' ]\4 ?6QE*#+9'.!\N:"0>J9^M?AQ^R?\
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M+=7'^*?V*?A]XK5_/T6.,OG/DG9CZ8KBI?\ @F-\*UWO%9ZC%.QSO^VOQ^M
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MZ /H71-/-CIEM%(=TL4(4MZGWK2@R(QFH%VQ(<>O3TJ>$Y2@!]%%% !1110
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MR;=W^T*^/_\ @I/<:%J_@O3VN/$UII=YH5R+TPS!Q#,0<[2%SF@#QK_@E_\
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MSVJ0G% "T4@.:6@ HHHH **** "BBB@ HHHH **** *]S^^A?Y1T[\5\-?\
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M9WL+3\!DU5UOP]I.G:5<3S6=O'! AD=MF-H'- #I_B1HL46_^T+;:.IW4?\
M"Q]&V!QJ%OC_ 'J\8\!?M9?"?Q[XSFT+3I4-Y$=I,L($#L.H#'@5Z ?&_@0>
M8'U'1$D@;:ZM<)@"@#IU^(^C>8$^W0<\]:>OQ&T=F(^W0\>]4]$L]!\00"YM
M8-.N,\*\)W CZUH_\(CIJC(L+;<>O% $?_"Q=&_Y_8*3_A8NC'_E^@_.I?\
MA$M-/_,/MORI#X+TLC_CPMA[^E $;?$71X?OWT'YTW_A8NC;]OV^V]?O5F>.
MKWPM\./#=QJ>MMI]CIUDF^::85Y_XC_:1^&?A[X+0>/9YK=_#UW^XMY5C_>2
M_P"Y0!ZH?B)HHDV?VA;9_P!ZE_X6-HP_Y?H/SKR[X,?M(_#/XZ^#6UO2KFTA
MMT_=R"[C^SO'_P!]UV5MKW@B]ECMEOM$:2?F,+/'ODH Z#_A8NC#_E]@I/\
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M_'O&[&,./;G]*_4K3_A;X>\/7/VJSTFQMIUY\R.,#-:PTJT:U;=!&T9(<+L
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M9>;#+';0EXAE6V8(^E 'AW_!/_P[J/A+X?ZGI=^)HK>UNF%NC_W0>*^B8?\
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M\8-2)>Q--M64.>NT$$B@"P8^GUJ2HQ*-AR<<=:CFG6+@R=LD[@.* )STJ,G
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ME-Q@X[5A:K\2=%T*V$MWJ5A!%G9N,PPA]SVJJGQ1\.WED\L>N:8\*XS*MRK
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MMTD>$!HOD_\ $O&6*CC=GDBL31OV>O"^G>,(-;MM/5+^",(C>@'0"@##\?\
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M7U[X3_9F\(>"+"**UTX3>3()XY)FW.KCD')[UIVGP.\-Z<)EMM(M]M\ZSSX
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M9'DMI!" 8"_WMO\ *OCKXC?&3Q?\#?VH?B3J=CJUQ>:=<$06EDW(@=@J!QZ
M$5ZS^R;\>_&FE?&FT\+^*M3M-<34+%;M9+8AO+)/0XZ4 ?1/Q-^&_@;7=8>?
MQ+'I9N;B/[,6NW569<Y'7M4<GP \ +I4IN=%T3['<QK$C-$GEE!TQGBOF_\
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M'XCZ</#>LW]SXM2_MI[J]:XQ#;1@KO7'0\9H _0O2;1K)8XHY=XMP(F#=2H
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MZ9)\X)P.V?:N/O?^"FOCZ7P+XS\?:AI>D0_#O0+V[TL$2G[6S(S(K 8YY*T
M>K_LM?\ !-7PQ\-_!.EKK7VK4;^V#2%'<M C$\%5Z U['X8_9'\&^%K354M+
M(1)K*-%. /O!NM?*G@3_ (* ^.O&&D^#=*\':;:7UUK6D/K#_:)B&BB$CCYO
MP45RWB'_ (+5Z[XAO&T_P]I5H^H:!.8=:29\ [>OE].: /J_Q3^P#X$UNTT@
M>2]K'HBXC$1VEE!SACWKU>W\#V.F^#(]!CA0Z:]O]G,#+]Y2,<_7-<_\"?BQ
M-\;?@WIOB:WMA;G4K;>(YCP)0.F?3-> ?L#_ !1^)'B?]K'XV>'O'NIVES#H
M=[ --BA8[((F56'X\T >F^ /V'_ WPY\8WVL:='=K<S*41"Y\NWSUV>GX5-\
M2_V'_!'Q6EL+G5(YOM6G'F42$/*#V)[BO(?VM?$GB?XM_M':GX*TCQ->^$K+
MPWHS:N9;1=S79"DA3]2*\C^'7Q>^*?B;X>Z)XJO=6U%M/L[B2%'MAOBG6-L'
MSO[IXH ^\-<^ ?A[6_"6G:'/;H-/TL*;>(#A0O2M'Q5X"TS7M$M(;KB'36!C
M!.-Q'05XO^RW^U%;>.=2$&JZS;OJ6KNR6ML&X"@9&/>N%_X*M^.O'GA/2_ !
M\'7L%K%>:\EM=_O=I.4<G'J,J* /:[K]D3PJ?$5_K&G)]BOM0@9(?+R%MY&Z
ML!VSU/O75_#OX>/X4^'=OX?O[E]1=8V2:5^=X/J:^*_A/_P4A^(_BJT;3$T6
MQ:_U*_N=+TAS)]]X9&0F3^[G::L>-_\ @ISX^\(^&=.T$:)8'QI/JHT^4>8Q
MM??#XH ^C_ O[!7@7P%XUNO$5C;W?VRZ9BI,AQ 6/)4=J[;Q)\$M'\7_  UO
M/"NHI+/I]V$C?SFR9-I#+@_A7R-X:_X*%?$=%MM0U[2]%M-'@U-=.NFBE+'<
MQ &#BNM_X*2_%#X@> _&_P )8_!-_#:?VYJ[12!W^1QY+MST[ 4 ?36H>!M/
MUGPC8Z.J*]I:*L<84X 10 !^5<CK?['_ (8U+Q0VKVT36=RD!C0(<*#CKBOC
M3X8_MQ?%3X4F;6-;M].N_#7]J)I\TKS_ +T2,3G:*ZOP7_P5FUOQS^T3%IT&
MDV[>%OMS6#X8FZ##OM]* /K_ .%7PI_X0'X:MHUY-)?*78NSMD[23_C7C.J?
M\$UOA2^O2:G/)<A[RY:YC FP%?\ BQZ5Z3^U3\;8/A+^SKJWB,W*0.+4FW+-
MM;S&'R@#O7PW^RKXON/VA/ WBKPUJ'CV_GUS2=/DU831[E>/S-S%!] 0/PH
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MC9B9&*]_7GI0!]@Z7 MO;HB?\LP$Y//'%7:R/#UW-<VD!NE5+HJ"ZJ<C-:]
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M]S7O?B?Q38^"],FU#4KL6]I%]]FZ"N/\#?M,^"OB1JK:9I'B"VO;TC(1#RM
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M6S6[2*.>:\?\'?L$6G@I'D_M.1Y_[#.DHQ48CR",_7FOI@C_ #BF^0,?CDT
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6%%% !1110 4444 %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>tm211152d1_10ksp2img004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm211152d1_10ksp2img004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" "+ 2X# 2(  A$! Q$!_\0
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M?VV?%,D(WVNAAB.@AD_^+JY8_MF^(WE"3V^BJ2<<12?_ !=?/^EZXLZ ?(&
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MH?1_"[Q[N0+>9"P]CYC#-=-=?#8K/M7:4.<AB>/I47_"O(8E59$RJ\X'/.:
M/?/V9?CS_P +S\+R7=S9-INHVQV3P%]RY]0<GBO3Z^>_V9?#$/AKQCJ"6S.%
MGBW;3TZK7T&HVKCTH 1S@@]N]?BS^WUXW73/VE?'L)E4/%?O]X_=%?M-(^P5
M_//_ ,%.?$%U)^V'\3K&(.[R:LT:C/(XH \*^)WQT2WU5H8)#<W3$JJJ,@>]
M<+8_"OQ#\8-93[=)<B&8Y$:C:#7KWP4_8WU+77BU62-'<MG$G5:]E\:>#;W]
MGGP@]WJ%A;_9BP.Z*9?M);!("J>@X//M0!\Z>-?V*IOA]X234Y(4BA4 NLKX
MW?GSFL?PGXU\)?#Z)_[6M#-(R90(W"U'^T1^UY=^*8I+:5_.>8A4+@R>6HS@
M''!->3S>%=6^)%C'.MM);Q\ RN"F[_=7O0!T&L_M2R:;JDLFA1P01[SL#<E?
MPKS[QE\6-0U[5I)Y+G-Q.-S-&,#/6NKU3]DJ\T7PR^M7TOV.Q W-(_RM-^%>
M/>(?&MH+YK'3;/[0Z':)'Z,10!I1:Q?:E<-*TF0.<OQ71>'?&MIH:YFNX_,]
MGZ5P'B.PUSQ+8P&X$5M"%P%A7K]3533?A1+<6_F,Q)/3.<$T >CR_$=7U1GM
M[RW(/4L_\JZ/1_'EV\2%;F&3)'1^E>26'P7=Y&#JP?&<#-2ZW\++G1[2.2.:
M=%]F- 'O&A^-SK,WV=@'<'&5J_.D5].%&U<<'W->#> ?$>O^!KHE59XFZ&0<
MFO4_".I/XU\J:V?$N3YJ \DT :VK>$RT9<1].F!UJ'0=6U/P==(T!?;UVD=J
MZO0;N1;!X[F,@QG&6-:\>A0ZMGI\Z8''2@#K?A7^T([+$OG?,GW@3TKZ(^&?
MQ0MO$=LG[Q?SKXV_X5Y+IS_:;<L&3KCHU>A_#76+B&9'4F*:/[ZYP&^E 'W)
M\.KB-O'.ANK _P"FQ8_[Z%>A?\%(;F*Q_;#U6509)I[*V5@>B_(*^?\ ]G+Q
MPVJ^+M#CEX/VV(<]OF%>X?\ !3+47M?VP=7QCRUL+4D_]LQ_A0!YA;ZQ]C1P
MX XP3VS6UX(\8I&VSS$&#Q[5Q-MK<=S9,+D@%SB.L;4M3?0S(\>%3&2Q'>@#
MW7Q5XV;PO<65]'(2RG]]M'&WUK0F^(VG^/O#375A=JS1H59"1N!R>HZU\N:O
M^T/]IQI\;I+.O"@M\I^M<!XO^*L_AOQ-'<RW/]B7S,/EMOGCEX'7\* /J"R^
M*UMJ=C?Z1J$R1%XF0 L!MVY9"/?=7(^ _P!O"T^'7C*."^O(P(5\NZ#C(R.-
MRGWZU\L^)]8O_B+?W5Y!?@,!E2DFTYZ<BM31OV<=9\>65I;[3+<S8PP4G&?4
MT ?7'C/]MKPK<.]]9ZG!Y&H8%Q&1]X#O]167\,?^"C$'A_$4>H&2*PN1Y4<\
M1+W$+'DJ?4?X5Y]\*O\ @E)XV\8740&V.UBZDJ2IKVO1O^".<^FI#=ZSK<=K
M'!ACY7!(]* /3_#/_!4WPUJEE%!-!J4=S%(4C4Q\NIZ9_$"N<E_X*$6FF>*M
M0@\B]BN+V)&\AU ())S63XL_8Q\ ^!IEG;6IHW8?ZQ90QR!7)VG['OA#Q'JB
MZA)XGN#-.PRY<;@H- 'J?PC_ &\-0U7XDRW-YIQ@,R+IEHK<%\G/'O7T+I_[
M2K0WEQ;&TFC-OM#*V"3D'.*\.\-_L!V?B)]$E\+:S]L;2[M;EWNFV 8]ZZG2
MO 'B;P/\2'NYM/M]6CL7,D[(=T:)GEL^V* /2]'^-MSJ0?S=/U2%(I20KP'I
MZ_2MBQ_:%TID_>R+#ER&\U2F/S%-^#OQ;E_MJ]GF0[+V5G#3* J1+C!4'L<G
MGVKU"XTWP3\6-"?S]/L6ADX#A0&8GKC% '#0?$73-9(^SS1R[_[K9Q4LNH0C
M<!@Y'K6'XS_83M-3DEO/!VNW6G3(.(2^4!KS'QM'X\^!L2QZ[8_;K2(C=>P
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M1AD^V:A+:74ASB&S_>O_ +S'I6]X1\,S_$R6*ZM_^/>VE"$W'+O^7%;/P_\
MA'I_C'QD]MI]NLWE\3RL!E_H*]E\(Z58>'?'5IHUC&D5A8L _P G+MU.??)-
M 'H/[,7[#MIXA\JY>VM!'("TCR0X=_F/K7Z _ K]EWPSX'L894LX9F"@,610
M0?85Y7\$9EM=.AV;0A QM6O<-0\;Q>$/"%Q? _ZI<AL]3CTH T/C)\:=%^$F
MEBVMH$%TZX1$C&0?>OS&_;L_X*U1?"369+*0OJNK2@K#9V\H5(NN"YZ#Z5N?
M\%&/VS;OX;_!W5_$2WJ#4IW:WM@XR03P,"OQ4UWQ+?\ B[Q1<:IJMT]Y?7<K
M2N\K$@$\\>U 'OWQ"_;J^(WQ=U)WFU>+2T=RZP6[$!#VR3U/O6=X>^-'Q%LY
MHKF/Q'?R-C&#<[AG/H#7C6F74Q?*D%BN#QBNF\(7<D4^6B^U9(&TDC:?8T ?
M>'[-G_!4/Q[\)I;*T\1^=/I_RAI848,![U^RO[$G[17A?]H3PQ9RPM&)+RW&
M[Y0PE!Z@FOP%^&7BV/4+"33TNK6*26+#PW:AO,_V5:OK;_@F7\?+?X3?%JS\
M/1W=Q:#4N+>$L2L4HX')[')_*@#]H_B/^SGHWCVVC!\W3_*C*#[+A 5..#Z]
M*\$\1?!#Q9\$P\ME<B]M5E+VJ,23D=,_G7TU\)?%@\;>"K>Y=R;J,>5< C^,
M=2/8UN7>DQZE"T4T8=&'<=* /G[X8_%K[3I_V0+(E]:$;L#;DM][.?>O2;/7
M-/\ %5O+8:E:PS+(0C&0!E8^F>U9OQ'_ &<;35[W^TM*>2QNQ'LD53\LGO7F
MO]K:QX N'TS5+=SY?S0S1@L77..: ._^&/[/FB_"OXLWVK:(?)CU6$B6 /E5
M.Y3D?E7LJ]3SFO'/@KXDDUGQ8\99FC2$LI;KU6O8HSEVH )FVE>,\_E7YI?M
MQ:'IVM?%?Q&9]/66Z-PX$J,58?4BOTO<X6OCGX^?"9-?^)6KND!D>YF!&T=Z
M /S/\2?L^2:[KB$I*Z9W8;+5[M^QK^Q_)K7C"!Y;*614/&5Z#(K[&^&G[&<5
MI ]]J2+YA&50KT%>M?!KX:67A+6#Y"*@YZ+CTH V/AG\)+'P9X?M[<1!&7MB
MN:_:ZTG_ (L9K/DK\PMV /\ <X/->JD'=[ D5S_Q6\*)XW^'NK:8ZEENK9TX
M_P!TT ?D5\)/$7AJY\4PV,4L$[Q[6FGD(.P@G*Y/?-?3'QH^*_AG5?#>D:4M
M_%&L<GS[6'R_(<' ]\5^8NG^,9OV?OC/XD\(:Y:/)+::M(Z$G#.-Y(Y^E:&I
M3W'C7Q,U[#?75D2&8H)20B_P_KB@#[S_ ."@7QVT#X?_ ++.KZ?H\\%YK&JV
ML:VZ@86., %BWN<5_.+^TAJUY-XYOI;M/*-T^5VCC;7[.^,_"LOQ-\$Q:?=W
MHNKIH4C+DX &.]?"_P"TI^Q(_B[7_L,481XY/*CF3D,?>@#\_0GFR?*V>>I[
M5]A_\$N?AY+J\VL7-R;BUMKN2-%89_>?*1Q53P=_P3%O]6\5>1J%ZQMA-AA&
MN,+WS7VA\+?AW!\%?"0T_2[*&7RE"2J@_>1 =Q[T )=7(-_'$)&%@I\B0GEC
MV)KRWX_6GEQW,5A'&UO$_$A')!%>T:?\/(O%SB]Q*O7<^=J*?<>M>1_M 1LT
MJ6MO$/O>7\A^_0!ZK_P32\-"+PMJ,F"_/4BO8/B@?L,N8_6L[]C'X?GP!\*4
M,R-')<KYAK0^)5^LK;')/S^E 'BOC31$GE^78"_48K%T'P(DGC"&)N6\HNVT
MD;*Z?6F6[\0E/]NNM\#>$+K4M7\ZQA\^XEE2QA!'WW;F@"_^Q1\5-?T3]I'1
M]"VR7VGRWJJ2<YB&X5V?_!9R22'_ (*">)-TYAM_[,M,<_?_ '35T_[%OA"U
M\)_M PV^J2V5K?3:@L3[@"T;!N@_&N&_X+6(VH?M_>(88T0@Z?:-N#9Q\@H
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ML^S\%2>')C:20>7,L@"L/XAV_2O1?"^A_:( FS8F<.?6@#\]_P#@H7^R?/\
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MG5\,P,FT(6/4 U!J4$6DIMR(QW '6NFN0%BSC\JQ+K3#JDA+9X[8ZT <G?\
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' **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>tm211152d1_10ksp2img005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm211152d1_10ksp2img005.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" #^ 7T# 2(  A$! Q$!_\0
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M^UX_[LO_ 'Q1_:\?]V7_ +XH E\V?_GDO_?PT>;/_P \E_[^&HO[7C_NR_\
M?%']KQ_W9?\ OB@"7S9_^>2_]_#1YL__ #R7_OX:B_M>/^[+_P!\4?VO'_=E
M_P"^* )?-G_YY+_W\-'FS_\ /)?^_AJ+^UX_[LO_ 'Q1_:\?]V7_ +XH E\V
M?_GDO_?PT>;/_P \E_[^&HO[7C_NR_\ ?%']KQ_W9?\ OB@"7S9_^>2_]_#1
MYL__ #R7_OX:B_M>/^[+_P!\4?VO'_=E_P"^* )?-G_YY+_W\-'FS_\ /)?^
M_AJ+^UX_[LO_ 'Q1_:\?]V7_ +XH E\V?_GDO_?PT>;/_P \E_[^&HO[7C_N
MR_\ ?%']KQ_W9?\ OB@"7S9_^>2_]_#1YL__ #R7_OX:B_M>/^[+_P!\4?VO
M'_=E_P"^* )?-G_YY+_W\-'FS_\ /)?^_AJ+^UX_[LO_ 'Q1_:\?]V7_ +XH
M E\V?_GDO_?PT>;/_P \E_[^&HO[7C_NR_\ ?%']KQ_W9?\ OB@"7S9_^>2_
M]_#2[Y_^>2_]_#42ZO$SA<29/JM74.Y!0!2O]0DLK8N\0VIRV'YJY'G9R,>V
M<UG^)_\ D$3_ .[_ %%:(Z4 9&O_ /'_ *9_U]#^5;%8^O\ _'_IG_7T/Y5L
M4 -D&8SVXZ^E<1\3/@SH'QC\-R:/XCTK^T=-FE#O ;F2,-['8RY'8KG!KN&;
M:I)Z#KFJ[ZE!$N7=$7&=S' 'XF@#/T+PVGA[1[6PL;>&QLK&,0V\$2A$C0#"
MJ%' 4#WK8VY'.#4:WL3@8=?FY [FI-P__50 ;?I^5&WZ?E1O'J*-X]10 ;?I
M^5&WZ?E1O'J*8UU&C8+@'&<4 /V_3\J-OT_*A6W"C<!W% !M^GY4;?I^5&\>
MHHWCU% !M^GY4;?I^5&\>HJ&]U&+3[:664L(X4,CE49L >P!)^@H FV_3\J-
MOT_*L/PE\2='\<R3KID]Q-]F8I(7LYH54CJ,NB@GZ5MB0$=10 NWZ?E1M^GY
M4;QZBC>/44 &WZ?E1M^GY4;QZBC>/44 &WZ?E1M^GY4;QZBC>/44 &WZ?E1M
M^GY4;QZBC>/44 &WZ?E1M^GY4;QZBC>/44 &WZ?E1M^GY4;QZBC>/44 &WZ?
ME1M^GY4;QZBC>/44 &WZ?E1M^GY4;QZBC>/44 &WZ?E1M^GY4;QZBC>/44 &
MWZ?E1M^GY5 ^IVZ=95Z%OP'4TY-0BD0$,2#T^4\_I0!+M^GY4;?I^51+?Q,>
M&)PVT_*?E.,\^G%,DU>WB7)DXR02 3M(Z@^GX^A/8T 6-OT_*C;]/RJ :I;G
MI,AR2HP<Y(ZBG-?Q(,EP,8SGWH EV_3\J-OT_*D64,H.>O//%+O'J* &F+<>
M@_*GBF^8/6E!R* ,[Q/_ ,@B?_=_J*T1TK.\3_\ ((G_ -W^HK1'2@#(U_\
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M_P"T#_SRF_(4?V@?^>4WY"K.?:C/^S0!6_M _P#/*;\A1_:)'_+*;\A5G/\
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M,?C[\:O"/Q'\-ZCH/BVSAUCPW.]AI5X\+O\ 96TJ#RD"QP;?M7VP.7;SQR'
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MGD"O,?VE]8%YX!TT?9[KCQ)HHP8B,G^T[;VKT ^(A!,5-K=GD@'RS\QR>G%
M&O164/$88\6=Y_WZ;_"E_P"$A_Z<KW_OTW^% &I167_PD/\ TY7O_?IO\*/^
M$A_Z<KW_ +]-_A0!?NUWP$5Y9X-\.V\'[1_BDYNF$-C:21JTTC*A??NPI.VO
M0U\1AR/]$N_^_1_PKS_PIK"K^T1XM<P7./[-L<#8>?\ 64 >HHF"/;I4E90\
M0+GBTNR<9'[MJ7_A(?\ IRO?^_3?X4 :E%9?_"0_].5[_P!^F_PH_P"$A_Z<
MKW_OTW^% &I167_PD/\ TY7O_?IO\*/^$A_Z<KW_ +]-_A0!J45E_P#"0_\
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MG^=?5W[=^H&?]CGXB9@F3_B42=3[BOE&Z_X^9O\ ?/\ .@#W/_@F9]SXH_\
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MY"@#1HJ@-38N!]GGY[^E78\[!GK[T 9_B?\ Y!$_^[_45HCI6=XG_P"01/\
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M>>0)' O<LQ( 'N: /-/'-ZQ_:F\#$V=QD:3J6#M7CF'_ &Z]1.H2#_ESNO\
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M?ZBM$=* ,C7QF^TS_KZ'\JI?%;QQ;_#+X>:[XCNT>2UT#3Y]0F1 "S)#&TA
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MZ9/_ (U](?L<#=^UIHV?^A?U+_T9:5\X?L6KM_9L\/>H-\.O_3]<'^IKZ/\
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M*% ?V$?!_P#U]ZQT/_47O:^B_+^OYFOG;_@E#_R8AX/_ .OO6/\ T[WM?1=
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MAX<X_P"WB\K[\U6,0Z9=;0HS!,I( R>O/UKX&^$"_P#%1_"\]_\ A1_AL?\
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MGQ2VQ^9_Q5-OT/\ U"+&OJ!=0G*C_1'_ .^A0!=KP/\ :4_Y..\!?]@O5/\
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MP(4 >9?MI?\ )%+3_L;?#/\ Z?K"L.3_ %K_ .\?Y5J?MF74DGP6M-T)0?\
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M (1?]C/-_P"D-Q6%^Q*2?"GCH^GCS6S_ .3-;WQYY^)_PBQD_P#%32D\=/\
M0;B@#Y5_8O7'[-OAX>C7W_I;/7TA^QP<_M9:-[:!J/\ Z,M*^;_V,B5_9O\
M#W#<O>CIC_E]GKZ/_8Y.S]K31N#_ ,@#4AS_ -=+2@#[=$8:E$86FI)3O,H
M\G_;33/P4M/^QM\,]O\ J/:?6)("&8 _Q>GL*VOVTY<?!2T_[&WPS_Z?K"L6
M5OWK?4_RH ^:_BOSI&D'_J>];'\JQ-1XM']U?K6W\5^-(TC@G_BN]<Z?45BZ
M@-]O)_LHYY- 'TM_P2C3?^PCX/\ ^OS6/_3O>U]%>2*^=?\ @E#*#^PGX1 _
MAO-8Z_\ 87O:^B_,H 1H@%/TKY T5-W[>/QLZ?\ 'EH/;_IC<5]?L^5/TKY
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M^Q]*Q?!?QA\.?$KP.GB70-:TW5="='E%[#/^YPAVL2W8*0P.>F#0!\M_%O\
MX)N>(_B3\,]:T*'7M(MI-4MFA65HW*IG'.._3UKZK^&GAZ^\%?#O0M&E2VFE
MTC3[>R>1)B%<QQJF1E>^,_C7)V?[87PVU'3-2N8_%NDM%I4>^Y59275,XW*N
M,R#/&4W9KO?"?BVR\:Z#:ZEIT[365X@DA?:5W+]& 8?B!0!;$MT?^6$/_?[_
M .QIDEQ<QDDPP@<<^:?7_=JZI(7G]:S?$WB2U\,:1<ZC>L8[2RC,DK@%MB]S
M@<T >#?L_P#[(^M?"#1?$-K<ZCI]TVL^(K_6EV97REN)=X3W('?OZ5H_$?\
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M8UM3;:+9WEM<+(H+2&5!Y?)]&%>H_99?^>Y_[YJ.339)),M*&4<X*_>/O]*
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M8]MM %A3E3SWJK>V*W43JVUPZ%2I'7-2BUE'_+<_]\BD>SE8']]G((^[T]*
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MS-Q)@8QD#DB@#P+_ ()W?!#QU\!OAKJFE>-+VU6WEU-GT/2H9S=_V/8K$J"
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0&4@_+U-78U*( 3G'>@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>tm211152d1_10ksp2img006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm211152d1_10ksp2img006.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" #^ <4# 2(  A$! Q$!_\0
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MWTK2EYC/TK$OS_Q66F?[C_\ H!H W:*** *.M?ZNV_Z[I_.KU4=:_P!7;?\
M7=/YU>H *:_W#3J,T >;_'+]GS1/VAM%BTSQ ^N?8$D)>VL]4N+**[7&"LRQ
M.JRI_LR!A[5VOA/0K3PIX?LM-L;>.SL=/@2VMX(UVI#&BA54#T  %7FG16Y-
M*LB2>XH -H8YZ_A1Y8]/T%/&%%+F@"/RQZ?H*/+'I^@J2B@"/RQZ?H*/+'I^
M@J2B@"/RQZ?H*-@';]!4E,D/(H 38#V_04>6/3]!2Q-N''-/H C\L>GZ"CRQ
MZ?H*DHH C\L>GZ"CRQZ?H*DHH C\L>GZ"CRQZ?H*DHH C\L>GZ"CRQZ?H*DH
MH C\L>GZ"CRQZ?H*>[;5)J+[1GC/UQVH =L'I^@H\L>GZ"C ?!W5)0!'Y8]/
MT%'ECT_05)10!'Y8]/T%'ECT_05)10!'Y8]/T%'ECT_05)10!'Y8]/T%'ECT
M_05)10!'Y8]/T%'ECT_05)10!'Y8]/T%'ECT_05)10!'Y8]/T%'ECT_05)10
M!'Y8]/T%'ECT_05)10!'Y8]/T%'ECT_05)10!'Y8]/T%'ECT_05)10!'Y8]/
MT%'ECT_05)10!'Y8]/T%'ECT_05)10!$R#'3_P =%.1<-WI]% "'I6!??\CM
MI?\ USD_]!-;YZ5@7W_([:7_ -<Y/_030!T%%%% %'6O]7;?]=T_G5ZJ.M?Z
MNV_Z[I_.KU !3)_]6:?3)?G&* /F'_@HQ\?_ !E\"/!FCW'@U[@7UT]P\J6^
MDG4YVCBB\SB(,I$?]]\_*O.*]R^ OC&;XA_!KPKKUS)9RW&M:1:WTKVA)@=Y
M(E<E">=N2<5)XV^%?A_XCJD6O:1I^KPP-OC2[@681DC!*@] 1P1WK<T+2+7P
M_HUM96-O!:6=K&L4$$$0BCA0# 55'"@#C% !=:H+>X9/(N7QW6$L#^--76P!
M_J+L?]N[5=\K=S3ECP* */\ ;@_YXW?_ (#M1_;@_P">-W_X#M5[91LH H_V
MX/\ GC=_^ [4?VX/^>-W_P" [5>V4;* */\ ;@S_ *F\_P# =J\U_:&\5>*M
M#TBSO?#6I1:8/M,5K-'=:.USO,LBJ&#;UVX!/8]:]8V5P7[1R[?AY%_V$[/_
M -'I0!T'AK4[BTT>&*\^T7%S&BB65+)HUD; R0.:O_VX/^>-W_X#M5X+N/X"
MC90!1_MP?\\;O_P':C^W!_SQN_\ P':KVRC90!1_MP?\\;O_ ,!VH_MP?\\;
MO_P':KVRC90!1_MP?\\;O_P':C^W!_SQN_\ P':KVRC90!1_MP?\\;O_ ,!V
MH;7!C_4W?_@.U7ME&R@#-DUI70CR;SUXMVKR7Q!XS\7V'[1FC:3;:I&F@:G;
MS7<EN=(9KC]WCY/,W<9SUP:]L9<*?I7EGC$;OVK_  G_ -@6\_F* /08=:4H
M#Y5[[_Z._7\JD_MP?\\;O_P':KJ1_(*790!1_MP?\\;O_P !VH_MP?\ /&[_
M / =JO;*-E %'^W!_P \;O\ \!VH_MP?\\;O_P !VJ]LHV4 4?[<'_/&[_\
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M_P \;O\ \!VJ]LHV4 4?[<'_ #QN_P#P':C^W!_SQN__  ':KVRC90!0DUT
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MYO\ TK:N*N-/M[[_ %T$,VUOEWH&QTZ9H M6CB0HP=)%E5905Z<[?\*^J/\
M@F]_R:%X7^MU_P"E,M?*UD@AF@10%0.JA0, #/3%?5/_  3<_P"3/?"OUNO_
M $JEH ]UZTF*6B@!,48I:* $Q1BEHH 3%!%+2'I0!^5_PP'_ !<GXO?]E#US
M_P!*Y*M7QS\3])_Z\I_YBJOPR_Y*/\7N ?\ BX>M\$X'_'W)6O-X*TZZ\2QZ
MD_VH7L/W=EV_EJ.X"YQ^% '"?MK<?LY:Y_UVLO\ TKAK]<8S\OY?TK\C/VUG
M"_LXZV%!QY]EU_Z^X:_7./[H_#^E #\48I:* $Q1BEHH 3%&*6B@!,48I:*
M$Q65K6IC2(;F>0XAMT,C'N !DD>O3H!6M61XBTLZQIE];JP!N('@#$?*I92,
MGZ9H ^?=-_X*B?#W4M=T6SDTOX@V</B#5K?1+*_N_"M];6$L\\XMXP;AXQ&
M9" #FMVP_P""@'@.\^,UYX*NYM2TF]MH]0F6[N[8QV4PL?*6Z_>] $,\?!QZ
MC->:7?[%?Q%UKPUX-\.ZCXB\%1^'_"_B+2M7>:VAN7NYULM02[5.3L!<IM)
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M3ZBX/]$KP#]FC]LO4OVA['Q6\VC2:$VD0&[TUI(RAO8 TJ&3DD$!XR,5X5\
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M9L[PYN+0O&K&*3_;7.T^X- '2"EJK/=S12D+!N Z'=UIOVZX_P"?8_\ ?0H
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M%!N9C_RZY^K"@#C?!'[/OACP!;&/2]-6VCDLGT_:K=(6=I"@_P"!.U8/B_\
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M?#R7.E[T2>./1;>Z27!P5;=<L./[HKUCP-J$.I^%=/FMI5N8#;1[7B;<I(4
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M^N#_ *;V1_\ )N&OURC^Z/P_I0!0_LJ7_G_O_P T_P#B:/[*E_Y_[_\ -/\
MXFM+%&* ,W^RI?\ G_O_ ,T_^)H_LN;_ )_[[_QS_P")K2Q1B@#Y=_;%MI+3
M]IWX([YY)<C6AS_URM*WM8\/:?XEM4AU+3[._@SDI<1"4$C_ 'LUD_MIK_QD
M[\$?8ZU_Z*M*Z%3D?[I- $6D:9;Z/:K;6D$5I;Q@*D4"[$7)]/Z5\T7>G/)^
MP]^WHZ7,T:_VQKQ*@+_T+.G>U?3\7W_Q%?-4G/["_P"WG_M:QKX_\MG3J .<
M\,HK^&].W#>OV6,$-_$-HZTNG^&=-TB=I;73[&VE8Y+Q0*K$^I/4T>&./#>G
M_P#7M'_Z"*O4 :_[-EMY_P"W'X# 9HS_ &?J9W*>>8"/ZU][#2I?^?\ OO\
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M8M,NTRP;=V",'[RFCP[I$VBZ<;>6_N;_ .;Y)+A4WJ/3*J*NC[@^E*IP/Q%
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MZ9GLN1V_TN&OUI32PT>/-EYQ_%["@"[N%&X53_L1?^>LW_?5']B+_P ]9O\
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M#I7Y_?LR(8OVXO TQ5A$FF:D'?:=J'R>YZ5]_+<H5'S+^8H DHJ/[2G]]?\
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MDMT4:279\\NQ%4;CW.% ^@%6O[!TJ= _V:V(/((7M7CG[:GC7Q+X=U#0-/\
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H8%+10 4444 (XRIK+NM,EE\2VESL_=Q*P9LC@E2*U:* "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140151711036792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Mar. 29, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Document and Entity Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">EYENOVIA, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.0001 Par Value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">EYEN<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,623,577<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001682639<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32,427,910<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140151715789128">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheets - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 28,371,828<span></span>
</td>
<td class="nump">$ 14,152,601<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsCurrent', window );">Deferred license costs</a></td>
<td class="nump">1,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_LicenseReceivableCurrent', window );">License receivable</a></td>
<td class="nump">2,966,039<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">453,478<span></span>
</td>
<td class="nump">196,680<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total Current Assets</a></td>
<td class="nump">33,391,345<span></span>
</td>
<td class="nump">14,349,281<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">396,380<span></span>
</td>
<td class="nump">230,538<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SecurityDeposit', window );">Security deposit</a></td>
<td class="nump">119,035<span></span>
</td>
<td class="nump">117,800<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total Assets</a></td>
<td class="nump">33,906,760<span></span>
</td>
<td class="nump">14,697,619<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">1,461,665<span></span>
</td>
<td class="nump">1,541,358<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WorkersCompensationLiabilityCurrent', window );">Accrued compensation</a></td>
<td class="nump">1,150,672<span></span>
</td>
<td class="nump">916,873<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_AccruedExpensesAndOtherLiabilitiesCurrent', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">1,480,692<span></span>
</td>
<td class="nump">453,430<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRentCreditCurrent', window );">Deferred rent - current portion</a></td>
<td class="nump">7,809<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred license fee</a></td>
<td class="nump">14,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermBankLoansAndNotesPayable', window );">Notes payable - current portion</a></td>
<td class="nump">97,539<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total Current Liabilities</a></td>
<td class="nump">18,198,377<span></span>
</td>
<td class="nump">2,911,661<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRentCreditNoncurrent', window );">Deferred rent - non-current portion</a></td>
<td class="nump">38,684<span></span>
</td>
<td class="nump">45,351<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermNotesPayable', window );">Notes payable - non-current portion</a></td>
<td class="nump">365,814<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total Liabilities</a></td>
<td class="nump">18,602,875<span></span>
</td>
<td class="nump">2,957,012<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 9)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' Equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.0001 par value, 6,000,000 shares authorized;0 shares issued and outstanding as of December 31, 2020 and 2019 respectively</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.0001 par value, 90,000,000 shares authorized; 24,978,585 and 17,100,726 shares issued and outstanding as of December 31, 2020 and 2019, respectively</a></td>
<td class="nump">2,498<span></span>
</td>
<td class="nump">1,710<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">92,742,306<span></span>
</td>
<td class="nump">69,409,949<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(77,440,919)<span></span>
</td>
<td class="num">(57,671,052)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Stockholders' Equity</a></td>
<td class="nump">15,303,885<span></span>
</td>
<td class="nump">11,740,607<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total Liabilities and Stockholders' Equity</a></td>
<td class="nump">$ 33,906,760<span></span>
</td>
<td class="nump">$ 14,697,619<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_AccruedExpensesAndOtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, of accrued expenses and other current liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_AccruedExpensesAndOtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_LicenseReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of license receivable classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_LicenseReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of deferred costs capitalized at the end of the reporting period that are expected to be charged against earnings within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRentCreditCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For a classified balance sheet, the cumulative difference as of the balance sheet date between the payments required by a lease agreement and the rental income or expense recognized on a straight-line basis, or other systematic and rational basis more representative of the time pattern in which use or benefit is granted or derived from the leased property, expected to be recognized in income or expense, by the lessor or lessee, respectively, within one year of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121549951&amp;loc=d3e39927-112707<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRentCreditCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRentCreditNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For a classified balance sheet, the cumulative difference between the rental income or payments required by a lease agreement and the rental income or expense recognized on a straight-line basis, or other systematic and rational basis more representative of the time pattern in which use or benefit is granted or derived from the leased property, expected to be recognized in income or expense, by the lessor or lessee, respectively, more than one year after the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.26(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121549951&amp;loc=d3e39927-112707<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRentCreditNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecurityDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8,17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecurityDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermBankLoansAndNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of borrowings from a bank classified as other, maturing within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.16)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermBankLoansAndNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WorkersCompensationLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations and payables pertaining to claims incurred of a workers compensation nature. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WorkersCompensationLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140151710958632">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Balance Sheets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred Stock, Par or Stated Value Per Share</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred Stock, Shares Authorized</a></td>
<td class="nump">6,000,000<span></span>
</td>
<td class="nump">6,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred Stock, Shares Issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred Stock, Shares Outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, Par or Stated Value Per Share</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common Stock, Shares Authorized</a></td>
<td class="nump">90,000,000<span></span>
</td>
<td class="nump">90,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common Stock, Shares, Issued</a></td>
<td class="nump">24,978,585<span></span>
</td>
<td class="nump">17,100,726<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common Stock, Shares, Outstanding</a></td>
<td class="nump">24,978,585<span></span>
</td>
<td class="nump">17,100,726<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140151712586952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Operations - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Operating Income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of revenue</a></td>
<td class="num">(800,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross Profit</a></td>
<td class="nump">1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating Expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">13,263,817<span></span>
</td>
<td class="nump">$ 14,102,449<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">7,725,408<span></span>
</td>
<td class="nump">7,206,095<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total Operating Expenses</a></td>
<td class="nump">20,989,225<span></span>
</td>
<td class="nump">21,308,544<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss From Operations</a></td>
<td class="num">(19,789,225)<span></span>
</td>
<td class="num">(21,308,544)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other Income (Expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_SmallBusinessAdministrationEconomicInjuryDisasterGrant', window );">Small Business Administration Economic Injury Disaster Grant</a></td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(17,042)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNonoperatingNet', window );">Interest income</a></td>
<td class="nump">26,400<span></span>
</td>
<td class="nump">151,786<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss</a></td>
<td class="num">$ (19,769,867)<span></span>
</td>
<td class="num">$ (21,156,758)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract', window );"><strong>Net Loss Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">- Basic and Diluted</a></td>
<td class="num">$ (0.94)<span></span>
</td>
<td class="num">$ (1.47)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract', window );"><strong>Weighted Average Number of Common Shares Outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">- Basic and Diluted</a></td>
<td class="nump">21,054,706<span></span>
</td>
<td class="nump">14,349,738<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_SmallBusinessAdministrationEconomicInjuryDisasterGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of small business administration economic injury disaster grant.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_SmallBusinessAdministrationEconomicInjuryDisasterGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNonoperatingNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of nonoperating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNonoperatingNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140151709838584">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Statements of Changes in Stockholders' Equity - USD ($)<br></strong></div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Accumulated Deficit [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2018</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 1,147<span></span>
</td>
<td class="nump">$ 53,388,216<span></span>
</td>
<td class="num">$ (36,514,294)<span></span>
</td>
<td class="nump">$ 16,875,069<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2018</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">11,468,996<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_StockIssuedDuringPeriodValueNewIssuesThree', window );">Issuance of common stock in public offering</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 505<span></span>
</td>
<td class="nump">12,958,070<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">12,958,575<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_StockIssuedDuringPeriodSharesNewIssuesThree', window );">Issuance of common stock in public offering (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">5,046,763<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_StockIssuedDuringPeriodValueStockOptionsExercisedOnCashlessBasis', window );">Exercise of stock options on a cashless basis</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 24<span></span>
</td>
<td class="num">(24)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodOnCashlessBasis', window );">Exercise of stock options on a cashless basis (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">236,466<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 34<span></span>
</td>
<td class="nump">551,743<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">551,777<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">348,501<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">2,511,944<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,511,944<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(21,156,758)<span></span>
</td>
<td class="num">(21,156,758)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2019</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 1,710<span></span>
</td>
<td class="nump">69,409,949<span></span>
</td>
<td class="num">(57,671,052)<span></span>
</td>
<td class="nump">11,740,607<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2019</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">17,100,726<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_StockIssuedDuringPeriodValueNewIssuesTwo', window );">Issuance of common stock and warrants in private placement</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">$ 267<span></span>
</td>
<td class="nump">5,451,475<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,451,742<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_StockIssuedDuringPeriodSharesNewIssuesTwo', window );">Issuance of common stock and warrants in private placement(in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">2,675,293<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_StockIssuedDuringPeriodValueNewIssuesThree', window );">Issuance of common stock in public offering</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">$ 383<span></span>
</td>
<td class="nump">12,495,325<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">12,495,708<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_StockIssuedDuringPeriodSharesNewIssuesThree', window );">Issuance of common stock in public offering (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">3,833,334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_StockIssuedDuringPeriodValueWarrantsExercised', window );">Exercise of stock warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 134<span></span>
</td>
<td class="nump">2,820,228<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,820,362<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_StockIssuedDuringPeriodSharesWarrantsExercised', window );">Exercise of stock warrants (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,332,841<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">82,157<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 82,161<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">36,391<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,391<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">2,483,172<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 2,483,172<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(19,769,867)<span></span>
</td>
<td class="num">(19,769,867)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2020</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 2,498<span></span>
</td>
<td class="nump">$ 92,742,306<span></span>
</td>
<td class="num">$ (77,440,919)<span></span>
</td>
<td class="nump">$ 15,303,885<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2020</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">24,978,585<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">[1] Includes gross proceeds of $14,030,001, less total issuance costs of $1,071,426</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">[2] Includes gross proceeds of $5,984,931, less total issuance costs of $533,189.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top">[3] Includes gross proceeds of $13,800,002, less total issuance costs of $1,304,294.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodOnCashlessBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised on cashless basis during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodOnCashlessBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_StockIssuedDuringPeriodSharesNewIssuesThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This represents common stock issued during period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_StockIssuedDuringPeriodSharesNewIssuesThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_StockIssuedDuringPeriodSharesNewIssuesTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock issuance of common stock one shares on public offering</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_StockIssuedDuringPeriodSharesNewIssuesTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_StockIssuedDuringPeriodSharesWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued as a result of the exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_StockIssuedDuringPeriodSharesWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_StockIssuedDuringPeriodValueNewIssuesThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This represents Stock Issued During Period Value New Issues three.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_StockIssuedDuringPeriodValueNewIssuesThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_StockIssuedDuringPeriodValueNewIssuesTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock issuance of common stock two value on public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_StockIssuedDuringPeriodValueNewIssuesTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_StockIssuedDuringPeriodValueStockOptionsExercisedOnCashlessBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options on cashless basis.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_StockIssuedDuringPeriodValueStockOptionsExercisedOnCashlessBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_StockIssuedDuringPeriodValueWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_StockIssuedDuringPeriodValueWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326096&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140151710930760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Changes in Stockholders' Equity (Parenthetical) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=eyen_CommonStockOneMember', window );">Common Stock One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_ProceedsOfStockIssuedDuringPeriodGross', window );">Proceeds Of Stock Issued During Period Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,030,001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,071,426<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=eyen_CommonStockTwoMember', window );">Common Stock Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_ProceedsOfStockIssuedDuringPeriodGross', window );">Proceeds Of Stock Issued During Period Gross</a></td>
<td class="nump">$ 5,984,931<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs</a></td>
<td class="nump">533,189<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=eyen_CommonStockThreeMember', window );">Common Stock Three [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_ProceedsOfStockIssuedDuringPeriodGross', window );">Proceeds Of Stock Issued During Period Gross</a></td>
<td class="nump">13,800,002<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs</a></td>
<td class="nump">$ 1,304,294<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_ProceedsOfStockIssuedDuringPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>It represents issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_ProceedsOfStockIssuedDuringPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=eyen_CommonStockOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=eyen_CommonStockOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=eyen_CommonStockTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=eyen_CommonStockTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=eyen_CommonStockThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=eyen_CommonStockThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140151710102344">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Statements of Cash Flows - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash Flows From Operating Activities</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (19,769,867)<span></span>
</td>
<td class="num">$ (21,156,758)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation of property and equipment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">95,415<span></span>
</td>
<td class="nump">15,343<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,483,172<span></span>
</td>
<td class="nump">2,511,944<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">218,418<span></span>
</td>
<td class="num">(63,924)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_IncreaseDecreaseInLicenseReceivable', window );">License receivable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(2,966,039)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredCharges', window );">Deferred license costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(1,600,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(79,693)<span></span>
</td>
<td class="nump">31,834<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">233,799<span></span>
</td>
<td class="nump">4,769<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,000,612<span></span>
</td>
<td class="num">(266,283)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred license fee</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">14,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInSecurityDeposits', window );">Security deposit</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(1,235)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_IncreaseDecreaseInDeferredRent', window );">Deferred rent</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,142<span></span>
</td>
<td class="nump">3,767<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net Cash Used In Operating Activities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(6,384,276)<span></span>
</td>
<td class="num">(18,919,308)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash Flows From Investing Activities</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(261,257)<span></span>
</td>
<td class="num">(166,643)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net Cash Used In Investing Activities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(261,257)<span></span>
</td>
<td class="num">(166,643)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash Flows From Financing Activities</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from sale of common stock in public offering</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">13,214,949<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from sale of common stock and warrants in private placement</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">5,569,136<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from sale of common stock in public offering</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">12,734,002<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from exercise of stock warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,820,362<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_ProceedsFromPaycheckProtectionProgramLoan', window );">Proceeds from PPP 7(a) Loan</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">463,353<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Repayments of notes payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(475,216)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_PaymentsForRepurchaseOfPublicOffering', window );">Payment of public offering issuance costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(329,038)<span></span>
</td>
<td class="num">(256,374)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock options</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">82,161<span></span>
</td>
<td class="nump">551,777<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net Cash Provided By Financing Activities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">20,864,760<span></span>
</td>
<td class="nump">13,510,352<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net Increase (Decrease) in Cash and Cash Equivalents</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">14,219,227<span></span>
</td>
<td class="num">(5,575,599)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents - Beginning of Year</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">14,152,601<span></span>
</td>
<td class="nump">19,728,200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents - End of Year</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">28,371,828<span></span>
</td>
<td class="nump">14,152,601<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental Disclosure of Cash Flow Information:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidCapitalized', window );">Interest</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">13,974<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Supplemental Disclosure of Non-Cash Investing and Financing Activities</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_PurchaseOfInsurancePremiumFinancedByShortTermNotePayable', window );">Purchase of insurance premium financed by note payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(475,216)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssued1', window );">Exercise of stock options on a cashless basis</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">24<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_AccruedPurchasesOfLeaseholdImprovements', window );">Accrued purchases of leasehold improvements</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 42,500<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Includes gross proceeds of $14,030,001, less issuance costs of $815,052 deducted directly from the offering proceeds.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">Includes gross proceeds of $5,984,931, less issuance costs of $415,795 deducted directly from the private placement proceeds.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top">Includes gross proceeds of $13,800,002, less issuance costs of $1,066,000 deducted directly from the offering proceeds.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_AccruedPurchasesOfLeaseholdImprovements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This represents accrued purchases of leasehold improvements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_AccruedPurchasesOfLeaseholdImprovements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_IncreaseDecreaseInDeferredRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of deferred rent that provides economic benefits in future periods.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_IncreaseDecreaseInDeferredRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_IncreaseDecreaseInLicenseReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of increase or decrease in license receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_IncreaseDecreaseInLicenseReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_PaymentsForRepurchaseOfPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the repurchase of amount received from entity's offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_PaymentsForRepurchaseOfPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_ProceedsFromPaycheckProtectionProgramLoan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from paycheck protection program loan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_ProceedsFromPaycheckProtectionProgramLoan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_PurchaseOfInsurancePremiumFinancedByShortTermNotePayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of purchase of insurance premium financed by short term notes payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_PurchaseOfInsurancePremiumFinancedByShortTermNotePayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the value of expenditures made during the current reporting period for benefits that will be received over a period of years. Deferred charges differ from prepaid expenses in that they usually extend over a long period of time and may or may not be regularly recurring costs of operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in other obligations or expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInSecurityDeposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in security deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInSecurityDeposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidCapitalized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest capitalized, classified as investing activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidCapitalized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value of stock issued in noncash financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140151710948328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Cash Flows (Parenthetical) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=eyen_CommonStockOneMember', window );">Common Stock One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_ProceedsOfStockIssuedDuringPeriodGross', window );">Proceeds Of Stock Issued During Period Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,030,001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Payments of Debt Issuance Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 815,052<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=eyen_CommonStockTwoMember', window );">Common Stock Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_ProceedsOfStockIssuedDuringPeriodGross', window );">Proceeds Of Stock Issued During Period Gross</a></td>
<td class="nump">$ 5,984,931<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Payments of Debt Issuance Costs</a></td>
<td class="nump">415,795<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=eyen_CommonStockThreeMember', window );">Common Stock Three [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_ProceedsOfStockIssuedDuringPeriodGross', window );">Proceeds Of Stock Issued During Period Gross</a></td>
<td class="nump">13,800,002<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Payments of Debt Issuance Costs</a></td>
<td class="nump">$ 1,066,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_ProceedsOfStockIssuedDuringPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>It represents issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_ProceedsOfStockIssuedDuringPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=eyen_CommonStockOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=eyen_CommonStockOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=eyen_CommonStockTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=eyen_CommonStockTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=eyen_CommonStockThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=eyen_CommonStockThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140151717930584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Organization and Nature of Operations<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Business Organization and Nature of Operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Business Organization and Nature of Operations</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt 0pt 12pt;text-align:left;line-height:100%;font-family:Times New Roman,Times,serif;font-weight:bold;font-size: 10pt;">
			<font style="display:inline;">Note&nbsp;1&nbsp;&#x2013; Business Organization and Nature of Operations</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Eyenovia,&nbsp;Inc. (&#x201C;Eyenovia&#x201D; or the &#x201C;Company&#x201D;) was organized as a corporation under the laws of the State of Florida on March&nbsp;12, 2014 under the name, PGP Holdings V,&nbsp;Inc. On May&nbsp;5, 2014, PGP Holdings V,&nbsp;Inc. changed its name to Eyenovia,&nbsp;Inc. On October&nbsp;6, 2014, Eyenovia,&nbsp;Inc. reincorporated in the State of Delaware by merging into Eyenovia,&nbsp;Inc., a Delaware corporation.</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Eyenovia. Inc. (&#x201C;Eyenovia&#x201D; or the &#x201C;Company&#x201D;) is a clinical stage ophthalmic company developing a pipeline of advanced therapeutics based on its propriety array print (MAP</font><font style="display:inline;font-size:5pt;top:-4pt;position:relative;line-height:100%">TM</font><font style="display:inline;">) platform technology. Eyenovia aims to achieve clinical microdosing of next-generation formulations of novel and existing ophthalmic pharmaceutical agents using its high-precision targeted ocular delivery system, branded the Opejet</font><font style="display:inline;font-size:5pt;top:-4pt;position:relative;line-height:100%">&#xAE;</font><font style="display:inline;">, which has the potential to replace conventional eye dropper delivery and improve safety, tolerability, patient compliance and topical delivery success for ophthalmic eye treatments. In the clinic, the Optejet has demonstrated the ability to horizontally deliver ophthalmic medication with a success rate significantly higher than that of traditional eye drops (~ 90% vs. ~ 50%). Using its proprietary delivery technology, Eyenovia is developing the next generation of smart ophthalmic therapies which target new indications or new combinations where there are currently no comparable drug therapies approved by the U.S. Food and Drug Administration (the &#x201C;FDA&#x201D;). Eyenovia&#x2019;s microdose therapeutics follow the FDA-designated pharmaceutical registration and regulatory process. Its products are classified by the FDA as drugs, and not medical devices or drug-device combination products. </font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;text-decoration:underline;">Risks and Uncertainties</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 8pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">Due to the COVID-19 pandemic, the company initially experienced delays in trial enrollment </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:10pt;">and initiation of its Phase III registration trial of its MicroPine drug candidate (the CHAPERONE study) </font><font style="display:inline;font-size:10pt;">as a result of reduced clinical trial activities and operations at trial sites. However, the company has since been able to resume enrollment in that study.</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140151713697080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-weight:bold;font-size: 10pt;">
			<font style="display:inline;">Note&nbsp;2&nbsp;&#x2013; Summary of Significant Accounting Policies</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-decoration:underline;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Use of Estimates</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Preparation of financial statements in conformity with accounting principles generally accepted in the United States of America (&#x201C;U.S. GAAP&#x201D;) requires management to make estimates, judgments and assumptions that affect the amounts reported in the financial statements and the amounts disclosed in the related notes to the financial statements. The Company bases its estimates and judgments on historical experience and on various other assumptions that it believes are reasonable under the circumstances. The amounts of assets and liabilities reported in the Company&#x2019;s balance sheets and the amounts of expenses reported for each of the periods presented are affected by estimates and assumptions, which are used for, but not limited to, fair value calculations for equity securities, establishment of valuation allowances for deferred tax assets, stock-based compensation, the recoverability and useful lives of long-lived assets, the recovery of deferred costs and the deferral of revenues. Certain of the Company&#x2019;s estimates could be affected by external conditions, including those unique to the Company and general economic conditions. It is reasonably possible that actual results could differ from those estimates.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">See Note 2 - Summary of Significant Accounting Policies&#x2009;&#x2014;&#x2009;Stock-Based Compensation for additional discussion of the use of estimates in estimating the fair value of the Company&#x2019;s common stock. </font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;text-decoration:underline;">Cash and Cash Equivalents</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents in the financial statements.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The Company has cash deposits and U.S. treasury bills in financial institutions which, at times, may be in excess of Federal Deposit Insurance Corporation (&#x201C;FDIC&#x201D;) insurance limits. The Company has not experienced losses in such accounts and periodically evaluates the creditworthiness of its financial institutions. As of December&nbsp;31, 2020 and 2019, the Company had cash and cash equivalent balances in excess of FDIC insurance limits of $28,121,828 and $13,902,601, respectively.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-decoration:underline;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Property and Equipment, Net</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Property and equipment are stated at cost, net of accumulated depreciation, which is recorded commencing at the in-service date using the straight-line method at rates sufficient to charge the cost of depreciable assets to operations over their estimated useful lives, which range from 1 to 10&nbsp;years. Leasehold improvements are amortized over the lesser of (a)&nbsp;the useful life of the asset; or (b)&nbsp;the remaining lease term. Maintenance and repairs are charged to operations as incurred. The Company capitalizes costs attributable to the betterment of property and equipment when such betterment extends the useful life of the assets.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-decoration:underline;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Impairment of Long-lived Assets</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The Company reviews for the impairment of long-lived assets whenever events or changes in circumstances indicate that the carrying amount of an asset might not be recoverable. An impairment would be recognized when estimated future cash flows expected to result from the use of the asset and its eventual disposition are less than its carrying amount. The Company did not record any impairment losses during the&nbsp;years ended December&nbsp;31, 2020 and 2019.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-decoration:underline;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Preferred Stock</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The Company applies the accounting standards for distinguishing liabilities from equity when determining the classification and measurement of its preferred stock. Preferred shares subject to mandatory redemption are classified as liability instruments and are measured at fair value. Conditionally redeemable preferred shares (including preferred shares that feature redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company&#x2019;s control) are classified as temporary equity. At all other times, preferred shares are classified as stockholders&#x2019; equity.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-decoration:underline;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Fair Value of Financial Instruments</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The Company measures the fair value of financial assets and liabilities based on Accounting Standards Codification (&#x201C;ASC&#x201D;) Topic 820 &#x201C;Fair Value Measurements and Disclosures&#x201D; (&#x201C;ASC 820&#x201D;), which defines fair value, establishes a framework for measuring fair value, and expands disclosures about fair value measurements.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">ASC 820 defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 describes three levels of inputs that may be used to measure fair value:</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Level 1&nbsp;&#x2014; quoted prices in active markets for identical assets or liabilities;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Level 2&nbsp;&#x2014; quoted prices for similar assets and liabilities in active markets or inputs that are observable; and</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Level 3&nbsp;&#x2014; inputs that are unobservable (for example, cash flow modeling inputs based on assumptions).</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The carrying amounts of the Company&#x2019;s financial instruments, such as cash and cash equivalents, accounts payable, accrued expenses and other current liabilities approximate fair values due to the short-term nature of these instruments.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-decoration:underline;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Income Taxes</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The Company is subject to Federal, New York State and City, and State of California income taxes and files tax returns in those jurisdictions.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of items that have been included or excluded in the consolidated financial statements or tax returns.&nbsp;&nbsp;Deferred tax assets and liabilities are determined on the basis of the difference between the tax basis of assets and liabilities and their respective financial reporting amounts (&#x201C;temporary differences&#x201D;) at enacted tax rates in effect for the years in which such temporary differences are expected to reverse. </font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The Company utilizes a recognition threshold and measurement process for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-decoration:none;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;text-decoration:none;">The Company&#x2019;s policy is to classify assessments, if any, for tax-related interest as interest expense and penalties as general and administrative expenses in the consolidated statements of operations.&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;text-decoration:underline;">Revenue Recognition</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Our revenues are generated primarily through research, development and commercialization agreements. The terms of such agreements may contain multiple promised goods and services, which may include (i) licenses to our intellectual property, and (ii) in certain cases, payment in connection with the manufacturing and delivery of clinical supply materials. Payments to us under these arrangements typically include one or more of the following: non-refundable, upfront license fees; milestone payments; payments for clinical product supply, and royalties on future product sales.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">We analyze our arrangements to assess whether such arrangements involve joint operating activities. For collaboration arrangements that are deemed to be within the scope of ASC Topic 808, &#x201C;Collaborative Arrangements&#x201D; (&#x201C;ASC 808&#x201D;), we allocate the contract consideration between such joint operating activities and elements that are reflective of a vendor-customer relationship and, therefore, within the scope of ASC Topic 606, &#x201C;Revenue from Contracts with Customers&#x201D; (&#x201C;ASC 606&#x201D;). Our policy is to recognize amounts allocated to joint operating activities as a reduction in research and development expense.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Under ASC 606, we recognize revenue when our customers obtain control of promised goods or services, in an amount that reflects the consideration which we expect to receive in exchange for those goods or services. To determine revenue recognition for arrangements that we determine are within the scope of ASC 606, we perform the following five steps:</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&#x2022; &nbsp;</font><font style="display:inline;text-decoration:underline;">Step 1:</font><font style="display:inline;"> Identify the contract with the customer;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&#x2022; &nbsp;</font><font style="display:inline;text-decoration:underline;">Step 2:</font><font style="display:inline;"> Identify the performance obligations in the contract;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&#x2022; &nbsp;</font><font style="display:inline;text-decoration:underline;">Step 3:</font><font style="display:inline;"> Determine the transaction price;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&#x2022; &nbsp;</font><font style="display:inline;text-decoration:underline;">Step 4:</font><font style="display:inline;"> Allocate the transaction price to the performance obligations in the contract; and</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&#x2022; &nbsp;</font><font style="display:inline;text-decoration:underline;">Step 5:</font><font style="display:inline;"> Recognize revenue when the company satisfies a performance obligation.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">We must make significant judgments in our revenue recognition process, including identifying performance obligations in the contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price to each performance obligation. In addition, arrangements that include rights to additional goods or services that are exercisable at a customer&#x2019;s discretion are generally considered discretionary purchase options. We assess if these options provide a material right to the customer and if so, they are considered performance obligations.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">For upfront license fees, we must consider how many performance obligations are in the contract and, if more than one, how to allocate the fee to those performance obligations upon satisfaction of the performance obligation(s). Milestone payments represent variable consideration that will be recognized when the performance obligation is achieved. Sales-based royalty payments derived from usage of intellectual property are recognized when those sales occur.</font>
		</p>
		<p style="margin:0pt 0pt 8pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">During 2020, the Company entered </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:10pt;">into a license agreement (the &#x201C;Arctic Vision License Agreement&#x201D;) with Arctic Vision (Hong Kong) Limited (&#x201C;Arctic Vision&#x201D;) and a license agreement (the &#x201C;</font><font style="display:inline;font-size:10pt;">Bausch License Agreement&#x2019;) </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:10pt;">with Bausch Health Companies, Inc. (&#x201C;Bausch Health&#x201D;). </font><font style="display:inline;font-size:10pt;">Each license has three revenue components: 1) an upfront license fee; 2) milestone payments and 3) royalty payments. See Note 9 &#x2013; Commitments and Contingencies for additional details.</font>
		</p>
		<p style="margin:0pt 0pt 8pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:10pt;text-decoration:underline;">Deferred License Fee</font>
		</p>
		<p style="margin:0pt 0pt 8pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:10pt;">The Company enters into license agreements which provides for the receipt of non-refundable, upfront licensing payments. These payments are recorded as deferred license fees and will be earned and recognized as revenue upon the satisfaction of performance obligations. See Note 9 &#x2013; Commitments and Contingencies for additional details.</font>
		</p>
		<p style="margin:0pt 0pt 8pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:10pt;text-decoration:underline;">Deferred License Costs</font>
		</p>
		<p style="margin:0pt 0pt 8pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:10pt;">The Company enters into license agreements which provides for payment of license costs in connection with the Company&#x2019;s receipt of license fees. These payments are recorded as deferred license costs and will be recorded as an expense when the related license fee revenue is recognized. See Note 10 &#x2013; Related Party Transactions for additional details.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-decoration:underline;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Research and Development</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Research and development expenses are charged to operations as incurred. The Company records prepaid expenses on its balance sheet for the payment of research and development expenses in advance of services being provided.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-decoration:underline;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Stock-Based Compensation</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The Company measures the cost of services received in exchange for an award of equity instruments based on the fair value of the award. The fair value of the award is measured on the grant date and the fair value amount is then recognized over the period during which services are required to be provided in exchange for the award, usually the vesting period. Upon the exercise of an option, the Company issues new shares of common stock out of the shares reserved for issuance under its equity plans.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-decoration:underline;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Net Loss Per Common Share</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Basic net loss per common share is computed by dividing net loss by the weighted average number of common shares outstanding during the period. Diluted loss per share reflects the potential dilution that could occur if securities or other instruments to issue common stock were exercised or converted into common stock.</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The following securities are excluded from the calculation of weighted average dilutive common shares because their inclusion would have been anti-dilutive:</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;">
			<tr>
				<td valign="bottom" style="width:72.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:72.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td colspan="3" valign="bottom" style="width:25.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">December&nbsp;31,&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:72.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">2020</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">2019</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:72.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Warrants</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 2,011,313</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> &nbsp;&#x2014;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:72.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Options</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 3,427,705</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 2,237,438</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:72.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Restricted stock units</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 104,083</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 60,355</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:72.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Total potentially dilutive shares</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 5,543,101</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 2,297,793</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-decoration:underline;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Subsequent Events</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The Company has evaluated subsequent events through the date which the financial statements were issued. Based upon the evaluation, the Company did not identify any recognized or non-recognized subsequent events that would have required adjustment or disclosure in the financial statements, except as disclosed.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-decoration:underline;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Recently Adopted Accounting Pronouncements</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">In July 2017, the FASB issued Accounting Standards Update (&#x201C;ASU&#x201D;) 2017-11 &#x201C;Earnings Per Share (Topic 260) and Derivatives and Hedging (Topic 815) - Accounting for Certain Financial Instruments with Down Round Features&#x201D; (&#x201C;ASU 2017-11&#x201D;). Equity-linked instruments, such as warrants and convertible instruments may contain down round features that result in the strike price being reduced on the basis of the pricing of future equity offerings. Under ASU 2017-11, a down round feature will no longer require a freestanding equity-linked instrument (or embedded conversion option) to be classified as a liability that is remeasured at fair value through the income statement (i.e. marked-to-market). However, other features of the equity-linked instrument (or embedded conversion option) must still be evaluated to determine whether liability or equity classification is appropriate. Equity classified instruments are not marked-to-market. For earnings per share ("EPS") reporting, the ASU requires companies to recognize the effect of the down round feature only when it is triggered by treating it as a dividend and as a reduction of income available to common shareholders in basic EPS. The amendments in this ASU are effective for all entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. This standard, which the Company adopted on January 1, 2020, did not have a material impact on the Company&#x2019;s financial position, results of operations, or cash flows.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">In March 2020, the FASB issued ASU 2020-03 &#x201C;Codification Improvements to Financial Instruments&#x201D; (&#x201C;ASU 2020-03&#x201D;). ASU 2020-03 improves and clarifies various financial instruments topics. ASU 2020-03 includes seven different issues that describe the areas of improvement and the related amendments to GAAP, intended to make the standards easier to understand and apply by eliminating inconsistencies and providing clarifications. The Company adopted ASU 2020-03 upon issuance, which did not have a material impact on the Company&#x2019;s financial position, results of operations or cash flow.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-decoration:underline;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Recently Issued Accounting Pronouncements</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">In February&nbsp;2016, the FASB issued ASU 2016&#8209;02 &#x201C;Leases (Topic 842)&#x201D; (&#x201C;ASU 2016&#8209;02&#x201D;). ASU 2016&#8209;02 requires that a lessee recognize the assets and liabilities that arise from operating leases. A lessee should recognize in the statement of financial position a liability to make lease payments (the lease liability) and a right-of-use asset representing its right to use the underlying asset for the lease term. For leases with a term of 12&nbsp;months or less, a lessee is permitted to make an accounting policy election by class of underlying asset not to recognize lease assets and lease liabilities. In transition, lessees and lessors are required to recognize and measure leases at the beginning of the earliest period presented using a modified retrospective approach. ASU 2016-02, as amended, is now effective for fiscal&nbsp;years beginning after December&nbsp;15, 2021, and interim periods within fiscal years beginning after December 15, 2022. The FASB issued ASU 2019-01 &#x201C;Leases (Topic 842) Codification Improvements&#x201D; in March 2019 and ASU 2018-10 &#x201C;Codification Improvements to Topic 842, Leases&#x201D; and ASU 2018-11 &#x201C;Leases (Topic 842) Targeted Improvements&#x201D; in July 2018, and ASU 2018-20 &#x201C;Leases (Topic 842) - Narrow Scope Improvements for Lessors&#x201D; in December 2018. ASU 2019-01, ASU 2018-10 and ASU 2018-20 provide certain amendments that affect narrow aspects of the guidance issued in ASU 2016-02. ASU 2018-11 allows all entities adopting ASU 2016-02 to choose an additional (and optional) transition method of adoption, under which an entity initially applies the new leases standard at the adoption date and recognizes a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption. The Company is currently evaluating ASU 2016-02 and its impact on its financial position, results of operations, and cash flows. The Company intends to adopt the ASU effective January 1, 2021 with no material impact.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">In August 2018, the FASB issued ASU No. 2018-13 &#x201C;Fair Value Measurement (Topic 820): Disclosure Framework&#x2014;Changes to the Disclosure Requirements for Fair Value Measurement&#x201D; (&#x201C;ASU 2018-13&#x201D;). The amendments in ASU 2018-13 modify the disclosure requirements on fair value measurements based on the concepts in the FASB Concepts Statement, including the consideration of costs and benefits. The amendments on changes in unrealized gains and losses, the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements, and the narrative description of measurement uncertainty should be applied prospectively for only the most recent interim or annual period presented in the initial fiscal year of adoption. All other amendments should be applied retrospectively to all periods presented upon their effective date. The amendments are effective for fiscal years beginning after December 15, 2020. Early adoption is permitted, including adoption in an interim period. The Company is currently evaluating ASU 2018-13 and its impact on its financial position, results of operations and cash flows.</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">In December 2019, the FASB issued ASU 2019-12, &#x201C;Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes,&#x201D; which is intended to simplify various aspects related to accounting for income taxes. ASU 2019-12 removes certain exceptions to the general principles in Topic 740 and also clarifies and amends existing guidance to improve consistent application. ASU 2019-12 is effective for fiscal years beginning after December 15, 2021. The Company is currently evaluating ASU 2019-12 and its impact financial position, results of operations, and cash flows.</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140151717930584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepaid Expenses and Other Current Assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsAbstract', window );"><strong>Prepaid Expenses and Other Current Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_PrepaidExpensesAndOtherCurrentAssetsDisclosureTextBlock', window );">Prepaid Expenses and Other Current Assets</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-weight:bold;font-size: 10pt;">
			<font style="display:inline;">Note&nbsp;3&nbsp;&#x2013; Prepaid Expenses and Other Current Assets</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">As of December&nbsp;31, 2020 and 2019, prepaid expenses and other current assets consisted of the following:</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;">
			<tr>
				<td valign="bottom" style="width:73.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td colspan="5" valign="bottom" style="width:24.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">December&nbsp;31,&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">2020</font></p>
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">2019</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Payroll tax receivable</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 151,942</font></p>
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 95,233</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Prepaid insurance expenses</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 110,094</font></p>
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 33,923</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Prepaid research and development expenses</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 17,978</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Prepaid licenses and subscriptions</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 57,051</font></p>
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> &nbsp;&#x2014;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Prepaid patent expenses</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 12,404</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Prepaid conference expenses</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 29,403</font></p>
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 10,600</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Prepaid board of directors expenses</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 68,250</font></p>
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> &nbsp;&#x2014;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Prepaid rent and security deposit</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 25,004</font></p>
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 2,463</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Other</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 11,734</font></p>
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 24,079</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Total prepaid expenses and other current assets</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 453,478</font></p>
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 196,680</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 1pt;">
			<font style="display:inline;font-size:1pt;">&nbsp;</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_PrepaidExpensesAndOtherCurrentAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of prepaid expenses and other current assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_PrepaidExpensesAndOtherCurrentAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140151713697080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property and Equipment, Net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment, Net</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-weight:bold;font-size: 10pt;">
			<font style="display:inline;">Note&nbsp;4&nbsp;&#x2013; Property and Equipment, Net</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">As of December&nbsp;31, 2020 and 2019, property and equipment consisted of the following:</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;">
			<tr>
				<td valign="bottom" style="width:72.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:72.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td colspan="5" valign="bottom" style="width:25.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">December&nbsp;31,&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:72.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">2020</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:11.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">2019</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:72.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Equipment</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 435,521</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 229,529</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:72.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Leasehold improvements</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 137,765</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 82,500</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:72.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 573,286</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 312,029</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:72.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Less: accumulated depreciation and amortization</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> (176,906)</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> (81,491)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:72.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Property and equipment, net</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 396,380</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 230,538</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Depreciation and amortization expense was $95,415 and $15,343 for the&nbsp;years ended December&nbsp;31, 2020 and 2019, respectively, of which $67,595 and $9,762 was included within research and development expenses and $27,820 and $5,581&nbsp;was included in general and administrative expenses in the statements of operations for the&nbsp;years ended December&nbsp;31, 2020 and 2019, respectively.</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140151717947672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Accrued Expenses and Other Current Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock', window );">Accrued Expenses and Other Current Liabilities</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-weight:bold;font-size: 10pt;">
			<font style="display:inline;">Note&nbsp;5&nbsp;&#x2013; Accrued Expenses and Other Current Liabilities</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">As of December&nbsp;31, 2020 and 2019, accrued expenses and other current liabilities consisted of the following:</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;">
			<tr>
				<td valign="bottom" style="width:71.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:71.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td colspan="5" valign="bottom" style="width:26.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">December&nbsp;31,&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:71.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:13.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">2020</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:11.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">2019</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:71.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Accrued research and development expenses</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 291,256</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 208,175</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:71.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Accrued consulting and professional services</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 235,355</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 97,396</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:71.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Credit card payable</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 50,002</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 56,979</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:71.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Leasehold improvements</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 42,500</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:71.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Accrued franchise tax</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 32,480</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 40,995</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:71.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Accrued travel and entertainment expenses</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 7,385</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:71.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Accrued licensing fees</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 804,447</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> &nbsp;&#x2014;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:71.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Accrued interest</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 3,068</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> &nbsp;&#x2014;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:71.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Accrued expense reimbursements</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 5,459</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> &nbsp;&#x2014;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:71.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Accrued shipping and packaging fees</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 56,998</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> &nbsp;&#x2014;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:71.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Other</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 1,627</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> &nbsp;&#x2014;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:71.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Total accrued expenses and other current liabilities</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 1,480,692</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 453,430</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 1pt;">
			<font style="display:inline;font-size:1pt;">&nbsp;</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140151718717320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsAbstract', window );"><strong>Accrued Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsGeneralTextBlock', window );">Accrued Compensation</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-weight:bold;font-size: 10pt;">
			<font style="display:inline;">Note&nbsp;6&nbsp;&#x2013; Accrued Compensation</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">As of December 31, 2020 and 2019, accrued compensation consisted of the following:</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;">
			<tr>
				<td valign="bottom" style="width:71.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:71.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td colspan="5" valign="bottom" style="width:26.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">December&nbsp;31,&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:71.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:13.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">2020</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:11.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">2019</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:71.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Accrued bonus expenses</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 938,873</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 897,839</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:71.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Accrued payroll expenses</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 211,799</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 19,034</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:71.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Total accrued compensation</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 1,150,672</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 916,873</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 1pt;">
			<font style="display:inline;font-size:1pt;">&nbsp;</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsGeneralTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for compensation costs, including compensated absences accruals, compensated absences liability, deferred compensation arrangements and income statement compensation items.  Deferred compensation arrangements may include a description of an arrangement with an individual employee, which is generally an employment contract between the entity and a selected officer or key employee containing a promise by the employer to pay certain amounts at designated future dates, usually including a period after retirement, upon compliance with stipulated requirements. This type of arrangement is distinguished from broader based employee benefit plans as it is usually tailored to the employee. Disclosure also typically includes the amount of related compensation expense recognized during the reporting period, the number of shares (units) issued during the period under such arrangements, and the carrying amount as of the balance sheet date of the related liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 710<br> -URI http://asc.fasb.org/topic&amp;trid=2127225<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 710<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6409950&amp;loc=d3e20396-108366<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsGeneralTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140151717931704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Notes Payable<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableAbstract', window );"><strong>Notes Payable</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_NotesPayableDisclosureTextBlock', window );">Notes Payable</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-weight:bold;font-size: 10pt;">
			<font style="display:inline;">Note&nbsp;7&nbsp;&#x2013; Notes Payable</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">As of December 31, 2020 and 2019, notes payable consisted of the following:</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="bottom" style="width:41.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:06.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:07.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:07.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:05.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:08.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:06.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:41.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td colspan="8" valign="bottom" style="width:29.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">December&nbsp;31,&nbsp;2020</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td colspan="8" valign="bottom" style="width:25.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">December&nbsp;31,&nbsp;2019</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:41.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:07.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">Current</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:09.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">Non-Current</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:07.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:06.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">Current</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:09.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">Non-Current</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:06.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:41.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:07.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">Portion</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:09.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">Portion</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:08.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">Total</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:06.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">Portion</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:09.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">Portion</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:07.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">Total</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:41.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Paycheck Protection Program loan</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:06.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 97,539</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:07.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 365,814</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:07.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 463,353</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:05.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:08.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:06.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> &nbsp;&#x2014;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:41.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Total</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:06.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 97,539</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:07.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 365,814</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:07.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 463,353</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:05.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:08.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:06.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> &nbsp;&#x2014;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt 0pt 0pt 54pt;line-height:100%;text-indent: -54pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">On February 24, 2020, the Company issued a note payable (the &#x201C;Note&#x201D;) for the purchase of a directors&#x2019; and officers&#x2019; liability insurance policy. The Note was payable in nine monthly payments of $53,750 for an aggregate principal amount of $475,216. The Note accrues interest at a rate of 4.29% per year and matured on November 24, 2020. During the year ended December 31, 2020, the Company repaid the principal amount of the Note. </font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">On May 8, 2020, the Company received cash proceeds of $463,353 pursuant to a loan provided in connection with the Paycheck Protection Program under the CARES Act (the &#x201C;PPP Loan&#x201D;). The PPP Loan provides for monthly installment payments of $19,508 beginning in August 2021 with the remaining balance due on May 3, 2022, the maturity date. The PPP Loan bears interest at a fixed rate of 1.00% per annum. The Company will be applying for loan forgiveness on the PPP Loan. </font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Under the terms of the CARES Act, as amended by the Paycheck Protection Program Flexibility Act of 2020, the Company is eligible to apply for and receive forgiveness for all or a portion of its PPP Loan. Such forgiveness will be determined, subject to limitations, based on the use of the loan proceeds for certain permissible purposes as set forth in the PPP Loan, including, but not limited to, payroll costs and mortgage interest, rent or utility costs (collectively, &#x201C;Qualifying Expenses&#x201D;) incurred during the 24 weeks subsequent to funding, and on the maintenance of employee and compensation levels following the funding of the PPP Loan. The Company intends to use the proceeds of its PPP Loan for Qualifying Expenses. However, no assurance is provided that the Company will be able to obtain forgiveness of its PPP Loan in whole or in part. Any amounts that are not forgiven incur interest at 1.0% per annum and monthly repayments of principal and interest are deferred until six months after the Small Business Administration makes a determination on forgiveness. While the PPP Loan currently has a two-year maturity, the amended law permits the borrower to request a five-year maturity from its lender.</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">During the years ended December 31, 2020 and 2019, the Company recorded interest expense of $17,042 and $0, respectively.</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_NotesPayableDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of notes payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_NotesPayableDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140151713848632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-weight:bold;font-size: 10pt;">
			<font style="display:inline;">Note&nbsp;8&nbsp;&#x2013; Income Taxes</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The provision for income taxes consists of the following expenses (benefits):</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="bottom" style="width:74.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:74.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="5" valign="bottom" style="width:24.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">For&nbsp;The&nbsp;Years&nbsp;Ended</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:74.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td colspan="5" valign="bottom" style="width:24.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">December&nbsp;31,</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:74.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:11.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">2020</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:11.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">2019</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:74.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Deferred tax provision (benefit):</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:74.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt 6pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Federal</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> (3,797,052)</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> (4,999,920)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:74.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt 6pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">State and local</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> (434,082)</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 68,762</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:74.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> (4,231,134)</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> (4,931,158)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:74.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Change in valuation allowance</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 4,231,134</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 4,931,158</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:74.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Provision for income taxes</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> &nbsp;&#x2014;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The provision for income taxes differs from the United States Federal statutory rate as follows:</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="bottom" style="width:74.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:74.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="3" valign="bottom" style="width:21.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">For&nbsp;The&nbsp;Years&nbsp;Ended</font></p>
				</td>
				<td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:74.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td colspan="3" valign="bottom" style="width:21.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">December&nbsp;31,</font></p>
				</td>
				<td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:74.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">2020</font></p>
				</td>
				<td valign="bottom" style="width:02.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">2019</font></p>
				</td>
				<td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:74.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Federal statutory rate</font></p>
				</td>
				<td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> (21.0)</font></p>
				</td>
				<td valign="bottom" style="width:02.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">%&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 21.0</font></p>
				</td>
				<td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">%</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:74.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">State tax rate, net of federal benefit</font></p>
				</td>
				<td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> (0.1)</font></p>
				</td>
				<td valign="bottom" style="width:02.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">%&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 0.1</font></p>
				</td>
				<td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">%</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:74.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Permanent differences</font></p>
				</td>
				<td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 0.5</font></p>
				</td>
				<td valign="bottom" style="width:02.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">%&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> (0.2)</font></p>
				</td>
				<td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">%</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:74.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Research &amp; development tax credits</font></p>
				</td>
				<td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> (1.4)</font></p>
				</td>
				<td valign="bottom" style="width:02.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">%&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 3.0</font></p>
				</td>
				<td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">%</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:74.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Prior period adjustments and other</font></p>
				</td>
				<td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 0.6</font></p>
				</td>
				<td valign="bottom" style="width:02.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">%&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> (0.6)</font></p>
				</td>
				<td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">%</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:74.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Change in valuation allowance</font></p>
				</td>
				<td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 21.4</font></p>
				</td>
				<td valign="bottom" style="width:02.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">%&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> (23.3)</font></p>
				</td>
				<td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">%</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:74.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Effective income tax rate</font></p>
				</td>
				<td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">%&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">%</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Deferred tax assets consist of the following:</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="bottom" style="width:72.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:72.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="5" valign="bottom" style="width:26.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">For&nbsp;The&nbsp;Years&nbsp;Ended</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:72.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td colspan="5" valign="bottom" style="width:26.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">December&nbsp;31,</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:72.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">2020</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">2019</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:72.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Net operating loss carryforwards</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 12,972,865</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 9,479,512</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:72.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Stock-based compensation</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 1,385,554</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 943,370</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:72.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Intangible assets</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 409,705</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 328,773</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:72.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Research and development tax credits</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 1,861,938</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 1,584,753</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:72.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Deferred tax assets, gross</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 16,630,062</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 12,336,408</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:72.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Property and equipment</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> (76,550)</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> (14,030)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:72.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Deferred tax assets, net before allowance</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 16,553,512</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 12,322,378</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:72.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Valuation allowance</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> (16,553,512)</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> (12,322,378)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:72.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Deferred tax assets, net</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> &nbsp;&#x2014;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">As of December 31, 2020, the Company had approximately $60,000,000 of domestic federal net operating loss carryforwards ("NOLs") that may be available to offset future Federal taxable income. Approximately $10,800,000 of those NOLs will expire during the years ranging from 2034 to 2037. The remaining NOLs of approximately $49,200,000 have no expiration dates. Internal Revenue Code Section 382 limits the utilization of approximately $35,000,000 of those NOLs to approximately $918,000 on an annual basis as a result of ownership changes that occurred through July 15, 2019. As of December 31, 2020, the Company had (a) minimal state net operating loss carryforwards that may be available to offset future state taxable income as it conducted most of its operations in Nevada which does not tax corporate income; and (b) approximately $5,500,000 of New York City net operating loss carryforwards.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The Company has assessed the likelihood that deferred tax assets will be realized in accordance with the provisions of ASC 740 &#x201C;</font><font style="display:inline;font-style:italic;">Income Taxes</font><font style="display:inline;">&nbsp;</font><font style="display:inline;font-style:italic;">Accounting</font><font style="display:inline;">&#x201D; ("ASC 740"). ASC 740 requires that such a review considers all available positive and negative evidence, including the scheduled reversal of deferred tax liabilities, projected future taxable income, and tax planning strategies. ASC 740 requires that a valuation allowance be established when it is &#x201C;more likely than not&#x201D; that all, or a portion of, deferred tax assets will not be realized. After the performance of such reviews as of December 31, 2020 and 2019, management believes that uncertainty exists with respect to future realization of its deferred tax assets and has, therefore, established a full valuation allowance as of those dates.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Management has evaluated and concluded that there were no material uncertain tax positions requiring recognition in the Company&#x2019;s consolidated financial statements as of December 31, 2020 and 2019. The Company does not expect any significant changes in its unrecognized tax benefits within twelve months of the reporting date.</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">No tax audits were commenced or were in process during the years ended December 31, 2020 and 2019. No tax related interest or penalties were incurred during the years ended December 31, 2020 and 2019. The Company's Federal, State and Local income tax returns beginning with the year ended December 31, 2017 remain subject to examination.</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140151713840696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-weight:bold;font-size: 10pt;">
			<font style="display:inline;">Note&nbsp;9&nbsp;&#x2013; Commitments and Contingencies</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-decoration:underline;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Operating Leases</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">On August&nbsp;8, 2018, the Company entered into a lease agreement to lease approximately 3,800 square feet of office space in New York, NY. The&nbsp;monthly base rent ranges from $19,633 to $22,486 per&nbsp;month over the term of the lease. The lease expires on September&nbsp;30, 2023. The security deposit is approximately $119,000.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">On July 17, 2020, the Company entered into a lease agreement to lease approximately 3,000 square feet of office space in Redwood City, California (the &#x201C;Gross Industrial Lease&#x201D;). The monthly base rent was for $7,500 per month over the term of the lease through August 31, 2021 with a security deposit of $7,500. On December 1, 2020, the Company agreed to amend the terms of the Gross Industrial Lease for a base rent that ranges from $7,500 to $7,957 per month over the term of the lease. The amended Gross Industrial Lease expires on August 31, 2023. &nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Concurrent with the amendment to the Gross Industrial Lease on December 1, 2020, the Company entered into a lease agreement to lease approximately 1,500 square feet of additional office space in Redwood City, California. The monthly base rent ranges from $3,000 to $3,183 per month over the term of the lease. The lease expires on August 31, 2023. The security deposit is $3,000.</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Future minimum payments under this operating lease agreement are as follows as:</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;">
			<tr>
				<td valign="bottom" style="width:74.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:21.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:74.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">For the Year Ending</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:21.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:74.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">December&nbsp;31,&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:23.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">Minimum&nbsp;Lease&nbsp;Payments</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:74.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">2021</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:21.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 378,486</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:74.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">2022</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:21.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 389,212</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:74.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">2023</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:21.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 285,700</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:74.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:21.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 1,053,398</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">See Note&nbsp;10&nbsp;&#x2013; Related Party Transactions&nbsp;&#x2013; Lease Agreements for details of a lease agreement with a related party.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-decoration:underline;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Employment Agreements</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;text-decoration:none;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;text-decoration:none;">Effective February 15, 2019, the Company entered into at-will executive employment agreements with Tsontcho Ianchulev, its Chief Executive Officer and Chief Medical Officer, John Gandolfo, its Chief Financial Officer, Jennifer Clasby, now its Vice President of Regulatory and Clinical, Luke Clauson, its Vice President, Research and Development and Manufacturing ("VP of R&amp;D"), and Michael Rowe, now its Chief Commercial Officer. Dr. Clasby and Mr. Rowe&#x2019;s employment agreements were amended on February 1, 2021 to provide for their new roles at the Company.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;text-decoration:none;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;text-decoration:none;">Each of the employment agreements provides that if the executive's employment is terminated by the Company without "Cause" or the executive suffers an "Involuntarily Termination" (each as defined in the employment agreements), provided that the executive has signed a full release of all claims, the executive will be entitled to receive: (i) severance pay equal to three months of his or her then-current base salary (currently estimated at approximately $419,000 in the aggregate), and (ii) a reimbursement for health insurance benefits under COBRA for the executive and his or her spouse and dependents for a period of three months or until the executive becomes eligible for comparable insurance benefits from another employer, whichever is earlier.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;text-decoration:none;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;text-decoration:none;">Each of the employment agreements also provides that if, within 12 months following any "Corporate Transaction" (as defined in the employment agreements) of the Company, the executive's employment is terminated by the Company without Cause or the executive suffers an Involuntary Termination, provided that the executive has signed a full release of all claims, the executive will be entitled to receive, in lieu of what is described in the above paragraph: (i) severance pay equal to 12 months of his or her then-current base salary (currently estimated at approximately $1,677,000 in the aggregate), and (ii) a reimbursement for health insurance benefits under COBRA for the executive and his or her spouse and dependents for a period of 12 months or until the executive becomes eligible for comparable insurance benefits from another employer, whichever is earlier.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-decoration:underline;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Litigations, Claims and Assessments</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">In the normal course of business, the Company may be involved in legal proceedings, claims and assessments arising in the ordinary course of business. The Company records legal costs associated with loss contingencies as incurred and accrues for all probable and estimable settlements.</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;text-decoration:underline;">Arctic Vision License Agreement </font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">On August 10, 2020, the Company entered into the &#x201C;Arctic Vision License Agreement&#x201D; pursuant to which Arctic Vision may develop and commercialize MicroPine for the treatment of progressive myopia and MicroLine for the treatment of presbyopia in Greater China (mainland China, Hong Kong, Macau and Taiwan) and South Korea.</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Under the terms of the Arctic Vision License Agreement, the Company received a non-refundable, upfront payment of $4.0 million, before any payments to Senju. The Company has recorded this payment as a deferred license fee until the payment is earned. The Company will consider payment earned once certain trial data has been fully submitted to Arctic Vision, permitting Arctic Vision to obtain regulatory approval with the National Medical Products Administration. The upfront payment had not been earned as of December 31, 2020. </font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">In addition, the Company may receive up to a total of $41.75 million in additional payments, based on various development and regulatory milestones, including the initiation of clinical research and approvals in Greater China and South Korea, and development costs. During December 2020, the Company satisfied a performance obligation which resulted in the Company recognizing $2.0 million of milestone revenues, pursuant to the Arctic Vision License Agreement.</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Arctic Vision also will purchase its supply of MicroPine and MicroLine from the Company or, for such products not supplied by the Company, pay the Company a mid-single digit percentage royalty on net sales of such products, subject to certain adjustments. No royalty payments were earned during the year ended December 31, 2020. The Company will pay a mid-double digit percentage of such payments, royalties, or net proceeds of such supply to Senju pursuant to the Senju License Agreement. See Note 2 &#x2013; Summary of Significant Accounting Policies and Note 10 &#x2013; Related Party Transactions for additional details. </font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;text-decoration:underline;">Bausch License Agreement</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">On October 9, 2020, the Company entered into the &#x201C;Bausch License Agreement&#x201D; pursuant to which Bausch Health may develop and commercialize the Bausch Licensed Product in the Licensed Territory. </font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">In connection with the Bausch License Agreement, Bausch Health paid the Company a non-refundable, upfront payment of $10.0 million. The Company has recorded this payment as a deferred license fee until the payment is earned. The Company will consider payment earned once certain trial data has been fully submitted to Bausch Health and certain administrative functions are transferred to Bausch Health, permitting Bausch Health to assume supervisory oversight of the ongoing MicroPine study (the CHAPERONE study). The upfront payment had not been earned as of December 31, 2020. </font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Bausch Health could also pay the Company up to an aggregate of approximately $35.0 million in additional payments, depending on the achievement of certain regulatory and launch-based milestones. No milestone payments were earned during the year ended December 31, 2020.Under the terms of the Bausch License Agreement, on a country-to-country basis and Bausch Licensed Product-by- Bausch Licensed Product basis, Bausch Health will pay the Company royalties on a tiered basis (ranging from mid-single digit to mid-teen percentages) on gross profits from the sales of the Bausch Licensed Product in the Licensed Territory, subject to certain adjustments in the event of generic entry, negative gross profits or patent expiration, for a period of the later to occur of the 10th anniversary of the first commercial sale of a Bausch Licensed Product in such country in the Licensed Territory or the expiration of the last valid patent claim for a Bausch Licensed Product in such country in the Licensed Territory. No royalty payments were earned during the year ended December 31, 2020. </font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Bausch Health may terminate the Bausch License Agreement, with respect to the Bausch Licensed Product to either country in the Licensed Territory, at any time for convenience upon 90 days&#x2019; written notice. Both parties have the right to terminate the Bausch License Agreement in the event of (i) an uncured material breach after a 60-day period or (ii) a bankruptcy event. See Note 2 &#x2013; Summary of Significant Accounting Policies for additional details.</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140151718592392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-weight:bold;font-size: 10pt;">
			<font style="display:inline;">Note&nbsp;10&nbsp;&#x2013; Related Party Transactions</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-decoration:underline;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Consulting Agreements</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">A company in which a member of the Company&#x2019;s Board of Directors is part owner is a party to a consulting agreement with the Company dated July 6, 2017 that provides for the payment of $9,567 per month, and $250 per hour for any additional work, for advisory services performed by such director. The consulting agreement was terminated on September 1, 2020. The director remains on the Board. The Company incurred expenses of $76,536 and $213,521 for the years ended December 31, 2020 and 2019, respectively, related to the agreement which was included within general and administrative expenses on the statements of operations.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-decoration:underline;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Lease Agreements</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The Company&#x2019;s Vice President of Research and Development and Manufacturing (&#x201C;VP of R&amp;D&#x201D;) owns a company that entered into a lease agreement with the Company on September&nbsp;15, 2016 to lease 953 square feet of space located in Reno, Nevada with respect to its research and development activities. The initial&nbsp;monthly base rent was $3,895 per&nbsp;month over the term of the lease and the security deposit was $3,895. On September&nbsp;15, 2020, the Company amended the lease agreement to extend it until September&nbsp;14, 2022 and increase the&nbsp;monthly base rent and security deposit to $5,404. The Company made $82,500 of leasehold improvements related to this lease which are included on the balance sheet.&nbsp;The Company&#x2019;s rent expense for this space is recorded in Research and Development on the income statement and amounted to $59,724 and $48,144 for the&nbsp;years ended December&nbsp;31, 2020 and 2019, respectively.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-decoration:underline;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Research and Development Activities</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The VP of R&amp;D is the sole owner and President of a company that performs contract engineering services for the Company. During the years ended December 31, 2020 and 2019, the Company recognized research and development expense of $1,024,430 and $851,746, respectively, related to services provided by such vendor. The Company had a liability of $0 and $89,052 to the vendor as of December 31, 2020 and 2019, respectively. The Company recognized $239,460 and $186,160 of compensation expense related to the VP of R&amp;D during the years ended December 31, 2020 and 2019, respectively.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:left;line-height:100%;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;text-decoration:underline;">Senju License Agreement</font>
		</p>
		<p style="margin:0pt;text-align:left;line-height:100%;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">During 2015, the Company entered into an Exclusive License Agreement with Senju whereby the Company agreed to grant to Senju an exclusive, royalty-bearing license for its microdose product candidates for Asia to sublicense, develop, make, have made, manufacture, use, import, market, sell, and otherwise distribute the microdose product candidates. In consideration for the license, Senju agreed to pay to Eyenovia five percent (5%) royalties on sales (net of certain manufacturing costs) for the term of the Exclusive License Agreement, subject to certain adjustments upon the loss of patent coverage for the term of the license agreement. The agreement will continue in full force and effect, on a country-by-country basis, until the latest to occur of: (i) the tenth (10th) anniversary of the first commercial sale of such a product candidate in a country; or (ii) the expiration of the licensed patents in a country. As of the date of this filing, there had been no commercial sales of a such a product in Asia, so no royalties had been earned. Senju is owned by the family of a former member of the Company&#x2019;s Board of Directors and, together, they beneficially own greater than 5% of the Company&#x2019;s common stock.</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">On April 8, 2020, Eyenovia entered into an amendment (the &#x201C;License Amendment&#x201D;) to the Exclusive License Agreement. Pursuant to the License Amendment, the Company can license to any third party the right to research, develop, commercialize, manufacture or use certain products identified below (the &#x201C;Senju Licensed Products&#x201D;) previously licensed to Senju in China (including the People&#x2019;s Republic of China, Hong Kong, Macao, and Taiwan) and South Korea (the &#x201C;Territory&#x201D;) if such a license is executed by the Company by April 8, 2021. The Senju Licensed Products are those using piezo-print technology in a microdose dispenser with (i) atropine sulfate as its sole active ingredient to treat myopia in humans and (ii) pilocarpine as its sole active ingredient to treat presbyopia in humans.</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Pursuant to the License Amendment, the Company must pay Senju (a) close to a mid-double digit percentage of revenue on any lump-sum payments the Company receives from the third party, revenue (net of costs) obtained by the Company from contract research and/or development of the Senju Licensed Product in the Territory, and revenue (net of costs) obtained by the Company from contract manufacture for the device of the Senju Licensed Product in the Territory, the aggregate of which must be at least a high seven figure dollar amount minimum payment to Senju; and (b) a lower-double digit percentage of any sales royalty revenue the Company receives from the third party. Unless a third-party license is executed by the Company prior to April 8, 2021 (in which case, subject to early termination the License Amendment shall remain in effect for the duration of such license), the License Amendment terminates on April 8, 2021, but may be terminated earlier by Senju upon the Company&#x2019;s material breach of the License Amendment, subject to a 60-day cure period.</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The Exclusive License Agreement was further amended in a Letter Agreement by and between the Company and Senju on August 10, 2020 (the &#x201C;Letter Agreement&#x201D;).&nbsp;&nbsp;Pursuant to the Letter Agreement, the Company will pay a mid-double digit percentage of certain payments, royalties, or net proceeds received from Arctic Vision in connection with the Arctic Vision License Agreement to Senju. During the year ended December 31, 2020, the Company paid Senju $1.6 million in connection with the Arctic Vision License Agreement which was recorded as deferred license costs in the Company&#x2019;s balance sheet and will be recognized as expense upon earning the related fee. See Note 2- Summary of Significant Accounting Policies &#x2013; Revenue Recognition and Note 9 &#x2013; Commitments and Contingencies for additional details.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140151717903640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-weight:bold;font-size: 10pt;">
			<font style="display:inline;">Note&nbsp;11&nbsp;&#x2013; Stockholders&#x2019; Equity</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-decoration:underline;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Authorized Capital</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The Company is authorized to issue 90,000,000 shares of common stock, par value of&#x2009;$0.0001 per share, and 6,000,000 shares of preferred stock, par value of&#x2009;$0.0001 per share. The holders of the Company&#x2019;s common stock are entitled to one vote per share. The Board of Directors is empowered, without stockholder approval, to issue preferred stock with dividend, liquidation, redemption, voting or other rights.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-decoration:underline;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Equity Incentive Plans</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">On April 7, 2020, the Company&#x2019;s Board of Directors approved the Company&#x2019;s Amended and Restated 2018 Omnibus Stock Incentive Plan (the &#x201C;Restated Plan&#x201D;), which stockholders approved on June 30, 2020. The Restated Plan makes certain changes to the Company&#x2019;s 2018 Omnibus Stock Incentive Plan, as amended (the &#x201C;2018 Plan, as amended&#x201D;). The Restated Plan increases the number of shares of Company&#x2019;s common stock reserved for issuance under the 2018 Plan, as amended to 2,950,000 shares. The Restated Plan requires that all equity awards issued under the Restated Plan vest at least twelve months from the applicable grant date, subject to accelerated vesting, and provides that no dividend or dividend equivalent will be paid on any unvested equity award, although dividends with respect to unvested portions of equity may accrue and be paid when, and if, the awards later vest and the shares are actually issued to the grantee. In addition, the Restated Plan sets an annual limit on the grant date fair value of awards to any non-employee director, together with any cash fees paid during the year, of $150,000, subject to certain exceptions for a non-executive chair of the Board. Finally, the Restated Plan makes several administrative changes to the 2018 Plan, as amended, including to clarify that awards made under the Restated Plan are intended to be exempt from or comply with Section 409(A) of the Internal Revenue Code of 1986, as amended. As of December 31, 2020, the number of securities remaining available for future issuance under equity compensation plans was 518,186.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;text-decoration:underline;">Warrants</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">A summary of the Warrant activity during the year ended December 31, 2020 is presented below:</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="bottom" style="width:58.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:05.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:07.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:58.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:05.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:07.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">Weighted</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:58.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:06.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">Weighted </font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:07.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">Average</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:58.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:06.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">Average</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:07.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">Remaining</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:10.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">Aggregate</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:58.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">Number of</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:06.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">Exercise</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:07.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">Life</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:10.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">Intrinsic</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:58.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">Warrants</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:06.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">Price</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">In Years</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:10.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">Value</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:58.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Outstanding January 1, 2020</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:05.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:58.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Granted</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 3,344,154</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:05.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 2.33</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:58.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Exercised</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> (1,332,841)</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:05.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 2.19</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:58.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Forfeited</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:05.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:58.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Outstanding December 31, 2020</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 2,011,313</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:05.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 2.43</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 3.8</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 7,215,147</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:58.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:05.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:07.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:58.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Exercisable December 31, 2020</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 2,011,313</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:05.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 2.43</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 3.8</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 7,215,147</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The following table presents information related to Warrants as of December 31, 2020:</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;">
			<tr>
				<td valign="bottom" style="width:22.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:03.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:22.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:03.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:22.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:03.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:22.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td colspan="3" valign="bottom" style="width:48.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">Warrants Outstanding</font></p>
				</td>
				<td valign="bottom" style="width:03.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td colspan="3" valign="bottom" style="width:48.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">Warrants Exercisable</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:22.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:03.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:22.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:03.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:22.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">Weighted</font></p>
				</td>
				<td valign="bottom" style="width:03.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:22.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:22.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:03.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:22.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">Outstanding</font></p>
				</td>
				<td valign="bottom" style="width:03.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:22.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">Average</font></p>
				</td>
				<td valign="bottom" style="width:03.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:22.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">Exercisable</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:22.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">Exercise</font></p>
				</td>
				<td valign="bottom" style="width:03.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:22.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">Number of</font></p>
				</td>
				<td valign="bottom" style="width:03.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:22.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">Remaining Life</font></p>
				</td>
				<td valign="bottom" style="width:03.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:22.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">Number of</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:22.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">Price</font></p>
				</td>
				<td valign="bottom" style="width:03.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:22.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">Warrants</font></p>
				</td>
				<td valign="bottom" style="width:03.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:22.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">In Years</font></p>
				</td>
				<td valign="bottom" style="width:03.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:22.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">Warrants</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:22.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">$2.0580 </font></p>
				</td>
				<td valign="bottom" style="width:03.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:22.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 48,549</font></p>
				</td>
				<td valign="bottom" style="width:03.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:22.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 0.2</font></p>
				</td>
				<td valign="bottom" style="width:03.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:22.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 48,549</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:22.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">$2.2700 </font></p>
				</td>
				<td valign="bottom" style="width:03.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:22.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 144,256</font></p>
				</td>
				<td valign="bottom" style="width:03.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:22.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 0.2</font></p>
				</td>
				<td valign="bottom" style="width:03.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:22.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 144,256</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:22.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">$2.4696 </font></p>
				</td>
				<td valign="bottom" style="width:03.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:22.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 1,602,128</font></p>
				</td>
				<td valign="bottom" style="width:03.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:22.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 4.2</font></p>
				</td>
				<td valign="bottom" style="width:03.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:22.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 1,602,128</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:22.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">$2.7240 </font></p>
				</td>
				<td valign="bottom" style="width:03.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:22.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 216,380</font></p>
				</td>
				<td valign="bottom" style="width:03.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:22.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 4.2</font></p>
				</td>
				<td valign="bottom" style="width:03.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:22.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 216,380</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:22.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:03.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:22.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 2,011,313</font></p>
				</td>
				<td valign="bottom" style="width:03.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:22.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 3.8</font></p>
				</td>
				<td valign="bottom" style="width:03.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:22.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 2,011,313</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">During the year ended December 31, 2020, Warrants for the purchase of 1,332,841 shares of the Company&#x2019;s common stock with exercise prices of either $2.058 or $2.4696 per share, respectively, were exercised for aggregate proceeds of approximately $2.8 million. </font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;text-decoration:underline;">Public Offerings</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">On July 15, 2019, the Company closed an underwritten public offering of 4,388,490 shares of its common stock at a public offering price of $2.78 per share. The Company granted the underwriters a 30-day over-allotment option to purchase up to an additional 658,273 shares of the Company&#x2019;s common stock at the same price, which was exercised in full on July 16, 2019. Including the over-allotment shares, the Company issued a total of 5,046,763 shares in the underwritten public offering, and received gross proceeds of approximately $14.0 million and net proceeds of approximately $13.0 million, after deducting underwriting discounts, commissions and other offering expenses, which were recorded as a reduction of additional paid-in capital.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;text-decoration:underline;">Securities Purchase Agreement</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">On March 24, 2020, the Company closed on a private placement of approximately $6.0 million of Units. Each Unit consists of (i) one share of the Company&#x2019;s common stock, (ii) a one-year warrant to purchase 0.5 of a share of common stock (&#x201C;Class A Warrant&#x201D;), and (iii) a five-year warrant to purchase 0.75 of a share of common stock (&#x201C;Class B Warrant&#x201D;) (collectively, the Class A Warrants and Class B Warrants, the &#x201C;Warrants&#x201D;). The Units were sold to the public at a price of $2.21425 per Unit and to certain directors and executive officers at a price of $2.42625 per Unit. The Company generated approximately $5.3 million of net proceeds in the offering after deducting placement agent fees and offering expenses. In the offering, the Company issued an aggregate of 2,675,293 shares of common stock, Class A Warrants to purchase up to 1,337,659 shares of common stock, and Class B Warrants to purchase up to 2,006,495 shares of common stock. The exercise price of the Class A Warrants issued to the public is $2.058 per share and the exercise price of the Class A Warrants issued to the directors and officers is $2.27 per share. The exercise price of the Class B Warrants issued to the public is $2.4696 per share and the exercise price of the Class B Warrants issued to the directors and officers is $2.724 per share.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">In connection with the private placement, on March 23, 2020, the Company also entered into a Registration Rights Agreement with the investors. Pursuant to the Registration Rights Agreement, the Company must file with the SEC, no later than 30 days following the date on which the Company files its Form 10-K for the year ended December 31, 2019 with the SEC, a registration statement on Form S-3 covering the shares of common stock issued in the offering and the shares of common stock underlying the Warrants. The Company timely filed the registration statement on Form S-3 (Registration Statement No. 333-237790), which was declared and has remained effective with the SEC since May 13, 2020.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;text-decoration:underline;">Underwritten Public Offering</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">On August 19, 2020, the Company entered into an Underwriting Agreement (the &#x201C;Underwriting Agreement&#x201D;) with several underwriters (the &#x201C;Underwriters&#x201D;) in connection with the public offering (the &#x201C;Offering&#x201D;) of 3,333,334 shares of the Company&#x2019;s common stock at a price of $3.60 per share, less underwriting discounts and commissions. In addition, pursuant to the terms of the Underwriting Agreement, the Company granted the Underwriters a 30-day option to purchase up to an additional 500,000 shares of the Company&#x2019;s common stock at the same price. The Underwriting Agreement contains customary representations, warranties and covenants of the Company and also provides for customary indemnification by the Company and the Underwriters against certain liabilities and customary contribution provisions in respect of those liabilities.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The closing of the Offering occurred on August 21, 2020. At closing, the Company issued 3,833,334 shares of common stock and received net proceeds of approximately $12.5 million after deducting underwriting discounts and commissions and offering expenses of approximately $1.2 million.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The Offering was made pursuant to the Company&#x2019;s effective registration statement on Form S-3 (Registration Statement No. 333-229365), including the prospectus dated February 12, 2019, as supplemented by the prospectus supplement dated August 19, 2020.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-decoration:underline;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Stock-Based Compensation Expense</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The Company records stock-based compensation expense related to stock options and restricted stock units (&#x201C;RSUs&#x201D;). For the&nbsp;years ended December&nbsp;31, 2020 and 2019, the Company recorded expense of $2,483,172 &nbsp;($1,350,894 of which was included within research and development expenses and $1,132,278 was included within general and administrative expenses on the statements of operations) and $2,511,944 &nbsp;($1,459,055 of which was included within research and development expenses and $1,052,889 was included within general and administrative expenses on the statements of operations), respectively. As of December&nbsp;31, 2020, there was $3,720,221 of unrecognized stock-based compensation expense which will be recognized over a weighted average period of 2.0&nbsp;years.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-decoration:underline;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Restricted Stock Units</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">On August 16, 2019, the Company granted to members of its Board of Directors an aggregate of 40,190 RSU under the 2018 Plan, as amended. The grants vest on the earlier of (i) the one-year anniversary of the date of grant and (ii) the date of the 2020 annual stockholders meeting, subject to the grantee remaining on the Board until then. The RSUs had a grant date fair value of $125,000, which were recognized over the vesting period.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">On September 11, 2020, the Company granted members of its Board of Directors an aggregate of 43,728 RSUs under the Restated Plan. Each RSU is subject to settlement into one share of the Company&#x2019;s common stock. The RSUs vest on the earlier of (i) the one-year anniversary of the date of grant and (ii) the date of the 2021 annual stockholders meeting, subject to the grantee remaining on the Board until then. The RSUs had a grant date fair value of $150,000, which will be recognized over the vesting period.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;text-decoration:underline;">Stock Option Exercises</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">During the year ended December 31, 2020, stock options for the purchase of an aggregate of 36,391 shares of the Company&#x2019;s common stock with exercise prices ranging from $1.95 to $3.11 per share were exercised for aggregate proceeds of $82,161.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;text-decoration:underline;">Stock Options</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">On January&nbsp;2, 2019, stock options to purchase 180,000 and 133,686 shares of common stock with an exercise price of $1.24 and $1.95 per share, respectively, were exercised for aggregate proceeds of $483,888. In connection with the exercise of the stock options, the Company remitted a portion of an employee&#x2019;s payroll taxes of $62,193 to the Internal Revenue Service.&nbsp;&nbsp;The Company was reimbursed in full by the employee.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">On January 14, 2019, the Company granted ten-year stock options to purchase an aggregate of 11,000 shares of common stock to its employees under the 2018 Plan. The 11,000 shares vest over three years from the date of grant with one-third vesting on the one-year anniversary of the date of grant and the balance vesting monthly over the remaining 24 months, subject to continued service to the Company. The stock options have an exercise price of $2.74 per share, which represents the Company&#x2019;s closing stock price on the date of grant. The stock options had a grant date value of $27,500, which the Company expects to recognize over the vesting period.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">On February&nbsp;6, 2019, stock options to purchase an aggregate of 320,001 shares of common stock with an exercise price of $1.24 per share were exercised on a cashless basis, which resulted in the issuance of an aggregate of 236,466 shares of common stock.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">On February&nbsp;13, 2019, the Board of Directors of the Company approved the acceleration and immediate vesting of 124,210 stock options originally granted to Dr.&nbsp;Ianchulev on July&nbsp;24, 2018 in connection with his employment. In connection with the acceleration and immediate vesting, the Company recognized $609,322 of stock-based compensation expense during the year ended December 31, 2019, which represents the remaining unamortized grant date fair value of the award.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">On May 14, 2019, stock options to purchase 34,815 shares of common stock with an exercise price of $1.95 per share were exercised for aggregate proceeds of $67,889.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">On August 16, 2019, the Company granted ten-year stock options to purchase an aggregate of 681,572 shares of common stock to its employees, consultants and directors under the 2018 Plan, as amended.&nbsp;&nbsp;Of the 681,572 shares, (i) 636,287 vest over three years from the date of grant with one-third vesting on the one-year anniversary of the date of grant and the balance vesting monthly over the remaining 24 months, subject to continued service to the Company and (ii) 45,285 vest on the earlier of the one-year anniversary of the date of grant and the date of the 2020 annual stockholders meeting, subject to continued service to the Company. The stock options have an exercise price of $3.11 per share, which represents the Company&#x2019;s closing stock price on the date of grant.&nbsp;&nbsp;The stock options had a grant date value of $1,909,700, which the Company expects to recognize over the vesting period.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">On January 31, 2020, the Company granted ten-year stock options to purchase 25,000 shares of common stock to its employees under the 2018 Plan, as amended. The shares vest over three years from the date of grant with one-third vesting on the one-year anniversary of the date of grant and the balance vesting monthly over the remaining 24 months. The stock options have an exercise price of $4.68 per share, which represents the Company&#x2019;s closing stock price on the date of grant. The stock options had a grant date fair value of $103,400, which the Company expects to recognize over the vesting period. </font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">On May 28, 2020, the Company granted ten-year stock options to purchase 263,500 shares of common stock to its employees under the Restated Plan. The shares vest over three years from the date of grant with one-third vesting on the one-year anniversary of the date of grant and the balance vesting monthly over the remaining 24 months. The stock options have an exercise price of $2.89 per share, which represents the Company&#x2019;s closing stock price on the date of grant. The stock options had a grant date fair value of $587,100, which the Company expects to recognize over the vesting period.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">On June 3, 2020, the Company granted ten-year stock options to purchase 764,419 shares of common stock to its executive officers under the Restated Plan. The shares vest over three years from the date of grant with one-third vesting on the one-year anniversary of the date of grant and the balance vesting monthly over the remaining 24 months. The stock options have an exercise price of $2.72 per share, which represents the Company&#x2019;s closing stock price on the date of grant. The stock options had a grant date fair value of $1,603,600, which the Company expects to recognize over the vesting period.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">On July 28, 2020, the Company granted ten-year stock options to purchase 43,000 shares of common stock to an employee under the Restated Plan. The shares vest over three years from the date of grant with one-third vesting on the one-year anniversary of the date of grant and the balance vesting monthly over the remaining 24 months. The stock options have an exercise price of $3.71 per share, which represents the Company&#x2019;s closing stock price on the date of grant. The stock options had a grant date fair value of $122,400, which the Company expects to recognize over the vesting period.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">On September 8, 2020, the Company granted ten-year stock options to purchase 45,000 shares of common stock to employees and consultants under the Restated Plan. The shares vest over three years from the date of grant with one-third vesting on the one-year anniversary of the date of grant and the balance vesting monthly over the remaining 24 months. The stock options have an exercise price of $3.48 per share, which represents the Company&#x2019;s closing stock price on the date of grant. The stock options had a grant date fair value of $126,700, which the Company expects to recognize over the vesting period.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;text-decoration:underline;">Stock Options - Continued</font><font style="display:inline;"> On September 11, 2020, the Company granted ten-year stock options to purchase 58,920 shares of common stock under the Restated Plan to members of its Board of Directors. The shares vest on the earlier of (i) the one-year anniversary of the date of grant and (ii) the date of the 2021 annual stockholders meeting, subject to the grantee remaining on the Board until then. The stock options have an exercise price of $3.43 per share, which represents the Company&#x2019;s closing stock price on the date of grant. The stock options had a grant date fair value of $155,400, which the Company expects to recognize over the vesting period.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">On December 23, 2020, the Company granted ten-year stock options to purchase 50,000 shares of common stock to an employee under the Restated Plan. The shares vest over three years from the date of grant with one-third vesting on the one-year anniversary of the date of grant and the balance vesting monthly over the remaining 24 months. The stock options have an exercise price of $5.77 per share, which represents the Company&#x2019;s closing stock price on the date of grant. The stock options had a grant date fair value of $218,700, which the Company expects to recognize over the vesting period.</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">In applying the Black-Scholes option pricing model to stock options granted, the Company used the following approximate assumptions:</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;">
			<tr>
				<td valign="bottom" style="width:64.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:64.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td colspan="3" valign="bottom" style="width:32.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">For&nbsp;the&nbsp;Year Ended </font></p>
				</td>
				<td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:64.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td colspan="3" valign="bottom" style="width:32.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">December&nbsp;31,&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:64.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:15.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">2020</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:15.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">2019</font></p>
				</td>
				<td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:64.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Expected term (years)</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:15.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">5.85 - 10.00</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:15.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">5.50 - 10.00</font></p>
				</td>
				<td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:64.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Risk free interest rate</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:15.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">0.26% - 1.32%</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">1.42% - 2.53%</font></p>
				</td>
				<td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:64.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Expected volatility</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:15.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">96% - 99%</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">134 - 139%</font></p>
				</td>
				<td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:64.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Expected dividends</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:15.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">0.00%</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">0.00%</font></p>
				</td>
				<td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The Company has computed the fair value of stock options granted using the Black-Scholes option pricing model. Option forfeitures are accounted for at the time of occurrence. The expected term used for options issued is the estimated period of time that options granted are expected to be outstanding. The Company utilizes the &#x201C;simplified&#x201D; method to develop an estimate of the expected term of &#x201C;plain vanilla&#x201D; option grants. The Company does not currently have a sufficient trading history to support its historical volatility calculations. Accordingly, the Company is utilizing an expected volatility figure based on a review of the historical volatility of three comparable entities over a period of time equivalent to the expected life of the instrument being valued. The risk-free interest rate was determined from the implied yields from U.S. Treasury zero-coupon bonds with a remaining term consistent with the expected term of the instrument being valued.&nbsp;&nbsp;The Company has not declared dividends, is currently in the development stage and has no plan to declare future dividends at this time.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The weighted average estimated grant date fair value of the stock options granted for the&nbsp;years ended December&nbsp;31, 2020 and 2019 was approximately $3.01 and $3.10 per share, respectively.</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">A summary of the option activity during the&nbsp;year ended December 31, 2020 is presented below:</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;">
			<tr>
				<td valign="bottom" style="width:48.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:07.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:48.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:07.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">Weighted</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:48.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:08.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">Weighted</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">Average</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:48.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:08.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">Average</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">Remaining</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:13.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">Aggregate</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:48.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">Number&nbsp;of</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:08.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">Exercise</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">Life</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:13.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">Intrinsic</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:48.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">Options</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:08.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">Price</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">In&nbsp;Years</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:13.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">Value</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:48.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Outstanding January 1, 2020</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 2,237,438</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:07.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 3.51</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:48.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Granted</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 1,249,839</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 3.01</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:48.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Exercised</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> (36,391)</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 2.26</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:48.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Forfeited</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> (23,181)</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 4.59</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:48.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Outstanding December&nbsp;31,&nbsp;2020</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 3,427,705</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:07.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 3.37</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 8.0</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 9,843,341</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:48.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:07.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:48.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Exercisable December&nbsp;31,&nbsp;2020</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 1,768,292</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:07.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 3.48</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 6.8</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 5,013,118</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The following table presents information related to stock options as of December 31, 2020:</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;">
			<tr>
				<td valign="bottom" style="width:02.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:20.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:18.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:25.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:18.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:02.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td colspan="3" valign="bottom" style="width:43.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">Options Outstanding</font></p>
				</td>
				<td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td colspan="3" valign="bottom" style="width:48.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">Options&nbsp;Exercisable</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:02.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:20.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:18.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:25.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">Weighted</font></p>
				</td>
				<td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:18.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:02.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:20.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:18.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">Outstanding</font></p>
				</td>
				<td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:25.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">Average</font></p>
				</td>
				<td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:18.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">Exercisable</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:02.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:20.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">Exercise</font></p>
				</td>
				<td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:18.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">Number&nbsp;of</font></p>
				</td>
				<td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:25.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">Remaining&nbsp;Life</font></p>
				</td>
				<td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:18.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">Number&nbsp;of</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:02.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:20.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">Price</font></p>
				</td>
				<td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:18.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">Options</font></p>
				</td>
				<td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:25.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">In&nbsp;Years</font></p>
				</td>
				<td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:18.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">Options</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:02.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:20.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 1.24</font></p>
				</td>
				<td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:18.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 260,000</font></p>
				</td>
				<td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:25.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 4.2</font></p>
				</td>
				<td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:18.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 260,000</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:02.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:20.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 1.95</font></p>
				</td>
				<td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:18.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 673,544</font></p>
				</td>
				<td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:25.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 6.5</font></p>
				</td>
				<td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:18.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 673,544</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:02.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:20.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 2.72</font></p>
				</td>
				<td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:18.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 764,419</font></p>
				</td>
				<td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:25.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:18.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> &nbsp;&#x2014;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:02.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:20.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 2.74</font></p>
				</td>
				<td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:18.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 6,000</font></p>
				</td>
				<td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:25.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 8.0</font></p>
				</td>
				<td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:18.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 3,833</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:02.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:20.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 2.89</font></p>
				</td>
				<td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:18.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 263,500</font></p>
				</td>
				<td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:25.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:18.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> &nbsp;&#x2014;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:02.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:20.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 3.11</font></p>
				</td>
				<td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:18.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 659,849</font></p>
				</td>
				<td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:25.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 8.6</font></p>
				</td>
				<td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:18.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 318,432</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:02.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:20.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 3.43</font></p>
				</td>
				<td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:18.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 58,920</font></p>
				</td>
				<td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:25.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:18.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> &nbsp;&#x2014;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:02.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:20.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 3.48</font></p>
				</td>
				<td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:18.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 45,000</font></p>
				</td>
				<td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:25.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:18.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> &nbsp;&#x2014;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:02.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:20.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 3.71</font></p>
				</td>
				<td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:18.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 43,000</font></p>
				</td>
				<td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:25.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:18.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> &nbsp;&#x2014;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:02.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:20.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 4.00</font></p>
				</td>
				<td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:18.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 2,000</font></p>
				</td>
				<td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:25.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 7.9</font></p>
				</td>
				<td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:18.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 1,390</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:02.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:20.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 4.68</font></p>
				</td>
				<td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:18.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 25,000</font></p>
				</td>
				<td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:25.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:18.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> &nbsp;&#x2014;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:02.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:20.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 5.10</font></p>
				</td>
				<td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:18.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 6,000</font></p>
				</td>
				<td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:25.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 7.7</font></p>
				</td>
				<td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:18.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 4,500</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:02.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:20.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 5.19</font></p>
				</td>
				<td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:18.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 16,500</font></p>
				</td>
				<td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:25.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 7.7</font></p>
				</td>
				<td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:18.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 12,375</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:02.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:20.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 5.25</font></p>
				</td>
				<td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:18.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 26,668</font></p>
				</td>
				<td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:25.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 5.8</font></p>
				</td>
				<td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:18.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 26,668</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:02.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:20.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 5.77</font></p>
				</td>
				<td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:18.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 50,000</font></p>
				</td>
				<td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:25.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:18.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> &nbsp;&#x2014;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:02.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:20.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 6.20</font></p>
				</td>
				<td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:18.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 300,387</font></p>
				</td>
				<td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:25.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 7.6</font></p>
				</td>
				<td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:18.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 270,476</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:02.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:20.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 6.30</font></p>
				</td>
				<td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:18.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 60,000</font></p>
				</td>
				<td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:25.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 7.5</font></p>
				</td>
				<td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:18.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 48,333</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:02.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:20.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 8.72</font></p>
				</td>
				<td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:18.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 166,918</font></p>
				</td>
				<td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:25.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 7.3</font></p>
				</td>
				<td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:18.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 148,741</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:02.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:20.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:18.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 3,427,705</font></p>
				</td>
				<td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:25.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 6.8</font></p>
				</td>
				<td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:18.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 1,768,292</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 1pt;">
			<font style="display:inline;font-size:1pt;">&nbsp;</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140151717046040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plans<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Employee Benefit Plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock', window );">Employee Benefit Plans</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-weight:bold;font-size: 10pt;">
			<font style="display:inline;">Note&nbsp;12&nbsp;&#x2013; Employee Benefit Plans</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;text-decoration:underline;">401(k) Plan</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">In April 2019, the Company adopted the Eyenovia 401(k) Plan (the &#x201C;Plan&#x201D;), which went into effect in May 2019. All Company employees are able to participate in the Plan, subject to eligibility requirements as outlined in the Plan documents. Under the terms of the Plan, eligible employees are able to defer a percentage of their pay every pay period up to annual limitations set by Congress and the Internal Revenue Service under Section 401(k) of the Internal Revenue Code. For 2019, the Company&#x2019;s Board of Directors has approved a matching contribution equal to 100% of elective deferrals up to 4% of eligible earnings with the matching contribution subject to certain vesting requirements as outlined in the Plan documents. For the years ended December 31, 2020 and 2019, the Company recorded expense of $138,785 and $71,285 associated with its matching contributions, respectively.</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 712<br> -URI http://asc.fasb.org/topic&amp;trid=2197446<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 710<br> -URI http://asc.fasb.org/topic&amp;trid=2127225<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI http://asc.fasb.org/topic&amp;trid=2235017<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndEmployeeBenefitPlansTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140151717949336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt 0pt 8pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-size:10pt;">Note&nbsp;13&nbsp;&#x2013; Subsequent Events</font>
		</p>
		<p style="margin:0pt 0pt 8pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;text-decoration:underline;">Management Option Grants</font>
		</p>
		<p style="margin:0pt 0pt 8pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:10pt;">Subsequent to December 31, 2020, the Company granted options to its executive officers for a total of&nbsp;</font><font style="display:inline;font-size:10pt;">652,899 shares, which grants are subject to stockholder approval of an amendment to the Restated Plan to increase the share reserve thereunder at the 2021 Annual Meeting of Stockholders. The options, would have a ten year term, vesting one-third on the one year anniversary of the date of grant and then in equal increments on each of the 24 one-month anniversaries thereafter, subject to continued employment, and bear an exercise price of&nbsp;$6.01, &nbsp;per share for total possible consideration to the Company of approximately $3.9 million. </font>
		</p>
		<p style="margin:0pt 0pt 8pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;text-decoration:underline;">Stock Warrant Exercises</font>
		</p>
		<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">Subsequent to December 31, 2020, the Company issued an aggregate of 644,992 shares of common stock pursuant to the exercise of warrants for aggregate proceeds of $1,530,989 at exercise prices ranging from $2.06&nbsp;to $2.47.</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140151710106456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-decoration:underline;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Use of Estimates</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Preparation of financial statements in conformity with accounting principles generally accepted in the United States of America (&#x201C;U.S. GAAP&#x201D;) requires management to make estimates, judgments and assumptions that affect the amounts reported in the financial statements and the amounts disclosed in the related notes to the financial statements. The Company bases its estimates and judgments on historical experience and on various other assumptions that it believes are reasonable under the circumstances. The amounts of assets and liabilities reported in the Company&#x2019;s balance sheets and the amounts of expenses reported for each of the periods presented are affected by estimates and assumptions, which are used for, but not limited to, fair value calculations for equity securities, establishment of valuation allowances for deferred tax assets, stock-based compensation, the recoverability and useful lives of long-lived assets, the recovery of deferred costs and the deferral of revenues. Certain of the Company&#x2019;s estimates could be affected by external conditions, including those unique to the Company and general economic conditions. It is reasonably possible that actual results could differ from those estimates.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">See Note 2 - Summary of Significant Accounting Policies&#x2009;&#x2014;&#x2009;Stock-Based Compensation for additional discussion of the use of estimates in estimating the fair value of the Company&#x2019;s common stock. </font>
		</p><div /></div> </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;text-decoration:underline;">Cash and Cash Equivalents</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents in the financial statements.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The Company has cash deposits and U.S. treasury bills in financial institutions which, at times, may be in excess of Federal Deposit Insurance Corporation (&#x201C;FDIC&#x201D;) insurance limits. The Company has not experienced losses in such accounts and periodically evaluates the creditworthiness of its financial institutions. As of December&nbsp;31, 2020 and 2019, the Company had cash and cash equivalent balances in excess of FDIC insurance limits of $28,121,828 and $13,902,601, respectively.</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment, Net</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-decoration:underline;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Property and Equipment, Net</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Property and equipment are stated at cost, net of accumulated depreciation, which is recorded commencing at the in-service date using the straight-line method at rates sufficient to charge the cost of depreciable assets to operations over their estimated useful lives, which range from 1 to 10&nbsp;years. Leasehold improvements are amortized over the lesser of (a)&nbsp;the useful life of the asset; or (b)&nbsp;the remaining lease term. Maintenance and repairs are charged to operations as incurred. The Company capitalizes costs attributable to the betterment of property and equipment when such betterment extends the useful life of the assets.</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-lived Assets</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-decoration:underline;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Impairment of Long-lived Assets</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The Company reviews for the impairment of long-lived assets whenever events or changes in circumstances indicate that the carrying amount of an asset might not be recoverable. An impairment would be recognized when estimated future cash flows expected to result from the use of the asset and its eventual disposition are less than its carrying amount. The Company did not record any impairment losses during the&nbsp;years ended December&nbsp;31, 2020 and 2019.</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy', window );">Preferred Stock</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-decoration:underline;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Preferred Stock</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The Company applies the accounting standards for distinguishing liabilities from equity when determining the classification and measurement of its preferred stock. Preferred shares subject to mandatory redemption are classified as liability instruments and are measured at fair value. Conditionally redeemable preferred shares (including preferred shares that feature redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company&#x2019;s control) are classified as temporary equity. At all other times, preferred shares are classified as stockholders&#x2019; equity.</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-decoration:underline;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Fair Value of Financial Instruments</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The Company measures the fair value of financial assets and liabilities based on Accounting Standards Codification (&#x201C;ASC&#x201D;) Topic 820 &#x201C;Fair Value Measurements and Disclosures&#x201D; (&#x201C;ASC 820&#x201D;), which defines fair value, establishes a framework for measuring fair value, and expands disclosures about fair value measurements.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">ASC 820 defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 describes three levels of inputs that may be used to measure fair value:</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Level 1&nbsp;&#x2014; quoted prices in active markets for identical assets or liabilities;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Level 2&nbsp;&#x2014; quoted prices for similar assets and liabilities in active markets or inputs that are observable; and</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Level 3&nbsp;&#x2014; inputs that are unobservable (for example, cash flow modeling inputs based on assumptions).</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The carrying amounts of the Company&#x2019;s financial instruments, such as cash and cash equivalents, accounts payable, accrued expenses and other current liabilities approximate fair values due to the short-term nature of these instruments.</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-decoration:underline;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Income Taxes</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The Company is subject to Federal, New York State and City, and State of California income taxes and files tax returns in those jurisdictions.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of items that have been included or excluded in the consolidated financial statements or tax returns.&nbsp;&nbsp;Deferred tax assets and liabilities are determined on the basis of the difference between the tax basis of assets and liabilities and their respective financial reporting amounts (&#x201C;temporary differences&#x201D;) at enacted tax rates in effect for the years in which such temporary differences are expected to reverse. </font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The Company utilizes a recognition threshold and measurement process for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return.</font>
		</p>
		<p style="margin:0pt 0pt 8pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;">The Company&#x2019;s policy is to classify assessments, if any, for tax-related interest as interest expense and penalties as general and administrative expenses in the consolidated statements of operations.</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;text-decoration:underline;">Revenue Recognition</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Our revenues are generated primarily through research, development and commercialization agreements. The terms of such agreements may contain multiple promised goods and services, which may include (i) licenses to our intellectual property, and (ii) in certain cases, payment in connection with the manufacturing and delivery of clinical supply materials. Payments to us under these arrangements typically include one or more of the following: non-refundable, upfront license fees; milestone payments; payments for clinical product supply, and royalties on future product sales.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">We analyze our arrangements to assess whether such arrangements involve joint operating activities. For collaboration arrangements that are deemed to be within the scope of ASC Topic 808, &#x201C;Collaborative Arrangements&#x201D; (&#x201C;ASC 808&#x201D;), we allocate the contract consideration between such joint operating activities and elements that are reflective of a vendor-customer relationship and, therefore, within the scope of ASC Topic 606, &#x201C;Revenue from Contracts with Customers&#x201D; (&#x201C;ASC 606&#x201D;). Our policy is to recognize amounts allocated to joint operating activities as a reduction in research and development expense.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Under ASC 606, we recognize revenue when our customers obtain control of promised goods or services, in an amount that reflects the consideration which we expect to receive in exchange for those goods or services. To determine revenue recognition for arrangements that we determine are within the scope of ASC 606, we perform the following five steps:</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&#x2022; &nbsp;</font><font style="display:inline;text-decoration:underline;">Step 1:</font><font style="display:inline;"> Identify the contract with the customer;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&#x2022; &nbsp;</font><font style="display:inline;text-decoration:underline;">Step 2:</font><font style="display:inline;"> Identify the performance obligations in the contract;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&#x2022; &nbsp;</font><font style="display:inline;text-decoration:underline;">Step 3:</font><font style="display:inline;"> Determine the transaction price;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&#x2022; &nbsp;</font><font style="display:inline;text-decoration:underline;">Step 4:</font><font style="display:inline;"> Allocate the transaction price to the performance obligations in the contract; and</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&#x2022; &nbsp;</font><font style="display:inline;text-decoration:underline;">Step 5:</font><font style="display:inline;"> Recognize revenue when the company satisfies a performance obligation.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">We must make significant judgments in our revenue recognition process, including identifying performance obligations in the contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price to each performance obligation. In addition, arrangements that include rights to additional goods or services that are exercisable at a customer&#x2019;s discretion are generally considered discretionary purchase options. We assess if these options provide a material right to the customer and if so, they are considered performance obligations.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">For upfront license fees, we must consider how many performance obligations are in the contract and, if more than one, how to allocate the fee to those performance obligations upon satisfaction of the performance obligation(s). Milestone payments represent variable consideration that will be recognized when the performance obligation is achieved. Sales-based royalty payments derived from usage of intellectual property are recognized when those sales occur.</font>
		</p>
		<p style="margin:0pt 0pt 8pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">During 2020, the Company entered </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:10pt;">into a license agreement (the &#x201C;Arctic Vision License Agreement&#x201D;) with Arctic Vision (Hong Kong) Limited (&#x201C;Arctic Vision&#x201D;) and a license agreement (the &#x201C;</font><font style="display:inline;font-size:10pt;">Bausch License Agreement&#x2019;) </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:10pt;">with Bausch Health Companies, Inc. (&#x201C;Bausch Health&#x201D;). </font><font style="display:inline;font-size:10pt;">Each license has three revenue components: 1) an upfront license fee; 2) milestone payments and 3) royalty payments. See Note 9 &#x2013; Commitments and Contingencies for additional details.</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_DeferredLicenseFeePolicyTextBlock', window );">Deferred License Fee</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt 0pt 8pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:10pt;text-decoration:underline;">Deferred License Fee</font>
		</p>
		<p style="margin:0pt 0pt 8pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:10pt;">The Company enters into license agreements which provides for the receipt of non-refundable, upfront licensing payments. These payments are recorded as deferred license fees and will be earned and recognized as revenue upon the satisfaction of performance obligations. See Note 9 &#x2013; Commitments and Contingencies for additional details.</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_DeferredLicenseCostsPolicyTextBlock', window );">Deferred License Costs</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt 0pt 8pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:10pt;text-decoration:underline;">Deferred License Costs</font>
		</p>
		<p style="margin:0pt 0pt 8pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:10pt;">The Company enters into license agreements which provides for payment of license costs in connection with the Company&#x2019;s receipt of license fees. These payments are recorded as deferred license costs and will be recorded as an expense when the related license fee revenue is recognized. See Note 10 &#x2013; Related Party Transactions for additional details.</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-decoration:underline;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Research and Development</font>
		</p>
		<p style="margin:0pt 0pt 8pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;">Research and development expenses are charged to operations as incurred. The Company records prepaid expenses on its balance sheet for the payment of research and development expenses in advance of services being provided.</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-decoration:underline;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Stock-Based Compensation</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The Company measures the cost of services received in exchange for an award of equity instruments based on the fair value of the award. The fair value of the award is measured on the grant date and the fair value amount is then recognized over the period during which services are required to be provided in exchange for the award, usually the vesting period. Upon the exercise of an option, the Company issues new shares of common stock out of the shares reserved for issuance under its equity plans.</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Common Share</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-decoration:underline;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Net Loss Per Common Share</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Basic net loss per common share is computed by dividing net loss by the weighted average number of common shares outstanding during the period. Diluted loss per share reflects the potential dilution that could occur if securities or other instruments to issue common stock were exercised or converted into common stock.</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The following securities are excluded from the calculation of weighted average dilutive common shares because their inclusion would have been anti-dilutive:</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;">
			<tr>
				<td valign="bottom" style="width:72.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:72.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td colspan="3" valign="bottom" style="width:25.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">December&nbsp;31,&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:72.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">2020</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">2019</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:72.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Warrants</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 2,011,313</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> &nbsp;&#x2014;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:72.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Options</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 3,427,705</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 2,237,438</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:72.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Restricted stock units</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 104,083</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 60,355</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:72.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Total potentially dilutive shares</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 5,543,101</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 2,297,793</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsPolicyPolicyTextBlock', window );">Subsequent Events</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-decoration:underline;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Subsequent Events</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The Company has evaluated subsequent events through the date which the financial statements were issued. Based upon the evaluation, the Company did not identify any recognized or non-recognized subsequent events that would have required adjustment or disclosure in the financial statements, except as disclosed.</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Adopted Accounting Pronouncements</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-decoration:underline;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Recently Adopted Accounting Pronouncements</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">In July 2017, the FASB issued Accounting Standards Update (&#x201C;ASU&#x201D;) 2017-11 &#x201C;Earnings Per Share (Topic 260) and Derivatives and Hedging (Topic 815) - Accounting for Certain Financial Instruments with Down Round Features&#x201D; (&#x201C;ASU 2017-11&#x201D;). Equity-linked instruments, such as warrants and convertible instruments may contain down round features that result in the strike price being reduced on the basis of the pricing of future equity offerings. Under ASU 2017-11, a down round feature will no longer require a freestanding equity-linked instrument (or embedded conversion option) to be classified as a liability that is remeasured at fair value through the income statement (i.e. marked-to-market). However, other features of the equity-linked instrument (or embedded conversion option) must still be evaluated to determine whether liability or equity classification is appropriate. Equity classified instruments are not marked-to-market. For earnings per share ("EPS") reporting, the ASU requires companies to recognize the effect of the down round feature only when it is triggered by treating it as a dividend and as a reduction of income available to common shareholders in basic EPS. The amendments in this ASU are effective for all entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. This standard, which the Company adopted on January 1, 2020, did not have a material impact on the Company&#x2019;s financial position, results of operations, or cash flows.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">In March 2020, the FASB issued ASU 2020-03 &#x201C;Codification Improvements to Financial Instruments&#x201D; (&#x201C;ASU 2020-03&#x201D;). ASU 2020-03 improves and clarifies various financial instruments topics. ASU 2020-03 includes seven different issues that describe the areas of improvement and the related amendments to GAAP, intended to make the standards easier to understand and apply by eliminating inconsistencies and providing clarifications. The Company adopted ASU 2020-03 upon issuance, which did not have a material impact on the Company&#x2019;s financial position, results of operations or cash flow.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-decoration:underline;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Recently Issued Accounting Pronouncements</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">In February&nbsp;2016, the FASB issued ASU 2016&#8209;02 &#x201C;Leases (Topic 842)&#x201D; (&#x201C;ASU 2016&#8209;02&#x201D;). ASU 2016&#8209;02 requires that a lessee recognize the assets and liabilities that arise from operating leases. A lessee should recognize in the statement of financial position a liability to make lease payments (the lease liability) and a right-of-use asset representing its right to use the underlying asset for the lease term. For leases with a term of 12&nbsp;months or less, a lessee is permitted to make an accounting policy election by class of underlying asset not to recognize lease assets and lease liabilities. In transition, lessees and lessors are required to recognize and measure leases at the beginning of the earliest period presented using a modified retrospective approach. ASU 2016-02, as amended, is now effective for fiscal&nbsp;years beginning after December&nbsp;15, 2021, and interim periods within fiscal years beginning after December 15, 2022. The FASB issued ASU 2019-01 &#x201C;Leases (Topic 842) Codification Improvements&#x201D; in March 2019 and ASU 2018-10 &#x201C;Codification Improvements to Topic 842, Leases&#x201D; and ASU 2018-11 &#x201C;Leases (Topic 842) Targeted Improvements&#x201D; in July 2018, and ASU 2018-20 &#x201C;Leases (Topic 842) - Narrow Scope Improvements for Lessors&#x201D; in December 2018. ASU 2019-01, ASU 2018-10 and ASU 2018-20 provide certain amendments that affect narrow aspects of the guidance issued in ASU 2016-02. ASU 2018-11 allows all entities adopting ASU 2016-02 to choose an additional (and optional) transition method of adoption, under which an entity initially applies the new leases standard at the adoption date and recognizes a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption. The Company is currently evaluating ASU 2016-02 and its impact on its financial position, results of operations, and cash flows. The Company intends to adopt the ASU effective January 1, 2021 with no material impact.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">In August 2018, the FASB issued ASU No. 2018-13 &#x201C;Fair Value Measurement (Topic 820): Disclosure Framework&#x2014;Changes to the Disclosure Requirements for Fair Value Measurement&#x201D; (&#x201C;ASU 2018-13&#x201D;). The amendments in ASU 2018-13 modify the disclosure requirements on fair value measurements based on the concepts in the FASB Concepts Statement, including the consideration of costs and benefits. The amendments on changes in unrealized gains and losses, the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements, and the narrative description of measurement uncertainty should be applied prospectively for only the most recent interim or annual period presented in the initial fiscal year of adoption. All other amendments should be applied retrospectively to all periods presented upon their effective date. The amendments are effective for fiscal years beginning after December 15, 2020. Early adoption is permitted, including adoption in an interim period. The Company is currently evaluating ASU 2018-13 and its impact on its financial position, results of operations and cash flows.</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">In December 2019, the FASB issued ASU 2019-12, &#x201C;Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes,&#x201D; which is intended to simplify various aspects related to accounting for income taxes. ASU 2019-12 removes certain exceptions to the general principles in Topic 740 and also clarifies and amends existing guidance to improve consistent application. ASU 2019-12 is effective for fiscal years beginning after December 15, 2021. The Company is currently evaluating ASU 2019-12 and its impact financial position, results of operations, and cash flows.</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_DeferredLicenseCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for deferral license costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_DeferredLicenseCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_DeferredLicenseFeePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for deferral license fee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_DeferredLicenseFeePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13279-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32847-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32840-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116657188&amp;loc=SL116659661-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e32280-109318<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130561-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130563-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130563-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130564-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for redeemable preferred stock issued. This disclosure may include the accounting treatment for the difference, if there is any, between the carrying value and redemption amount. For example, describe whether the issuer accretes changes in the redemption value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116854557&amp;loc=d3e20905-112640<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for reporting subsequent events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140151714037272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of anti-dilutive weighted average diluted common shares</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The following securities are excluded from the calculation of weighted average dilutive common shares because their inclusion would have been anti-dilutive:</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;">
			<tr>
				<td valign="bottom" style="width:72.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:72.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td colspan="3" valign="bottom" style="width:25.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">December&nbsp;31,&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:72.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">2020</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">2019</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:72.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Warrants</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 2,011,313</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> &nbsp;&#x2014;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:72.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Options</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 3,427,705</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 2,237,438</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:72.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Restricted stock units</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 104,083</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 60,355</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:72.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Total potentially dilutive shares</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 5,543,101</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 2,297,793</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt 0pt 8pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140151717945112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepaid Expenses and Other Current Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsAbstract', window );"><strong>Prepaid Expenses and Other Current Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock', window );">Schedule of prepaid expenses and other current assets</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">As of December&nbsp;31, 2020 and 2019, prepaid expenses and other current assets consisted of the following:</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;">
			<tr>
				<td valign="bottom" style="width:73.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td colspan="5" valign="bottom" style="width:24.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">December&nbsp;31,&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">2020</font></p>
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">2019</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Payroll tax receivable</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 151,942</font></p>
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 95,233</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Prepaid insurance expenses</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 110,094</font></p>
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 33,923</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Prepaid research and development expenses</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 17,978</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Prepaid licenses and subscriptions</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 57,051</font></p>
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> &nbsp;&#x2014;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Prepaid patent expenses</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 12,404</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Prepaid conference expenses</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 29,403</font></p>
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 10,600</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Prepaid board of directors expenses</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 68,250</font></p>
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> &nbsp;&#x2014;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Prepaid rent and security deposit</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 25,004</font></p>
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 2,463</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Other</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 11,734</font></p>
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 24,079</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Total prepaid expenses and other current assets</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 453,478</font></p>
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 196,680</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt 0pt 8pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140151717952696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property and Equipment, Net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of property and equipment</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">As of December&nbsp;31, 2020 and 2019, property and equipment consisted of the following:</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;">
			<tr>
				<td valign="bottom" style="width:72.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:72.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td colspan="5" valign="bottom" style="width:25.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">December&nbsp;31,&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:72.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">2020</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:11.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">2019</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:72.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Equipment</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 435,521</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 229,529</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:72.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Leasehold improvements</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 137,765</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 82,500</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:72.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 573,286</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 312,029</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:72.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Less: accumulated depreciation and amortization</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> (176,906)</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> (81,491)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:72.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Property and equipment, net</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 396,380</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 230,538</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt 0pt 8pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140151713892072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Accrued Expenses and Other Current Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of accrued expenses and other current liabilities</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">As of December&nbsp;31, 2020 and 2019, accrued expenses and other current liabilities consisted of the following:</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;">
			<tr>
				<td valign="bottom" style="width:71.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:71.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td colspan="5" valign="bottom" style="width:26.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">December&nbsp;31,&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:71.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:13.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">2020</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:11.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">2019</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:71.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Accrued research and development expenses</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 291,256</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 208,175</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:71.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Accrued consulting and professional services</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 235,355</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 97,396</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:71.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Credit card payable</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 50,002</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 56,979</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:71.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Leasehold improvements</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 42,500</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:71.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Accrued franchise tax</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 32,480</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 40,995</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:71.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Accrued travel and entertainment expenses</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 7,385</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:71.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Accrued licensing fees</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 804,447</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> &nbsp;&#x2014;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:71.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Accrued interest</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 3,068</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> &nbsp;&#x2014;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:71.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Accrued expense reimbursements</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 5,459</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> &nbsp;&#x2014;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:71.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Accrued shipping and packaging fees</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 56,998</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> &nbsp;&#x2014;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:71.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Other</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 1,627</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> &nbsp;&#x2014;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:71.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Total accrued expenses and other current liabilities</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 1,480,692</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 453,430</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt 0pt 8pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140151713792408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsAbstract', window );"><strong>Accrued Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_DisclosureOfAccruedCompensationTableTextBlock', window );">Schedule of accrued compensation</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">As of December 31, 2020 and 2019, accrued compensation consisted of the following:</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;">
			<tr>
				<td valign="bottom" style="width:71.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:71.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td colspan="5" valign="bottom" style="width:26.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">December&nbsp;31,&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:71.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:13.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">2020</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:11.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">2019</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:71.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Accrued bonus expenses</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 938,873</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 897,839</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:71.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Accrued payroll expenses</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 211,799</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 19,034</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:71.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Total accrued compensation</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 1,150,672</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 916,873</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt 0pt 8pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_DisclosureOfAccruedCompensationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of accrued compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_DisclosureOfAccruedCompensationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140151717889048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Notes Payable (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableAbstract', window );"><strong>Notes Payable</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_ScheduleOfNotesPayableTableTextBlock', window );">Schedule of notes payable</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">As of December 31, 2020 and 2019, notes payable consisted of the following:</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="bottom" style="width:41.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:06.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:07.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:07.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:05.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:08.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:06.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:41.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td colspan="8" valign="bottom" style="width:29.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">December&nbsp;31,&nbsp;2020</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td colspan="8" valign="bottom" style="width:25.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">December&nbsp;31,&nbsp;2019</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:41.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:07.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">Current</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:09.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">Non-Current</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:07.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:06.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">Current</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:09.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">Non-Current</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:06.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:41.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:07.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">Portion</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:09.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">Portion</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:08.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">Total</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:06.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">Portion</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:09.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">Portion</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:07.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">Total</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:41.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Paycheck Protection Program loan</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:06.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 97,539</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:07.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 365,814</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:07.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 463,353</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:05.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:08.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:06.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> &nbsp;&#x2014;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:41.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Total</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:06.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 97,539</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:07.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 365,814</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:07.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 463,353</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:05.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:08.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:06.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> &nbsp;&#x2014;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt 0pt 0pt 54pt;line-height:100%;text-indent: -54pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_ScheduleOfNotesPayableTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of notes payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_ScheduleOfNotesPayableTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140151712462648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of provision for income taxes</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The provision for income taxes consists of the following expenses (benefits):</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="bottom" style="width:74.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:74.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="5" valign="bottom" style="width:24.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">For&nbsp;The&nbsp;Years&nbsp;Ended</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:74.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td colspan="5" valign="bottom" style="width:24.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">December&nbsp;31,</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:74.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:11.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">2020</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:11.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">2019</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:74.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Deferred tax provision (benefit):</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:74.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt 6pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Federal</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> (3,797,052)</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> (4,999,920)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:74.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt 6pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">State and local</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> (434,082)</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 68,762</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:74.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> (4,231,134)</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> (4,931,158)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:74.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Change in valuation allowance</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 4,231,134</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 4,931,158</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:74.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Provision for income taxes</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> &nbsp;&#x2014;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of effective income tax rate reconciliation</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The provision for income taxes differs from the United States Federal statutory rate as follows:</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="bottom" style="width:74.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:74.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="3" valign="bottom" style="width:21.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">For&nbsp;The&nbsp;Years&nbsp;Ended</font></p>
				</td>
				<td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:74.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td colspan="3" valign="bottom" style="width:21.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">December&nbsp;31,</font></p>
				</td>
				<td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:74.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">2020</font></p>
				</td>
				<td valign="bottom" style="width:02.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">2019</font></p>
				</td>
				<td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:74.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Federal statutory rate</font></p>
				</td>
				<td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> (21.0)</font></p>
				</td>
				<td valign="bottom" style="width:02.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">%&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 21.0</font></p>
				</td>
				<td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">%</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:74.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">State tax rate, net of federal benefit</font></p>
				</td>
				<td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> (0.1)</font></p>
				</td>
				<td valign="bottom" style="width:02.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">%&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 0.1</font></p>
				</td>
				<td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">%</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:74.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Permanent differences</font></p>
				</td>
				<td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 0.5</font></p>
				</td>
				<td valign="bottom" style="width:02.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">%&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> (0.2)</font></p>
				</td>
				<td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">%</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:74.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Research &amp; development tax credits</font></p>
				</td>
				<td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> (1.4)</font></p>
				</td>
				<td valign="bottom" style="width:02.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">%&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 3.0</font></p>
				</td>
				<td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">%</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:74.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Prior period adjustments and other</font></p>
				</td>
				<td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 0.6</font></p>
				</td>
				<td valign="bottom" style="width:02.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">%&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> (0.6)</font></p>
				</td>
				<td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">%</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:74.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Change in valuation allowance</font></p>
				</td>
				<td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 21.4</font></p>
				</td>
				<td valign="bottom" style="width:02.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">%&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> (23.3)</font></p>
				</td>
				<td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">%</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:74.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Effective income tax rate</font></p>
				</td>
				<td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">%&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">%</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt 0pt 8pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of deferred tax assets</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Deferred tax assets consist of the following:</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="bottom" style="width:72.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:72.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="5" valign="bottom" style="width:26.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">For&nbsp;The&nbsp;Years&nbsp;Ended</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:72.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td colspan="5" valign="bottom" style="width:26.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">December&nbsp;31,</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:72.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">2020</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">2019</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:72.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Net operating loss carryforwards</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 12,972,865</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 9,479,512</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:72.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Stock-based compensation</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 1,385,554</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 943,370</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:72.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Intangible assets</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 409,705</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 328,773</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:72.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Research and development tax credits</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 1,861,938</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 1,584,753</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:72.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Deferred tax assets, gross</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 16,630,062</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 12,336,408</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:72.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Property and equipment</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> (76,550)</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> (14,030)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:72.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Deferred tax assets, net before allowance</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 16,553,512</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 12,322,378</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:72.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Valuation allowance</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> (16,553,512)</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> (12,322,378)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:72.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Deferred tax assets, net</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> &nbsp;&#x2014;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt 0pt 8pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140151713900728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock', window );">Schedule of future minimum operating lease payments</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Future minimum payments under this operating lease agreement are as follows as:</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;">
			<tr>
				<td valign="bottom" style="width:74.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:21.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:74.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">For the Year Ending</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:21.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:74.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">December&nbsp;31,&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:23.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">Minimum&nbsp;Lease&nbsp;Payments</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:74.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">2021</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:21.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 378,486</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:74.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">2022</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:21.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 389,212</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:74.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">2023</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:21.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 285,700</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:74.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:21.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 1,053,398</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt 0pt 8pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121573735&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140151715925016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Summary of the Warrant activity and related information</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">A summary of the Warrant activity during the year ended December 31, 2020 is presented below:</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="bottom" style="width:58.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:05.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:07.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:58.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:05.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:07.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">Weighted</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:58.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:06.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">Weighted </font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:07.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">Average</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:58.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:06.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">Average</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:07.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">Remaining</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:10.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">Aggregate</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:58.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">Number of</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:06.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">Exercise</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:07.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">Life</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:10.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">Intrinsic</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:58.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">Warrants</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:06.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">Price</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">In Years</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:10.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">Value</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:58.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Outstanding January 1, 2020</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:05.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:58.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Granted</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 3,344,154</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:05.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 2.33</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:58.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Exercised</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> (1,332,841)</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:05.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 2.19</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:58.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Forfeited</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:05.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:58.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Outstanding December 31, 2020</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 2,011,313</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:05.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 2.43</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 3.8</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 7,215,147</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:58.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:05.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:07.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:58.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Exercisable December 31, 2020</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 2,011,313</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:05.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 2.43</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 3.8</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 7,215,147</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The following table presents information related to Warrants as of December 31, 2020:</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;">
			<tr>
				<td valign="bottom" style="width:22.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:03.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:22.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:03.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:22.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:03.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:22.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td colspan="3" valign="bottom" style="width:48.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">Warrants Outstanding</font></p>
				</td>
				<td valign="bottom" style="width:03.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td colspan="3" valign="bottom" style="width:48.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">Warrants Exercisable</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:22.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:03.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:22.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:03.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:22.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">Weighted</font></p>
				</td>
				<td valign="bottom" style="width:03.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:22.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:22.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:03.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:22.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">Outstanding</font></p>
				</td>
				<td valign="bottom" style="width:03.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:22.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">Average</font></p>
				</td>
				<td valign="bottom" style="width:03.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:22.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">Exercisable</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:22.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">Exercise</font></p>
				</td>
				<td valign="bottom" style="width:03.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:22.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">Number of</font></p>
				</td>
				<td valign="bottom" style="width:03.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:22.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">Remaining Life</font></p>
				</td>
				<td valign="bottom" style="width:03.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:22.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">Number of</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:22.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">Price</font></p>
				</td>
				<td valign="bottom" style="width:03.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:22.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">Warrants</font></p>
				</td>
				<td valign="bottom" style="width:03.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:22.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">In Years</font></p>
				</td>
				<td valign="bottom" style="width:03.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:22.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">Warrants</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:22.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">$2.0580 </font></p>
				</td>
				<td valign="bottom" style="width:03.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:22.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 48,549</font></p>
				</td>
				<td valign="bottom" style="width:03.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:22.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 0.2</font></p>
				</td>
				<td valign="bottom" style="width:03.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:22.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 48,549</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:22.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">$2.2700 </font></p>
				</td>
				<td valign="bottom" style="width:03.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:22.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 144,256</font></p>
				</td>
				<td valign="bottom" style="width:03.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:22.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 0.2</font></p>
				</td>
				<td valign="bottom" style="width:03.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:22.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 144,256</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:22.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">$2.4696 </font></p>
				</td>
				<td valign="bottom" style="width:03.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:22.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 1,602,128</font></p>
				</td>
				<td valign="bottom" style="width:03.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:22.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 4.2</font></p>
				</td>
				<td valign="bottom" style="width:03.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:22.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 1,602,128</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:22.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">$2.7240 </font></p>
				</td>
				<td valign="bottom" style="width:03.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:22.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 216,380</font></p>
				</td>
				<td valign="bottom" style="width:03.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:22.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 4.2</font></p>
				</td>
				<td valign="bottom" style="width:03.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:22.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 216,380</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:22.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:03.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:22.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 2,011,313</font></p>
				</td>
				<td valign="bottom" style="width:03.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:22.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 3.8</font></p>
				</td>
				<td valign="bottom" style="width:03.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:22.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 2,011,313</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Black-Scholes option pricing model to stock options granted</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">In applying the Black-Scholes option pricing model to stock options granted, the Company used the following approximate assumptions:</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;">
			<tr>
				<td valign="bottom" style="width:64.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:64.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td colspan="3" valign="bottom" style="width:32.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">For&nbsp;the&nbsp;Year Ended </font></p>
				</td>
				<td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:64.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td colspan="3" valign="bottom" style="width:32.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">December&nbsp;31,&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:64.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:15.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">2020</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:15.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">2019</font></p>
				</td>
				<td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:64.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Expected term (years)</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:15.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">5.85 - 10.00</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:15.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">5.50 - 10.00</font></p>
				</td>
				<td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:64.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Risk free interest rate</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:15.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">0.26% - 1.32%</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">1.42% - 2.53%</font></p>
				</td>
				<td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:64.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Expected volatility</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:15.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">96% - 99%</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">134 - 139%</font></p>
				</td>
				<td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:64.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Expected dividends</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:15.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">0.00%</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">0.00%</font></p>
				</td>
				<td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of the stock option activity</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">A summary of the option activity during the&nbsp;year ended December 31, 2020 is presented below:</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;">
			<tr>
				<td valign="bottom" style="width:48.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:07.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:48.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:07.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">Weighted</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:48.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:08.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">Weighted</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">Average</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:48.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:08.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">Average</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">Remaining</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:13.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">Aggregate</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:48.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">Number&nbsp;of</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:08.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">Exercise</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">Life</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:13.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">Intrinsic</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:48.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">Options</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:08.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">Price</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">In&nbsp;Years</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:13.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">Value</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:48.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Outstanding January 1, 2020</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 2,237,438</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:07.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 3.51</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:48.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Granted</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 1,249,839</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 3.01</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:48.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Exercised</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> (36,391)</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 2.26</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:48.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Forfeited</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> (23,181)</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 4.59</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:48.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Outstanding December&nbsp;31,&nbsp;2020</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 3,427,705</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:07.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 3.37</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 8.0</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 9,843,341</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:48.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:07.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:48.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Exercisable December&nbsp;31,&nbsp;2020</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 1,768,292</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:07.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 3.48</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 6.8</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 5,013,118</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt 0pt 8pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock', window );">Schedule of information related to stock options</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The following table presents information related to stock options as of December 31, 2020:</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;">
			<tr>
				<td valign="bottom" style="width:02.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:20.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:18.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:25.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:18.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:02.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td colspan="3" valign="bottom" style="width:43.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">Options Outstanding</font></p>
				</td>
				<td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td colspan="3" valign="bottom" style="width:48.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">Options&nbsp;Exercisable</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:02.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:20.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:18.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:25.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">Weighted</font></p>
				</td>
				<td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:18.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:02.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:20.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:18.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">Outstanding</font></p>
				</td>
				<td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:25.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">Average</font></p>
				</td>
				<td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:18.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">Exercisable</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:02.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:20.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">Exercise</font></p>
				</td>
				<td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:18.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">Number&nbsp;of</font></p>
				</td>
				<td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:25.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">Remaining&nbsp;Life</font></p>
				</td>
				<td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:18.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">Number&nbsp;of</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:02.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:20.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">Price</font></p>
				</td>
				<td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:18.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">Options</font></p>
				</td>
				<td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:25.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">In&nbsp;Years</font></p>
				</td>
				<td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:18.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">Options</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:02.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:20.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 1.24</font></p>
				</td>
				<td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:18.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 260,000</font></p>
				</td>
				<td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:25.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 4.2</font></p>
				</td>
				<td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:18.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 260,000</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:02.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:20.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 1.95</font></p>
				</td>
				<td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:18.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 673,544</font></p>
				</td>
				<td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:25.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 6.5</font></p>
				</td>
				<td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:18.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 673,544</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:02.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:20.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 2.72</font></p>
				</td>
				<td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:18.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 764,419</font></p>
				</td>
				<td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:25.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:18.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> &nbsp;&#x2014;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:02.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:20.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 2.74</font></p>
				</td>
				<td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:18.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 6,000</font></p>
				</td>
				<td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:25.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 8.0</font></p>
				</td>
				<td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:18.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 3,833</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:02.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:20.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 2.89</font></p>
				</td>
				<td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:18.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 263,500</font></p>
				</td>
				<td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:25.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:18.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> &nbsp;&#x2014;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:02.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:20.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 3.11</font></p>
				</td>
				<td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:18.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 659,849</font></p>
				</td>
				<td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:25.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 8.6</font></p>
				</td>
				<td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:18.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 318,432</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:02.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:20.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 3.43</font></p>
				</td>
				<td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:18.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 58,920</font></p>
				</td>
				<td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:25.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:18.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> &nbsp;&#x2014;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:02.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:20.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 3.48</font></p>
				</td>
				<td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:18.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 45,000</font></p>
				</td>
				<td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:25.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:18.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> &nbsp;&#x2014;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:02.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:20.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 3.71</font></p>
				</td>
				<td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:18.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 43,000</font></p>
				</td>
				<td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:25.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:18.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> &nbsp;&#x2014;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:02.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:20.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 4.00</font></p>
				</td>
				<td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:18.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 2,000</font></p>
				</td>
				<td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:25.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 7.9</font></p>
				</td>
				<td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:18.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 1,390</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:02.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:20.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 4.68</font></p>
				</td>
				<td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:18.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 25,000</font></p>
				</td>
				<td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:25.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:18.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> &nbsp;&#x2014;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:02.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:20.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 5.10</font></p>
				</td>
				<td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:18.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 6,000</font></p>
				</td>
				<td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:25.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 7.7</font></p>
				</td>
				<td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:18.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 4,500</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:02.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:20.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 5.19</font></p>
				</td>
				<td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:18.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 16,500</font></p>
				</td>
				<td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:25.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 7.7</font></p>
				</td>
				<td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:18.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 12,375</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:02.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:20.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 5.25</font></p>
				</td>
				<td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:18.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 26,668</font></p>
				</td>
				<td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:25.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 5.8</font></p>
				</td>
				<td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:18.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 26,668</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:02.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:20.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 5.77</font></p>
				</td>
				<td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:18.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 50,000</font></p>
				</td>
				<td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:25.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:18.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> &nbsp;&#x2014;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:02.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:20.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 6.20</font></p>
				</td>
				<td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:18.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 300,387</font></p>
				</td>
				<td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:25.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 7.6</font></p>
				</td>
				<td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:18.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 270,476</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:02.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:20.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 6.30</font></p>
				</td>
				<td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:18.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 60,000</font></p>
				</td>
				<td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:25.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 7.5</font></p>
				</td>
				<td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:18.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 48,333</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:02.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:20.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 8.72</font></p>
				</td>
				<td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:18.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 166,918</font></p>
				</td>
				<td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:25.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 7.3</font></p>
				</td>
				<td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:18.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 148,741</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:02.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:20.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:18.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 3,427,705</font></p>
				</td>
				<td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:25.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 6.8</font></p>
				</td>
				<td valign="bottom" style="width:04.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:18.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 1,768,292</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt 0pt 8pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6784392&amp;loc=d3e188667-122775<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140151712391368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Organization and Nature of Operations (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Business Organization and Nature of Operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">FL<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationDateOfIncorporation', window );">Entity Incorporation, Date of Incorporation</a></td>
<td class="text">Mar. 12,  2014<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_PercentageOfSuccessRateOfOptejet', window );">Percentage Of Success Rate Of Optejet</a></td>
<td class="nump">90.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_PercentageOfSuccessfulRateOfTraditionalEyeDrops', window );">Percentage of Successful Rate of Traditional Eye Drops</a></td>
<td class="nump">50.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationDateOfIncorporation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date when an entity was incorporated</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationDateOfIncorporation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_PercentageOfSuccessRateOfOptejet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This refers percentage of success rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_PercentageOfSuccessRateOfOptejet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_PercentageOfSuccessfulRateOfTraditionalEyeDrops">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This represents successful percentage rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_PercentageOfSuccessfulRateOfTraditionalEyeDrops</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140151709667512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Anti-dilutive weighted average diluted common shares (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total potentially dilutive shares</a></td>
<td class="nump">5,543,101<span></span>
</td>
<td class="nump">2,297,793<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total potentially dilutive shares</a></td>
<td class="nump">104,083<span></span>
</td>
<td class="nump">60,355<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OptionIndexedToIssuersEquityTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total potentially dilutive shares</a></td>
<td class="nump">3,427,705<span></span>
</td>
<td class="nump">2,237,438<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total potentially dilutive shares</a></td>
<td class="nump">2,011,313<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OptionIndexedToIssuersEquityTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OptionIndexedToIssuersEquityTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140151638350392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 09, 2020</div></th>
<th class="th"><div>Aug. 10, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28,371,828<span></span>
</td>
<td class="nump">$ 14,152,601<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(77,440,919)<span></span>
</td>
<td class="num">(57,671,052)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(19,769,867)<span></span>
</td>
<td class="num">(21,156,758)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Cash used in operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,384,276)<span></span>
</td>
<td class="num">(18,919,308)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashUninsuredAmount', window );">Cash, Uninsured Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,121,828<span></span>
</td>
<td class="nump">$ 13,902,601<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=eyen_BauschLicenseAgreementMember', window );">Bausch License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_LicenseAgreementsTerminationWrittenNoticePeriod', window );">Written notice period for termination of agreement</a></td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_LicenseAgreementsTerminationPeriodUponUncuredMaterialBreach', window );">Termination period upon uncured material breach</a></td>
<td class="text">60 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_LicenseAgreementsUpfrontPaymentsReceived', window );">Upfront payment received</a></td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_LicenseAgreementsMaximumAdditionalPaymentsReceivable', window );">Maximum additional payments receivable</a></td>
<td class="nump">$ 35,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=eyen_ArcticVisionLicenseAgreementMember', window );">Arctic Vision License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_LicenseAgreementsUpfrontPaymentsReceived', window );">Upfront payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_LicenseAgreementsMaximumAdditionalPaymentsReceivable', window );">Maximum additional payments receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 41,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, Plant and Equipment, Useful Life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, Plant and Equipment, Useful Life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_LicenseAgreementsMaximumAdditionalPaymentsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum amount of additional payments receivable by the company pursuant to a license agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_LicenseAgreementsMaximumAdditionalPaymentsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_LicenseAgreementsTerminationPeriodUponUncuredMaterialBreach">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period after which the license agreement can be terminated by either of the party in the event of uncured material breach, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_LicenseAgreementsTerminationPeriodUponUncuredMaterialBreach</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_LicenseAgreementsTerminationWrittenNoticePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period for providing written notice for termination of license agreement by the counterparty, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_LicenseAgreementsTerminationWrittenNoticePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_LicenseAgreementsUpfrontPaymentsReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of upfront payments received by the entity, pursuant to a license agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_LicenseAgreementsUpfrontPaymentsReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashUninsuredAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash as of the balance sheet date that is not insured by the Federal Deposit Insurance Corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashUninsuredAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=eyen_BauschLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=eyen_BauschLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=eyen_ArcticVisionLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=eyen_ArcticVisionLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140151710809944">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Prepaid Expenses and Other Current Assets (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsAbstract', window );"><strong>Prepaid Expenses and Other Current Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_PayrollTaxesReceivable', window );">Payroll tax receivable</a></td>
<td class="nump">$ 151,942<span></span>
</td>
<td class="nump">$ 95,233<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidInsurance', window );">Prepaid insurance expenses</a></td>
<td class="nump">110,094<span></span>
</td>
<td class="nump">33,923<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_PrepaidResearchAndDevelopmentExpenses', window );">Prepaid research and development expenses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">17,978<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_PrepaidLicensesAndSubscriptions', window );">Prepaid licenses and subscriptions</a></td>
<td class="nump">57,051<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_PrepaidPatentExpense', window );">Prepaid patent expenses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">12,404<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_PrepaidConferenceExpenses', window );">Prepaid conference expenses</a></td>
<td class="nump">29,403<span></span>
</td>
<td class="nump">10,600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_PrepaidDirectorFeesCurrent', window );">Prepaid board of director expenses</a></td>
<td class="nump">68,250<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_PrepaidRentAndSecurityDeposit', window );">Prepaid rent and security deposit</a></td>
<td class="nump">25,004<span></span>
</td>
<td class="nump">2,463<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssets', window );">Other</a></td>
<td class="nump">11,734<span></span>
</td>
<td class="nump">24,079<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Total prepaid expenses and other current assets</a></td>
<td class="nump">$ 453,478<span></span>
</td>
<td class="nump">$ 196,680<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_PayrollTaxesReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Payroll Taxes Receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_PayrollTaxesReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_PrepaidConferenceExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets related to prepaid conference expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_PrepaidConferenceExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_PrepaidDirectorFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of director fees prepaid, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_PrepaidDirectorFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_PrepaidLicensesAndSubscriptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of prepaid licenses and subscriptions, current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_PrepaidLicensesAndSubscriptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_PrepaidPatentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for patent expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_PrepaidPatentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_PrepaidRentAndSecurityDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for rent and security deposits that provides economic benefits within a future period of one year or the normal operating cycle.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_PrepaidRentAndSecurityDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_PrepaidResearchAndDevelopmentExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for research and development expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_PrepaidResearchAndDevelopmentExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidInsurance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=68074540&amp;loc=d3e5879-108316<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6787-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidInsurance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140151712585080">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property and Equipment, Net - Property and Equipment (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 573,286<span></span>
</td>
<td class="nump">$ 312,029<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation and amortization</a></td>
<td class="num">(176,906)<span></span>
</td>
<td class="num">(81,491)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">396,380<span></span>
</td>
<td class="nump">230,538<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">435,521<span></span>
</td>
<td class="nump">229,529<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 137,765<span></span>
</td>
<td class="nump">$ 82,500<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140151730598152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization expense</a></td>
<td class="nump">$ 95,415<span></span>
</td>
<td class="nump">$ 15,343<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="nump">13,263,817<span></span>
</td>
<td class="nump">14,102,449<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">7,725,408<span></span>
</td>
<td class="nump">7,206,095<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_PropertyPlantAndEquipmentMember', window );">Property, Plant and Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization expense</a></td>
<td class="nump">95,415<span></span>
</td>
<td class="nump">15,343<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="nump">67,595<span></span>
</td>
<td class="nump">9,762<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">$ 27,820<span></span>
</td>
<td class="nump">$ 5,581<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_PropertyPlantAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_PropertyPlantAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140151709737416">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Accrued Expenses and Other Current Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_AccruedResearchAndDevelopmentExpensesCurrent', window );">Accrued research and development expenses</a></td>
<td class="nump">$ 291,256<span></span>
</td>
<td class="nump">$ 208,175<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_AccruedConsultingAndProfessionalServicesCurrent', window );">Accrued consulting and professional services</a></td>
<td class="nump">235,355<span></span>
</td>
<td class="nump">97,396<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_CreditCardPayable', window );">Credit card payable</a></td>
<td class="nump">50,002<span></span>
</td>
<td class="nump">56,979<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_LeaseholdImprovements', window );">Leasehold improvements</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">42,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_AccruedFranchiseTax', window );">Accrued franchise tax</a></td>
<td class="nump">32,480<span></span>
</td>
<td class="nump">40,995<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_AccruedTravelAndEntertainmentExpenses', window );">Accrued travel and entertainment expenses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">7,385<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_AccruedLicensingFees', window );">Accrued licensing fees</a></td>
<td class="nump">804,447<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPayableCurrent', window );">Accrued interest</a></td>
<td class="nump">3,068<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_AccruedExpenseReimbursements', window );">Accrued expense reimbursements</a></td>
<td class="nump">5,459<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_AccruedShippingAndPackagingFees', window );">Accrued shipping and packaging fees</a></td>
<td class="nump">56,998<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">1,627<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities', window );">Total accrued expenses and other current liabilities</a></td>
<td class="nump">$ 1,480,692<span></span>
</td>
<td class="nump">$ 453,430<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_AccruedConsultingAndProfessionalServicesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for consulting and professional service, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_AccruedConsultingAndProfessionalServicesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_AccruedExpenseReimbursements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for expense reimbursements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_AccruedExpenseReimbursements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_AccruedFranchiseTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accrued franchise tax expenses paid by the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_AccruedFranchiseTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_AccruedLicensingFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of accrued licensing fees, current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_AccruedLicensingFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_AccruedResearchAndDevelopmentExpensesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accrued research and development expenses paid by the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_AccruedResearchAndDevelopmentExpensesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_AccruedShippingAndPackagingFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for shipping and packaging fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_AccruedShippingAndPackagingFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_AccruedTravelAndEntertainmentExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accrued travel and entertainment expenses paid by the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_AccruedTravelAndEntertainmentExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_CreditCardPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of credit card expenses payable by the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_CreditCardPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_LeaseholdImprovements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This represents accrued purchases balances of Leasehold improvements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_LeaseholdImprovements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e7018-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140151712546360">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Compensation (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsAbstract', window );"><strong>Accrued Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedBonusesCurrent', window );">Accrued bonus expenses</a></td>
<td class="nump">$ 938,873<span></span>
</td>
<td class="nump">$ 897,839<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedSalariesCurrent', window );">Accrued payroll expenses</a></td>
<td class="nump">211,799<span></span>
</td>
<td class="nump">19,034<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Total accrued compensation</a></td>
<td class="nump">$ 1,150,672<span></span>
</td>
<td class="nump">$ 916,873<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedBonusesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedBonusesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedSalariesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedSalariesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140151712584920">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Notes Payable - Schedule of notes payable (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Current Portion</a></td>
<td class="nump">$ 97,539<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermNotesPayable', window );">Non-Current Portion</a></td>
<td class="nump">365,814<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Total</a></td>
<td class="nump">463,353<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=eyen_PaycheckProtectionProgramLoanMember', window );">Paycheck Protection Program loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Current Portion</a></td>
<td class="nump">97,539<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermNotesPayable', window );">Non-Current Portion</a></td>
<td class="nump">365,814<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Total</a></td>
<td class="nump">$ 463,353<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=eyen_PaycheckProtectionProgramLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=eyen_PaycheckProtectionProgramLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140151709655544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Notes Payable - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 08, 2020</div></th>
<th class="th"><div>Feb. 24, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Notes Payable</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Repayments of loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 475,216<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,042<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember', window );">Notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Notes Payable</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_NumberOfMonthlyPayments', window );">Number of monthly payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">9 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPayment', window );">Debt Instrument, Periodic Payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 53,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAnnualPrincipalPayment', window );">Aggregate principal payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 475,216<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.29%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=eyen_PaycheckProtectionProgramLoanMember', window );">Paycheck Protection Program loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Notes Payable</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPayment', window );">Debt Instrument, Periodic Payment</a></td>
<td class="nump">$ 19,508<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate (as a percent)</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromLongTermLinesOfCredit', window );">Cash proceeds from loan</a></td>
<td class="nump">$ 463,353<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_PeriodConsideredForUsageOfLoanProceedsFromFundingDate', window );">Period for usage of loan proceeds</a></td>
<td class="text">168 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_PercentageOfInterestOnAmountWhichIsNotForgiven', window );">Interest rate on non forgiven amount</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=eyen_PaycheckProtectionProgramLoanMember', window );">Paycheck Protection Program loan | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Notes Payable</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Maturity term</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=eyen_PaycheckProtectionProgramLoanMember', window );">Paycheck Protection Program loan | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Notes Payable</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Maturity term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_NumberOfMonthlyPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of monthly payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_NumberOfMonthlyPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_PercentageOfInterestOnAmountWhichIsNotForgiven">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of interest on amount which is not forgiven.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_PercentageOfInterestOnAmountWhichIsNotForgiven</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_PeriodConsideredForUsageOfLoanProceedsFromFundingDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period allowed to use loan proceeds for the requirements subsequent to the date of funding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_PeriodConsideredForUsageOfLoanProceedsFromFundingDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAnnualPrincipalPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the total principal payments made during the annual reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAnnualPrincipalPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentPeriodicPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the required periodic payments including both interest and principal payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=75038535&amp;loc=d3e64711-112823<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentPeriodicPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLongTermLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLongTermLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=eyen_PaycheckProtectionProgramLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=eyen_PaycheckProtectionProgramLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140151710963576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - provision for income taxes (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Deferred tax provision (benefit):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Federal</a></td>
<td class="num">$ (3,797,052)<span></span>
</td>
<td class="num">$ (4,999,920)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">State and local</a></td>
<td class="num">(434,082)<span></span>
</td>
<td class="nump">68,762<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_DeferredIncomeTaxExpenseBenefitBeforeAdjustmentsForChangeInValuationAllowance', window );">Total</a></td>
<td class="num">(4,231,134)<span></span>
</td>
<td class="num">(4,931,158)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Change in valuation allowance</a></td>
<td class="nump">$ 4,231,134<span></span>
</td>
<td class="nump">$ 4,931,158<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_DeferredIncomeTaxExpenseBenefitBeforeAdjustmentsForChangeInValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) before adjustments for change in valuation allowance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_DeferredIncomeTaxExpenseBenefitBeforeAdjustmentsForChangeInValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140151709817880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Effective income tax rate reconciliation (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_EffectiveIncomeTaxRateReconciliationNetAtFederalStatutoryIncomeTaxRate', window );">Federal statutory rate</a></td>
<td class="num">(21.00%)<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State tax rate, net of federal benefit</a></td>
<td class="num">(0.10%)<span></span>
</td>
<td class="nump">0.10%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Permanent differences</a></td>
<td class="nump">0.50%<span></span>
</td>
<td class="num">(0.20%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch', window );">Research &amp; development tax credits</a></td>
<td class="num">(1.40%)<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes', window );">Prior period adjustments and other</a></td>
<td class="nump">0.60%<span></span>
</td>
<td class="num">(0.60%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="nump">21.40%<span></span>
</td>
<td class="num">(23.30%)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_EffectiveIncomeTaxRateReconciliationNetAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the federal statutory income tax rates to pretax income (loss) from continuing operations applicable to federal income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_EffectiveIncomeTaxRateReconciliationNetAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to revisions of previously reported income tax expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140151729363976">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Deferred tax assets (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetAbstract', window );"><strong>Deferred Tax Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 12,972,865<span></span>
</td>
<td class="nump">$ 9,479,512<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock-based compensation expense</a></td>
<td class="nump">1,385,554<span></span>
</td>
<td class="nump">943,370<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets', window );">Intangibles</a></td>
<td class="nump">409,705<span></span>
</td>
<td class="nump">328,773<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">Research and development tax credits</a></td>
<td class="nump">1,861,938<span></span>
</td>
<td class="nump">1,584,753<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Deferred tax assets</a></td>
<td class="nump">16,630,062<span></span>
</td>
<td class="nump">12,336,408<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_DeferredTaxAssetsLiabilityPropertyAndEquipment', window );">Property and equipment</a></td>
<td class="num">(76,550)<span></span>
</td>
<td class="num">(14,030)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_DeferredTaxAssetsNetBeforeValuationAllowance', window );">Deferred tax assets, net before allowance</a></td>
<td class="nump">16,553,512<span></span>
</td>
<td class="nump">12,322,378<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">$ (16,553,512)<span></span>
</td>
<td class="num">$ (12,322,378)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_DeferredTaxAssetsLiabilityPropertyAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_DeferredTaxAssetsLiabilityPropertyAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_DeferredTaxAssetsNetBeforeValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_DeferredTaxAssetsNetBeforeValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140151709749800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional information (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating Loss Carryforwards</a></td>
<td class="nump">$ 60,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_NetOperatingLossLimitForUtilizationAsPerInternalRevenueCode', window );">Net Operating Loss Limit for Utilization as per Internal Revenue Code</a></td>
<td class="nump">35,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_NetOperatingLossAnnualUtilizationLimitAsPerInternalRevenueCode', window );">Net Operating Loss Annual Utilization Limit as per Internal Revenue Code</a></td>
<td class="nump">$ 918,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_OperatingLossCarryForwardsExpirationTerm', window );">Operating Loss Carry forwards Expiration Term</a></td>
<td class="text">2034 to 2037<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration', window );">Deferred Tax Assets, Operating Loss Carryforwards, Not Subject to Expiration</a></td>
<td class="nump">$ 49,200,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration', window );">Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration</a></td>
<td class="nump">10,800,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued', window );">Tax related interest or penalties were incurred</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_NY', window );">New York City</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating Loss Carryforwards</a></td>
<td class="nump">$ 5,500,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_NetOperatingLossAnnualUtilizationLimitAsPerInternalRevenueCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This represents Annual utilization limit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_NetOperatingLossAnnualUtilizationLimitAsPerInternalRevenueCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_NetOperatingLossLimitForUtilizationAsPerInternalRevenueCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This represents amount of net operating loss limit of usage determined by the Internal revenue code.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_NetOperatingLossLimitForUtilizationAsPerInternalRevenueCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_OperatingLossCarryForwardsExpirationTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The expiry term of carryforward operating losses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_OperatingLossCarryForwardsExpirationTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are not subject to expiration dates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are subject to expiration dates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_NY">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_NY</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140151715887400">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Future Minimum Payments under Operating Lease Agreement (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent', window );">2021</a></td>
<td class="nump">$ 378,486<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears', window );">2022</a></td>
<td class="nump">389,212<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears', window );">2023</a></td>
<td class="nump">285,700<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue', window );">Minimum Lease Payments</a></td>
<td class="nump">$ 1,053,398<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121573735&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121580752&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121573735&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121580752&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121580752&amp;loc=d3e38371-112697<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121573735&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121573735&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121580752&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140151639004696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 01, 2020 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Oct. 09, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 10, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 17, 2020 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Aug. 08, 2018 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetRentableArea', window );">Net Rentable Area | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000<span></span>
</td>
<td class="nump">3,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_LeaseMonthlyBaseRent', window );">Lease, Monthly Base Rent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseExpirationDate1', window );">Lease Expiration Date</a></td>
<td class="text">Aug. 31,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Sep. 30,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SecurityDeposit', window );">Security Deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,500<span></span>
</td>
<td class="nump">$ 119,000<span></span>
</td>
<td class="nump">$ 119,035<span></span>
</td>
<td class="nump">$ 117,800<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Severance Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">419,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalUnemploymentBenefitsSalaryContinuation', window );">Supplemental Unemployment Benefits, Salary Continuation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,677,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=eyen_AdditionalOfficeSpaceMember', window );">Additional Office Space</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetRentableArea', window );">Net Rentable Area | ft&#178;</a></td>
<td class="nump">1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseExpirationDate1', window );">Lease Expiration Date</a></td>
<td class="text">Aug. 31,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SecurityDeposit', window );">Security Deposit</a></td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=eyen_ArcticVisionLicenseAgreementMember', window );">Arctic Vision License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_LicenseAgreementsUpfrontPaymentsReceived', window );">Upfront payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_LicenseAgreementsMaximumAdditionalPaymentsReceivable', window );">Maximum additional payments receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 41,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized', window );">Recognizing milestone revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_RoyaltyRevenuePayments', window );">Royalty payments earned</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=eyen_BauschLicenseAgreementMember', window );">Bausch License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_LicenseAgreementsUpfrontPaymentsReceived', window );">Upfront payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_LicenseAgreementsMaximumAdditionalPaymentsReceivable', window );">Maximum additional payments receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_LicenseAgreementsTerminationWrittenNoticePeriod', window );">Written notice period for termination of agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_LicenseAgreementsTerminationPeriodUponUncuredMaterialBreach', window );">Termination period upon uncured material breach</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">60 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_RoyaltyRevenuePayments', window );">Royalty payments earned</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_MilestoneRevenuePayments', window );">Milestone payments earned</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_LeaseMonthlyBaseRent', window );">Lease, Monthly Base Rent</a></td>
<td class="nump">7,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,633<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Additional Office Space</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_LeaseMonthlyBaseRent', window );">Lease, Monthly Base Rent</a></td>
<td class="nump">3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_LeaseMonthlyBaseRent', window );">Lease, Monthly Base Rent</a></td>
<td class="nump">7,957<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,486<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Additional Office Space</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_LeaseMonthlyBaseRent', window );">Lease, Monthly Base Rent</a></td>
<td class="nump">$ 3,183<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_LeaseMonthlyBaseRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The base rent per month for lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_LeaseMonthlyBaseRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_LicenseAgreementsMaximumAdditionalPaymentsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum amount of additional payments receivable by the company pursuant to a license agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_LicenseAgreementsMaximumAdditionalPaymentsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_LicenseAgreementsTerminationPeriodUponUncuredMaterialBreach">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period after which the license agreement can be terminated by either of the party in the event of uncured material breach, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_LicenseAgreementsTerminationPeriodUponUncuredMaterialBreach</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_LicenseAgreementsTerminationWrittenNoticePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period for providing written notice for termination of license agreement by the counterparty, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_LicenseAgreementsTerminationWrittenNoticePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_LicenseAgreementsUpfrontPaymentsReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of upfront payments received by the entity, pursuant to a license agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_LicenseAgreementsUpfrontPaymentsReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_MilestoneRevenuePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of milestone revenue payment earned during period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_MilestoneRevenuePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_RoyaltyRevenuePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of royalty revenue payment earned during period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_RoyaltyRevenuePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized arising from contract liability from change in timeframe for performance obligation to be satisfied.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130551-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseExpirationDate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date which lease or group of leases is set to expire, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseExpirationDate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetRentableArea">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net rentable area for properties owned.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetRentableArea</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecurityDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8,17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecurityDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeveranceCosts1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SeveranceCosts1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalUnemploymentBenefitsSalaryContinuation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Liability for agreement to continue an employee's salary after termination of employment (but before retirement) including death, disability, or other event. For example, a company may agree to continue a disabled employee's salary for six months.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalUnemploymentBenefitsSalaryContinuation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=eyen_AdditionalOfficeSpaceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=eyen_AdditionalOfficeSpaceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=eyen_ArcticVisionLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=eyen_ArcticVisionLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=eyen_BauschLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=eyen_BauschLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140151637179976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jul. 17, 2020 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Mar. 24, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 15, 2019 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 06, 2019 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 06, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 15, 2016 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th">
<div>Sep. 15, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 08, 2018 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetRentableArea', window );">Net Rentable Area | ft&#178;</a></td>
<td class="nump">3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,800<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_LeaseMonthlyBaseRent', window );">Lease, Monthly Base Rent</a></td>
<td class="nump">$ 7,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SecurityDeposit', window );">Security Deposit</a></td>
<td class="nump">$ 7,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 119,035<span></span>
</td>
<td class="nump">$ 117,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 119,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from Contract with Customer, Excluding Assessed Tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Aggregate number of shares issued including over-allotment option (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,675,293<span></span>
</td>
<td class="nump">5,046,763<span></span>
</td>
<td class="nump">236,466<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_GrossProceedsOfStockValueIssuedDuringPeriod', window );">Gross Proceeds Of Stock Value Issued During Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_NetProceedsFromIssuanceOfCommonStock', window );">Net Proceeds From Issuance Of Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,300,000<span></span>
</td>
<td class="nump">$ 13,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Aggregate number of shares issued including over-allotment option (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,000,000<span></span>
</td>
<td class="nump">4,388,490<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares Issued, Price Per Share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.21425<span></span>
</td>
<td class="nump">$ 2.78<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_GrossProceedsOfStockValueIssuedDuringPeriod', window );">Gross Proceeds Of Stock Value Issued During Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.42625<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=eyen_ClassWarrantsMember', window );">Class A Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Aggregate number of shares issued including over-allotment option (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,337,659<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares Issued, Price Per Share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.058<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=eyen_ClassWarrantsMember', window );">Class A Warrants [Member] | IPO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares Issued, Price Per Share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=eyen_ClassBWarrantsMember', window );">Class B Warrants [Member ]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Aggregate number of shares issued including over-allotment option (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,006,495<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares Issued, Price Per Share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.4696<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.724<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=eyen_ClassBWarrantsMember', window );">Class B Warrants [Member ] | IPO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares Issued, Price Per Share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_OwnershipAxis=eyen_LicenseAgreementMember', window );">License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners', window );">Minority Interest Ownership Percentage In Company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=eyen_VicePresidentOfResearchAndDevelopmentMember', window );">Vice President of Research and Development [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetRentableArea', window );">Net Rentable Area | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">953<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_LeaseMonthlyBaseRent', window );">Lease, Monthly Base Rent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,895<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseAndRentalExpense', window );">Operating Leases, Rent Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59,724<span></span>
</td>
<td class="nump">48,144<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SecurityDeposit', window );">Security Deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,895<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,404<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OfficersCompensation', window );">Officers' Compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">239,460<span></span>
</td>
<td class="nump">186,160<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseholdImprovementsGross', window );">Leasehold Improvements, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">82,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=eyen_SenjuPharmaceuticalCoMember', window );">Senju Pharmaceutical Co [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_RoyaltyPercentage', window );">Royalty Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=eyen_SenjuPharmaceuticalCoMember', window );">Senju Pharmaceutical Co [Member] | Arctic Vision License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_PaymentsForLicenseCosts', window );">License costs paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense [Member] | Vice President of Research and Development [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_CostOfServicesEngineeringServices', window );">Cost Of Services Engineering Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,024,430<span></span>
</td>
<td class="nump">851,746<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent', window );">Due to Related Parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">89,052<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=eyen_CuraPartnersMember', window );">Cura Partners [Member] | Consulting Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_ConsultingAgreementPaymentPermonth', window );">Consulting agreement payment, Per month</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,567<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_ConsultingAgreementPaymentPerhour', window );">Consulting agreement payment, Per hour</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=eyen_CuraPartnersMember', window );">Cura Partners [Member] | General and Administrative Expense [Member] | Consulting Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty', window );">Related Party Transaction, Expenses from Transactions with Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 76,536<span></span>
</td>
<td class="nump">$ 213,521<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_ConsultingAgreementPaymentPerhour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>It represents hourly consulting fee expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_ConsultingAgreementPaymentPerhour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_ConsultingAgreementPaymentPermonth">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>It represents monthly consulting fee expenses</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_ConsultingAgreementPaymentPermonth</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_CostOfServicesEngineeringServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represent the cost of services engineering services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_CostOfServicesEngineeringServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_GrossProceedsOfStockValueIssuedDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_GrossProceedsOfStockValueIssuedDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_LeaseMonthlyBaseRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The base rent per month for lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_LeaseMonthlyBaseRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_NetProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_NetProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_PaymentsForLicenseCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of payments made for license costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_PaymentsForLicenseCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_RoyaltyPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>It represents the percentage rate of royalty.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_RoyaltyPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of obligations due all related parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(3),(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseAndRentalExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseAndRentalExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseholdImprovementsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation of additions or improvements to assets held under a lease arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6812-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseholdImprovementsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetRentableArea">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net rentable area for properties owned.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetRentableArea</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OfficersCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for salary and wage arising from service rendered by officer. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OfficersCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecurityDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8,17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecurityDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=eyen_ClassWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=eyen_ClassWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=eyen_ClassBWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=eyen_ClassBWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=eyen_LicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=eyen_LicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=eyen_VicePresidentOfResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=eyen_VicePresidentOfResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=eyen_SenjuPharmaceuticalCoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=eyen_SenjuPharmaceuticalCoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=eyen_ArcticVisionLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=eyen_ArcticVisionLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=eyen_CuraPartnersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=eyen_CuraPartnersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=eyen_ConsultingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=eyen_ConsultingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140151709766008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Warrants Activity (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_ClassOfWarrantOrRightGranted', window );">Granted | shares</a></td>
<td class="nump">3,344,154<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_ClassOfWarrantOrRightExercised', window );">Exercised | shares</a></td>
<td class="num">(1,332,841)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Outstanding at ending balance | shares</a></td>
<td class="nump">2,011,313<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_ClassOfWarrantOrRightExercisable', window );">Exercisable Number of warrants | shares</a></td>
<td class="nump">2,011,313<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_ClassOfWarrantOrRightGrantedWeightedAverageExercisePrice', window );">Granted | $ / shares</a></td>
<td class="nump">$ 2.33<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_ClassOfWarrantOrRightExercisedWeightedAverageExercisePrice', window );">Exercised | $ / shares</a></td>
<td class="nump">2.19<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice', window );">Outstanding at ending balance | $ / shares</a></td>
<td class="nump">2.43<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice', window );">Exercisable | $ / shares</a></td>
<td class="nump">$ 2.43<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_ClassOfWarrantOrRightOutstandingWeightedAverageRemainingLife', window );">Weighted Average Remaining Life, Outstanding</a></td>
<td class="text">3 years 9 months 18 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_ClassOfWarrantOrRightExercisableWeightedAverageRemainingLife', window );">Weighted Average Remaining Life, Exercisable</a></td>
<td class="text">3 years 9 months 18 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_ClassOfWarrantOrRightOutstandingAggregateIntrinsicValue', window );">Aggregate Intrinsic Value, Outstanding | $</a></td>
<td class="nump">$ 7,215,147<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_ClassOfWarrantOrRightExercisableAggregateIntrinsicValue', window );">Aggregate Intrinsic Value, Exercisable | $</a></td>
<td class="nump">$ 7,215,147<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_ClassOfWarrantOrRightExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_ClassOfWarrantOrRightExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_ClassOfWarrantOrRightExercisableAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate intrinsic value of warrants or rights exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_ClassOfWarrantOrRightExercisableAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average exercise price of warrants or rights exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_ClassOfWarrantOrRightExercisableWeightedAverageRemainingLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining life of warrants or rights exercisable, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_ClassOfWarrantOrRightExercisableWeightedAverageRemainingLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_ClassOfWarrantOrRightExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights exercised during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_ClassOfWarrantOrRightExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_ClassOfWarrantOrRightExercisedWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average exercise price of warrants or rights exercised during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_ClassOfWarrantOrRightExercisedWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_ClassOfWarrantOrRightGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_ClassOfWarrantOrRightGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_ClassOfWarrantOrRightGrantedWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average exercise price of warrants or rights granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_ClassOfWarrantOrRightGrantedWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_ClassOfWarrantOrRightOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate intrinsic value of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_ClassOfWarrantOrRightOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average exercise price of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_ClassOfWarrantOrRightOutstandingWeightedAverageRemainingLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining life of warrants or rights outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_ClassOfWarrantOrRightOutstandingWeightedAverageRemainingLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140151638283864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Additional information related to Warrants (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Outstanding Number of Warrants</a></td>
<td class="nump">2,011,313<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_ClassOfWarrantOrRightExercisableWeightedAverageRemainingLife', window );">Weighted Average Remaining Life, Exercisable</a></td>
<td class="text">3 years 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_ClassOfWarrantOrRightExercisable', window );">Exercisable Number of Warrants</a></td>
<td class="nump">2,011,313<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_ClassOfWarrantOrRightExercised', window );">Number of warrants exercised</a></td>
<td class="num">(1,332,841)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from exercise of warrants</a></td>
<td class="nump">$ 2,820,362<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=eyen_WarrantsAtExercisePriceOneMember', window );">Warrants at exercise price of $2.0580</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price of Warrants Outstanding</a></td>
<td class="nump">$ 2.0580<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Outstanding Number of Warrants</a></td>
<td class="nump">48,549<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_ClassOfWarrantOrRightExercisableWeightedAverageRemainingLife', window );">Weighted Average Remaining Life, Exercisable</a></td>
<td class="text">2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_ClassOfWarrantOrRightExercisable', window );">Exercisable Number of Warrants</a></td>
<td class="nump">48,549<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=eyen_WarrantsAtExercisePriceTwoMember', window );">Warrants at exercise price of $2.2700</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price of Warrants Outstanding</a></td>
<td class="nump">$ 2.2700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Outstanding Number of Warrants</a></td>
<td class="nump">144,256<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_ClassOfWarrantOrRightExercisableWeightedAverageRemainingLife', window );">Weighted Average Remaining Life, Exercisable</a></td>
<td class="text">2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_ClassOfWarrantOrRightExercisable', window );">Exercisable Number of Warrants</a></td>
<td class="nump">144,256<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=eyen_WarrantsAtExercisePriceThreeMember', window );">Warrants at exercise price of $2.4696</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price of Warrants Outstanding</a></td>
<td class="nump">$ 2.4696<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Outstanding Number of Warrants</a></td>
<td class="nump">1,602,128<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_ClassOfWarrantOrRightExercisableWeightedAverageRemainingLife', window );">Weighted Average Remaining Life, Exercisable</a></td>
<td class="text">4 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_ClassOfWarrantOrRightExercisable', window );">Exercisable Number of Warrants</a></td>
<td class="nump">1,602,128<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=eyen_WarrantsAtExercisePriceFourMember', window );">Warrants at exercise price of $2.7240</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price of Warrants Outstanding</a></td>
<td class="nump">$ 2.7240<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Outstanding Number of Warrants</a></td>
<td class="nump">216,380<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_ClassOfWarrantOrRightExercisableWeightedAverageRemainingLife', window );">Weighted Average Remaining Life, Exercisable</a></td>
<td class="text">4 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_ClassOfWarrantOrRightExercisable', window );">Exercisable Number of Warrants</a></td>
<td class="nump">216,380<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_ClassOfWarrantOrRightExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_ClassOfWarrantOrRightExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_ClassOfWarrantOrRightExercisableWeightedAverageRemainingLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining life of warrants or rights exercisable, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_ClassOfWarrantOrRightExercisableWeightedAverageRemainingLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_ClassOfWarrantOrRightExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights exercised during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_ClassOfWarrantOrRightExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=eyen_WarrantsAtExercisePriceOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=eyen_WarrantsAtExercisePriceOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=eyen_WarrantsAtExercisePriceTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=eyen_WarrantsAtExercisePriceTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=eyen_WarrantsAtExercisePriceThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=eyen_WarrantsAtExercisePriceThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=eyen_WarrantsAtExercisePriceFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=eyen_WarrantsAtExercisePriceFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140151709845512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Black Scholes option (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividends</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (years)</a></td>
<td class="text">5 years 10 months 6 days<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate</a></td>
<td class="nump">0.26%<span></span>
</td>
<td class="nump">1.42%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">96.00%<span></span>
</td>
<td class="nump">134.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (years)</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate</a></td>
<td class="nump">1.32%<span></span>
</td>
<td class="nump">2.53%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">99.00%<span></span>
</td>
<td class="nump">139.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140151638413752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Summary of option activity (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 14, 2019</div></th>
<th class="th"><div>Feb. 06, 2019</div></th>
<th class="th"><div>Feb. 06, 2019</div></th>
<th class="th"><div>Jan. 02, 2019</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of Options Exercised | Shares</a></td>
<td class="num">(34,815)<span></span>
</td>
<td class="num">(320,001)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(36,391)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Granted | $ / Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.01<span></span>
</td>
<td class="nump">$ 3.10<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercised</a></td>
<td class="nump">$ 1.95<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.24<span></span>
</td>
<td class="nump">$ 1.24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember', window );">Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options Outstanding | Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,237,438<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of Options Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,249,839<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of Options Exercised | Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(180,000)<span></span>
</td>
<td class="num">(36,391)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of Options Forfeited | Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(23,181)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options Outstanding | Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,427,705<span></span>
</td>
<td class="nump">2,237,438<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of Options Exercisable | Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,768,292<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Outstanding | $ / Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Granted | $ / Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Forfeited | $ / Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.59<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Outstanding | $ / Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.37<span></span>
</td>
<td class="nump">$ 3.51<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercisable | $ / Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Life In Years, Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">8 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Life In Years, Exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Outstanding | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,843,341<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Intrinsic Value, Exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,013,118<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140151638831688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Summary of information related to stock options (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2020 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options Outstanding, Outstanding Number of Options</a></td>
<td class="nump">3,427,705<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Options Exercisable, Weighted Average Remaining Life In Years</a></td>
<td class="text">6 years 9 months 18 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options Exercisable, Exercisable Number of Options</a></td>
<td class="nump">1,768,292<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=eyen_ExercisePriceOneMember', window );">Exercise Price 1.24 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Options Outstanding, Outstanding Exercise Price | $ / shares</a></td>
<td class="nump">$ 1.24<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options Outstanding, Outstanding Number of Options</a></td>
<td class="nump">260,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Options Exercisable, Weighted Average Remaining Life In Years</a></td>
<td class="text">4 years 2 months 12 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options Exercisable, Exercisable Number of Options</a></td>
<td class="nump">260,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=eyen_ExercisePriceTwoMember', window );">Exercise Price 1.95 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Options Outstanding, Outstanding Exercise Price | $ / shares</a></td>
<td class="nump">$ 1.95<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options Outstanding, Outstanding Number of Options</a></td>
<td class="nump">673,544<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Options Exercisable, Weighted Average Remaining Life In Years</a></td>
<td class="text">6 years 6 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options Exercisable, Exercisable Number of Options</a></td>
<td class="nump">673,544<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=eyen_ExercisePrice2.72Member', window );">Exercise Price 2.72 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Options Outstanding, Outstanding Exercise Price | $ / shares</a></td>
<td class="nump">$ 2.72<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options Outstanding, Outstanding Number of Options</a></td>
<td class="nump">764,419<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Options Exercisable, Weighted Average Remaining Life In Years</a></td>
<td class="text">0 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options Exercisable, Exercisable Number of Options</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=eyen_ExercisePriceThreeMember', window );">Exercise Price 2.74 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Options Outstanding, Outstanding Exercise Price | $ / shares</a></td>
<td class="nump">$ 2.74<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options Outstanding, Outstanding Number of Options</a></td>
<td class="nump">6,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Options Exercisable, Weighted Average Remaining Life In Years</a></td>
<td class="text">8 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options Exercisable, Exercisable Number of Options</a></td>
<td class="nump">3,833<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=eyen_ExercisePrice2.89Member', window );">Exercise Price 2.89 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Options Outstanding, Outstanding Exercise Price | $ / shares</a></td>
<td class="nump">$ 2.89<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options Outstanding, Outstanding Number of Options</a></td>
<td class="nump">263,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Options Exercisable, Weighted Average Remaining Life In Years</a></td>
<td class="text">0 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options Exercisable, Exercisable Number of Options</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=eyen_ExercisePriceFourMember', window );">Exercise Price 3.11 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Options Outstanding, Outstanding Exercise Price | $ / shares</a></td>
<td class="nump">$ 3.11<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options Outstanding, Outstanding Number of Options</a></td>
<td class="nump">659,849<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Options Exercisable, Weighted Average Remaining Life In Years</a></td>
<td class="text">8 years 7 months 6 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options Exercisable, Exercisable Number of Options</a></td>
<td class="nump">318,432<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=eyen_ExercisePrice3.43Member', window );">Exercise price 3.43 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Options Outstanding, Outstanding Exercise Price | $ / shares</a></td>
<td class="nump">$ 3.43<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options Outstanding, Outstanding Number of Options</a></td>
<td class="nump">58,920<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Options Exercisable, Weighted Average Remaining Life In Years</a></td>
<td class="text">0 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options Exercisable, Exercisable Number of Options</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=eyen_ExercisePrice3.48Member', window );">Exercise price 3.48 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Options Outstanding, Outstanding Exercise Price | $ / shares</a></td>
<td class="nump">$ 3.48<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options Outstanding, Outstanding Number of Options</a></td>
<td class="nump">45,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Options Exercisable, Weighted Average Remaining Life In Years</a></td>
<td class="text">0 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options Exercisable, Exercisable Number of Options</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=eyen_ExercisePrice3.71Member', window );">Exercise price 3.71 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Options Outstanding, Outstanding Exercise Price | $ / shares</a></td>
<td class="nump">$ 3.71<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options Outstanding, Outstanding Number of Options</a></td>
<td class="nump">43,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Options Exercisable, Weighted Average Remaining Life In Years</a></td>
<td class="text">0 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options Exercisable, Exercisable Number of Options</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=eyen_ExercisePriceFiveMember', window );">Exercise Price 4.00 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Options Outstanding, Outstanding Exercise Price | $ / shares</a></td>
<td class="nump">$ 4.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options Outstanding, Outstanding Number of Options</a></td>
<td class="nump">2,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Options Exercisable, Weighted Average Remaining Life In Years</a></td>
<td class="text">7 years 10 months 24 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options Exercisable, Exercisable Number of Options</a></td>
<td class="nump">1,390<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=eyen_ExercisePrice4.68Member', window );">Exercise price 4.68 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Options Outstanding, Outstanding Exercise Price | $ / shares</a></td>
<td class="nump">$ 4.68<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options Outstanding, Outstanding Number of Options</a></td>
<td class="nump">25,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Options Exercisable, Weighted Average Remaining Life In Years</a></td>
<td class="text">0 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options Exercisable, Exercisable Number of Options</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=eyen_ExercisePriceSixMember', window );">Exercise Price 5.10 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Options Outstanding, Outstanding Exercise Price | $ / shares</a></td>
<td class="nump">$ 5.10<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options Outstanding, Outstanding Number of Options</a></td>
<td class="nump">6,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Options Exercisable, Weighted Average Remaining Life In Years</a></td>
<td class="text">7 years 8 months 12 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options Exercisable, Exercisable Number of Options</a></td>
<td class="nump">4,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=eyen_ExercisePriceSevenMember', window );">Exercise Price 5.19 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Options Outstanding, Outstanding Exercise Price | $ / shares</a></td>
<td class="nump">$ 5.19<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options Outstanding, Outstanding Number of Options</a></td>
<td class="nump">16,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Options Exercisable, Weighted Average Remaining Life In Years</a></td>
<td class="text">7 years 8 months 12 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options Exercisable, Exercisable Number of Options</a></td>
<td class="nump">12,375<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=eyen_ExercisePriceEightMember', window );">Exercise Price 5.25 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Options Outstanding, Outstanding Exercise Price | $ / shares</a></td>
<td class="nump">$ 5.25<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options Outstanding, Outstanding Number of Options</a></td>
<td class="nump">26,668<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Options Exercisable, Weighted Average Remaining Life In Years</a></td>
<td class="text">5 years 9 months 18 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options Exercisable, Exercisable Number of Options</a></td>
<td class="nump">26,668<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=eyen_ExercisePrice5.77Member', window );">Exercise Price 5.77 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Options Outstanding, Outstanding Exercise Price | $ / shares</a></td>
<td class="nump">$ 5.77<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options Outstanding, Outstanding Number of Options</a></td>
<td class="nump">50,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Options Exercisable, Weighted Average Remaining Life In Years</a></td>
<td class="text">0 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options Exercisable, Exercisable Number of Options</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=eyen_ExercisePriceNineMemberMember', window );">Exercise Price 6.20 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Options Outstanding, Outstanding Exercise Price | $ / shares</a></td>
<td class="nump">$ 6.20<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options Outstanding, Outstanding Number of Options</a></td>
<td class="nump">300,387<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Options Exercisable, Weighted Average Remaining Life In Years</a></td>
<td class="text">7 years 7 months 6 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options Exercisable, Exercisable Number of Options</a></td>
<td class="nump">270,476<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=eyen_ExercisePriceTenMember', window );">Exercise Price 6.30 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Options Outstanding, Outstanding Exercise Price | $ / shares</a></td>
<td class="nump">$ 6.30<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options Outstanding, Outstanding Number of Options</a></td>
<td class="nump">60,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Options Exercisable, Weighted Average Remaining Life In Years</a></td>
<td class="text">7 years 6 months<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options Exercisable, Exercisable Number of Options</a></td>
<td class="nump">48,333<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=eyen_ExercisePriceElevenMember', window );">Exercise Price 8.72 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Options Outstanding, Outstanding Exercise Price | $ / shares</a></td>
<td class="nump">$ 8.72<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options Outstanding, Outstanding Number of Options</a></td>
<td class="nump">166,918<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Options Exercisable, Weighted Average Remaining Life In Years</a></td>
<td class="text">7 years 3 months 18 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options Exercisable, Exercisable Number of Options</a></td>
<td class="nump">148,741<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average exercise price as of the balance sheet date for those equity-based payment arrangements exercisable and outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=eyen_ExercisePriceOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=eyen_ExercisePriceOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=eyen_ExercisePriceTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=eyen_ExercisePriceTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=eyen_ExercisePrice2.72Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=eyen_ExercisePrice2.72Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=eyen_ExercisePriceThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=eyen_ExercisePriceThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=eyen_ExercisePrice2.89Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=eyen_ExercisePrice2.89Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=eyen_ExercisePriceFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=eyen_ExercisePriceFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=eyen_ExercisePrice3.43Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=eyen_ExercisePrice3.43Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=eyen_ExercisePrice3.48Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=eyen_ExercisePrice3.48Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=eyen_ExercisePrice3.71Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=eyen_ExercisePrice3.71Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=eyen_ExercisePriceFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=eyen_ExercisePriceFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=eyen_ExercisePrice4.68Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=eyen_ExercisePrice4.68Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=eyen_ExercisePriceSixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=eyen_ExercisePriceSixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=eyen_ExercisePriceSevenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=eyen_ExercisePriceSevenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=eyen_ExercisePriceEightMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=eyen_ExercisePriceEightMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=eyen_ExercisePrice5.77Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=eyen_ExercisePrice5.77Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=eyen_ExercisePriceNineMemberMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=eyen_ExercisePriceNineMemberMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=eyen_ExercisePriceTenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=eyen_ExercisePriceTenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=eyen_ExercisePriceElevenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=eyen_ExercisePriceElevenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140151631194712">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 23, 2020</div></th>
<th class="th"><div>Sep. 11, 2020</div></th>
<th class="th"><div>Sep. 08, 2020</div></th>
<th class="th"><div>Aug. 21, 2020</div></th>
<th class="th"><div>Aug. 19, 2020</div></th>
<th class="th"><div>Jul. 28, 2020</div></th>
<th class="th"><div>Jun. 03, 2020</div></th>
<th class="th"><div>May 28, 2020</div></th>
<th class="th"><div>Apr. 07, 2020</div></th>
<th class="th"><div>Mar. 24, 2020</div></th>
<th class="th"><div>Jan. 31, 2020</div></th>
<th class="th"><div>Aug. 16, 2019</div></th>
<th class="th"><div>Jul. 15, 2019</div></th>
<th class="th"><div>May 14, 2019</div></th>
<th class="th"><div>Feb. 06, 2019</div></th>
<th class="th"><div>Feb. 06, 2019</div></th>
<th class="th"><div>Jan. 14, 2019</div></th>
<th class="th"><div>Jan. 02, 2019</div></th>
<th class="th"><div>Feb. 13, 2019</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90,000,000<span></span>
</td>
<td class="nump">90,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, Par or Stated Value Per Share</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred Stock, Shares Authorized</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,000,000<span></span>
</td>
<td class="nump">6,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred Stock, Par or Stated Value Per Share</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Aggregate number of shares issued including over-allotment option (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,675,293<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,046,763<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">236,466<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_GrossProceedsOfStockValueIssuedDuringPeriod', window );">Gross Proceeds Of Stock Value Issued During Period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_NetProceedsFromIssuanceOfCommonStock', window );">Net Proceeds From Issuance Of Common Stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from Issuance of Common Stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,734,002<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based Compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,483,172<span></span>
</td>
<td class="nump">2,511,944<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized stock - based compensation expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,720,221<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average period of recognition</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from Stock Options Exercised</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 67,889<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 483,888<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 82,161<span></span>
</td>
<td class="nump">$ 551,777<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.01<span></span>
</td>
<td class="nump">$ 3.10<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost', window );">Share-based Compensation Arrangement by Share-based Payment Award Accelerated Compensation Cost</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 609,322<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.95<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from exercise of stock warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,820,362<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_RemittanceOfEmployeeSPayrollTaxes', window );">Remittance of employee's Payroll Taxes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 62,193<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants for purchase of common stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,332,841<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber', window );">Share-based Compensation Arrangement by Share-based Payment Award, Accelerated Vesting, Number</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">124,210<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,815<span></span>
</td>
<td class="nump">320,001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,391<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based Compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,350,894<span></span>
</td>
<td class="nump">1,459,055<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expense [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based Compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,132,278<span></span>
</td>
<td class="nump">$ 1,052,889<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of awards granted</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,728<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,190<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=eyen_ClassWarrantsMember', window );">Class A Warrants [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Aggregate number of shares issued including over-allotment option (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,337,659<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares Issued, Price Per Share</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.058<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=eyen_ClassBWarrantsMember', window );">Class B Warrants [Member ]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Aggregate number of shares issued including over-allotment option (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,006,495<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares Issued, Price Per Share</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.4696<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.724<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.95<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">133,686<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,391<span></span>
</td>
<td class="nump">348,501<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_NumberOfCommonShares', window );">Number of common shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Aggregate number of shares issued including over-allotment option (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,388,490<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares Issued, Price Per Share</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.21425<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.78<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_GrossProceedsOfStockValueIssuedDuringPeriod', window );">Gross Proceeds Of Stock Value Issued During Period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.42625<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO [Member] | Class A Warrants [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares Issued, Price Per Share</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_ClassOfWarrantOrRightNumberOfYearsSecuritiesCalledByWarrantsToPurchaseCommonStock', window );">Warrant to purchase common stock in period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO [Member] | Class B Warrants [Member ]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares Issued, Price Per Share</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_ClassOfWarrantOrRightNumberOfYearsSecuritiesCalledByWarrantsToPurchaseCommonStock', window );">Warrant to purchase common stock in period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=eyen_UnderwrittenPublicOfferingMember', window );">Underwritten Public Offering</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Aggregate number of shares issued including over-allotment option (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,833,334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_NumberOfSharesAgreedToBeIssued', window );">Number of shares agreed to be issued (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,333,334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Price per share (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from Issuance of Common Stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payments of Stock Issuance Costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Over Allotment Option</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Aggregate number of shares issued including over-allotment option (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">658,273<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_NumberOfSharesAgreedToBeIssued', window );">Number of shares agreed to be issued (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_OverAllotmentOptionPeriod', window );">Over-allotment option period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember', window );">Share-based Compensation Award, Tranche One [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0.33%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.33%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.33%<span></span>
</td>
<td class="nump">0.33%<span></span>
</td>
<td class="nump">0.33%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.33%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">636,287<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember', window );">Share-based Compensation Award, Tranche Two [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">24 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">24 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">24 months<span></span>
</td>
<td class="text">24 months<span></span>
</td>
<td class="text">24 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">24 months<span></span>
</td>
<td class="text">24 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">24 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,285<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares Issued, Price Per Share</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.95<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares Issued, Price Per Share</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=eyen_EmployeesConsultantsAndDirectorsUnder2018PlanMember', window );">Employees Consultants and Directors Under the 2018 Plan [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Aggregate number of shares issued including over-allotment option (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">50,000<span></span>
</td>
<td class="nump">58,920<span></span>
</td>
<td class="nump">45,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,000<span></span>
</td>
<td class="nump">764,419<span></span>
</td>
<td class="nump">263,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 5.77<span></span>
</td>
<td class="nump">$ 3.43<span></span>
</td>
<td class="nump">$ 3.48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.71<span></span>
</td>
<td class="nump">$ 2.72<span></span>
</td>
<td class="nump">$ 2.89<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.68<span></span>
</td>
<td class="nump">$ 3.11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.74<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Share based Compensation Arrangement by Share based Payment Award Options Grants in Period Grant Date Fair Value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 218,700<span></span>
</td>
<td class="nump">$ 155,400<span></span>
</td>
<td class="nump">$ 126,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 122,400<span></span>
</td>
<td class="nump">$ 1,603,600<span></span>
</td>
<td class="nump">$ 587,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 103,400<span></span>
</td>
<td class="nump">$ 1,909,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">681,572<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=eyen_OmnibusStockIncentivePlan2018Member', window );">Omnibus Stock Incentive Plan 2018 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for issuance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,950,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">518,186<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_ShareBasedCompensationArrangementByShareBasedPaymentAwardCashFeePaid', window );">Cash fee paid</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=eyen_WarrantsAtExercisePriceOneMember', window );">Warrants at exercise price of $2.0580</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.0580<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=eyen_WarrantsAtExercisePriceThreeMember', window );">Warrants at exercise price of $2.4696</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.4696<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="22"></td></tr>
<tr><td colspan="22"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Includes gross proceeds of $13,800,002, less issuance costs of $1,066,000 deducted directly from the offering proceeds.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_ClassOfWarrantOrRightNumberOfYearsSecuritiesCalledByWarrantsToPurchaseCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Information about number of years warrant to purchase share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_ClassOfWarrantOrRightNumberOfYearsSecuritiesCalledByWarrantsToPurchaseCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_GrossProceedsOfStockValueIssuedDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_GrossProceedsOfStockValueIssuedDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_NetProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_NetProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_NumberOfCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Information about number of share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_NumberOfCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_NumberOfSharesAgreedToBeIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares agreed to be issued by the company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_NumberOfSharesAgreedToBeIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_OverAllotmentOptionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period during which the underwriters can exercise their overallotment option, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_OverAllotmentOptionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_RemittanceOfEmployeeSPayrollTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This represents company remitted portion of employee's payroll taxes to internal revenue service.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_RemittanceOfEmployeeSPayrollTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_ShareBasedCompensationArrangementByShareBasedPaymentAwardCashFeePaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash fees paid subject to certain exceptions for a non-executive chair of the Board.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_ShareBasedCompensationArrangementByShareBasedPaymentAwardCashFeePaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of additional cost recognized for award under share-based payment arrangement from occurrence of event accelerating recognition of cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares for which recognition of cost was accelerated for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=eyen_ClassWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=eyen_ClassWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=eyen_ClassBWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=eyen_ClassBWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=eyen_UnderwrittenPublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=eyen_UnderwrittenPublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=eyen_EmployeesConsultantsAndDirectorsUnder2018PlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=eyen_EmployeesConsultantsAndDirectorsUnder2018PlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=eyen_OmnibusStockIncentivePlan2018Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=eyen_OmnibusStockIncentivePlan2018Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=eyen_WarrantsAtExercisePriceOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=eyen_WarrantsAtExercisePriceOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=eyen_WarrantsAtExercisePriceThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=eyen_WarrantsAtExercisePriceThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140151714004120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plans (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Employee Benefit Plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch', window );">Defined Contribution Plan, Employer Matching Contribution, Percent of Match</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage', window );">Defined Contribution Plan, Employers Matching Contribution, Annual Vesting Percentage</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount', window );">Defined Contribution Plan, Maximum Annual Contributions Per Employee, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 138,785<span></span>
</td>
<td class="nump">$ 71,285<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage employer matches of the employee's percentage contribution matched.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of employer's matching contributions to a defined contribution plan that vests in a given year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum amount the employee may contribute to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140151709205160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 26, 2021</div></th>
<th class="th"><div>Aug. 16, 2019</div></th>
<th class="th"><div>May 14, 2019</div></th>
<th class="th"><div>Feb. 06, 2019</div></th>
<th class="th"><div>Jan. 14, 2019</div></th>
<th class="th"><div>Jan. 02, 2019</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from Stock Options Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 67,889<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 483,888<span></span>
</td>
<td class="nump">$ 82,161<span></span>
</td>
<td class="nump">$ 551,777<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants for purchase of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,332,841<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from exercise of stock warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,820,362<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercise price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.95<span></span>
</td>
<td class="nump">$ 1.24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares Issued, Price Per Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares Issued, Price Per Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.95<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants for purchase of common stock</a></td>
<td class="nump">644,992<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from exercise of stock warrants</a></td>
<td class="nump">$ 1,530,989<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of Options Granted</a></td>
<td class="nump">652,899<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercise price per share</a></td>
<td class="nump">$ 6.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Total exercise price</a></td>
<td class="nump">$ 3,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Term of the options</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants</a></td>
<td class="nump">$ 2.06<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants</a></td>
<td class="nump">$ 2.47<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=eyen_EmployeesConsultantsAndDirectorsUnder2018PlanMember', window );">Employees Consultants and Directors Under the 2018 Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of Options Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">681,572<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=eyen_EmployeesConsultantsAndDirectorsUnder2018PlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=eyen_EmployeesConsultantsAndDirectorsUnder2018PlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>87
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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MPXB2D K] -S?<JY.)WJ ZA/,Y#]02P,$%     @ <(A^4LB#XQ.@!0  WA4
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M.H8[E:0L"AB+9JB1#"Q-_"P-QZY=N2NX@=7(Q49F[EZ#3)GY+$DBP'!P1N_
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M_^<[AQ/L:,O%L\P %'K-62%G3J;4YMIU99)!3N2 ;Z#0=U9<Y$3IJ5B[<B.
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MHI"?X>*^I.H)CB9$Z+T9*IJ0_!B^P.WT'(X^'?==I<482C>I X^KP,&.P'X
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MD\CW'1J-<&HL'0/&H[2/SRR7+0,:U;RU8!,N]61V'9W@Q+ZC?L8XIY8FG&3
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M;N%!S&Q^TCY$J8V?9:;0Q9,('[K!@@'R*BH7'S+T[VT\;(F.#TY0;L$25)O
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MT..]=Z;CFA?L&(QT_#LFXLY$3KS4S(N;0+*^[L?#;+ZF!LOZZ@<X))AS^?)
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MC _ _4;C(9PF7F"^9+?_ 5!+ P04    " !PB'Y2RG5H9U8"  !/!0  &0
M 'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6REE$MOVS ,Q^_^%((W[&34KS1Q
MLB1 TF[8#AV"=H^S8M.Q43T\25[2;S]*=EP72'O8+K8H\?\C*8E:'J5ZU!6
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M2J.KV;5/5->^G6%DXUIF+PTVH!M6^.*!L@ZX7DH\L=ZP 88W=/T74$L#!!0
M   ( '"(?E+)/1N#*08  (X.   9    >&PO=V]R:W-H965T<R]S:&5E=#$U
M+GAM;*57;6_;-A#^[E]!>-W0 :I?9+M)FA? 25MTP-IY3;M^IB7:XD*1*DG%
M\;_?<Z0DVZG38AL0Q!1%/G?WW'-'ZF)C[)TKA/#LH53:7?8+[ZM7PZ'+"E%R
M-S"5T'BS,K;D'H]V/725%3P/FTHU3$>CE\.22]V_N@AS"WMU86JOI!8+RUQ=
MEMQNKX4RF\O^N-].?)3KPM/$\.JBXFMQ*_SG:F'Q-.Q0<ED*[:31S(K597\^
M?G4]I?5AP5]2;-S>F%$D2V/NZ.&W_+(_(H>$$IDG!(Z?>W$CE"(@N/&UP>QW
M)FGC_KA%?QMB1RQ+[L2-45]D[HO+_FF?Y6+%:^4_FLT[T<0S([S,*!?^LTU<
M.Y[V658[;\IF,SPHI8Z__*'A86_#Z>B)#6FS(0U^1T/!R]?<\ZL+:S;,TFJ@
MT2"$&G;#.:DI*;?>XJW$/G_UP7CAV()O^5*)BZ$')+T89LWVZ[@]?6+[.&7O
MC?:%8V]T+O)#@"%\Z1Q*6X>NT^\BOA;9@$W&"4M'Z>@[>),NP$G F_S[  _P
MIAW>-.!-_RMA/][.3M@O/YVFX_$Y.T#KS1TS*P8&1+D4MF.!<9UC,#Y+F [K
MJ[B>90;%X;S(:9LO!%L9A2J3>OVJ]PW*XYGQ6>^FME9HW_M@](MV?&QN82R5
M4/?[R7BNGIKE6S2.[(XM+'R-I8?AVO*2*<-U[UGO["293<XPF+R<):?C*4;3
MEY-D,IM@%)A)SX^.HH7_ ?"'9F_%TM9H/RR=1EZ2P-R-*2NNMTPZ5X-/'ICN
MB'Y.2P@D'9U3RL)P?/XK"+=A>U7;K$!SH$1PEDN+R(UUP>[)>4B@6:UD)G9S
M2O*E5-+#IG:UY3H#C%$RVP[8)T &I6SX+MM2,PTUL9(*3FUI'MW1!\T\FTV2
MD]DH^,/1Z]9K*]:<(K!29[+BBO'2U-J'Q=.369*.7^[9X5EF:RA+:B^L<)YQ
M_#%+"-@P':1G/[,*TMD*;D,TZ(>U)>%I -Q'7;6,#MCK&F;7@9FP0U!S^%;8
MA]1;47&91SJ/>.T;7P>4Q?=\RTZ/@V0";3YG&7<%<$PF1!XI:B1"N7(U!Z@W
MB)$T2>ON);D(CE%4NM'M1OHBH']/U#5BBR*XF7]\<\OFF3_0RV*Q8+_#2*N9
MR'H[VYIV(75M:J$(*%U1>@_3C!XP&YVRI5A+K8EB.#ROUS@GB(OQSF,KZ$2F
M%4NN@K;R6E"VB+E)8"Z-S(5,D@QS9/N1<TLD[[$H5O(!1+72& ]&HR@-KG5=
MQOUM,C92*6 P7E5J2[Y0C(%P#-9(DQ;.D5-^S^B@][EC%'9+UR:_HS=AJ I>
M1E$MMS_,T%LE'F13:Y0=X!TK?":47$NJ-!(&N=R44]ZJZL#M\ [QT0\*-_1
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M"W@^,[ X7M &S8^P7OX;4$L#!!0    ( '"(?E)@A",>O@H  +(<   9
M>&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;*U9VW+;.!)]]U>@O)XINXJ6)5F2
M[=AQE>-D:V8GF779F>PS1$(2)B3! 4#+FJ_?TPV0(GW;I+(O$B] HR^G3S?
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M2V+YXQ4I$FR$25'2H,@;L:\/HF94MO='0[\Z@/02CK .&^1&VX6VC@PJ"@2
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M&LI2;/-:1WUSH ?BCQ("Z(R!GQX&GOR&5$>:DC--/^&)JZ)74DG-6*?C 23
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M"")E[[:EN.P:J6<3;-@)PD(@OOO,#,,G=,][]@2XMQ&+S9!W TQ 5C]V();
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M 5.]FD[%3A80'7M71^2/L9+*,1FOS$0!US?')2,Q7JI- \6O3EF5;4B/-/!
MOA?Z$3DADA)5%'V*O>Q+>2R/3&X-Z@H@\/847NC' W@3G\9+59M-="=R@J'N
MC.Q.&;HQD*F=]3H)P1W^IX*"#&MJ4E3\#&'-.YUR$&8 &=^.D\CVL^#@TM2>
MY/9],(;2Q(ZC[""0.6G/ ((8[\80=J(#@"3#Q_'7&-@4SW&)J#0$LF<5I$UD
M,G7F%\$=ZY#1'#F/GTP#X&USO+H7[N.TXE[('P1\*_*0EPVPQXP0G%RI"C-*
MA BWJ?.TT:DJUQO,N=Z\:"I<1\2U0"P)(89#0;=6Y2@,IKV)IO?E_62"%AH
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MLHB9F29V4/,A.0[2! #&EI^X=IC$]"@ #%R%0H0?50B(QRE*QHMC.P.M3IS
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M"J-C ]+O+8V38<,!QG=]^Q=02P,$%     @ <(A^4D6?CY R&P  $U4  !D
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M *^.WM-"A-*VP)'\V=444##_./B13HBEKW@X9.XX?1[4,N(5M/*Y!3K= Y1
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MDL,<7:07C\_3R7A"L)]AEV?GAQ0FC)Y.#H^*WG8SZ9JVR9N[?5-,WPICYYJ
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M7LM[+L/C\KI0!+H+LK*EFF/I>/3TXEAR,_>AK=?\ULM9W;;UBO]<J@PFGA[
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M#H-V#GA>*<QG;SB"<;(O_P)02P,$%     @ <(A^4JZF'#H" P  V@8  !D
M  !X;"]W;W)K<VAE971S+W-H965T,C0N>&ULI57=;YLP$'_GK[#8-&T2*L9
M$KHD4K^F[:%:U';;LP.78!4PLTV3_O<[FX1D6AM5VDMBF_M]W!T^IANI'G4)
M8,BVKAH]\TMCVO,PU'D)-==GLH4&GZRDJKG!K5J'NE7 "P>JJY!1.@IK+AI_
M/G5G"S6?RLY4HH&%(KJK:ZZ>+Z&2FYD?^?N#.[$NC3T(Y].6K^$>S(]VH7 7
M#BR%J*'10C9$P6KF7T3GEXF-=P$_!6STT9K83)92/MK-MV+F4VL(*LB-9>#X
M]P174%66"&W\WG'Z@Z0%'J_W[%]<[IC+DFNXDM4O49ARYD]\4L"*=Y6YDYNO
ML,LGM7RYK+3[)9L^-DU\DG?:R'H'1@>U:/I_OMW5X0@PH:\ V [ G.]>R+F\
MYH;/ITINB++1R&87+E6'1G.BL4VY-PJ?"L29^4)!RT5!;K;89@V:\*8@WTT)
MBEQU2D%CR(768#3Y^,"7%>A/T]"@KD6'^4[CLM=@KVA$C-S*QI2:W#0%%'\3
MA&AX<,WVKB_92<9KR,](' 6$449/\,5#%6+'%_]O%4YH)8-6XK225[3N\5X5
M705$KDB[TX5C7>ET\YTN?T&W+]%IF0MM!;!04"^1;E\LI\!HE 5O%R>YQ$NH
M#126$@/(2E9XFT6S/O>.%3RKX%EV;\&?%081P[=X=W,03_;M\=Y[41H%6<)P
ME:4!BV-O7WO1Z$[Q)H?!D!=%-*!9XL5QD+%#I (-7.6E,US $TZ6MK9V!^"'
M=Q,6L<]>- ZR\60 5B(_9*J[I<Z5:.UPT%XZ#F@:#< ]HN7F96(6)#09PK!
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MIX(E@_: G'/9O RC21']H -2*KR8QB( >3&*U$KB#1?=\3JXE F<3. D@KG
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M)(.<-LP\R.UGZ.H96UXJF79?LFU]HXE'TD8;R;M@S(!7HEWI<_<.!P'3X$1
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M9(D#%)1UP/-<XI-U&WM!/Y*7OP!02P,$%     @ <(A^4C='C=A0!   M H
M !D   !X;"]W;W)K<VAE971S+W-H965T,CDN>&ULE5;;;N,V$'WG5Q!N=^$
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M$[Q\K#P/O/Q_*C_!GX[\:>!/W^ _X/Q4G0"B:U)WKC/@SX_+3A(<*<-\,"(
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M16!=&'E[VZ0)0\#D[=+0M5[NA4F0 9E%1OUR#+?F+L@H8+0[7Q(D*/0'\LN
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MNB/[VKIN@O6"5.D;SZ,BV\;\=&._&ZA=@MW/E:+#PADT7Z+I;U!+ P04
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M)L#SE1#Z]<)\%K0?FN-_ 5!+ P04    " !PB'Y25>P^4#8#  "0"@  &0
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MR&P2U+[]V4^,;'P'L93&]B-^N+8M(R@G8/^OI#1/$]>4=$WH_!]02P,$%
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MZTCED-=CLEY(MC*39LZDFEOF-E=?%L"U@7J^8$SN%_J YEME] =02P,$%
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M970S.2YX;6R55%UOVR 4_2O(VD,K;<%?^7#E6&H33=O#I*A9MV=BW\2HV'B
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M&D]8.]S@'0C2 '!_)3!%S<0<L^VMFKX!4$L#!!0    ( '"(?E+ @-/$UP,
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M1V;1<]H.1#AC:6SN9?85-PXUK%XH8YW_0U;,;;4<"%-M9+(Q)H*$B^+)UIM
M[!@$_A&#8&,0Y-S%0CGEF!G6[RJ9@;*S2<TV<E=S:X+CPN[*Q"AZR\G.]*]$
M*!.$![9&#9]A$$7<1HO%P$6QYS9V)V,TC,?ZM.L:6M2:NN%F@6&Q0'!D 3^
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MR<Q$D%W_=A,M&M<S.Z%-![IA99X\D+; [.^%T*>);</A$<U> 5!+ P04
M" !PB'Y2YF?'/2L%   K%@  &0   'AL+W=O<FMS:&5E=',O<VAE970T-RYX
M;6RM6%UOVS84?>Y^!>$-0PMDL4C9DMTY!F(G33HT:Y$L[<.P!T:^MHE*I$91
M^1CVXW?U$<F.)-KNFH=8LGG//9<\/+S2Y$'IK\D:P)#'*)3)26]M3/RVWT^"
M-40\.58Q2/QEJ73$#=[J53^)-?!%'A2%?>8X7C_B0O:FD_R[3WHZ4:D)A81/
MFB1I%'']-(-0/9ST:._YBVNQ6IOLB_YT$O,5W("YC3]IO.M7* L1@4R$DD3#
M\J1W2M]>NGE /N*S@(=DXYIDI=PI]36[>;\XZ3D9(P@A,!D$QX][F$,89DC(
MX^\2M%?ES (WKY_1W^7%8S%W/(&Y"K^(A5F?]$8]LH E3T-SK1XNH2QHF.$%
M*DSR_^2A&.L->R1($Z.B,A@91$(6G_RQG(B- #;H"&!E 'L90#L"W#+ W3=@
M4 8,]J4T+ .&^P9X98"W+R6_#/#W#1B5 :-\=8OER-?RC!L^G6CU0'0V&M&R
MBUP0>30NH9"9=F^,QE\%QIGI7$61,"A&DQ N%V2NI!%R!3(0D)!?R.EB(3*1
M\9"\E\56R23W^@P,%V'R9M(WR"+#Z@=EQEF1D75D/(/@F#CTB#"'.;<W9^3U
M3V^6YN<?J3_ZM05M;D?[&!A$&V^AM:"<V5%.T]4QH<XNE',[RF]IB"C^OI6]
MVX.3,\K0Z&@WVL4>L^[2715>[HU"QZTH?=1?)4)6B9#EL(,.V-_1HZ]1@OPN
M!'**%DS^)992SPNT88Z6F?/]U'4<9]*_WYS=ED&CC4%;1-V*J&LE^@'0)H_(
M%6Z2=?A$9GB7$V\C62!Y&_G]85?^095_L#L_.7^,A2[V(>YY:-N"=IA<6KB,
M/[QZA7)PV[1I![B!& &<=H"MRH959<,=B$&JA7DB9Q"K1+3.Z- ^HP7QYB!*
MQPUU7+0/<X?;PR[;AOF=,O*J8KT=Q=Z#YC( M-O$)&V[V6NH=[!=QE9BOTKL
MVQ.G<1Q"YO;HY[<2HCA43]DMF8&$I3#)$;GA(38QY4&0YC)K(^@W"%+/]SL9
MCBJ&([LTZ_/FXW(I<(IN8AZ 16'C"GG\/4UF-FX6V+E_J5,?M\[WV<$[<*Q;
M>)O;1BM _^\>G)407I?W;J>N#P!J/P%.-?:P ?DL\I[X ZZ[Q&DZ76G(U6HK
MK_9N:C?OVWBI4=0DYH7D-02 ??.BM5UHNO? R?\Z*JT=G-JM\XH_BBB-"*^%
M7A)*2D:90%LY#9J<:.: G:1J\Z5V][V&0*VD^ <[/VPR0\"V4P+2N0>90JL_
ME8";VX-9)ZCV1FHWQVOUQ$,4834KP+5L7:4+VG3)KO2U0U*[1<YXB@^(ATFP
M-C=J=[<#)#@OH;;.'L<ZQ;434KL5?K,&YR7PUO8?VDBQVAF9W=&^H/48D$0J
MD]E^#%JH!<%'#F) XY-/89=J27C[DA0$=R09.V3!GQ);SUK;);/;Y1\;M$JV
M:8S7J40;A04^I2%Q@7-[AX=-L&YE:\_@[6:[T6+;'?: ;<6:K7/7ZM;FR^SF
M>U6YRCX$FN[;1:#V7;;#=X7,-?_G%41WH/^R36KMF\SNFP<\#\Q8TS%;VM>6
M473LN6Y'^;6K,KNKOBP?FY_#6RU6NRBSN^A!$]-L);M;"E9[+;-[[;/)[;/@
MM7,RNW,>5%>S@_3'0__E@C<=E;'!R.MX4*WMU+4[W<OROVG!W=H,7;M5'3(Q
M;DL/24<O)=[?>*F5O4:]XGHE9$)"6&*8<^SCQ.KBS61Q8U2<O^>Z4\:H*+]<
M U^ S@;@[TNES/--]NJL>C\\_0]02P,$%     @ <(A^4MOH,6NS!P  H2(
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M%O&>E(E59.6"2')YSMD+X%I>V=,?BM0N]%4R)KFNPD?)U;>)TI.7#S0EDJ[
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MZAT.%0.W'9,=2+8T7<J<2=7SF-M,=9G(]0+U?,&8W RT0=.W3O\ 4$L#!!0
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MUWKTA,Q[P/(ZX:-?@X_U\-]P)N&H$S[1PT<DZ@$;*CBR6N#3B^''T4U9^TH
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M'RL#^7Q)J7BZ42?PZJW1\!]02P,$%     @ <(A^4LM+=ZX'!P  +CP  !D
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M/P1) (%$!L&$O6D0* "!P@"!\@:! A"H62"02^H% @4@4+@@4,,!0.FT(PR
M H6! C5G(D !"A0R"B;LG5!@_%=(*""!PB"!&I) .%\YJ]Y"H5DS V7'\IH9
M4$ "A4L"-21!Y;0C#D "A4$"-20!5>Z[!"10R"28L/<?\D$#&C0&&O00#91Q
M[5@HHP$/>B8>F->"(0UXT+AXT&-X8*XX !\T!A_TR%!!*=>#FP9 :&1 3-B3
M\Q>2:@"$Q@"$'@+B7*B!$'HF(;3V2HC>8E+DU:1CA-#:$0<@A,8@A!Z9+'"O
M<]1 "(U,B E[TV,% T P&$ PWF,% S PLV"@ELQKK&  !@87!F8(@])I1QB
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M%2& QJC<-E).ITK2RL,JHVY8V@D3XAX>%S^R+>Y%MK%NU:K)IFD-U4U'XSK
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M_.4!  !_(0  &@   'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QSS=H[3L-
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M][G$Y!-02P$"% ,4    " !PB'Y2!T%-8H$   "Q    $
M@ $     9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( '"(?E)5LGB)[0
M "L"   1              "  :\   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4
M Q0    ( '"(?E*97)PC$ 8  )PG   3              "  <L!  !X;"]T
M:&5M92]T:&5M93$N>&UL4$L! A0#%     @ <(A^4DP[+R]Z!   CA$  !@
M             ("!# @  'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4
M Q0    ( '"(?E+(@^,3H 4  -X5   8              " @;P,  !X;"]W
M;W)K<VAE971S+W-H965T,BYX;6Q02P$"% ,4    " !PB'Y2=)9\GZ4"  !(
M"0  &               @(&2$@  >&PO=V]R:W-H965T<R]S:&5E=#,N>&UL
M4$L! A0#%     @ <(A^4JP)]"X9!   L@T  !@              ("!;14
M 'AL+W=O<FMS:&5E=',O<VAE970T+GAM;%!+ 0(4 Q0    ( '"(?E(DP"[?
M/@8  .4<   8              " @;P9  !X;"]W;W)K<VAE971S+W-H965T
M-2YX;6Q02P$"% ,4    " !PB'Y2#3=-_.T"   2"0  &
M@($P(   >&PO=V]R:W-H965T<R]S:&5E=#8N>&UL4$L! A0#%     @ <(A^
M4J<%X_/J!P  5"$  !@              ("!4R,  'AL+W=O<FMS:&5E=',O
M<VAE970W+GAM;%!+ 0(4 Q0    ( '"(?E**#[*/QP(  (0(   8
M      " @7,K  !X;"]W;W)K<VAE971S+W-H965T."YX;6Q02P$"% ,4
M" !PB'Y2OSJK;<0%   -#0  &               @(%P+@  >&PO=V]R:W-H
M965T<R]S:&5E=#DN>&UL4$L! A0#%     @ <(A^4EK5H@% &@  @$T  !D
M             ("!:C0  'AL+W=O<FMS:&5E=',O<VAE970Q,"YX;6Q02P$"
M% ,4    " !PB'Y2<D24^?T"  #^!@  &0              @('A3@  >&PO
M=V]R:W-H965T<R]S:&5E=#$Q+GAM;%!+ 0(4 Q0    ( '"(?E+&/(7K) ,
M "<'   9              " @152  !X;"]W;W)K<VAE971S+W-H965T,3(N
M>&UL4$L! A0#%     @ <(A^4L\MN0PN P  < <  !D              ("!
M<%4  'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6Q02P$"% ,4    " !PB'Y2
MRG5H9U8"  !/!0  &0              @('56   >&PO=V]R:W-H965T<R]S
M:&5E=#$T+GAM;%!+ 0(4 Q0    ( '"(?E+)/1N#*08  (X.   9
M      " @6);  !X;"]W;W)K<VAE971S+W-H965T,34N>&UL4$L! A0#%
M  @ <(A^4D;*3NG0!P  SA(  !D              ("!PF$  'AL+W=O<FMS
M:&5E=',O<VAE970Q-BYX;6Q02P$"% ,4    " !PB'Y29?M@Q5P,  "0)0
M&0              @('):0  >&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+
M 0(4 Q0    ( '"(?E)@A",>O@H  +(<   9              " @5QV  !X
M;"]W;W)K<VAE971S+W-H965T,3@N>&UL4$L! A0#%     @ <(A^4@<RYKB=
M%   !E$  !D              ("!48$  'AL+W=O<FMS:&5E=',O<VAE970Q
M.2YX;6Q02P$"% ,4    " !PB'Y2Z2[(J(P#  #]!P  &0
M@($EE@  >&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;%!+ 0(4 Q0    ( '"(
M?E),7SRUGP,  .,'   9              " @>B9  !X;"]W;W)K<VAE971S
M+W-H965T,C$N>&UL4$L! A0#%     @ <(A^4D6?CY R&P  $U4  !D
M         ("!OIT  'AL+W=O<FMS:&5E=',O<VAE970R,BYX;6Q02P$"% ,4
M    " !PB'Y2(:W'<,D"  #E!0  &0              @($GN0  >&PO=V]R
M:W-H965T<R]S:&5E=#(S+GAM;%!+ 0(4 Q0    ( '"(?E*NIAPZ @,  -H&
M   9              " @2>\  !X;"]W;W)K<VAE971S+W-H965T,C0N>&UL
M4$L! A0#%     @ <(A^4JE1NAF7 @  E04  !D              ("!8+\
M 'AL+W=O<FMS:&5E=',O<VAE970R-2YX;6Q02P$"% ,4    " !PB'Y2&V:M
M3#0#  !'!P  &0              @($NP@  >&PO=V]R:W-H965T<R]S:&5E
M=#(V+GAM;%!+ 0(4 Q0    ( '"(?E('GLG65P(  $ %   9
M  " @9G%  !X;"]W;W)K<VAE971S+W-H965T,C<N>&UL4$L! A0#%     @
M<(A^4GQ+*QIC @  G@4  !D              ("!)\@  'AL+W=O<FMS:&5E
M=',O<VAE970R."YX;6Q02P$"% ,4    " !PB'Y2-T>-V% $  "T"@  &0
M            @('!R@  >&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM;%!+ 0(4
M Q0    ( '"(?E(>'S)F9P(  #(%   9              " @4C/  !X;"]W
M;W)K<VAE971S+W-H965T,S N>&UL4$L! A0#%     @ <(A^4IT45B*K!0
MQ@\  !D              ("!YM$  'AL+W=O<FMS:&5E=',O<VAE970S,2YX
M;6Q02P$"% ,4    " !PB'Y2G98LX7@"  "5!@  &0              @('(
MUP  >&PO=V]R:W-H965T<R]S:&5E=#,R+GAM;%!+ 0(4 Q0    ( '"(?E);
M3K/BO (  /L'   9              " @7?:  !X;"]W;W)K<VAE971S+W-H
M965T,S,N>&UL4$L! A0#%     @ <(A^4@V)$FLC!   = X  !D
M     ("!:MT  'AL+W=O<FMS:&5E=',O<VAE970S-"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( '"(?E(KPYD4+P(  *<%   9              "
M@>'N  !X;"]W;W)K<VAE971S+W-H965T,SDN>&UL4$L! A0#%     @ <(A^
M4OCGEA9I @  80<  !D              ("!1_$  'AL+W=O<FMS:&5E=',O
M<VAE970T,"YX;6Q02P$"% ,4    " !PB'Y2P(#3Q-<#  #_#@  &0
M        @('G\P  >&PO=V]R:W-H965T<R]S:&5E=#0Q+GAM;%!+ 0(4 Q0
M   ( '"(?E*8S9><F@(  /D&   9              " @?7W  !X;"]W;W)K
M<VAE971S+W-H965T-#(N>&UL4$L! A0#%     @ <(A^4JLV#[;W @  3@D
M !D              ("!QOH  'AL+W=O<FMS:&5E=',O<VAE970T,RYX;6Q0
M2P$"% ,4    " !PB'Y2NR8Z;1X#   O"0  &0              @('T_0
M>&PO=V]R:W-H965T<R]S:&5E=#0T+GAM;%!+ 0(4 Q0    ( '"(?E(\PED'
M" ,  /8(   9              " @4D! 0!X;"]W;W)K<VAE971S+W-H965T
M-#4N>&UL4$L! A0#%     @ <(A^4NVM]1<Q @  4 4  !D
M ("!B 0! 'AL+W=O<FMS:&5E=',O<VAE970T-BYX;6Q02P$"% ,4    " !P
MB'Y2YF?'/2L%   K%@  &0              @('P!@$ >&PO=V]R:W-H965T
M<R]S:&5E=#0W+GAM;%!+ 0(4 Q0    ( '"(?E+;Z#%KLP<  *$B   9
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M970U,BYX;6Q02P$"% ,4    " !PB'Y2RTMWK@<'   N/   &0
M    @(&P(P$ >&PO=V]R:W-H965T<R]S:&5E=#4S+GAM;%!+ 0(4 Q0    (
M '"(?E("65SY0@T  #U,   9              " @>XJ 0!X;"]W;W)K<VAE
M971S+W-H965T-30N>&UL4$L! A0#%     @ <(A^4HRH4^68 @  =P<  !D
M             ("!9S@! 'AL+W=O<FMS:&5E=',O<VAE970U-2YX;6Q02P$"
M% ,4    " !PB'Y2SRWJ.5P$  !W$0  &0              @($V.P$ >&PO
M=V]R:W-H965T<R]S:&5E=#4V+GAM;%!+ 0(4 Q0    ( '"(?E(T>T#N1 ,
M !H5   -              "  <D_ 0!X;"]S='EL97,N>&UL4$L! A0#%
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K 0!;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@    !  $  =Q$  "!- 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>210</ContextCount>
  <ElementCount>387</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>64</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="eyen-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00090 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyenoviabio.com/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="eyen-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00100 - Statement - Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyenoviabio.com/role/StatementBalanceSheets</Role>
      <ShortName>Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="eyen-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00105 - Statement - Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyenoviabio.com/role/StatementBalanceSheetsParenthetical</Role>
      <ShortName>Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="eyen-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00200 - Statement - Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyenoviabio.com/role/StatementStatementsOfOperations</Role>
      <ShortName>Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="eyen-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00300 - Statement - Statements of Changes in Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyenoviabio.com/role/StatementStatementsOfChangesInStockholdersEquity</Role>
      <ShortName>Statements of Changes in Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="eyen-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00305 - Statement - Statements of Changes in Stockholders' Equity (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyenoviabio.com/role/StatementStatementsOfChangesInStockholdersEquityParenthetical</Role>
      <ShortName>Statements of Changes in Stockholders' Equity (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="eyen-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>00400 - Statement - Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyenoviabio.com/role/StatementStatementsOfCashFlows</Role>
      <ShortName>Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="eyen-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>00405 - Statement - Statements of Cash Flows (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyenoviabio.com/role/StatementStatementsOfCashFlowsParenthetical</Role>
      <ShortName>Statements of Cash Flows (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="eyen-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>10101 - Disclosure - Business Organization and Nature of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyenoviabio.com/role/DisclosureBusinessOrganizationAndNatureOfOperations</Role>
      <ShortName>Business Organization and Nature of Operations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="eyen-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>10201 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="eyen-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>10301 - Disclosure - Prepaid Expenses and Other Current Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyenoviabio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssets</Role>
      <ShortName>Prepaid Expenses and Other Current Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="eyen-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>10401 - Disclosure - Property and Equipment, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyenoviabio.com/role/DisclosurePropertyAndEquipmentNet</Role>
      <ShortName>Property and Equipment, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="eyen-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>10501 - Disclosure - Accrued Expenses and Other Current Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyenoviabio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="eyen-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>10601 - Disclosure - Accrued Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyenoviabio.com/role/DisclosureAccruedCompensation</Role>
      <ShortName>Accrued Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="eyen-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>10701 - Disclosure - Notes Payable</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.eyenoviabio.com/role/DisclosureNotesPayable</Role>
      <ShortName>Notes Payable</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="eyen-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>10801 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyenoviabio.com/role/DisclosureIncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="eyen-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>10901 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyenoviabio.com/role/DisclosureCommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="eyen-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>11001 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyenoviabio.com/role/DisclosureRelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="eyen-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>11101 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyenoviabio.com/role/DisclosureStockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="eyen-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>11201 - Disclosure - Employee Benefit Plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyenoviabio.com/role/DisclosureEmployeeBenefitPlans</Role>
      <ShortName>Employee Benefit Plans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="eyen-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>11301 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyenoviabio.com/role/DisclosureSubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="eyen-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>20202 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="eyen-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>30203 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="eyen-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>30303 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyenoviabio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsTables</Role>
      <ShortName>Prepaid Expenses and Other Current Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.eyenoviabio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssets</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="eyen-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>30403 - Disclosure - Property and Equipment, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyenoviabio.com/role/DisclosurePropertyAndEquipmentNetTables</Role>
      <ShortName>Property and Equipment, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.eyenoviabio.com/role/DisclosurePropertyAndEquipmentNet</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="eyen-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>30503 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyenoviabio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.eyenoviabio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="eyen-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>30603 - Disclosure - Accrued Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyenoviabio.com/role/DisclosureAccruedCompensationTables</Role>
      <ShortName>Accrued Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.eyenoviabio.com/role/DisclosureAccruedCompensation</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="eyen-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>30703 - Disclosure - Notes Payable (Tables)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.eyenoviabio.com/role/DisclosureNotesPayableTables</Role>
      <ShortName>Notes Payable (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.eyenoviabio.com/role/DisclosureNotesPayable</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="eyen-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>30803 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyenoviabio.com/role/DisclosureIncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.eyenoviabio.com/role/DisclosureIncomeTaxes</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="eyen-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>30903 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyenoviabio.com/role/DisclosureCommitmentsAndContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.eyenoviabio.com/role/DisclosureCommitmentsAndContingencies</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="eyen-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>31103 - Disclosure - Stockholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyenoviabio.com/role/DisclosureStockholdersEquityTables</Role>
      <ShortName>Stockholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.eyenoviabio.com/role/DisclosureStockholdersEquity</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="eyen-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>40101 - Disclosure - Business Organization and Nature of Operations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyenoviabio.com/role/DisclosureBusinessOrganizationAndNatureOfOperationsDetails</Role>
      <ShortName>Business Organization and Nature of Operations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.eyenoviabio.com/role/DisclosureBusinessOrganizationAndNatureOfOperations</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="eyen-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>40201 - Disclosure - Summary of Significant Accounting Policies - Anti-dilutive weighted average diluted common shares (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAntiDilutiveWeightedAverageDilutedCommonSharesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Anti-dilutive weighted average diluted common shares (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="eyen-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>40202 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="eyen-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>40301 - Disclosure - Prepaid Expenses and Other Current Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyenoviabio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails</Role>
      <ShortName>Prepaid Expenses and Other Current Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.eyenoviabio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsTables</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="eyen-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>40401 - Disclosure - Property and Equipment, Net - Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyenoviabio.com/role/DisclosurePropertyAndEquipmentNetPropertyAndEquipmentDetails</Role>
      <ShortName>Property and Equipment, Net - Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="eyen-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>40402 - Disclosure - Property and Equipment, Net - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyenoviabio.com/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetails</Role>
      <ShortName>Property and Equipment, Net - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="eyen-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>40501 - Disclosure - Accrued Expenses and Other Current Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyenoviabio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.eyenoviabio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="eyen-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>40601 - Disclosure - Accrued Compensation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyenoviabio.com/role/DisclosureAccruedCompensationDetails</Role>
      <ShortName>Accrued Compensation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.eyenoviabio.com/role/DisclosureAccruedCompensationTables</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="eyen-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>40701 - Disclosure - Notes Payable - Schedule of notes payable (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.eyenoviabio.com/role/DisclosureNotesPayableScheduleOfNotesPayableDetails</Role>
      <ShortName>Notes Payable - Schedule of notes payable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="eyen-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>40702 - Disclosure - Notes Payable - Additional Information (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.eyenoviabio.com/role/DisclosureNotesPayableAdditionalInformationDetails</Role>
      <ShortName>Notes Payable - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="eyen-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>40801 - Disclosure - Income Taxes - provision for income taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyenoviabio.com/role/DisclosureIncomeTaxesProvisionForIncomeTaxesDetails</Role>
      <ShortName>Income Taxes - provision for income taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="eyen-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>40802 - Disclosure - Income Taxes - Effective income tax rate reconciliation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyenoviabio.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxRateReconciliationDetails</Role>
      <ShortName>Income Taxes - Effective income tax rate reconciliation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="eyen-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>40803 - Disclosure - Income Taxes - Deferred tax assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyenoviabio.com/role/DisclosureIncomeTaxesDeferredTaxAssetsDetails</Role>
      <ShortName>Income Taxes - Deferred tax assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="eyen-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>40804 - Disclosure - Income Taxes - Additional information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyenoviabio.com/role/DisclosureIncomeTaxesAdditionalInformationDetails</Role>
      <ShortName>Income Taxes - Additional information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="eyen-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>40901 - Disclosure - Commitments and Contingencies - Future Minimum Payments under Operating Lease Agreement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyenoviabio.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumPaymentsUnderOperatingLeaseAgreementDetails</Role>
      <ShortName>Commitments and Contingencies - Future Minimum Payments under Operating Lease Agreement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="eyen-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>40902 - Disclosure - Commitments and Contingencies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyenoviabio.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails</Role>
      <ShortName>Commitments and Contingencies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="eyen-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>41001 - Disclosure - Related Party Transactions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyenoviabio.com/role/DisclosureRelatedPartyTransactionsDetails</Role>
      <ShortName>Related Party Transactions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.eyenoviabio.com/role/DisclosureRelatedPartyTransactions</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="eyen-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>41101 - Disclosure - Stockholders' Equity - Warrants Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyenoviabio.com/role/DisclosureStockholdersEquityWarrantsActivityDetails</Role>
      <ShortName>Stockholders' Equity - Warrants Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="eyen-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>41102 - Disclosure - Stockholders' Equity - Additional information related to Warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyenoviabio.com/role/DisclosureStockholdersEquityAdditionalInformationRelatedToWarrantsDetails</Role>
      <ShortName>Stockholders' Equity - Additional information related to Warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="eyen-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>41103 - Disclosure - Stockholders' Equity - Black Scholes option (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyenoviabio.com/role/DisclosureStockholdersEquityBlackScholesOptionDetails</Role>
      <ShortName>Stockholders' Equity - Black Scholes option (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="eyen-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>41104 - Disclosure - Stockholders' Equity - Summary of option activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyenoviabio.com/role/DisclosureStockholdersEquitySummaryOfOptionActivityDetails</Role>
      <ShortName>Stockholders' Equity - Summary of option activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="eyen-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>41105 - Disclosure - Stockholders' Equity - Summary of information related to stock options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyenoviabio.com/role/DisclosureStockholdersEquitySummaryOfInformationRelatedToStockOptionsDetails</Role>
      <ShortName>Stockholders' Equity - Summary of information related to stock options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="eyen-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>41106 - Disclosure - Stockholders' Equity - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyenoviabio.com/role/DisclosureStockholdersEquityAdditionalInformationDetails</Role>
      <ShortName>Stockholders' Equity - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="eyen-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>41201 - Disclosure - Employee Benefit Plans (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyenoviabio.com/role/DisclosureEmployeeBenefitPlansDetails</Role>
      <ShortName>Employee Benefit Plans (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.eyenoviabio.com/role/DisclosureEmployeeBenefitPlans</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="eyen-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>41301 - Disclosure - Subsequent Events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyenoviabio.com/role/DisclosureSubsequentEventsDetails</Role>
      <ShortName>Subsequent Events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.eyenoviabio.com/role/DisclosureSubsequentEvents</ParentRole>
      <Position>56</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>eyen-20201231.xml</File>
    <File>eyen-20201231.xsd</File>
    <File>eyen-20201231_cal.xml</File>
    <File>eyen-20201231_def.xml</File>
    <File>eyen-20201231_lab.xml</File>
    <File>eyen-20201231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/stpr/2018-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>92
<FILENAME>0001104659-21-043991-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001104659-21-043991-xbrl.zip
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MC KLGG*Y.[JX:1KU2W.9>*JM&2OXJAZL;=>\V**R5%JYU%I?9$EJ? =?'T+
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M0#A/G,+/,O@H@>=C]]7>TTAR9UQ\4NNJ-G6=3+2O81K2=PNRB4'@/ )PW \
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MM>.01;)U"K9V';D5@:UP/>?.M3CN8\ R\6]XAGP+!I"0> V1^X(? 20_#P:
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M^M>I2HWJI+,&_8XJ)7WCXI$E',"?_O;=:IN=AO0J5A4>"*Q5HH9V8'U,&YK
MNF9@O>*(R8\.T*_XLN??E_^Z9N-7MK+]8WGK_YPEJ3^:RU]E'V K4N (W^/1
M7>Q,QT?8]PV;_ER@HECW=,,Z!;:85GT6?)6P:,3><9=/;GG,;--@V-7<8.F8
ML[?19.J$<S9V/.9,IW'TW9\X*0_F[(=>VP">PW_Q^UX$\TE]EXTXR+$3B$S
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MD*?Y@_H!*LH2==//U'&J-CGIU ^PQOQ _0!5P -"9Y6HH14Z4S_ &O-#9?T
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MESQZ6J=OHX]^B])2[]!RSR3QT]^^ \K8KUFVATPR=GD7GU%C^VU$U<W%%N+
M"GDXT2J5:VYSA:V_1$LI/\S::CEL(B0X[_.3]9Q:<,?P=<+>1$XL.@&]\V/N
MIE&<8#^Q*3 +BQX !?"3(S[/L1N5(]H'99OLY)LL^NR6QQ"MQCSVO[-@SGK8
MF,CLPY^=%'L2W</6%,UOX<WSO*_5#T.CV^LST-AL JL=&UE7WFY;_&X<S6+Q
M-7P_VNG(8T[ 'J+X+T/^P;OWDRB>LZSA68+?@S],8"JW<]D;R\N6*=MPK5^,
MDXA&7WXH%A&%["N?IG(KLRY+\MOYN[(V80D^BFL2>[K<YROO_K7H#HP+[O?
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M&+A\E(@T<O_:4XO5Q>[;ZN12@W6"@WLUC4&0![E+6^#BJG82_JU D!?((>4
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M)K-)?NR3K#KX'/@1C)8XFDB+:P&#1O&NPGR5AFITB]CV6'K%2XH(13EB\!/
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M/WM\Q$4&0P[$0N/E&FDM!BT=I0GF$"2YY>5XMI,4P6J!:!A/R+<@CUZ/.,<
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M7/XJ^P!$2D'<?8]'=[$S'1]!J+9AARN6S"8P[3F+1BP=<Q:)76-.MFO,F\4
M)OBG!>?,N1,S#C3TV#ON\LDMCYEM&@PWB_D)FP*Q.2S'8[<\B!Y>/<-I&FSA
M5A*5?T*I6E8EN+"+7,X$H#"7!T&&XC]?M"_$YV3JN/GG3#6YN,=QH9HRA0$
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MW/QSAE0NQZTKD"K##Y"'P)DF_%7^PVLY$!N S.=C[7W>8%DML]+SAIRU8"U
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M^P0:7 O?C<X*]_7J.KUA3T>OCD* "F@+.A6H)5LPT^BU+<.T3M%!DH"A!AQ
MP$# L/9L0$O_D2!! 4C0A ,:!PG[V0I:>)WD6S[O6_:M#IT8DE90R5#<[0(#
M@?\&\+?,GF$/VB3C)./JR#B=*9#+1^*MC'A7>P>1Y/L$*EP+[TWWJ,\9Q;QR
M.->=EK4 ^F/:<1;\W8MFMP$_Y+8YQ?"VU %&VS0-V[0)&@@:5(<&"NZ?#QA
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MQ%$SAK':E3!,M]/N')-RYO)2KN-HRF$9UP$(%\P/!4[,[LW\9C[EBR5=@=K
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MR3"':2%F,C*%B3',(4T#/[['G$Y(,<FC@7&#@,N7%2&>+.<($)C8?^3:S7U
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MA3Y6KB/(RO7UV[?OWE4.2O3%S,QQL23K\'>^&:M4[-A80Z+X7^9_W<S%F23
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MI'?EG>K<"!97>?(O:@4(%3X)"PM9I5"VEN;!$D\K24NAK!=[D-GE"'OHY&>
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M:$<1SR,0*E?,6#2VQ9!?%AATFS[SF]\AIFE>&.9P..Z^RL<:X.FY5L"AV2&
MA= -7C,&7U"8#3>G!>*1D'F@X!\@8M*EY+5 .3<XQ5_R$5,I$]!\XB0^\55\
MCTJ/28!%0"IBD4>^Y$.Y#(5>EIVQY<\573\NGR'%&\G=8G2_NCGXM=@(6P&]
MI73#0HLIGPNM@<J;X);@/[U]D@-YO\_L#+KY]!U 8+@B%.9:G(N&N5>6A+,:
M^CL%/ <JS-)Q+:=TD8OY-,J7Y6F4[?(F_6Y7PT6+9^=-$K]\J30!0]'3AC9
M,$'@@R> MSET"#]R1<:4@$!?1A/B/5"/^RK%,?$?N54%Y_D!M$LD=+.&&0QA
MYC'P803ZWCTMO+Y(M7L<791&!"ZS[IC+LL&DK>-, G87\Z;Y"$2V UZ2V5PQ
M7H@\\ZVT )KY@R@#&';+;"(2^F.:7;3M. A$0"XARI#9^0ZYBI+WEL8KIC9:
MT.&B/.:S89MR6P8$V&DN;*O45EF?E\=>R_KJ&&EROD4RD#(=79N9Y= %R%L*
M,9FK<P@G"\+901^<+%9(T0)[N)[&(?=O'?*.W@4QZK9N)+ES&'08S^<N;Q >
MD1B2>S7[6;92,KI'8O92U^<T;+U%/;OXQ<*4&C(/)%Y0_JV0_A9)=P).(G4=
M"@BZN..DL?.DD<  #[I<2$#V!5P)ZQQ*V (A9C;^GH0E&%@5,FZ?;K^4TV#O
M1+B5+?ABW!66 J_LUV0AE'>YN$*49N&3(?-$E]8;F9H^-$C6SLL?=,WL=[71
MN(?/9 &,T#)H 5TV80XI#XRQ0P><0M>?<WU)T1)_@-9TT]",X6AI(R*9Y@JC
M[\R8)Q7^@>9 5P1]*4AP&/;G5.A)^$KT8VA]7=?&O5YI+KW^6.OV^P>:2[=O
M:*/1^&AS*:X9@]GD#ZSF-F=R0/EX?C"U(7QC&#J^$WO(\GL/],#9+,"2-&#(
MR)U8LI%O8FP.3J>X6 BC5W3^[RFZR<QW>&JQTRW):/.P\5.FPAPF17ZZ)8B8
MBS@'RQ:?TUC%)S,NINFB\B^^%7 9>9-+0!83T[VNIH^[!/!/>&:\9>AC1&Y<
MR^.6&D(0Q#P1@-R+_"9FSA)E I%S&5^&Y*LV/$&4++]8G@>:%(1H_J6_ZLB>
M>4O)"LJKPD]B#!Q+O1@TFJO/U'<=G-N,THB[L6%\]R?& ]+A$62@,J_#'6(Q
M/D$%\#*9BY\],1%$?#*U<*%8C(1W/K%8@ 5NL0!HW>AC]+:PGII73NP"R<&7
M$;A6ML41!<&\I?-(9"!U?5DV))'-/003T70DV)1))@(!M_0HG7+M$&67A7EQ
M"&D42>>1IV%V7TC,R<A)1%T_OZCWNP517V&*6BGMFTH%N$GZ.)?>NE@@:HMU
MVKH^L.B8+RL2+$. .=#,\8$J!D'N[W&<D\"?8=9@W$=E^L'LZ'INE6_K$L$?
M1H:F#W0E^WG9;XO(8RV@Y6%*(W.\T]1&4<SSZ6%])%+!: =TT]0&H\&J;!L7
M8<M;LMJ,":^>C(90B)]?[?H#QJ"CT8BGT)>M#*2#D!I8F&$YRIWAVA!:FKD?
MI&5F,)'9W/6?*"VJ[=QZ"GRP,Y'U71#AAP&HU=A,[-Q[9"]FT3]!2.B!H;JE
MP0/FPG-5V.E?^<3!(U_?8[.[.,A7%\HT4S*8%FAO25Z)WEL;05!/^#*KA;B,
MT>#V%9<W"G(,;Z*[EQ \7!9C"!^EV([PN82_$5!A64*!W8M^%1=4=,.B*0/O
M)_%.I$NTFW^&W]Y9,"H[<W-@.M'4?<K\G\SM E7DOX8%%PW7,)B':?50R&LI
M)RMF7*3Q% +[%1IO=(:]O)X+!RU=WPG7F$6Y4B"ZDBUZBU-?/J"2OYBYBL90
MZV>>8F'Q\SLB$)>8U'%LL=^8:%^2 <_ :K#97"QX0P::#WU?D['2R>'EF[85
M3OERZYT5LC"3L3!VHZSN Q>+N&HL<=8,\-9Z@U46K=7,%O4C">@NB7W+*["X
MQ/4@5Y\MVZ:NS$]RB&*S&748U\@$Z0"&C9YFZ-V2./D! T):KEM($KT)<O;S
M/?!S&KOT(2F]S[DTPE:,EE4,3%F"ZAAEKW0=-@]^,4LNH\T?!MVQ9AH&SFYC
M^M39)@A!!BS%S@S/8\^:H=_R'U[ROR)4YA-[!":V2*AY&51O,VB9/6VDKRHK
M78]1>6=V!^]U,,0%@1:Q8KM<\.Z>W&"D:_VAL:TKI_%R?3 /:<%Y5N6Z*9.\
MS'W_*!2K. J-I]D&8%J,T;#A7F&6'^SU8;K]58G'_8:_=VK]P,YL,>%R%&=V
M57"XM7^K:V.P/4/EXNX18)IKEP&V@"6QXO*<@')QT:JN4>6.NM7K#$85"!3+
M"PM=4^L=0)=:L/4Z[VT9H^<JTL#$,'T/32HMLK5(@XS.:%P]#>J/AIJNK-%.
M6_4]B$6>J4##04_KZ:LVVZ4*M+B=46F2V-=6/4W"&RU,^$?ITH['7CS;&O7,
M#6Y=;I%(*1 /E(;'#I3V42##.(@SUQ[UR2JDGJU"FR*CS)<3NRFR](Q2*%2H
M7A6C(V.@,@T'+T0A%T!%F;=:.,IND]*2'>H:MU#;_D@;&RO5=H5F;E7,NT1]
MZURFN(LFFQ74Y'Y?F<:=3&.Z/K?\:(===*R\R59YE^M5J-\9#JNG0H8^.J,Q
MK(OFX$[W^3P[5N,7U[*_7=S: ,<H_'.Y=9K90G8<ZB[NBY.Z552X.)0U!]DI
M);G=ML0*PW@FWG_=; KO=,BKPQZ2ML01R'QB+Q)O@Q^$2VSJNO+TX9]>=%_P
MS^'<LI//\DAE<6%D>J2R/.@8#_RRYB%]G?QQ*3HBHVXG[2N=W*ZWM0QZG=[@
MG&=V)_( <P%./>.<[N<<P%P<! ++!%3@]90Y#O5RXK37X<SBF.637-=B=+J*
MF?LSL\B:YW)#[RO5J@XWE&Y4B1M*-ZK$C6ZWTS_KQ1UMX8;X_+S[]<[NL2VY
M8<.*([]R=ZR,]G;61JUPUH[ QUQ )X*9(UV2HC\?$&%@$((!<\P7Z_ED&IVQ
MXM/I-'#;+L2A**_O?-=9>;E-.H!W?N[XEBA_KL\?F)Q[RW<,'$''SVU8&XW5
MS[CUZ+D(KPQYU85#&?(:&(C:&_+=[BRO+Z.J8\F7GL9V5/56-ES9<&7#E0VO
M&Q]K;AIV4?OU?QU<6HZ1O:Z@)U%Q =G==\ J(X4=];(!"BD44IP#*?2Q"B5:
MC10JE"!_N;Y^^_;=N\J)AUX>R+'E(^OP+:]$Y77)P8R\Y)7!K]KA4RAA* M#
MW3R'\TO J?+*YY.)?F?4)Q<P@DZW);&&P@6%"PH7-N-"OWM$7*A@9%%57'C&
MFF,C_/S*,>1\2OF)A=_(!+?X\:U&N.T/+Y=OH-U63&^'=58V> WGNQUC\%<T
MPAW3^*M2\DJ;6J5NM5<WO=,S4-V,3M\\AKJ=V^=MDKHUPK.M41!2@0SV@^]:
M$=Z@_M1 4ZA$H>V>L,I3[2438^XAC\=-](]K! J-]YR5>N[G4YL]#&#-H^CG
MN1WJ=NAG(USMRC&D @ZUPQZ80STG;*#I5/QNA]=<Q;+0LV:,N]TF>L*54^?&
M^[M*L4ZB6.=V89ND6"5'57S$ RU3=H''D_^U+8=^-N$$YL^YHU^G5LAO5HVC
MY C8PLF\2P^/)7&X_1&T'7DT.U[E.:$LBO&49;SIT[)M"/>BY)+/B+<7P22Q
M7]^VXR"@GDW%<<*T4'L=)U>#)@/#^XGQMF)Q?#&>"3SCQSN+8X'YH<O8<#2%
M;LJ3L8)\\SZY@P'$41A9'FJSZ#X]*!>3YO^AHIOL>.3KRY#-YBZ;,.IDW[ZY
M)#,:37W>JD,?J.O/^:G,<GC)6=#%N<&7^8:!><P#?GC,=:U"VY+8?!IA<9B.
M#T/T_(@((D;NDSP2FH0QWE7$X#L2!19.$&_TC?S@B1\5',_G?A#Q4^?%U\RV
MW-QJ 8&/=NSR<_BASRM@88"-N$_% X6!$8)4_"AA+YMBKJD)NP=9(.)R7WX7
M=4 ?&(B[),OR ? ?L6H'A=8*^!F[,!L6,90_/!;:*G.=_CMF(-!\SGZ1XL"R
ME W,"Z,@QEN-001PW%P)Y$6" 0N_72Q6"Y%'4!^'(N- NYSLG' N#O#%$Z.N
M(\\/_]*YA<8":H4QD/L_-/ O0 /F,/4['R)'>4EN[HQO+@]XFP=0@B;'C2^5
MF'7C7[;;K8P *"L.M5W0A5PLJR$?,Q&2=X%+2>8=@9;<4WY\N6B%S.45!K(Q
M,HE1X;,FA9ZCG@)GVG+B/5);;$%#N $91:)E(+7VONGE (S85SC*2AQ37[S]
MNG!,1G+WJ\/O#N9RFSOB&[C[@]GIZOP!O*JUFS\C'L0=Y8T!WY\:?L3Z%6#@
M;)8[J%^BK(731_S)+APO$G_YS>- <I!U>;8^_'Q'\5C)9I.P56>H]T:=X4@=
MG]J<,]05,ZMR,K&N=X;J9.*J<./L:4O%C3PW]([95=RH"C>&BAL5XH9"JBIQ
M8]P9*"M>&6XHW:@2-_2.H>*-JG!#Q1LUN@GE['F71A^G==K#5Q4?:W(LVJD/
M4#PW(-?W8-ZCUU2=W9%LN][RYW8ZU_)\BGSV;%5=A.7X:GON3)6"5 6I"E(;
MD%:KKR)71WQ^ES5!QPFK%):HL*J26<>ZR,;Q-Z:H +<">QM4_K%R *ORCY7C
MHP+#9H*A<B>KQHGT4E-CPZ6FW5%GH)(YE7+[50S84J55R9JF*^J5V+>E]+3!
M>JHR(Q7AA H&5&:D0JRKCFE3F9'*\5&!83/!4#EO5>.$RHRH@$OI;+UT5B5&
MFJZGGY+SBI2FUEI3M[:NNLD/3FD45UJGM5?W]P&]W_7"0Y4@4 D"E2"HFANE
M$@0- .3?XN*9??Y$^5.U5EF5K6B3^K[]3@.;A2I=46^E5>F*IBOJKVRBE+3>
M2JHR%6U2V/=>%# O9+;*5%15J56FHAE\K&6F(O1=YA!)"87()T!D<:%+$Z\Z
M;).BGC4_H93VU$I[$S!;!3[U5MF39R>4FIX^VLG$X@^\U$>I;*U5]JRY"J6^
MIU;??^'=72I1 :)S??WV[;MWU=/I\D .)2N;[[W]F-TJ2?YI>3'>,B9O"6M'
MSD.)Q$GODZ]@5<B>$F"F$H#"D+<JO._&B04Q-,,<:CUSU [OKZK </20K8('
MXU:5%^?3QA^.H(05/(=78?-VV&QV^KJ"Y79"0=N.]'V^!#0>#TYT:*N"AWK)
MPN$EH(*'TU15 NI8QG!^7BBH;D6NMG+:>CZ!^$=@>4<[>U$QN1I,;G2.547K
M&Z)U73-Z8VUDCAOHDU=.R1N?+ZT<Q9L)JV=/CRI8W9@$[38Q":KTNQVI3A4E
MMSZAJ52]'6G+RO&Y\<E)!:XJ!=F8I83SB4IRHD@3TY-* -J>N%0K6'O%W2_-
M@6:.]5<-=,AKA F-SW/6B!?-Q.>S9T!5@>C^Q?L=8Z#P66%"X[*FRF=3^50%
M#Y6%AW-G6FLD 8W/P2JH5MG9QJR8G$\@WOG!A#)5(MIP-M<MT[K;N2X*\=<E
M5 U3TT>-3*A63L'KF#8]F:HU3;/JEAT]+J-;EP3M=?JJY%XI>(52G<IIJDR8
MK'2]OARO1=ZRYEY;'=.3"EXK Z^-R$+6:#7A?**2/U+T#;5I\0I)4]>R#^J8
MT?:*29WRFP;\[OCQG4N?<W"UJE7:<A^GUC.&VK#;;Z#_7B-HJ%MF]*Q*VF"@
MKL%1HPJ?3XK/'7.HH+F=8%"G!*M"A5.BPJASI%!.@4)E_+6#YD25OU8;?TW%
MTS66!S+61CU3,WN['8[4B(1M,V#AE#[8N7.GE>-8'=>]%,4K[52VC^+GWCO>
M/HJ?>Z]V^RBN4*4!ETLKBBL9KQ3%S[V!MG445_[X 2G>B"2"RCIN?S*@A3D]
M5?6EQ$15?:DL]4Y9:ET;#D::,3;4*F)-C;VJ^FJ0/JJJ+X7/I:JOWDA!<SO!
M0%5]*518C@J#C@*%IOMKJNJK!IJHJKX4,A>0N:]U=5/3]=WPN92P%1\QJ9>^
M[+"'_*]+:%VB'KC\.6K_&8<1FSR)K^0'F'T$0L <ZM\'UGQZ %)OH/,ZKR:=
M][PA\_P\I63BNZ[_B%MR.3?)/* A]:*0,&_B!S,K8KY' NI:$75(Y$-SOOV-
M^'/\/B162/Q)FM8EIJX13.*^;C;==I(/4(L2>N+$7B1J(ZAN4]>5P/73B^X+
M_CF<6W;R6:*Q37&^*1I+C 2==ZUY2%\G?UR*CL@(<"WI:^]5%O"YQF=-GR?R
M ',!3CW#LC\'NXN#\!]H, &U>3UECD.]G#@]HXSS%#&5T3US]4_-F7E@%[K7
M&2IN5(4;^JC3/VMPJ;BA=*.BW##ZG;[B1E6XH72C2MQ0=N-$W#A$S=C9HYDE
MB2LKCOP#G3$G L3CY*Q&>X<VZ9O/#&U@6A 4 VO-%QLJ \W#J^1N1P:VC,W;
M=O$HAG?GN\[*5&4Z@(\RR90[-^X(2TKGMJ5'D)3*+BAMK\"CSE I<$,4.).3
M7"WP<Q8?E.6O@40=U/)7.ZG9)@A7QK06G#A[4%I?M%-:TAHM.7M:L[Y:4ATO
M\W?^\%%N/52*6A%%5>:LMKMT5=REXJ[Z<+9R*J@,5:TXH0Q5 SQ*M>#0"EU5
MT5\#=/7J@0;6_6[+"4I/:Z6GRJ8V0$_5TE][!$B%H$WE[#&A0=EP9<-KQ8G6
M*>IO<?'P/G^B5+:Y*JO"XP:H["<ZLYB'B:Q4.'YE$V5J&ZRWRM0V0&^?:6I5
MU'Q"C3Z6U&P4DAQPK/^K%G&WJL\_-<C<!,Q6KH "CA,"QS&<$P4<Y]K8HZ!#
M0<?I?(XCY",4=)P:.MY[F8S\0:U @8@"$>5_*! YNO_1U)2(.O'X!"<>5['.
M0)UWO.7]01VCUPXGHZI0T,85#Z6=VVFG,>AJ\*-2T"8K:!5+"92";J>@O<XQ
M+MY3RED9Y536L[[*N8_U;$0@7#DM5>'N.=G;.L77.^-^ \URY=2Z\<97:=JF
MBPR'IM;O-3&#U#IE.WL8JI1MXZVARJHU0-&45:N\HNUAU1H1.-8H\:-"RFHR
MOG5@872&*@>L#'8]>-$Z[1P.>EI/'RL%;;*"GCUT50JZMX*6*EO_\MWHZKTC
MU+8J?:V.OBJ#VFI];42H7#FE50&QRI&=-NQ5RS[*%BM-.WXVNJ$EP*U3M;.'
MJ4K5-JC:J*,4K0&*IFQ:U17-U$:FV;Z@L48Y(!5.5I/QK8,*HS-2RS?*7->#
M%^W3SH&I]1L9GBH%K4[@JA14K:\J?54&5>EK:T+ERBFM"HA5ANR4&;*.KC?0
M2E=.K1MOBY6F;5I?[8^U4:^).:;6*=O9 U6E;!M76 =*T>JO:,JJ55W13'VD
M]<S==J8U(G"L41Y(A9359'S[P*+3VZT:HQYFN490T'B#K;1S;^WLC[2QH998
M&ZV?9X]<E7ZJ)5:EK\J>*GUM3:1<.:55\;!*D9TVZATUT$I73JT;;XN5IFVZ
M)J.O]K V0]?.'J<J75/1:$MU3]FY%NA>(R++&B6*5,Q93<:W#CO,SK")!;\U
M@H+&VV^EG?M'L&9#(UBEG]6);95^JJA7Z:NRITI?6Q,I5TYI53RL,F:G]*L[
MC?2J*Z?6C;?%2M,VG=34T "V=:IV]C!5J=JF2Z<Z:C=Y Q1-V;2J*YJNF>/=
M;%HC@L8:Y8!4.%E-QK<.*GJ=01.+?6L$!8TWUTH[]P].FUH@K/2S.G&KTD^U
MO*KT5=E3I:^MB90KI[0J'E8)LA/B0+^C-]&KKIQ:-]X6*TU3M[2V0]7.'J8J
M5=NXO#I4BE9_15,VK>J*UMOY:K=&!(TUR@&I<+*:C&\=5$"@V<2:IQI!0>/-
MM=+._>ND!NJ2UJ;KY]GC5J6?*J)5RJF,9].44S<T<]AO7QA<.255P:[*?ITT
MI#5VT_IZ6.7*J77C;:_2M$W5OP-MT,CJ_-;IVMF#4*5K&ZV:4K0&*)HR:E57
MM#V,6B/"QAIE?51 64W&MPXK^IVA2@ K>UT/7K1/.[L-K>U5^EF=P%7II]J<
MJO15V5.EKZV)E"NGM"H>5AFR4VZ9ZQA-]*HKI]:-M\5*TS;=+=7M:N:HB2FF
MUBG;V0-5I6P;BWD'2M'JKVC*JE5=T8QA5^L-=U.V1@2.-<H#J9"RFHQO'5@,
M@'4--,LU@H+&&VREG?MKIUIB;;Q^GCUR5?KYC)BVB5MAE'(JX]D Y>R---,T
MVQ<&5TY)5;"K\E\GU/M19V@TT"I73JWK:'M#WV4.D910JO;\ Y0&VEA7.^<:
MH&UG#T.5LFT,-G=S9I6B55+1E%FKO*;I$#H.>WK[0L<:97[V$H\2HTN:W:PX
ML4:\/#;DGMW(*5X<S?P9\+OCQW<NW=K^J9SJ_A6S6L\8:L.N6O9HM)*>/1A4
M*OJ,BIXFYF.4<BH+V@CUU+7A8*09X]V6*$K1I?AH <O2EQWVD/]U":U+U -U
MSE'[SSB,V.1)?"4_P.PC$ +F4/\^L.;3O4A=H/3V,=J&$"TEPCPA ,R?_%BF
M!LE_^/N/<7AQ;UGSU[>1;W^;^BZ(>/CVWS&+GG[S(_J&A;;KAW% /P,1?G'A
MF9__Y[\)^?OZUSY1A](9\N(FH!,:!-3A#[X/PYC>^"ZSGX@-PX8V/]')3R_>
MQ($5,=_[JL/_C:[1_?K9_ZH;7TWQZ<7/<C;I^#=SEF.:;JQDL4-M7W3Z&E26
M!CO)]&J]V<!-_F!*$\*)LH:)SYC?D45X]UE_GE)R[<_FEO=$K/G<9=!/!-]9
MM@V@&0% PMN6YUB!$Y*)'Q!H!+^-63C%'UUFW3&71?C>)/!GA')Q(X]3ZA&'
MPI1FS,,'L5';M<*039C-.4R@63*C%LKQC,(P_0EA44CF*2-"9$2'9)P)IU8
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MW/S$E9]>Z.51[D0 ?04!]"H00%]# /- !.@.5DC H ($2 :QC #&H0C07T&
M?A4(T#^^"J H+26 604"F"<@@+&" $85"&"<@ "]%03H58$ O1-8@148H%<!
M _0U&' H*Z"OP "]"AB@K\& @Q%@!0;H5<  ?0T&'(P *S! KP(&Z&LPX& $
MZ*X@0+<*!.B>P!$:K; "HPH0(!G$40DP7$& 814(,#P! <8K"#"N @'&QR>
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M%I/H?(_(#@* VP4"C0*"1UN>;ODE_JM?A=D%XD]RGM,2[XA6A_8QH%W<^=0
M[;",'NOMX\#E2#>@U.-\7,2YP962/<Q;!(>KD-5EUH-Y4@9F]6&S'K[=1HS+
M 6U*KH?X4Q'BIG=!]JBW#"-K\2W)J$?R<S62V8L@>[R:QI;+@2K)H4?H2Q&A
M[&'.'IJF >=R9(H9],#47=G7X[)M%+H<IWH"/6ZG1=ST1^9Z(%O&.ROFAU7Y
MM+ 9GX+IT6J)5GPXK/$QERI"'9XGIK%L^)R<6IO\?SS6(O^13UO-\-Q2;S:=
MR8=TO@T$\59R 3O\MN1X_FT@,1_&K_;\"]0]>//<.(ODKWGJ2-E'OH:B@F,6
MT8M6^C>E@(F:[4'7.8J%'UBCG:D%5=I4K2P*753*1<]-E0(2['95'V@P3?7)
MM;'=:_5UE'Y9"GYE7Y[Z"DHQ[ENT]&VLJ@?PPG?S;IFM&&E(Y*]A3#>4GX;C
MH^'Q^.!-.+&,3438Z-=,A)BNL0CE[^$9%AX3R%(_M5/Y-#03BA=R/=JL9)?S
M#)4L_E0J/?[<0.FJ!^3*)!!51/*/X8:Z11T4'U,TJ8(\5>,J,'A]KID<C-ZW
M%"7]=)Z$5=3"$:-1^NC>"+N^2'@U!D?[D%][8>27]K+DWXXTDB,F"F60C_4U
M+5__'J510TFHU%_##7U&@N@E0B7"MT%%6#,5:8R"CP,K'+G4RZ9G'J/@0/+U
MC8\]Z7(-+/0L?(YL_]M@CESUCJC*"(,)8<Z3(@W[;N!$B>O*.<:W@0^%A_ZQ
M'/W^U4 :$4"!Q ]D??R3LV 5BT9 I+CTY_!N[V\#FV.'^(4Z2 I6CO.-$%#X
M9<#E*IN2^W?D!CA]LOCJ#7.;*.]3WD8+1B_.D2#@XX?5N0,^N;K1U[I1+:0Q
M< (>[:4UJZ%(+7GII7I*-QW3G,A9Q2*\CWV]R1)=BC]Y1=S)J2MN:%@A!;73
M:H97;#8RK8U:E;;U_CK4@%%E>P^<V1@[8CJOL![@)1(+,\Z])SMR\'.E&=U0
M^8:SP)<X_/^&7D9O<LQVT\,8F$&=#,WZE7)M4] :O!F83."?\)M_[@*H&ZS;
MDI>"'SZ*>^;'^78"?Y7J&[FF\ZJUE8+"38GVIF8&GQE,^6%VM01\+O$+=IE:
MG(U1^Y"!TU"271AW1O4'F!,D!7RDIKF"=Z[8+#P9_8AMZ%IE1&[%!/D8)ZA&
M@IVK>L$H=( 8LN_#9,M*WZ&*: U3$U>M)\VPC<E+>&CE(_2K*'IWRD4]I+[1
M[\%]-Q1HMQ[\A4J_ '\M.9D4UE)9POOZ1DE%-7&QH5J0/"% ,1=WV'O&/#>>
M.<Q#A)8A%BK1RALJ*[69&QM)#PYRX,HEO^3-JP]4HKKP-KK\3FRY,4\0![Y-
MY^76_'':-1*GC;Z/F/X9/,#4QT,V#M2#*A?LX_33%M_.%@74TR/F+U!SXHHN
M",58SH_B3Q\ST3 08Z=SC9)6$,UB85ZX9 $?5+?50L8.3A[5DWIWC/I+=WVN
MEC8^:LI87O+NQO$96R/77T/MVW+I<+&9R4";6X5?=ZU329EMVEH<%'G@8-%3
MBC^NVZ@J>6LMGEX_L/.K*GE[+9;0M/>E1[KLK36YAAYI3XJDB]Y>#_*R+T#2
M16^MQR-YVY,:J9*WUP)\)[HO/=)E;ZW)E7RO:D^:9,K>6I-[$G?C>U*G*,#V
M_?#>K.RIK8WEI_/7'%R8);!]0F^#;.@AE]2I:76BQCWVXT63:\X\N6(B":?S
MZ*DY/Q6 -LS;*?<X452M_.36A]3*8W&1*-:W&4FWEB;S=OK$$<R'P^LL,?>A
M>66#WQG+K<W<35O6K2_?XU>5(L"/-%F/SN7O*+@5&H0/1#90N91 HW-^$?H=
MELA2?4IJ A-/TDO3= M>^2&E1N(F(XZ!!JG)2T&#=%K'-(CN,*6+6^@(+Q#G
MZVO&Y:J_@+Z A-1/F'NQ5@WRZXS+EX;YSL:EB?)X,IAA% ^*<W9SQ(NO!Q&1
M#B@\TG)).+9]QL5WZF N]T'):T.RYMF.M&/6>PM^'HQ7A;!W%#&K2NV8%E./
MDN= A!TWE?$HF*_*:I?5GU7)+&O'](M:DX">8H97 ;>72(!+^1 \N\2>SN<J
M*ISL^3#,W-'A.CL]=-,SW;*Y:S9#QW"+7,6'" 3PCU4D6)ZON?%6G+V$3]/G
M/$N#[!W%+CUBIT-XQ?$\D]HQU,Q<7JE!,R<YHN@H=H9>KX':%23[=94WZQ0P
M20UL&PLQ#USYPNMT#E.Y^$66JS6^Y&RUV2S9F*S<F,O68=Y!2VWWLI_.9(N@
M2\95OB4>\6%,^^X3-WZI0  \-W+Z#1#,Y$ 0X OF)/:Y'8O]5$N-OYI7:0*=
M)')3"BD=FU9,8RZ=K)L9!J'],-H6.^>/Z4U4L?HF&3NI8;S1&(0,]^[&YQK6
M9;<%)7MBFU)ULT.(U4@NB8AB;='%CN=XSCB>.'\&PH_]WXNEW)I_0^5 '#9W
MUV6OX:G!;-WLBFDW9[D7+A(B/L.=<\I*DSKFD2DASS4*%-,ZID%FTG)R\/E7
MS9PFD]PQ/>X#*==T'FUFB>>:R<!2F:QI&'&I[^O_)1/A&RH"N>HD]\1Y)/"N
M"96_''EZAW%?QM[D[3ZY3:!;T'>S3RCQ;$.W=KKR\9_8UWC ^7Q[=7FAGNTE
MMG_"6.9C=2LV_+7@R+ME^8B=6=:.M;A,UW!T\.5(TW-DDKNMQZ^G6CU2R1W3
MX]%#KAL_;C9Q/$*)9"J)KFQ&F4?L&_IGP->71" !SO,_.=KX8JVI_UY1 Q7Y
MB,?DY*BJ2;BDC.COI7L8_FBJ?#75GN,FJ<T,VOXS?[S4A*";(V/Z?D#-V<KZ
M;/L_0_D(U>\$+HS6A4L/"_H8YMV_4F&#D:MNQ,'01F5$1RC_1)I5VOZN ^I
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M.\[1DKI81-V&U*ZQ):.^3$/;!$&Q8!3XV;U'K1]SZH"N+O<Y[S5GPE2<M&%
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MB]+OEHG$VL*.+#2U(+_RW43Y_#PP$R:@/&3$&V3^?FC1_@.IA"WCL 18J<N
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M=>E\M]P0W:!G\87>/_L9>9>LVRD&QU4P*,E07[A$*E(1&%GE3I$Y:1H9&4=
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M[6QF6AG(]%9&0\N "6C:ZP#.M#OP]/3D^ 2.J[-=B*6L T#]\WSA^J\H>2E
MN_!IRD-8!,LI<6H_HF8, $SB&ES!4I@IT\.:5V1C*]>\#.D !%YX5Y&J+BMN
M>/&<6]?R;JRY?NYLIRL@"Z=4<7/Y81KG?JM!=;L"O5;WHE50E_ )H@'!=H <
ML78],%SHY.ZA(!6>M@Z$I;S-\9-.J*<5!0" MZ=5 \BKQ]W8*R_V';)#PD2-
MZ.<7VPT=Y%PQR7 U#@.AQ>/I*GWC+2)"B<_FW#6NVMDUTS;\T[&&&1["R8SV
M51## YC#>@<P:Q)&"1I^S2,62H($D>Q?60+93W],^ HD,<0RWX9P5)(AN?G%
MSER@TOU*[FO/9HT4_I0@V]LW-"O*U&[V9)_M9O?[W]^;BE=*?$\2_V:]X'DX
M5\H\\[W/K;5"058"SE#:ESR95+3R3'_O<U-3),\TI0 L"6X4C:<)&TKC3E24
M'=)1FH(% $ DS5AFI=XP2C:_))^OU+\U4+85($Y!K1JF[("R#/ZJT()<S=N&
MN_E=@")P]=P*J3W[BFW&-SI[(D@0I([BUI>'X%RKJ*3K"%8]AZVG]V/R"K#]
M'5-AHIO"8E(+@H^D+C@F? *8*+=NS0&X-?EE6?Y../L_?HJ^M%RAE<$%4\E7
M[#WITJL9UH4PY,Q -60(6MA^]LF@,]L.YZ%X:_F2B=S&*K^S2<7A!/&;< ,-
M.N@IZFIEKBR=H:YSV?.1?DO\)7:0<_[ZP.;B:V^\$&_2>D_Q.^U8F:B_3 /P
MGRRIPA4T2#GA#VSP\V,21WOD)BT)_^D2+?G0T& JQ)0F>.5G] %;5_F:NN"L
M,8V:ANY7/%7M+(QJPG_(I!0[K1M565.!WB,RQYXX#?S!>@Z0=^,'Z_RN,@NK
M=!/PWRBIQE>O8$5$/"Q\[\&S^03PC3%(L.6>$V39L[+ %38WD/=):O'8/: /
M"\:A%ZRNGDZ0C?!2_E:!>=VA/!5BSE'WP,3'9,GD6DFB) $+-=H9R@,@U;B#
MMB.9H"7R0A0%&'D!L>S@!PYF%R$-F)E"H@ DOL>E%+'_.??6B])TKM#2 -X0
MJ<4?-+@O0W3O3Y!P =Q:A-LL%R'A&>$BMZL=_4,!L7'M ;T;8LQ3KZ%UJ_UR
M<JO,S%+9S^5"Z8[SN0Q6C8XLSQFMF_V_$>M/^?77C)UKSOX[+[KU:U1S"/%W
MI1@",&,JZ2R\(6I4$TA\0@G%- (1V$W?5D%,'\H?GK*_X40BM >LE&T 6*])
MU=_JS9:"$*-00DVSB452O ! X2NR*.)/SUS/%\1?QA:2#A%M#0@GIA71T?(%
M *EM4,( @A*4NB=+(&A:"<*@JGE< #1M8.J@?4&0C>-;3@L7"3%[_(B*&9O_
MB7RQ*O94H9*--3^<6(;F>(:F+$I2F<%==F2+*L.)A]#S ='CTL#MQ>/\[46]
MRV5[7;$&H5<6)B)*[?R5>V:CM.X:1XNF_)#<*QHV $QY:^H$;6PW;(FPC;$W
MX5>?>59@\;S]@^<_4D3$T<FUMP@#_L*J9V,WFON3K&F-^/:Z ^*^*51RJ6HT
M+HVM9C757=JY<G1Z<G@ QZ<$0MND$@*@@,HMC=;Y45@+@GNJ[;%EM#/<>DZV
MGI-2)]X&QJ+JN-NHZG"\*&;\0#./)X@B)A1^#>42+9'KBVG@\PM/D*4R/ KJ
M#,?K4< (-*R^( \1R^4ZY<R99&G (^272(]68:WA.#0*6>G5IW'C!XC>6J]\
M1K^S9\@)732>)G\MY\GXD \>$8V-XM9X7J:X&YZ8R1/?%O&WK?O";/EZ#*X]
MID9A]AIY;K'*%QR2PT)&/X 9+4U685Y2=7$@G@*U/JG! )9FMB%(T@;D\>G)
MP3$<$[L>3%+6VH@49_,\F]_MG\Q:"Y =G[L\$6O^U;?D6=7-JT&P>(M4;?.^
MF0E' ,;.UF0=@,F:W)!=: .RI26'8Y!*R8=FTWSUO2=^;RI)K"J$25IT.-:F
MG'YH@!@ T2, ]?(#E!1\1[9B X?>'_*'WEE3$>0Q]]I*OIOY)."#@^\)M%:C
MMDH_[S(DZ=#?,U"4!61)&B"2?A=!RA" >2Q'6<&+%XK20 Q+K9)I 0%D6C8"
M"6C#LBY,S9N6S6\*QL$,D?AO?<QY82T(1FB!4JKV#U)^MDZ "K9,L?S[] $,
M/(&_2NB&R_PVG?\;2^</.1EZR>3R;2=#'WRR_L-R\FP[67^][6*A1U51N$>O
MJI;\U&90.QMW[V=5[$1N0JX:X^DWUO7,?5WE7Y'M/I1%P>TXI,#H>8#FL4L?
MHT29I[ =TVMT;)>K \*I:CQ^"IB!C=>9YX66>TNP9^/%.JN161B"HBH(CVQ%
M]%0\P0;QFDW&!-%@8@5(^*(=IH4V^V ]J1R991H D<RU(J!ZSJ#!.D&+>)Y/
M1VXI0%07!Y':U1@R-1_0 &)&OXV00WFBL-6!&F>-$7Y!D*-,/6Y0#T1^5V/(
M#!AJ/95AM-1>^,PT9DPAY\HG#Y2-Z_&4.V62%%Z%'L_>=LG&O]1;5:TA$-E>
MS7:3%3GL L)X,AY/5U/UV(LR//^887MV3=F$P*A]PDN4==57:@%$=E=CT$JQ
M!FVR3*_$G%^CS4A4$$9JUXJ[CH@%:'BL="B.5^<D*P"1EH21N]48$2D/O49=
M1*]#W%LOC;R3_''_.!MT$74P$CVD8RXPF)@+R"\AK_O]@OC9SH+-L9:K.%C1
ME 443Z%]*5G#0D_^[+O(C9BD1WI(7U 6P#%,H2JM05"S,600TJ$$'TZ/3P'D
M36P&&"EKM;&B*PXILG>?_.4>#1:$@77P4?RUP_]* L5^^^/F7UE(5K_V?7)6
MJ$-"RBMJ >R-MK'S XB=7S_*Q%_8$J_4L5W-LT4<%5BZ"B#.@HS@TW'1NH5^
M@X)4_U_Q''.;\R' ;GRM_(PR2U5LMUFW<2;]"]^1NEIJ-0?B7*CX\8A:/'8.
M:'3DD:!-D%L'T[(M@C@P*@]K639;1S8_3US%\P2S@3$1-$J\,"7K@C@-*D;+
MG"%H;II+-$6$B#=&HEP\ZOG_Q@_NPL=_(SNX]S=L*;ULM=L%<:QDF ZE-K,#
MUHM6E*)_C:CU*F%=3J&IPX-'D.T_>?@_@J=SY#$$ KIV,MXB1AI_\>;,<U:^
MT#/;9IOW[*-KC;0(XC#,2!%JL=FK _G"G[,=AC@HY^]V,WN-:2_R;-R(0_DT
M?XLOT:'(7IOJ$NJM/L@>9KBA^I4\R-O@_&UP_C8X?QN<W_DDSV]JC:=GA'"B
M"Y)G*<H"N@Y5F#]+P0( (!(TT>A-16OSRSW[BUKBMIS^JF;I5H#<B]:J8>J!
MB[(,MN$?8A(*L/T=4[$+33]PJ[[*:5(+PDW:BIJX=AB9\-FZ"^_<"JD],P='
M7Q["$4==6/0< I@!W]ZSGT4G']MG/[?/?K:Q/*V=">/IE(WWNX5ERTV[XN(0
M%J223PH6,P7- [F-F1A S,0-"B8\B)QG^B+(4B"4*P5AZV"85BU+>NN;-/'H
M9WPO]YS].<G?F-24&T@0@YQX:%.0H')S2L-OK1PH5%Q>%'[L@9Y^:(#<\==B
M&#V7:.%3Y76X7"GX005*TMN?;C*V#WU8,,*]8)428()LA)>Y4[V2=>$?[9=D
MJ'M<8C?I9@^7)DIR'%6C'?@'[S68ZQX['@J$/3&S_F ]!\B[\0-6*+HX:01;
M41/P3\BK\=4K6!$1#PO?>_!L_F#9-\8@P99[SO:"]JPL<(7-@;@^6@_$0A[A
M[2F6B%B>C2Y\&E#5_BY7"L8-4L--189V<!"$BT5DXUKN@X?F"]<7L_8J>.;.
M<BWR&H6'A+IXLRH-P;AX:@9D!?:@8<VI(Y8=_,#!["*D@3]'Y"N/27(9D1<S
M[KN_]N[Q'$V)->>K@ C\8<H[?G3QDV#JCOV73C%RX@#HR3K@2J$6+??9K0;5
M<F>T+(G6%^N)_VJYP6O<M2Y+FZIDMV!5]Y"HZ&]=Q-^PBYAB>,A R.JRW8JY
M^K4+-0>]QF).D"NR25DD>$T>8Y:*N3S8SS^R%S<\$BV/DDW_FG&5I0E5(7/^
MFORB.9<MT\ 0(C6K\ 5@'Y(D2GLH*RL(Y RVO"ZJ  /TD$(-8%)WY]\?G!Y_
M..P_+4!;8$F9;6-#<!$2B_?K(2*/LU.6@G!.KE:G]1Y 1CJ @1!=&=GL87A/
M7(+JI45;8T@1J5I&X$*CG:X*Z@!94@R4S@ H0,M)XU"!7F2:A*_Y!::I#8+F
M87MM(+A130B+EI'2IK<'!IP!P*[@D7LM>H9U(<06E<;/D#< ""JVL>4-WN$%
M(&L9@0N-L1$EJ0-D5V*@= 9  =J5- Y5>K$^/#U^_Q[.KJ1)^*2,MF+V,MN<
M\8:])X.;,IK"$/831NJVL8?5S+0AZ.\\VH,@GCO<"\93^59&+?I2U2%L#LJ!
M48J]-N"Y0]Z_P]N91>:6C<* )UN\\-5P:(M#B$XN)WXM.SU=_1X_<T_5#"\4
MJ1XRWWO88A6=QTG3/63([ENXRJRTN1( 4C](52(GV)Y3_Y86+<A-35EQ=[9A
M,;_7"^)&KTZLBLFX_8O3OW+^B**+"]O\$=O\$=O\$8#S1P 8<.O)@E]'#EXO
M_/G"]P3/ZAFPH$X/,V'1!2+E3%C "@" ,H1I'4Z*LD!F-R-52X*C8*<5WY%K
M4?I#C/! %S,A*P9AMM)JR<9/)"._-7&>&\HS5PZ"SZ>$0'/T Y@U[L)'BAUL
MD=<[2SSE'?CV3]V4KB[?PW1>=+]0/9VKV8  RH:F&VO._C0]2#"I"&62+U*\
M%%P&?+UMW-*^AN/3XY.3_ATF+6$IY14 O->W8ZTUF?@.8:DWU\94X-"&"0 B
MWZ8*&D"J(,6Y2QSA(EX'3MK!_(9:LDJY0W'S5B'L#LT4H3:KK5\=DQP<Q_>I
M;A&9\VP_AF?GN5H0#@X-;I.9L-(O"C,_- U@R%:"G\S(E),.(* !6U0166(;
MT<_>$Z,6$4;2ZB<Y!(65X"<R,N4$VI'-$!+9U7JR:)O(KIT,1,-)9'?F.4(#
MW'C'H-!Q15GX^84*&("&R1!RV55*$:0D'1H"41)<0KE;ENF(+K&,O.B <@#)
M&8"&B!BZ,]]UKN<+XB^CX](OQ*<J@UY784")?71L0,/H,D3W?L*PQ(A>A(0@
MD87ZQN=)OTA^I2]=>T!)=8QY@@9EG/.$>PYDB8$^O]ANZ'!#BE+$_L??LU.Z
M82JT-(!4/+7XZRH;$K-K;;[7>9(F )44&DIR'@GIT(;0-^P)>E9/.:Y#&#=$
MG[_R.8!KC>^R_I^B(HJ!5*.];E&ME>:X!I>M#ZI5!J@KG\2!5B)MHFQH*8MV
M"T7U?,=*!J -,W$^=4UIB)S+D'N2HC2C=S.+J<\->A:?U*<^9I6[1:W6<\.F
M+('#41 8$7Y+HC2_XC<5=.KRW:)5RR.AX:+UZ4Q8$;?$MQ%R:'S0^]UR0Y37
M'MD45ZIZMY!4SU]<BJG6$;I!P8H6OK_D-(B,FU/^/K+O">IDT)C5Z_9\LY*/
MH@0WT.8S$;$WGL8A>V,RP4^SX/,+V\5@BL107W^D\5=EBNF*;74+<"TW1T4.
M>\W$*12/NV;8[C.*XI0^AAZ;__?^BOYRF3H/\J^C)SO^RRCJ.OTH.DX\BD[B
MO)Z!/UI1T&]"3RG6NN2>N@I@AK8FYE53'DX:SV)4"L<KF/A7*77: $IM#2 1
MKX5J5P@0H%#71B%*!7Q^V#\]/@24>*TIV*1,MK'K7*T29YD%V-,\BEE<!T)$
MJX'2K7>=Q1RUOOU7D'#_K$FR45P'0EAC T D..H-"%:I_)A(U8(0O=@$&$F>
M^H+CR@]):322E2"$,38 1I*E05C%.<O09.7_"B%.WXR=P@5^X/'[OYRKHU5E
M:,+K 0#_<1C0P/+XT7<9J%/5P*Z.Y5%-\=5^E+E&L?A<\P/Q'Y!SQI]_>T(3
MQ 7"2/N*I])(@7KM@5U7U3[G>@SWCF\5#&'<(6@8IYZQD#^.7%0#PM6!!G%H
M]OFW9I:LY(%23/2*6M4N5%\%PJ6$\DN5GB=@IROGKF7_O+/9;XB.!2%E3U*.
M#$]21$^CN*M1Q/2O^0B:4?;&"<]6I<@XFO@&YZQ#GVTT07)/Z3 %!5)71NXK
M@ RC.?A3@NPY(^XW)I1Y.%<*,_.][SR7$N17TLQ0VI<\K1>]/-/?^[3+B^29
MIA3 IF2;K&( SBX1G?=H,2J2%Z8221S/7S=%XBC:LV>+.%<6)B*4[(S2<"X8
MI_P*HLV#0Q"9*]^7;[%#"&ZS$H&2+4D!FG$B&#DOYO7<A-<)IC^O"$*K@/H)
MD[9.T]KM%X)'KX3"M2N,-ZUWJS'VW7=9,_P1^:XT3]4S!#=D#[JG$L<OH7V7
M>,F?1W&ZUKUTOQ <JSUJ7EH8P+Q*=^%\;I'7\31R*9W9 :.6IR8HYUHZ-G0M
MQ=V-_.G*KV3%/?Z:#J;2A%XB@I?B!<1KCS(S@)/#EU=-_*V^RA#<4F:< )C$
M-P2N+D/SIP:T<9WZ*D!B;TVT3@Z4C*FW!U0Z./7P]/@ 4 1ND^!)&06 IUAN
MHB5,FV-64@Y"9*Z).N9NN:;9  '"UH$W# =>E2UNI&XT$<ES$^I&6O/]#,Q=
MURSS;\9>C5G\(L+ZKKWH-K$NE54K/?T"GC@=^^"T29>V(;':455D49V&!N09
MJ\ =.*AKZO.53Z8(!R%/'.%)\S.TVM,OX,S2L?_6M"D1+-GJ=D;2#X0XQVXT
M2<+\6].CQ(XM$QR=NM#0_F99WSN$.,W.M]!ZD0Q.$VFI#5\;VM@D!<-)G]VI
M6-Z<5JX#J_M4S))$#"BE>,>2&9QZFN]USSSG\\L"$]%"J]K:+DT#RL'>LZ3>
MFC*K+^IUH;;&O0\H#7UG,@&IBE7B3@MWX>L[HZL3K]!R>4#JH4XMNZ9D0+GV
M>Y'/6U-7@RO.&2$T'K9>AY(!O1O0BWQ JFLS/HYKQBOV*+9%%&+[;J9L?P-X
M.:$#*8!4L&9&69K5#J:]7(<#>L:A33% #2"6Y?Q-'DF6#2D^*1]2K,C[2WG%
M.-ZXY^2_@XDSED^2T4'S61C,F K^!SD/##N2 /G6M3QZ_IHR:E37XUOM:4A1
MS:T( ,KB4XVO/%?:T-Q6>@(2>MWB0&Q("=4BW"IAO9[2T=;'I\?[1W#"RH>K
MF%*QMI$;RSR!-.2TT2T.H74"+17_K:.BS28-.8=TYZ@D^&\=E</=#X>&L"2+
M@@CJ[1J7I !:S_97)@$XD+3?*E]1Y^,G*8$.1M#'4^,1M"D*(KJU^Q&T$4"W
M(TB?LQU&IG95Y&C7*"4%T#HP1[O'1X; )(N""*_L&IBD +H=/JSGC^8H?>P%
M)57(80\H?>P+I0\'QBAMBH((ONL>I8T .EZ*\-)T+Y<L"B/*K/.U*"&!UI$Y
MWGUO.LLEB\((K^H:F:0$NAU =_C%$*5$21@!1EV#E!! ^["@)9+GA"@H"R.8
MIG-HDB)H'9S//'+'$)Q461CA)EV#DQ)!Z^"<['[X8(A-LBB,,(VNH4E*H-MU
MYP:OW.6&8.4K= L9%(="7@[M>TR-EZ+[OA8B*%Z%^RZ7(;?$)B%=N%MPH#@3
MTC( %_6XS4,UD#Q4N1#)BCJ;B)>,HPUUUVS*!:]V11*(0^4:T:U=R0G<;-/D
MY!NEQQA/$S'FL52ZB#K2]0[B;+U&?'\+(@&IB4V-RSS#K5S@ZX$Z$-$'W4^T
M=40&4M.;'N+YE:C+.5?6.XAHC/[F7)E(@-U^.7,<''6?N/Y2]J;+>\.;+IO.
M1HG>MA=:JK_2K;F6HBD_I,LE&C8 S.-2ZK11]MH:0*YL%*I:(4"-7*!0>+[B
MGNA9D)IYM>'IQ74@!*H;:-/:G57,48>R+PBD-:D%P7O0@/R;"Y)MZ*%LMD.Y
ML>:Z^XOI(CVL#46^'.7:D*8<D+2U*T"V$)!)7Z8I,F$#NAM70=SIJU/O3X\^
M KJ15@X"*2NM'#7-%Z[_BA!E=C5E;(AISW,N,4$V:X,*JXA5^LCITQQ"56D&
MPK(L5[/-P5(5OMK :3SW\&,8I5&_]FPV<^(EXIWRSM6X&%6#L#P7X&#$1Y\O
MPDO6X,RW'A;?(D]U;O'-D-RG0)6OF*>^]KR^2N%/";+O)^'3#]/GA)GYWN>,
M7/0D?)K2ON29?I@^+\_T]SYGUB)YIBD%L./[CFB O2>--9,JT<-\6G1>HC1F
M4H3#$;5V;YTI \22D2B)1-" [)C2HDYO_3^PK?\'.%9,&?%+&0& B"+%'L]P
M=D\LSYXIW8V56H!@Y4B5T"#MH)RC06"HRIU1J04(%E(#&#:5):,A#,-'BAUL
MD=<[RT7CJ3#N=+G8U.5[V L4G4BK,ZJIV8  RH8F;HZ/IUQU*'\'W??T&:8,
M*@+90Q0J7@HN [X X'9].]9.=XGO$!8D<S5+8I%@H@T?FW#F/1,<!,B[#1]=
M;(^G4\1?,E0[V(KK0%@[RHG;D#%H<5?C)2)GKNL'?/J-8G*T0T)3'D0\::4A
MHF$* $3KU3$*&^+[%-_C#P#IEGU]G1Z6_J+G"M5+OYX5  !E"-.N^(JR4!9Y
M$U5+@J-@!P H<3B"=C++E(&PQFMU*2GY#.UM+.TB^F,5UJ%>S:7%(,A2J@+K
MM5I*=NL7?46OYX9"S96#L"TRD&J.;FB['C:^YKXGM@G:"4)2#@($QI.$A'X
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M0?UKC_*R$%:B0D74@-3S:]BYI\^SS[3WMIH4>9ASJTF&Y#X%JGQ<//6UY_5
M"G]*D-N7VDUG@KY?:C>3)Y.*5I[I[WTFLRV29YI2""O9-MLS_&S/0TWQ5.OB
M62<9GK:W<AK+\3S 2SG;H^Z:.:+?W$GWL"//:B:,[B;P;!N2T'VZZ#<4D; -
M=&LO!?4O%>>V#8(?=F+K-QX#7W<,YM@723FNO8!@CV*[E;O@I;J&G\R[6WF
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MCZ]E0A,1-+=!"^O[\+VG*^=M+&.AY;YLUDF*[*A>OJ[ ;;-=/X<7Y@#BKH&
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MCFP7UAH9">QP%E([L1K^:V<6P^8@].4XCF/JB,NKZ%FQFCK@A6(V&H',9G.
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M#6LIU,CWEM=DFA[,&@D%9946(EM8IX%**%8ZR**KM38$7T!!"G?A#T-9E;2
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M[&*T*+"IY(\XV^.W1)-H<CN]:OLMJ1Y.]V5%N"OL+,&5"%3&[QA1NTF_+A0
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M]]27X758SDJ^R)5GZ5BXW-$.RI5P.$YIW)0,.2(WJD$XGS$L.SRS/_ Q-=7
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MY%$P[TF=)_T/VKR/.;X]YP9M!3OHCO'S7UYVTG<;\+C"PR)*%@FZJ":,..7
MW.^X>9!E%GYX3V76:-V2?OCCCKBIK*I?8]!2S40'[:)1+6X('G9 ,+T[U2 &
MXCN-W/4/JMB6FCDTCM<\AJ&O:1EF'4QB=N.X0KM]4>[I)JG*4=1WJ= ^R$U^
ME<,1%-HW5#6-$%R+FW@?NQ^U^:8@)9\\R3*G\WL??:8OQH[7]05'EU>:5&4E
MJ16=$)RB@\!Z!VE!)!!G:<UI3QL%)HH:!QHU1 Y]*,N]:[;DVUV4/8?N1<=/
MC,JCUI/5DCMTKJI"3A#N=0:%,*H!8.7W/;[-KWFVXQ79TB2X/.4%-X^S]8<\
M$]4W-4>KUMA ==S=A.N4:[=#]5^5W86O?B'(/::>1> C00#F'G$62>H\7;8;
MGS.=)WHF4J2WM(R4>5'704(DYQB9;G-PE&! J38&7@R[$H&&&)ZT5OC.I''A
M7L<S2- ]BG-642F -4NT5[B@][]1%NMO5P_!H*Y2U>QV[TV[, "7I"H&%#>B
MO!U% P?U8L21WZ2&:RJ,S[E8\$&,O:W5&9]VB!!+B8M([<IB@P6TT-BS9EAW
M6)4I^7$0F<<R6>-"G,ER52/!_B/3-7JP7\A]R]=2C_9:$7VO61,FHK:F09E@
MUC0(R::[#;'9I-70:#/2N$CX4S.#B'H4.%<Q),:AD]#!@[H',U.*%&\LG?34
MK9K$J0TOR5?*9%9U,PL8FW>4KK:)=[(\'42 HYEIHN@_S?QV?155K=\QB'(
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M:='0A!;&1M_<B9GX"[SMO\5D_QJE&ID'9FH(&=:B[413&:\9$\Q.;=C2ZZ#
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M'&ED[D'!F(N&6=DL#D"\J[]R?.5%< V&*-R,-[I,L]BV+7VF52&N-6_IU'
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MXZ4$YYYK_3@OS+D-3=@LSDPWR,MQ7F8)EG!6E[5WZN2Z\E'AVD;XFL"V *A
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M#O!XT "_IJ;LU,:2;<?IZ-:*#@Y:/@ER7"=#QO5A 3RO:;R6"PT-R\:^%Y:
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MDDY3:3V'M'FJ_#X<#)N[7> V:+O+[X&7((V'F:&?;OO>*C<<'/F[7]S=ZS?
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MW'@'3;GQUM&\#4N#)R^Z][&F36;GC'<:![68=DFS>*-8P\_@L!;RS'.BPLN
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M%F:)=PUGM"TI1TU["-%6V)P@1W((TN$^D&*WV#YO1X\@7$(_Q>0G^E0,_)L
MG<[!'4#?GFY1H4T3P^>$-*ES<AR;L8"T8$@FVX]5X/_P73Q5?D>J#*'CG8;
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M5TF,?@Y\%WK9EJ@L-]/0J>ISQO%(C!(,2O6A*$NL:=0IG&E1:ZAE+K/Z8(;
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MFG<15(FP/,179@(UC0.]+7X"3&B0WM1%8F-POIW-T-3WL')<LNVEJ?AP0&^
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MGQB$)W..9M8Q#E-1>+@!-GFJEK5JDU*HY@FBF<_$.&H.A2A<*T%7N2TAS#>
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M2+E(515'2!4[ URY&R5B@*OYVJWH.G-]KA8R#K-&]=,18TADZCQ\L5QYP1L
MT1DZJ"=>G,XU_O0<AL!%;43IX1]5&F,9&7?RXLT8"SP#Q>V+=DE2FTJ.VZ4/
MGY,L]>F5[R+]P1> 9<$RT<G 4<T"\-M*:>;2'(5Q:9I'_[4]Q:,_/=&"?U5^
M,PY:H46X612&L5[NZLL/"7$H;OUJ#"S-&B:@8?+DV1Z\[]"'RV1)A:_RNWD
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H;BTR,#(P,3(S,5]P<F4N>&UL4$L%!@     &  8 B@$  /P\ @    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
